For|O this|O reason|O ,|O we|O compared|O the|O incidence|O of|O death|O from|O malignant|B-DISE neoplasms|I-DISE in|O 2|O families|O of|O patients|O with|O A|B-DISE -|I-DISE T|I-DISE to|O that|O expected|O in|O a|O random|O sample|O of|O the|O general|O population|O .|O
Through|O gene|O targeting|O ,|O we|O have|O generated|O a|O line|O of|O Atm|O mutant|O mice|O ,|O Atm|O (|O y|O /|O y|O )|O mice|O .|O
Ankylosing|B-DISE spondylitis|I-DISE is|O diagnosed|O once|O or|O twice|O in|O each|O 1000|O males|O and|O one|O tenth|O as|O frequently|O in|O females|O ,|O but|O the|O true|O prevalence|O is|O unknown|O .|O
In|O this|O study|O ,|O we|O have|O collected|O data|O on|O 13|O additional|O unrelated|O patients|O to|O identify|O the|O causative|O mutations|O and|O to|O determine|O the|O prevalence|O of|O the|O 11|O -|O kb|O deletion|O .|O
Mutations|O in|O the|O human|O phenylalanine|O hydroxylase|O gene|O producing|O phenylketonuria|B-DISE or|O hyperphenylalaninemia|B-DISE have|O now|O been|O identified|O in|O many|O patients|O from|O various|O ethnic|O groups|O .|O
The|O cost|O of|O screening|O per|O sample|O was|O calculated|O to|O be|O approximately|O US|O $|O 70|O for|O the|O manual|O technique|O used|O in|O this|O study|O ,|O and|O may|O be|O reduced|O to|O approximately|O US|O $|O 10|O with|O the|O introduction|O of|O commercially|O available|O PCR|O robotics|O and|O fluorescent|O imaging|O .|O
Estimates|O from|O heterogeneity|O tests|O suggest|O that|O ,|O within|O Sweden|O ,|O as|O many|O as|O 50|O %|O of|O early|O -|O onset|O families|O had|O evidence|O of|O linkage|O to|O the|O HPC1|O region|O .|O
Papillon|B-DISE -|I-DISE Lefevre|I-DISE syndrome|I-DISE (|O PLS|B-DISE )|O is|O an|O autosomal|O recessive|O disorder|O characterised|O by|O palmoplantar|B-DISE hyperkeratosis|I-DISE and|O severe|O early|O onset|O periodontitis|B-DISE that|O results|O in|O the|O premature|B-DISE loss|I-DISE of|I-DISE the|I-DISE primary|I-DISE and|I-DISE secondary|I-DISE dentitions|I-DISE .|O
Seven|O further|O molecular|O bases|O of|O C7|B-DISE deficiency|I-DISE are|O described|O .|O
A|O myotonic|B-DISE dystrophy|I-DISE (|O DM|B-DISE )|O family|O is|O described|O in|O which|O discordant|O DM|B-DISE phenotypes|O were|O found|O in|O the|O children|O of|O two|O affected|O sisters|O with|O similar|O CTG|O expansion|O and|O clinical|O manifestations|O .|O
None|O had|O chronic|O or|O prolonged|O manifestations|O of|O FMF|B-DISE ,|O for|O example|O ,|O amyloidosis|B-DISE ,|O chronic|B-DISE arthritis|I-DISE ,|O or|O protracted|O myalgia|B-DISE ,|O P|O <|O 0|O .|O 001|O .|O
Consequently|O ,|O 86|O %|O of|O afibrinogenemia|B-DISE alleles|O analyzed|O to|O date|O have|O truncating|O mutations|O of|O FGA|O ,|O though|O mutations|O in|O all|O 3|O fibrinogen|O genes|O ,|O FGG|O ,|O FGA|O ,|O and|O FGB|O ,|O might|O be|O predicted|O to|O cause|O congenital|B-DISE afibrinogenemia|I-DISE .|O .|O
Phenylketonuria|B-DISE (|O PKU|B-DISE )|O is|O caused|O by|O deficiency|B-DISE of|I-DISE the|I-DISE hepatic|I-DISE enzyme|I-DISE phenylalanine|I-DISE hydroxylase|I-DISE PAH|O .|O
A|O boy|O developed|O contractures|B-DISE of|I-DISE the|I-DISE Achilles|I-DISE tendons|I-DISE at|I-DISE 3|I-DISE years|I-DISE and|I-DISE of|I-DISE the|I-DISE postcervical|I-DISE muscles|I-DISE at|O 7|O years|O ,|O although|O neither|O contractures|B-DISE of|I-DISE the|I-DISE elbows|I-DISE nor|O cardiac|B-DISE abnormality|I-DISE were|O recognized|O by|O the|O age|O of|O 9|O years|O .|O
Relatives|O with|O splice|O -|O site|O or|O major|O structural|O defects|O in|O the|O PROS1|O gene|O were|O more|O likely|O to|O have|O had|O a|O thrombotic|B-DISE event|I-DISE and|O had|O significantly|B-DISE lower|I-DISE total|I-DISE and|I-DISE free|I-DISE protein|I-DISE S|I-DISE levels|I-DISE than|O those|O relatives|O having|O missense|O mutations|O .|O
The|O M694V|O homozygous|O genotype|O was|O found|O to|O be|O associated|O with|O a|O higher|O prevalence|O of|O renal|B-DISE amyloidosis|I-DISE and|O arthritis|B-DISE ,|O compared|O with|O other|O genotypes|O P|O =|O .|O 0002|O and|O P|O =|O .|O 006|O ,|O respectively|O .|O
These|O results|O support|O the|O theory|O that|O human|O aniridia|B-DISE is|O caused|O by|O haploinsufficiency|O of|O PAX6|O .|O .|O
There|O was|O no|O obvious|O correlation|O between|O the|O type|O of|O mutation|O and|O phenotypic|O expression|O .|O
Lowe|O syndrome|O ,|O also|O known|O as|O oculocerebrorenal|B-DISE syndrome|I-DISE ,|O is|O caused|O by|O mutations|O in|O the|O X|O chromosome|O -|O encoded|O OCRL|O gene|O .|O
Biochemical|O characterization|O has|O shown|O that|O most|O of|O the|O G6PD|B-DISE deficiency|I-DISE in|O this|O population|O is|O accounted|O for|O by|O G6PD|O Mediterranean|O .|O
Friedreich|B-DISE ataxia|I-DISE is|O usually|O caused|O by|O an|O expansion|O of|O a|O GAA|O trinucleotide|O repeat|O in|O intron|O 1|O of|O the|O FRDA|O gene|O .|O
Mutant|O BRCA1|O has|O no|O effect|O on|O growth|O of|O breast|B-DISE cancer|I-DISE cells|O ;|O ovarian|B-DISE cancer|Mention text="ovarian cancer" start=12 end=14 type=DISE prob=null&Mention text="cancer cell growth" start=13 end=16 type=DISE prob=null cell|I-DISE growth|I-DISE is|O not|O affected|O by|O BRCA1|O mutations|O in|O the|O 5|O '|O portion|O of|O the|O gene|O ,|O but|O is|O inhibited|O by|O 3|O '|O BRCA1|O mutations|O .|O
Hypermethylation|O of|O the|O expanded|O repeat|O and|O of|O the|O FMR1|O promoter|O is|O almost|O always|O present|O and|O apparently|O suppresses|O transcription|O ,|O resulting|O in|O absence|O of|O the|O FMR1|O protein|O .|O
Aspartylglucosaminuria|B-DISE (|O AGU|B-DISE )|O is|O a|O rare|O disorder|B-DISE of|I-DISE glycoprotein|I-DISE metabolism|I-DISE caused|O by|O the|O deficiency|B-DISE of|I-DISE the|I-DISE lysosomal|I-DISE enzyme|I-DISE aspartylglucosaminidase|I-DISE AGA|O .|O
In|O this|O family|O ,|O the|O phenotype|O in|O three|O generations|O of|O affected|O individuals|O was|O confined|O to|O the|O cardinal|O signs|O of|O VWS|B-DISE .|O
Familial|B-DISE Mediterranean|I-DISE fever|I-DISE (|O FMF|B-DISE )|O is|O a|O recessive|B-DISE disorder|I-DISE characterized|O by|O episodes|O of|O fever|O with|O serositis|B-DISE or|O synovitis|B-DISE .|O
The|O evidence|O of|O linkage|O to|O this|O region|O originated|O almost|O exclusively|O from|O the|O subset|O of|O 12|O early|O -|O onset|O (|O age|O <|O 65|O years|O )|O families|O ,|O which|O yielded|O a|O maximum|O LOD|O score|O of|O 2|O .|O 38|O at|O D1S413|O (|O straight|O theta|O =|O 0|O )|O and|O an|O NPL|O Z|O score|O of|O 1|O .|O 95|O at|O D1S422|O P|O =|O .|O 03|O .|O
Previous|O linkage|O and|O association|O studies|O have|O suggested|O the|O presence|O of|O a|O susceptibility|O gene|O for|O AS|B-DISE close|O to|O ,|O or|O within|O ,|O the|O cytochrome|O P450|O 2D6|O gene|O (|O CYP2D6|O ,|O debrisoquine|O hydroxylase|O )|O located|O at|O chromosome|O 22q13|O .|O 1|O .|O
Here|O we|O report|O the|O autoinhibited|O structure|O of|O the|O GTPase|O -|O binding|O domain|O of|O WASP|O ,|O which|O can|O be|O induced|O by|O the|O C|O -|O terminal|O region|O or|O by|O organic|O co|O -|O solvents|O .|O
The|O Type|O II|O C2|O null|O allele|O (|O C2Q0|O )|O is|O linked|O to|O two|O major|O histocompatibility|O haplotypes|O (|O MHC|O )|O that|O differ|O from|O the|O MHC|O of|O the|O more|O common|O Type|O I|O C2|B-DISE deficiency|I-DISE .|O
A|O third|O family|O has|O previously|O been|O reported|O ,|O in|O which|O affected|O members|O had|O an|O extra|O copy|O of|O the|O PLP|O gene|O detected|O at|O Xq26|O in|O a|O chromosome|O with|O an|O otherwise|O normal|O banding|O pattern|O .|O
MAIN|O OUTCOME|O MEASURES|O :|O Age|O at|O diagnosis|O ,|O surgical|O stage|O ,|O histologic|O cell|O type|O and|O grade|O ,|O and|O surgical|O outcome|O ;|O and|O response|O to|O chemotherapy|O and|O survival|O for|O advanced|O -|O stage|O (|O II|O and|O IV|O )|O cases|O .|O
This|O same|O AR|O mutation|O has|O been|O reported|O previously|O in|O a|O metastatic|B-DISE prostate|I-DISE cancer|I-DISE cell|O line|O ,|O LNCaP|O ,|O where|O this|O mutation|O confers|O upon|O the|O AR|O an|O altered|O ligand|O -|O binding|O specificity|O which|O is|O stimulated|O by|O estrogens|O ,|O progestagens|O ,|O and|O antiandrogens|O .|O
Mutations|O in|O the|O ATP7B|O gene|O lead|O to|O Wilson|B-DISE disease|I-DISE ,|O a|O copper|O toxicity|O disorder|O characterized|O by|O dramatic|O build|O -|O up|O of|O intracellular|O hepatic|O copper|O with|O subsequent|O hepatic|O and|O neuro|O -|O logical|O abnormalities|O .|O
In|O one|O case|O ,|O previously|O described|O ,|O the|O enzyme|O was|O of|O the|O A|O -|O type|O .|O
Meiotic|O recombination|O events|O have|O localized|O the|O critical|O region|O containing|O ALMS1|O to|O a|O 6|O .|O 1|O -|O cM|O interval|O flanked|O by|O markers|O D2S327|O and|O D2S286|O .|O
We|O report|O a|O novel|O missense|O change|O in|O BRCA1|O ,|O 2640|O C|O -|O -|O T|O (|O R841W|O )|O ,|O found|O in|O 3|O cases|O from|O a|O subject|O group|O of|O 305|O breast|B-DISE and|I-DISE 79|I-DISE ovarian|I-DISE cancer|I-DISE cases|O from|O Orange|O County|O ,|O CA|O .|O
Using|O phosphorus|O magnetic|O resonance|O spectroscopy|O we|O demonstrated|O a|O maximum|O rate|O of|O muscle|O mitochondrial|O ATP|O production|O V|O max|O below|O the|O normal|O range|O in|O all|O 12|O FRDA|B-DISE patients|O and|O a|O strong|O negative|O correlation|O between|O mitochondrial|O V|O (|O max|O )|O and|O the|O number|O of|O GAA|O repeats|O in|O the|O smaller|O allele|O .|O
The|O patient|O responded|O positively|O to|O treatment|O with|O L|O -|O dopa|O .|O
In|O northwestern|O Europe|O ,|O >|O 80|O %|O of|O GH|B-DISE patients|O are|O homozygous|O for|O one|O mutation|O ,|O the|O substitution|O of|O tyrosine|O for|O cysteine|O at|O position|O 282|O (|O C282Y|O )|O in|O the|O unprocessed|O protein|O .|O
The|O NBS1|O protein|O is|O specifically|O mutated|O in|O patients|O with|O Nijmegen|B-DISE breakage|I-DISE syndrome|I-DISE and|O forms|O a|O complex|O with|O the|O DNA|O repair|O proteins|O Rad50|O and|O Mrel1|O .|O
To|O elucidate|O the|O mechanism|O underlying|O these|O events|O ,|O we|O characterized|O the|O regions|O that|O contain|O two|O proximal|O breakpoint|O clusters|O and|O a|O distal|O cluster|O .|O
In|O contrast|O ,|O lymphocytes|O from|O all|O the|O carriers|O except|O two|O lacked|O the|O WASPdim|O population|O .|O
These|O results|O provide|O a|O new|O insight|O into|O the|O role|O of|O mutant|O PAX6|O in|O causing|O aniridia|B-DISE .|O .|O
HLA|O histocompatibility|O typing|O of|O the|O family|O members|O did|O not|O demonstrate|O evidence|O for|O genetic|O linkage|O of|O C7|B-DISE deficiency|I-DISE with|O the|O major|O histocompatibility|O loci|O .|O
The|O BRCA1|O gene|O on|O chromosome|O 17q21|O is|O responsible|O for|O an|O autosomal|O dominant|O syndrome|O of|O increased|O susceptibility|O to|O breast|B-DISE and|I-DISE ovarian|I-DISE cancer|I-DISE but|O no|O somatic|O mutations|O in|O tumours|O have|O yet|O been|O described|O .|O
Sjogren|B-DISE -|I-DISE Larsson|I-DISE syndrome|I-DISE (|O SLS|B-DISE )|O is|O an|O autosomal|B-DISE recessive|I-DISE disorder|I-DISE characterized|O by|O ichthyosis|B-DISE ,|O mental|B-DISE retardation|I-DISE ,|O spasticity|B-DISE ,|O and|O deficient|B-DISE activity|I-DISE of|I-DISE fatty|I-DISE aldehyde|I-DISE dehydrogenase|I-DISE FALDH|I-DISE .|O
However|O ,|O several|O truncation|O mutations|O have|O been|O found|O to|O occur|O in|O the|O C|O -|O terminal|O half|O of|O PAX6|O in|O patients|O with|O Aniridia|B-DISE resulting|O in|O mutant|O proteins|O that|O retain|O the|O DNA|O -|O binding|O domains|O but|O have|O lost|O most|O of|O the|O transactivation|O domain|O .|O
Molecular|O analysis|O of|O the|O patients|O '|O RNA|O and|O DNA|O identified|O two|O new|O RNA|O splicing|O defects|O ,|O three|O new|O and|O three|O previously|O described|O amino|O acid|O substitutions|O .|O
Although|O almost|O half|O of|O the|O YACs|O appear|O to|O contain|O chimeric|O inserts|O and|O several|O contain|O internal|O deletions|O or|O other|O rearrangements|O ,|O we|O were|O able|O to|O obtain|O over|O 2|O .|O 2|O Mb|O of|O the|O HD|O region|O in|O YACs|O ,|O including|O one|O continuous|O segment|O of|O 2|O .|O 0|O Mb|O covering|O the|O region|O that|O most|O likely|O contains|O the|O HD|O gene|O .|O
Mice|O with|O a|O partial|O or|O complete|O deficiency|B-DISE of|I-DISE Hmgic|I-DISE resisted|O diet|O -|O induced|O obesity|B-DISE .|O
To|O determine|O the|O molecular|O basis|O of|O type|O I|O C2|B-DISE deficiency|I-DISE ,|O the|O C2|O gene|O and|O cDNA|O were|O characterized|O from|O a|O homozygous|O type|O I|O C2|O -|O deficient|O individual|O with|O the|O common|O associated|O haplotype|O /|O complotype|O .|O
Fewer|O than|O half|O of|O the|O splicing|O mutations|O involved|O the|O canonical|O AG|O splice|O -|O acceptor|O site|O or|O GT|O splice|O -|O donor|O site|O .|O
Both|O mutations|O were|O tested|O in|O a|O eukaryotic|O expression|O system|O in|O which|O enzyme|O activities|O of|O different|O mutant|O PAH|O enzymes|O reflect|O the|O relative|O severities|O of|O the|O mutations|O ,|O although|O these|O in|O vitro|O activities|O cannot|O be|O translated|O directly|O into|O in|O vivo|O hepatic|O activities|O .|O
In|O order|O to|O elucidate|O the|O cellular|O and|O molecular|O processes|O which|O are|O involved|O in|O Norrie|B-DISE disease|I-DISE (|O ND|B-DISE )|O ,|O we|O have|O used|O gene|O targeting|O technology|O to|O generate|O ND|O mutant|O mice|O .|O
It|O is|O not|O known|O whether|O BRCA1|O phosphorylation|O and|O dispersion|O and|O its|O function|O in|O DNA|O damage|O response|O are|O related|O .|O
Immunohistochemically|O ,|O expression|O of|O AGA|O in|O AGU|B-DISE patients|O '|O mucosal|B-DISE lesions|I-DISE did|O not|O differ|O from|O that|O seen|O in|O corresponding|O lesions|O of|O normal|O subjects|O .|O
APC|O (|O AS9|O )|O was|O found|O to|O down|O -|O regulate|O beta|O -|O catenin|O -|O regulated|O transcription|O ,|O the|O major|O tumor|B-DISE -|O suppressor|O function|O of|O APC|O ,|O as|O did|O the|O wild|O -|O type|O APC|O .|O
These|O results|O refine|O understanding|O of|O MEFV|O by|O placing|O the|O gene|O in|O the|O myelomonocytic|O -|O specific|O proinflammatory|O pathway|O and|O identifying|O it|O as|O an|O IFN|O -|O gamma|O immediate|O early|O gene|O .|O .|O
Genomic|O DNA|O was|O prepared|O from|O the|O peripheral|O blood|O leukocytes|O of|O at|O least|O one|O affected|O woman|O from|O each|O family|O .|O
Our|O results|O indicate|O that|O the|O mutations|O identified|O in|O this|O study|O are|O A|B-DISE -|I-DISE T|I-DISE disease|O -|O causing|O "|O mutations|O that|O might|O be|O associated|O with|O an|O increased|O risk|O of|O breast|B-DISE cancer|I-DISE in|O heterozygotes|O .|O "|O
Thus|O ,|O we|O screened|O 16|O endometrial|B-DISE carcinomas|I-DISE with|O microsatellite|O instability|O for|O alterations|O in|O FEN1|O (|O the|O human|O homolog|O of|O RTH|O )|O and|O in|O MSH3|O refs|O 12|O -|O 14|O .|O
The|O mechanism|O responsible|O for|O this|O strong|O male|O bias|O in|O the|O duplications|O may|O involve|O an|O unequal|O sister|O chromatid|O exchange|O ,|O since|O two|O deletion|O events|O ,|O responsible|O for|O mild|O clinical|O manifestations|O ,|O have|O been|O reported|O in|O PLP|O -|O related|O diseases|O .|O .|O
ovarian|B-DISE cancer|I-DISE were|O different|O from|O those|O in|O reports|O of|O the|O Ashkenazi|O founder|O mutations|O .|O
We|O found|O a|O correlation|O between|O the|O size|O of|O the|O smaller|O of|O the|O two|O expanded|O alleles|O and|O age|O at|O onset|O ,|O age|O into|O wheelchair|O ,|O scoliosis|B-DISE ,|O impaired|O vibration|O sense|O ,|O and|O the|O presence|O of|O foot|B-DISE deformity|I-DISE .|O
The|O distribution|O of|O the|O two|O mutations|O differ|O ,|O C282Y|O being|O limited|O to|O those|O of|O northwestern|O European|O ancestry|O and|O H63D|O being|O found|O at|O allele|O frequencies|O >|O 5|O %|O ,|O in|O Europe|O ,|O in|O countries|O bordering|O the|O Mediterranean|O ,|O in|O the|O Middle|O East|O ,|O and|O in|O the|O Indian|O subcontinent|O .|O
About|O 50|O of|O these|O mutations|O are|O single|O -|O base|O substitutions|O ,|O including|O six|O nonsense|O mutations|O and|O eight|O splicing|O mutations|O ,|O with|O the|O remainder|O being|O missense|O mutations|O .|O
The|O gene|O (|O CTSC|O )|O encoding|O the|O lysosomal|O protease|O cathepsin|O C|O (|O or|O dipeptidyl|O aminopeptidase|O I|O )|O lies|O within|O this|O interval|O .|O
Our|O results|O demonstrate|O that|O the|O rate|O and|O severity|O of|O cataract|B-DISE formation|O is|O inversely|O related|O to|O Six5|O dosage|O and|O is|O temporally|O progressive|O .|O
Five|O patients|O had|O evidence|O of|O a|O sero|B-DISE -|I-DISE negative|I-DISE peripheral|I-DISE arthritis|I-DISE resembling|O peripheral|O psoriatic|B-DISE arthritis|I-DISE and|O 3|O of|O these|O were|O B27|O negative|O .|O
The|O cancer|B-DISE incidence|O among|O the|O siblings|O or|O the|O parents|O did|O not|O differ|O from|O the|O average|O cancer|O incidence|O in|O the|O Finnish|O population|O .|O
Our|O results|O provide|O information|O helpful|O to|O an|O understanding|O of|O the|O APC|O gene|O and|O will|O also|O contribute|O to|O presymptomatic|O diagnosis|O of|O members|O in|O FAP|B-DISE families|O .|O .|O
To|O investigate|O the|O origin|O of|O this|O mutation|O in|O colorectal|B-DISE cancer|I-DISE families|O from|O England|O (|O n|O =|O 4|O )|O ,|O Newfoundland|O (|O n|O =|O 10|O )|O ,|O and|O the|O United|O States|O (|O n|O =|O 3|O )|O ,|O haplotype|O analysis|O using|O microsatellite|O markers|O linked|O to|O MSH2|O was|O performed|O .|O
In|O this|O study|O we|O used|O denaturing|O gradient|O gel|O electrophoresis|O DGGE|O .|O
The|O mutations|O associated|O with|O Pendred|B-DISE syndrome|I-DISE have|O complete|O loss|O of|O pendrin|O -|O induced|O chloride|O and|O iodide|O transport|O ,|O while|O alleles|O unique|O to|O people|O with|O DFNB4|O are|O able|O to|O transport|O both|O iodide|O and|O chloride|O ,|O albeit|O at|O a|O much|O lower|O level|O than|O wild|O -|O type|O pendrin|O .|O
OBJECTIVE|O :|O Previous|O reports|O have|O suggested|O an|O increased|O risk|O of|O cancer|B-DISE among|O patients|O with|O cartilage|B-DISE -|I-DISE hair|I-DISE hypoplasia|I-DISE CHH|B-DISE .|O
These|O results|O demonstrate|O that|O BRCA1|O interacts|O with|O components|O of|O the|O histone|O deacetylase|O complex|O ,|O and|O therefore|O may|O explain|O the|O involvement|O of|O BRCA1|O in|O multiple|O processes|O such|O as|O transcription|O ,|O DNA|O repair|O ,|O and|O recombination|O .|O .|O
Prader|B-DISE -|I-DISE Willi|I-DISE syndrome|I-DISE (|O PWS|B-DISE )|O is|O associated|O with|O paternally|O derived|O chromosomal|O deletions|O in|O region|O 15q11|O -|O 13|O or|O with|O maternal|O disomy|O for|O chromosome|O 15|O .|O
Although|O recent|O data|O established|O that|O a|O specific|O very|O -|O long|O -|O chain|O fatty|O acyl|O -|O CoA|O synthetase|O is|O defective|O in|O X|O -|O linked|O adrenoleukodystrophy|B-DISE (|O ALD|B-DISE )|O ,|O the|O ALD|O gene|O is|O still|O unidentified|O .|O
A|O model|O which|O accounts|O for|O the|O dominant|O negative|O effect|O of|O this|O lesion|O is|O presented|O .|O
The|O Atp7b|O protein|O is|O a|O copper|O -|O transporting|O ATPase|O expressed|O predominantly|O in|O the|O liver|O and|O to|O a|O lesser|O extent|O in|O most|O other|O tissues|O .|O
This|O method|O involves|O the|O selective|O amplification|O of|O a|O DNA|O fragment|O from|O human|O G6PD|O gene|O with|O specific|O oligonucleotide|O primers|O followed|O by|O digestion|O with|O restriction|O enzymes|O that|O recognize|O artificially|O created|O or|O naturally|O occurring|O restriction|O sites|O .|O
We|O verified|O these|O events|O by|O in|O vivo|O splicing|O experiments|O and|O transient|O expression|O analysis|O of|O mutant|O cDNAs|O .|O
Such|O intragenic|O polymorphisms|O offer|O a|O practical|O approach|O to|O a|O more|O rapid|O procedure|O for|O presymptomatic|O diagnosis|O of|O FAP|B-DISE by|O linkage|O analysis|O in|O informative|O families|O .|O .|O
We|O describe|O two|O brothers|O with|O identical|O inherited|O deletions|O of|O one|O single|O exon|O within|O the|O middle|O of|O the|O DMD|O gene|O ;|O one|O brother|O has|O Becker|B-DISE muscular|I-DISE dystrophy|I-DISE diagnosed|O at|O 11|O years|O of|O age|O ,|O whereas|O the|O older|O brother|O is|O normal|O at|O 18|O .|O
We|O have|O previously|O described|O four|O mutations|O (|O M1V|O ,|O IVS12nt1|O ,|O R408W|O ,|O and|O S349P|O )|O at|O the|O PAH|O locus|O in|O French|O Canadians|O with|O ancestry|O in|O eastern|O Quebec|O .|O
In|O this|O study|O ,|O direct|O mutation|O analysis|O of|O the|O APC|O gene|O was|O performed|O to|O determine|O genotype|O -|O phenotype|O correlations|O for|O nine|O extracolonic|O manifestations|O and|O to|O investigate|O the|O incidence|O of|O APC|O mutations|O in|O non|O -|O FAP|B-DISE colorectal|B-DISE cancer|I-DISE .|O
Thus|O the|O most|O common|O polymorphisms|O of|O the|O BRCA1|O gene|O do|O not|O make|O a|O significant|O contribution|O to|O breast|B-DISE or|I-DISE ovarian|I-DISE cancer|I-DISE risk|O .|O
We|O identified|O a|O patient|O suffering|O from|O late|B-DISE -|I-DISE infantile|I-DISE metachromatic|I-DISE leukodystrophy|I-DISE (|O MLD|O )|O who|O has|O a|O residual|O arylsulfatase|O A|O (|O ARSA|O )|O activity|O of|O about|O 10|O %|O .|O
These|O studies|O demonstrate|O for|O the|O first|O time|O that|O a|O complex|O ultrastructural|O cell|O defect|O can|O be|O corrected|O both|O morphologically|O and|O functionally|O by|O in|O vivo|O gene|O transfer|O .|O .|O
Six5|O -|O mutant|O mice|O showed|O reporter|O expression|O in|O multiple|O tissues|O ,|O including|O the|O developing|O lens|O .|O
Thus|O ,|O it|O appears|O that|O C3|B-DISE deficiency|I-DISE in|O Brittany|O spaniel|O dogs|O not|O only|O shares|O biochemical|O and|O clinical|O features|O with|O C3|B-DISE deficiency|I-DISE in|O humans|O ,|O but|O also|O shares|O some|O genetic|O characteristics|O with|O the|O human|O disorder|O .|O .|O
Familial|B-DISE gastric|I-DISE cancer|I-DISE is|O genetically|O heterogeneous|O and|O it|O is|O not|O clear|O what|O proportion|O of|O gastric|O cancer|O susceptibility|O in|O non|O -|O Maori|O populations|O is|O due|O to|O germline|O CDH1|O mutations|O .|O
An|O obligate|O carrier|O of|O the|O Wiskott|B-DISE -|I-DISE Aldrich|I-DISE syndrome|I-DISE (|O WAS|B-DISE )|O who|O was|O also|O heterozygous|O for|O the|O A|O and|O B|O types|O of|O X|O -|O linked|O glucose|B-DISE -|I-DISE 6|I-DISE -|I-DISE phosphate|I-DISE dehydrogenase|I-DISE was|O found|O .|O
In|O order|O to|O investigate|O the|O molecular|O basis|O for|O argininemia|B-DISE in|O four|O unrelated|O Portuguese|O patients|O (|O two|O from|O northern|O Portugal|O and|O two|O from|O Madeira|O Island|O )|O we|O performed|O a|O DNA|O sequence|O analysis|O of|O all|O the|O exons|O and|O exon|O /|O intron|O boundaries|O of|O the|O liver|O -|O type|O arginase|O gene|O ARG1|O .|O
Mutations|O at|O codon|O 172|O of|O the|O rds|O gene|O have|O been|O identified|O in|O three|O families|O with|O autosomal|O dominantly|O inherited|O ,|O progressive|O macular|B-DISE dystrophy|I-DISE .|O
In|O summary|O ,|O our|O data|O suggest|O a|O role|O for|O some|O uncharacterized|O variants|O and|O rare|O forms|O of|O polymorphisms|O in|O determining|O ovarian|B-DISE cancer|I-DISE risk|O ,|O and|O highlight|O the|O necessity|O to|O screen|O for|O missense|O alterations|O as|O well|O as|O truncating|O mutations|O in|O this|O population|O .|O .|O
X|B-DISE -|I-DISE linked|I-DISE Adrenoleukodystrophy|I-DISE (|O X|B-DISE -|I-DISE ALD|I-DISE )|O is|O the|O most|O frequent|O peroxisomal|B-DISE disease|I-DISE .|O
The|O retinoblastoma|B-DISE -|O predisposition|O gene|O ,|O RB1|O ,|O segregates|O as|O an|O autosomal|O dominant|O trait|O with|O high|O (|O 90|O %|O )|O penetrance|O .|O
A|O C|O -|O to|O -|O T|O transition|O in|O exon|O 4|O of|O the|O PLP|O gene|O was|O found|O in|O 2|O affected|O males|O and|O two|O obligate|O carriers|O in|O a|O German|O family|O with|O Pelizaeus|B-DISE -|I-DISE Merzbacher|I-DISE disease|I-DISE .|O
Friedreich|B-DISE ataxia|I-DISE (|O FRDA|B-DISE )|O ,|O the|O most|O common|O autosomal|B-DISE recessive|I-DISE ataxia|I-DISE ,|O is|O caused|O in|O almost|O all|O cases|O by|O homozygous|O intronic|O expansions|O resulting|O in|O the|O loss|O of|O frataxin|O ,|O a|O mitochondrial|O protein|O conserved|O through|O evolution|O ,|O and|O involved|O in|O mitochondrial|O iron|O homeostasis|O .|O
In|O contrast|O ,|O the|O MSH2|O mutation|O was|O identified|O in|O 10|O of|O 20|O (|O 50|O %|O )|O separately|O identified|O colorectal|B-DISE families|O from|O Newfoundland|O .|O
The|O patient|O reported|O here|O is|O a|O human|O homologue|O of|O the|O Fas|O -|O null|O mouse|O ,|O inasmuch|O as|O she|O carries|O an|O autosomal|O homozygous|O mutation|O in|O the|O FAS|O gene|O and|O she|O shows|O the|O severe|O and|O accelerated|O ALPS|B-DISE phenotype|O .|O
For|O females|O there|O was|O a|O high|O risk|O of|O endometrial|B-DISE cancer|I-DISE (|O 0|O .|O 5|O at|O age|O 60|O years|O )|O and|O premenopausal|O ovarian|B-DISE cancer|I-DISE 0|O .|O 2|O at|O 50|O years|O .|O
The|O effects|O of|O the|O mutations|O at|O the|O mRNA|O and|O protein|O level|O were|O ascertained|O by|O RT|O -|O PCR|O and|O Western|O blot|O analyses|O .|O
Evaluation|O by|O postal|O questionnaires|O ,|O and|O pelvic|O radiography|O of|O 78|O HL|O -|O A|O 27W|O -|O positive|O blood|O donors|O selected|O from|O a|O group|O of|O apparently|O healthy|O subjects|O revealed|O 14|O who|O satisfied|O the|O criteria|O for|O definite|O ankylosing|B-DISE spondylitis|I-DISE .|O
Familial|B-DISE neurohypophyseal|I-DISE diabetes|I-DISE insipidus|I-DISE is|O an|O autosomal|B-DISE dominant|I-DISE disorder|I-DISE characterized|O by|O post|O -|O natal|O development|O of|O arginine|B-DISE vasopressin|I-DISE (|I-DISE AVP|I-DISE )|I-DISE deficiency|I-DISE due|O to|O mutations|O in|O the|O AVP|O gene|O .|O
Formation|O of|O irradiation|O -|O induced|O foci|O positive|O for|O BRCA1|O ,|O hRad50|O ,|O hMre11|O ,|O or|O p95|O was|O dramatically|O reduced|O in|O HCC|O /|O 1937|O breast|B-DISE cancer|I-DISE cells|O carrying|O a|O homozygous|O mutation|O in|O BRCA1|O but|O was|O restored|O by|O transfection|O of|O wild|O -|O type|O BRCA1|O .|O
FMRP|O is|O an|O RNA|O -|O binding|O protein|O that|O shuttles|O between|O the|O nucleus|O and|O cytoplasm|O .|O
Thus|O ,|O diverse|O point|O mutations|O may|O account|O largely|O for|O the|O phenotypic|O heterogeneity|O of|O G6PD|B-DISE deficiency|I-DISE .|O .|O
Remarkably|O ,|O a|O previously|O unreported|O deficient|O variant|O ,|O G6PD|O Orissa|O (|O 44|O Ala|O -|O -|O Gly|O )|O ,|O is|O responsible|O for|O most|O of|O the|O G6PD|B-DISE deficiency|I-DISE in|O tribal|O Indian|O populations|O but|O is|O not|O found|O in|O urban|O populations|O ,|O where|O most|O of|O the|O G6PD|B-DISE deficiency|I-DISE is|O due|O to|O the|O G6PD|O Mediterranean|O (|O 188|O Ser|O -|O -|O Phe|O )|O variant|O .|O
We|O examined|O somatic|O mutations|O of|O the|O adenomatous|B-DISE polyposis|I-DISE coli|I-DISE (|O APC|O )|O gene|O in|O 63|O colorectal|B-DISE tumors|I-DISE (|O 16|O adenomas|B-DISE and|O 47|O carcinomas|B-DISE )|O developed|O in|O familial|B-DISE adenomatous|I-DISE polyposis|I-DISE (|O FAP|B-DISE )|O and|O non|O -|O FAP|B-DISE patients|O .|O
The|O I1307K|O APC|O gene|O variant|O was|O found|O in|O 6|O .|O 1|O %|O of|O American|O Jews|O ,|O 28|O %|O of|O their|O familial|O colorectal|B-DISE cancer|I-DISE cases|O ,|O but|O not|O in|O non|O -|O Jews|O .|O
Phenylketonuria|B-DISE (|O PKU|B-DISE )|O is|O an|O autosomal|O recessive|O disease|O due|O to|O deficiency|B-DISE of|I-DISE a|I-DISE hepatic|I-DISE enzyme|I-DISE ,|O phenylalanine|O hydroxylase|O PAH|O .|O
CONCLUSIONS|O :|O In|O a|O population|O of|O white|O adults|O of|O northern|O European|O ancestry|O ,|O 0|O .|O 5|O percent|O were|O homozygous|O for|O the|O C282Y|O mutation|O in|O the|O HFE|O gene|O .|O
These|O studies|O suggest|O that|O the|O genes|O for|O Factor|O B|O and|O C2|B-DISE deficiency|I-DISE are|O located|O outside|O those|O for|O HLA|O ,|O that|O the|O order|O of|O genese|O is|O HLA|O -|O A|O ,|O -|O B|O ,|O -|O D|O ,|O Factor|O B|O allotype|O ,|O C2|B-DISE deficiency|I-DISE ,|O that|O the|O genes|O coding|O for|O C2|B-DISE deficiency|I-DISE and|O Factor|O B|O allotypes|O are|O approximately|O 3|O -|O -|O 5|O centimorgans|O from|O the|O HLA|O -|O A|O and|O HLA|O -|O B|O loci|O ,|O and|O that|O the|O apparent|O lack|O of|O recombinants|O between|O the|O Factor|O B|O gene|O and|O C2|B-DISE deficiency|I-DISE gene|O suggests|O that|O these|O two|O genes|O lie|O in|O close|O proximity|O to|O one|O another|O .|O .|O
It|O was|O rare|O ,|O as|O not|O observed|O in|O controls|O ,|O but|O not|O segregating|O with|O the|O BFIC|B-DISE phenotype|O .|O .|O
Myotonic|B-DISE dystrophy|I-DISE ,|O or|O dystrophia|B-DISE myotonica|I-DISE (|O DM|B-DISE )|O ,|O is|O an|O autosomal|O dominant|O multisystem|B-DISE disorder|I-DISE caused|O by|O the|O expansion|O of|O a|O CTG|O trinucleotide|O repeat|O in|O the|O 3|O '|O untranslated|O region|O of|O the|O DMPK|O protein|O kinase|O gene|O on|O chromosome|O 19q13|O .|O 3|O refs|O 1|O -|O 3|O .|O
The|O demonstration|O of|O both|O the|O diagnostic|O and|O prognostic|O value|O of|O MEFV|O analysis|O and|O particular|O modes|O of|O inheritance|O should|O lead|O to|O new|O ways|O for|O management|O of|O FMF|B-DISE -|O including|O genetic|O counseling|O and|O therapeutic|O decisions|O in|O affected|O families|O .|O .|O
Our|O data|O indicate|O for|O the|O first|O time|O that|O beta|O -|O catenin|O accumulation|O may|O play|O a|O role|O in|O the|O development|O of|O hepatoblastoma|B-DISE and|O that|O activating|O mutations|O of|O the|O beta|O -|O catenin|O gene|O may|O substitute|O biallelic|O APC|O inactivation|O in|O this|O tumor|B-DISE type|O .|O
Diagnosis|O is|O usually|O based|O on|O the|O VLCFA|O levels|O in|O plasma|O or|O cultured|O skin|O fibroblasts|O in|O both|O patients|O and|O carriers|O .|O
Mutations|O at|O the|O PEPD|O locus|O cause|O prolidase|B-DISE deficiency|I-DISE (|O McKusick|O 170100|O )|O ,|O a|O rare|B-DISE autosomal|I-DISE recessive|I-DISE disorder|I-DISE characterized|O by|O iminodipeptiduria|B-DISE ,|O skin|B-DISE ulcers|I-DISE ,|O mental|B-DISE retardation|I-DISE ,|O and|O recurrent|O infections|B-DISE .|O
We|O present|O here|O the|O effect|O ,|O on|O emerin|O protein|O expression|O ,|O of|O two|O missense|O mutations|O identified|O in|O unrelated|O EDMD|B-DISE patients|O .|O
The|O hereditary|B-DISE breast|I-DISE and|I-DISE ovarian|I-DISE cancer|I-DISE syndrome|O is|O associated|O with|O a|O high|O frequency|O of|O BRCA1|O mutations|O .|O
The|O results|O demonstrated|O that|O the|O genetic|O heterogeneity|O of|O G6PD|B-DISE deficiency|I-DISE was|O high|O in|O this|O area|O .|O .|O
Our|O findings|O ,|O thus|O ,|O suggest|O that|O PDGF|O receptors|O could|O be|O a|O target|O for|O pharmacological|O treatment|O of|O DFSP|O and|O giant|B-DISE cell|I-DISE fibroblastoma|I-DISE ,|O e|O .|O g|O .|O ,|O through|O the|O use|O of|O PDGF|O receptor|O kinase|O inhibitors|O such|O as|O CGP57148B|O .|O .|O
In|O situ|O hybridization|O mapping|O locates|O the|O fragile|O site|O between|O 150|O kb|O and|O 600|O kb|O distal|O to|O FRAXA|O .|O
Two|O other|O Mexican|O males|O with|O G6PD|B-DISE deficiency|I-DISE were|O found|O to|O have|O the|O same|O mutation|O .|O
Keratosis|B-DISE also|O affects|O other|O sites|O such|O as|O elbows|O and|O knees|O .|O
ATP7B|O ,|O the|O gene|O altered|O in|O Wilson|B-DISE disease|I-DISE (|O WD|B-DISE )|O patients|O ,|O lies|O in|O a|O block|O of|O homology|O shared|O between|O human|O chromosome|O 13q14|O and|O the|O central|O region|O of|O mouse|O chromosome|O 14|O .|O
The|O serum|O ferritin|O levels|O in|O the|O four|O other|O homozygous|O patients|O remained|O in|O the|O normal|O range|O .|O
Thus|O ,|O mutations|O resulting|O in|O truncated|O proteins|O may|O lead|O to|O a|O higher|O risk|O of|O RCC|B-DISE in|O VHL|B-DISE patients|O .|O .|O
We|O propose|O that|O iron|O -|O dependent|O self|O -|O assembly|O of|O recombinant|O mYfh1p|O reflects|O a|O physiological|O role|O for|O frataxin|O in|O mitochondrial|O iron|O sequestration|O and|O bioavailability|O .|O .|O
The|O locus|O for|O non|O -|O syndromic|O sensorineural|B-DISE hearing|I-DISE loss|I-DISE with|O EVA|B-DISE has|O been|O mapped|O to|O the|O same|O chromosomal|O region|O ,|O 7q31|O ,|O as|O the|O Pendred|B-DISE syndrome|I-DISE locus|O .|O
Despite|O heterozygosity|O for|O the|O abnormal|O allele|O ,|O lymphocytes|O from|O ALPS|B-DISE patients|O showed|O markedly|O decreased|O FADD|O association|O and|O a|O loss|O of|O caspase|O recruitment|O and|O activation|O after|O CD95|O crosslinking|O .|O
Heterozygous|O mutations|O in|O the|O human|O PAX6|O gene|O result|O in|O various|O phenotypes|O ,|O including|O aniridia|B-DISE ,|O Peter|B-DISE '|I-DISE s|I-DISE anomaly|I-DISE ,|O autosomal|B-DISE dominant|I-DISE keratitis|I-DISE ,|O and|O familial|O foveal|O dysplasia|B-DISE .|O
RESULTS|O :|O Sixteen|O of|O the|O subjects|O (|O 0|O .|O 5|O percent|O )|O were|O homozygous|O for|O the|O C282Y|O mutation|O ,|O and|O 424|O (|O 14|O .|O 1|O percent|O )|O were|O heterozygous|O .|O
It|O is|O characterized|O by|O a|O complete|O failure|O to|O develop|O photoreceptor|O discs|O and|O outer|O segments|O ,|O downregulation|O of|O rhodopsin|O and|O apoptotic|O loss|O of|O photoreceptor|O cells|O .|O
In|O addition|O to|O highlighting|O the|O effect|O of|O the|O normal|O repeat|O length|O upon|O AO|O in|O maternally|O inherited|O HD|B-DISE and|O in|O male|O patients|O ,|O we|O show|O that|O the|O APOE|O epsilon2epsilon3|O genotype|O is|O associated|O with|O significantly|O earlier|O AO|O in|O males|O than|O in|O females|O .|O
Significant|O within|O -|O family|O association|O of|O CYP2D6|O *|O 4|O alleles|O and|O AS|B-DISE was|O demonstrated|O .|O
In|O contrast|O ,|O a|O common|O haplotype|O was|O identified|O at|O the|O two|O flanking|O markers|O (|O CA5|O and|O D2S288|O )|O in|O eight|O of|O the|O Newfoundland|O families|O .|O
This|O article|O reviews|O the|O clinical|O and|O molecular|O genetics|O of|O primary|B-DISE dystonias|I-DISE ,|O critically|O discusses|O present|O findings|O ,|O and|O proposes|O referring|O to|O the|O known|O forms|O ,|O most|O of|O which|O can|O be|O distinguished|O by|O genetic|O criteria|O ,|O as|O dystonias|O 1|O -|O 12|O .|O .|O
Germ|O -|O line|O mutations|O of|O the|O BRCA1|O gene|O predispose|O women|O to|O early|B-DISE -|I-DISE onset|I-DISE breast|I-DISE and|I-DISE ovarian|I-DISE cancer|I-DISE by|O compromising|O the|O gene|O '|O s|O presumptive|O function|O as|O a|O tumor|O suppressor|O .|O
Thus|O ,|O the|O location|O of|O mutations|O within|O APT1|O strongly|O influences|O the|O development|O and|O the|O severity|O of|O ALPS|B-DISE .|O .|O
We|O report|O here|O the|O characterization|O of|O a|O transgene|O insertion|O (|O Epstein|B-DISE -|I-DISE Barr|I-DISE virus|I-DISE Latent|O Membrane|O Protein|O 2A|O ,|O LMP2A|O )|O into|O mouse|O chromosome|O 7C|O ,|O which|O has|O resulted|O in|O mouse|O models|O for|O PWS|B-DISE and|O AS|B-DISE dependent|O on|O the|O sex|O of|O the|O transmitting|O parent|O .|O
While|O PLS|B-DISE cases|O have|O been|O identified|O throughout|O the|O world|O ,|O HMS|B-DISE has|O only|O been|O described|O among|O descendants|O of|O a|O religious|O isolate|O originally|O from|O Cochin|O ,|O India|O .|O
Of|O the|O many|O palmoplantar|B-DISE keratoderma|I-DISE (|O PPK|B-DISE )|O conditions|O ,|O only|O Papillon|B-DISE -|I-DISE Lefevre|I-DISE syndrome|I-DISE (|O PLS|B-DISE )|O and|O Haim|B-DISE -|I-DISE Munk|I-DISE syndrome|I-DISE (|O HMS|B-DISE )|O are|O associated|O with|O premature|B-DISE periodontal|I-DISE destruction|I-DISE .|O
To|O our|O knowledge|O this|O is|O the|O first|O documented|O case|O of|O an|O association|O between|O discoid|B-DISE lupus|I-DISE erythematosus|I-DISE and|O C5|B-DISE deficiency|I-DISE .|O .|O
In|O the|O present|O report|O we|O analyze|O 40|O (|O 12|O original|O and|O 28|O newly|O identified|O )|O Swedish|O families|O with|O hereditary|O prostate|B-DISE cancer|I-DISE (|O HPC|O )|O that|O ,|O on|O the|O basis|O of|O 40|O markers|O spanning|O a|O 25|O -|O cM|O interval|O within|O 1q24|O -|O 25|O ,|O have|O evidence|O of|O linkage|O .|O
As|O yet|O ,|O our|O understanding|O of|O HFE|O function|O in|O iron|O homeostasis|O is|O only|O partial|O ;|O an|O even|O more|O open|O question|O is|O its|O possible|O role|O in|O the|O immune|O system|O .|O
We|O identified|O a|O new|O splice|O -|O site|O mutation|O affecting|O intron|O 4|O of|O the|O PDS|O gene|O ,|O at|O nucleotide|O position|O 639|O +|O 7|O .|O
The|O event|O triggering|O malignant|O proliferation|O in|O 70|O %|O of|O retinoblastoma|B-DISE tumours|O is|O loss|O of|O heterozygosity|O for|O chromosome|O 13q14|O ,|O whereby|O the|O normal|O retinoblastoma|B-DISE gene|O (|O RB1|O )|O allele|O is|O lost|O and|O an|O already|O mutated|O RB1|O allele|O remains|O in|O the|O tumour|O .|O
Thirty|O -|O seven|O families|O with|O four|O or|O more|O cases|O of|O breast|B-DISE cancer|I-DISE or|O breast|B-DISE and|I-DISE ovarian|I-DISE cancer|I-DISE were|O analyzed|O for|O mutations|O in|O BRCA1|O .|O
Post|O -|O mortem|O examination|O of|O one|O of|O the|O patients|O showed|O extensive|O myelin|B-DISE loss|I-DISE in|O these|O columns|O .|O
We|O report|O on|O nine|O patients|O with|O craniofrontonasal|B-DISE dysplasia|I-DISE CFND|B-DISE .|O
Monoclonal|O antibodies|O which|O recognize|O different|O epitopes|O on|O either|O titin|O or|O nebulin|O show|O normal|O staining|O patterns|O on|O frozen|O sections|O of|O three|O muscle|O biopsies|O of|O Duchenne|B-DISE muscular|I-DISE dystrophy|I-DISE DMD|B-DISE .|O
The|O adenomatous|B-DISE polyposis|I-DISE coli|I-DISE gene|O (|O APC|O )|O is|O mutated|O in|O familial|B-DISE adenomatous|I-DISE polyposis|I-DISE and|O in|O sporadic|O colorectal|B-DISE tumors|I-DISE .|O
Other|O neoplasms|B-DISE that|O may|O be|O associated|O with|O this|O gene|O in|O heterozygotes|O include|O pancreatic|B-DISE ,|I-DISE basal|I-DISE cell|I-DISE ,|I-DISE colonic|I-DISE ,|I-DISE breast|I-DISE ,|I-DISE and|I-DISE cervical|I-DISE carcinomas|I-DISE .|O .|O
The|O present|O study|O supports|O the|O view|O that|O circulating|O lymphocytes|O give|O easy|O access|O to|O PAH|O gene|O transcripts|O whose|O nucleotide|O sequence|O is|O identical|O to|O that|O reported|O in|O liver|O and|O therefore|O represent|O a|O useful|O tool|O for|O molecular|O genetic|O studies|O in|O phenylketonuria|B-DISE .|O .|O
We|O analyzed|O the|O HEXA|O gene|O of|O one|O pseudodeficient|O subject|O and|O identified|O both|O a|O C739|O -|O to|O -|O T|O substitution|O that|O changes|O Arg247|O -|O -|O -|O -|O Trp|O on|O one|O allele|O and|O a|O previously|O identified|O Tay|B-DISE -|I-DISE Sachs|I-DISE disease|I-DISE mutation|O on|O the|O second|O allele|O .|O
Here|O we|O report|O that|O FCM|O -|O WASP|O analysis|O in|O monocytes|O could|O be|O a|O useful|O tool|O for|O the|O WAS|B-DISE carrier|O diagnosis|O .|O
Coexpression|O of|O hbeta|O (|O 1|O )|O did|O not|O significantly|O alter|O current|O decay|O or|O recovery|O from|O inactivation|O of|O wild|O -|O type|O hH1|O ;|O however|O ,|O it|O further|O shifted|O the|O V|O (|O 1|O /|O 2|O )|O and|O accelerated|O the|O recovery|O from|O inactivation|O of|O T1620M|O .|O
Investigating|O 82|O strictly|O selected|O sporadic|O cases|O of|O PMD|B-DISE ,|O we|O found|O PLP|O mutations|O in|O 77|O %|O ;|O complete|O PLP|O -|O gene|O duplications|O were|O the|O most|O frequent|O abnormality|O (|O 62|O %|O )|O ,|O whereas|O point|O mutations|O in|O coding|O or|O splice|O -|O site|O regions|O of|O the|O gene|O were|O involved|O less|O frequently|O 38|O %|O .|O
These|O are|O located|O in|O the|O human|O 15q11|O -|O q13|O and|O mouse|O 7C|O regions|O ,|O in|O close|O proximity|O to|O NDN|O /|O Ndn|O .|O
To|O study|O this|O dosage|O effect|O ,|O we|O characterized|O two|O PAX6|O mutations|O in|O a|O family|O segregating|O aniridia|B-DISE and|O a|O milder|O syndrome|O consisting|O of|O congenital|B-DISE cataracts|I-DISE and|O late|B-DISE onset|I-DISE corneal|I-DISE dystrophy|I-DISE .|O
Mutation|O analysis|O of|O ACTC|O revealed|O an|O Ala295Ser|O mutation|O in|O exon|O 5|O close|O to|O 2|O missense|O mutations|O recently|O described|O to|O cause|O the|O inherited|O form|O of|O idiopathic|B-DISE dilated|I-DISE cardiomyopathy|I-DISE IDC|O .|O
Allele|O -|O specific|O oligonucleotide|O hybridization|O confirmed|O homozygosity|O in|O the|O proband|O .|O
DNA|O analysis|O for|O Prader|B-DISE -|I-DISE Willi|I-DISE syndrome|I-DISE showed|O no|O abnormalities|O .|O
Treatment|O of|O mitotically|O stimulated|O lymphocytes|O with|O cyclosporin|O ,|O which|O inhibits|O proliferation|O ,|O blocked|O the|O increase|O in|O p19|O /|O nm23|O ;|O treatment|O of|O the|O leukemia|B-DISE cell|O line|O HL|O -|O 60|O with|O dimethylsulfoxide|O ,|O which|O induces|O terminal|O differentiation|O ,|O resulted|O in|O diminished|O levels|O of|O p19|O /|O nm23|O .|O
However|O ,|O previous|O studies|O have|O focused|O on|O mildly|O affected|O patients|O and|O there|O is|O still|O no|O report|O of|O two|O mutant|O PEX1|O alleles|O in|O any|O Zellweger|B-DISE syndrome|I-DISE patient|O .|O
Expansion|O of|O a|O CTG|O trinucleotide|O repeat|O in|O the|O 3|O '|O UTR|O of|O the|O gene|O DMPK|O at|O the|O DM1|O locus|O on|O chromosome|O 19|O causes|O myotonic|B-DISE dystrophy|I-DISE ,|O a|O dominantly|O inherited|O disease|O characterized|O by|O skeletal|O muscle|B-DISE dystrophy|I-DISE and|O myotonia|B-DISE ,|O cataracts|B-DISE and|O cardiac|B-DISE conduction|I-DISE defects|I-DISE .|O
Bipolar|B-DISE affective|I-DISE disorder|I-DISE (|O BPAD|B-DISE ;|O manic|B-DISE -|I-DISE depressive|I-DISE illness|I-DISE )|O is|O characterized|O by|O episodes|O of|O mania|B-DISE and|O /|O or|O hypomania|B-DISE interspersed|O with|O periods|O of|O depression|B-DISE .|O
This|O report|O represents|O the|O first|O cases|O of|O C7|B-DISE deficiency|I-DISE associated|O with|O infectious|B-DISE complications|I-DISE and|O suggests|O that|O bactericidal|O activity|O may|O be|O important|O in|O host|O defense|O against|O bacteremic|O neisseria|B-DISE infections|I-DISE .|O .|O
CONCLUSIONS|O :|O This|O study|O confirms|O an|O increased|O risk|O of|O cancer|B-DISE ,|O especially|O non|B-DISE -|I-DISE Hodgkin|I-DISE '|I-DISE s|I-DISE lymphoma|I-DISE ,|O probably|O attributable|O to|O defective|O immunity|O ,|O among|O patients|O with|O CHH|B-DISE .|O .|O
The|O 4|O .|O 7|O kb|O CTSC|O gene|O consists|O of|O two|O exons|O .|O
Here|O ,|O we|O explore|O the|O cell|O origin|O and|O aetiology|O of|O this|O common|O human|O skin|B-DISE tumour|I-DISE .|O
Development|O of|O knockout|O and|O knockin|O mouse|O models|O may|O provide|O further|O insights|O into|O the|O functional|O evolution|O of|O this|O gene|O .|O .|O
Association|O of|O alleles|O of|O the|O CYP2D6|O gene|O was|O examined|O by|O both|O case|O -|O control|O and|O within|O -|O family|O means|O .|O
The|O present|O studies|O suggest|O that|O a|O skewed|O X|O -|O chromosomal|O inactivation|O pattern|O observed|O in|O WAS|B-DISE carrier|O peripheral|O blood|O cells|O is|O not|O fixed|O at|O the|O hemopoietic|O stem|O cell|O level|O but|O progresses|O after|O the|O lineage|O commitment|O .|O .|O
CETP|B-DISE deficiency|I-DISE was|O not|O found|O in|O six|O unrelated|O subjects|O with|O elevated|O HDL|O cholesterol|O levels|O who|O were|O from|O different|O parts|O of|O the|O United|O States|O .|O
We|O aimed|O to|O determine|O whether|O the|O common|O germline|O mutations|O of|O BRCA1|O or|O BRCA2|O in|O Ashkenazi|O Jewish|O men|O predisposed|O them|O to|O prostate|B-DISE cancer|I-DISE .|O
Thus|O ,|O a|O tertiary|O structural|O model|O of|O human|O GALNS|O was|O constructed|O from|O the|O X|O -|O ray|O crystal|O structure|O of|O N|O -|O acetylgalacto|O -|O samine|O -|O 4|O -|O sulfatase|O and|O arylsulfatase|O A|O ,|O using|O homology|O modeling|O ,|O and|O 32|O missense|O mutations|O were|O investigated|O .|O
The|O majority|O of|O patients|O were|O compound|O heterozygotes|O for|O two|O mutations|O ,|O and|O there|O was|O no|O common|O founder|O mutation|O .|O
Abnormal|O CAG|O expansions|O in|O the|O IT|O -|O 15|O gene|O are|O associated|O with|O Huntington|B-DISE disease|I-DISE HD|B-DISE .|O
These|O selection|O pressures|O could|O be|O due|O to|O infectious|B-DISE diseases|I-DISE ,|O environmental|O conditions|O ,|O or|O other|O genetic|B-DISE disorders|I-DISE such|O as|O anemia|B-DISE .|O .|O
Thus|O ,|O the|O high|O frequency|O of|O mucosal|O overgrowth|O in|O AGU|B-DISE patients|O does|O not|O appear|O to|O be|O directly|O associated|O with|O lysosomal|O storage|O or|O with|O alterations|O in|O the|O level|O of|O AGA|O expression|O .|O .|O
These|O observations|O indicated|O that|O C9|O may|O play|O a|O critical|O role|O in|O haemolytic|O attacks|O in|O patients|O with|O PNH|B-DISE and|O that|O characteristic|O haemolysis|B-DISE in|O PNH|B-DISE may|O be|O tempered|O by|O coexisting|O C9|B-DISE deficiency|I-DISE .|O .|O
Mutations|O were|O found|O in|O 35|O (|O 53|O %|O )|O of|O the|O 66|O families|O studied|O .|O
We|O identified|O four|O novel|O mutations|O in|O three|O unrelated|O patients|O .|O
A|O C|O -|O -|O greater|O than|O G|O transversion|O has|O been|O found|O in|O exon|O 3|O of|O the|O PLP|O gene|O of|O affected|O males|O and|O their|O mother|O in|O a|O single|O sibship|O with|O Pelizaeus|B-DISE -|I-DISE merzbacher|I-DISE disease|I-DISE PMD|B-DISE .|O
We|O have|O analyzed|O the|O 27|O exons|O and|O the|O promoter|O region|O of|O the|O RB1|O gene|O in|O familial|B-DISE or|I-DISE sporadic|I-DISE bilateral|I-DISE retinoblastoma|I-DISE by|O using|O single|O -|O strand|O conformation|O polymorphism|O analysis|O .|O
The|O significant|O relationship|O among|O genotype|O ,|O biochemical|O phenotype|O ,|O and|O cognitive|O performance|O observed|O in|O the|O present|O study|O is|O of|O importance|O for|O the|O development|O of|O an|O optimal|O strategy|O for|O future|O treatment|O of|O females|O with|O PKU|B-DISE who|O plan|O pregnancy|O .|O .|O
Little|O effort|O has|O yet|O been|O made|O to|O find|O alterations|O involving|O this|O gene|O in|O human|O solid|B-DISE tumors|I-DISE .|O
The|O principal|O biochemical|O abnormality|O is|O the|O accumulation|O of|O saturated|O very|O -|O long|O -|O chain|O fatty|O acids|O (|O VLCFAs|O :|O >|O C22|O :|O 0|O ,|O mainly|O C26|O :|O 0|O )|O ,|O which|O is|O due|O to|O impaired|O capacity|O for|O beta|O -|O oxidation|O in|O peroxisomes|O .|O
Both|O patients|O had|O a|O family|O history|O of|O breast|B-DISE or|I-DISE ovarian|I-DISE cancer|I-DISE .|O
Most|O mutations|O are|O linked|O to|O specific|O haplotypes|O ,|O as|O defined|O by|O eight|O polymorphic|O restriction|O sites|O in|O the|O PAH|O gene|O .|O
The|O mutation|O causing|O myotonic|B-DISE dystrophy|I-DISE (|O DM|B-DISE )|O has|O been|O identified|O as|O an|O amplification|O of|O an|O unstable|O trinucleotide|O (|O CTG|O )|O n|O repeat|O in|O over|O 99|O %|O of|O the|O global|O DM|B-DISE population|O .|O
We|O recently|O reported|O that|O HFE|O ,|O the|O protein|O defective|O in|O HH|B-DISE ,|O was|O physically|O associated|O with|O the|O transferrin|O receptor|O (|O TfR|O )|O in|O duodenal|O crypt|O cells|O and|O proposed|O that|O mutations|O in|O HFE|O attenuate|O the|O uptake|O of|O transferrin|O -|O bound|O iron|O from|O plasma|O by|O duodenal|O crypt|O cells|O ,|O leading|O to|O up|O -|O regulation|O of|O transporters|O for|O dietary|O iron|O .|O
A|O higher|O percentage|O of|O mutations|O occurred|O at|O less|O stringently|O conserved|O sites|O ,|O including|O silent|O mutations|O of|O the|O last|O nucleotide|O of|O exons|O ,|O mutations|O in|O nucleotides|O other|O than|O the|O conserved|O AG|O and|O GT|O in|O the|O consensus|O splice|O sites|O ,|O and|O creation|O of|O splice|O -|O acceptor|O or|O splice|O -|O donor|O sites|O in|O either|O introns|O or|O exons|O .|O
The|O R1|O domain|O mutation|O prevents|O interaction|O of|O EGR2|O with|O the|O NAB|O co|O -|O repressors|O and|O thereby|O increases|O transcriptional|O activity|O .|O
Like|O APC|O ,|O APC2|O regulates|O the|O formation|O of|O active|O betacatenin|O -|O Tcf|O complexes|O ,|O as|O demonstrated|O using|O transient|O transcriptional|O activation|O assays|O in|O APC|O -|O /|O -|O colon|B-DISE carcinoma|I-DISE cells|O .|O
We|O report|O the|O identification|O of|O a|O female|O patient|O with|O the|O X|O -|O linked|O recessive|O Lesch|B-DISE -|I-DISE Nyhan|I-DISE syndrome|I-DISE hypoxanthine|O phosphoribosyltransferase|O HPRT|B-DISE deficiency|I-DISE .|O
The|O phenotypic|O expression|O is|O highly|O variable|O ,|O childhood|O cerebral|O ALD|B-DISE (|O CCALD|O )|O and|O adrenomyeloneuropathy|B-DISE (|O AMN|B-DISE )|O being|O the|O main|O variants|O .|O
Six|O of|O the|O eight|O patients|O with|O the|O infantile|O ,|O severe|O form|O of|O the|O disease|O presented|O cardiac|O involvement|O ,|O a|O feature|O rarely|O associated|O with|O GM1|B-DISE -|I-DISE gangliosidosis|I-DISE .|O
The|O method|O is|O based|O on|O SSCP|O analysis|O of|O nested|O PCR|O fragments|O followed|O by|O sequence|O -|O determination|O reactions|O .|O
Three|O of|O these|O mutations|O were|O in|O the|O zinc|O finger|O domains|O of|O WT1|O .|O
FRDA|B-DISE is|O caused|O by|O a|O GAA|O triplet|O expansion|O in|O the|O first|O intron|O of|O the|O FRDA|O gene|O on|O chromosome|O 9q13|O in|O 97|O %|O of|O patients|O .|O
Patients|O were|O diagnosed|O at|O the|O Hospital|O Universitario|O Gregorio|O Maranon|O Madrid|O ,|O Spain|O .|O
PWS|B-DISE becomes|O apparent|O when|O genes|O on|O the|O paternally|O inherited|O chromosome|O are|O not|O expressed|O .|O
In|O the|O present|O study|O ,|O leukocyte|O DNA|O from|O 143|O patients|O with|O familial|O clustering|O of|O breast|B-DISE and|I-DISE /|I-DISE or|I-DISE ovarian|I-DISE cancer|I-DISE and|O tumour|O DNA|O from|O 96|O breast|B-DISE carcinomas|I-DISE were|O screened|O for|O base|O mutations|O in|O the|O estrogen|O receptor|O gene|O ESR|O .|O
GM1|B-DISE -|I-DISE gangliosidosis|I-DISE is|O a|O lysosomal|B-DISE storage|I-DISE disorder|I-DISE caused|O by|O deficiency|B-DISE of|I-DISE acid|I-DISE beta|I-DISE -|I-DISE galactosidase|I-DISE GLB1|I-DISE .|O
We|O have|O identified|O four|O mutations|O in|O each|O of|O the|O breast|B-DISE cancer|I-DISE -|O susceptibility|O genes|O ,|O BRCA1|O and|O BRCA2|O ,|O in|O French|O Canadian|O breast|B-DISE cancer|I-DISE and|O breast|B-DISE /|I-DISE ovarian|I-DISE cancer|I-DISE families|O from|O Quebec|O .|O
X|B-DISE -|I-DISE linked|I-DISE Emery|I-DISE -|I-DISE Dreifuss|I-DISE muscular|I-DISE dystrophy|I-DISE (|O EDMD|B-DISE )|O is|O a|O relatively|O rare|O benign|O neuromuscular|B-DISE disorder|I-DISE which|O can|O vary|O remarkably|O in|O onset|O ,|O course|O and|O severity|O .|O
In|O a|O second|O unrelated|O family|O with|O signs|O of|O PMD|B-DISE ,|O cytogenetic|O analysis|O showed|O a|O pericentric|O inversion|O of|O the|O X|O chromosome|O .|O
Pyruvate|O carboxylase|O (|O E|O .|O C|O .|O activity|O was|O determined|O in|O the|O circulating|O peripheral|O lymphocytes|O and|O cultured|O skin|O fibroblasts|O from|O the|O family|O of|O a|O patient|O with|O hepatic|O ,|O cerebral|O ,|O renal|O cortical|O ,|O leukocyte|O ,|O and|O fibroblast|O pyruvate|B-DISE carboxylase|I-DISE deficiency|I-DISE PC|O Portland|O deficiency|O .|O
In|O a|O family|O with|O three|O siblings|O ,|O one|O developed|O classical|O late|O infantile|B-DISE metachromatic|I-DISE leukodystrophy|I-DISE (|O MLD|B-DISE )|O ,|O fatal|O at|O age|O 5|O years|O ,|O with|O deficient|B-DISE arylsulfatase|I-DISE A|I-DISE (|O ARSA|O )|O activity|O and|O increased|O galactosylsulfatide|O (|O GS|O )|O excretion|O .|O
We|O identified|O two|O heterozygous|O insertion|O mutations|O in|O exon|O 1|O of|O TNFRSF11A|O in|O affected|O members|O of|O four|O families|O with|O FEO|B-DISE or|O familial|O Paget|B-DISE disease|I-DISE of|I-DISE bone|I-DISE PDB|B-DISE .|O
One|O family|O is|O homozygous|O ,|O three|O families|O are|O compound|O heterozygotes|O ,|O and|O two|O families|O are|O heterozygous|O but|O with|O no|O other|O mutation|O detected|O .|O
We|O discovered|O a|O missense|O mutation|O ,|O GCA|O to|O GTA|O (|O Ala|O 54|O Val|O )|O ,|O in|O exon|O 2|O in|O a|O neurofibrosarcoma|B-DISE patient|O (|O case|O 1|O )|O ,|O two|O missense|O mutations|O ,|O AAA|O to|O CAA|O (|O Lys|O 118|O Gln|O )|O and|O GAA|O to|O GGA|O (|O Glu|O 154|O Gly|O )|O in|O exon|O 5|O of|O another|O neurofibrosarcoma|B-DISE patient|O (|O case|O 2|O )|O ,|O and|O 3|O amino|O acid|O substitutions|O ,|O GTG|O to|O GCG|O (|O Val|O 179|O Ala|O )|O ,|O GTT|O to|O GCT|O (|O Val|O 181|O Ala|O )|O and|O TTC|O to|O CTC|O (|O Phe|O 186|O Leu|O )|O ,|O in|O a|O third|O neurofibrosarcoma|B-DISE patient|O case|O 3|O .|O
The|O remaining|O eight|O cases|O (|O 89|O %|O )|O of|O male|B-DISE breast|I-DISE cancer|I-DISE with|O a|O family|O history|O of|O breast|B-DISE /|I-DISE ovarian|I-DISE cancer|I-DISE in|O first|O -|O degree|O relatives|O remain|O unaccounted|O for|O by|O mutations|O in|O either|O the|O BRCA1|O gene|O or|O the|O BRCA2|O gene|O .|O .|O
Human|O APC2|O maps|O to|O chromosome|O 19p13|O .|O 3|O .|O
Furthermore|O ,|O his|O T|O lymphocytes|O proliferated|O normally|O in|O response|O to|O phytohemagglutinin|O ,|O concanavalin|O A|O ,|O and|O the|O combination|O of|O neuraminidase|O /|O galactose|O oxidase|O .|O
The|O PAX6|O gene|O is|O involved|O in|O ocular|O morphogenesis|O ,|O and|O PAX6|O mutations|O have|O been|O detected|O in|O various|O types|O of|O ocular|B-DISE anomalies|I-DISE ,|O including|O aniridia|B-DISE ,|O Peters|B-DISE anomaly|I-DISE ,|O corneal|B-DISE dystrophy|I-DISE ,|O congenital|B-DISE cataract|I-DISE ,|O and|O foveal|B-DISE hypoplasia|I-DISE .|O
The|O alteration|O found|O in|O the|O second|O exon|O of|O the|O gene|O in|O this|O family|O seems|O to|O be|O responsible|O for|O the|O disease|O ,|O as|O all|O individuals|O harboring|O the|O mutation|O had|O been|O previously|O diagnosed|O or|O have|O eventually|O developed|O FNDI|B-DISE .|O
With|O a|O new|O method|O we|O measured|O the|O saturated|O very|O long|O chain|O fatty|O acids|O in|O the|O plasma|O of|O adrenoleukodystrophy|B-DISE (|O ALD|B-DISE )|O hemizygotes|O ,|O ALD|B-DISE heterozygotes|O ,|O and|O controls|O .|O
Targeted|O deletion|O of|O Dm15|O ,|O the|O mouse|O orthologue|O of|O human|O DMPK|O ,|O produced|O mice|O with|O a|O mild|O myopathy|B-DISE and|O cardiac|B-DISE conduction|I-DISE abnormalities|I-DISE ,|O but|O without|O other|O features|O of|O myotonic|B-DISE dystrophy|I-DISE ,|O such|O as|O myotonia|B-DISE and|O cataracts|B-DISE .|O
Expression|O of|O FMRP|O in|O hair|O roots|O was|O studied|O by|O use|O of|O an|O FMRP|O -|O specific|O antibody|O test|O ,|O and|O the|O percentage|O of|O FMRP|O -|O expressing|O hair|O roots|O in|O controls|O and|O in|O male|O fragile|B-DISE X|I-DISE patients|O was|O determined|O .|O
Serum|O immunoglobulin|O levels|O were|O within|O normal|O limits|O in|O his|O parents|O and|O brother|O who|O were|O heterozygous|O for|O C2|B-DISE deficiency|I-DISE .|O
Two|O yeast|O artificial|O chromosomes|O (|O YACs|O )|O spanning|O a|O total|O distance|O of|O 1|O .|O 1|O megabase|O pairs|O of|O DNA|O around|O the|O MCC|O (|O for|O mutated|O in|O colorectal|B-DISE carcinoma|I-DISE )|O and|O APC|O (|O for|O adenomatous|B-DISE polyposis|I-DISE coli|I-DISE )|O genes|O at|O 5q21|O have|O been|O isolated|O and|O characterized|O .|O
After|O 1|O year|O he|O became|O obese|B-DISE despite|O a|O normal|O appetite|O .|O
The|O specific|O processing|O and|O accumulation|O of|O toxic|O fragments|O of|O N|O -|O terminal|O huntingtin|O in|O HD|B-DISE -|O affected|O striatal|O neurons|O ,|O especially|O in|O their|O neuronal|O processes|O and|O axonal|O terminals|O ,|O may|O contribute|O to|O the|O selective|O neuropathology|O of|O HD|B-DISE .|O .|O
The|O genetic|O defect|O is|O a|O CTG|O triplet|O repeat|O expansion|O in|O the|O 3|O '|O -|O untranslated|O region|O of|O the|O myotonic|B-DISE dystrophy|I-DISE protein|O kinase|O (|O DMPK|O )|O gene|O ,|O consisting|O of|O 15|O exons|O .|O
However|O ,|O a|O probable|O germline|O mutation|O in|O a|O pancreatic|B-DISE tumour|I-DISE cell|O line|O suggests|O a|O role|O for|O BRCA2|O in|O susceptibility|O to|O pancreatic|B-DISE cancer|I-DISE .|O .|O
The|O retinal|B-DISE degeneration|I-DISE mouse|O (|O gene|O symbol|O ,|O rd|O )|O is|O an|O animal|O model|O for|O certain|O forms|O of|O human|O hereditary|O retinopathies|B-DISE .|O
The|O patient|O has|O a|O previously|O uncharacterized|O submicroscopic|O deletion|O encompassing|O the|O CCG|O repeat|O ,|O the|O entire|O FMR1|O gene|O and|O about|O 2|O .|O 5|O megabases|O of|O flanking|O sequences|O .|O
Samples|O were|O tested|O for|O duplication|O of|O the|O PLP|O gene|O ,|O by|O interphase|O FISH|O ,|O in|O lymphocyte|O preparations|O from|O the|O proband|O ,|O his|O aunt|O and|O an|O amniotic|O fluid|O cell|O preparation|O from|O the|O fetus|O .|O
The|O gene|O for|O ataxia|B-DISE -|I-DISE telangiectasia|I-DISE ,|O ATM|O ,|O spans|O about|O 150|O kb|O of|O genomic|O DNA|O .|O
CONCLUSIONS|O :|O The|O incidence|O of|O each|O of|O the|O germline|O mutations|O in|O these|O prostate|B-DISE cancer|I-DISE patients|O closely|O matched|O their|O incidence|O (|O about|O 1|O %|O )|O in|O the|O general|O Ashkenazi|O Jewish|O population|O .|O
Biochemical|O analysis|O has|O demonstrated|O that|O the|O mobility|O and|O expression|O levels|O of|O the|O mutant|O forms|O of|O emerin|O are|O indistinguishable|O from|O that|O of|O wild|O -|O type|O emerin|O ,|O but|O that|O they|O have|O weakened|O interactions|O with|O nuclear|O lamina|O components|O .|O
To|O study|O its|O role|O in|O adipogenesis|O and|O obesity|B-DISE ,|O we|O examined|O Hmgic|O expression|O in|O the|O adipose|O tissue|O of|O adult|O ,|O obese|B-DISE mice|O .|O
Germline|O mutations|O in|O BRCA1|O are|O responsible|O for|O most|O cases|O of|O inherited|B-DISE breast|I-DISE and|I-DISE ovarian|I-DISE cancer|I-DISE .|O
We|O used|O RT|O -|O PCR|O to|O amplify|O the|O Hgd|O cDNA|O from|O Hgd|O aku|B-DISE /|O Hgd|O (|O aku|B-DISE )|O mice|O .|O
We|O describe|O three|O HEXA|O mutations|O associated|O with|O infantile|B-DISE Tay|I-DISE -|I-DISE Sachs|I-DISE disease|I-DISE (|O TSD|B-DISE )|O in|O three|O unrelated|O nonconsanguineous|O Chinese|O families|O .|O
In|O this|O family|O ,|O a|O missense|O mutation|O in|O SCN1B|O cosegregates|O with|O the|O GEFS|B-DISE +|I-DISE phenotype|O .|O
DNA|O sequencing|O confirmed|O all|O alterations|O represented|O by|O aberrant|O bands|O .|O
Furthermore|O ,|O in|O contrast|O to|O the|O normal|O DMPK|O 3|O '|O -|O UTR|O mRNA|O ,|O a|O mutant|O DMPK|O 3|O '|O -|O UTR|O mRNA|O with|O CUG|O (|O 200|O )|O selectively|O inhibited|O myogenic|O differentiation|O of|O C2C12|O myoblasts|O .|O
Germline|O mutations|O of|O the|O adenomatous|B-DISE polyposis|I-DISE coli|I-DISE (|O APC|O )|O tumor|B-DISE -|O suppressor|O gene|O result|O in|O familial|B-DISE adenomatous|I-DISE polyposis|I-DISE FAP|B-DISE .|O
Furthermore|O ,|O tissues|O from|O DM|B-DISE patients|O exhibit|O somatic|B-DISE mosaicism|I-DISE that|O increases|O with|O age|O .|O
The|O other|O mutation|O is|O a|O G|O -|O to|O -|O A|O transition|O resulting|O in|O an|O Arg170|O -|O to|O -|O Gln|O substitution|O .|O
In|O other|O cases|O as|O well|O ,|O a|O correlation|O was|O found|O between|O the|O amount|O of|O normal|O or|O mutant|O WASP|O present|O and|O the|O phenotypes|O of|O the|O affected|O individuals|O .|O
Imprinting|O of|O this|O region|O involves|O a|O bipartite|O '|O imprinting|O centre|O '|O (|O IC|O )|O ,|O which|O overlaps|O SNRPN|O refs|O 10|O ,|O 11|O .|O
We|O described|O 6|O patients|O (|O from|O 3|O families|O )|O affected|O with|O cerebrotendinous|B-DISE xanthomatosis|I-DISE CTX|B-DISE .|O
In|O the|O remaining|O cases|O three|O different|O variants|O were|O identified|O .|O
We|O infer|O that|O the|O coexistence|O of|O the|O two|O mutations|O is|O responsible|O for|O enzyme|B-DISE deficiency|I-DISE in|O G6PD|O A|O -|O because|O they|O act|O synergistically|O in|O causing|O instability|O of|O the|O enzyme|O .|O .|O
To|O address|O the|O molecular|O basis|O of|O disease|O in|O Zellweger|B-DISE syndrome|I-DISE patients|O from|O CG1|O ,|O we|O examined|O all|O 24|O PEX1|O exons|O in|O four|O patients|O ,|O including|O both|O patients|O that|O have|O mutations|O in|O PMP70|O .|O
Immunochemical|O studies|O demonstrated|O that|O the|O Sit|O (|O a|O )|O epitopes|O reside|O on|O platelet|O glycoprotein|O (|O GP|O )|O Ia|O .|O
Normal|O feline|O beta|O -|O glucuronidase|O cDNA|O was|O cloned|O and|O characterized|O ,|O and|O amplified|O from|O affected|O cat|O fibroblasts|O by|O reverse|O transcription|O coupled|O polymerase|O chain|O reaction|O .|O
Two|O brothers|O ,|O 6|O and|O 13|O years|O old|O ,|O had|O histidinemia|B-DISE .|O
Myotonic|B-DISE dystrophy|I-DISE (|O DM|B-DISE )|O is|O the|O most|O prevalent|O inherited|O neuromuscular|B-DISE disease|I-DISE in|O adults|O .|O
At|O least|O two|O of|O these|O mutations|O have|O been|O identified|O on|O two|O different|O chromosome|O 19p13|O haplotypes|O and|O thus|O represent|O recurrent|O mutations|O .|O
So|O far|O 17|O mutations|O have|O been|O characterised|O in|O AKU|B-DISE patients|O of|O different|O ethnic|O origin|O .|O
Abnormalities|O of|O chromosome|O region|O 15q11|O -|O 13|O are|O associated|O with|O Angelman|B-DISE syndrome|I-DISE (|O AS|B-DISE )|O and|O Prader|B-DISE -|I-DISE Willi|I-DISE syndrome|I-DISE PWS|B-DISE .|O
These|O results|O suggest|O a|O large|O homozygous|O deletion|O (|O at|O least|O 30|O kb|O )|O in|O the|O patient|O .|O
At|O least|O 75|O %|O of|O these|O tumours|B-DISE possess|O mutations|O affecting|O the|O amino|O -|O terminal|O segment|O ,|O normally|O involved|O in|O phosphorylation|O -|O dependent|O ,|O ubiquitin|O -|O mediated|O degradation|O of|O the|O protein|O .|O
We|O conclude|O that|O persons|O with|O PROS1|O gene|O defects|O and|O protein|B-DISE S|I-DISE deficiency|I-DISE are|O at|O increased|O risk|O of|O thrombosis|B-DISE and|O that|O free|O protein|O S|O estimation|O offers|O the|O most|O reliable|O way|O of|O diagnosing|O the|O deficiency|O .|O
CLINICAL|O RELEVANCE|O :|O Identification|O of|O mutations|O in|O the|O XLRS1|O gene|O and|O expanded|O information|O on|O clinical|O manifestations|O will|O facilitate|O early|O diagnosis|O ,|O appropriate|O early|O therapy|O ,|O and|O genetic|O counseling|O regarding|O the|O prognosis|O of|O XLRS|B-DISE .|O .|O
Moreover|O ,|O we|O were|O able|O to|O restore|O the|O peroxisomal|O beta|O -|O oxidation|O defect|O in|O the|O liver|O of|O ALDP|O -|O deficient|O mice|O by|O stimulation|O of|O ALDRP|O and|O PMP70|O gene|O expression|O through|O a|O dietary|O treatment|O with|O the|O peroxisome|O proliferator|O fenofibrate|O .|O
mtDNA|O deletions|O have|O been|O described|O ,|O and|O a|O gene|O (|O WFS1|O )|O recently|O has|O been|O identified|O ,|O on|O chromosome|O 4p16|O ,|O encoding|O a|O predicted|O 890|O amino|O acid|O transmembrane|O protein|O .|O
These|O in|O vitro|O activities|O are|O the|O highest|O reported|O for|O mutant|O PAH|O enzymes|O produced|O in|O the|O same|O expression|O system|O .|O ABSTRACT|O TRUNCATED|O AT|O 250|O WORDS|O .|O
Patients|O homozygous|O for|O a|O single|O truncating|O mutation|O ,|O typically|O near|O the|O N|O -|O terminal|O end|O of|O the|O gene|O ,|O or|O heterozygous|O for|O the|O in|O -|O frame|O deletion|O 2546|O 3|O ,|O were|O shorter|O and|O had|O significantly|O shorter|O survival|O than|O those|O heterozygous|O for|O a|O splice|O site|O or|O missense|O mutation|O ,|O or|O heterozygous|O for|O two|O truncating|O mutations|O .|O
As|O this|O mutation|O leads|O to|O a|O loss|O of|O protein|O function|O its|O frequency|O makes|O it|O the|O most|O common|O cause|O of|O Zellweger|B-DISE syndrome|I-DISE ,|O helping|O to|O explain|O the|O high|O percentage|O of|O patients|O that|O belong|O to|O CG1|O .|O .|O
We|O recently|O identified|O the|O gene|O causing|O FMF|B-DISE ,|O designated|O MEFV|O ,|O and|O found|O it|O to|O be|O expressed|O in|O mature|O neutrophils|O ,|O suggesting|O that|O it|O functions|O as|O an|O inflammatory|O regulator|O .|O
Seven|O new|O paternally|O expressed|O transcripts|O localize|O to|O an|O approximately|O 1|O .|O 5|O -|O Mb|O domain|O surrounding|O the|O SNRPN|O -|O associated|O imprinting|O center|O ,|O which|O already|O includes|O four|O imprinted|O ,|O paternally|O expressed|O genes|O .|O
Using|O a|O combination|O of|O affinity|O -|O and|O conventional|O chromatographic|O techniques|O ,|O we|O have|O isolated|O a|O predominant|O form|O of|O a|O multiprotein|O BRCA1|O -|O containing|O complex|O from|O human|O cells|O displaying|O chromatin|O -|O remodeling|O activity|O .|O
Five|O of|O the|O mutations|O are|O newly|O reported|O herein|O .|O
OCRL1|O encodes|O a|O phosphatidylinositol|O 4|O ,|O 5|O -|O biphosphate|O PtdIns|O 4|O ,|O 5|O P2|O 5|O -|O phosphatase|O .|O
Homozygosity|O for|O either|O mutation|O results|O in|O postnatal|O iron|O loading|O .|O
The|O murine|O equivalent|O of|O CHS|B-DISE ,|O beige|O mice|O ,|O present|O similar|O characteristics|O but|O do|O not|O develop|O the|O lymphoproliferative|B-DISE syndrome|I-DISE .|O
Argininemia|B-DISE is|O a|O rare|O autossomal|O recessive|O disorder|O caused|O by|O deficiency|B-DISE in|I-DISE the|I-DISE cytosolic|I-DISE liver|I-DISE -|I-DISE type|I-DISE arginase|I-DISE enzyme|I-DISE L|I-DISE -|I-DISE arginine|I-DISE urea|I-DISE -|I-DISE hydrolase|I-DISE ;|O E|O .|O C|O .|O 3|O .|O 5|O .|O 3|O .|O 1|O .|O
Atelosteogenesis|B-DISE type|I-DISE II|I-DISE (|O AO|B-DISE II|I-DISE )|O is|O a|O neonatally|O lethal|O chondrodysplasia|B-DISE whose|O clinical|O and|O histological|O characteristics|O resemble|O those|O of|O another|O chondrodysplasia|B-DISE ,|O the|O much|O less|O severe|O diastrophic|B-DISE dysplasia|I-DISE DTD|B-DISE .|O
To|O expedite|O screening|O ,|O we|O sequentially|O loaded|O the|O SSCP|O gels|O with|O three|O different|O sets|O of|O PCR|O products|O that|O were|O pretested|O to|O avoid|O overlapping|O patterns|O .|O
This|O finding|O is|O consistent|O with|O the|O presence|O of|O the|O N370S|O mutation|O in|O the|O non|O -|O Jewish|O European|O population|O prior|O to|O the|O founding|O of|O the|O AJ|O population|O .|O
Four|O single|O -|O nucleotide|O polymorphisms|O (|O SNPs|O )|O were|O found|O in|O the|O FALDH|O gene|O .|O
Therefore|O ,|O loss|O of|O the|O expressed|O paternal|O alleles|O of|O maternally|O imprinted|O genes|O must|O be|O responsible|O for|O the|O PWS|B-DISE phenotype|O .|O
This|O complex|O localizes|O to|O DSBs|O within|O 30|O minutes|O after|O cellular|O exposure|O to|O ionizing|O radiation|O (|O IR|O )|O and|O is|O observed|O in|O brightly|O staining|O nuclear|O foci|O after|O a|O longer|O period|O of|O time|O .|O
No|O TSG101|O defects|O were|O found|O in|O matched|O normal|O breast|O tissue|O from|O the|O breast|B-DISE cancer|I-DISE patients|O .|O
However|O ,|O analysis|O of|O the|O variance|O in|O repeat|O number|O in|O sperm|O from|O the|O French|O MJD|B-DISE patients|O overlapped|O significantly|O with|O the|O variance|O in|O repeat|O number|O observed|O in|O the|O C|O /|O C|O homozygous|O Japanese|O patients|O .|O .|O
Biochemical|O studies|O indicated|O VLCAD|B-DISE deficiency|I-DISE caused|O by|O a|O stable|O yet|O inactive|O enzyme|O .|O
Thus|O ,|O PRAD1|O is|O an|O excellent|O candidate|O "|O BCL1|O oncogene|O .|O "|O Its|O overexpression|O may|O be|O a|O key|O consequence|O of|O rearrangement|O of|O the|O BCL1|O vicinity|O in|O B|O -|O cell|O neoplasms|B-DISE and|I-DISE a|I-DISE unifying|O pathogenetic|O feature|O in|O centrocytic|B-DISE lymphoma|I-DISE .|O .|O
The|O PDGF|O receptor|O kinase|O inhibitor|O CGP57148B|O reversed|O the|O transformed|O phenotype|O and|O reduced|O the|O growth|O rate|O of|O COLIA1|O /|O PDGFB|O -|O expressing|O cells|O but|O had|O no|O effects|O on|O control|O cells|O .|O
A|O highly|O conserved|O haplotype|O at|O four|O markers|O flanking|O GBA|O (|O PKLR|O ,|O D1S1595|O ,|O D1S2721|O ,|O and|O D1S2777|O )|O was|O observed|O on|O both|O the|O AJ|O chromosomes|O and|O the|O non|O -|O Jewish|O N370S|O chromosomes|O ,|O suggesting|O the|O occurrence|O of|O a|O founder|O common|O to|O both|O populations|O .|O
A|O more|O complete|O understanding|O of|O the|O functional|O physiology|O of|O cathepsin|O C|O carries|O significant|O implications|O for|O understanding|O normal|O and|O abnormal|B-DISE skin|I-DISE development|I-DISE and|O periodontal|B-DISE disease|I-DISE susceptibility|O .|O .|O
These|O data|O implicate|O Bax|O and|O caspase|O -|O 3|O as|O death|O effectors|O in|O neurodegenerative|O pathways|O .|O .|O
Recently|O ,|O a|O gene|O responsible|O for|O this|O disease|O ,|O designated|O XLRS1|O ,|O was|O identified|O ,|O and|O several|O deleterious|O gene|O mutations|O were|O reported|O .|O
Molecular|O genetic|O and|O fluorescent|O hybridisation|O studies|O have|O shown|O that|O loci|O D5S37|O and|O D5S98|O are|O outside|O the|O deletion|O whereas|O loci|O detected|O by|O probes|O EF5|O .|O 44|O and|O YN5|O .|O 48|O are|O lost|O .|O
BRCA1|O encodes|O a|O tumor|O suppressor|O that|O is|O mutated|O in|O familial|B-DISE breast|I-DISE and|I-DISE ovarian|I-DISE cancers|I-DISE .|O
The|O ATM|O (|O A|O -|O T|O ,|O mutated|O )|O gene|O on|O human|O chromosome|O 11q22|O .|O 3|O has|O recently|O been|O identified|O as|O the|O gene|O responsible|O for|O the|O human|O recessive|O disease|O ataxia|B-DISE -|I-DISE telangiectasia|I-DISE A|B-DISE -|I-DISE T|I-DISE .|O
These|O findings|O have|O diagnostic|O implications|O as|O well|O as|O pointing|O to|O functionally|O important|O regions|O of|O the|O emerin|O protein|O .|O .|O
The|O human|O PAX6|O gene|O produces|O two|O alternative|O splice|O isoforms|O that|O have|O the|O distinct|O structure|O of|O the|O paired|O domain|O .|O
Myotonic|B-DISE dystrophy|I-DISE (|O DM|B-DISE )|O ,|O the|O most|O common|O form|O of|O muscular|B-DISE dystrophy|I-DISE in|O adult|O humans|O ,|O results|O from|O expansion|O of|O a|O CTG|O repeat|O in|O the|O 3|O '|O untranslated|O region|O of|O the|O DMPK|O gene|O .|O
We|O conclude|O that|O the|O APC|O I1307K|O variant|O leads|O to|O increased|O adenoma|B-DISE formation|O and|O directly|O contributes|O to|O 3|O %|O -|O 4|O %|O of|O all|O Ashkenazi|O Jewish|O colorectal|B-DISE cancer|I-DISE .|O
We|O cloned|O and|O sequenced|O the|O four|O G6PD|O variants|O from|O Sardinia|O and|O found|O that|O only|O two|O mutations|O are|O responsible|O for|O G6PD|B-DISE deficiency|I-DISE in|O this|O area|O :|O one|O mutation|O is|O the|O cause|O of|O the|O G6PD|O Seattle|O -|O like|O phenotype|O ,|O a|O milder|O form|O of|O G6PD|B-DISE deficiency|I-DISE ;|O the|O other|O mutation|O is|O responsible|O for|O all|O forms|O of|O very|O severe|O G6PD|B-DISE deficiency|I-DISE in|O Sardinia|O and|O ,|O possibly|O ,|O in|O the|O Mediterranean|O .|O .|O
To|O date|O gene|O loci|O have|O been|O identified|O in|O at|O least|O six|O autosomal|O dominant|O forms|O ,|O i|O .|O e|O .|O ,|O in|O idiopathic|B-DISE torsion|I-DISE dystonia|I-DISE (|O 9q34|O )|O ,|O focal|B-DISE dystonia|I-DISE (|O 18p|O )|O ,|O adult|B-DISE -|I-DISE onset|I-DISE idiopathic|I-DISE torsion|I-DISE dystonia|I-DISE of|O mixed|O type|O (|O 8p21|O -|O q22|O )|O ,|O dopa|B-DISE -|I-DISE responsive|I-DISE dystonia|I-DISE (|O 14q22|O .|O 1|O -|O q22|O .|O 2|O )|O ,|O and|O paroxysmal|B-DISE dystonic|I-DISE choreoathetosis|I-DISE 2q25|O -|O q33|O ;|O 1p21|O -|O p13|O .|O 3|O .|O
Type|O I|O C2|B-DISE deficiency|I-DISE was|O described|O in|O a|O family|O in|O which|O the|O C2|O null|O allele|O (|O C2Q0|O )|O is|O associated|O with|O the|O major|O histocompatibility|O haplotype|O /|O complotype|O HLA|O -|O A25|O ,|O B18|O ,|O C2Q0|O ,|O BfS|O ,|O C4A4|O ,|O C4B2|O ,|O Drw2|O ;|O this|O extended|O haplotype|O occurs|O in|O over|O 90|O %|O of|O C2|O -|O deficient|O individuals|O common|O complotype|O /|O haplotype|O .|O
Eleven|O of|O the|O 15|O kindreds|O manifesting|O BRCA1|O mutations|O were|O breast|B-DISE -|I-DISE ovarian|I-DISE cancer|I-DISE families|O ,|O several|O of|O them|O with|O a|O predominant|O ovarian|B-DISE cancer|I-DISE phenotype|O .|O
Although|O this|O mutation|O was|O initially|O detected|O in|O four|O of|O 33|O colorectal|B-DISE cancer|I-DISE families|O analysed|O from|O eastern|O England|O ,|O more|O extensive|O analysis|O has|O reduced|O the|O frequency|O to|O four|O of|O 52|O (|O 8|O %|O )|O English|O HNPCC|B-DISE kindreds|O analysed|O .|O
The|O molecular|O basis|O of|O C7|B-DISE deficiency|I-DISE has|O been|O investigated|O in|O two|O Irish|O families|O and|O a|O number|O of|O Israeli|O families|O of|O Moroccan|O Sephardic|O Jewish|O origin|O .|O
None|O of|O control|O individuals|O possessed|O the|O WASPdim|O population|O .|O
These|O findings|O are|O thought|O to|O provide|O evidence|O against|O the|O concept|O that|O the|O gene|O for|O ankylosing|B-DISE spondylitis|I-DISE is|O not|O B27|O but|O a|O closely|O linked|O gene|O and|O favour|O the|O occurrence|O of|O an|O environmental|O event|O affecting|O approximately|O one|O -|O fifth|O of|O B27|O positive|O males|O to|O result|O in|O disease|O .|O .|O
The|O Huntington|B-DISE disease|I-DISE (|O HD|B-DISE )|O phenotype|O is|O associated|O with|O expansion|O of|O a|O trinucleotide|O repeat|O in|O the|O IT15|O gene|O ,|O which|O is|O predicted|O to|O encode|O a|O 348|O -|O kDa|O protein|O named|O huntington|O .|O
Functional|O analysis|O showed|O that|O 4666insA|O ,|O a|O common|O somatic|O mutation|O in|O APC|O (|O AS9|O )|O in|O these|O tumors|B-DISE ,|O did|O not|O inactivate|O the|O wild|O -|O type|O APC|O .|O
Palmoplantar|B-DISE keratosis|I-DISE ,|O varying|O from|O mild|O psoriasiform|B-DISE scaly|O skin|O to|O overt|O hyperkeratosis|B-DISE ,|O typically|O develops|O within|O the|O first|O three|O years|O of|O life|O .|O
Analysis|O of|O genomic|O DNA|O from|O 22|O Sit|O (|O a|O )|O -|O negative|O normal|O individuals|O showed|O that|O the|O Thr|O (|O 799|O )|O is|O encoded|O by|O ACG|O (|O 2532|O )|O (|O 90|O .|O 9|O %|O )|O or|O ACA|O (|O 2532|O )|O 9|O .|O 1|O %|O .|O
X|B-DISE -|I-DISE linked|I-DISE retinoschisis|I-DISE is|O characterized|O by|O microcystic|O -|O like|O changes|O of|O the|O macular|O region|O and|O schisis|O within|O the|O inner|O retinal|O layers|O ,|O leading|O to|O visual|B-DISE deterioration|I-DISE in|O males|O .|O
Monocytes|O from|O all|O nine|O WAS|B-DISE carriers|O showed|O varied|O population|O of|O WASPdim|O together|O with|O WASPbright|O .|O
We|O have|O previously|O identified|O the|O protein|O product|O of|O the|O nm23|O -|O H1|O gene|O in|O two|O -|O dimensional|O electrophoretic|O gels|O and|O have|O designated|O it|O p19|O /|O nm23|O .|O
All|O VWS|B-DISE families|O studied|O to|O date|O map|O the|O disease|O gene|O to|O a|O <|O 2|O cM|O region|O of|O chromosome|O 1q32|O ,|O with|O no|O evidence|O of|O locus|O heterogeneity|O .|O
Recently|O we|O have|O isolated|O the|O adenomatous|B-DISE polyposis|I-DISE coli|I-DISE (|O APC|O )|O gene|O which|O causes|O familial|B-DISE adenomatous|I-DISE polyposis|I-DISE (|O FAP|B-DISE )|O ,|O and|O its|O germ|O -|O line|O mutations|O in|O a|O substantial|O number|O of|O FAP|B-DISE patients|O have|O been|O identified|O .|O
Using|O homozygosity|O mapping|O in|O eight|O small|O consanguineous|O families|O ,|O we|O have|O narrowed|O the|O candidate|O region|O to|O a|O 1|O .|O 2|O -|O cM|O interval|O between|O D11S4082|O and|O D11S931|O .|O
In|O this|O case|O ,|O PWS|B-DISE does|O not|O become|O evident|O as|O long|O as|O the|O deletion|O is|O passed|O through|O the|O matrilineal|O line|O .|O
The|O monoclonal|O antibody|O 1C2|O is|O known|O preferentially|O to|O bind|O expanded|O polyglutamine|O ,|O but|O we|O find|O that|O it|O also|O binds|O a|O fragment|O of|O ataxin|O -|O 3|O containing|O a|O normal|O glutamine|O repeat|O .|O
In|O order|O to|O determine|O whether|O there|O are|O particular|O regions|O on|O 22q11|O that|O are|O prone|O to|O rearrangements|O ,|O the|O deletion|O end|O -|O points|O in|O a|O large|O number|O of|O VCFS|B-DISE /|O DGS|B-DISE patients|O were|O defined|O by|O haplotype|O analysis|O .|O
The|O gene|O Prph2|O encodes|O a|O photoreceptor|O -|O specific|O membrane|O glycoprotein|O ,|O peripherin|O -|O 2|O (|O also|O known|O as|O peripherin|O /|O rds|O )|O ,|O which|O is|O inserted|O into|O the|O rims|O of|O photoreceptor|O outer|O segment|O discs|O in|O a|O complex|O with|O rom|O -|O 1|O ref|O .|O 2|O .|O
To|O establish|O a|O DNA|O typing|O technique|O ,|O we|O elucidated|O the|O organization|O of|O the|O GPIa|O gene|O adjacent|O to|O the|O polymorphic|O bases|O .|O
To|O investigate|O whether|O the|O presence|O of|O rare|O HRAS1|O alleles|O increases|O susceptibility|O to|O hereditary|B-DISE breast|I-DISE and|I-DISE ovarian|I-DISE cancer|I-DISE ,|O we|O have|O typed|O a|O panel|O of|O 307|O female|O BRCA1|O carriers|O at|O this|O locus|O using|O a|O PCR|O -|O based|O technique|O .|O
Whole|O genomic|O hprt|O clones|O were|O used|O in|O Southern|O analysis|O to|O screen|O the|O integrity|O of|O the|O hprt|O gene|O in|O a|O family|O that|O includes|O a|O patient|O with|O HPRT|O enzyme|B-DISE deficiency|I-DISE causal|O to|O Lesch|B-DISE -|I-DISE Nyhan|I-DISE syndrome|I-DISE .|O
We|O determined|O by|O deletion|O analysis|O that|O an|O expanded|O (|O CTG|O )|O (|O n|O )|O tract|O alone|O was|O sufficient|O to|O mediate|O these|O cis|O effects|O .|O
Of|O 133|O living|O female|O relatives|O ,|O 83|O (|O 62|O %|O )|O were|O tested|O for|O the|O presence|O of|O a|O mutation|O .|O
No|O clinical|O disease|O was|O associated|O with|O this|O deficiency|O which|O was|O transmitted|O through|O the|O subject|O '|O s|O family|O as|O a|O single|O genetic|O characteristic|O ,|O the|O C6|B-DISE deficiency|I-DISE being|O associated|O with|O a|O silent|O allele|O at|O the|O structural|O locus|O .|O
In|O the|O inv|O (|O X|O )|O carried|O by|O several|O affected|O family|O members|O ,|O FISH|O showed|O PLP|O signals|O at|O Xp11|O .|O 4|O and|O Xq22|O .|O
OBJECTIVES|O :|O To|O conduct|O mutational|O analyses|O in|O 29|O Japanese|O patients|O with|O ALD|B-DISE from|O 29|O unrelated|O families|O ,|O to|O obtain|O knowledge|O of|O the|O spectrum|O of|O mutations|O in|O this|O gene|O ,|O and|O to|O study|O genotype|O -|O phenotype|O correlations|O in|O Japanese|O patients|O .|O
A|O case|O of|O human|O complete|O C6|B-DISE deficiency|I-DISE is|O reported|O .|O
Twenty|O -|O eight|O YAC|O clones|O were|O identified|O by|O screening|O human|O YAC|O libraries|O with|O twelve|O PCR|O -|O based|O sequence|O -|O tagged|O sites|O (|O STSs|O )|O from|O the|O region|O .|O
Truncated|O ATM|O protein|O was|O not|O detected|O in|O lymphoblasts|O from|O ataxia|B-DISE -|I-DISE telangiectasia|I-DISE patients|O homozygous|O for|O mutations|O leading|O to|O premature|O protein|O termination|O .|O
We|O studied|O a|O previously|O described|O Swiss|O family|O with|O inherited|O C9|B-DISE deficiency|I-DISE .|O
Aspartylglucosaminuria|B-DISE (|O AGU|B-DISE )|O is|O caused|O by|O deficient|O activity|O of|O the|O enzyme|O aspartylglucosaminidase|O AGA|O .|O
About|O 98|O %|O of|O mutant|O alleles|O have|O an|O expansion|O of|O a|O GAA|O trinucleotide|O repeat|O in|O intron|O 1|O of|O the|O gene|O .|O
We|O also|O have|O developed|O rapid|O ,|O nonradioactive|O assays|O for|O the|O detection|O of|O each|O mutation|O ,|O which|O should|O be|O helpful|O for|O carrier|O screening|O .|O .|O
The|O high|O prevalence|O of|O HFE|O mutations|O in|O Denmark|O suggests|O that|O population|O screening|O for|O the|O C282Y|O mutation|O could|O be|O highly|O advantageous|O in|O terms|O of|O preventive|O health|O care|O .|O
Surprisingly|O ,|O in|O the|O frataxin|O knockout|O mouse|O ,|O no|O iron|O accumulation|O was|O observed|O during|O embryonic|O resorption|O ,|O suggesting|O that|O cell|O death|O could|O be|O due|O to|O a|O mechanism|O independent|O of|O iron|O accumulation|O .|O .|O
Phosphorylation|O of|O this|O site|O appears|O to|O be|O functionally|O important|O because|O mutated|O nibrin|O (|O S343A|O )|O does|O not|O completely|O complement|O radiosensitivity|O in|O NBS|B-DISE cells|O .|O
In|O this|O study|O we|O describe|O a|O three|O -|O generation|O family|O in|O which|O two|O siblings|O were|O affected|O by|O Duchenne|B-DISE muscular|I-DISE dystrophy|I-DISE DMD|B-DISE .|O
We|O report|O five|O new|O beta|O -|O galactosidase|O gene|O mutations|O in|O nine|O Italian|O patients|O and|O one|O fetus|O ,|O segregating|O in|O seven|O unrelated|O families|O .|O
However|O ,|O his|O oral|O clearance|O of|O nifedipine|O and|O chlorpheniramine|O did|O not|O differ|O from|O individuals|O in|O other|O studies|O performed|O at|O our|O laboratories|O .|O
Alstrom|B-DISE syndrome|I-DISE is|O a|O rare|O autosomal|O recessive|O disorder|O characterized|O by|O retinal|B-DISE degeneration|I-DISE ,|O sensorineural|B-DISE hearing|I-DISE loss|I-DISE ,|O early|B-DISE -|I-DISE onset|I-DISE obesity|I-DISE ,|O and|O non|B-DISE -|I-DISE insulin|I-DISE -|I-DISE dependent|I-DISE diabetes|I-DISE mellitus|I-DISE .|O
The|O gene|O responsible|O for|O the|O disease|B-DISE (|O PDS|O )|O has|O been|O cloned|O ,|O but|O its|O function|O is|O as|O yet|O unknown|O and|O the|O connection|O between|O thyroid|B-DISE goiter|I-DISE and|O sensory|B-DISE -|I-DISE neural|I-DISE deafness|I-DISE remains|O an|O enigma|O .|O
A|O family|O in|O which|O two|O male|O siblings|O were|O affected|O with|O Wiskott|B-DISE -|I-DISE Aldrich|I-DISE syndrome|I-DISE (|O WAS|B-DISE )|O was|O studied|O using|O G|O -|O 6|O -|O PD|O isoenzymes|O as|O an|O X|O -|O linked|O marker|O in|O order|O to|O investigate|O the|O nature|O of|O cellular|O abnormalities|O .|O
This|O phosphorylation|O is|O also|O important|O for|O the|O ability|O of|O BRCA1|O to|O restore|O survival|O after|O DNA|O damage|O in|O the|O BRCA1|O -|O mutated|O cell|O line|O HCC1937|O .|O .|O
Cytotoxic|O T|O lymphocyte|O -|O associated|O antigen|O 4|O (|O CTLA|O -|O 4|O ,|O also|O known|O as|O CD152|O )|O has|O been|O shown|O to|O play|O a|O major|O role|O in|O the|O regulation|O of|O T|O cell|O activation|O .|O
Since|O some|O gastric|B-DISE cancers|I-DISE are|O considered|O to|O originate|O from|O the|O intestinal|B-DISE metaplasia|I-DISE ,|O it|O is|O likely|O that|O the|O adenomatous|B-DISE polyposis|I-DISE coli|I-DISE (|O APC|O )|O gene|O ,|O the|O mutation|O of|O which|O causes|O adenomatous|B-DISE polyps|I-DISE in|I-DISE the|I-DISE colon|I-DISE ,|O is|O associated|O with|O carcinogenesis|O of|O gastric|B-DISE cancer|I-DISE .|O
In|O the|O complete|O set|O of|O families|O ,|O a|O maximum|O two|O -|O point|O LOD|O score|O of|O 1|O .|O 10|O was|O observed|O at|O D1S413|O at|O a|O recombination|O fraction|O theta|O of|O .|O 1|O ,|O with|O a|O maximum|O NPL|O (|O nonparametric|O linkage|O )|O Z|O score|O of|O 1|O .|O 64|O at|O D1S202|O P|O =|O .|O 05|O .|O
On|O the|O basis|O of|O this|O homology|O and|O the|O presence|O of|O a|O slightly|O modified|O sulfate|O -|O transporter|O signature|O sequence|O comprising|O its|O putative|O second|O transmembrane|O domain|O ,|O pendrin|O has|O been|O proposed|O to|O function|O as|O a|O sulfate|O transporter|O .|O
Eighteen|O (|O 69|O %|O )|O of|O 26|O mutations|O were|O missense|O mutations|O .|O
These|O findings|O demonstrate|O that|O the|O DNA|O -|O binding|O domains|O of|O HMG|O I|O -|O C|O ,|O in|O the|O absence|O of|O a|O C|O -|O terminal|O fusion|O partner|O ,|O are|O sufficient|O to|O perturb|O adipogenesis|O and|O predispose|O to|O lipomas|B-DISE .|O
The|O rapid|O identification|O of|O mutations|O causing|O Tay|B-DISE -|I-DISE Sachs|I-DISE disease|I-DISE requires|O the|O capacity|O to|O readily|O screen|O the|O regions|O of|O the|O HEXA|O gene|O most|O likely|O to|O be|O affected|O by|O mutation|O .|O
Factor|B-DISE H|I-DISE deficiency|I-DISE is|O the|O only|O complement|O deficiency|O associated|O with|O HUS|B-DISE .|O
The|O size|O of|O this|O fragment|O varies|O between|O affected|O siblings|O ,|O and|O increases|O in|O size|O through|O generations|O in|O parallel|O with|O increasing|O severity|O of|O the|O disease|O .|O
Single|O -|O sperm|O typing|O techniques|O were|O performed|O for|O each|O sample|O by|O study|O of|O two|O informative|O short|O tandem|O repeats|O located|O either|O in|O or|O close|O to|O the|O retinoblastoma|B-DISE gene|O RB1|O .|O
The|O discovery|O of|O the|O FRDA|O gene|O and|O its|O possible|O function|O has|O raised|O hope|O that|O rational|O therapeutic|O strategies|O will|O be|O developed|O .|O .|O
We|O subsequently|O showed|O that|O all|O the|O deletions|O were|O identical|O to|O the|O base|O pair|O and|O probably|O resulted|O from|O a|O nonhomologous|O recombination|O mediated|O by|O 7|O -|O bp|O direct|O repeats|O .|O
Third|O ,|O toxic|O effects|O of|O the|O repeat|O expansion|O may|O be|O intrinsic|O to|O the|O repeated|O elements|O at|O the|O level|O of|O DNA|O or|O RNA|O refs|O 10|O ,|O 11|O .|O
None|O of|O the|O patients|O harbored|O identical|O mutations|O suggesting|O that|O the|O mutational|O heterogeneity|O in|O VLCAD|B-DISE deficiency|I-DISE is|O large|O .|O .|O
A|O considerable|O amino|O acid|O sequence|O homology|O was|O observed|O between|O the|O mouse|O and|O human|O (|O 47|O .|O 6|O %|O identity|O and|O 65|O .|O 5|O %|O similarity|O )|O and|O between|O the|O mouse|O and|O rat|O genes|O 73|O .|O 5|O %|O identity|O and|O 82|O .|O 1|O %|O similarity|O .|O
Of|O all|O the|O inherited|O thrombophilic|B-DISE conditions|I-DISE ,|O it|O remains|O the|O most|O difficult|O to|O diagnose|O because|O of|O phenotypic|O variability|O ,|O which|O can|O lead|O to|O inconclusive|O results|O .|O
These|O analyses|O identified|O two|O novel|O single|O -|O nucleotide|O polymorphisms|O (|O INV4|O +|O 31A|O -|O -|O >|O G|O and|O INV11|O +|O 18A|O -|O -|O >|O G|O )|O and|O six|O novel|O AKU|B-DISE mutations|O (|O INV1|O -|O 1G|O -|O -|O >|O A|O ,|O W60G|O ,|O Y62C|O ,|O A122D|O ,|O P230T|O ,|O and|O D291E|O )|O ,|O which|O further|O illustrates|O the|O remarkable|O allelic|O heterogeneity|O found|O in|O AKU|O .|O
Four|O probands|O failed|O to|O inherit|O a|O maternal|O allele|O ,|O and|O one|O failed|O to|O inherit|O a|O paternal|O allele|O .|O
Both|O mutations|O caused|O an|O increase|O in|O RANK|O -|O mediated|O nuclear|O factor|O -|O kappaB|O (|O NF|O -|O kappaB|O )|O signalling|O in|O vitro|O ,|O consistent|O with|O the|O presence|O of|O an|O activating|O mutation|O .|O .|O
FMR1|O YAC|O transgenic|O mice|O overexpressing|O the|O human|O protein|O did|O produce|O opposing|O behavioral|O responses|O and|O additional|O abnormal|B-DISE behaviors|I-DISE were|O also|O observed|O .|O
A|O susceptibility|O gene|O on|O chromosome|O 18|O and|O a|O parent|O -|O of|O -|O origin|O effect|O have|O been|O suggested|O for|O bipolar|B-DISE affective|I-DISE disorder|I-DISE BPAD|B-DISE .|O
The|O mutations|O found|O in|O our|O cases|O occurred|O in|O the|O same|O exon|O of|O the|O WT1|O gene|O as|O detected|O in|O Denys|B-DISE -|I-DISE Drash|I-DISE syndrome|I-DISE (|O DDS|B-DISE )|O and|O could|O not|O be|O explained|O by|O the|O previously|O proposed|O mechanism|O .|O
Chromosome|O translocations|O involving|O 11p13|O have|O been|O associated|O with|O familial|O aniridia|B-DISE in|O two|O kindreds|O highlighting|O the|O chromosomal|O localization|O of|O the|O AN2|O locus|O .|O
The|O serum|O transferrin|O saturation|O was|O 45|O percent|O or|O higher|O in|O 15|O of|O the|O 16|O who|O were|O homozygous|O ;|O in|O 1|O subject|O it|O was|O 43|O percent|O .|O
Inactivation|O of|O both|O alleles|O of|O the|O RB1|O gene|O during|O normal|O retinal|O development|O initiates|O the|O formation|O of|O a|O retinoblastoma|B-DISE (|O RB|B-DISE )|O tumor|O .|O
There|O was|O no|O significant|O correlation|O between|O the|O size|O of|O the|O smaller|O allele|O and|O cardiomyopathy|B-DISE ,|O diabetes|B-DISE mellitus|I-DISE ,|O loss|B-DISE of|I-DISE proprioception|I-DISE ,|O or|O bladder|B-DISE symptoms|I-DISE .|O
Of|O 13|O B27|O positive|O fathers|O 3|O could|O be|O diagnosed|O as|O having|O definite|O ankylosing|B-DISE spondylitis|I-DISE 23|O %|O .|O
This|O observation|O raises|O doubts|O concerning|O the|O most|O recently|O published|O assignment|O of|O ESD|O to|O 13q14|O .|O 1|O .|O A|O deletion|O in|O an|O individual|O with|O retinoblastoma|B-DISE was|O reported|O to|O separate|O the|O closely|O linked|O ESD|O and|O retinoblastoma|B-DISE (|O RB1|O )|O loci|O ,|O placing|O ESD|O proximal|O to|O RB1|O .|O
More|O ovarian|B-DISE cancers|I-DISE than|O breast|B-DISE cancers|I-DISE were|O recorded|O .|O
Expression|O experiments|O by|O transfection|O of|O the|O mutant|O NIS|O complimentary|O DNA|O into|O COS|O -|O 7|O cells|O showed|O no|O perchlorate|O -|O sensitive|O iodide|O uptake|O ,|O confirming|O that|O the|O mutation|O is|O the|O direct|O cause|O of|O the|O iodide|B-DISE transport|I-DISE defect|I-DISE in|O these|O patients|O .|O
An|O apparent|O abnormal|O clone|O of|O cells|O ,|O possessing|O a|O large|O acrocentric|O marker|O chromosome|O (|O 14q|O +|O )|O ,|O was|O observed|O in|O varying|O proportions|O among|O cells|O of|O all|O the|O propositi|O 2|O -|O 5|O %|O of|O lymphocytes|O ;|O 1|O -|O 9|O %|O of|O fibroblasts|O .|O .|O
Alterations|O of|O the|O length|O or|O amino|O acid|O composition|O of|O the|O A|O -|O T|O gene|O product|O affect|O the|O A|B-DISE -|I-DISE T|I-DISE clinical|O phenotype|O in|O different|O ways|O .|O
RNA|O blotting|O analysis|O has|O revealed|O that|O GLDC|O is|O expressed|O in|O human|O liver|O ,|O kidney|O ,|O brain|O ,|O and|O placenta|O .|O
We|O have|O previously|O assigned|O the|O Friedreich|B-DISE ataxia|I-DISE locus|O (|O FRDA|O )|O to|O chromosome|O 9|O ;|O the|O current|O maximal|O lod|O score|O between|O FRDA|O and|O MCT112|O (|O D9S15|O )|O is|O greater|O than|O 50|O at|O a|O recombination|O fraction|O of|O theta|O =|O 0|O .|O
In|O addition|O to|O the|O 19|O mutations|O ,|O a|O total|O of|O 15|O different|O polymorphic|O variants|O were|O scored|O ,|O most|O of|O which|O were|O recurring|O .|O
No|O locus|O other|O than|O chromosome|O 11p13|O has|O been|O implicated|O in|O aniridia|B-DISE ,|O and|O PAX6|O is|O clearly|O the|O major|O ,|O if|O not|O only|O ,|O gene|O responsible|O .|O
These|O patients|O were|O mostly|O men|O ,|O of|O non|O -|O North|O African|O origin|O ,|O P|O <|O 0|O .|O 05|O compared|O to|O controls|O .|O
Haplotype|O analysis|O of|O the|O STM7|O /|O X25|O region|O of|O chromosome|O 9|O demonstrated|O that|O the|O relevant|O portion|O of|O chromosome|O 9|O differs|O in|O the|O patients|O .|O
BRCA1|O exists|O in|O nuclear|O foci|O but|O is|O hyperphosphorylated|O and|O disperses|O after|O DNA|O damage|O .|O
We|O show|O here|O that|O an|O evolutionary|O analysis|O is|O a|O key|O to|O understanding|O the|O biology|O of|O a|O housekeeping|O gene|O .|O
The|O identification|O of|O the|O second|O mutational|O event|O in|O 10|O (|O 43|O %|O )|O tumors|O establishes|O PTEN|O /|O MMAC1|O as|O a|O main|O inactivation|O target|O of|O 10q|O loss|O in|O sporadic|O prostate|B-DISE cancer|I-DISE .|O .|O
These|O results|O suggest|O that|O emerin|O anchors|O at|O the|O inner|O nuclear|O membrane|O through|O the|O hydrophobic|O stretch|O ,|O and|O protrudes|O from|O the|O hydrophilic|O region|O to|O the|O nucleoplasm|O where|O it|O interacts|O with|O the|O nuclear|O lamina|O .|O
This|O indicates|O that|O there|O is|O a|O heavy|O ascertainment|O bias|O in|O the|O selection|O of|O patients|O for|O PAX6|O mutation|O analysis|O and|O that|O the|O '|O missing|O '|O PAX6|O missense|O mutations|O frequently|O may|O underlie|O phenotypes|O distinct|O from|O textbook|O aniridia|B-DISE .|O
Moreover|O ,|O we|O observed|O the|O occurrence|O of|O de|O novo|O mutations|O between|O parental|O and|O grandparental|O generations|O in|O 17|O three|O -|O generation|O families|O ,|O which|O allowed|O a|O direct|O estimation|O of|O the|O k|O value|O k|O =|O 11|O .|O
BRCA1|O abnormalities|O were|O identified|O in|O all|O four|O families|O with|O ovarian|B-DISE cancer|I-DISE only|O ,|O in|O 67|O %|O of|O 27|O families|O with|O both|O breast|B-DISE and|I-DISE ovarian|I-DISE cancer|I-DISE ,|O and|O in|O 34|O %|O of|O 35|O families|O with|O breast|B-DISE cancer|I-DISE only|O .|O
A|O diagnosis|O of|O Pelizaeus|B-DISE -|I-DISE Merzbacher|I-DISE disease|I-DISE (|O MIM|O 312080|O )|O was|O made|O in|O a|O young|O boy|O .|O
Friedreich|B-DISE ataxia|I-DISE (|O FRDA|B-DISE )|O is|O the|O most|O common|O inherited|O ataxia|O .|O
We|O previously|O reported|O a|O recombination|O in|O an|O individual|O with|O myotonic|B-DISE dystrophy|I-DISE (|O DM|B-DISE )|O which|O placed|O the|O markers|O D19S19|O and|O APOC2|O on|O the|O same|O side|O of|O the|O DM|O locus|O .|O
The|O adenomatous|B-DISE polyposis|I-DISE coli|I-DISE (|O APC|O )|O tumour|B-DISE -|O suppressor|O protein|O controls|O the|O Wnt|O signalling|O pathway|O by|O forming|O a|O complex|O with|O glycogen|O synthase|O kinase|O 3beta|O (|O GSK|O -|O 3beta|O )|O ,|O axin|O /|O conductin|O and|O betacatenin|O .|O
As|O a|O cause|O of|O C9|B-DISE deficiency|I-DISE ,|O we|O found|O two|O different|O point|O mutations|O ,|O both|O generating|O TGA|O stop|O codons|O in|O the|O coding|O sequence|O .|O
Sequence|O analysis|O of|O the|O amplified|O products|O has|O revealed|O a|O single|O missense|O mutation|O in|O SGLT1|O which|O cosegregates|O with|O the|O GGM|O phenotype|O and|O results|O in|O a|O complete|O loss|O of|O Na|O (|O +|O )|O -|O dependent|O glucose|O transport|O in|O Xenopus|O oocytes|O injected|O with|O this|O complementary|O RNA|O .|O .|O
The|O first|O predictive|O testing|O for|O Huntington|B-DISE disease|I-DISE (|O HD|B-DISE )|O was|O based|O on|O analysis|O of|O linked|O polymorphic|O DNA|O markers|O to|O estimate|O the|O likelihood|O of|O inheriting|O the|O mutation|O for|O HD|B-DISE .|O
Hereditary|B-DISE hyperparathyroidism|I-DISE -|I-DISE jaw|I-DISE tumor|I-DISE syndrome|I-DISE (|O HPT|B-DISE -|I-DISE JT|I-DISE )|O is|O an|O autosomal|O dominant|O disease|O (|O OMIM|O 145001|O )|O that|O has|O recently|O been|O mapped|O to|O chromosomal|O region|O 1q21|O -|O q32|O HRPT2|O .|O
It|O is|O possible|O that|O analogous|O to|O an|O activated|O /|O altered|O growth|O factor|O receptor|O oncogene|O ,|O codon|O 877|O mutant|O AR|O with|O altered|O ligand|O binding|O may|O provide|O a|O selective|O growth|O advantage|O in|O the|O genesis|O of|O a|O subset|O of|O advanced|B-DISE prostate|I-DISE cancer|I-DISE .|O
To|O investigate|O this|O mechanism|O ,|O we|O analyzed|O sperm|O samples|O from|O six|O individuals|O from|O five|O unrelated|O families|O affected|O with|O hereditary|B-DISE retinoblastoma|I-DISE .|O
These|O data|O demonstrate|O that|O the|O disease|O is|O inherited|O in|O an|O autosomal|O recessive|O manner|O and|O that|O lymphocytes|O and|O fibroblasts|O can|O be|O used|O to|O detect|O carriers|O .|O
Numerous|O additional|O splice|O products|O were|O detected|O ,|O most|O involving|O skipping|O of|O one|O or|O more|O surrounding|O exons|O .|O
The|O results|O indicate|O close|O linkage|O between|O the|O WAS|B-DISE and|O OATL1|O loci|O (|O Z|O =|O 6|O .|O 08|O at|O theta|O =|O 0|O .|O 00|O )|O and|O localize|O the|O TIMP|O ,|O OATL1|O ,|O DXS255|O ,|O and|O WAS|O loci|O distal|O to|O DXS146|O and|O the|O OATL1|O and|O WAS|O loci|O proximal|O to|O TIMP|O .|O
Activation|O of|O the|O ATM|O kinase|O by|O ionizing|O radiation|O and|O induction|O of|O ATM|O -|O dependent|O responses|O in|O NBS|B-DISE cells|O indicated|O that|O p95|O /|O nbs1|O may|O not|O be|O required|O for|O signalling|O to|O ATM|O after|O ionizing|O radiation|O .|O
Six5|O +|O /|O -|O and|O Six5|O -|O /|O -|O mice|O show|O increased|O steady|O -|O state|O levels|O of|O the|O Na|O +|O /|O K|O +|O -|O ATPase|O alpha|O -|O 1|O subunit|O and|O decreased|O Dm15|O mRNA|O levels|O .|O
HFE|O specifically|O reduces|O iron|O uptake|O from|O Tf|O ,|O as|O non|O -|O Tf|O -|O mediated|O iron|O uptake|O from|O Fe|O -|O nitrilotriacetic|O acid|O is|O not|O altered|O .|O
We|O have|O searched|O for|O mutations|O in|O the|O choroideremia|B-DISE gene|O (|O CHM|O )|O in|O patients|O from|O 12|O Danish|O families|O in|O which|O CHM|O is|O segregating|O .|O
Mutations|O in|O Prph2|O have|O been|O shown|O to|O result|O in|O a|O variety|O of|O photoreceptor|B-DISE dystrophies|I-DISE ,|O including|O autosomal|B-DISE dominant|I-DISE retinitis|I-DISE pigmentosa|I-DISE and|O macular|B-DISE dystrophy|I-DISE .|O
Disruption|O of|O Hmgic|O caused|O a|O reduction|O in|O the|O obesity|B-DISE induced|O by|O leptin|B-DISE deficiency|I-DISE (|O Lepob|O /|O Lepob|O )|O in|O a|O gene|O -|O dose|O -|O dependent|O manner|O .|O
Presence|O of|O a|O large|O deletion|O involving|O exons|O 9|O ,|O 10|O and|O 11|O of|O the|O phenylalanine|O hydroxylase|O gene|O was|O confirmed|O by|O long|O -|O range|O PCR|O .|O
In|O view|O of|O this|O discrepancy|O ,|O we|O examined|O the|O frequency|O of|O ATM|O germline|O mutations|O in|O a|O selected|O group|O of|O Dutch|O patients|O with|O breast|B-DISE cancer|I-DISE .|O
Fragments|O of|O the|O arylsulfatase|O A|O (|O ARSA|O )|O gene|O from|O a|O patient|O with|O juvenile|O -|O onset|O metachromatic|B-DISE leukodystrophy|I-DISE (|O MLD|B-DISE )|O were|O amplified|O by|O PCR|O and|O ligated|O into|O MP13|O cloning|O vectors|O .|O
The|O rare|O diseases|O ataxia|B-DISE -|I-DISE telangiectasia|I-DISE (|O AT|B-DISE )|O ,|O caused|O by|O mutations|O in|O the|O ATM|O gene|O ,|O and|O Nijmegen|B-DISE breakage|I-DISE syndrome|I-DISE (|O NBS|B-DISE )|O ,|O with|O mutations|O in|O the|O p95|O /|O nbs1|O gene|O ,|O share|O a|O variety|O of|O phenotypic|O abnormalities|O such|O as|O chromosomal|B-DISE instability|I-DISE ,|O radiation|O sensitivity|O and|O defects|O in|O cell|O -|O cycle|O checkpoints|O in|O response|O to|O ionizing|O radiation|O .|O
Frataxin|B-DISE deficiency|I-DISE is|O the|O primary|O cause|O of|O Friedreich|B-DISE ataxia|I-DISE (|O FRDA|B-DISE )|O ,|O an|O autosomal|B-DISE recessive|I-DISE cardiodegenerative|B-DISE and|I-DISE neurodegenerative|I-DISE disease|I-DISE .|O
Recent|O studies|O demonstrated|O the|O existence|O of|O a|O genetically|O distinct|O ,|O usually|O lethal|O form|O of|O the|O Schwartz|B-DISE -|I-DISE Jampel|I-DISE syndrome|I-DISE (|O SJS|B-DISE )|O of|O myotonia|B-DISE and|O skeletal|B-DISE dysplasia|I-DISE ,|O which|O we|O called|O SJS|B-DISE type|O 2|O .|O
Although|O Kaposi|B-DISE sarcoma|I-DISE can|O arise|O in|O the|O face|O of|O the|O severe|O immunosuppression|O that|O follows|O allograft|O transplantation|O and|O in|O patients|O infected|O with|O HIV|B-DISE ,|O we|O postulate|O that|O longevity|O in|O the|O face|O of|O mild|O immunosuppression|O was|O the|O major|O factor|O in|O the|O development|O of|O Kaposi|B-DISE sarcoma|I-DISE in|O this|O patient|O .|O .|O
None|O of|O the|O 13|O families|O with|O cases|O of|O male|B-DISE breast|I-DISE cancer|I-DISE appear|O to|O be|O linked|O ,|O but|O it|O is|O estimated|O that|O 92|O %|O (|O 95|O %|O confidence|O interval|O 76|O %|O -|O 100|O %|O )|O of|O families|O with|O no|O male|B-DISE breast|I-DISE cancer|I-DISE and|O with|O two|O or|O more|O ovarian|B-DISE cancers|I-DISE are|O linked|O to|O BRCA1|O .|O
It|O is|O concluded|O that|O mutation|O analysis|O at|O the|O DNA|O level|O is|O not|O sufficient|O for|O predicting|O clinical|O course|O .|O
We|O defined|O the|O genomic|O structure|O of|O CTSC|O and|O found|O mutations|O in|O all|O eight|O families|O .|O
Therefore|O ,|O although|O the|O major|O IR|O -|O induced|O apoptotic|O pathway|O in|O the|O CNS|O requires|O Atm|O and|O Bax|O ,|O a|O p53|O -|O dependent|O collateral|O pathway|O exists|O that|O has|O both|O Atm|O -|O and|O Bax|O -|O independent|O branches|O .|O
We|O have|O developed|O an|O inexpensive|O system|O for|O gene|O mutational|O scanning|O ,|O based|O on|O a|O combination|O of|O extensive|O multiplex|O PCR|O amplification|O and|O two|O dimensional|O electrophoresis|O .|O
CONCLUSIONS|O :|O The|O I1307K|O APC|O variant|O may|O represent|O a|O susceptibility|O gene|O for|O colorectal|B-DISE ,|I-DISE or|I-DISE other|I-DISE ,|I-DISE cancers|I-DISE in|O Ashkenazi|O Jews|O ,|O and|O partially|O explains|O the|O higher|O incidence|O of|O colorectal|B-DISE cancer|I-DISE in|O European|O Israelis|O .|O .|O
The|O finding|O that|O ATM|O -|O heterozygotes|O have|O an|O increased|O relative|O risk|O for|O breast|B-DISE cancer|I-DISE was|O supported|O by|O some|O studies|O but|O not|O confirmed|O by|O others|O .|O
Our|O findings|O are|O consistent|O with|O a|O novel|O molecular|O pathogenetic|O mechanism|O for|O myotonic|B-DISE dystrophy|I-DISE :|O both|O the|O normal|O and|O expanded|O DM|O kinase|O genes|O are|O transcribed|O in|O patient|O muscle|O ,|O but|O the|O abnormal|O expansion|O -|O containing|O RNA|O has|O a|O dominant|O effect|O on|O RNA|O metabolism|O by|O preventing|O the|O accumulation|O of|O poly|O (|O A|O )|O +|O RNA|O .|O
The|O human|O eye|O malformation|O aniridia|B-DISE results|O from|O haploinsufficiency|O of|O PAX6|O ,|O a|O paired|O box|O DNA|O -|O binding|O protein|O .|O
The|O present|O study|O describes|O a|O combined|O analysis|O for|O six|O markers|O in|O the|O 1q24|O -|O 25|O region|O in|O 772|O families|O affected|O by|O hereditary|O prostate|B-DISE cancer|I-DISE and|O ascertained|O by|O the|O members|O of|O the|O International|O Consortium|O for|O Prostate|B-DISE Cancer|I-DISE Genetics|O (|O ICPCG|O )|O from|O North|O America|O ,|O Australia|O ,|O Finland|O ,|O Norway|O ,|O Sweden|O ,|O and|O the|O United|O Kingdom|O .|O
The|O advantages|O of|O this|O test|O are|O (|O 1|O )|O plucking|O of|O hair|O follicles|O does|O no|O appreciable|O harm|O to|O the|O mentally|B-DISE retarded|I-DISE patient|O ,|O (|O 2|O )|O hairs|O can|O be|O sent|O in|O a|O simple|O envelope|O to|O a|O diagnostic|O center|O ,|O and|O (|O 3|O )|O the|O result|O of|O the|O test|O is|O available|O within|O 5|O h|O of|O plucking|O .|O
To|O investigate|O this|O hypothesis|O ,|O we|O developed|O hamster|O -|O human|O somatic|O hybrid|O cell|O lines|O from|O VCFS|B-DISE /|O DGS|B-DISE patients|O with|O all|O three|O classes|O of|O deletions|O and|O we|O now|O show|O that|O the|O breakpoints|O occur|O within|O similar|O low|O copy|O repeats|O ,|O termed|O LCR22s|O .|O
In|O leukemia|B-DISE cells|O obtained|O from|O patients|O with|O different|O subtypes|O of|O acute|B-DISE leukemia|I-DISE ,|O p19|O /|O nm23|O levels|O were|O also|O increased|O relative|O to|O resting|O normal|O lymphocytes|O .|O
One|O of|O the|O target|O genes|O for|O beta|O -|O catenin|O /|O TCF|O encodes|O c|O -|O MYC|O ,|O explaining|O why|O constitutive|O activation|O of|O the|O WNT|O pathway|O can|O lead|O to|O cancer|B-DISE ,|O particularly|O in|O the|O colon|O .|O
The|O absence|O of|O severe|O phenylketonuria|B-DISE (|O PKU|B-DISE )|O in|O both|O Polynesians|O and|O Southeast|O Asians|O is|O consistent|O with|O the|O lack|O of|O PAH|O haplotypes|O 2|O and|O 3|O ,|O on|O which|O the|O severe|O PKU|B-DISE mutants|O have|O arisen|O among|O Caucasians|O .|O .|O
Three|O congenital|B-DISE anomaly|I-DISE disorders|I-DISE ,|O cat|B-DISE -|I-DISE eye|I-DISE syndrome|I-DISE ,|O der|B-DISE (|I-DISE )|I-DISE syndrome|I-DISE and|O velo|B-DISE -|I-DISE cardio|I-DISE -|I-DISE facial|I-DISE syndrome|I-DISE /|O DiGeorge|B-DISE syndrome|I-DISE (|O VCFS|B-DISE /|O DGS|B-DISE )|O are|O associated|O with|O tetrasomy|B-DISE ,|O trisomy|B-DISE or|O monosomy|B-DISE ,|O respectively|O ,|O for|O part|O of|O chromosome|O 22q11|O .|O
The|O genetic|O defects|O responsible|O for|O most|O phenylketonuria|B-DISE (|O PKU|B-DISE )|O and|O hyperphenylalaninemia|B-DISE (|O HPA|B-DISE )|O cases|O are|O located|O in|O the|O phenylalanine|O hydroxylase|O (|O PAH|O )|O gene|O .|O
Several|O alleles|O for|O the|O CYP2C9|O gene|O have|O been|O reported|O .|O
Restriction|O mapping|O of|O the|O YAC|O indicates|O that|O it|O contains|O both|O MAOA|O and|O MAOB|O genes|O in|O addition|O to|O the|O DXS7|O locus|O .|O
Genetic|O analyses|O of|O Japanese|O C9|B-DISE deficiency|I-DISE have|O shown|O that|O a|O C|O -|O to|O -|O T|O transition|O leading|O to|O TGA|O stop|O codon|O for|O Arg95|O in|O exon|O 4|O of|O the|O C9|O gene|O (|O Arg95Stop|O )|O is|O common|O in|O Japanese|O C9|B-DISE deficiency|I-DISE .|O
The|O primary|O defect|O could|O ,|O indeed|O ,|O be|O traced|O to|O an|O augmented|O duodenal|O iron|O absorption|O .|O
The|O mouse|O WASP|O gene|O ,|O the|O homolog|O of|O the|O gene|O mutated|O in|O Wiskott|B-DISE -|I-DISE Aldrich|I-DISE syndrome|I-DISE ,|O has|O been|O isolated|O and|O sequenced|O .|O
In|O 0|O .|O 1|O %|O of|O affected|O males|O ,|O however|O ,|O the|O plasma|O C26|O :|O 0|O level|O is|O borderline|O normal|O ,|O and|O 15|O %|O of|O obligate|O female|O carriers|O have|O normal|O results|O .|O
Of|O the|O 15|O families|O that|O contain|O cases|O of|O ovarian|B-DISE cancer|I-DISE ,|O 94|O %|O were|O estimated|O to|O be|O linked|O to|O BRCA1|O .|O
Apoptosis|B-DISE has|O recently|O been|O recognized|O as|O a|O mode|O of|O cell|O death|O in|O Huntington|B-DISE disease|I-DISE HD|B-DISE .|O
For|O within|O -|O family|O association|O studies|O ,|O 361|O families|O including|O 161|O parent|O -|O case|O trios|O and|O 200|O affected|O sibling|O -|O pair|O families|O were|O employed|O .|O
We|O show|O that|O hCds1|O and|O BRCA1|O interact|O and|O co|O -|O localize|O within|O discrete|O nuclear|O foci|O but|O separate|O after|O gamma|O irradiation|O .|O
The|O present|O results|O question|O the|O sensitivity|O of|O the|O perchlorate|O test|O for|O the|O diagnosis|O of|O Pendred|B-DISE syndrome|I-DISE and|O support|O the|O use|O of|O a|O molecular|O analysis|O of|O the|O PDS|O gene|O in|O the|O assessment|O of|O individuals|O with|O severe|O to|O profound|O congenital|B-DISE hearing|I-DISE loss|I-DISE associated|O with|O inner|B-DISE ear|I-DISE morphological|I-DISE anomaly|I-DISE even|O in|O the|O absence|O of|O a|O thyroid|O goiter|B-DISE .|O .|O
This|O is|O the|O most|O comprehensive|O compilation|O of|O ATM|O polymorphisms|O assembled|O to|O date|O .|O
Anterior|B-DISE segment|I-DISE developmental|I-DISE disorders|I-DISE ,|O including|O Axenfeld|B-DISE -|I-DISE Rieger|I-DISE anomaly|I-DISE (|O ARA|B-DISE )|O ,|O variably|O associate|O with|O harmfully|O elevated|B-DISE intraocular|I-DISE pressure|I-DISE (|O IOP|O )|O ,|O which|O causes|O glaucoma|B-DISE .|O
There|O are|O at|O least|O eight|O clinically|O distinct|O autosomal|O dominant|O and|O two|O X|O -|O linked|O recessive|O forms|O .|O
Therefore|O ,|O HFE|O appears|O to|O reduce|O cellular|O acquisition|O of|O iron|O from|O Tf|O within|O endocytic|O compartments|O .|O
These|O studies|O shed|O further|O light|O on|O the|O genotype|O -|O phenotype|O correlation|O of|O MPS|B-DISE IVA|I-DISE and|O structure|O -|O function|O relationship|O in|O the|O sulfatase|O family|O .|O .|O
Nucleotide|O sequence|O analysis|O of|O GPIa|O cDNA|O derived|O from|O Sit|O (|O a|O )|O -|O positive|O platelets|O showed|O C|O 2531|O -|O -|O >|O T|O (|O 2531|O )|O point|O mutation|O ,|O resulting|O in|O Thr|O (|O 799|O )|O Met|O dimorphism|O .|O
This|O effect|O ,|O rather|O than|O depending|O on|O ligand|O -|O induced|O receptor|O oligomerization|O ,|O was|O found|O to|O stem|O from|O ligand|O -|O independent|O interaction|O of|O wild|O -|O type|O and|O mutant|O Fas|O receptors|O through|O a|O specific|O region|O in|O the|O extracellular|O domain|O .|O
We|O also|O found|O random|O X|O -|O inactivation|O in|O the|O mother|O of|O the|O patient|O who|O was|O shown|O to|O be|O a|O carrier|O of|O this|O deletion|O .|O .|O
Its|O membrane|O expression|O is|O highly|O regulated|O by|O endocytosis|O and|O trafficking|O through|O the|O secretory|O lysosome|O pathway|O .|O
There|O were|O no|O obvious|O mutation|O hot|O spots|O or|O clusters|O .|O
Prader|B-DISE -|I-DISE Willi|I-DISE syndrome|I-DISE (|O PWS|B-DISE )|O is|O caused|O by|O the|O loss|O of|O expression|O of|O imprinted|O genes|O in|O chromosome|O 15q11|O -|O q13|O .|O
Studies|O at|O the|O mRNA|O level|O showed|O that|O the|O latter|O led|O to|O altered|O pre|O -|O mRNA|O splicing|O with|O consequent|O alteration|O of|O the|O mRNA|O translational|O reading|O frame|O and|O generation|O of|O a|O premature|O termination|O codon|O of|O translation|O .|O
The|O patient|O was|O hemizygous|O for|O both|O the|O KIT|O and|O PDGFRA|O genes|O ,|O indicating|O that|O both|O of|O these|O genes|O are|O included|O within|O the|O deleted|O region|O .|O
We|O detected|O a|O significant|O segregation|O distortion|O in|O the|O data|O as|O a|O whole|O (|O P|O =|O .|O 0099|O )|O and|O a|O significant|O heterogeneity|O in|O the|O segregation|O rate|O across|O donors|O .|O 0092|O .|O
Overall|O ,|O the|O establishment|O of|O a|O likely|O "|O hemochromatosis|B-DISE critical|O region|O "|O centromeric|O boundary|O and|O the|O identification|O of|O a|O linkage|O -|O disequilibrium|O zone|O both|O significantly|O contribute|O to|O a|O reduction|O in|O the|O amount|O of|O DNA|O required|O to|O be|O searched|O for|O novel|O coding|O sequences|O constituting|O the|O HFE|O defect|O .|O .|O
Here|O we|O describe|O a|O new|O diagnostic|O test|O to|O identify|O male|O patients|O with|O fragile|B-DISE X|I-DISE syndrome|I-DISE ,|O on|O the|O basis|O of|O lack|O of|O FMRP|O in|O their|O hair|O roots|O .|O
Emerin|O was|O not|O detected|O in|O the|O biopsied|O muscle|O ,|O and|O RT|O -|O PCR|O and|O PCR|O -|O based|O genomic|O DNA|O analyses|O of|O the|O emerin|O gene|O demonstrated|O no|O amplification|O product|O in|O the|O patient|O .|O
Short|O regions|O of|O sequence|O homology|O were|O present|O at|O the|O three|O sites|O .|O
In|O addition|O ,|O preliminary|O pedigree|O analysis|O suggests|O that|O the|O gene|O for|O canine|O C3|B-DISE deficiency|I-DISE is|O apparently|O not|O closely|O linked|O to|O the|O major|O histocompatibility|O complex|O of|O the|O dog|O .|O
The|O hyperalphalipoproteinemia|B-DISE caused|O by|O CETP|B-DISE deficiency|I-DISE is|O fairly|O common|O in|O Japan|O and|O one|O of|O the|O most|O common|O mutations|O in|O the|O CETP|O gene|O is|O the|O splicing|O defect|O of|O the|O intron|O 14|O ,|O the|O allelic|O frequency|O of|O which|O has|O been|O shown|O to|O be|O 0|O .|O 0049|O in|O the|O Japanese|O general|O population|O .|O
C7|O M|O /|O N|O protein|O polymorphism|O allotyping|O ,|O used|O to|O investigate|O the|O segregation|O of|O the|O C7|B-DISE deficiency|I-DISE genes|O ,|O showed|O that|O the|O apparently|O complement|O sufficient|O brother|O was|O heterozygous|O C7|O deficient|O and|O a|O carrier|O of|O one|O of|O the|O deficiency|O genes|O .|O
HFE|O is|O an|O MHC|O -|O related|O protein|O that|O is|O mutated|O in|O the|O iron|O -|O overload|O disease|O hereditary|B-DISE hemochromatosis|I-DISE .|O
It|O is|O well|O known|O that|O an|O elevated|O frequency|O of|O TSD|B-DISE mutations|O exists|O among|O Ashkenazi|O Jews|O .|O
The|O disease|O gene|O (|O PDS|O )|O has|O been|O mapped|O to|O chromosome|O 7q22|O -|O q31|O ,|O and|O encodes|O a|O chloride|O -|O iodide|O transport|O protein|O .|O
Wilms|B-DISE tumor|I-DISE has|O so|O far|O only|O been|O associated|O with|O sporadic|O de|O novo|O aniridia|B-DISE cases|O .|O
Constitutional|O mutations|O of|O the|O WT1|O gene|O ,|O encoding|O a|O zinc|O -|O finger|O transcription|O factor|O involved|O in|O renal|O and|O gonadal|O development|O ,|O are|O found|O in|O most|O patients|O with|O Denys|B-DISE -|I-DISE Drash|I-DISE syndrome|I-DISE (|O DDS|B-DISE )|O ,|O or|O diffuse|B-DISE mesangial|I-DISE sclerosis|I-DISE (|O DMS|B-DISE )|O associated|O with|O pseudohermaphroditism|B-DISE and|O /|O or|O Wilms|B-DISE tumor|I-DISE WT|B-DISE .|O
The|O gene|O structure|O of|O FHF2|O was|O determined|O and|O two|O new|O exons|O were|O identified|O ,|O including|O a|O new|O 5|O '|O end|O exon|O ,|O 1B|O .|O
One|O hundred|O and|O twenty|O -|O eight|O of|O 145|O patients|O with|O ankylosing|B-DISE spondylitis|I-DISE (|O AS|B-DISE )|O were|O found|O to|O be|O HLA|O B27|O positive|O .|O
Women|O who|O carry|O a|O mutation|O in|O the|O BRCA1|O gene|O (|O on|O chromosome|O 17q21|O )|O ,|O have|O an|O 80|O %|O risk|O of|O breast|B-DISE cancer|I-DISE and|O a|O 40|O %|O risk|O of|O ovarian|B-DISE cancer|I-DISE by|O the|O age|O of|O 70|O ref|O .|O 1|O .|O
Here|O we|O demonstrate|O that|O nibrin|O is|O phosphorylated|O within|O one|O hour|O of|O treatment|O of|O cells|O with|O IR|O .|O
Here|O we|O describe|O the|O use|O of|O two|O sequences|O from|O the|O human|O Duchenne|B-DISE muscular|I-DISE dystrophy|I-DISE (|O DMD|O )|O gene|O that|O cross|O -|O hybridize|O to|O mouse|O X|O -|O linked|O sequences|O to|O localize|O the|O gene|O homologous|O to|O DMD|O in|O the|O mouse|O .|O
In|O order|O to|O test|O the|O effect|O of|O this|O substitution|O ,|O an|O in|O vitro|O mutagenized|O cDNA|O construct|O was|O introduced|O into|O a|O mammalian|O expression|O vector|O and|O transfected|O into|O monkey|O Cos|O -|O 1|O cells|O separately|O or|O along|O with|O a|O beta|O -|O cDNA|O expression|O vector|O .|O
We|O found|O constitutional|O deletions|O in|O 29|O of|O 30|O VHL|B-DISE patients|O in|O this|O group|O using|O cosmid|O and|O P1|O probes|O that|O cover|O the|O VHL|O locus|O .|O
We|O observed|O a|O consistent|O ,|O although|O modest|O ,|O reactivation|O of|O the|O FMR1|O gene|O with|O 4|O -|O phenylbutyrate|O ,|O sodium|O butyrate|O and|O trichostatin|O A|O ,|O as|O shown|O by|O RT|O -|O PCR|O .|O
We|O searched|O for|O criteria|O that|O could|O indicate|O breast|O cancer|O families|O with|O a|O high|O prior|O probability|O of|O being|O caused|O by|O the|O breast|B-DISE /|I-DISE ovarian|I-DISE cancer|I-DISE susceptibility|O locus|O BRCA1|O on|O chromosome|O 17|O .|O
The|O serum|O of|O a|O 29|O -|O year|O old|O woman|O with|O a|O recent|O episode|O of|O disseminated|B-DISE gonococcal|I-DISE infection|I-DISE and|O a|O history|O of|O meningococcal|B-DISE meningitis|I-DISE and|O arthritis|B-DISE as|O a|O child|O was|O found|O to|O lack|O serum|O hemolytic|O complement|O activity|O .|O
We|O conclude|O that|O the|O codon|O change|O N314D|O in|O cis|O with|O the|O base|O -|O pair|O transition|O 1721C|O -|O -|O T|O produces|O the|O LA|O variant|O of|O galactosemia|B-DISE and|O that|O this|O nucleotide|O change|O increases|O GALT|O activity|O by|O increasing|O GALT|O protein|O abundance|O without|O increasing|O transcription|O or|O decreasing|O thermal|O lability|O .|O
Three|O of|O these|O patients|O had|O pure|O spinal|O SEP|O abnormalities|O and|O in|O the|O remaining|O two|O patients|O SEPs|O showed|O signs|O of|O involvement|O of|O both|O the|O spinal|O and|O cerebral|O somatosensory|O tracts|O .|O
We|O observed|O RCC|B-DISE in|O at|O least|O one|O member|O of|O the|O VHL|B-DISE families|O in|O 77|O %|O of|O cases|O with|O mutations|O leading|O to|O truncated|O proteins|O versus|O 55|O %|O in|O cases|O with|O missense|O mutations|O P|O <|O 0|O .|O 05|O .|O
Because|O the|O CCC|O sequence|O motifs|O comprise|O a|O significant|O proportion|O (|O 34|O .|O 5|O %|O )|O of|O all|O mutated|O bases|O that|O have|O been|O observed|O in|O HGO|O ,|O we|O conclude|O that|O the|O CCC|O triplet|O is|O a|O mutational|O hot|O spot|O in|O HGO|O .|O .|O
The|O chromosome|O 22q11|O region|O is|O susceptible|O to|O rearrangements|O that|O are|O associated|O with|O congenital|B-DISE anomaly|I-DISE disorders|I-DISE and|O malignant|B-DISE tumors|I-DISE .|O
The|O diagnosis|O was|O clarified|O by|O molecular|O analysis|O of|O the|O DTDST|O gene|O ,|O which|O revealed|O homozygosity|O for|O a|O previously|O undescribed|O mutation|O leading|O to|O a|O Q454P|O substitution|O in|O the|O 10th|O transmembrane|O domain|O of|O the|O DTDST|O sulfate|O transporter|O .|O
Five|O of|O nine|O siblings|O of|O the|O patient|O ,|O comprising|O two|O cerebral|O ALD|B-DISE ,|O one|O adrenomyeloneuropathy|B-DISE ,|O one|O Addison|O only|O as|O well|O as|O the|O symptomatic|O mother|O (|O all|O accumulating|O very|O long|O chain|O fatty|O acids|O )|O carried|O this|O mutation|O ,|O which|O was|O not|O found|O in|O the|O unaffected|O persons|O ,|O in|O five|O unrelated|O ALD|B-DISE patients|O ,|O and|O in|O twenty|O controls|O .|O
This|O represents|O the|O first|O point|O mutation|O not|O resulting|O in|O a|O proposed|O truncated|O protein|O .|O
Since|O the|O newly|O created|O donor|O splice|O site|O is|O likely|O to|O compete|O with|O the|O normal|O one|O ,|O variations|O of|O the|O levels|O of|O normal|O and|O aberrant|O transcripts|O of|O the|O PDS|O gene|O in|O the|O cochlea|O may|O explain|O the|O variability|O in|O the|O deafness|B-DISE presentation|O .|O .|O
The|O 8|O ARSA|O exons|O and|O adjacent|O intron|O boundaries|O from|O a|O patient|O with|O late|B-DISE -|I-DISE infantile|I-DISE metachromatic|I-DISE leukodystrophy|I-DISE were|O polymerase|O chain|O reaction|O (|O PCR|O )|O amplified|O in|O seven|O discrete|O reactions|O .|O
CONCLUSIONS|O :|O Oral|O -|O contraceptive|O use|O may|O reduce|O the|O risk|O of|O ovarian|B-DISE cancer|I-DISE in|O women|O with|O pathogenic|O mutations|O in|O the|O BRCA1|O or|O BRCA2|O gene|O .|O .|O
The|O map|O derived|O from|O the|O YL1|O .|O 28|O -|O YAC|O is|O compatible|O both|O with|O the|O map|O from|O an|O independently|O derived|O YAC|O carrying|O MAOA|O and|O B|O genes|O and|O with|O the|O long|O range|O genomic|O map|O for|O the|O region|O .|O
Choroideremia|B-DISE (|O CHM|B-DISE )|O is|O an|O X|O -|O linked|O progressive|O degeneration|B-DISE of|I-DISE the|I-DISE choroid|I-DISE and|I-DISE retina|I-DISE .|O 12|O %|O of|O unrelated|O male|O patients|O carry|O deletions|O of|O the|O partially|O cloned|O CHM|O gene|O .|O
The|O results|O reported|O here|O indicate|O that|O (|O 1|O )|O familial|B-DISE adenomatous|I-DISE polyposis|I-DISE is|O caused|O by|O an|O extremely|O heterogeneous|O spectrum|O of|O point|O mutations|O ;|O (|O 2|O )|O all|O the|O mutations|O found|O in|O this|O study|O are|O chain|O terminating|O ;|O and|O (|O 3|O )|O DGGE|O represents|O a|O rapid|O and|O sensitive|O technique|O for|O the|O detection|O of|O mutations|O in|O the|O unusually|O large|O APC|O gene|O .|O
Juvenile|B-DISE retinoschisis|I-DISE is|O an|O X|B-DISE -|I-DISE linked|I-DISE recessive|I-DISE disease|I-DISE caused|O by|O mutations|O in|O the|O XLRS1|O gene|O .|O
Inherited|O defects|O in|O the|O peroxisomal|O ATP|O -|O binding|O cassette|O (|O ABC|O )|O transporter|O adrenoleukodystrophy|B-DISE protein|O (|O ALDP|O )|O lead|O to|O the|O lethal|O peroxisomal|O disorder|O X|O -|O linked|O adrenoleukodystrophy|O (|O X|O -|O ALD|B-DISE )|O ,|O for|O which|O no|O efficient|O treatment|O has|O been|O established|O so|O far|O .|O
Homozygous|O C2|B-DISE deficiency|I-DISE in|O a|O 19|O -|O year|O -|O old|O boy|O was|O associated|O with|O variable|O immunodeficiency|B-DISE manifested|O by|O marked|O hypoimmunoglobulinemia|O and|O impaired|O antibody|O responses|O ,|O normal|O circulating|O B|O lymphocytes|O ,|O and|O subnormal|O T|O -|O cell|O functions|O .|O
The|O segregation|O probability|O of|O mutant|O RB1|O alleles|O in|O sperm|O samples|O was|O assessed|O by|O use|O of|O the|O SPERMSEG|O program|O ,|O which|O includes|O experimental|O parameters|O ,|O recombination|O fractions|O between|O the|O markers|O ,|O and|O segregation|O parameters|O .|O
One|O family|O manifesting|O an|O autosomal|O dominant|O pattern|O of|O inheritance|O possessed|O three|O clinically|O affected|O members|O who|O were|O heterozygous|O for|O a|O splice|O -|O site|O mutation|O that|O was|O predicted|O to|O lead|O to|O the|O production|O of|O a|O truncated|O protein|O product|O .|O
The|O PAX3|O /|O FKHR|O fusion|O gene|O ,|O formed|O by|O a|O t|O 2|O ;|O 13|O (|O q35|O ;|O q14|O )|O in|O alveolar|B-DISE rhabdomyosarcoma|I-DISE ,|O encodes|O a|O hybrid|O protein|O that|O contains|O both|O PAX3|O DNA|O binding|O domains|O ,|O the|O paired|O box|O and|O homeodomain|O ,|O linked|O to|O the|O bisected|O DNA|O binding|O domain|O of|O FKHR|O ,|O a|O member|O of|O the|O forkhead|O family|O of|O transcription|O factors|O .|O
We|O then|O analyzed|O the|O occurrence|O of|O RCC|O in|O VHL|B-DISE families|O ,|O based|O on|O the|O nature|O of|O mutations|O .|O
In|O total|O ,|O recurrent|O mutations|O were|O found|O in|O 33|O (|O 94|O %|O )|O of|O the|O 35|O families|O with|O detected|O mutations|O .|O
Deficiency|B-DISE of|I-DISE arylsulfatase|I-DISE A|I-DISE (|O ARSA|O )|O enzyme|O activity|O causes|O metachromatic|B-DISE leukodystrophy|I-DISE MLD|B-DISE .|O
There|O were|O no|O behavioural|B-DISE problems|I-DISE or|O sleep|B-DISE disturbance|I-DISE .|O
CONCLUSION|O :|O These|O results|O indicate|O that|O mutations|O in|O the|O rds|O gene|O can|O be|O expressed|O as|O a|O macular|B-DISE dystrophy|I-DISE ,|O with|O evidence|O of|O primary|O cone|B-DISE dysfunction|I-DISE and|O preservation|O of|O peripheral|B-DISE rod|I-DISE function|I-DISE .|O .|O
These|O and|O other|O variants|O reported|O in|O the|O literature|O ,|O which|O must|O thus|O far|O be|O regarded|O as|O sporadic|O ,|O are|O found|O to|O map|O in|O parts|O of|O Italy|O where|O common|O types|O of|O G6PD|B-DISE deficiency|I-DISE are|O also|O prevalent|O .|O .|O
We|O hypothesize|O that|O ACTC|O mutations|O affecting|O sarcomere|O contraction|O lead|O to|O FHC|O and|O that|O mutations|O affecting|O force|O transmission|O from|O the|O sarcomere|O to|O the|O surrounding|O syncytium|O lead|O to|O IDC|B-DISE .|O .|O
Here|O ,|O we|O report|O that|O the|O human|O homolog|O ,|O TSG101|O ,|O which|O we|O isolated|O and|O mapped|O to|O chromosome|O 11|O ,|O bands|O 15|O .|O 1|O -|O 15|O .|O 2|O ,|O a|O region|O proposed|O to|O contain|O tumor|O suppressor|O gene|O (|O s|O )|O ,|O is|O mutated|O at|O high|O frequency|O in|O human|O breast|B-DISE cancer|I-DISE .|O
An|O allogeneic|O bone|O marrow|O transplant|O (|O BMT|O )|O from|O a|O normal|O HLA|O identical|O sibling|O donor|O was|O performed|O in|O a|O 13|O -|O year|O -|O old|O boy|O with|O rapidly|O progressive|O adrenoleukodystrophy|B-DISE ALD|B-DISE .|O
Histology|O ,|O grade|O ,|O stage|O ,|O and|O success|O of|O cytoreductive|O surgery|O were|O similar|O for|O hereditary|O and|O sporadic|O cases|O .|O
Pair|O -|O wise|O analyses|O resulted|O in|O maximum|O lod|O (|O logarithm|O of|O the|O odds|O ratio|O )|O scores|O of|O 3|O .|O 84|O and|O 2|O .|O 9|O ,|O respectively|O .|O
We|O have|O previously|O described|O a|O disorder|O ,|O normotriglyceridemic|O abetalipoproteinemia|B-DISE ,|O that|O is|O characterized|O by|O the|O virtual|O absence|O of|O plasma|O low|O density|O lipoproteins|O and|O complete|O absence|O of|O apoB|O -|O 100|O ,|O but|O with|O apparently|O normal|O secretion|O of|O triglyceride|O -|O rich|O lipoproteins|O containing|O apoB|O -|O 48|O .|O
The|O emerin|O gene|O has|O been|O mapped|O to|O Xq28|O and|O encodes|O a|O 34|O -|O kDa|O serine|O -|O rich|O protein|O ,|O emerin|O ,|O which|O has|O been|O localized|O to|O the|O nuclear|O envelope|O in|O a|O wide|O variety|O of|O tissues|O ,|O including|O skeletal|O and|O cardiac|O muscle|O .|O
We|O present|O a|O large|O kindred|O that|O contained|O patients|O with|O either|O adrenoleukodystrophy|B-DISE (|O ALD|B-DISE )|O or|O adrenomyeloneuropathy|B-DISE AMN|B-DISE .|O
This|O study|O illustrates|O the|O extreme|O heterogeneity|O of|O G6PD|B-DISE deficiency|I-DISE among|O the|O people|O of|O Papua|O New|O Guinea|O .|O .|O
Autosomal|O recessive|O Alport|B-DISE syndrome|I-DISE is|O a|O progressive|O hematuric|O glomerulonephritis|B-DISE characterized|O by|O glomerular|O basement|O membrane|O abnormalities|O and|O associated|O with|O mutations|O in|O either|O the|O COL4A3|O or|O the|O COL4A4|O gene|O ,|O which|O encode|O the|O alpha3|O and|O alpha4|O type|O IV|O collagen|O chains|O ,|O respectively|O .|O
A|O linkage|O study|O in|O 30|O Becker|B-DISE muscular|I-DISE dystrophy|I-DISE (|O BMD|B-DISE )|O kindreds|O using|O three|O cloned|O DNA|O sequences|O from|O the|O X|O chromosome|O which|O demonstrate|O restriction|O fragment|O length|O polymorphisms|O (|O RFLPs|O )|O ,|O suggests|O that|O the|O BMD|O gene|O is|O located|O on|O the|O short|O arm|O of|O the|O X|O chromosome|O ,|O in|O the|O p21|O region|O .|O
We|O describe|O a|O 19|O -|O year|O -|O old|O woman|O with|O typical|O MG|B-DISE and|O heterozygous|O C2|B-DISE deficiency|I-DISE ,|O along|O with|O HLA|O typing|O of|O the|O patient|O and|O her|O immediate|O family|O .|O .|O
Adult|O -|O onset|O cerebral|O ALD|B-DISE also|O presents|O with|O rapidly|O progressive|O neurologic|O dysfunction|O .|O
We|O identified|O a|O treatment|O regimen|O that|O resulted|O in|O the|O presence|O of|O dystrophin|O in|O the|O cell|O membrane|O in|O all|O striated|O muscles|O examined|O and|O that|O provided|O functional|O protection|O against|O muscular|O injury|O .|O
APC|O and|O APC2|O may|O therefore|O have|O comparable|O functions|O in|O development|O and|O cancer|B-DISE .|O .|O
Hereditary|B-DISE hemochromatosis|I-DISE (|O HH|B-DISE )|O is|O a|O common|O autosomal|O recessive|O genetic|B-DISE disorder|Mention text="genetic disorder" start=10 end=12 type=DISE prob=null&Mention text="disorder of iron metabolism" start=11 end=15 type=DISE prob=null of|I-DISE iron|I-DISE metabolism|I-DISE .|O
The|O cosmids|O isolated|O from|O these|O experiments|O were|O used|O to|O screen|O a|O panel|O of|O somatic|O cell|O hybrids|O containing|O chromosome|O 5|O segregated|O from|O patients|O suspected|O to|O carry|O putative|O interstitial|O deletions|O .|O
Wilson|B-DISE disease|I-DISE (|O WD|B-DISE )|O is|O an|O autosomal|O recessive|O disorder|O characterized|O by|O copper|O accumulation|O in|O the|O liver|O ,|O brain|O ,|O kidneys|O ,|O and|O corneas|O ,|O and|O culminating|O in|O copper|B-DISE toxication|I-DISE in|O these|O organs|O .|O
Although|O the|O link|O between|O the|O BRCA1|O tumour|O -|O suppressor|O gene|O and|O hereditary|B-DISE breast|I-DISE and|I-DISE ovarian|I-DISE cancer|I-DISE is|O established|O ,|O the|O role|O ,|O if|O any|O ,|O of|O BRCA1|O in|O non|O -|O familial|O cancers|O is|O unclear|O .|O
Atm|O -|O deficient|O mice|O then|O exhibit|O many|O of|O the|O same|O symptoms|O found|O in|O ataxia|B-DISE -|I-DISE telangiectasia|I-DISE patients|O and|O in|O cells|O derived|O from|O them|O .|O
We|O generated|O mice|O in|O which|O two|O loxP|O sites|O flank|O part|O of|O Piga|O exon|O 2|O .|O
These|O mutations|O segregated|O with|O mutant|O haplotype|O 12|O alleles|O in|O nuclear|O families|O but|O were|O not|O present|O on|O normal|O or|O other|O mutant|O alleles|O .|O
Parent|O -|O of|O -|O origin|O studies|O were|O performed|O in|O five|O families|O .|O
Familial|B-DISE Mediterranean|I-DISE fever|I-DISE (|O FMF|B-DISE )|O is|O a|O recessive|B-DISE disorder|I-DISE characterized|O by|O episodes|O of|O fever|O and|O neutrophil|O -|O mediated|O serosal|B-DISE inflammation|I-DISE .|O
These|O techniques|O should|O prove|O useful|O in|O identifying|O carriers|O of|O severe|O von|B-DISE Willebrand|I-DISE disease|I-DISE and|O also|O in|O defining|O patients|O predictably|O at|O risk|O of|O developing|O alloantibodies|O to|O vWF|O .|O .|O
A|O male|O Caucasian|O who|O participated|O in|O six|O bioavailability|O studies|O in|O our|O laboratory|O over|O a|O period|O of|O several|O years|O showed|O extremely|O low|O clearance|O of|O two|O drugs|O :|O phenytoin|O and|O glipizide|O (|O both|O substrates|O of|O CYP2C9|O )|O ,|O but|O not|O for|O nifedipine|O (|O a|O CYP3A4|O substrate|O )|O and|O chlorpheniramine|O a|O CYP2D6|O substrate|O .|O
We|O have|O performed|O a|O mutation|O survey|O of|O the|O RB1|O gene|O in|O 232|O patients|O with|O hereditary|O or|O non|O hereditary|B-DISE retinoblastoma|I-DISE .|O
The|O fragile|O site|O is|O not|O associated|O with|O mental|B-DISE retardation|I-DISE ,|O it|O does|O not|O give|O abnormal|O results|O when|O subjected|O to|O Southern|O analysis|O with|O probe|O pfxa3|O which|O detects|O the|O unstable|O DNA|O sequence|O characteristic|O of|O fragile|B-DISE X|I-DISE syndrome|I-DISE .|O
We|O also|O show|O that|O ATM|O physically|O interacts|O with|O and|O phosphorylates|O nibrin|O on|O serine|O 343|O both|O in|O vivo|O and|O in|O vitro|O .|O
It|O is|O concluded|O that|O the|O most|O likely|O explanation|O for|O this|O defect|O is|O that|O the|O subject|O has|O a|O structural|O mutation|O in|O his|O C6|O gene|O which|O produces|O hyopsynthesis|O not|O only|O of|O C6|O but|O also|O of|O the|O closely|O linked|O gene|O for|O C7|O .|O
DiGeorge|B-DISE syndrome|I-DISE (|O DGS|B-DISE )|O ,|O a|O developmental|O field|O defect|B-DISE of|I-DISE the|I-DISE third|I-DISE and|I-DISE fourth|I-DISE pharyngeal|I-DISE pouches|I-DISE ,|O is|O characterized|O by|O aplasia|B-DISE or|I-DISE hypoplasia|I-DISE of|I-DISE the|I-DISE thymus|I-DISE and|I-DISE parathyroid|I-DISE glands|O and|O by|O conotruncal|O cardiac|B-DISE malformations|I-DISE .|O
We|O measured|O resting|O ventilation|O ,|O airway|O occlusion|O pressure|O P|O 0|O .|O 1|O and|O ventilatory|O response|O to|O CO|O (|O 2|O )|O in|O nine|O children|O ,|O aged|O 7|O -|O 14|O years|O ,|O before|O and|O 6|O -|O 9|O months|O after|O the|O start|O of|O GH|O treatment|O .|O
The|O classic|O form|O of|O ALD|B-DISE usually|O has|O onset|O in|O childhood|O (|O childhood|O cerebral|O ALD|B-DISE )|O ,|O with|O rapid|O neurologic|B-DISE deterioration|I-DISE leading|O to|O a|O vegetative|O state|O .|O
Oocyte|O macropatch|O analysis|O revealed|O that|O the|O activation|O kinetics|O of|O T1620M|O were|O normal|O .|O
The|O mAb|O L10|O was|O used|O to|O determine|O the|O distribution|O and|O the|O function|O of|O sialophorin|O ,|O the|O heavily|O glycosylated|O surface|O molecule|O that|O is|O deficient|O /|O defective|O in|O lymphocytes|O of|O patients|O with|O the|O X|O -|O linked|O immunodeficiency|O Wiskott|B-DISE -|I-DISE Aldrich|I-DISE syndrome|I-DISE .|O
Identification|O of|O the|O FMR1|O gene|O and|O the|O repeat|O -|O amplification|O mechanism|O causing|O fragile|B-DISE X|I-DISE syndrome|I-DISE led|O to|O development|O of|O reliable|O DNA|O -|O based|O diagnostic|O methods|O ,|O including|O Southern|O blot|O hybridization|O and|O PCR|O .|O
Most|O VCFS|B-DISE /|O DGS|B-DISE patients|O have|O a|O similar|O 3|O Mb|O deletion|O ,|O some|O have|O a|O nested|O distal|O deletion|O breakpoint|O resulting|O in|O a|O 1|O .|O 5|O Mb|O deletion|O and|O a|O few|O rare|O patients|O have|O unique|O deletions|O or|O translocations|O .|O
Our|O data|O support|O a|O tumour|O suppressor|O mechanism|O for|O BRCA1|O ;|O somatic|O mutations|O and|O LOH|O may|O result|O in|O inactivation|O of|O BRCA1|O in|O at|O least|O a|O small|O number|O of|O ovarian|B-DISE cancers|I-DISE .|O .|O
These|O findings|O suggested|O a|O founder|O effect|O within|O Newfoundland|O similar|O to|O that|O reported|O by|O others|O for|O two|O MLH1|O mutations|O in|O Finnish|O HNPCC|B-DISE families|O .|O
Myotonic|B-DISE dystrophy|I-DISE (|O DM|B-DISE )|O is|O caused|O by|O a|O CTG|O repeat|O expansion|O in|O the|O 3|O '|O UTR|O of|O the|O DM|O protein|O kinase|O (|O DMPK|O )|O gene|O .|O
Recently|O ,|O a|O missense|O mutation|O in|O transmembrane|O domain|O 2|O of|O CHRNA4|O was|O found|O to|O be|O associated|O with|O autosomal|O dominant|O nocturnal|O frontal|B-DISE lobe|I-DISE epilepsy|I-DISE in|O one|O extended|O pedigree|O .|O
About|O half|O of|O all|O missense|O mutations|O have|O been|O examined|O by|O in|O vitro|O expression|O analysis|O ,|O and|O a|O significant|O correlation|O has|O been|O observed|O between|O residual|O PAH|O activity|O and|O disease|O phenotype|O .|O
Our|O data|O support|O the|O hypothesis|O that|O DM|B-DISE is|O a|O contiguous|B-DISE gene|I-DISE syndrome|I-DISE associated|O with|O the|O partial|O loss|O of|O both|O DMPK|O and|O SIX5|O .|O .|O
The|O other|O was|O at|O position|O 1186|O converting|O an|O asp|O >|O asn|O in|O the|O predicted|O resultant|O protein|O .|O
We|O have|O detected|O a|O submicroscopic|O 11p13|O deletion|O in|O a|O child|O with|O inherited|O aniridia|B-DISE who|O subsequently|O presented|O with|O Wilms|B-DISE tumor|I-DISE in|O a|O horseshoe|B-DISE kidney|I-DISE ,|O only|O revealed|O at|O surgery|O .|O
Our|O data|O therefore|O provide|O evidence|O that|O nm23|O -|O H1|O expression|O is|O related|O to|O cell|O proliferative|O activity|O .|O .|O
Recently|O ,|O we|O discovered|O that|O transgenic|O mice|O expressing|O an|O activated|O beta|O -|O catenin|O are|O predisposed|O to|O developing|O skin|B-DISE tumours|I-DISE resembling|O pilomatricomas|B-DISE .|O
Patients|O lacking|O this|O serum|O protein|O are|O essentially|O asymptomatic|O ,|O apart|O from|O minimal|O ankle|B-DISE edema|I-DISE and|O ease|O of|O fatigue|O .|O
The|O penetrance|O of|O clinically|O obvious|O abnormalities|O varies|O with|O genetic|O background|O .|O
Although|O we|O did|O not|O observe|O dramatic|O expansions|O (|O or|O '|O big|O jumps|O '|O over|O several|O hundred|O CTG|O repeats|O )|O as|O in|O congenital|B-DISE forms|I-DISE of|I-DISE DM|I-DISE ,|O our|O model|O carrying|O >|O 300|O CTG|O is|O the|O first|O to|O show|O instability|O so|O close|O to|O the|O human|O DM|O situation|O .|O
These|O data|O suggest|O that|O intracytoplasmic|O CD95|O mutations|O in|O ALPS|B-DISE impair|O apoptosis|O chiefly|O by|O disrupting|O death|O -|O domain|O interactions|O with|O the|O signaling|O protein|O FADD|O /|O MORT1|O .|O .|O
Thus|O ,|O genetic|O CETP|B-DISE deficiency|I-DISE appears|O to|O be|O an|O independent|O risk|O factor|O for|O CHD|O ,|O primarily|O due|O to|O increased|O CHD|O prevalence|O in|O men|O with|O the|O D442G|O mutation|O and|O HDL|O cholesterol|O between|O 41|O and|O 60|O mg|O /|O dl|O .|O
No|O inherited|O form|O of|O GPI|B-DISE -|I-DISE anchor|I-DISE deficiency|I-DISE has|O been|O described|O .|O
In|O summary|O ,|O inactivation|O of|O the|O murine|O ATP7B|O gene|O produces|O a|O form|O of|O cirrhotic|B-DISE liver|I-DISE disease|I-DISE that|O resembles|O Wilson|B-DISE disease|I-DISE in|O humans|O and|O the|O '|O toxic|O milk|O '|O phenotype|O in|O the|O mouse|O .|O .|O
On|O the|O basis|O of|O the|O present|O study|O ,|O the|O mechanism|O of|O anhaptoglobinemia|B-DISE and|O the|O mechanism|O of|O anomalous|O inheritance|O of|O Hp|O phenotypes|O were|O well|O explained|O .|O
We|O report|O a|O novel|O mutation|O in|O the|O XK|O gene|O (|O XK|O )|O in|O a|O Japanese|O patient|O with|O McLeod|B-DISE syndrome|I-DISE .|O
The|O incidence|O of|O ovarian|B-DISE ,|I-DISE gastric|I-DISE ,|I-DISE and|I-DISE biliary|I-DISE system|I-DISE carcinomas|I-DISE and|O of|O leukemia|B-DISE and|O lymphoma|B-DISE was|O increased|O in|O these|O A|B-DISE -|I-DISE T|I-DISE families|O .|O
Forty|O -|O six|O per|O cent|O of|O patients|O with|O mutations|O 5|O '|O of|O the|O Dp260|O transcript|O start|O site|O have|O abnormal|O ERGs|O ,|O as|O opposed|O to|O 94|O %|O with|O more|O distal|O mutations|O .|O
Interestingly|O ,|O all|O CHM|O gene|O mutations|O detected|O thus|O far|O in|O choroideremia|B-DISE patients|O give|O rise|O to|O the|O introduction|O of|O a|O premature|O stop|O codon|O .|O .|O
Mutations|O were|O retrieved|O in|O most|O rhabdoid|B-DISE tumors|I-DISE ,|O whatever|O their|O sites|O of|O occurrence|O ,|O indicating|O the|O common|O pathogenetic|O origin|O of|O these|O tumors|O .|O
Primary|B-DISE dystonias|I-DISE are|O movement|B-DISE disorders|I-DISE with|O dystonia|B-DISE as|O a|O major|O symptom|O .|O
These|O results|O are|O distinct|O from|O those|O previously|O noted|O in|O abetalipoproteinemia|B-DISE ,|O which|O was|O characterized|O by|O an|O elevated|O level|O of|O hepatic|O apoB|O mRNA|O and|O accumulation|O of|O intracellular|O hepatic|O apoB|O protein|O .|O .|O
Our|O results|O suggest|O that|O the|O most|O important|O determinant|O in|O the|O ERG|O b|O -|O wave|O phenotype|O is|O the|O mutation|O position|O ,|O rather|O than|O muscle|O disease|O severity|O .|O
BACKGROUND|O :|O SEPs|O and|O MEPs|O have|O proved|O useful|O in|O revealing|O signs|O of|O progressively|O severe|O ,|O central|O dying|O -|O back|O axonopathy|O in|O early|O stages|O of|O adult|O -|O onset|O ALD|B-DISE .|O
Recurrent|O middle|B-DISE ear|I-DISE infections|I-DISE ,|O a|O high|O pain|O threshold|O ,|O and|O a|O great|O skill|O with|O jigsaw|O puzzles|O were|O reported|O .|O
These|O results|O confirmed|O the|O diagnosis|O of|O X|B-DISE -|I-DISE linked|I-DISE Emery|I-DISE -|I-DISE Dreifuss|I-DISE muscular|I-DISE dystrophy|I-DISE (|O EDMD|B-DISE )|O ,|O and|O reinforce|O the|O necessity|O of|O molecular|O genetic|O diagnosis|O of|O the|O membrane|O protein|O emerin|O in|O younger|O patients|O with|O possible|O EDMD|B-DISE before|O appearance|O of|O the|O typical|O symptoms|O ,|O to|O avoid|O sudden|B-DISE cardiac|I-DISE death|I-DISE .|O .|O
Analysis|O ,|O using|O in|O addition|O two|O overlapping|O YAC|O clones|O from|O this|O region|O ,|O allowed|O orientation|O of|O the|O MAOA|O and|O MAOB|O genes|O in|O a|O 5|O '|O -|O 3|O '|O -|O 3|O '|O -|O 5|O '|O configuration|O .|O
In|O addition|O ,|O we|O found|O that|O the|O GCH1|O mRNA|O was|O transcribed|O from|O only|O one|O allele|O ,|O indicating|O that|O the|O other|O allele|O was|O in|O an|O inactive|O state|O .|O
BRCA1|O mutations|O cause|O increased|O risk|O for|O breast|B-DISE and|I-DISE ovarian|I-DISE cancer|I-DISE ,|O frequently|O of|O early|O onset|O .|O
These|O splicing|O mutations|O led|O to|O a|O variety|O of|O consequences|O ,|O including|O exon|O skipping|O and|O ,|O to|O a|O lesser|O degree|O ,|O intron|O retention|O ,|O activation|O of|O cryptic|O splice|O sites|O ,|O or|O creation|O of|O new|O splice|O sites|O .|O
The|O imprinting|O status|O of|O 22|O expressed|O sequence|O tags|O derived|O from|O the|O radiation|O -|O hybrid|O human|O transcript|O maps|O or|O physical|O maps|O was|O determined|O in|O a|O reverse|O transcriptase|O -|O PCR|O assay|O and|O correlated|O with|O the|O position|O of|O the|O transcripts|O on|O the|O physical|O map|O .|O
The|O results|O indicate|O that|O mutation|O of|O the|O VHL|O gene|O is|O associated|O exclusively|O with|O the|O development|O of|O non|O -|O papillary|O renal|B-DISE cell|I-DISE carcinoma|I-DISE .|O .|O
Three|O more|O frameshift|O mutations|O ,|O 2|O nonsense|O mutations|O ,|O and|O a|O second|O splice|O site|O mutation|O were|O also|O identified|O .|O
Here|O ,|O Luria|O and|O Delbruck|O '|O s|O classical|O methods|O for|O analysing|O bacterial|O cultures|O are|O adapted|O to|O the|O study|O of|O human|O isolated|O founder|O populations|O in|O order|O to|O estimate|O (|O i|O )|O the|O recombination|O fraction|O between|O a|O disease|O locus|O and|O a|O marker|O ;|O (|O ii|O )|O the|O expected|O degree|O of|O allelic|O homogeneity|O in|O a|O population|O ;|O and|O (|O iii|O )|O the|O mutation|O rate|O of|O marker|O loci|O .|O
Clinical|O and|O biochemical|O evidence|O suggested|O that|O the|O increased|O carrier|O frequency|O was|O due|O to|O at|O least|O two|O altered|O alleles|O for|O the|O hexosaminidase|O A|O alpha|O -|O subunit|O .|O
Altogether|O ,|O 70|O %|O of|O missense|O mutations|O are|O located|O in|O exon|O 15|O ,|O and|O 52|O %|O of|O all|O mutations|O cluster|O in|O exons|O 11|O -|O 15|O .|O
Comparing|O the|O distribution|O of|O mutations|O in|O a|O human|O housekeeping|O gene|O with|O evolutionary|O conservation|O is|O a|O useful|O tool|O for|O pinpointing|O amino|O acid|O residues|O important|O for|O the|O stability|O or|O the|O function|O of|O the|O corresponding|O protein|O .|O
Our|O results|O indicate|O that|O the|O severe|O form|O of|O prolidase|B-DISE deficiency|I-DISE is|O caused|O by|O multiple|O PEPD|O alleles|O .|O
We|O propose|O a|O model|O for|O pendrin|O function|O in|O the|O thyroid|O in|O which|O pendrin|O transports|O iodide|O across|O the|O apical|O membrane|O of|O the|O thyrocyte|O into|O the|O colloid|O space|O .|O .|O
Genetically|O determined|O C3|B-DISE deficiency|I-DISE in|O Brittany|O spaniel|O dogs|O shares|O a|O number|O of|O biochemical|O and|O clinical|O characteristics|O with|O the|O human|O disorder|O .|O
The|O apparent|O order|O of|O these|O loci|O is|O telomere|O .|O .|O .|O
Finally|O ,|O an|O extensive|O phenotyping|O of|O primary|O and|O secondary|O lymphoid|O organs|O including|O the|O gut|O provides|O no|O compelling|O evidence|O for|O an|O obvious|O immune|O -|O linked|O function|O for|O HFE|O .|O .|O
We|O conclude|O that|O the|O onset|O of|O FMF|B-DISE in|O a|O late|O age|O defines|O a|O milder|O form|O of|O disease|O with|O typical|O clinical|O ,|O demographic|O ,|O and|O molecular|O genetic|O characteristics|O .|O .|O
We|O have|O mapped|O the|O entire|O human|O SGLT1|O Na|O +|O /|O glucose|O cotransporter|O gene|O from|O cosmid|O and|O lambda|O phage|O clones|O representing|O a|O genomic|O region|O of|O 112|O kilobases|O .|O
Here|O we|O report|O that|O BRCA1|O interacts|O in|O vivo|O and|O in|O vitro|O with|O the|O Rb|O -|O binding|O proteins|O ,|O RbAp46|O and|O RbAp48|O ,|O as|O well|O as|O with|O Rb|O .|O
Direct|O DNA|O sequencing|O was|O done|O to|O screen|O the|O entire|O coding|O region|O of|O the|O WFS1|O gene|O in|O 30|O patients|O from|O 19|O British|O kindreds|O with|O Wolfram|B-DISE syndrome|I-DISE .|O
Inherited|O mutations|O in|O the|O E|O -|O cadherin|O gene|O (|O CDH1|O )|O were|O described|O recently|O in|O three|O Maori|O kindreds|O with|O familial|O gastric|B-DISE cancer|I-DISE .|O
It|O is|O disrupted|O and|O misexpressed|O in|O a|O number|O of|O mesenchymal|B-DISE tumour|I-DISE cell|O types|O ,|O including|O fat|O -|O cell|O tumours|B-DISE lipomas|B-DISE .|O
The|O human|O Lesch|B-DISE -|I-DISE Nyhan|I-DISE syndrome|I-DISE is|O a|O rare|O neurological|B-DISE and|I-DISE behavioural|I-DISE disorder|I-DISE ,|O affecting|O only|O males|O ,|O which|O is|O caused|O by|O an|O inherited|O deficiency|B-DISE in|I-DISE the|I-DISE level|I-DISE of|I-DISE activity|I-DISE of|I-DISE the|I-DISE purine|I-DISE salvage|I-DISE enzyme|I-DISE hypoxanthine|I-DISE -|I-DISE guanosine|I-DISE phosphoribosyl|I-DISE transferase|I-DISE HPRT|I-DISE .|O
The|O RB1|O gene|O mutation|O was|O investigated|O in|O a|O child|O with|O ectopic|O intracranial|O retinoblastoma|B-DISE using|O DNA|O obtained|O from|O both|O the|O pineal|B-DISE and|I-DISE retinal|I-DISE tumours|I-DISE of|O the|O patient|O .|O
Further|O linkage|O analyses|O of|O plausible|O candidate|O genes|O highly|O expressed|O in|O the|O adult|O human|O heart|O identified|O ACTC|O as|O the|O most|O likely|O disease|O gene|O ,|O showing|O a|O maximal|O lod|O score|O of|O 3|O .|O 6|O .|O
Mutations|O in|O the|O ARP|O gene|O are|O thus|O commonly|O observed|O in|O pancreatic|B-DISE cancer|I-DISE ,|O as|O well|O as|O many|O other|B-DISE cancers|I-DISE .|O .|O
Phenylketonuria|B-DISE (|O PKU|B-DISE )|O is|O a|O metabolic|B-DISE disease|I-DISE caused|B-DISE by|I-DISE recessive|I-DISE mutations|I-DISE of|I-DISE the|I-DISE gene|I-DISE encoding|I-DISE the|I-DISE hepatic|I-DISE enzyme|I-DISE phenylalanine|O hydroxylase|O PAH|O .|O
However|O ,|O the|O limited|O data|O failed|O to|O reveal|O a|O correlation|O between|O mutation|O and|O disease|O phenotype|O .|O
We|O identified|O a|O novel|O NIS|O gene|O mutation|O ,|O G395R|O (|O Gly395|O -|O -|O >|O Arg|O ;|O GGA|O -|O -|O >|O AGA|O )|O ,|O in|O 10|O patients|O examined|O in|O the|O present|O study|O .|O
These|O data|O demonstrate|O that|O ATM|O and|O the|O hMre11|O /|O hRad50|O /|O Nbs1|O protein|O complex|O act|O in|O the|O same|O DNA|O damage|O response|O pathway|O and|O link|O hMre11|O to|O the|O complex|O pathology|O of|O A|O -|O T|O .|O .|O
Moreover|O ,|O the|O BRCT|O domain|O associates|O with|O the|O histone|O deacetylases|O HDAC1|O and|O HDAC2|O .|O
They|O are|O frequently|O inherited|O as|O Mendelian|O traits|O .|O
Renal|B-DISE amyloidosis|I-DISE ,|O prevented|O by|O colchicine|O ,|O is|O the|O most|O severe|O complication|O of|O FMF|B-DISE ,|O a|O disorder|O associated|O with|O mutations|O in|O the|O MEFV|O gene|O .|O
These|O patients|O eventually|O go|O into|O end|B-DISE stage|I-DISE renal|I-DISE failure|I-DISE .|O
The|O other|O family|O members|O had|O heterozygous|O C2|B-DISE deficiency|I-DISE and|O each|O member|O had|O the|O HLA|O -|O A25|O ,|O B18|O ,|O DR2|O (|O w15|O )|O haplotype|O .|O
Subretinal|O injection|O of|O recombinant|O adeno|O -|O associated|O virus|O (|O AAV|O )|O encoding|O a|O Prph2|O transgene|O results|O in|O stable|O generation|O of|O outer|O segment|O structures|O and|O formation|O of|O new|O stacks|O of|O discs|O containing|O both|O perpherin|O -|O 2|O and|O rhodopsin|O ,|O which|O in|O many|O cases|O are|O morphologically|O similar|O to|O normal|O outer|O segments|O .|O
BRCA1|O and|O BRCA2|O account|O for|O most|O cases|O of|O familial|B-DISE ,|I-DISE early|I-DISE onset|I-DISE breast|I-DISE and|I-DISE /|I-DISE or|I-DISE ovarian|I-DISE cancer|I-DISE and|O encode|O products|O that|O each|O interact|O with|O hRAD51|O .|O
A|O very|O high|O level|O of|O instability|O is|O observed|O through|O successive|O generations|O and|O the|O size|O of|O the|O repeat|O is|O generally|O correlated|O with|O the|O severity|O of|O the|O disease|O and|O with|O age|O at|O onset|O .|O
In|O response|O to|O this|O stimulus|O ,|O cytoplasmic|O beta|O -|O catenin|O (|O encoded|O by|O CTNNB1|O )|O is|O stabilized|O ,|O enabling|O downstream|O transcriptional|O activation|O by|O members|O of|O the|O LEF|O /|O TCF|O family|O .|O
Therefore|O ,|O we|O screened|O eight|O familial|B-DISE gastric|I-DISE cancer|I-DISE kindreds|O of|O British|O and|O Irish|O origin|O for|O germline|O CDH1|O mutations|O ,|O by|O SSCP|O analysis|O of|O all|O 16|O exons|O and|O flanking|O sequences|O .|O
Opsonization|O and|O generation|O of|O chemotactic|O activity|O functioned|O normally|O .|O
In|O the|O 22|O point|O mutations|O ,|O 68|O %|O of|O mothers|O were|O heterozygous|O for|O the|O mutation|O ,|O a|O value|O identical|O to|O the|O two|O -|O thirds|O of|O carrier|O mothers|O that|O would|O be|O expected|O if|O there|O were|O an|O equal|O mutation|O rate|O in|O male|O and|O female|O germ|O cells|O .|O
PWS|B-DISE is|O due|O to|O a|O lack|O of|O paternal|O genetic|O information|O at|O 15q11|O -|O q13|O ref|O .|O 2|O .|O
Our|O limited|O data|O set|O on|O galactosemia|O mutations|O in|O Japanese|O suggests|O that|O the|O N314D|O GALT|O mutation|O encoding|O the|O Duarte|O variant|O arose|O before|O Asian|O and|O Caucasian|O people|O diverged|O and|O that|O classic|B-DISE galactosemia|I-DISE mutations|O arose|O and|O /|O or|O accumulated|O after|O the|O divergence|O of|O Asian|O and|O Caucasian|O populations|O .|O .|O
One|O hundred|O and|O seven|O ovarian|B-DISE cancer|I-DISE cases|O were|O analyzed|O for|O BRCA1|O alterations|O using|O the|O RNase|O mismatch|O cleavage|O assay|O followed|O by|O direct|O sequencing|O .|O
These|O findings|O show|O that|O BRCA1|O is|O implicated|O in|O a|O small|O fraction|O of|O breast|B-DISE /|I-DISE ovarian|I-DISE cancer|I-DISE families|O suggesting|O the|O involvement|O of|O another|O susceptibility|O gene|O s|O .|O .|O
Germ|O -|O line|O mutations|O of|O the|O BRCA1|O gene|O are|O responsible|O for|O a|O substantial|O proportion|O of|O families|O with|O multiple|O cases|O of|O early|B-DISE -|I-DISE onset|I-DISE breast|I-DISE and|I-DISE /|I-DISE or|I-DISE ovarian|I-DISE cancer|I-DISE .|O
By|O 4|O weeks|O of|O age|O ,|O the|O HFE|O -|O /|O -|O mice|O demonstrated|O iron|O loading|O when|O compared|O with|O HFE|O +|O /|O +|O littermates|O ,|O with|O elevated|O transferrin|O saturations|O (|O 68|O .|O 4|O %|O vs|O .|O 49|O .|O 8|O %|O )|O and|O elevated|O liver|O iron|O concentrations|O 985|O micrograms|O vs|O .|O 381|O micrograms|O .|O
A|O missense|O mutation|O ,|O Gly|O -|O 561|O -|O -|O Ser|O ,|O was|O identified|O within|O the|O proposed|O glycoprotein|O Ib|O binding|O domain|O of|O vWF|O in|O the|O proband|O with|O von|B-DISE Willebrand|I-DISE disease|I-DISE type|O B|O ,|O a|O unique|O variant|O characterized|O by|O no|O ristocetin|O -|O induced|O ,|O but|O normal|O botrocetin|O -|O induced|O ,|O binding|O to|O glycoprotein|O Ib|O .|O
In|O addition|O ,|O since|O all|O of|O the|O families|O originated|O in|O a|O population|O with|O a|O proven|O founder|O effect|O -|O the|O Saguenay|O Lac|O -|O St|O .|O -|O Jean|O region|O of|O Quebec|O -|O a|O common|O disease|O haplotype|O was|O sought|O .|O
Here|O we|O report|O that|O ,|O in|O two|O large|O case|O -|O control|O studies|O of|O over|O 2|O ,|O 000|O African|O children|O ,|O the|O common|O African|O form|O of|O G6PD|B-DISE deficiency|I-DISE (|O G6PD|O A|O -|O )|O is|O associated|O with|O a|O 46|O -|O 58|O %|O reduction|O in|O risk|O of|O severe|O malaria|B-DISE for|O both|O female|O heterozygotes|O and|O male|O hemizygotes|O .|O
Interestingly|O ,|O Arg|O -|O 610|O is|O located|O within|O one|O of|O the|O two|O pleckstrin|O homology|O (|O PH|O )|O domains|O of|O the|O FGD1|O gene|O and|O it|O corresponds|O to|O a|O highly|O conserved|O residue|O which|O has|O been|O involved|O in|O InsP|O binding|O in|O PH|O domains|O of|O other|O proteins|O .|O
There|O were|O 59|O deaths|O from|O malignant|B-DISE neoplasms|I-DISE in|O relatives|O dying|O before|O age|O 75|O ,|O compared|O to|O 42|O .|O 6|O expected|O p|O less|O than|O 0|O .|O 02|O .|O
In|O neuroblastoma|B-DISE ,|O higher|O levels|O of|O p19|O /|O nm23|O ,|O which|O are|O associated|O with|O amplification|O of|O the|O N|O -|O myc|O oncogene|O ,|O large|O tumor|O mass|O ,|O and|O metastasis|B-DISE ,|O were|O observed|O in|O advanced|O stage|O tumors|O compared|O with|O limited|O stage|O disease|O .|O
This|O is|O in|O accordance|O with|O molecular|O findings|O in|O other|O patients|O with|O Kniest|B-DISE dysplasia|I-DISE and|O confirms|O ,|O in|O the|O original|O patient|O ,|O that|O the|O disorder|O is|O caused|O by|O small|O inframe|O deletions|O often|O due|O to|O exon|O skipping|O as|O a|O result|O of|O COL2A1|O splice|O site|O mutations|O .|O .|O
This|O idea|O is|O based|O partly|O on|O the|O phenotype|O of|O homozygous|O Krox20|O (|O Egr2|O )|O knockout|O mice|O ,|O which|O display|O hypomyelination|O of|O the|O PNS|O and|O a|O block|O of|O Schwann|O cells|O at|O an|O early|O stage|O of|O differentiation|O .|O
Here|O ,|O we|O characterize|O the|O altered|O effects|O of|O a|O human|O beta|O (|O 1|O )|O -|O subunit|O hbeta|O 1|O on|O the|O heterologously|O expressed|O hH1|O mutation|O (|O T1620M|O )|O previously|O associated|O with|O IVF|B-DISE .|O
In|O contrast|O ,|O goiter|B-DISE was|O present|O in|O only|O 11|O affected|O individuals|O ,|O who|O interestingly|O had|O a|O normal|O result|O of|O the|O perchlorate|O discharge|O test|O whenever|O performed|O .|O
DMR|O -|O N9|O transcripts|O ,|O mainly|O expressed|O in|O brain|O and|O testis|O ,|O possess|O a|O single|O ,|O large|O open|O reading|O frame|O ,|O but|O the|O function|O of|O its|O protein|O product|O is|O unknown|O .|O
The|O risk|O for|O ovarian|B-DISE cancer|I-DISE was|O 2|O .|O 11|O times|O greater|O for|O BRCA1|O carriers|O harbouring|O one|O or|O two|O rare|O HRAS1|O alleles|O ,|O compared|O to|O carriers|O with|O only|O common|O alleles|O P|O =|O 0|O .|O 015|O .|O
Factor|B-DISE X|I-DISE deficiency|I-DISE is|O a|O rare|O haemorrhagic|B-DISE condition|I-DISE ,|O normally|O inherited|O as|O an|O autosomal|O recessive|O trait|O ,|O in|O which|O a|O variable|O clinical|O presentation|O correlates|O poorly|O with|O laboratory|O phenotype|O .|O
No|O pathogenic|O mtDNA|O mutations|O were|O found|O in|O our|O cohort|O .|O
Using|O large|O human|O flanking|O sequences|O and|O a|O large|O amplification|O ,|O we|O demonstrate|O that|O the|O intergenerational|O CTG|O repeat|O instability|O is|O reproduced|O in|O mice|O ,|O with|O a|O strong|O bias|O towards|O expansions|O and|O with|O the|O same|O sex|O -|O and|O size|O -|O dependent|O characteristics|O as|O in|O humans|O .|O
Additionally|O ,|O the|O existence|O of|O a|O shared|O common|O haplotype|O for|O genetic|O loci|O flanking|O the|O cathepsin|O C|O gene|O suggests|O that|O affected|O subjects|O descended|O from|O the|O Cochin|O isolate|O are|O homozygous|O for|O a|O mutation|O inherited|O identical|O by|O descent|O "|O from|O a|O common|O ancestor|O .|O "|O
We|O have|O analysed|O over|O 300|O patients|O suffering|O from|O Duchenne|B-DISE or|I-DISE Becker|I-DISE muscular|I-DISE dystrophy|I-DISE DMD|B-DISE or|O BMD|B-DISE .|O
Out|O of|O a|O total|O of|O 71|O unique|O mutations|O ,|O 50|O were|O found|O only|O in|O a|O single|O family|O ,|O and|O 51|O had|O not|O been|O reported|O previously|O .|O
N314D|O is|O in|O linkage|O disequilibrium|O with|O other|O base|O changes|O that|O differ|O on|O the|O D1|O and|O D2|O alleles|O .|O
Allele|O specific|O oligonucleotide|O hybridization|O analysis|O using|O amplified|O genomic|O DNA|O showed|O that|O the|O mutant|O gene|O was|O transmitted|O from|O the|O maternal|O germ|O line|O .|O
Pediatric|B-DISE alveolar|I-DISE rhabdomyosarcoma|I-DISE is|O characterized|O by|O a|O chromosomal|O translocation|O that|O fuses|O parts|O of|O the|O PAX3|O and|O FKHR|O genes|O .|O
Linkage|O analysis|O was|O carried|O out|O to|O 6|O microsatellite|O markers|O (|O D1S249|O ,|O D1S425|O ,|O D1S491|O ,|O D1S205|O ,|O D1S414|O ,|O D1S425|O )|O ,|O yielding|O a|O maximum|O cumulative|O LOD|O score|O of|O Z|O =|O 3|O .|O 27|O at|O theta|O =|O 0|O .|O 00|O for|O D1S245|O .|O
Consistent|O with|O another|O recent|O report|O ,|O the|O E148Q|O mutation|O was|O observed|O in|O patients|O of|O several|O ethnicities|O and|O on|O multiple|O microsatellite|O haplotypes|O ,|O but|O haplotype|O data|O indicate|O an|O ancestral|O relationships|O between|O non|O -|O Jewish|O Italian|O and|O Ashkenazi|O Jewish|O patients|O with|O FMF|B-DISE and|O other|O affected|O populations|O .|O
A|O candidate|O Wilms|B-DISE '|I-DISE tumor|I-DISE gene|O ,|O WT1|O ,|O from|O the|O 11p13|O chromosome|O region|O has|O recently|O been|O cloned|O .|O
A|O new|O fragile|O site|O (|O FRAXE|O )|O in|O Xq28|O is|O described|O .|O
RANK|O is|O essential|O in|O osteoclast|O formation|O .|O
Mutations|O causing|O disruption|O of|O the|O intracellular|O Fas|O death|O domain|O also|O showed|O a|O higher|O penetrance|O of|O ALPS|B-DISE phenotype|O features|O in|O mutation|O -|O bearing|O relatives|O .|O
Patients|O with|O FAP|B-DISE typically|O develop|O hundreds|O to|O thousands|O of|O benign|O colorectal|B-DISE tumors|I-DISE and|O early|O -|O onset|O colorectal|B-DISE cancer|I-DISE .|O
To|O ascertain|O the|O molecular|O mechanism|O that|O causes|O murine|O C5|B-DISE deficiency|I-DISE ,|O genomic|O and|O cDNA|O libraries|O were|O constructed|O from|O mouse|O liver|O DNA|O and|O mRNA|O employing|O the|O congenic|O strains|O B10|O .|O D2|O /|O nSnJ|O and|O B10|O .|O D2|O /|O oSnJ|O that|O are|O sufficient|O and|O deficient|B-DISE for|I-DISE C5|I-DISE ,|O respectively|O .|O
Our|O findings|O suggest|O that|O in|O some|O patients|O ,|O Pelizaeus|B-DISE -|I-DISE Merzbacher|I-DISE disease|I-DISE is|O caused|O by|O overexpression|O of|O PLP|O gene|O transcripts|O ,|O and|O that|O in|O these|O families|O a|O 50|O %|O increase|O of|O DM20|O messenger|O RNA|O in|O females|O ,|O relative|O to|O the|O increase|O in|O affected|O males|O ,|O can|O identify|O a|O female|O carrier|O .|O .|O
The|O 68|O Val|O -|O -|O >|O Met|O mutation|O has|O not|O been|O found|O in|O a|O B|O background|O .|O
This|O observation|O confirms|O the|O existence|O of|O this|O entity|O and|O assigns|O it|O to|O the|O phenotypic|O spectrum|O associated|O with|O mutations|O at|O the|O DTDST|O locus|O .|O .|O
Eight|O mutations|O ,|O one|O of|O which|O (|O R408Q|O )|O is|O new|O ,|O were|O found|O to|O account|O for|O 93|O %|O of|O the|O 163|O independent|O FMF|O alleles|O ,|O with|O both|O FMF|O alleles|O identified|O in|O 89|O %|O of|O the|O patients|O .|O
Using|O reverse|O transcriptase|O combined|O with|O polymerase|O chain|O reactions|O in|O the|O analysis|O of|O a|O number|O of|O lipoma|O cell|O lines|O and|O primary|O lipomas|B-DISE ,|O it|O appeared|O that|O LPP|O is|O frequently|O rearranged|O also|O in|O cases|O without|O a|O cytogenetically|O detectable|O involvement|O of|O 3q27|O -|O q28|O .|O
Mutant|O fibroblasts|O contain|O multiple|O ,|O functional|O centrosomes|O ,|O which|O lead|O to|O unequal|O chromosome|O segregation|O ,|O abnormal|O nuclear|O division|O ,|O and|O aneuploidy|B-DISE .|O
The|O non|O -|O deficient|O polymorphic|O variant|O G6PD|O A|O contains|O only|O the|O mutation|O 126|O Asn|O -|O -|O >|O Asp|O .|O
The|O patient|O '|O s|O parents|O were|O remotely|O related|O .|O
We|O evaluated|O the|O hypothesis|O that|O Huntington|B-DISE disease|I-DISE (|O HD|B-DISE )|O is|O influenced|O by|O the|O normal|O HD|O allele|O by|O comparing|O transmission|O patterns|O of|O genetically|O linked|O markers|O at|O the|O D4S10|O locus|O in|O the|O normal|O parent|O against|O age|O at|O onset|O in|O the|O affected|O offspring|O .|O
The|O third|O is|O a|O previously|O reported|O mutation|O (|O G|O -|O -|O >|O A|O transition|O at|O nt|O 1444|O )|O Nakano|O et|O al|O .|O ,|O 1988|O .|O
MAGEL2|O is|O expressed|O predominantly|O in|O brain|O ,|O the|O primary|O tissue|O affected|O in|O PWS|B-DISE and|O in|O several|O fetal|O tissues|O as|O shown|O by|O northern|O blot|O analysis|O .|O
The|O SCA3|O locus|O remains|O within|O the|O 29|O -|O cM|O region|O on|O 14q24|O .|O 3|O -|O q32|O .|O 2|O containing|O the|O gene|O for|O the|O Machado|B-DISE -|I-DISE Joseph|I-DISE disease|I-DISE ,|O which|O is|O clinically|O related|O to|O the|O phenotype|O determined|O by|O SCA3|O ,|O but|O it|O cannot|O yet|O be|O concluded|O that|O both|O diseases|O result|O from|O alterations|O of|O the|O same|O gene|O .|O .|O
The|O forkhead|O transcription|O factor|O genes|O Foxc1|O (|O formerly|O Mf1|O )|O and|O Foxc2|O (|O formerly|O Mfh1|O )|O are|O expressed|O in|O the|O mesenchyme|O from|O which|O the|O ocular|O drainage|O structures|O derive|O .|O
An|O increase|O in|O copper|O concentration|O was|O also|O observed|O in|O the|O kidney|O ,|O brain|O ,|O placenta|O and|O lactating|O mammary|O glands|O of|O homo|O -|O zygous|O mutants|O ,|O although|O milk|O from|O the|O mutant|O glands|O was|O copper|B-DISE deficient|I-DISE .|O
The|O data|O support|O the|O hypothesis|O that|O G6PD|B-DISE deficiency|I-DISE may|O confer|O a|O selective|O advantage|O in|O a|O malarious|O area|O ;|O the|O female|O heterozygote|O may|O be|O at|O a|O particular|O advantage|O because|O resistance|O to|O malaria|B-DISE equals|O that|O of|O male|O hemizygotes|O ,|O but|O the|O risk|O of|O fatal|O hemolysis|B-DISE may|O be|O less|O .|O
The|O mutations|O most|O frequently|O cited|O are|O Q188R|O ,|O K285N|O ,|O S135L|O ,|O and|O N314D|O .|O
Myotonic|B-DISE dystrophy|I-DISE (|O DM|B-DISE )|O is|O caused|O by|O a|O CTG|O expansion|O in|O the|O 3|O '|O untranslated|O region|O of|O the|O DM|O gene|O .|O
The|O authors|O report|O a|O mutation|O in|O exon|O 5|O of|O GCH1|O in|O a|O patient|O with|O adult|O -|O onset|O oromandibular|O dystonia|B-DISE and|O no|O obvious|O family|O history|O of|O dystonia|O .|O
Analbuminemia|B-DISE was|O fortuitously|O detected|O in|O a|O nonedematous|O 12|O -|O year|O -|O old|O American|O Indian|O girl|O with|O atopic|B-DISE dermatitis|I-DISE ,|O mild|O bronchial|B-DISE asthma|I-DISE ,|O a|O mild|O seizure|B-DISE disorder|I-DISE ,|O and|O hyperlipoproteinemia|B-DISE with|O a|O corneal|B-DISE arcus|I-DISE .|O
Only|O 7|O percent|O of|O women|O from|O families|O with|O a|O history|O of|O breast|B-DISE cancer|I-DISE but|O not|O ovarian|B-DISE cancer|I-DISE had|O BRCA1|O mutations|O .|O
Morphological|B-DISE abnormalities|I-DISE resembling|O cirrhosis|B-DISE developed|O in|O the|O majority|O of|O the|O livers|O from|O homozygous|O mutants|O older|O than|O 7|O months|O of|O age|O .|O
The|O gene|O mutated|O in|O ataxia|B-DISE -|I-DISE telangiectasia|I-DISE (|O AT|B-DISE )|O patients|O ,|O denoted|O ATM|O ,|O encodes|O a|O putative|O protein|O or|O lipid|O kinase|O .|O
Friedreich|B-DISE ataxia|I-DISE (|O FRDA|B-DISE )|O is|O the|O most|O common|O form|O of|O autosomal|B-DISE recessive|I-DISE ataxia|I-DISE .|O
Consistent|O with|O the|O tissue|O specificity|O of|O expression|O ,|O complete|O sequencing|O and|O analysis|O of|O upstream|O regulatory|O regions|O of|O MEFV|O revealed|O homology|O to|O myeloid|O -|O specific|O promoters|O and|O to|O more|O broadly|O expressed|O inflammatory|O promoter|O elements|O .|O
Germline|O mutation|O in|O APC|O at|O 5q21|O -|O 22|O results|O in|O the|O dominantly|O inherited|O syndrome|O adenomatous|B-DISE polyposis|I-DISE coli|I-DISE APC|B-DISE .|O
Two|O of|O these|O four|O rearrangements|O were|O complex|O ,|O involving|O deletion|O and|O insertion|O of|O nucleotides|O .|O
We|O have|O found|O that|O chemical|O inhibitors|O of|O metalloproteases|O potentiate|O netrin|O -|O mediated|O axon|O outgrowth|O in|O vitro|O .|O
Among|O approximately|O 200|O anonymous|O Ashkenazi|O Jewish|O DNA|O samples|O ,|O the|O MEFV|O carrier|O frequency|O was|O 21|O %|O ,|O with|O E148Q|O the|O most|O common|O mutation|O .|O
This|O mutation|O is|O identical|O to|O the|O disease|O -|O causing|O mutation|O in|O patients|O with|O hereditary|B-DISE hemochromatosis|I-DISE .|O
Mutations|O in|O a|O gene|O coding|O for|O an|O ATP|O -|O binding|O protein|O were|O detected|O in|O idiopathic|B-DISE torsion|I-DISE dystonia|I-DISE (|O DYT1|O )|O ,|O and|O the|O GTP|O cyclohydrolase|O 1|O gene|O is|O mutated|O in|O dopa|B-DISE -|I-DISE responsive|I-DISE dystonia|I-DISE DYT5|B-DISE .|O
CONCLUSIONS|O :|O There|O are|O no|O obvious|O correlations|O between|O the|O phenotypes|O of|O patients|O with|O ALD|B-DISE and|O their|O genotypes|O ,|O suggesting|O that|O other|O genetic|O or|O environmental|O factors|O modify|O the|O phenotypic|O expressions|O of|O ALD|B-DISE .|O .|O
These|O findings|O are|O interpreted|O as|O suggesting|O some|O degree|O of|O clinical|O and|O genetic|O heterogeneity|O in|O ankylosing|B-DISE spondylitis|I-DISE with|O genes|O for|O psoriasis|B-DISE and|O inflammatory|B-DISE bowel|I-DISE disease|I-DISE being|O important|O in|O some|O individuals|O ,|O particularly|O those|O who|O are|O B27|O negative|O .|O
The|O second|O mutation|O introduces|O a|O missense|O mutation|O (|O C282Y|O )|O into|O the|O Hfe|O locus|O ,|O but|O otherwise|O leaves|O the|O gene|O intact|O .|O
Golden|O retriever|O muscular|B-DISE dystrophy|I-DISE (|O GRMD|O )|O is|O a|O spontaneous|O ,|O X|O -|O linked|O ,|O progressively|O fatal|O disease|B-DISE of|I-DISE dogs|I-DISE and|O is|O also|O a|O homologue|O of|O Duchenne|B-DISE muscular|I-DISE dystrophy|I-DISE DMD|B-DISE .|O
The|O classical|O form|O of|O Coats|B-DISE '|I-DISE disease|I-DISE is|O almost|O invariably|O isolated|O ,|O unilateral|O and|O seen|O in|O males|O .|O
Co|O -|O amplification|O of|O 11|O exons|O from|O genomic|O DNA|O of|O Duchenne|B-DISE and|I-DISE Becker|I-DISE muscular|I-DISE dystrophy|I-DISE (|O DMD|B-DISE /|O BMD|B-DISE )|O patients|O with|O no|O deletion|O or|O duplication|O was|O performed|O and|O the|O samples|O subjected|O to|O multiple|O SSCP|O analysis|O .|O
We|O hypothesize|O that|O this|O residual|O level|O of|O anion|O transport|O is|O sufficient|O to|O eliminate|O or|O postpone|O the|O onset|O of|O goiter|B-DISE in|O individuals|O with|O DFNB4|O .|O
OBJECTIVE|O :|O To|O determine|O the|O relative|O effects|O of|O genetic|O and|O environmental|O factors|O in|O susceptibility|O to|O ankylosing|B-DISE spondylitis|I-DISE AS|B-DISE .|O
These|O results|O suggest|O that|O a|O correction|O of|O the|O biochemical|O defect|O in|O X|O -|O ALD|B-DISE could|O be|O possible|O by|O drug|O -|O induced|O overexpression|O or|O ectopic|O expression|O of|O ALDRP|O .|O .|O
This|O mutation|O is|O at|O a|O CpG|O site|O in|O a|O Japanese|O infant|O with|O Tay|B-DISE -|I-DISE Sachs|I-DISE disease|I-DISE and|O was|O described|O elsewhere|O .|O
We|O studied|O the|O molecular|O basis|O of|O C9|B-DISE deficiency|I-DISE in|O four|O Japanese|O C9|O -|O deficient|O patients|O who|O had|O suffered|O from|O meningococcal|B-DISE meningitis|I-DISE .|O
Identification|O of|O the|O molecular|O defect|O underlying|O FNDI|B-DISE in|O affected|O families|O is|O a|O powerful|O tool|O for|O early|O asymptomatic|O diagnosis|O in|O infants|O .|O .|O
We|O extensively|O analyzed|O genomic|O DNA|O and|O messenger|O RNA|O (|O mRNA|O )|O from|O 62|O unrelated|O Korean|O patients|O with|O familial|B-DISE adenomatous|I-DISE polyposis|I-DISE (|O FAP|B-DISE )|O for|O identification|O of|O germline|O adenomatous|B-DISE polyposis|I-DISE coli|I-DISE (|O APC|O )|O gene|O mutations|O .|O
We|O have|O characterised|O a|O novel|O missense|O mutation|O ,|O G5260A|O ,|O in|O exon|O 32|O in|O a|O family|O segregating|O for|O EA|B-DISE -|I-DISE 2|I-DISE .|O
Preassociated|O Fas|O complexes|O were|O found|O in|O living|O cells|O by|O means|O of|O fluorescence|O resonance|O energy|O transfer|O between|O variants|O of|O green|O fluorescent|O protein|O .|O
DESIGN|O AND|O SETTING|O :|O Retrospective|O cohort|O study|O of|O a|O consecutive|O series|O of|O 933|O ovarian|O cancers|O diagnosed|O and|O treated|O at|O our|O institution|O ,|O which|O is|O a|O comprehensive|O cancer|O center|O as|O designated|O by|O the|O National|O Cancer|O Institute|O ,|O over|O a|O 12|O -|O year|O period|O December|O 1986|O to|O August|O 1998|O .|O
Among|O the|O new|O mutations|O ,|O two|O nonsense|O mutations|O (|O R317X|O and|O E558X|O )|O and|O three|O other|O frameshift|O mutations|O caused|O premature|O termination|O of|O the|O protein|O .|O
Therefore|O ,|O the|O isolation|O of|O new|O genes|O in|O this|O region|O remains|O crucial|O for|O a|O better|O understanding|O of|O the|O molecular|O basis|O of|O PWS|B-DISE .|O
This|O disorder|O may|O account|O for|O up|O to|O 10|O %|O of|O cases|O of|O hereditary|B-DISE deafness|I-DISE .|O
We|O have|O undertaken|O a|O hospital|O -|O based|O study|O ,|O to|O identify|O possible|O BRCA1|O and|O BRCA2|O founder|O mutations|O in|O the|O Polish|O population|O .|O
These|O abnormalities|O include|O small|O or|O absent|B-DISE Schlemm|I-DISE '|I-DISE s|I-DISE canal|I-DISE ,|O aberrantly|B-DISE developed|I-DISE trabecular|I-DISE meshwork|I-DISE ,|O iris|B-DISE hypoplasia|I-DISE ,|O severely|O eccentric|B-DISE pupils|I-DISE and|O displaced|B-DISE Schwalbe|I-DISE '|I-DISE s|I-DISE line|I-DISE .|O
We|O recently|O mapped|O the|O gene|O for|O ataxia|B-DISE -|I-DISE telangiectasia|I-DISE group|O A|O (|O ATA|O )|O to|O chromosome|O 11q22|O -|O 23|O by|O linkage|O analysis|O ,|O using|O the|O genetic|O markers|O THY1|O and|O pYNB3|O .|O 12|O D11S144|O .|O
In|O several|O instances|O ,|O family|O studies|O provided|O molecular|O evidence|O for|O pseudodominant|O transmission|O and|O incomplete|O penetrance|O of|O the|O disease|O phenotype|O .|O
We|O have|O analyzed|O ATM|O germline|O mutations|O in|O normal|O blood|O lymphocytes|O ,|O using|O the|O protein|O -|O truncation|O test|O followed|O by|O genomic|O -|O sequence|O analysis|O .|O
We|O studied|O an|O unusual|O Palestinian|O family|O consisting|O of|O asymptomatic|O first|O cousin|O parents|O and|O three|O children|O affected|O with|O neurohypophyseal|B-DISE diabetes|I-DISE insipidus|I-DISE ,|O suggesting|O autosomal|O recessive|O inheritance|O .|O
The|O UBE3A|O gene|O encodes|O the|O E6|O -|O AP|O ubiquitin|O -|O protein|O ligase|O and|O has|O recently|O been|O shown|O to|O be|O mutated|O in|O Angelman|B-DISE syndrome|I-DISE patients|O who|O lack|O 15q11|O -|O q13|O deletions|O or|O chromosome|O 15|O paternal|O uniparental|B-DISE disomy|I-DISE .|O
After|O addition|O of|O (|O 55|O )|O Fe|O to|O the|O medium|O ,|O immunoprecipitates|O of|O this|O species|O contain|O >|O 16|O atoms|O of|O (|O 55|O )|O Fe|O per|O molecule|O of|O mYfh1p|O .|O
These|O findings|O ,|O and|O the|O absence|O of|O functionally|O relevant|O base|O changes|O in|O healthy|O controls|O ,|O emphasize|O the|O causal|O role|O of|O this|O candidate|O gene|O in|O Norrie|B-DISE disease|I-DISE and|O pave|O the|O way|O for|O reliable|O diagnosis|O and|O carrier|O detection|O .|O .|O
Deficiency|B-DISE of|I-DISE the|I-DISE ninth|I-DISE component|I-DISE of|I-DISE human|I-DISE complement|I-DISE (|O C9|O )|O is|O the|O most|O common|O complement|B-DISE deficiency|I-DISE in|O Japan|O ,|O with|O an|O incidence|O of|O approximately|O one|O homozygote|O in|O 1000|O ,|O but|O is|O very|O rare|O in|O other|O countries|O .|O
We|O report|O the|O spectrum|O of|O 59|O ATM|O mutations|O observed|O in|O ataxia|B-DISE -|I-DISE telangiectasia|I-DISE (|O A|B-DISE -|I-DISE T|I-DISE )|O patients|O in|O the|O British|O Isles|O .|O
To|O define|O the|O possible|O role|O of|O the|O VHL|O gene|O in|O the|O development|O of|O sporadic|O renal|B-DISE cell|I-DISE carcinomas|I-DISE ,|O 91|O different|O parenchymal|O tumours|O of|O the|O kidney|O have|O been|O investigated|O for|O mutation|O of|O the|O VHL|O gene|O by|O single|O strand|O conformation|O polymorphism|O (|O SSCP|O )|O and|O /|O or|O heteroduplex|O (|O HD|O )|O techniques|O .|O
Although|O gastric|B-DISE cancer|I-DISE is|O the|O most|O common|O cancer|O in|O the|O world|O ,|O genetic|O changes|O during|O its|O carcinogenesis|O are|O not|O well|O understood|O .|O
These|O results|O provide|O further|O examples|O of|O mutations|O in|O PLP|O that|O cause|O Pelizaeus|B-DISE -|I-DISE Merzbacher|I-DISE disease|I-DISE and|O illustrate|O the|O value|O of|O SSCP|O in|O genetic|O analysis|O .|O .|O
Here|O ,|O our|O goal|O was|O to|O estimate|O the|O frequency|O and|O geographic|O diversity|O of|O carriers|O of|O this|O duplication|O .|O
We|O identified|O the|O alpha|O -|O cardiac|O actin|O gene|O (|O ACTC|O )|O as|O a|O novel|O disease|O gene|O in|O a|O pedigree|O suffering|O from|O familial|B-DISE hypertrophic|I-DISE cardiomyopathy|I-DISE FHC|B-DISE .|O
Consequently|O ,|O both|O molecules|O are|O affected|O by|O the|O mutations|O ,|O and|O they|O may|O contribute|O differently|O to|O the|O occurrence|O of|O specific|O clinical|O manifestations|O .|O .|O
Along|O with|O cleft|B-DISE lip|I-DISE /|I-DISE palate|I-DISE and|O lip|B-DISE pits|I-DISE ,|O affected|O relatives|O exhibit|O developmental|B-DISE delays|I-DISE ,|O suggesting|O that|O the|O function|O of|O a|O gene|O nearby|O may|O also|O be|O disrupted|O .|O
Four|O of|O the|O homozygous|O subjects|O had|O previously|O been|O given|O a|O diagnosis|O of|O hemochromatosis|B-DISE ,|O and|O 12|O had|O not|O .|O
A|O missense|B-DISE mutation|I-DISE has|I-DISE been|I-DISE identified|I-DISE in|I-DISE the|I-DISE human|I-DISE phenylalanine|I-DISE hydroxylase|I-DISE PAH|I-DISE ;|I-DISE phenylalanine|I-DISE 4|I-DISE -|I-DISE monooxygenase|I-DISE ;|I-DISE L|I-DISE -|I-DISE phenylalanine|I-DISE ,|I-DISE tetrahydrobiopterin|I-DISE :|I-DISE oxygen|I-DISE oxidoreductase|I-DISE (|I-DISE 4|I-DISE -|I-DISE hydroxylating|I-DISE )|I-DISE ,|I-DISE EC|O 1|O .|O 14|O .|O 16|O .|O 1|O gene|O in|O a|O Chinese|O patient|O with|O classic|O phenylketonuria|B-DISE PKU|B-DISE .|O
Complement|O C7|B-DISE deficiency|I-DISE (|O C7D|O )|O is|O associated|O frequently|O with|O recurrent|B-DISE bacterial|I-DISE infections|I-DISE ,|O especially|O meningitis|B-DISE caused|O by|O Neisseria|B-DISE meningitidis|I-DISE .|O
In|O this|O study|O three|O mutations|O (|O a|O missense|O mutation|O Pro183Thr|O and|O two|O in|O -|O frame|O deletions|O removing|O residues|O 95|O -|O 99|O and|O 236|O -|O 241|O ,|O respectively|O )|O were|O unusual|O in|O being|O associated|O with|O expression|O of|O mutant|O protein|O .|O
In|O this|O report|O ,|O 17|O WASP|O gene|O mutations|O were|O identified|O ,|O 12|O of|O which|O are|O novel|O .|O
We|O previously|O reported|O evidence|O of|O linkage|O to|O the|O 1q24|O -|O 25|O region|O (|O HPC1|O )|O in|O 91|O North|O American|O and|O Swedish|O families|O each|O with|O multiple|O cases|O of|O prostate|B-DISE cancer|I-DISE Smith|O et|O al|O .|O 1996|O .|O
Samples|O of|O RNA|O were|O subjected|O to|O reverse|O transcription|O PCR|O (|O RT|O -|O PCR|O )|O and|O the|O product|O of|O the|O proband|O was|O amplified|O with|O nested|O primers|O and|O sequenced|O .|O
We|O have|O examined|O 26|O Canadian|O families|O with|O hereditary|B-DISE breast|I-DISE or|I-DISE ovarian|I-DISE cancer|I-DISE for|O linkage|O to|O markers|O flanking|O the|O BRCA1|O gene|O on|O chromosome|O 17q12|O -|O q21|O .|O
We|O have|O observed|O over|O 25|O different|O mutations|O in|O the|O diastrophic|B-DISE dysplasia|I-DISE sulphate|O transporter|O gene|O (|O DTDST|O )|O in|O association|O with|O the|O recessive|O disorders|O achondrogenesis|B-DISE 1B|O ,|O atelosteogenesis|B-DISE 2|I-DISE ,|O and|O diastrophic|B-DISE dysplasia|I-DISE .|O
The|O rare|O form|O of|O the|O Q356R|O polymorphism|O was|O significantly|O (|O P|O =|O 0|O .|O 03|O )|O associated|O with|O a|O family|O history|O of|O ovarian|B-DISE cancer|I-DISE ,|O suggesting|O that|O this|O polymorphism|O may|O influence|O ovarian|O cancer|O risk|O .|O
Familial|B-DISE expansile|I-DISE osteolysis|I-DISE (|O FEO|B-DISE ,|O MIM|O 174810|O )|O is|O a|O rare|O ,|O autosomal|O dominant|O bone|B-DISE disorder|I-DISE characterized|O by|O focal|O areas|O of|O increased|B-DISE bone|I-DISE remodelling|I-DISE .|O
The|O PAX6|O gene|O was|O isolated|O as|O a|O candidate|O aniridia|B-DISE gene|O by|O positional|O cloning|O from|O the|O smallest|O region|O of|O overlap|O of|O aniridia|B-DISE -|O associated|O deletions|O .|O
Alkaptonuria|B-DISE (|O aku|B-DISE )|O ,|O an|O inborn|B-DISE error|I-DISE of|I-DISE metabolism|I-DISE caused|O by|O the|O loss|O of|O homogentisate|O 1|O ,|O 2|O -|O dioxygenase|O (|O HGD|O )|O ,|O has|O been|O described|O in|O a|O mouse|O model|O created|O by|O ethylnitrosourea|O mutagenesis|O but|O the|O mutation|O in|O these|O mice|O has|O not|O previously|O been|O identified|O .|O
A|O total|O of|O 24|O individuals|O ,|O including|O seven|O propositi|O ,|O was|O investigated|O .|O
Their|O parents|O originated|O from|O Calabria|O ,|O from|O Sardinia|O and|O from|O Sicily|O .|O
The|O identification|O of|O three|O separate|O families|O in|O which|O PLP|O is|O duplicated|O at|O a|O noncontiguous|O site|O suggests|O that|O such|O duplications|O could|O be|O a|O relatively|O common|O but|O previously|O undetected|O cause|O of|O genetic|B-DISE disorders|I-DISE .|O .|O
Type|B-DISE 1|I-DISE Gaucher|I-DISE disease|I-DISE (|O GD|B-DISE )|O ,|O a|O non|O -|O neuronopathic|O lysosomal|B-DISE storage|I-DISE disorder|I-DISE ,|O results|O from|O the|O deficient|B-DISE activity|I-DISE of|I-DISE acid|I-DISE beta|I-DISE -|I-DISE glucosidase|I-DISE GBA|I-DISE .|O
The|O sodium|O channel|O beta1|O subunit|O gene|O (|O SCN1B|O )|O maps|O to|O this|O candidate|O region|O and|O has|O been|O shown|O to|O be|O involved|O in|O one|O Australian|O pedigree|O with|O generalized|B-DISE epilepsy|I-DISE and|I-DISE febrile|I-DISE seizures|I-DISE plus|I-DISE "|O GEFS|B-DISE +|I-DISE .|O "|O
Whether|O the|O reported|O differences|O reflect|O true|O differences|O and|O /|O or|O methodological|O problems|O is|O discussed|O .|O
Aniridia|B-DISE in|O man|O and|O Small|O eye|O in|O mice|O are|O semidominant|O developmental|O disorders|O caused|O by|O mutations|O within|O the|O paired|O box|O gene|O PAX6|O .|O
This|O is|O an|O example|O of|O an|O exonic|O mutation|O which|O affects|O exon|O -|O splicing|O .|O .|O
C5|O levels|O of|O other|O family|O members|O were|O either|O normal|O or|O approximately|O half|O -|O normal|O ,|O consistent|O with|O autosomal|O codominant|O inheritance|O of|O the|O gene|O determining|O C5|B-DISE deficiency|I-DISE .|O
Diagnostic|O DNA|O analyses|O should|O include|O a|O comprehensive|O examination|O of|O the|O whole|O relevant|O gene|O in|O the|O patient|O and|O confirmation|O of|O carrier|O status|O in|O both|O parents|O .|O .|O
Of|O particular|O concern|O are|O female|O members|O of|O kindreds|O segregating|O X|B-DISE -|I-DISE ALD|I-DISE mutations|O ,|O because|O normal|O VLCFA|O levels|O do|O not|O guarantee|O lack|O of|O carrier|O status|O .|O
In|O order|O to|O investigate|O whether|O retained|B-DISE tendon|I-DISE reflexes|I-DISE are|O characteristic|O of|O FRDA|B-DISE caused|O by|O the|O second|O locus|O ,|O FRDA2|O ,|O we|O studied|O an|O unrelated|O FRDA|B-DISE patient|O with|O retained|B-DISE tendon|I-DISE reflexes|I-DISE .|O
Current|O evidence|O suggests|O that|O aniridia|B-DISE (|O absence|O of|O iris|O )|O is|O caused|O by|O loss|O of|O function|O of|O one|O copy|O of|O the|O PAX6|O gene|O ,|O which|O maps|O to|O 11p13|O .|O
Genomic|O sequencing|O of|O a|O BAC|O clone|O H|O _|O RG364P16|O revealed|O the|O presence|O of|O another|O ,|O highly|O homologous|O gene|O 3|O '|O of|O the|O CLD|O gene|O ,|O with|O a|O similar|O genomic|O structure|O ,|O recently|O identified|O as|O the|O Pendred|B-DISE syndrome|I-DISE gene|O PDS|O .|O .|O
Inactivation|O of|O the|O adenomatous|B-DISE polyposis|I-DISE coli|I-DISE (|O APC|O )|O gene|O product|O initiates|O colorectal|B-DISE tumorigenesis|I-DISE .|O
This|O disease|O gene|O was|O previously|O linked|O to|O the|O DXS7|O (|O L1|O .|O 28|O )|O locus|O and|O the|O MAO|O genes|O in|O band|O Xp11|O .|O 3|O .|O
Although|O this|O patient|O did|O not|O have|O a|O detectable|O deletion|O within|O PAX6|O ,|O her|O aniridia|B-DISE may|O have|O resulted|O from|O a|O disruption|O of|O the|O distal|O chromatin|O domain|O containing|O either|O enhancers|O or|O regulators|O for|O PAX6|O .|O
We|O present|O the|O further|O characterisation|O of|O two|O aniridia|B-DISE pedigrees|O in|O which|O the|O disease|O segregates|O with|O chromosomal|O rearrangements|O which|O involve|O 11p13|O but|O do|O not|O disrupt|O the|O PAX6|O gene|O .|O
These|O results|O suggest|O a|O molecular|O explanation|O for|O the|O genotype|O -|O phenotype|O correlation|O in|O FAP|B-DISE patients|O and|O support|O the|O idea|O that|O colorectal|B-DISE tumor|I-DISE growth|O might|O be|O ,|O in|O part|O ,|O driven|O by|O selection|O for|O a|O mutation|O in|O the|O mutation|O cluster|O region|O .|O .|O
Thirty|O -|O seven|O mutations|O were|O private|O ,|O and|O 12|O mutations|O were|O seen|O in|O two|O or|O more|O probands|O of|O European|O or|O Middle|O Eastern|O descent|O .|O
This|O suggests|O that|O unlike|O cases|O of|O breast|B-DISE and|I-DISE ovarian|I-DISE cancers|I-DISE ,|O mutations|O in|O BRCA1|O or|O BRCA2|O do|O not|O significantly|O predispose|O men|O to|O prostate|B-DISE cancer|I-DISE .|O .|O
This|O mutation|O would|O lead|O to|O an|O amino|O acid|O substitution|O of|O Asp|O for|O Gly|O at|O the|O amino|O acid|O position|O 140|O located|O within|O the|O putative|O 5|O -|O phosphoribosyl|O -|O 1|O -|O pyrophosphate|O (|O PRPP|O )|O binding|O region|O .|O
In|O humans|O ,|O the|O gene|O for|O C3|B-DISE deficiency|I-DISE is|O a|O null|O gene|O that|O is|O allelic|O to|O the|O structural|O gene|O for|O C3|O and|O is|O not|O linked|O to|O the|O major|O histocompatibility|O locus|O .|O
Our|O data|O show|O that|O a|O mutant|O DMPK|O 3|O '|O -|O UTR|O ,|O with|O as|O few|O as|O 57|O CTGs|O ,|O had|O a|O negative|O cis|O effect|O on|O protein|O expression|O and|O resulted|O in|O the|O aggregation|O of|O reporter|O transcripts|O into|O discrete|O nuclear|O foci|O .|O
Ataxia|B-DISE -|I-DISE telangiectasia|I-DISE (|O A|B-DISE -|I-DISE T|I-DISE )|O and|O Nijmegen|B-DISE breakage|I-DISE syndrome|I-DISE (|O NBS|B-DISE )|O are|O recessive|B-DISE genetic|I-DISE disorders|I-DISE with|O susceptibility|O to|O cancer|B-DISE and|O similar|O cellular|O phenotypes|O .|O
Skeletal|O changes|O consistent|O with|O multiple|B-DISE epiphyseal|I-DISE dysplasia|I-DISE ,|O with|O the|O peculiar|O finding|O of|O a|O double|B-DISE layered|I-DISE patella|I-DISE ,|O were|O recognised|O during|O childhood|O .|O
Emerin|O is|O a|O nuclear|O membrane|O protein|O which|O is|O missing|O or|O defective|O in|O Emery|B-DISE -|I-DISE Dreifuss|I-DISE muscular|I-DISE dystrophy|I-DISE EDMD|B-DISE .|O
This|O study|O establishes|O that|O the|O Leu359|O mutation|O is|O responsible|O for|O the|O phenytoin|O and|O glipizide|O /|O tolbutamide|O poor|O metabolizer|O phenotype|O .|O .|O
As|O expected|O ,|O null|O mutations|O were|O found|O in|O patients|O 2|O and|O 3|O :|O patient|O 2|O is|O homozygous|O for|O a|O frameshift|O mutation|O ,|O del|O 4|O bp|O at|O 798|O -|O 801|O ,|O and|O patient|O 3|O is|O homozygous|O for|O a|O nonsense|O mutation|O 65C|O >|O A|O S22X|O .|O
The|O dark|O -|O adapted|O electroretinogram|O (|O ERG|O )|O of|O patients|O with|O Duchenne|B-DISE and|I-DISE Becker|I-DISE muscular|I-DISE dystrophy|I-DISE (|O DMD|B-DISE /|O BMD|B-DISE )|O shows|O a|O marked|O reduction|O in|O b|O -|O wave|O amplitude|O .|O
Targeted|O mutagenesis|B-DISE was|O used|O to|O produce|O two|O mutations|O in|O the|O murine|O hemochromatosis|B-DISE gene|O (|O Hfe|O )|O locus|O .|O
Analysis|O of|O stable|O Chinese|O hamster|O ovary|O transfectants|O expressing|O allele|O -|O specific|O recombinant|O forms|O of|O GPIa|O showed|O that|O anti|O -|O Sit|O (|O a|O )|O exclusively|O reacted|O with|O the|O Glu|O 505|O Met|O (|O 799|O )|O ,|O but|O not|O with|O the|O Glu|O 505|O Thr|O (|O 799|O )|O and|O the|O Lys|O 505|O Thr|O (|O 799|O )|O isoforms|O .|O
Using|O DNA|O of|O a|O patient|O with|O piebaldism|B-DISE ,|O mental|B-DISE retardation|I-DISE ,|O and|O multiple|B-DISE congenital|I-DISE anomalies|I-DISE associated|O with|O a|O 46|O ,|O XY|O ,|O del|O (|O 4|O )|O (|O q12q21|O .|O 1|O )|O karyotype|O ,|O we|O carried|O out|O quantitative|O Southern|O blot|O hybridization|O analyses|O of|O the|O KIT|O gene|O and|O the|O adjacent|O PDGFRA|O (|O platelet|O -|O derived|O growth|O factor|O receptor|O alpha|O subunit|O )|O genes|O .|O
To|O do|O this|O ,|O a|O collaborative|O screening|O study|O was|O set|O up|O that|O involved|O 39|O institutions|O from|O 19|O countries|O and|O included|O 3|O ,|O 580|O unrelated|O individuals|O with|O a|O family|O history|O of|O the|O disease|O and|O 934|O early|O -|O onset|O breast|B-DISE and|I-DISE /|I-DISE or|I-DISE ovarian|I-DISE cancer|I-DISE cases|O .|O
Further|O ,|O Atm|O -|O and|O Bax|O -|O dependent|O apoptosis|O in|O the|O CNS|O also|O required|O caspase|O -|O 3|O activation|O .|O
Direct|O evidence|O that|O mutation|O of|O the|O KHK|O structural|O gene|O is|O the|O cause|O of|O essential|O fructosuria|B-DISE was|O also|O obtained|O .|O
Furthermore|O ,|O we|O have|O devised|O a|O semi|O -|O quantitative|O PCR|O to|O estimate|O the|O number|O of|O GLDC|O alleles|O by|O using|O psiGLDC|O as|O an|O internal|O control|O and|O have|O confirmed|O the|O homozygosity|O and|O heterozygosity|O of|O the|O deletion|O in|O the|O patient|O and|O his|O parents|O ,|O respectively|O .|O
HLA|O -|O D|O typing|O showed|O that|O 5|O members|O typed|O with|O homozygous|O Dw2|O typing|O cells|O from|O an|O individual|O with|O C2|B-DISE deficiency|I-DISE but|O not|O with|O Dw2|O typing|O cells|O from|O 2|O individuals|O with|O normal|O C2|O .|O
These|O results|O provide|O genetic|O evidence|O for|O distinct|O functional|O roles|O of|O the|O WT1|O isoforms|O in|O urogenital|O development|O .|O .|O
Myotonic|B-DISE dystrophy|I-DISE (|O DM|B-DISE )|O is|O associated|O with|O a|O (|O CTG|O )|O n|O trinucleotide|O repeat|O expansion|O in|O the|O 3|O '|O -|O untranslated|O region|O of|O a|O protein|O kinase|O -|O encoding|O gene|O ,|O DMPK|O ,|O which|O maps|O to|O chromosome|O 19q13|O .|O 3|O .|O
To|O investigate|O the|O nature|O of|O somatic|B-DISE von|I-DISE Hippel|I-DISE -|I-DISE Lindau|I-DISE (|I-DISE VHL|I-DISE )|I-DISE mutations|O ,|O we|O analyzed|O 173|O primary|O sporadic|O human|O renal|B-DISE cell|I-DISE carcinomas|I-DISE for|O mutations|O of|O the|O VHL|O tumor|O suppressor|O gene|O ,|O using|O polymerase|O chain|O reaction|O (|O PCR|O )|O and|O single|O -|O strand|O conformational|O polymorphism|O analysis|O (|O SSCP|O )|O of|O DNA|O .|O
Here|O we|O demonstrate|O that|O ataxin|O -|O 3|O ,|O the|O disease|O protein|O in|O SCA3|B-DISE /|O MJD|B-DISE ,|O adopts|O a|O unique|O conformation|O when|O expressed|O within|O the|O nucleus|O of|O transfected|O cells|O .|O
Examination|O of|O the|O entire|O coding|O region|O of|O the|O APC|O gene|O ,|O based|O on|O a|O ribonuclease|O protection|O assay|O coupled|O with|O the|O polymerase|O chain|O reaction|O (|O PCR|O )|O ,|O disclosed|O mutations|O that|O were|O considered|O to|O cause|O significant|O defects|O in|O the|O APC|O product|O in|O 97|O of|O 150|O unrelated|O FAP|B-DISE patients|O .|O
This|O disease|O -|O causing|O mutation|O is|O a|O single|O basepair|O change|O (|O G|O to|O A|O )|O in|O the|O splice|O -|O acceptor|O region|O of|O APC|O intron|O 3|O that|O creates|O a|O mutant|O RNA|O without|O exon|O 4|O of|O APC|O .|O
This|O observation|O has|O direct|O implications|O for|O genetic|O counseling|O of|O Lowe|B-DISE syndrome|I-DISE families|O .|O .|O
Mutations|O located|O at|O the|O extreme|O 5|O '|O end|O of|O the|O APC|O gene|O ,|O however|O ,|O are|O associated|O with|O a|O less|O severe|O disease|O known|O as|O attenuated|B-DISE adenomatous|I-DISE polyposis|I-DISE coli|I-DISE AAPC|B-DISE .|O
BRCA1|O allelic|O patterns|O were|O determined|O for|O four|O of|O these|O individuals|O and|O for|O 12|O additional|O non|O -|O Ashkenazi|O 185delAG|O mutation|O carriers|O who|O had|O breast|B-DISE /|I-DISE ovarian|I-DISE cancer|I-DISE .|O
Ataxia|B-DISE -|I-DISE telangiectasia|I-DISE (|O A|B-DISE -|I-DISE T|I-DISE )|O is|O characterized|O by|O a|O markedly|O increased|O sensitivity|O to|O ionizing|O radiation|O ,|O increased|O incidence|O of|O cancer|B-DISE ,|O and|O neurodegeneration|B-DISE ,|O especially|O of|O the|O cerebellar|O Purkinje|O cells|O .|O
Nine|O different|O germ|O -|O line|O mutations|O in|O the|O BRCA1|O breast|B-DISE and|I-DISE ovarian|I-DISE cancer|I-DISE susceptibility|O gene|O were|O identified|O in|O 15|O of|O 47|O kindreds|O from|O southern|O Sweden|O ,|O by|O use|O of|O SSCP|O and|O heteroduplex|O analysis|O of|O all|O exons|O and|O flanking|O intron|O region|O and|O by|O a|O protein|O -|O truncation|O test|O for|O exon|O 11|O ,|O followed|O by|O direct|O sequencing|O .|O
The|O EWS|O gene|O ,|O which|O maps|O to|O band|O q12|O of|O human|O chromosome|O 22|O ,|O is|O involved|O in|O a|O wide|O variety|O of|O human|O solid|B-DISE tumors|I-DISE including|O Ewing|B-DISE sarcoma|I-DISE ,|O related|O primitive|B-DISE neuroectodermal|I-DISE tumors|I-DISE ,|O malignant|B-DISE melanoma|I-DISE of|O soft|O parts|O and|O desmoplastic|B-DISE small|I-DISE round|I-DISE cell|I-DISE tumors|I-DISE .|O
These|O results|O further|O demonstrate|O that|O the|O WT1|O gene|O is|O important|O in|O both|O the|O development|O of|O the|O kidney|O and|O the|O genito|O -|O urinary|O system|O .|O .|O
CD34|O hematopoietic|O stem|O -|O cell|O cultures|O induced|O toward|O the|O granulocytic|O lineage|O expressed|O MEFV|O at|O the|O myelocyte|O stage|O ,|O concurrently|O with|O lineage|O commitment|O .|O
Cytoplasmic|B-DISE vacuolisation|I-DISE was|O evident|O in|O four|O .|O
A|O single|O ancestral|O couple|O from|O France|O was|O found|O to|O be|O common|O to|O most|O of|O the|O carriers|O of|O the|O exon|O 11|O insertion|O .|O
Sequencing|O of|O amplified|O cDNA|O fragments|O revealed|O a|O single|O alteration|O ,|O guanine|O to|O adenine|O at|O nt|O 749|O creating|O a|O G250D|O mutation|O .|O
The|O spectrum|O of|O PAX6|O mutations|O in|O aniridia|B-DISE patients|O is|O highly|O biased|O ,|O with|O 92|O %|O of|O all|O reported|O mutations|O leading|O to|O premature|O truncation|O of|O the|O protein|O (|O nonsense|O ,|O splicing|O ,|O insertions|O and|O deletions|O )|O and|O just|O 2|O %|O leading|O to|O substitution|O of|O one|O amino|O acid|O by|O another|O missense|O .|O
Galactosemia|B-DISE is|O an|O autosomal|B-DISE recessive|I-DISE disorder|Mention text="autosomal recessive disorder" start=3 end=6 type=DISE prob=null&Mention text="disorder of human galactose metabolism" start=5 end=10 type=DISE prob=null of|I-DISE human|I-DISE galactose|I-DISE metabolism|I-DISE caused|O by|O deficiency|O of|O the|O enzyme|O galactose|O -|O 1|O -|O phosphate|O uridyl|O transferase|O GALT|O .|O
Prostate|B-DISE cancer|I-DISE clusters|O in|O some|O families|O ,|O and|O an|O estimated|O 5|O %|O -|O 10|O %|O of|O all|O cases|O are|O estimated|O to|O result|O from|O inheritance|O of|O prostate|O cancer|O -|O susceptibility|O genes|O .|O
Autosomal|O dominant|O myotonia|B-DISE congenita|I-DISE is|O an|O inherited|O disorder|B-DISE of|I-DISE skeletal|I-DISE muscle|I-DISE caused|O by|O mutations|O in|O a|O voltage|O -|O gated|O Cl|O -|O channel|O gene|O CLCN1|O ,|O 7q35|O .|O
The|O functional|O mechanism|O of|O frataxin|O ,|O however|O ,|O is|O still|O unknown|O .|O
ATM|O mutations|O are|O found|O along|O the|O entire|O gene|O ,|O with|O no|O evidence|O of|O a|O mutational|O hot|O spot|O .|O
Ninety|O -|O four|O Chinese|O males|O with|O G6PD|B-DISE deficiency|I-DISE were|O studied|O .|O
Because|O of|O the|O variable|O expression|O of|O nm23|O -|O H1|O in|O different|O tumors|B-DISE ,|O we|O have|O investigated|O the|O relationship|O between|O amounts|O of|O the|O protein|O and|O cell|O proliferation|O .|O
Mutants|O found|O in|O the|O mild|O phenotype|O had|O a|O considerable|O residual|O activity|O 1|O .|O 3|O -|O 13|O .|O 3|O %|O of|O wild|O -|O type|O GALNS|O activity|O .|O
The|O BRCA1|O gene|O is|O in|O large|O part|O responsible|O for|O hereditary|B-DISE human|I-DISE breast|I-DISE and|I-DISE ovarian|I-DISE cancer|I-DISE .|O
Treatments|O by|O oral|O administration|O of|O chenodeoxycholic|O acid|O (|O CDCA|O )|O alone|O ,|O 3|O -|O hydroxy|O -|O 3|O -|O methylglutaryl|O (|O HMG|O )|O CoA|O reductase|O inhibitor|O (|O pravastatin|O )|O alone|O ,|O and|O combination|O of|O the|O two|O drugs|O were|O attempted|O for|O 7|O patients|O with|O cerebrotendinous|B-DISE xanthomatosis|I-DISE CTX|B-DISE .|O
Two|O pregnancies|O at|O risk|O for|O Wolman|B-DISE disease|I-DISE were|O monitored|O by|O assay|O and|O electrophoresis|O of|O acid|O lipase|O in|O cultured|O amniotic|O -|O fluid|O cells|O .|O
The|O set|O of|O 32|O families|O in|O which|O no|O BRCA1|O alterations|O were|O detected|O included|O 1|O breast|B-DISE -|I-DISE ovarian|I-DISE cancer|I-DISE kindred|O manifesting|O clear|O linkage|O to|O the|O BRCA1|O region|O and|O loss|O of|O the|O wild|O -|O type|O chromosome|O in|O associated|O tumors|O .|O
Among|O 503|O subjects|O ,|O 43|O showed|O an|O enzyme|B-DISE deficiency|I-DISE ;|O in|O 39|O the|O defect|O was|O of|O the|O Mediterranean|O type|O .|O
Binding|O of|O Cdc42|O to|O the|O GTPase|O -|O binding|O domain|O causes|O a|O dramatic|O conformational|O change|O ,|O resulting|O in|O disruption|O of|O the|O hydrophobic|O core|O and|O release|O of|O the|O C|O terminus|O ,|O enabling|O its|O interaction|O with|O the|O actin|O regulatory|O machinery|O .|O
Fabry|B-DISE disease|I-DISE (|O FD|B-DISE )|O (|O angiokeratoma|B-DISE corporis|I-DISE diffusum|I-DISE )|O is|O an|O X|O -|O linked|O inborn|B-DISE error|I-DISE of|I-DISE glycosphingolipid|I-DISE metabolism|I-DISE caused|O by|O defects|O in|O the|O lysosomal|O alpha|O -|O galactosidase|O A|O gene|O GLA|O .|O
Missense|O mutations|O in|O human|O HPRT|B-DISE deficient|I-DISE patients|O thus|O far|O reported|O tend|O to|O accumulate|O in|O this|O functionally|O active|O region|O .|O
Predictions|O about|O allelic|O homogeneity|O in|O Finland|O and|O mutation|O rates|O in|O simple|O sequence|O repeats|O are|O confirmed|O by|O independent|O observations|O .|O .|O
Together|O with|O a|O recently|O identified|O allele|O responsible|O for|O Hex|O A|O pseudodeficiency|O Triggs|O -|O Raine|O et|O al|O .|O
We|O have|O mapped|O BFIC|B-DISE to|O chromosome|O 19q|O in|O five|O Italian|O pedigrees|O .|O
We|O hypothesized|O that|O there|O is|O at|O least|O one|O mild|O mutation|O linked|O to|O haplotype|O 12|O in|O the|O Swedish|O PKU|B-DISE /|O HPA|B-DISE population|O ,|O since|O 7|O of|O 8|O patients|O carrying|O haplotype|O 12|O had|O mild|O HPA|B-DISE .|O
The|O results|O of|O these|O studies|O are|O consistent|O with|O a|O significant|O bottleneck|O occurring|O in|O the|O AJ|O population|O during|O the|O first|O millennium|O ,|O when|O the|O population|O became|O established|O in|O Europe|O .|O .|O
Genes|O Chromosomes|O Cancer|B-DISE 25|O :|O 399|O -|O 402|O ,|O 1999|O .|O .|O
This|O YAC|O has|O been|O shown|O to|O contain|O the|O entire|O APC|O gene|O ,|O in|O addition|O to|O a|O significant|O portion|O of|O DNA|O flanking|O the|O 5|O '|O end|O of|O the|O gene|O ,|O and|O should|O therefore|O prove|O a|O valuable|O resource|O for|O functional|O studies|O by|O transfer|O to|O colorectal|B-DISE tumor|I-DISE -|O derived|O cell|O lines|O .|O .|O
The|O mature|O transcript|O is|O approximately|O 6|O kb|O in|O length|O .|O
Mutations|O have|O now|O been|O defined|O for|O every|O exon|O of|O the|O ATM|O gene|O .|O
These|O findings|O as|O well|O as|O data|O obtained|O by|O others|O for|O patients|O with|O ataxia|O -|O telangiectasia|O suggest|O that|O structural|O rearrangement|O of|O 14q|O is|O the|O initial|O chromosomal|O change|O in|O lymphocyte|O clones|O of|O patients|O with|O this|O disorder|O .|O
All|O donor|O and|O acceptor|O sites|O adhere|O to|O the|O canonical|O GT|O -|O AG|O rule|O ,|O except|O for|O the|O donor|O site|O of|O intron|O 21|O ,|O where|O a|O variant|O form|O GC|O is|O used|O instead|O of|O GT|O .|O
We|O reported|O previously|O a|O family|O whose|O underlying|O mutation|O is|O a|O 500|O -|O 800|O kb|O deletion|O localized|O to|O chromosome|O bands|O 1q32|O -|O q41|O Sander|O et|O al|O .|O ,|O 1994|O :|O Hum|O Mol|O Genet|O 3|O :|O 576|O -|O 578|O .|O
We|O report|O the|O isolation|O of|O an|O expressed|O sequence|O from|O this|O region|O which|O detects|O a|O DNA|O fragment|O that|O is|O larger|O in|O affected|O individuals|O than|O in|O normal|O siblings|O or|O unaffected|O controls|O .|O
To|O study|O the|O potential|O role|O of|O BRCA1|O in|O sporadic|O carcinogenesis|B-DISE ,|O we|O analysed|O the|O genomic|O DNA|O of|O tumour|O and|O normal|O fractions|O of|O 47|O ovarian|B-DISE cancers|I-DISE for|O mutations|O in|O BRCA1|O using|O the|O single|O -|O strand|O conformation|O polymorphism|O technique|O .|O
These|O clones|O provide|O reagents|O for|O the|O complete|O characterization|O of|O this|O region|O of|O the|O genome|O and|O for|O the|O eventual|O isolation|O of|O the|O HD|O gene|O .|O .|O
The|O proband|O is|O homozygous|O for|O this|O allele|O .|O
Type|O II|O complement|O protein|O C2|B-DISE deficiency|I-DISE is|O characterized|O by|O a|O selective|O block|O in|O C2|O secretion|O .|O
We|O used|O heteroduplex|O analysis|O to|O identify|O sequence|O anomalies|O in|O five|O individuals|O with|O Kniest|B-DISE dysplasia|I-DISE .|O
By|O northern|O blot|O analysis|O we|O did|O not|O detect|O any|O expression|O of|O MAGEL2|O /|O Magel2|O but|O by|O RT|O -|O PCR|O analysis|O ,|O specific|O expression|O was|O detected|O in|O fetal|O and|O adult|O brain|O and|O in|O placenta|O .|O
Chromosomal|O locations|O of|O the|O Atm|O ataxia|B-DISE -|I-DISE telangiectasia|I-DISE AT|B-DISE -|O mutated|O and|O Acat1|O (|O mitochondrial|O acetoacetyl|O -|O CoA|O thiolase|O )|O genes|O in|O mouse|O ,|O rat|O ,|O and|O Syrian|O hamster|O were|O determined|O by|O direct|O R|O -|O banding|O FISH|O .|O
We|O show|O that|O hypomorphic|O mutations|O in|O hMRE11|O ,|O but|O not|O in|O ATM|O ,|O are|O present|O in|O certain|O individuals|O with|O an|O ataxia|B-DISE -|I-DISE telangiectasia|I-DISE -|I-DISE like|I-DISE disorder|I-DISE ATLD|B-DISE .|O
The|O common|O mutation|O at|O codon|O 95|O in|O exon|O 4|O might|O be|O responsible|O for|O most|O Japanese|O C9|B-DISE deficiency|I-DISE .|O .|O
Analysis|O of|O nine|O obligate|O carriers|O from|O seven|O unrelated|O families|O showed|O that|O four|O harbor|O the|O delta|O F304|O /|O 305|O mutation|O ,|O two|O the|O Arg170|O -|O -|O -|O -|O Gln|O mutation|O ,|O and|O one|O the|O Tyr180|O -|O -|O -|O -|O Stop|O mutation|O .|O
Although|O some|O interesting|O cases|O were|O noted|O ,|O consideration|O of|O the|O small|O sample|O size|O and|O frequency|O of|O each|O mutation|O indicated|O no|O clear|O -|O cut|O correlations|O between|O any|O of|O the|O observed|O mutations|O and|O disease|O severity|O .|O
In|O all|O ,|O 12|O of|O 16|O kindreds|O manifesting|O BRCA1|O mutation|O or|O linkage|O contained|O ovarian|B-DISE cancer|I-DISE ,|O as|O compared|O with|O only|O 6|O of|O the|O remaining|O 31|O families|O P|O <|O .|O 001|O .|O
Both|O the|O occurrence|O of|O CL|B-DISE /|I-DISE P|I-DISE and|O CP|B-DISE within|O the|O same|O genealogy|O and|O a|O recurrence|O risk|O <|O 40|O %|O for|O CP|B-DISE among|O descendants|O with|O VWS|B-DISE have|O suggested|O that|O the|O development|O of|O clefts|B-DISE in|O this|O syndrome|O is|O influenced|O by|O modifying|O genes|O at|O other|O loci|O .|O
We|O hypothesize|O that|O large|O expansions|O also|O occur|O in|O the|O female|O germline|O and|O that|O a|O negative|O selection|O of|O oocytes|O with|O long|O repeats|O might|O explain|O the|O different|O instability|O behavior|O of|O the|O male|O and|O the|O female|O germlines|O .|O .|O
The|O data|O were|O also|O analyzed|O for|O genotype|O -|O phenotype|O relationships|O .|O
We|O describe|O the|O outcome|O of|O a|O 5|O -|O year|O -|O old|O girl|O with|O VLCAD|B-DISE deficiency|I-DISE who|O was|O first|O seen|O at|O 5|O months|O of|O age|O with|O severe|O hypertrophic|B-DISE cardiomyopathy|I-DISE ,|O hepatomegaly|B-DISE ,|O encephalopathy|B-DISE ,|O and|O hypotonia|B-DISE .|O
We|O have|O identified|O two|O residues|O of|O NBS1|O ,|O Ser|O 278|O and|O Ser|O 343|O that|O are|O phosphorylated|O in|O vitro|O by|O ATM|O and|O whose|O modification|O in|O vivo|O is|O essential|O for|O the|O cellular|O response|O to|O DNA|O damage|O .|O
In|O addition|O ,|O evidence|O for|O locus|O heterogeneity|O has|O been|O provided|O by|O the|O identification|O of|O other|O putative|O hereditary|O prostate|B-DISE cancer|I-DISE loci|O on|O Xq27|O -|O 28|O ,|O 1q42|O -|O 43|O ,|O and|O 1p36|O .|O
To|O our|O knowledge|O this|O is|O the|O first|O report|O of|O heterozygous|O C2|B-DISE deficiency|I-DISE in|O association|O with|O this|O combination|O of|O '|O autoimmune|B-DISE '|I-DISE disorders|I-DISE ,|O and|O we|O discuss|O the|O aetiological|O implications|O .|O .|O
This|O is|O therefore|O a|O rare|O case|O of|O an|O inherited|O WAGR|O deletion|O .|O
The|O BRCA1|O region|O is|O also|O subject|O to|O allelic|O loss|O in|O sporadic|B-DISE breast|I-DISE and|I-DISE ovarian|I-DISE cancers|I-DISE ,|O an|O indication|O that|O BRCA1|O mutations|O may|O occur|O somatically|O in|O these|O tumors|O .|O
Direct|O sequencing|O of|O the|O emerin|O gene|O in|O 22|O families|O with|O Emery|B-DISE -|I-DISE Dreifuss|I-DISE muscular|I-DISE dystrophy|I-DISE (|O EMD|B-DISE )|O revealed|O mutations|O in|O 21|O (|O 95|O %|O )|O ,|O confirming|O that|O emerin|O mutations|O can|O be|O identified|O in|O the|O majority|O of|O families|O with|O X|O -|O linked|O EMD|B-DISE .|O
Approximately|O 0|O .|O 5|O %|O -|O 1|O %|O of|O the|O general|O population|O has|O been|O estimated|O to|O be|O heterozygous|O for|O a|O germline|O mutation|O in|O the|O ATM|O gene|O .|O
Subjects|O with|O homozygous|O CETP|B-DISE deficiency|I-DISE caused|O by|O a|O gene|O splicing|O defect|O have|O markedly|O elevated|O HDL|O ;|O however|O ,|O heterozygotes|O have|O only|O mild|O increases|O in|O HDL|O .|O
At|O that|O time|O precocious|B-DISE puberty|I-DISE was|O evident|O .|O
We|O analysed|O 50|O probands|O with|O a|O family|O history|O of|O breast|B-DISE and|I-DISE /|I-DISE or|I-DISE ovarian|I-DISE cancer|I-DISE for|O germline|O mutations|O in|O the|O coding|O region|O of|O the|O BRCA1|O candidate|O gene|O ,|O using|O single|O -|O strand|O conformation|O polymorphism|O (|O SSCP|O )|O analysis|O on|O PCR|O -|O amplified|O genomic|O DNA|O .|O
APC|O is|O often|O cited|O as|O a|O prime|O example|O of|O a|O tumor|B-DISE suppressor|O gene|O .|O
In|O the|O present|O study|O ,|O seven|O mutations|O in|O the|O PDS|O gene|O (|O PDS|O )|O ,|O the|O gene|O responsible|O for|O Pendred|B-DISE syndrome|I-DISE ,|O have|O been|O found|O in|O families|O of|O non|O -|O syndromic|O sensorineural|B-DISE hearing|I-DISE loss|I-DISE with|O EVA|B-DISE .|O
Wiskott|B-DISE -|I-DISE Aldrich|I-DISE syndrome|I-DISE (|O WAS|B-DISE )|O is|O an|O X|O -|O linked|O recessive|O immunodeficiency|O characterized|O by|O thrombocytopenia|B-DISE ,|O eczema|B-DISE ,|O and|O recurrent|O infections|B-DISE ,|O and|O caused|O by|O mutations|O in|O the|O WAS|O protein|O (|O WASP|O )|O gene|O .|O
Following|O the|O birth|O of|O two|O infants|O with|O Tay|B-DISE -|I-DISE Sachs|I-DISE disease|I-DISE (|O TSD|B-DISE )|O ,|O a|O non|O -|O Jewish|O ,|O Pennsylvania|O Dutch|O kindred|O was|O screened|O for|O TSD|B-DISE carriers|O using|O the|O biochemical|O assay|O .|O
Patients|O with|O generalized|B-DISE atrophic|I-DISE benign|I-DISE epidermolysis|I-DISE bullosa|I-DISE often|O show|O decreased|O expression|O of|O type|O XVII|O collagen|O ,|O a|O transmembrane|O hemidesmosomal|O protein|O encoded|O by|O COL17A1|O .|O
This|O enrichment|O of|O S65C|O among|O HH|O chromosomes|O suggests|O that|O the|O S65C|O substitution|O is|O associated|O with|O the|O mild|O form|O of|O hemochromatosis|B-DISE .|O .|O
When|O both|O mutations|O were|O introduced|O together|O ,|O there|O was|O a|O roughly|O additive|O effect|O on|O specific|O activity|O ,|O but|O a|O much|O more|O drastic|O effect|O on|O enzyme|O yield|O 4|O %|O of|O normal|O .|O
A|O domain|O of|O exclusive|O paternal|O expression|O surrounding|O the|O imprinting|O center|O suggests|O strong|O regional|O control|O of|O the|O imprinting|O process|O .|O
We|O provide|O data|O supporting|O the|O central|O utility|O of|O this|O animal|O model|O as|O a|O tool|O to|O understand|O the|O molecular|O mechanisms|O underlying|O the|O development|O of|O one|O of|O the|O most|O common|O kind|O of|O human|O benign|B-DISE tumors|I-DISE .|O .|O
We|O show|O that|O BRCA1|O can|O directly|O interact|O with|O the|O BRG1|O subunit|O of|O the|O SWI|O /|O SNF|O complex|O .|O
Therefore|O ,|O to|O study|O the|O effects|O of|O the|O DM|B-DISE mutation|O in|O a|O controlled|O environment|O ,|O we|O have|O established|O a|O cell|O culture|O model|O system|O using|O C2C12|O mouse|O myoblasts|O .|O
The|O other|O 2|O %|O are|O point|O mutations|O .|O
Molecular|O analysis|O may|O be|O of|O particular|O value|O in|O such|O atypical|O cases|O .|O .|O
No|O evidence|O of|O genetic|O heterogeneity|O was|O observed|O in|O these|O families|O .|O
This|O evidence|O was|O not|O observed|O by|O a|O nonparametric|O approach|O ,|O presumably|O because|O of|O the|O extensive|O heterogeneity|O .|O
CONCLUSIONS|O :|O The|O discovery|O of|O new|O point|O mutations|O in|O this|O study|O increases|O the|O available|O information|O regarding|O the|O spectrum|O of|O genetic|O abnormalities|O and|O clinical|O manifestations|O of|O XLRS|B-DISE .|O
We|O recommended|O liver|O biopsy|O for|O subjects|O with|O serum|O ferritin|O levels|O of|O 300|O ng|O per|O milliliter|O or|O higher|O .|O
Thus|O ,|O transcripts|O with|O expanded|O CUG|O repeats|O are|O sufficient|O to|O generate|O a|O DM|B-DISE phenotype|O .|O
The|O probability|O that|O a|O mutation|O will|O cause|O disease|O tends|O to|O be|O higher|O when|O the|O missense|O mutation|O is|O within|O a|O functionally|O important|O sequence|O .|O .|O
The|O hSNF5|O /|O INI1|O gene|O which|O encodes|O a|O member|O of|O the|O SWI|O /|O SNF|O chromatin|O ATP|O -|O dependent|O remodeling|O complex|O ,|O is|O a|O new|O tumor|B-DISE suppressor|O gene|O localized|O on|O chromosome|O 22q11|O .|O 2|O and|O recently|O shown|O to|O be|O mutated|O in|O malignant|O rhabdoid|B-DISE tumors|I-DISE .|O
The|O salient|O exceptions|O were|O spleen|O ,|O thymus|O ,|O and|O red|O blood|O cells|O ,|O which|O had|O almost|O equal|O numbers|O of|O cells|O expressing|O the|O wild|O -|O type|O or|O the|O recombined|O allele|O ,|O implying|O that|O GPI|O -|O linked|O proteins|O are|O not|O essential|O for|O the|O derivation|O of|O these|O tissues|O .|O
We|O have|O utilized|O backcross|O analysis|O in|O mice|O to|O verify|O and|O define|O more|O precisely|O the|O location|O of|O the|O Pdeb|O locus|O 6|O .|O 1|O +|O /|O -|O 2|O .|O 3|O cM|O distal|O of|O Mgsa|O on|O mouse|O chromosome|O 5|O .|O
To|O avoid|O selection|O bias|O ,|O we|O confined|O analysis|O of|O total|O and|O free|O protein|O S|O levels|O and|O thrombotic|O risk|O to|O the|O patients|O '|O relatives|O .|O
Ankylosing|B-DISE spondylitis|I-DISE (|O AS|B-DISE )|O is|O a|O common|O and|O highly|O familial|O rheumatic|B-DISE disorder|I-DISE .|O
In|O the|O pediatric|B-DISE solid|I-DISE tumor|I-DISE alveolar|I-DISE rhabdomyosarcoma|I-DISE ,|O a|O consistent|O t|O 2|O ;|O 13|O (|O q35|O ;|O q14|O )|O or|O variant|O t|O 1|O ;|O 13|O (|O p36|O ;|O q14|O )|O translocation|O generates|O PAX3|O -|O FKHR|O or|O PAX7|O -|O FKHR|O fusion|O proteins|O ,|O respectively|O .|O
Seventy|O families|O with|O Duchenne|B-DISE muscular|I-DISE dystrophy|I-DISE (|O DMD|B-DISE )|O known|O to|O the|O Institute|O of|O Child|O Health|O fall|O into|O three|O categories|O with|O respect|O to|O potential|O linkage|O analysis|O with|O the|O X|O chromosome|O DNA|O markers|O RC8|O and|O L1|O .|O 28|O that|O bridge|O the|O DMD|O gene|O .|O
Here|O ,|O we|O tested|O the|O hypothesis|O that|O HFE|O -|O /|O -|O mice|O have|O increased|O duodenal|O expression|O of|O the|O divalent|O metal|O transporter|O DMT1|O .|O
Moreover|O ,|O in|O patients|O without|O clear|O signs|O of|O inflammatory|O damage|O ,|O this|O treatment|O does|O not|O modify|O significantly|O the|O natural|O course|O of|O the|O disease|B-DISE .|O
Mutations|O that|O alter|O splice|O sites|O led|O to|O the|O synthesis|O of|O several|O types|O of|O mRNAs|O ,|O a|O fraction|O of|O which|O represented|O the|O normally|O spliced|O product|O .|O
We|O report|O on|O 4|O sibs|O (|O 2F|O ,|O 2M|O )|O with|O Prader|B-DISE -|I-DISE Willi|I-DISE syndrome|I-DISE PWS|B-DISE .|O
In|O granulocytes|O ,|O MEFV|O was|O up|O -|O regulated|O by|O IFN|O -|O gamma|O and|O the|O combination|O of|O IFN|O -|O alpha|O and|O colchicine|O .|O
Thus|O ,|O abnormalities|B-DISE in|I-DISE extracellular|I-DISE matrix|I-DISE synthesis|O or|O organization|O may|O contribute|O to|O development|O of|O the|O ocular|O phenotypes|O .|O
Further|O analysis|O shows|O that|O this|O result|O can|O be|O explained|O by|O segregation|O distortion|O in|O favor|O of|O the|O normal|O allele|O in|O one|O donor|O only|O and|O that|O it|O does|O not|O provide|O evidence|O of|O a|O significant|O segregation|O distortion|O in|O the|O other|O donors|O .|O
The|O overall|O severity|O score|O indicated|O a|O mild|O disease|O ,|O P|O <|O 0|O .|O 001|O .|O
Huntington|B-DISE disease|I-DISE (|O HD|B-DISE )|O has|O been|O shown|O to|O be|O associated|O with|O an|O expanded|O CAG|O repeat|O within|O a|O novel|O gene|O on|O 4p16|O .|O 3|O IT15|O .|O
The|O only|O instance|O of|O disassociation|O of|O B27|O and|O spondylitis|B-DISE in|O a|O family|O was|O where|O the|O proband|O had|O ulcerative|B-DISE colitis|I-DISE as|O well|O as|O spondylitis|B-DISE .|O
Fourth|O ,|O the|O disease|O phenotype|O is|O significantly|O more|O severe|O and|O had|O an|O early|O age|O of|O onset|O (|O 16|O years|O )|O in|O a|O subject|O homozygous|O for|O the|O expanded|O allele|O ,|O which|O contrasts|O with|O Huntington|B-DISE disease|I-DISE and|O suggests|O that|O the|O expanded|O allele|O in|O the|O MJD1|O gene|O could|O exert|O its|O effect|O either|O by|O a|O dominant|O negative|O effect|O (|O putatively|O excluded|O in|O HD|B-DISE )|O or|O by|O a|O gain|O of|O function|O effect|O as|O proposed|O for|O HD|B-DISE .|O
In|O this|O group|O of|O relatives|O ,|O a|O low|O free|O protein|O S|O level|O was|O the|O most|O reliable|O predictor|O of|O a|O PROS1|O gene|O defect|O sensitivity|O 97|O .|O 7|O %|O ,|O specificity|O 100|O %|O .|O
Of|O the|O 17|O point|O mutations|O so|O far|O described|O ,|O three|O appear|O to|O be|O more|O common|O .|O
The|O frequency|O ,|O origin|O ,|O and|O phenotypic|O expression|O of|O a|O germline|O MSH2|O gene|O mutation|O previously|O identified|O in|O seven|O kindreds|O with|O hereditary|B-DISE non|I-DISE -|I-DISE polyposis|I-DISE cancer|I-DISE syndrome|I-DISE (|O HNPCC|B-DISE )|O was|O investigated|O .|O
Genet|O .|O ,|O 4|O :|O 2233|O -|O 2237|O ,|O 1995|O ;|O
Since|O BRCA1|O ,|O the|O first|O major|O gene|O responsible|O for|O inherited|B-DISE breast|I-DISE cancer|I-DISE ,|O was|O cloned|O ,|O more|O than|O 50|O unique|O mutations|O have|O been|O detected|O in|O the|O germline|O of|O individuals|O with|O breast|B-DISE and|I-DISE ovarian|I-DISE cancer|I-DISE .|O
The|O frequency|O distribution|O of|O common|O polymorphisms|O was|O determined|O in|O the|O 91|O Caucasian|O cancer|B-DISE cases|O in|O this|O series|O and|O 24|O sister|O controls|O using|O allele|O -|O specific|O amplification|O .|O
Male|O genital|O defects|O also|O were|O evident|O and|O there|O was|O a|O single|O case|O of|O Wilms|B-DISE tumor|I-DISE in|O which|O the|O transcript|O of|O the|O nontargeted|O allele|O showed|O an|O exon|O 9|O skipping|O event|O ,|O implying|O a|O causal|O link|O between|O Wt1|O dysfunction|O and|O Wilms|O tumorigenesis|O in|O mice|O .|O
Familial|B-DISE Mediterranean|I-DISE fever|I-DISE (|O FMF|B-DISE )|O is|O a|O recessive|O disorder|O characterized|O by|O episodes|O of|O fever|O with|O serositis|B-DISE or|O synovitis|B-DISE .|O
We|O have|O developed|O a|O rapid|O and|O simple|O method|O to|O diagnose|O the|O molecular|O defects|O of|O glucose|B-DISE -|I-DISE 6|I-DISE -|I-DISE phosphate|I-DISE dehydrogenase|I-DISE (|I-DISE G6PD|I-DISE )|I-DISE deficiency|I-DISE in|O Chinese|O in|O Taiwan|O .|O
The|O grandmother|O of|O the|O cousins|O is|O deceased|O and|O not|O available|O for|O study|O ,|O and|O their|O grandfather|O is|O not|O deleted|O for|O SNRPN|O .|O
The|O last|O patient|O carried|O a|O constitutional|O deletion|O of|O the|O 11p13|O region|O and|O no|O additional|O mutation|O was|O found|O .|O
This|O fact|O encourages|O the|O hypothesis|O that|O the|O described|O kindred|O segregates|O for|O a|O variant|O of|O Cohen|B-DISE syndrome|I-DISE and|O suggests|O a|O redefinition|O of|O its|O phenotype|O .|O .|O
The|O cousins|O '|O fathers|O and|O two|O paternal|O aunts|O have|O the|O same|O deletion|O and|O are|O clinically|O normal|O .|O
Despite|O the|O early|O recognition|O of|O this|O disorder|O ,|O the|O primary|O structure|O of|O human|O KHK|O and|O the|O molecular|O basis|O of|O essential|O fructosuria|B-DISE have|O not|O been|O previously|O defined|O .|O
In|O this|O study|O we|O investigated|O 45|O German|O breast|B-DISE /|I-DISE ovarian|I-DISE cancer|I-DISE families|O for|O germline|O mutations|O in|O the|O BRCA1|O gene|O .|O
The|O frequency|O of|O G6PD|B-DISE deficiency|I-DISE ,|O ranging|O from|O 7|O .|O 2|O %|O on|O the|O Ionian|O Coast|O to|O zero|O on|O the|O eastern|O side|O of|O the|O Lucanian|O Apennines|O ,|O appears|O to|O be|O inversely|O related|O to|O the|O distance|O of|O each|O town|O examined|O from|O the|O Ionian|O Coast|O ,|O suggesting|O that|O this|O geographic|O distribution|O may|O reflect|O ,|O at|O least|O in|O part|O ,|O gene|O flow|O from|O Greek|O settlers|O .|O
Alkaptonuria|B-DISE (|O AKU|B-DISE )|O ,|O the|O prototypic|O inborn|B-DISE error|I-DISE of|I-DISE metabolism|I-DISE ,|O has|O recently|O been|O shown|O to|O be|O caused|O by|O loss|O of|O function|O mutations|O in|O the|O homogentisate|O -|O 1|O ,|O 2|O -|O dioxygenase|O gene|O HGO|O .|O
We|O suggest|O that|O PLP|O has|O a|O vital|O function|O in|O glial|O cell|O development|O ,|O distinct|O from|O its|O later|O role|O in|O myelin|O assembly|O ,|O and|O that|O this|O dichotomy|O of|O action|O may|O explain|O the|O clinical|O spectrum|O of|O Pelizaeus|B-DISE -|I-DISE Merzbacher|I-DISE disease|I-DISE .|O .|O
Most|O likely|O ,|O deletion|O and|O translation|O arose|O simultaneously|O from|O a|O complex|O rearrangement|O event|O that|O involves|O three|O chromosomal|O breakpoints|O .|O
Among|O the|O probands|O ,|O significantly|O elevated|O rates|O of|O chromosome|O damage|O were|O observed|O in|O both|O blood|O and|O skin|O .|O
The|O orthologous|O mouse|O gene|O (|O Magel2|O )|O is|O located|O within|O 150|O kb|O of|O NDN|O :|O ,|O is|O imprinted|O with|O paternal|O -|O only|O expression|O and|O is|O expressed|O predominantly|O in|O late|O developmental|O stages|O and|O adult|O brain|O as|O shown|O by|O northern|O blotting|O ,|O RT|O -|O PCR|O and|O whole|O -|O mount|O RNA|O in|O situ|O hybridization|O .|O
BFIC|B-DISE and|O GEFS|B-DISE +|I-DISE have|O clinical|O features|O in|O common|O ,|O therefore|O SCN1B|O is|O a|O candidate|O gene|O for|O BFIC|B-DISE .|O
The|O overall|O rate|O of|O G6PD|B-DISE deficiency|I-DISE was|O 2|O .|O 6|O %|O .|O
We|O then|O tested|O six|O phenotypically|O normal|O offspring|O from|O four|O of|O these|O VHL|B-DISE families|O :|O two|O were|O found|O to|O carry|O the|O deletion|O and|O the|O other|O four|O were|O deletion|O -|O free|O .|O
Epidemiologic|O studies|O have|O shown|O an|O increased|O frequency|O of|O this|O tumor|B-DISE type|O in|O families|O affected|O by|O adenomatous|B-DISE polyposis|I-DISE coli|I-DISE .|O
Heterozygote|O detection|O was|O performed|O with|O an|O allele|O -|O specific|O polymerase|O chain|O reaction|O (|O PCR|O )|O system|O designed|O to|O detect|O exclusively|O only|O one|O of|O the|O normal|O and|O mutant|O alleles|O ,|O followed|O by|O confirmation|O with|O PCR|O /|O single|O -|O strand|O conformation|O polymorphism|O (|O SSCP|O )|O analysis|O and|O direct|O sequencing|O .|O
However|O ,|O only|O half|O of|O those|O who|O were|O homozygous|O had|O clinical|O features|O of|O hemochromatosis|B-DISE ,|O and|O one|O quarter|O had|O serum|O ferritin|O levels|O that|O remained|O normal|O over|O a|O four|O -|O year|O period|O .|O .|O
Herein|O ,|O we|O present|O 35|O new|O mutations|O and|O 34|O new|O intragenic|O polymorphisms|O or|O rare|O variants|O within|O the|O ATM|O gene|O .|O
Classical|O phenylketonuria|B-DISE is|O an|O autosomal|O recessive|O disease|O caused|O by|O a|O deficiency|B-DISE of|I-DISE hepatic|I-DISE phenylalanine|I-DISE hydroxylase|I-DISE PAH|O .|O
BACKGROUND|O :|O Families|O with|O a|O high|O incidence|O of|O hereditary|B-DISE breast|I-DISE cancer|I-DISE ,|O and|O subsequently|O shown|O to|O have|O terminating|O mutations|O in|O BRCA1|O or|O BRCA2|O ,|O appear|O to|O have|O a|O higher|O incidence|O of|O prostate|B-DISE cancer|I-DISE among|O male|O relatives|O .|O
The|O predicted|O rodent|O proteins|O have|O several|O important|O domains|O and|O signals|O found|O in|O human|O pyrin|O ,|O including|O a|O B|O -|O box|O zinc|O finger|O domain|O ,|O Robbins|O -|O Dingwall|O nuclear|O localization|O signal|O ,|O and|O coiled|O -|O coil|O domain|O .|O
In|O vitro|O stimulation|O of|O monocytes|O with|O the|O proinflammatory|O agents|O interferon|O (|O IFN|O )|O gamma|O ,|O tumor|B-DISE necrosis|O factor|O ,|O and|O lipopolysaccharide|O induced|O MEFV|O expression|O ,|O whereas|O the|O antiinflammatory|O cytokines|O interleukin|O (|O IL|O )|O 4|O ,|O IL|O -|O 10|O ,|O and|O transforming|O growth|O factor|O beta|O inhibited|O such|O expression|O .|O
Van|B-DISE der|I-DISE Woude|I-DISE syndrome|I-DISE (|O VWS|B-DISE )|O is|O an|O autosomal|O dominant|O craniofacial|B-DISE disorder|I-DISE with|O high|O penetrance|O and|O variable|O expression|O .|O
It|O is|O therefore|O proposed|O that|O the|O defective|O surface|O expression|O of|O CTLA|O -|O 4|O by|O CHS|B-DISE T|O cells|O is|O involved|O in|O the|O generation|O of|O lymphoproliferative|B-DISE disease|I-DISE .|O
Sporadic|O cerebellar|B-DISE haemangioblastoma|I-DISE and|O some|O renal|B-DISE cell|I-DISE carcinoma|I-DISE may|O arise|O from|O somatic|O mutations|O inactivating|O both|O alleles|O at|O the|O VHL|O locus|O .|O .|O
This|O allowed|O the|O detection|O of|O some|O residual|O activity|O (|O 12|O %|O of|O the|O positive|O control|O )|O when|O the|O mutant|O alpha|O -|O cDNA|O replaced|O its|O wild|O -|O type|O counterpart|O .|O
However|O ,|O since|O this|O original|O report|O on|O identification|O of|O a|O mutated|O FGD1|O gene|O in|O an|O AAS|B-DISE patient|O ,|O no|O additional|O mutations|O in|O the|O FGD1|O gene|O have|O been|O described|O .|O
Rearrangement|O of|O the|O BCL1|O (|O B|B-DISE -|I-DISE cell|I-DISE lymphoma|I-DISE 1|O )|O region|O on|O chromosome|O 11q13|O appears|O to|O be|O highly|O characteristic|O of|O centrocytic|B-DISE lymphoma|I-DISE and|O also|O is|O found|O infrequently|O in|O other|O B|B-DISE -|I-DISE cell|I-DISE neoplasms|I-DISE .|O
This|O screening|O approach|O led|O to|O the|O confirmation|O of|O a|O small|O heterozygous|O deletion|O in|O a|O polyposis|B-DISE patient|O that|O overlaps|O one|O of|O the|O two|O isolated|O YACs|O .|O
Mutations|O in|O the|O SMAD4|O /|O DPC4|O tumor|O suppressor|O gene|O ,|O a|O key|O signal|O transducer|O in|O most|O TGFbeta|O -|O related|O pathways|O ,|O are|O involved|O in|O 50|O %|O of|O pancreatic|B-DISE cancers|I-DISE .|O
Mutations|O of|O the|O BRCA1|O gone|O in|O humans|O are|O associated|O with|O predisposition|O to|O breast|B-DISE and|I-DISE ovarian|I-DISE cancers|I-DISE .|O
The|O seventh|O component|O of|O complement|O (|O C7|O )|O was|O not|O detected|O by|O functional|O or|O immunochemical|O assays|O ,|O whereas|O other|O components|O were|O normal|O by|O hemolytic|O and|O immunochemical|O assessment|O .|O
A|O total|O of|O 63|O families|O with|O Huntington|B-DISE disease|I-DISE (|O HD|B-DISE )|O were|O examined|O for|O linkage|O between|O HD|O and|O G8|O D4S10|O .|O
The|O disease|O genes|O have|O been|O identified|O in|O two|O autosomal|O dominant|O forms|O and|O in|O one|O X|O -|O linked|O recessive|O form|O .|O
These|O data|O suggest|O an|O autosomal|O codominant|O mode|O of|O inheritance|O of|O C5|B-DISE deficiency|I-DISE .|O
Intriguingly|O enough|O ,|O the|O identified|O gene|O region|O overlaps|O the|O refined|O gene|O region|O for|O Cohen|B-DISE syndrome|I-DISE (|O COH1|O )|O Kolehmainen|O et|O al|O .|O ,|O 1997|O :|O Euro|O J|O Hum|O Genet|O 5|O :|O 206|O -|O 213|O .|O
Partial|O HPRT|O deficiencies|O are|O associated|O with|O gouty|B-DISE arthritis|I-DISE ,|O while|O absence|O of|O activity|O results|O in|O Lesch|B-DISE -|I-DISE Nyhan|I-DISE syndrome|I-DISE L|B-DISE -|I-DISE N|I-DISE .|O
Mentally|B-DISE retarded|I-DISE female|O patients|O with|O a|O full|O mutation|O showed|O FMRP|O expression|O in|O only|O some|O of|O their|O hair|O roots|O (|O <|O 55|O %|O )|O ,|O and|O no|O overlap|O with|O normal|O female|O controls|O was|O observed|O .|O
N314D|O does|O not|O impair|O GALT|O activity|O in|O in|O vitro|O expression|O systems|O .|O
Our|O results|O demonstrate|O that|O pendrin|O functions|O as|O a|O transporter|O of|O chloride|O and|O iodide|O ,|O but|O not|O sulfate|O ,|O and|O may|O provide|O insight|O into|O thyroid|O physiology|O and|O the|O pathophysiology|O of|O Pendred|B-DISE syndrome|I-DISE .|O .|O
We|O also|O examined|O 29|O human|O tumor|B-DISE cell|O lines|O consisting|O of|O 12|O esophageal|B-DISE cancers|I-DISE ,|O 7|O glioma|B-DISE /|O glioblastomas|B-DISE and|O 10|O others|O for|O Mxi1|O mutations|O in|O exons|O 1|O ,|O 2|O ,|O 4|O (|O HLH|O domain|O )|O ,|O 5|O and|O 6|O .|O
Our|O results|O show|O that|O FRDA|B-DISE is|O a|O nuclear|O -|O encoded|O mitochondrial|O disorder|O affecting|O oxidative|O phosphorylation|O and|O give|O a|O rationale|O for|O treatments|O aimed|O to|O improve|O mitochondrial|O function|O in|O this|O condition|O .|O .|O
In|O one|O family|O there|O was|O evidence|O of|O non|O -|O penetrance|O and|O susceptibility|O to|O both|O gastric|B-DISE and|I-DISE colorectal|I-DISE cancer|I-DISE ;|O thus|O ,|O in|O addition|O to|O six|O cases|O of|O gastric|B-DISE cancer|I-DISE ,|O a|O CDH1|O mutation|O carrier|O developed|O colorectal|O cancer|O at|O age|O 30|O years|O .|O
It|O appears|O to|O be|O a|O typical|O folate|O sensitive|O fragile|O site|O .|O
To|O date|O ,|O several|O mutations|O in|O the|O Duchenne|B-DISE muscular|I-DISE dystrophy|I-DISE gene|O ,|O DMD|O ,|O have|O been|O identified|O in|O patients|O with|O XLDCM|B-DISE ,|O but|O a|O pathogenic|O correlation|O of|O these|O cardiospecific|O mutations|O in|O DMD|O with|O the|O XLDCM|B-DISE phenotype|O has|O remained|O to|O be|O elucidated|O .|O
We|O were|O able|O to|O examine|O 66|O Finnish|O AGU|B-DISE patients|O for|O changes|O in|O the|O oral|O mucosa|O and|O 44|O of|O these|O for|O changes|O in|O facial|O skin|O .|O
Age|O at|O onset|O was|O later|O for|O first|O symptoms|O and|O for|O development|O of|O ankle|B-DISE contractures|I-DISE and|O muscle|B-DISE weakness|I-DISE .|O
The|O additional|O effects|O of|O nonallelic|O variation|O and|O other|O constitutional|O factors|O on|O phenotypic|O variability|O remain|O to|O be|O elucidated|O .|O .|O
Furthermore|O ,|O APC|O enhanced|O the|O GEF|O activity|O of|O Asef|O and|O stimulated|O Asef|O -|O mediated|O cell|O flattening|O ,|O membrane|O ruffling|O ,|O and|O lamellipodia|O formation|O in|O MDCK|O cells|O .|O
To|O investigate|O a|O possible|O physiological|O role|O for|O emerin|O ,|O we|O examined|O the|O ultrastructural|O localization|O of|O the|O protein|O in|O human|O skeletal|O muscle|O and|O HeLa|O cells|O ,|O using|O ultrathin|O cryosections|O .|O
(|O Genomics|O 11|O :|O 124|O -|O 134|O ,|O 1991|O )|O ,|O is|O a|O common|O disease|O allele|O in|O non|O -|O Jewish|O Caucasians|O 10|O /|O 58|O alleles|O examined|O .|O
Haplotype|O analysis|O was|O undertaken|O on|O the|O four|O families|O who|O have|O been|O described|O with|O this|O mutation|O .|O
It|O is|O predicted|O to|O cause|O a|O very|O premature|O translational|O termination|O accounting|O for|O the|O severe|O phenotype|O observed|O .|O
Mutations|O in|O the|O gene|O ATM|O are|O responsible|O for|O the|O genetic|O disorder|O ataxia|B-DISE -|I-DISE telangiectasia|I-DISE (|O A|B-DISE -|I-DISE T|I-DISE )|O ,|O which|O is|O characterized|O by|O cerebellar|B-DISE dysfunction|I-DISE ,|O radiosensitivity|O ,|O chromosomal|B-DISE instability|I-DISE and|O cancer|O predisposition|O .|O
These|O findings|O further|O support|O the|O association|O of|O C3|B-DISE deficiency|I-DISE with|O immune|B-DISE -|I-DISE complex|I-DISE disease|I-DISE and|O suggest|O that|O plasma|O infusion|O may|O be|O an|O adjunct|O to|O antibiotic|O therapy|O in|O the|O management|O of|O severe|O pyogenic|B-DISE infections|I-DISE in|O patients|O with|O C3|B-DISE deficiency|I-DISE .|O .|O
For|O a|O person|O of|O either|O sex|O with|O HL|O -|O A|O W27|O ,|O there|O appears|O to|O be|O about|O a|O 20|O per|O cent|O chance|O that|O ankylosing|B-DISE spondylitis|I-DISE will|O develop|O ,|O suggesting|O a|O prevalence|O of|O 10|O to|O 15|O per|O thousand|O .|O
The|O mutation|O of|O intron|O 9|O inducing|O defective|O alternative|O splicing|O was|O reported|O to|O be|O responsible|O for|O this|O syndrome|O .|O
We|O investigated|O the|O metabolism|O of|O the|O HDL|O apolipoproteins|O (|O apo|O )|O apoA|O -|O I|O and|O apoA|O -|O II|O in|O a|O total|O of|O five|O patients|O with|O LCAT|B-DISE deficiency|I-DISE ,|O one|O with|O classic|O LCAT|B-DISE deficiency|I-DISE and|O four|O with|O Fish|B-DISE -|I-DISE eye|I-DISE disease|I-DISE .|O
A|O panel|O of|O eight|O unrelated|O subjects|O with|O inherited|O type|O I|O protein|B-DISE S|I-DISE deficiency|I-DISE was|O screened|O for|O mutations|O in|O the|O PROS1|O gene|O .|O
By|O routine|O screening|O of|O sera|O ,|O a|O subject|O was|O discovered|O who|O showed|O a|O sub|O -|O total|O deficiency|B-DISE of|I-DISE C6|I-DISE and|I-DISE C7|I-DISE .|O
The|O frequency|O and|O genetic|O basis|O of|O G6PD|B-DISE deficiency|I-DISE have|O been|O studied|O in|O Africa|O ,|O around|O the|O Mediterranean|O ,|O and|O in|O the|O Far|O East|O ,|O but|O little|O such|O information|O is|O available|O about|O the|O situation|O in|O India|O .|O
We|O have|O previously|O reported|O two|O BRCA1|O founder|O mutations|O in|O the|O Norwegian|O population|O .|O
The|O pattern|O of|O retention|O of|O subclones|O in|O the|O deletion|O patient|O place|O the|O end|O point|O of|O the|O deletion|O within|O 30|O -|O 130|O kb|O of|O the|O proximal|O end|O of|O the|O YAC|O .|O
The|O mouse|O displayed|O reduced|O anxiety|O -|O related|O responses|O with|O increased|O exploratory|O behavior|O .|O
Twenty|O -|O eight|O index|O patients|O with|O protein|B-DISE S|I-DISE deficiency|I-DISE and|O a|O PROS1|O gene|O defect|O were|O studied|O ,|O together|O with|O 109|O first|O -|O degree|O relatives|O .|O
Furthermore|O ,|O the|O identification|O of|O this|O germline|O mutation|O strengthens|O the|O correlation|O between|O the|O 5|O '|O location|O of|O an|O APC|O disease|O -|O causing|O mutation|O and|O the|O attenuated|B-DISE polyposis|I-DISE phenotype|I-DISE .|O .|O
The|O protein|O product|O of|O the|O gene|O responsible|O for|O A|B-DISE -|I-DISE T|I-DISE ,|O designated|O ATM|O ,|O is|O a|O member|O of|O a|O family|O of|O kinases|O characterized|O by|O a|O carboxy|O -|O terminal|O phosphatidylinositol|O 3|O -|O kinase|O -|O like|O domain|O .|O
Results|O of|O DNA|O analysis|O with|O the|O probe|O M27|O beta|O are|O consistent|O with|O X|O linkage|O and|O indicate|O also|O that|O the|O locus|O of|O the|O relevant|O gene|O lies|O close|O to|O or|O is|O identical|O to|O the|O locus|O of|O the|O gene|O for|O the|O Wiskott|B-DISE -|I-DISE Aldrich|I-DISE syndrome|I-DISE WAS|B-DISE .|O
Furthermore|O ,|O compared|O with|O noncarriers|O ,|O APC|O I1307K|O carriers|O had|O increased|O numbers|O of|O adenomas|B-DISE and|O colorectal|B-DISE cancers|I-DISE per|O patient|O (|O P|O =|O .|O 03|O )|O ,|O as|O well|O as|O a|O younger|O age|O at|O diagnosis|O .|O
The|O fourth|O rearrangement|O grossly|O altered|O the|O sequence|O within|O intron|O 14|O .|O
Several|O BRCA1|O mutations|O have|O now|O been|O found|O to|O occur|O in|O geographically|O diverse|O breast|B-DISE and|I-DISE ovarian|I-DISE cancer|I-DISE families|O .|O
Herein|O we|O describe|O haplotype|O and|O mutational|O analyses|O of|O HGO|O in|O seven|O new|O AKU|B-DISE pedigrees|O .|O
Prader|B-DISE -|I-DISE Willi|I-DISE syndrome|I-DISE (|O PWS|B-DISE )|O is|O a|O complex|O neurogenetic|B-DISE disorder|I-DISE .|O
PATIENTS|O :|O The|O study|O was|O restricted|O to|O patients|O of|O Jewish|O origin|O because|O of|O the|O ease|O of|O BRCA1|O and|O BRCA2|O genotyping|O in|O this|O ethnic|O group|O .|O
In|O particular|O ,|O R778L|O is|O known|O to|O be|O more|O prevalent|O in|O Asian|O countries|O than|O in|O other|O countries|O of|O the|O world|O .|O
We|O performed|O mutation|O analysis|O of|O individual|O exons|O of|O the|O PDS|O gene|O in|O one|O Spanish|O family|O that|O shows|O intrafamilial|O variability|O of|O the|O deafness|B-DISE phenotype|O two|O patients|O with|O profound|O and|O one|O with|O moderate|O -|O severe|O deafness|B-DISE .|O
Twenty|O individuals|O were|O heterozygous|O for|O the|O Arg95Stop|O mutation|O .|O
Novel|O mutations|O were|O found|O in|O two|O of|O these|O families|O .|O
To|O study|O the|O molecular|O genetics|O of|O classical|B-DISE and|I-DISE Duarte|I-DISE galactosemia|I-DISE ,|O we|O analyzed|O the|O GALT|O mutations|O in|O 30|O families|O with|O classical|B-DISE galactosemia|I-DISE ,|O in|O 10|O families|O with|O the|O D|O -|O 2|O variant|O and|O in|O 3|O individuals|O carrying|O the|O D|O -|O 1|O allele|O by|O denaturing|O gradient|O gel|O electrophoresis|O DGGE|O .|O
The|O FHF2|O gene|O localisation|O and|O tissue|O -|O specific|O expression|O pattern|O suggest|O it|O to|O be|O a|O candidate|O gene|O for|O familial|O cases|O of|O the|O BFLS|B-DISE syndrome|O and|O other|O syndromal|O and|O non|O -|O specific|O forms|O of|O X|O -|O linked|O mental|B-DISE retardation|I-DISE mapping|O to|O the|O region|O .|O .|O
The|O identification|O of|O a|O rearrangement|O that|O did|O not|O alter|O any|O coding|O exons|O yet|O affected|O the|O splicing|O further|O underscores|O the|O importance|O of|O using|O cDNA|O for|O mutation|O analysis|O .|O
The|O mutation|O causing|O myotonic|B-DISE dystrophy|I-DISE (|O DM|B-DISE )|O has|O been|O identified|O as|O a|O CTG|O expansion|O in|O the|O 3|O '|O -|O untranslated|O region|O (|O 3|O '|O -|O UTR|O )|O of|O the|O DM|O protein|O kinase|O gene|O (|O DMPK|O )|O ,|O but|O the|O mechanism|O (|O s|O )|O of|O pathogenesis|O remain|O unknown|O .|O
Our|O results|O indicate|O that|O carriers|O of|O APC|O (|O AS9|O )|O develop|O fewer|O colorectal|B-DISE tumors|I-DISE than|O do|O typical|O patients|O with|O FAP|B-DISE because|O somatic|O inactivation|O of|O both|O APC|O alleles|O is|O necessary|O for|O colorectal|O tumorigenesis|B-DISE .|O
A|O new|O glucose|O -|O 6|O -|O phosphate|O dehydrogenase|O (|O G6PD|O )|O variant|O with|O severe|O erythrocytic|O G6PD|B-DISE deficiency|I-DISE and|O a|O unique|O pH|O optimum|O is|O described|O in|O a|O young|O patient|O with|O chronic|B-DISE nonspherocytic|I-DISE hemolytic|I-DISE anemia|I-DISE (|O CNSHA|B-DISE )|O and|O familial|B-DISE amyloidotic|I-DISE polyneuropathy|I-DISE FAP|B-DISE .|O
In|O contrast|O ,|O the|O intron|O 9|O mutation|O apparently|O was|O introduced|O within|O the|O last|O century|O and|O probably|O is|O limited|O to|O a|O few|O Louisiana|O families|O .|O .|O
Necdin|O ,|O a|O protein|O implicated|O in|O the|O terminal|O differentiation|O of|O neurons|O ,|O is|O the|O only|O PWS|B-DISE candidate|O gene|O to|O reduce|O viability|O when|O disrupted|O in|O a|O mouse|O model|O .|O
We|O have|O therefore|O extended|O studies|O on|O their|O relationship|O through|O the|O characterisation|O of|O a|O 650|O kb|O YAC|O isolated|O using|O L1|O .|O 28|O (|O recognising|O the|O DXS7|O locus|O )|O as|O a|O probe|O .|O
RESULTS|O :|O The|O biochemical|O phenotype|O predicted|O from|O the|O genotype|O in|O functionally|O hemizygous|O patients|O was|O related|O significantly|O to|O the|O assigned|O phenylalanine|O level|O .|O
This|O novel|O sequence|O ,|O cpXr318|O (|O DXS742|O )|O ,|O detects|O a|O new|O submicroscopic|O deletion|O interval|O at|O the|O Norrie|B-DISE disease|I-DISE locus|O NDP|O .|O
The|O A322G|O mutant|O PAH|O had|O about|O 75|O %|O and|O the|O R408Q|O mutant|O PAH|O about|O 55|O %|O of|O the|O wild|O -|O type|O PAH|O enzyme|O activity|O .|O
To|O test|O the|O role|O of|O Six5|O loss|O in|O DM|B-DISE ,|O we|O have|O analysed|O a|O strain|O of|O mice|O in|O which|O Six5|O was|O deleted|O .|O
A|O widened|O vestibular|O aqueduct|O was|O found|O in|O all|O patients|O who|O underwent|O computed|O tomography|O (|O CT|O )|O scan|O exploration|O of|O the|O inner|O ear|O .|O
In|O the|O subset|O of|O 491|O such|O families|O ,|O the|O peak|O HLOD|O was|O 2|O .|O 56|O (|O P|O =|O .|O 0006|O )|O and|O alpha|O =|O .|O 11|O (|O 1|O -|O LOD|O support|O interval|O .|O 04|O -|O .|O 19|O )|O ,|O compared|O with|O HLODs|O of|O 0|O in|O the|O remaining|O 281|O families|O .|O
It|O is|O now|O possible|O to|O use|O gene|O diagnostics|O of|O this|O unique|O NIS|O mutation|O to|O identify|O patients|O with|O congenital|B-DISE hypothyroidism|I-DISE due|O to|O an|O iodide|B-DISE transport|I-DISE defect|I-DISE in|O this|O family|O and|O to|O determine|O the|O carrier|O state|O of|O potential|O parents|O for|O genetic|O counseling|O and|O arranging|O rapid|O and|O early|O diagnosis|O of|O their|O infants|O .|O .|O
Four|O of|O the|O mutations|O were|O in|O exon|O 9|O ,|O all|O resulting|O in|O missense|O mutations|O .|O
We|O report|O here|O the|O identification|O of|O a|O 5|O '|O APC|O germline|O mutation|O in|O five|O separately|O ascertained|O AAPC|B-DISE families|O from|O Newfoundland|O ,|O Canada|O .|O
Frataxin|O is|O a|O nuclear|O -|O encoded|O mitochondrial|O protein|O that|O is|O widely|O conserved|O among|O eukaryotes|O .|O
The|O GLDC|O gene|O spans|O at|O least|O 135|O kb|O and|O consists|O of|O 25|O exons|O .|O
We|O studied|O whether|O the|O beneficial|O effects|O of|O growth|O hormone|O (|O GH|O )|O treatment|O on|O growth|O and|O body|O composition|O in|O PWS|B-DISE are|O accompanied|O by|O an|O improvement|O in|O respiratory|O function|O .|O
ATM|O ,|O the|O gene|O mutated|O in|O the|O inherited|O human|O disease|O ataxia|B-DISE -|I-DISE telangiectasia|I-DISE ,|O is|O a|O member|O of|O a|O family|O of|O kinases|O involved|O in|O DNA|O metabolism|O and|O cell|O -|O cycle|O checkpoint|O control|O .|O
Close|O linkage|O between|O HL|O -|O A|O and|O C2|B-DISE deficiency|I-DISE was|O first|O reported|O by|O FU|O and|O co|O -|O workers|O in|O 1974|O .|O
Consequently|O ,|O we|O propose|O that|O there|O are|O at|O least|O three|O different|O reasons|O for|O the|O severe|O phenotype|O :|O (|O i|O )|O destruction|O of|O the|O hydrophobic|O core|O or|O modification|O of|O the|O packing|O ;|O (|O ii|O )|O removal|O of|O a|O salt|O bridge|O to|O destabilize|O the|O entire|O conformation|O ;|O (|O iii|O )|O modification|O of|O the|O active|O site|O .|O
Cells|O from|O patient|O 1|O had|O 5|O %|O of|O control|O levels|O of|O acid|O lipase|O ,|O using|O 14C|O -|O triolein|O as|O substrate|O ;|O however|O ,|O when|O artificial|O substrates|O (|O esters|O of|O 4|O -|O methylumbelliferone|O and|O p|O -|O nitrophenol|O )|O were|O used|O to|O measure|O acid|O lipase|O ,|O these|O cells|O had|O 30|O %|O of|O control|O levels|O .|O
Lymphocyte|O activities|O were|O :|O mother|O ,|O 33|O -|O -|O 39|O %|O ;|O father|O ,|O 11|O -|O -|O 29|O %|O ;|O brother|O ,|O 82|O -|O -|O 103|O %|O ;|O and|O sister|O ,|O 38|O -|O -|O 48|O %|O of|O the|O lowest|O normal|O .|O
The|O locus|O for|O Friedreich|B-DISE ataxia|I-DISE (|O FRDA|B-DISE )|O ,|O a|O severe|O neurodegenerative|B-DISE disease|I-DISE ,|O is|O tightly|O linked|O to|O markers|O D9S5|O and|O D9S15|O ,|O and|O analysis|O of|O rare|O recombination|O events|O has|O suggested|O the|O order|O cen|O -|O FRDA|O -|O D9S5|O -|O D9S15|O -|O qter|O .|O
Mutations|O in|O the|O STA|O gene|O at|O the|O Xq28|O locus|O have|O been|O found|O in|O patients|O with|O X|B-DISE -|I-DISE linked|I-DISE Emery|I-DISE -|I-DISE Dreifuss|I-DISE muscular|I-DISE dystrophy|I-DISE EDMD|B-DISE .|O
A|O probe|O for|O the|O 5|O '|O end|O of|O the|O Duchenne|B-DISE muscular|I-DISE dystrophy|I-DISE (|O DMD|O )|O gene|O was|O used|O to|O study|O expression|O of|O the|O gene|O in|O normal|O human|O muscle|O ,|O myogenic|O cell|O cultures|O ,|O and|O muscle|O from|O patients|O with|O DMD|B-DISE .|O
Duchenne|B-DISE muscular|I-DISE dystrophy|I-DISE (|O DMD|B-DISE )|O is|O caused|O by|O mutations|O in|O the|O dystrophin|O gene|O ,|O leading|O to|O the|O absence|O of|O the|O dystrophin|O protein|O in|O striated|O muscle|O .|O
Isolated|O mYfh1p|O is|O a|O soluble|O monomer|O (|O 13|O ,|O 783|O Da|O )|O that|O contains|O no|O iron|O and|O shows|O no|O significant|O tendency|O to|O self|O -|O associate|O .|O
Amniotic|O -|O fluid|O cells|O from|O patient|O 2|O showed|O normal|O levels|O of|O acid|O lipase|O with|O all|O substrates|O tested|O ;|O the|O electrophoretic|O pattern|O of|O acid|O lipase|O was|O normal|O .|O
Milder|O phenotypes|O such|O as|O adrenomyeloneuropathy|B-DISE and|O Addison|B-DISE disease|I-DISE only|O also|O have|O been|O recognized|O .|O
The|O pathological|O form|O of|O ataxin|O -|O 3|O with|O an|O expanded|O polyglutamine|O domain|O also|O associates|O with|O the|O nuclear|O matrix|O .|O
We|O report|O four|O children|O with|O hepatoblastoma|B-DISE from|O four|O unrelated|O families|O with|O Gardner|B-DISE syndrome|I-DISE GS|B-DISE .|O
To|O further|O localize|O the|O VWS|O gene|O we|O searched|O for|O other|O deletions|O that|O cause|O VWS|B-DISE .|O
These|O results|O support|O the|O finding|O of|O a|O prostate|B-DISE cancer|I-DISE -|O susceptibility|O gene|O linked|O to|O 1q24|O -|O 25|O ,|O albeit|O in|O a|O defined|O subset|O of|O prostate|O cancer|O families|O .|O
It|O has|O been|O shown|O from|O pulsed|O -|O field|O gel|O electrophoresis|O (|O PFGE|O )|O that|O the|O monoamine|O oxidase|O genes|O A|O and|O B|O (|O MAOA|O &|O MAOB|O )|O and|O DXS7|O loci|O are|O physically|O very|O close|O .|O
RNA|O analysis|O from|O lymphocytes|O of|O the|O affected|O patients|O showed|O that|O mutation|O 639|O +|O 7A|O -|O -|O >|O G|O generates|O a|O new|O donor|O splice|O site|O ,|O leading|O to|O an|O mRNA|O with|O an|O insertion|O of|O six|O nucleotides|O from|O intron|O 4|O of|O PDS|O .|O
Phenylketonuria|B-DISE (|O PKU|B-DISE )|O is|O caused|O by|O a|O genetic|O deficiency|B-DISE of|I-DISE the|I-DISE enzyme|I-DISE phenylalanine|O hydroxylase|O PAH|O .|O
Enlarged|B-DISE vestibular|I-DISE aqueduct|I-DISE (|O EVA|B-DISE )|O ,|O known|O as|O the|O most|O common|O form|O of|O inner|O ear|O abnormality|O ,|O has|O recently|O been|O of|O particular|O genetic|O interest|O because|O this|O anomaly|O is|O inherited|O in|O a|O recessive|O manner|O .|O
Genotyping|O for|O APOE|O was|O performed|O blind|O to|O clinical|O information|O .|O
The|O observation|O of|O typical|O mutations|O in|O STM7|O /|O X25|O (|O GAA|O expansions|O )|O in|O this|O patient|O demonstrates|O that|O the|O two|O genetically|O different|O forms|O of|O FRDA|B-DISE cannot|O be|O distinguished|O clinically|O .|O .|O
This|O is|O consistent|O with|O the|O notion|O that|O all|O human|O mutants|O have|O residual|O enzyme|O activity|O and|O that|O null|O mutations|O are|O lethal|O at|O some|O stage|O of|O development|O .|O
This|O study|O was|O carried|O out|O to|O further|O evaluate|O this|O risk|O among|O patients|O with|O CHH|B-DISE and|O their|O first|O -|O degree|O relatives|O .|O
Mutation|O in|O the|O gene|O encoding|O the|O recently|O isolated|O WASP|O protein|O has|O now|O been|O identified|O as|O the|O genetic|O defect|O responsible|O for|O the|O X|O -|O linked|O Wiskott|B-DISE -|I-DISE Aldrich|I-DISE syndrome|I-DISE (|O WAS|B-DISE )|O ,|O a|O primary|B-DISE immunodeficiency|I-DISE disease|I-DISE associated|O with|O extensive|O phenotypic|O variability|O .|O
These|O results|O suggest|O a|O potentially|O important|O genetic|O connection|O between|O fasting|O glycerolemia|O and|O glucose|O homeostasis|O ,|O not|O only|O in|O this|O X|B-DISE -|I-DISE linked|I-DISE deficiency|I-DISE but|O ,|O potentially|O ,|O in|O individuals|O within|O the|O normal|O "|O range|O of|O plasma|O glycerol|O concentrations|O .|O .|O "|O
We|O have|O analyzed|O a|O single|O multi|O -|O affected|O breast|B-DISE /|I-DISE ovarian|I-DISE cancer|I-DISE pedigree|O (|O BOV3|O )|O and|O have|O shown|O consistent|O inheritance|O of|O markers|O on|O chromosome|O 17q|O with|O the|O disease|O confirming|O that|O this|O family|O is|O due|O to|O the|O BRCA1|O gene|O .|O
Genetic|O epidemiological|O evidence|O suggests|O that|O mutations|O in|O BRCA1|O may|O be|O responsible|O for|O approximately|O one|O half|O of|O early|O onset|O familial|B-DISE breast|I-DISE cancer|I-DISE and|O the|O majority|O of|O familial|B-DISE breast|I-DISE /|I-DISE ovarian|I-DISE cancer|I-DISE .|O
Activation|O relieves|O an|O autoinhibitory|O contact|O between|O the|O GTPase|O -|O binding|O domain|O and|O the|O carboxy|O -|O terminal|O region|O of|O WASP|O proteins|O .|O
Although|O autosomal|O recessive|O transmission|O of|O PLS|B-DISE is|O evident|O ,|O a|O more|O complex|O "|O autosomal|O recessive|O pattern|O of|O inheritance|O with|O phenotypic|O influences|O from|O a|O closely|O linked|O modifying|O locus|O has|O been|O hypothesised|O for|O HMS|B-DISE .|O "|O
We|O have|O estimated|O the|O haplotype|O distribution|O of|O mutant|O and|O normal|O phenylalanine|O hydroxylase|O (|O PAH|O )|O alleles|O for|O 17|O Turkish|O phenylketonuria|B-DISE (|O PKU|B-DISE )|O families|O :|O 20|O normal|O and|O 27|O mutated|O PAH|O alleles|O could|O be|O identified|O .|O
A|O (|O CTG|O )|O nexpansion|O in|O the|O 3|O '|O -|O untranslated|O region|O (|O UTR|O )|O of|O the|O DM|O protein|O kinase|O gene|O (|O DMPK|O )|O is|O responsible|O for|O causing|O myotonic|B-DISE dystrophy|I-DISE DM|B-DISE .|O
Thus|O ,|O there|O is|O no|O evidence|O that|O the|O paternal|O RB1|O allele|O is|O preferentially|O retained|O in|O retinoblastoma|B-DISE ,|O as|O has|O been|O suggested|O to|O be|O the|O case|O in|O osteosarcoma|B-DISE .|O
Mucopolysaccharidosis|O IVA|O (|O MPS|O IVA|O )|O is|O an|O autosomal|O recessive|O lysosomal|B-DISE storage|I-DISE disorder|I-DISE caused|O by|O a|O genetic|O defect|O in|O N|O -|O acetylgalactosamine|O -|O 6|O -|O sulfate|O sulfatase|O GALNS|O .|O
Genomic|O fragments|O were|O isolated|O which|O correspond|O to|O PvuII|O and|O HindIII|O restriction|O fragment|O length|O polymorphisms|O associated|O with|O C5|B-DISE deficiency|I-DISE .|O
Mutations|O in|O BRCA1|O account|O for|O approximately|O 45|O %|O of|O familial|B-DISE breast|I-DISE cancer|I-DISE and|O 90|O %|O of|O inherited|B-DISE breast|I-DISE /|I-DISE ovarian|I-DISE cancer|I-DISE ,|O whereas|O mutations|O in|O BRCA2|O account|O for|O a|O comparable|O percentage|O of|O inherited|B-DISE breast|I-DISE cancer|I-DISE cases|O .|O
CONTEXT|O :|O Most|O hereditary|O ovarian|B-DISE cancers|I-DISE are|O associated|O with|O germline|O mutations|O in|O BRCA1|O or|O BRCA2|O .|O
The|O mutation|O (|O A|O -|O -|O >|O T|O at|O nt943|O +|O 3|O )|O disrupts|O the|O 3|O '|O splice|O site|O of|O exon|O 5|O leading|O to|O the|O deletion|O of|O this|O exon|O from|O MSH2|O mRNA|O and|O represents|O the|O only|O frequent|O MSH2|O mutation|O so|O far|O reported|O .|O
Huntington|B-DISE disease|I-DISE (|O HD|B-DISE )|O is|O caused|O by|O expansion|O of|O a|O glutamine|O repeat|O in|O the|O amino|O -|O terminal|O region|O of|O huntingtin|O .|O
These|O observations|O suggest|O that|O genetic|O searches|O for|O microdeletions|O should|O be|O routine|O in|O screening|O patients|O for|O causes|O of|O VWS|B-DISE and|O may|O facilitate|O the|O positional|O cloning|O efforts|O of|O the|O VWS|O gene|O and|O of|O a|O nearby|O gene|O or|O genes|O that|O may|O be|O involved|O in|O brain|O development|O .|O .|O
Here|O we|O used|O field|O inversion|O gel|O electrophoresis|O (|O FIGE|O )|O to|O construct|O a|O restriction|O map|O of|O approximately|O 1|O ,|O 000|O kb|O of|O DNA|O surrounding|O the|O RB1|O locus|O and|O to|O detect|O the|O translocation|O breakpoints|O in|O three|O retinoblastoma|B-DISE patients|O .|O
Impaired|B-DISE glucose|I-DISE tolerance|I-DISE (|O IGT|B-DISE )|O and|O hypertriglyceridemia|B-DISE are|O associated|O with|O an|O increased|O risk|O of|O diabetes|B-DISE mellitus|I-DISE and|O cardiovascular|B-DISE disease|I-DISE .|O
To|O study|O mechanisms|O underlying|O BRCA1|O -|O related|O tumorigenesis|B-DISE ,|O we|O derived|O mouse|O embryonic|O fibroblast|O cells|O carrying|O a|O targeted|O deletion|O of|O exon|O 11|O of|O the|O Brca1|O gene|O .|O
All|O were|O confirmed|O by|O nucleotide|O sequencing|O .|O
Clinical|O manifestation|O of|O DM|B-DISE may|O be|O caused|O by|O the|O expanded|O CTG|O -|O repeat|O compromising|O the|O (|O alternative|O )|O expression|O of|O DM|O -|O kinase|O or|O DMR|O -|O N9|O proteins|O .|O .|O
The|O von|O Hippel|O -|O Lindau|O tumor|O suppressor|O gene|O (|O VHL|O )|O has|O a|O critical|O role|O in|O the|O pathogenesis|O of|O clear|B-DISE -|I-DISE cell|I-DISE renal|I-DISE cell|I-DISE carcinoma|I-DISE (|O RCC|O )|O ,|O as|O VHL|O mutations|O have|O been|O found|O in|O both|O von|B-DISE Hippel|I-DISE -|I-DISE Lindau|I-DISE disease|I-DISE -|O associated|O and|O sporadic|O RCCs|B-DISE .|O
We|O describe|O a|O fast|O method|O for|O detection|O of|O X|B-DISE -|I-DISE ALD|I-DISE mutations|O .|O
To|O determine|O whether|O SIX5|B-DISE deficiency|I-DISE contributes|O to|O the|O myotonic|B-DISE dystrophy|I-DISE phenotype|O ,|O we|O disrupted|O mouse|O Six5|O by|O replacing|O the|O first|O exon|O with|O a|O beta|O -|O galactosidase|O reporter|O .|O
We|O have|O identified|O a|O new|O mutation|O of|O Norrie|B-DISE disease|I-DISE (|O ND|O )|O gene|O in|O two|O Japanese|O males|O from|O unrelated|O families|O ;|O they|O showed|O typical|O ocular|O features|O of|O ND|B-DISE but|O no|O mental|B-DISE retardation|I-DISE or|O hearing|B-DISE impairment|I-DISE .|O
Functional|O analyses|O demonstrated|O that|O the|O V54D|O mutation|O slightly|O increased|O NTS|O binding|O and|O decreased|O CTS|O transactivation|O activity|O to|O almost|O half|O .|O .|O
The|O deletion|O allele|O of|O a|O novel|O hexanucleotide|O insertion|O /|O deletion|O polymorphism|O in|O the|O F10|O gene|O promoter|O region|O was|O shown|O by|O reporter|O gene|O assay|O ,|O to|O reduce|O promoter|O activity|O by|O approximately|O 20|O %|O .|O
We|O analyzed|O the|O entire|O protein|O -|O coding|O sequence|O of|O this|O gene|O by|O reverse|O -|O transcription|O PCR|O ,|O SSCP|O ,|O and|O DNA|O sequencing|O in|O five|O patients|O with|O different|O clinical|O expression|O of|O X|B-DISE -|I-DISE ALD|I-DISE and|O in|O their|O female|O relatives|O ;|O these|O clinical|O expressions|O were|O cerebral|O childhood|O ALD|B-DISE ,|O adrenomyeloneuropathy|B-DISE (|O AMN|B-DISE )|O ,|O and|O "|O Addison|B-DISE disease|I-DISE only|I-DISE "|I-DISE (|O ADO|O )|O phenotype|O .|O
The|O detection|O and|O mapping|O of|O the|O translocation|O breakpoints|O of|O all|O three|O retinoblastoma|B-DISE patients|O to|O within|O the|O putative|O RB1|O gene|O substantiated|O the|O authenticity|O of|O this|O candidate|O sequence|O and|O demonstrated|O the|O utility|O of|O FIGE|O in|O detecting|O chromosomal|O rearrangements|O affecting|O this|O locus|O .|O .|O
Two|O truncating|O mutations|O ,|O 962del4|O and|O 3600del11|O ,|O were|O identified|O .|O
Hereditary|B-DISE progressive|I-DISE dystonia|I-DISE with|O marked|O diurnal|B-DISE fluctuation|I-DISE (|O HPD|B-DISE ;|O dopa|B-DISE -|I-DISE responsive|I-DISE dystonia|I-DISE ,|O DRD|B-DISE )|O have|O been|O recently|O found|O to|O be|O caused|O by|O a|O genetic|O defect|O in|O the|O GTP|O cyclohydrolase|O I|O (|O GCH1|O )|O gene|O .|O
Phenylketonuria|B-DISE (|O PKU|B-DISE )|O is|O an|O autosomal|B-DISE recessive|I-DISE human|I-DISE genetic|I-DISE disorder|I-DISE caused|O by|O a|O deficiency|B-DISE of|I-DISE hepatic|I-DISE phenylalanine|I-DISE hydroxylase|I-DISE PAH|O ,|O phenylalanine|O 4|O -|O monooxygenase|O ,|O EC|O 1|O .|O 14|O .|O 16|O .|O 1|O .|O
The|O current|O study|O used|O allotype|O analysis|O of|O canine|O C3|O in|O order|O to|O demonstrate|O that|O the|O gene|O for|O C3|B-DISE deficiency|I-DISE in|O these|O dogs|O is|O also|O a|O null|O gene|O allelic|O to|O the|O structural|O gene|O for|O C3|O .|O
Yeast|O knockout|O models|O ,|O and|O histological|O and|O biochemical|O data|O from|O patient|O heart|O biopsies|O or|O autopsies|O indicate|O that|O the|O frataxin|O defect|O causes|O a|O specific|O iron|B-DISE -|I-DISE sulfur|I-DISE protein|I-DISE deficiency|I-DISE and|O mitochondrial|B-DISE iron|I-DISE accumulation|I-DISE leading|O to|O the|O pathological|O changes|O .|O
Using|O 3|O '|O -|O RACE|O analysis|O of|O HMGIC|O fusion|O transcripts|O in|O lipoma|B-DISE cell|O line|O Li|O -|O 501|O /|O SV40|O ,|O ectopic|O genetic|O sequences|O were|O obtained|O ,|O which|O by|O CASH|O (|O chromosome|O assignment|O using|O somatic|O cell|O hybrids|O )|O and|O FISH|O (|O fluorescence|O in|O situ|O hybridization|O )|O analysis|O were|O found|O to|O originate|O from|O chromosome|O segment|O 3q27|O -|O q28|O .|O
This|O finding|O confirms|O that|O the|O fragile|O X|O phenotype|O can|O exist|O ,|O without|O amplification|O of|O the|O CCG|O repeat|O or|O cytogenetic|O expression|O of|O the|O fragile|O X|O ,|O and|O that|O fragile|B-DISE X|I-DISE syndrome|I-DISE is|O a|O genetically|O homogeneous|O disorder|O involving|O FMR1|O .|O
In|O most|O patients|O with|O isolated|O unilateral|B-DISE retinoblastoma|I-DISE ,|O tumor|O development|O is|O initiated|O by|O somatic|O inactivation|O of|O both|O alleles|O of|O the|O RB1|O gene|O .|O
A|O novel|O procedure|O is|O presented|O to|O estimate|O the|O ratio|O of|O male|O to|O female|O mutation|O rates|O for|O Duchenne|B-DISE muscular|I-DISE dystrophy|I-DISE DMD|B-DISE .|O
Canavan|B-DISE disease|I-DISE is|O inherited|O as|O an|O autosomal|O recessive|O trait|O that|O is|O caused|O by|O the|O deficiency|B-DISE of|I-DISE aspartoacylase|I-DISE ASPA|O .|O
Novel|O germline|O CDH1|O mutations|O (|O a|O nonsense|O and|O a|O splice|O site|O )|O were|O detected|O in|O two|O families|O 25|O %|O .|O
Genet|O .|O ,|O 55|O :|O 1092|O -|O 1102|O ,|O 1994|O ;|O Clinical|O Research|O Group|O for|O Japan|O ,|O Hum|O .|O
We|O report|O a|O Japanese|O family|O with|O adrenoleukodystrophy|B-DISE (|O ALD|B-DISE )|O with|O a|O three|O base|O pair|O deletion|O (|O delGAG|O 291|O )|O in|O the|O ALD|O gene|O .|O
Novel|O DNA|O sequences|O potentially|O associated|O with|O the|O breakpoints|O were|O positionally|O cloned|O from|O YACs|O within|O or|O near|O these|O regions|O .|O
A|O T|O -|O -|O >|O A|O transition|O at|O the|O 20th|O nucleotide|O position|O of|O exon|O 5a|O results|O in|O a|O Val|O -|O -|O >|O Asp|O (|O GTC|O -|O -|O >|O GAC|O )|O substitution|O at|O the|O 7th|O codon|O of|O the|O alternative|O splice|O region|O .|O
A|O new|O platelet|O -|O specific|O alloantigen|O ,|O termed|O Sit|O (|O a|O )|O ,|O was|O identified|O in|O a|O severe|O case|O of|O neonatal|B-DISE alloimmune|I-DISE thrombocytopenia|I-DISE .|O
In|O high|O -|O risk|O pedigrees|O ,|O female|O carriers|O of|O BRCA1|O mutations|O have|O an|O 80|O -|O 90|O %|O lifetime|O risk|O of|O breast|B-DISE cancer|I-DISE ,|O and|O a|O 40|O -|O 50|O %|O risk|O of|O ovarian|B-DISE cancer|I-DISE .|O
In|O a|O previous|O study|O we|O found|O that|O a|O Tay|B-DISE -|I-DISE Sachs|I-DISE disease|I-DISE (|O TSD|B-DISE )|O causing|O mutation|O in|O the|O intron|O 9|O donor|O splice|O site|O of|O the|O HEXA|O gene|O occurs|O at|O high|O frequency|O in|O non|O -|O Jewish|O patients|O and|O carriers|O from|O the|O British|O Isles|O .|O
Genomic|O DNA|O was|O isolated|O from|O leukocytes|O ,|O and|O all|O exons|O of|O the|O XLRS1|O gene|O were|O amplified|O by|O polymerase|O chain|O reaction|O and|O analyzed|O using|O a|O direct|O sequencing|O method|O .|O
However|O ,|O the|O mutant|O WT1|O (|O tmT396|O )|O protein|O accounted|O for|O only|O 5|O %|O of|O WT1|O in|O both|O heterozygous|O embryonic|O stem|O cells|O and|O the|O WT|B-DISE .|O
The|O gene|O for|O human|O apolipoprotein|O C2|O (|O APOC2|O )|O ,|O situated|O on|O the|O proximal|O long|O arm|O of|O chromosome|O 19|O ,|O is|O closely|O linked|O to|O the|O gene|O for|O the|O most|O common|O form|O of|O adult|O muscular|B-DISE dystrophy|I-DISE ,|O myotonic|B-DISE dystrophy|I-DISE DM|B-DISE .|O
Although|O the|O patients|O studied|O had|O typical|O FRDA|B-DISE ,|O one|O sibpair|O had|O the|O uncommon|O symptom|O of|O retained|B-DISE tendon|I-DISE reflexes|I-DISE .|O
Here|O we|O report|O identification|O of|O a|O mutation|O of|O cathepsin|O C|O (|O exon|O 6|O ,|O 2127A|O -|O -|O >|O G|O )|O that|O changes|O a|O highly|O conserved|O amino|O acid|O in|O the|O cathepsin|O C|O peptide|O .|O
Affected|O individuals|O exhibit|O neonatal|B-DISE hypotonia|I-DISE ,|O developmental|B-DISE delay|I-DISE and|O childhood|O -|O onset|O obesity|B-DISE .|O
Complete|O absence|O of|O C7|O was|O also|O found|O in|O one|O sibling|O who|O had|O the|O clinical|O syndrome|O of|O meningococcal|B-DISE meningitis|I-DISE and|O arthritis|B-DISE as|O a|O child|O and|O in|O this|O sibling|O '|O s|O clinically|O well|O eight|O -|O year|O -|O old|O son|O .|O
Overall|O ,|O it|O accounts|O for|O 60|O -|O 70|O %|O of|O mutant|O chromosomes|O ,|O but|O there|O are|O significant|O differences|O in|O its|O relative|O frequency|O in|O individual|O populations|O .|O
Genotype|O -|O phenotype|O studies|O of|O mouse|O models|O for|O DMD|B-DISE show|O position|O -|O specific|O effects|O of|O the|O mutations|O upon|O the|O phenotype|O :|O mice|O with|O 5|O '|O defects|O of|O dystrophin|O have|O normal|O ERGs|O ,|O those|O with|O defects|O in|O the|O central|O region|O have|O a|O normal|O b|O -|O wave|O amplitude|O associated|O with|O prolonged|O implicit|O times|O for|O both|O the|O b|O -|O wave|O and|O oscillatory|O potentials|O ,|O and|O mice|O with|O 3|O '|O defects|O have|O a|O phenotype|O similar|O to|O that|O seen|O in|O DMD|B-DISE /|O BMD|B-DISE patients|O .|O
These|O patients|O are|O considered|O functionally|O hemizygous|O .|O
In|O this|O manuscript|O we|O report|O the|O mouse|O and|O rat|O homologs|O of|O MEFV|O .|O
Currently|O there|O is|O no|O known|O treatment|O that|O alters|O the|O natural|O course|O of|O the|O disease|O .|O
Here|O ,|O we|O provide|O experimental|O evidence|O for|O a|O dominant|O negative|O effect|O of|O APC|O gene|O products|O associated|O with|O severe|O polyposis|B-DISE .|O
There|O was|O a|O G|O -|O to|O -|O A|O transition|O in|O the|O affected|O cat|O cDNA|O that|O predicted|O an|O E351K|O substitution|O ,|O destroyed|O a|O BssSI|O site|O ,|O and|O eliminated|O GUSB|O enzymatic|O activity|O in|O expression|O studies|O .|O
Oral|O -|O contraceptive|O use|O protected|O against|O ovarian|B-DISE cancer|I-DISE both|O for|O carriers|O of|O the|O BRCA1|O mutation|O (|O odds|O ratio|O ,|O 0|O .|O 5|O ;|O 95|O percent|O confidence|O interval|O ,|O 0|O .|O 3|O to|O 0|O .|O 9|O )|O and|O for|O carriers|O of|O the|O BRCA2|O mutation|O odds|O ratio|O ,|O 0|O .|O 4|O ;|O 95|O percent|O confidence|O interval|O ,|O 0|O .|O 2|O to|O 1|O .|O 1|O .|O
We|O identified|O 24|O mutations|O in|O the|O WFS1|O gene|O :|O 8|O nonsense|O mutations|O ,|O 8|O missense|O mutations|O ,|O 3|O in|O -|O frame|O deletions|O ,|O 1|O in|O -|O frame|O insertion|O ,|O and|O 4|O frameshift|O mutations|O .|O
Molecular|O genetic|O and|O cell|O biology|O studies|O have|O shown|O that|O PEX1|O is|O deficient|O in|O many|O CG1|O patients|O .|O
The|O rat|O and|O human|O ataxin|O -|O 3|O genes|O are|O highly|O homologous|O with|O an|O overall|O sequence|O identity|O of|O approximately|O 88|O %|O .|O
Borjeson|B-DISE -|I-DISE Forssman|I-DISE -|I-DISE Lehmann|I-DISE syndrome|I-DISE (|O BFLS|B-DISE )|O is|O a|O syndromal|O X|O -|O linked|O mental|B-DISE retardation|I-DISE ,|O which|O maps|O by|O linkage|O to|O the|O q26|O region|O of|O the|O human|O X|O chromosome|O .|O
The|O seven|O deficient|O fibroblast|O lines|O were|O characterized|O by|O measuring|O acyl|O -|O coenzyme|O A|O dehydrogenation|O activities|O ,|O overall|O palmitic|O acid|O oxidation|O ,|O and|O VLCAD|O protein|O synthesis|O using|O pulse|O -|O chase|O ,|O further|O confirming|O the|O diagnosis|O of|O VLCAD|B-DISE deficiency|I-DISE .|O
HFE|O does|O not|O remain|O at|O the|O cell|O surface|O ,|O but|O traffics|O with|O TfR|O to|O Tf|O -|O positive|O internal|O compartments|O Gross|O et|O al|O .|O ,|O 1998|O .|O
We|O have|O expressed|O the|O mature|O form|O of|O Yfh1p|O (|O mYfh1p|O )|O in|O Escherichia|O coli|O and|O have|O analyzed|O its|O function|O in|O vitro|O .|O
In|O preliminary|O screens|O ,|O mutations|O of|O PTEN|O were|O detected|O in|O 31|O %|O (|O 13|O /|O 42|O )|O of|O glioblastoma|O cell|O lines|O and|O xenografts|O ,|O 100|O %|O (|O 4|O /|O 4|O )|O of|O prostate|B-DISE cancer|I-DISE cell|O lines|O ,|O 6|O %|O (|O 4|O /|O 65|O )|O of|O breast|B-DISE cancer|I-DISE cell|O lines|O and|O xenografts|O ,|O and|O 17|O %|O (|O 3|O /|O 18|O )|O of|O primary|B-DISE glioblastomas|I-DISE .|O
An|O extension|O of|O the|O DGGE|O analysis|O to|O the|O entire|O coding|O region|O in|O a|O sufficient|O number|O of|O clinically|O well|O -|O characterized|O ,|O unrelated|O patients|O will|O facilitate|O the|O establishment|O of|O genotype|O -|O phenotype|O correlations|O .|O
Loss|O of|O E|O -|O cadherin|O function|O has|O been|O implicated|O in|O the|O pathogenesis|O of|O sporadic|O colorectal|B-DISE and|I-DISE other|I-DISE cancers|I-DISE ,|O and|O our|O findings|O provide|O evidence|O that|O germline|O CDH1|O mutations|O predispose|O to|O early|O onset|O colorectal|B-DISE cancer|I-DISE .|O
The|O application|O of|O blood|O leucocytes|O can|O be|O a|O simple|O technique|O on|O analysing|O a|O constructive|O abnormality|O of|O CYP27|O mRNA|O .|O .|O
Complement|B-DISE component|I-DISE C6|I-DISE deficiency|I-DISE (|O C6D|B-DISE )|O was|O diagnosed|O in|O a|O 16|O -|O year|O -|O old|O African|O -|O American|O male|O with|O meningococcal|B-DISE meningitis|I-DISE .|O
One|O of|O the|O mutations|O is|O a|O novel|O C|O -|O to|O -|O G|O transversion|O ,|O resulting|O in|O a|O replacement|O of|O Tyr180|O by|O a|O stop|O codon|O .|O
In|O addition|O ,|O expression|O of|O ataxin|O -|O 3|O within|O the|O nucleus|O exposes|O the|O glutamine|O domain|O of|O the|O full|O -|O length|O non|O -|O pathological|O protein|O ,|O allowing|O it|O to|O bind|O the|O monoclonal|O antibody|O 1C2|O .|O
To|O confirm|O these|O results|O ,|O sperm|O typing|O analysis|O was|O also|O performed|O using|O a|O polymorphic|O marker|O ,|O D14S1050|O ,|O closely|O linked|O to|O the|O MJD1|O gene|O .|O
Ten|O of|O the|O twenty|O eight|O YAC|O clones|O comprise|O a|O minimal|O set|O spanning|O the|O 2|O .|O 2|O Mb|O .|O
The|O PDS|O gene|O encodes|O a|O transmembrane|O protein|O ,|O known|O as|O pendrin|O ,|O which|O functions|O as|O a|O transporter|O of|O iodide|O and|O chloride|O .|O
The|O ATM|O gene|O encodes|O a|O protein|O kinase|O that|O is|O activated|O by|O ionizing|O radiation|O or|O radiomimetic|O drugs|O ,|O whereas|O p95|O /|O nbs1|O is|O part|O of|O a|O protein|O complex|O that|O is|O involved|O in|O responses|O to|O DNA|O double|O -|O strand|O breaks|O .|O
Cotransfection|O of|O normal|O alpha|O -|O cDNA|O and|O beta|O -|O cDNA|O followed|O by|O immunoprecipitation|O of|O human|O Hex|O A|O resulted|O in|O 20|O -|O fold|O increase|O in|O the|O ratio|O between|O positive|O and|O negative|O (|O mock|O transfection|O )|O control|O values|O .|O
We|O conclude|O that|O the|O C282Y|O mutation|O does|O not|O result|O in|O a|O null|O allele|O .|O .|O
Individuals|O homozygous|O for|O the|O Leu359|O variant|O (|O CYP2C9|O *|O 3|O )|O have|O been|O shown|O to|O have|O significantly|O lower|O drug|O clearances|O compared|O with|O Ile359|O (|O CYP2C9|O *|O 1|O )|O homozygous|O individuals|O .|O
These|O findings|O suggest|O the|O possibility|O that|O C6|O and|O C7|O may|O function|O as|O a|O single|O genetic|O unit|O and|O that|O the|O primary|O transcript|O copied|O from|O the|O genome|O includes|O information|O for|O both|O proteins|O .|O .|O
Studies|O at|O the|O transcript|O and|O protein|O level|O are|O needed|O for|O a|O better|O assessment|O .|O .|O
All|O but|O one|O of|O the|O mutations|O were|O detected|O within|O the|O BRCA1|O gene|O .|O
He|O showed|O short|O stature|O ,|O obesity|B-DISE ,|O mild|O developmental|B-DISE delay|I-DISE ,|O cryptorchidism|B-DISE ,|O and|O some|O mild|O dysmorphic|B-DISE features|I-DISE .|O
In|O family|O studies|O of|O three|O first|O -|O degree|O relatives|O with|O heterozygous|O C9|B-DISE deficiency|I-DISE ,|O we|O demonstrated|O that|O the|O two|O mutations|O are|O segregating|O independently|O .|O
These|O results|O also|O have|O implications|O for|O the|O understanding|O of|O cellular|O iron|O homeostasis|O in|O organs|O such|O as|O the|O liver|O ,|O pancreas|O ,|O heart|O ,|O and|O spleen|O that|O are|O iron|O loaded|O in|O hereditary|B-DISE hemochromatotic|I-DISE individuals|O lacking|O functional|O HFE|O .|O .|O
Mutation|O analysis|O showed|O that|O both|O APC|O (|O AS9|O )|O and|O the|O wild|O -|O type|O APC|O alleles|O were|O somatically|O mutated|O in|O most|O colorectal|B-DISE tumors|I-DISE from|O these|O patients|O .|O
Defining|O polymorphic|O sites|O as|O well|O as|O mutations|O in|O the|O ATM|O gene|O will|O be|O of|O great|O importance|O in|O designing|O automated|O methods|O for|O detecting|O mutations|O .|O .|O
Recently|O ,|O we|O reported|O five|O Austrian|O families|O with|O generalized|B-DISE atrophic|I-DISE benign|I-DISE epidermolysis|I-DISE bullosa|I-DISE who|O share|O the|O same|O COL17A1|O mutation|O .|O
We|O analysed|O 13|O independent|O patients|O with|O clinical|O diagnosis|O of|O AAS|B-DISE .|O
Inherited|O mutations|O of|O the|O APC|O gene|O predispose|O carriers|O to|O multiple|B-DISE adenomatous|Mention text="multiple adenomatous polyps" start=9 end=12 type=DISE prob=null&Mention text="adenomatous polyps of the colon and rectum" start=10 end=17 type=DISE prob=null polyps|Mention text="multiple adenomatous polyps" start=9 end=12 type=DISE prob=null&Mention text="adenomatous polyps of the colon and rectum" start=10 end=17 type=DISE prob=null of|I-DISE the|I-DISE colon|I-DISE and|I-DISE rectum|I-DISE and|O to|O colorectal|B-DISE cancer|I-DISE .|O
Homozygosity|O for|O M1V|O and|O codominant|O inheritance|O of|O I65T|O /|O R408W|O were|O both|O associated|O with|O classical|B-DISE phenylketonuria|I-DISE .|O .|O
The|O 2|O .|O 6|O A|O crystal|O structure|O of|O HFE|O reveals|O the|O locations|O of|O hemochromatosis|B-DISE mutations|O and|O a|O patch|O of|O histidines|O that|O could|O be|O involved|O in|O pH|O -|O dependent|O interactions|O .|O
We|O report|O the|O case|O of|O a|O nonsense|O mutation|O in|O a|O Duchenne|B-DISE patient|O identified|O by|O this|O approach|O .|O
BACKGROUND|O AND|O OBJECTIVES|O :|O Mutations|O of|O the|O peripherin|O /|O RDS|O gene|O have|O been|O reported|O in|O autosomal|B-DISE dominant|I-DISE retinitis|I-DISE pigmentosa|I-DISE ,|O pattern|O macular|B-DISE dystrophy|I-DISE ,|O and|O retinitis|B-DISE punctata|I-DISE albescens|I-DISE .|O
The|O risk|O of|O colorectal|B-DISE cancer|I-DISE was|O significantly|O higher|O (|O p|O <|O 0|O .|O 01|O )|O in|O males|O than|O females|O 0|O .|O 63|O v|O 0|O .|O 30|O and|O 0|O .|O 84|O v|O 0|O .|O 44|O at|O ages|O 50|O and|O 60|O years|O ,|O respectively|O .|O
In|O ataxia|B-DISE -|I-DISE telangiectasia|I-DISE (|O A|B-DISE -|I-DISE T|I-DISE )|O patients|O ,|O mutations|O in|O a|O single|O gene|O ,|O ATM|O ,|O result|O in|O an|O autosomal|O recessive|O syndrome|O that|O embraces|O a|O variety|O of|O clinical|O features|O and|O manifests|O extreme|O radiosensitivity|O and|O a|O strong|O pre|O -|O disposition|O to|O malignancy|O .|O
This|O percentage|O of|O CTNNB1|O mutations|O is|O greater|O than|O in|O all|O other|O human|O tumours|B-DISE examined|O thus|O far|O ,|O and|O directly|O implicates|O beta|O -|O catenin|O /|O LEF|O misregulation|O as|O the|O major|O cause|O of|O hair|O matrix|O cell|O tumorigenesis|O in|O humans|O .|O .|O
Subsequently|O analysis|O of|O the|O retinas|O of|O nine|O enucleated|O eyes|O from|O males|O with|O Coats|B-DISE '|I-DISE disease|I-DISE demonstrated|O in|O one|O a|O somatic|O mutation|O in|O the|O NDP|O gene|O which|O was|O not|O present|O within|O non|O -|O retinal|O tissue|O .|O
Chronic|B-DISE neisserial|I-DISE infection|I-DISE can|O be|O associated|O with|O C7|B-DISE deficiency|I-DISE and|O must|O be|O distinguished|O from|O other|O causes|O of|O cutaneous|B-DISE vasculitis|I-DISE .|O .|O
The|O authors|O '|O earlier|O findings|O of|O a|O negative|O electroretinogram|O (|O ERG|O )|O in|O a|O boy|O with|O Duchenne|B-DISE muscular|I-DISE dystrophy|I-DISE (|O DMD|B-DISE )|O led|O them|O to|O investigate|O dystrophin|O gene|O deletions|O and|O ERGs|O in|O five|O boys|O with|O DMD|B-DISE .|O
Oedemic|B-DISE buccal|I-DISE mucosa|I-DISE (|O leucoedema|B-DISE )|O and|O gingival|B-DISE overgrowths|I-DISE were|O more|O frequent|O in|O AGU|B-DISE patients|O than|O in|O controls|O p|O <|O 0|O .|O 001|O .|O
Therefore|O ,|O deletion|O of|O the|O KIT|O and|O PDGFRA|O genes|O may|O account|O for|O the|O piebald|B-DISE phenotype|I-DISE in|O this|O patient|O .|O .|O
We|O calculated|O age|O related|O risks|O of|O all|O ,|O colorectal|B-DISE ,|I-DISE endometrial|I-DISE ,|I-DISE and|I-DISE ovarian|I-DISE cancers|I-DISE in|O nt943|O +|O 3|O A|O -|O -|O T|O MSH2|O mutation|O carriers|O (|O n|O =|O 76|O )|O for|O all|O patients|O and|O for|O men|O and|O women|O separately|O .|O
Mutations|O in|O this|O gene|O are|O responsible|O for|O Pendred|B-DISE syndrome|I-DISE and|O autosomal|B-DISE recessive|I-DISE non|O -|O syndromic|O hearing|B-DISE loss|I-DISE at|O the|O DFNB4|O locus|O on|O chromosome|O 7q31|O .|O
Although|O this|O association|O may|O be|O coincidental|O ,|O it|O prompts|O further|O attention|O to|O the|O possibility|O that|O under|O certain|O circumstances|O G6PD|B-DISE deficiency|I-DISE may|O favor|O cataract|B-DISE formation|O .|O
Approximately|O 50|O -|O 60|O mutations|O have|O been|O reported|O in|O Caucasians|O and|O are|O reflected|O in|O a|O wide|O range|O of|O clinical|O severities|O .|O
Effective|O mutation|O detection|O in|O these|O families|O is|O therefore|O fundamental|O to|O unambiguously|O determine|O the|O genetic|O status|O of|O each|O individual|O at|O risk|O .|O
Aerobic|O addition|O of|O ferrous|O iron|O to|O mYfh1p|O results|O in|O assembly|O of|O regular|O spherical|O multimers|O with|O a|O molecular|O mass|O of|O approximately|O 1|O .|O 1|O MDa|O (|O megadaltons|O )|O and|O a|O diameter|O of|O 13|O +|O /|O -|O 2|O nm|O .|O
To|O assess|O the|O risk|O of|O this|O common|O APC|O allelic|O variant|O in|O colorectal|O carcinogenesis|O ,|O we|O have|O analyzed|O a|O large|O cohort|O of|O unselected|O Ashkenazi|O Jewish|O subjects|O with|O adenomatous|B-DISE polyps|I-DISE and|O .|O or|O colorectal|B-DISE cancer|I-DISE ,|O for|O the|O APC|O I1307K|O polymorphism|O .|O
Mutations|O in|O the|O human|O homolog|O of|O Foxc1|O ,|O FKHL7|O ,|O cause|O dominant|O anterior|B-DISE segment|I-DISE defects|I-DISE and|O glaucoma|B-DISE in|O various|O families|O .|O
We|O also|O identified|O two|O new|O microsatellite|O markers|O for|O the|O OCRL1|O locus|O ,|O and|O we|O detected|O a|O germline|O mosaicism|O in|O one|O family|O .|O
A|O small|O -|O for|O -|O gestational|O -|O age|O infant|O ,|O found|O to|O have|O analbuminemia|B-DISE in|O the|O neonatal|O period|O ,|O is|O reported|O and|O the|O twelve|O cases|O recorded|O in|O the|O world|O literature|O are|O reviewed|O .|O
No|O deletions|O were|O detected|O in|O seven|O cases|O of|O popliteal|B-DISE pterygia|I-DISE syndrome|I-DISE ,|O 76|O cases|O of|O mixed|O syndromic|O forms|O of|O cleft|B-DISE lip|I-DISE and|I-DISE palate|I-DISE ,|O and|O 178|O cases|O of|O nonsyndromic|O cleft|B-DISE lip|I-DISE and|I-DISE palate|I-DISE .|O
It|O shows|O tissue|O -|O specific|O alternative|O splicing|O and|O alternative|O transcription|O starts|O .|O
We|O conducted|O detailed|O mutational|O analyses|O of|O 29|O unrelated|O Japanese|O patients|O with|O ALD|B-DISE by|O genomic|O Southern|O blot|O analysis|O and|O direct|O nucleotide|O sequence|O analysis|O of|O reverse|O transcriptase|O -|O polymerase|O chain|O reaction|O products|O derived|O from|O total|O RNA|O that|O was|O extracted|O from|O cultured|O skin|O fibroblasts|O ,|O lymphoblastoid|O cells|O ,|O or|O peripheral|O blood|O leukocytes|O .|O
In|O sharp|O contrast|O ,|O among|O the|O 34|O duplicated|O cases|O ,|O 91|O %|O of|O mothers|O were|O carriers|O ,|O a|O value|O significantly|O (|O chi2|O =|O 9|O .|O 20|O ,|O P|O <|O .|O 01|O )|O in|O favor|O of|O a|O male|O bias|O ,|O with|O an|O estimation|O of|O the|O male|O /|O female|O mutation|O frequency|O (|O k|O )|O of|O 9|O .|O 3|O .|O
An|O array|O of|O genotypes|O was|O found|O in|O these|O patients|O .|O
Very|B-DISE long|I-DISE chain|I-DISE acyl|I-DISE -|I-DISE CoA|I-DISE dehydrogenase|I-DISE (|I-DISE VLCAD|I-DISE )|I-DISE deficiency|I-DISE is|O a|O life|O -|O threatening|O disorder|O of|O mitochondrial|O fatty|O acid|O beta|O -|O oxidation|O .|O
Of|O these|O ,|O 23|O were|O novel|O mutations|O ,|O and|O most|O occurred|O in|O exon|O 8|O .|O
Mutations|O in|O the|O HEXA|O gene|O ,|O encoding|O the|O alpha|O -|O subunit|O of|O beta|O -|O hexosaminidase|O A|O (|O Hex|O A|O )|O ,|O that|O abolish|O Hex|O A|O enzyme|O activity|O cause|O Tay|B-DISE -|I-DISE Sachs|I-DISE disease|I-DISE (|O TSD|B-DISE )|O ,|O the|O fatal|O infantile|O form|O of|O G|O (|O M2|O )|O gangliosidosis|B-DISE ,|O Type|O 1|O .|O
Mutation|O analysis|O at|O the|O A|O -|O T|O locus|O may|O help|O estimate|O the|O prognosis|O of|O A|B-DISE -|I-DISE T|I-DISE patients|O .|O .|O
The|O absence|O of|O functional|O C7|O activity|O could|O not|O be|O accounted|O for|O on|O the|O basis|O of|O an|O inhibitor|O .|O
The|O central|O nervous|O system|O (|O CNS|O )|O of|O Atm|O -|O null|O mice|O shows|O a|O pronounced|O defect|O in|O apoptosis|O induced|O by|O genotoxic|O stress|O ,|O suggesting|O ATM|O functions|O to|O eliminate|O neurons|O with|O excessive|O genomic|O damage|O .|O
Analysis|O of|O fetal|O tissues|O following|O prostaglandin|O termination|O of|O this|O pregnancy|O confirmed|O the|O diagnosis|O .|O
Segregation|O distortion|O has|O been|O reported|O to|O occur|O in|O a|O number|O of|O the|O trinucleotide|O repeat|O disorders|O .|O
The|O genetic|O instability|O observed|O in|O the|O tumor|O and|O cell|O line|O DNA|O ,|O together|O with|O the|O germ|O -|O line|O mutation|O in|O a|O mismatch|O -|O repair|O gene|O ,|O suggest|O that|O the|O MSH2|O gene|O is|O involved|O in|O the|O onset|O and|O /|O or|O progression|O in|O a|O subset|O of|O ovarian|B-DISE cancer|I-DISE .|O .|O
Surprisingly|O ,|O mapping|O of|O the|O new|O deletion|O showed|O that|O it|O extended|O 0|O .|O 2|O -|O 1|O Mb|O beyond|O the|O proximal|O breakpoint|O for|O the|O deletion|O described|O previously|O .|O
The|O haplotype|O has|O been|O found|O in|O combination|O with|O a|O number|O of|O other|O haplotypes|O containing|O defective|O genes|O that|O lead|O either|O to|O C6|B-DISE or|I-DISE C7|I-DISE deficiency|I-DISE ,|O but|O with|O different|O consequences|O .|O
Macro|B-DISE -|I-DISE orchidism|I-DISE was|O absent|O in|O knockout|O mice|O carrying|O the|O YAC|O transgene|O indicating|O functional|O rescue|O by|O the|O human|O protein|O .|O
The|O largest|O two|O -|O point|O LOD|O score|O was|O 5|O .|O 87|O .|O
Of|O note|O ,|O the|O presence|O of|O different|O divergent|O haplotypes|O suggested|O the|O occurrence|O of|O de|O novo|O ,|O recurrent|O N370S|O mutations|O .|O
Identification|O of|O each|O mutant|O gene|O provides|O valuable|O information|O as|O to|O the|O type|O of|O mutation|O that|O occurs|O spontaneously|O .|O
Among|O family|O members|O ,|O an|O average|O age|O of|O less|O than|O 55|O years|O at|O the|O diagnosis|O of|O breast|B-DISE cancer|I-DISE ,|O the|O presence|O of|O ovarian|B-DISE cancer|I-DISE ,|O the|O presence|O of|O breast|B-DISE and|I-DISE ovarian|I-DISE cancer|I-DISE in|O the|O same|O woman|O ,|O and|O Ashkenazi|O Jewish|O ancestry|O were|O all|O associated|O with|O an|O increased|O risk|O of|O detecting|O a|O BRCA1|O mutation|O .|O
These|O results|O strongly|O suggest|O that|O somatic|O mutations|O of|O the|O APC|O gene|O are|O associated|O with|O development|O of|O a|O great|O majority|O of|O colorectal|B-DISE tumors|I-DISE .|O .|O
In|O 12|O patients|O altered|O PCR|O fragments|O were|O detected|O which|O were|O studied|O in|O detail|O by|O direct|O sequencing|O .|O
By|O direct|O sequencing|O ,|O we|O identified|O five|O mutations|O ,|O of|O which|O two|O were|O novel|O ,|O and|O 16|O polymorphisms|O ,|O of|O which|O 6|O were|O novel|O .|O
Tay|B-DISE -|I-DISE Sachs|I-DISE disease|I-DISE is|O an|O autosomal|O recessive|O genetic|O disorder|O resulting|O from|O mutation|O of|O the|O HEXA|O gene|O encoding|O the|O alpha|O -|O subunit|O of|O the|O lysosomal|O enzyme|O ,|O beta|O -|O N|O -|O acetylhexosaminidase|O A|O ref|O .|O 1|O .|O
Using|O DNA|O as|O the|O starting|O material|O ,|O we|O screened|O the|O ATM|O gene|O in|O 92|O A|B-DISE -|I-DISE T|I-DISE patients|O ,|O using|O an|O optimized|O single|O -|O strand|O conformation|O polymorphism|O (|O SSCP|O )|O technique|O that|O detected|O all|O previously|O known|O mutations|O in|O the|O polymerase|O chain|O reaction|O (|O PCR|O )|O segments|O being|O analyzed|O .|O
The|O recent|O isolation|O of|O the|O responsible|O gene|O (|O adenomatous|B-DISE polyposis|I-DISE coli|I-DISE or|O APC|O )|O has|O facilitated|O the|O search|O for|O germ|O line|O mutations|O in|O affected|O individuals|O .|O
Seven|O distinct|O mutations|O were|O identified|O ;|O five|O of|O these|O occurred|O in|O two|O or|O more|O families|O .|O
The|O ATM|O gene|O is|O responsible|O for|O the|O autosomal|O recessive|O disorder|O ataxia|B-DISE -|I-DISE telangiectasia|I-DISE (|O A|B-DISE -|I-DISE T|I-DISE )|O ,|O characterized|O by|O cerebellar|B-DISE degeneration|I-DISE ,|O immunodeficiency|B-DISE and|O cancer|B-DISE predisposition|O .|O
Our|O findings|O provide|O additional|O evidence|O for|O the|O pathogenetic|O role|O of|O CHM|O mutations|O and|O provide|O a|O diagnostic|O tool|O for|O one|O fifth|O of|O the|O world|O '|O s|O known|O CHM|B-DISE patients|O .|O .|O
HFE|O is|O the|O protein|O product|O of|O the|O gene|O mutated|O in|O the|O autosomal|B-DISE recessive|I-DISE disease|I-DISE hereditary|B-DISE hemochromatosis|I-DISE Feder|O ,|O J|O .|O N|O .|O ,|O Gnirke|O ,|O A|O .|O ,|O Thomas|O ,|O W|O .|O ,|O Tsuchihashi|O ,|O Z|O .|O ,|O Ruddy|O ,|O D|O .|O A|O .|O ,|O Basava|O ,|O A|O .|O ,|O Dormishian|O ,|O F|O .|O ,|O Domingo|O ,|O R|O .|O J|O .|O ,|O Ellis|O ,|O M|O .|O C|O .|O ,|O Fullan|O ,|O A|O .|O ,|O Hinton|O ,|O L|O .|O M|O .|O ,|O Jones|O ,|O N|O .|O L|O .|O ,|O Kimmel|O ,|O B|O .|O E|O .|O ,|O Kronmal|O ,|O G|O .|O S|O .|O ,|O Lauer|O ,|O P|O .|O ,|O Lee|O ,|O V|O .|O K|O .|O ,|O Loeb|O ,|O D|O .|O B|O .|O ,|O Mapa|O ,|O F|O .|O A|O .|O ,|O McClelland|O ,|O E|O .|O ,|O Meyer|O ,|O N|O .|O C|O .|O ,|O Mintier|O ,|O G|O .|O A|O .|O ,|O Moeller|O ,|O N|O .|O ,|O Moore|O ,|O T|O .|O ,|O Morikang|O ,|O E|O .|O ,|O Prasss|O ,|O C|O .|O E|O .|O ,|O Quintana|O ,|O L|O .|O ,|O Starnes|O ,|O S|O .|O M|O .|O ,|O Schatzman|O ,|O R|O .|O C|O .|O ,|O Brunke|O ,|O K|O .|O J|O .|O ,|O Drayna|O ,|O D|O .|O T|O .|O ,|O Risch|O ,|O N|O .|O J|O .|O ,|O Bacon|O ,|O B|O .|O R|O .|O ,|O and|O Wolff|O ,|O R|O .|O R|O .|O (|O 1996|O )|O Nat|O .|O
The|O gene|O alterations|O in|O TP53|O and|O P16INK4A|O genes|O may|O be|O used|O as|O tumor|B-DISE markers|O in|O our|O family|O .|O .|O
The|O plasma|O lipoprotein|O profiles|O and|O high|O density|O lipoproteins|O (|O HDL|O )|O were|O characterized|O in|O patients|O with|O the|O genetic|O disease|O cerebrotendinous|B-DISE xanthomatosis|I-DISE CTX|B-DISE .|O
We|O have|O also|O examined|O a|O patient|O with|O NKH|B-DISE with|O no|O detectable|O GLDC|O mRNA|O in|O his|O lymphoblasts|O .|O
Q188R|O is|O the|O most|O common|O mutation|O in|O European|O populations|O or|O in|O those|O predominantly|O of|O European|O descent|O .|O
In|O the|O initial|O 48|O patients|O ,|O SSCP|O analysis|O was|O followed|O by|O PTT|O for|O those|O patients|O for|O whom|O no|O detectable|O mutations|O were|O found|O by|O SSCP|O .|O
Germline|O mutations|O of|O the|O adenomatous|B-DISE polyposis|I-DISE coli|I-DISE (|O APC|O )|O tumor|O -|O suppressor|O gene|O result|O in|O the|O hereditary|O colorectal|B-DISE cancer|I-DISE syndrome|O familial|B-DISE adenomatous|I-DISE polyposis|I-DISE FAP|B-DISE .|O
Mucopolysaccharidosis|B-DISE IVA|I-DISE (|O MPS|B-DISE IVA|I-DISE ;|O OMIM|O #|O 253000|O )|O ,|O a|O lysosomal|B-DISE storage|I-DISE disorder|I-DISE caused|O by|O a|O deficiency|B-DISE of|I-DISE N|I-DISE -|I-DISE acetylgalactosamine|I-DISE -|I-DISE 6|I-DISE -|I-DISE sulfate|I-DISE sulfatase|I-DISE (|O GALNS|O )|O ,|O has|O variable|O clinical|O phenotypes|O .|O
The|O severity|O of|O the|O disease|B-DISE correlates|O with|O the|O position|O of|O the|O inherited|O APC|O mutation|O genotype|O -|O phenotype|O correlation|O .|O
We|O show|O that|O Foxc1|O (|O +|O /|O -|O )|O mice|O have|O anterior|B-DISE segment|I-DISE abnormalities|I-DISE similar|O to|O those|O reported|O in|O human|O patients|O .|O
In|O addition|O ,|O our|O screening|O showed|O that|O the|O S65C|O substitution|O was|O significantly|O enriched|O in|O probands|O with|O at|O least|O one|O chromosome|O without|O an|O assigned|O mutation|O .|O
We|O report|O three|O new|O cases|O ,|O two|O carrying|O a|O previously|O described|O WT1|O exon|O 9|O mutation|O and|O one|O with|O a|O novel|O WT1|O exon|O 8|O mutation|O .|O
Recurrent|O mutation|O has|O been|O observed|O at|O several|O of|O these|O sites|O ,|O producing|O associations|O with|O different|O haplotypes|O in|O different|O populations|O .|O
Myotonic|B-DISE dystrophy|I-DISE (|O DM|B-DISE )|O is|O an|O autosomal|B-DISE dominant|I-DISE disorder|I-DISE characterized|O by|O skeletal|O muscle|B-DISE wasting|I-DISE ,|O myotonia|B-DISE ,|O cardiac|B-DISE arrhythmia|I-DISE ,|O hyperinsulinaemia|B-DISE ,|O mental|B-DISE retardation|I-DISE and|O ocular|O cataracts|B-DISE .|O
All|O patients|O were|O found|O to|O be|O homozygous|O for|O a|O newly|O identified|O C|O -|O >|O T|O transition|O in|O codon|O 21|O (|O exon|O 2|O )|O substituting|O arginine|O for|O a|O premature|O stop|O codon|O (|O R21X|O :|O CGA|O to|O TGA|O )|O and|O generating|O a|O NlaIII|O restriction|O site|O .|O
HMGIC|O is|O predominantly|O expressed|O in|O proliferating|O ,|O undifferentiated|O mesenchymal|O cells|O and|O is|O not|O detected|O in|O adult|O tissues|O .|O
Only|O 20|O of|O 4000|O (|O 0|O .|O 5|O %|O )|O patients|O had|O late|O -|O onset|O FMF|B-DISE .|O
We|O previously|O reported|O nine|O children|O with|O an|O autosomally|O recessive|O form|O of|O congenital|B-DISE hypothyroidism|I-DISE due|O to|O an|O iodide|B-DISE transport|I-DISE defect|I-DISE in|O a|O large|O Hutterite|O family|O with|O extensive|O consanguinity|O living|O in|O central|O Canada|O .|O
A|O muscle|O biopsy|O from|O an|O Emery|B-DISE -|I-DISE Dreifuss|I-DISE muscular|I-DISE dystrophy|I-DISE (|O EMDM|B-DISE )|O patient|O showed|O complete|O absence|O of|O emerin|O by|O both|O Western|O blotting|O and|O immunohistochemistry|O ,|O suggesting|O a|O simple|O diagnostic|O antibody|O test|O for|O EDMD|O families|O .|O
Four|O of|O these|O mutations|O were|O genomic|O rearrangements|O resulting|O from|O homologous|O and|O nonhomologous|O recombinations|O mediated|O by|O Alu|O elements|O .|O
The|O response|O to|O treatment|O was|O good|O despite|O using|O low|O colchicine|O dose|O ,|O P|O <|O 0|O .|O 05|O .|O
The|O mutation|O was|O found|O to|O segregate|O with|O the|O AAS|B-DISE phenotype|O in|O affected|O males|O and|O carrier|O females|O in|O the|O family|O of|O this|O patient|O .|O
A|O high|O risk|O of|O colorectal|B-DISE cancer|I-DISE was|O predicted|O when|O an|O interstitial|O deletion|O of|O the|O long|O arm|O of|O chromosome|O 5|O ,|O del|O 5|O (|O q15q22|O .|O 3|O )|O ,|O was|O detected|O in|O her|O lymphocytes|O and|O deletion|O of|O the|O MCC|O and|O APC|O genes|O confirmed|O by|O molecular|O analysis|O .|O
Therefore|O ,|O the|O accumulation|O of|O the|O types|O of|O mutations|O in|O Japanese|O patients|O with|O WD|B-DISE will|O facilitate|O the|O fast|O and|O effective|O genetic|O diagnosis|O of|O WD|B-DISE in|O Japanese|O patients|O .|O .|O
Our|O data|O demonstrate|O that|O mutations|O occur|O in|O the|O Mxi1|O gene|O in|O neurofibrosarcoma|B-DISE .|O
The|O disease|O is|O characterized|O by|O progressive|O muscle|B-DISE weakness|I-DISE and|O sustained|B-DISE muscle|I-DISE contraction|I-DISE ,|O often|O with|O a|O wide|O range|O of|O accompanying|O symptoms|O .|O
We|O generated|O transgenic|O mice|O carrying|O large|O human|O genomic|O sequences|O with|O 20|O ,|O 55|O or|O >|O 300|O CTG|O ,|O cloned|O from|O patients|O from|O the|O same|O affected|O DM|B-DISE family|O .|O
The|O major|O cause|O of|O hepatic|O copper|O accumulation|O in|O man|O is|O a|O dysfunctional|O ATP7B|O gene|O ,|O causing|O Wilson|B-DISE disease|I-DISE WD|B-DISE .|O
Indentification|O of|O genetic|O marker|O ,|O HL|O -|O A|O W27|O ,|O for|O susceptible|O persons|O has|O provided|O a|O tool|O facilitating|O epidemiologic|O studies|O and|O allowing|O identification|O of|O control|O "|O populations|O without|O the|O marker|O .|O "|O
The|O remaining|O 101|O cases|O from|O the|O same|O series|O not|O associated|O with|O a|O BRCA|O mutation|O and|O 2|O additional|O groups|O (|O Gynecologic|O Oncology|O Group|O protocols|O 52|O and|O 111|O )|O with|O ovarian|B-DISE cancer|I-DISE from|O clinical|O trials|O (|O for|O the|O survival|O analysis|O )|O were|O included|O for|O comparison|O .|O
In|O the|O present|O study|O we|O have|O analyzed|O the|O AVP|O -|O neurophysin|O II|O (|O AVP|O -|O NPII|O )|O gene|O in|O a|O Spanish|O kindred|O .|O
Direct|O sequencing|O of|O PCR|O products|O identified|O a|O novel|O insertion|O of|O an|O A|O after|O nt|O 547|O in|O family|O 1|O .|O
We|O have|O reported|O isolation|O of|O a|O cDNA|O fragment|O that|O recognizes|O chromosomal|O sequences|O possessing|O many|O of|O the|O attributes|O of|O the|O retinoblastoma|B-DISE gene|O associated|O with|O the|O RB1|O locus|O .|O
Using|O linkage|O disequilibrium|O analysis|O based|O on|O haplotype|O data|O of|O seven|O polymorphic|O markers|O close|O to|O the|O frataxin|O gene|O ,|O the|O age|O of|O FRDA|B-DISE founding|O mutational|O event|O (|O s|O )|O is|O estimated|O to|O be|O at|O least|O 682|O +|O /|O -|O 203|O generations|O (|O 95|O %|O confidence|O interval|O :|O 564|O -|O 801|O g|O )|O ,|O a|O dating|O which|O is|O consistent|O with|O little|O or|O no|O negative|O selection|O and|O provides|O further|O evidence|O for|O an|O ancient|O spread|O of|O a|O pre|O -|O mutation|O (|O at|O -|O risk|O alleles|O )|O in|O western|O Europe|O .|O .|O
Furthermore|O ,|O SNRPN|O was|O mapped|O to|O the|O minimal|O deletion|O interval|O that|O is|O critical|O for|O PWS|B-DISE .|O
Northern|O blot|O analysis|O and|O sequencing|O of|O cloned|O PCR|O amplified|O VLCAD|O cDNA|O from|O four|O unrelated|O patients|O with|O VLCAD|B-DISE deficiency|I-DISE showed|O that|O VLCAD|O mRNA|O was|O undetectable|O in|O one|O patient|O and|O that|O the|O other|O three|O have|O mutations|O in|O both|O VLCAD|O alleles|O .|O
Each|O family|O contained|O :|O (|O i|O )|O two|O cases|O of|O gastric|B-DISE cancer|I-DISE in|O first|O degree|O relatives|O with|O one|O affected|O before|O age|O 50|O years|O ;|O or|O (|O ii|O )|O three|O or|O more|O cases|O of|O gastric|O cancer|O .|O
In|O this|O family|O of|O disorders|O ,|O a|O normally|O polymorphic|O CAG|O repeat|O becomes|O expanded|O ,|O resulting|O in|O expression|O of|O an|O expanded|O polyglutamine|O domain|O in|O the|O disease|O gene|O product|O .|O
In|O 17|O unrelated|O patients|O and|O 15|O controls|O ,|O PCR|O products|O derived|O from|O the|O promoter|O region|O ,|O exons|O 1|O and|O 2|O as|O well|O as|O the|O coding|O part|O of|O exon|O 3|O were|O analysed|O with|O the|O single|O strand|O conformation|O polymorphism|O (|O SSCP|O )|O technique|O .|O
These|O data|O demonstrate|O that|O :|O 1|O type|O I|O human|O complement|O C2|B-DISE deficiency|I-DISE is|O caused|O by|O a|O 28|O -|O base|O pair|O genomic|O deletion|O that|O causes|O skipping|O of|O exon|O 6|O during|O RNA|O splicing|O ,|O resulting|O in|O generation|O of|O a|O premature|O termination|O codon|O ,|O 2|O the|O 28|O -|O base|O pair|O deletion|O in|O the|O type|O I|O C2Q0|O gene|O is|O strongly|O associated|O with|O the|O HLA|O haplotype|O /|O complotype|O A25|O ,|O B18|O ,|O C2Q0|O ,|O BfS|O ,|O C4A4|O ,|O C4B2|O ,|O Drw2|O ,|O suggesting|O that|O all|O C2|O -|O deficient|O individuals|O with|O this|O haplotype|O /|O complotype|O will|O harbor|O the|O 28|O -|O base|O pair|O C2|O gene|O deletion|O ,|O and|O 3|O type|O II|O C2|B-DISE deficiency|I-DISE is|O caused|O by|O a|O different|O ,|O as|O yet|O uncharacterized|O ,|O molecular|O genetic|O defect|O .|O .|O
A|O deficiency|B-DISE of|I-DISE AAT|I-DISE in|O individuals|O homozygous|O for|O the|O PI|O Z|O allele|O occurs|O in|O about|O 1|O in|O 2|O ,|O 000|O -|O 8|O ,|O 000|O caucasians|O and|O is|O associated|O with|O an|O increased|O risk|O of|O early|B-DISE adult|I-DISE onset|I-DISE emphysema|I-DISE and|I-DISE liver|I-DISE disease|I-DISE in|I-DISE childhood|I-DISE .|O
This|O pattern|O corresponds|O to|O mutations|O leading|O mainly|O to|O truncated|O proteins|O with|O few|O specific|O missense|O mutations|O .|O
From|O the|O alignment|O of|O the|O amino|O acid|O (|O aa|O )|O sequence|O of|O 52|O glucose|O 6|O -|O phosphate|O dehydrogenase|O (|O G6PD|O )|O species|O from|O 42|O different|O organisms|O ,|O we|O found|O a|O striking|O correlation|O between|O the|O aa|O replacements|O that|O cause|O G6PD|B-DISE deficiency|I-DISE in|O humans|O and|O the|O sequence|O conservation|O of|O G6PD|O :|O two|O -|O thirds|O of|O such|O replacements|O are|O in|O highly|O and|O moderately|O conserved|O (|O 50|O -|O 99|O %|O )|O aa|O ;|O relatively|O few|O are|O in|O fully|O conserved|O aa|O (|O where|O they|O might|O be|O lethal|O )|O or|O in|O poorly|O conserved|O aa|O ,|O where|O presumably|O they|O simply|O would|O not|O cause|O G6PD|B-DISE deficiency|I-DISE .|O
However|O ,|O a|O defective|O G2|O -|O M|O checkpoint|O in|O these|O cells|O is|O accompanied|O by|O extensive|O chromosomal|B-DISE abnormalities|I-DISE .|O
Age|O penetrance|O is|O greater|O for|O BRCA1|O -|O linked|O than|O for|O BRCA2|O -|O linked|O cancers|B-DISE in|O this|O population|O .|O .|O
A|O screen|O of|O human|O tissues|O with|O this|O antibody|O reveals|O retinoschisin|O to|O be|O retina|O specific|O and|O the|O antibody|O detects|O a|O protein|O of|O similar|O size|O in|O bovine|O and|O murine|O retinae|O .|O
Kinzler|O (|O eds|O .|O )|O ,|O The|O Genetic|O Basis|O of|O Human|O Cancer|B-DISE ,|O pp|O .|O 455|O -|O 473|O ,|O McGraw|O -|O Hill|O ,|O 1998|O .|O
Abnormal|O color|O vision|O has|O been|O observed|O in|O 12|O of|O 27|O patients|O with|O adrenomyeloneuropathy|B-DISE (|O AMN|B-DISE )|O ,|O a|O milder|O form|O of|O ALD|B-DISE .|O
In|O view|O of|O the|O current|O explosive|O increase|O in|O full|O genome|O sequencing|O projects|O ,|O this|O tool|O will|O become|O rapidly|O available|O for|O numerous|O other|O genes|O .|O .|O
In|O parallel|O ,|O measurement|O of|O the|O gut|O mucosal|O iron|O content|O as|O well|O as|O iron|O regulatory|O proteins|O allows|O a|O more|O informed|O evaluation|O of|O various|O hypotheses|O regarding|O the|O precise|O role|O of|O HFE|O in|O iron|O homeostasis|O .|O
We|O therefore|O conclude|O that|O the|O HGO|O cDNA|O encodes|O the|O gene|O responsible|O for|O alkaptonuria|B-DISE .|O .|O
Elsewhere|O we|O reported|O an|O in|O -|O frame|O deletion|O of|O one|O of|O the|O two|O adjacent|O phenylalanine|O codons|O at|O position|O 304|O or|O 305|O (|O delta|O F304|O /|O 305|O )|O in|O one|O HEXA|O allele|O of|O a|O Moroccan|O Jewish|O TSD|B-DISE patient|O and|O in|O three|O obligate|O carriers|O from|O six|O unrelated|O Moroccan|O Jewish|O families|O .|O
The|O APC|O gene|O is|O located|O within|O band|O 5q22|O .|O
In|O addition|O ,|O this|O test|O enabled|O us|O to|O identify|O two|O fragile|B-DISE X|I-DISE patients|O who|O did|O not|O show|O the|O full|O mutation|O by|O analysis|O of|O DNA|O isolated|O from|O blood|O cells|O .|O .|O
Several|O distinct|O clinical|O phenotypes|O are|O known|O .|O
The|O mutated|O CDK4|O allele|O was|O present|O in|O autologous|O cultured|O melanoma|B-DISE cells|O and|O metastasis|B-DISE tissue|O ,|O but|O not|O in|O the|O patient|O '|O s|O lymphocytes|O .|O
We|O screened|O 31|O human|O gastric|B-DISE cancers|I-DISE ,|O 7|O esophageal|B-DISE cancers|I-DISE ,|O 85|O bone|B-DISE and|I-DISE soft|I-DISE tissue|I-DISE tumors|I-DISE of|O various|O types|O ,|O including|O 4|O neurofibrosarcomas|B-DISE .|O
We|O adopted|O both|O single|O -|O strand|O conformation|O polymorphism|O (|O SSCP|O )|O analysis|O and|O a|O method|O of|O analysis|O involving|O the|O reverse|O transcription|O -|O polymerase|O chain|O reaction|O (|O RT|O -|O PCR|O )|O followed|O by|O a|O protein|O truncation|O test|O PTT|O .|O
The|O estimated|O proportion|O of|O families|O (|O alpha|O )|O linked|O to|O the|O locus|O was|O .|O 06|O 1|O -|O LOD|O support|O interval|O .|O 01|O -|O .|O 12|O .|O
Emery|B-DISE -|I-DISE Dreifuss|I-DISE muscular|I-DISE dystrophy|I-DISE (|O EDMD|B-DISE )|O is|O an|O X|O -|O linked|O recessive|O muscular|O dystrophy|O characterized|O by|O early|O contractures|O of|O the|O elbows|O ,|O Achilles|O tendons|O and|O spine|O ,|O slowly|O progressive|O muscle|B-DISE wasting|I-DISE and|I-DISE weakness|I-DISE ,|O and|O cardiomyopathy|B-DISE associated|O with|O cardiac|B-DISE conduction|I-DISE defects|I-DISE .|O
A|O recombination|O event|O between|O a|O (|O GT|O )|O n|O polymorphism|O in|O intron|O 2|O of|O the|O MAOB|O gene|O and|O the|O NDP|O locus|O ,|O in|O a|O family|O previously|O reported|O to|O have|O a|O recombination|O between|O DXS7|O and|O NDP|O ,|O delineates|O a|O flanking|O marker|O telomeric|O to|O this|O disease|O gene|O .|O
The|O larger|O allele|O size|O correlated|O with|O bladder|B-DISE symptoms|I-DISE and|O the|O presence|O of|O foot|B-DISE deformity|I-DISE .|O
Among|O these|O patients|O we|O identified|O seven|O (|O 8|O .|O 5|O %|O )|O ATM|O germline|O mutations|O ,|O of|O which|O five|O are|O distinct|O .|O
This|O leads|O to|O reduced|O levels|O of|O the|O protein|O ,|O frataxin|O .|O
Parasite|O growth|O was|O approximately|O one|O -|O third|O of|O normal|O in|O both|O hemi|O -|O and|O heterozygotes|O for|O G6PD|B-DISE deficiency|I-DISE .|O
Hereditary|B-DISE coproporphyria|I-DISE (|O HC|B-DISE )|O is|O an|O acute|B-DISE hepatic|I-DISE porphyria|I-DISE with|O autosomal|O dominant|O inheritance|O caused|O by|O deficient|B-DISE activity|I-DISE of|I-DISE coproporphyrinogen|I-DISE III|I-DISE oxidase|I-DISE CPO|O .|O
In|O the|O Caucasian|O population|O ,|O it|O has|O been|O demonstrated|O that|O the|O insulin|O gene|O (|O INS|O )|O region|O contains|O the|O insulin|B-DISE -|I-DISE dependent|I-DISE diabetes|I-DISE mellitus|I-DISE locus|O IDDM2|O .|O
Germline|O mutations|O were|O identified|O in|O 38|O patients|O 61|O %|O .|O
On|O the|O basis|O of|O these|O families|O ,|O and|O of|O six|O maternally|O and|O five|O paternally|O derived|O unbalanced|O -|O translocation|O DGS|O probands|O in|O the|O literature|O ,|O parent|O of|O origin|O or|O imprinting|O does|O not|O appear|O to|O play|O an|O important|O role|O in|O the|O pathogenesis|O of|O DGS|B-DISE .|O
In|O RT|O -|O PCR|O analysis|O ,|O only|O a|O truncated|O transcript|O was|O detected|O in|O the|O patient|O ,|O whereas|O both|O normal|O and|O truncated|O transcripts|O were|O detected|O in|O the|O siblings|O .|O
One|O splicing|O mutation|O results|O in|O a|O 3|O amino|O acid|O in|O -|O frame|O insertion|O .|O
In|O this|O group|O of|O patients|O ,|O 7|O different|O mutations|O have|O been|O identified|O ,|O including|O 2|O deletions|O 295|O -|O 298delTCAT|O ,|O 1897delC|O ,|O 1|O splice|O -|O site|O mutation|O IVS14|O +|O 1G|O >|O A|O and|O 4|O missense|O mutations|O 85T|O >|O C|O ,|O 703C|O >|O T|O ,|O 2658G|O >|O A|O ,|O 2983G|O >|O T|O .|O
We|O report|O details|O of|O a|O family|O with|O classic|O Li|B-DISE -|I-DISE Fraumeni|I-DISE syndrome|I-DISE in|O which|O there|O is|O a|O mutation|O in|O codon|O 344|O of|O the|O tumour|O suppressor|O gene|O TP53|O .|O
Our|O results|O confirm|O that|O the|O mutation|O detection|O rate|O with|O PTT|O was|O superior|O to|O that|O with|O SSCP|O ,|O and|O suggest|O that|O PTT|O would|O be|O a|O more|O practical|O screening|O method|O to|O detect|O germline|O mutations|O of|O the|O APC|O gene|O in|O FAP|B-DISE patients|O .|O .|O
We|O propose|O that|O the|O (|O CUG|O )|O n|O is|O an|O essential|O cis|O acting|O element|O for|O this|O splicing|O event|O .|O
We|O have|O analyzed|O 20|O breast|B-DISE -|I-DISE ovarian|I-DISE cancer|I-DISE families|O ,|O the|O majority|O of|O which|O show|O positive|O evidence|O of|O linkage|O to|O chromosome|O 17q12|O for|O germ|O -|O line|O mutations|O in|O the|O BRCA1|O gene|O .|O
Multiple|O species|O comparison|O and|O the|O crystal|O structure|O of|O human|O beta|O -|O glucuronidase|O indicated|O that|O E351|O is|O a|O highly|O conserved|O residue|O most|O likely|O essential|O in|O maintenance|O of|O the|O enzyme|O '|O s|O conformation|O .|O
After|O crossbreeding|O with|O female|O mice|O of|O the|O EIIa|O -|O cre|O strain|O ,|O the|O floxed|O allele|O undergoes|O Cre|O -|O mediated|O recombination|O with|O high|O efficiency|O during|O early|O embryonic|O development|O .|O
On|O the|O basis|O of|O a|O sperm|O typing|O study|O performed|O in|O patients|O of|O Japanese|O descent|O with|O Machado|B-DISE -|I-DISE Joseph|I-DISE disease|I-DISE (|O MJD|B-DISE )|O ,|O it|O was|O reported|O that|O disease|O alleles|O are|O preferentially|O transmitted|O during|O meiosis|O .|O
Thus|O ,|O a|O homozygous|O germ|O -|O line|O MLH1|O mutation|O and|O consequent|O mismatch|O repair|O deficiency|O results|O in|O a|O mutator|O phenotype|O characterized|O by|O leukemia|B-DISE and|O /|O or|O lymphoma|B-DISE associated|O with|O neurofibromatosis|B-DISE type|O 1|O .|O .|O
Biopsy|O specimens|O of|O 16|O oral|B-DISE lesions|I-DISE ,|O 12|O of|O them|O associated|O with|O the|O teeth|O ,|O plus|O two|O facial|B-DISE lesions|I-DISE were|O studied|O histologically|O .|O
The|O fourth|O mutation|O is|O recessive|O and|O affects|O the|O inhibitory|O domain|O (|O R1|O )|O that|O binds|O the|O NAB|O transcriptional|O co|O -|O repressors|O .|O
We|O have|O designed|O high|O -|O density|O arrays|O consisting|O of|O over|O 96|O ,|O 600|O oligonucleotides|O 20|O -|O nucleotides|O (|O nt|O )|O in|O length|O to|O screen|O for|O a|O wide|O range|O of|O heterozygous|O mutations|O in|O the|O 3|O .|O 45|O -|O kilobases|O (|O kb|O )|O exon|O 11|O of|O the|O hereditary|B-DISE breast|I-DISE and|I-DISE ovarian|I-DISE cancer|I-DISE gene|O BRCA1|O .|O
Myotonic|B-DISE dystrophy|I-DISE (|O DM|B-DISE )|O is|O commonly|O associated|O with|O CTG|O repeat|O expansions|O within|O the|O gene|O for|O DM|O -|O protein|O kinase|O DMPK|O .|O
Mutations|O resulting|O in|O defective|O splicing|O constitute|O a|O significant|O proportion|O 30|O /|O 62|O 48|O %|O of|O a|O new|O series|O of|O mutations|O in|O the|O ATM|O gene|O in|O patients|O with|O ataxia|B-DISE -|I-DISE telangiectasia|I-DISE (|O AT|B-DISE )|O that|O were|O detected|O by|O the|O protein|O -|O truncation|O assay|O followed|O by|O sequence|O analysis|O of|O genomic|O DNA|O .|O
G130V|O ,|O when|O present|O with|O an|O expanded|O GAA|O repeat|O on|O the|O other|O allele|O ,|O is|O associated|O with|O an|O atypical|O FRDA|B-DISE phenotype|O .|O
The|O mRNA|O expression|O pattern|O of|O one|O of|O them|O ,|O designated|O as|O XK|O ,|O correlates|O closely|O to|O the|O McLeod|B-DISE phenotype|O .|O
Analyses|O of|O rodent|O -|O human|O somatic|O -|O cell|O hybrids|O ,|O YAC|O contigs|O ,|O and|O FISH|O of|O normal|O or|O rearranged|O chromosomes|O 15|O identified|O duplicated|O sequences|O (|O the|O END|O repeats|O )|O at|O or|O near|O the|O breakpoints|O .|O
We|O have|O used|O this|O technique|O to|O analyze|O BRCA1|O in|O 162|O families|O with|O a|O history|O of|O breast|B-DISE and|I-DISE /|I-DISE or|I-DISE ovarian|I-DISE cancer|I-DISE and|O identified|O 12|O distinct|O mutations|O in|O 35|O families|O .|O .|O
The|O significance|O of|O this|O association|O is|O controversial|O ,|O though|O the|O association|O of|O C2|B-DISE deficiency|I-DISE with|O certain|O histocompatibility|O antigens|O suggests|O possible|O linkage|O to|O immune|O response|O genes|O .|O
The|O entire|O coding|O region|O of|O BRCA1|O and|O BRCA2|O was|O screened|O for|O the|O presence|O of|O germline|O mutations|O ,|O by|O use|O of|O SSCP|O followed|O by|O direct|O sequencing|O of|O observed|O variants|O .|O
The|O Na|O +|O /|O glucose|O cotransporter|O gene|O SGLT1|O encodes|O the|O primary|O carrier|O protein|O responsible|O for|O the|O uptake|O of|O the|O dietary|O sugars|O glucose|O and|O galactose|O from|O the|O intestinal|O lumen|O .|O
It|O contains|O the|O C|O -|O terminal|O and|O the|O cysteine|O -|O rich|O domains|O of|O dystrophin|O ,|O seven|O additional|O amino|O acids|O at|O the|O N|O terminus|O ,|O and|O some|O modifications|O formed|O by|O alternative|O splicing|O in|O the|O C|O -|O terminal|O domain|O .|O
There|O are|O three|O mechanisms|O by|O which|O CTG|O expansion|O can|O result|O in|O DM|B-DISE .|O
An|O expansion|O of|O a|O GAA|O trinucleotide|O repeat|O in|O intron|O 1|O of|O the|O gene|O is|O present|O in|O more|O than|O 95|O %|O of|O mutant|O alleles|O .|O
In|O 16|O of|O 17|O breast|B-DISE and|I-DISE ovarian|I-DISE cancer|I-DISE lines|O and|O 17|O of|O 17|O samples|O of|O cells|O obtained|O from|O malignant|O effusions|O ,|O however|O ,|O BRCA1|O localized|O mainly|O in|O cytoplasm|O .|O
We|O have|O shown|O that|O a|O cosmid|O probe|O for|O a|O candidate|O aniridia|B-DISE gene|O ,|O homologous|O to|O the|O mouse|O Pax|O -|O 6|O gene|O ,|O is|O deleted|O in|O cell|O lines|O from|O aniridia|B-DISE patients|O with|O previously|O characterized|O deletions|O at|O 11p13|O ,|O while|O another|O cosmid|O marker|O mapping|O between|O two|O aniridia|B-DISE -|O associated|O translocation|O breakpoints|O (|O and|O hence|O a|O second|O candidate|O marker|O )|O is|O present|O on|O both|O chromosomes|O .|O
Wolfram|B-DISE syndrome|I-DISE is|O an|O autosomal|O recessive|O neurodegenerative|B-DISE disorder|I-DISE characterized|O by|O juvenile|B-DISE -|I-DISE onset|I-DISE diabetes|I-DISE mellitus|I-DISE and|O progressive|O optic|B-DISE atrophy|I-DISE .|O
This|O disorder|O was|O mapped|O to|O chromosome|O 7|O and|O the|O gene|O causing|O Pendred|B-DISE syndrome|I-DISE (|O PDS|B-DISE )|O was|O subsequently|O identified|O by|O positional|O cloning|O .|O
Using|O this|O methodology|O we|O have|O found|O X|B-DISE -|I-DISE ALD|I-DISE mutations|O in|O 30|O kindreds|O ,|O including|O 15|O not|O previously|O reported|O .|O .|O
The|O results|O of|O the|O genotype|O testing|O showed|O that|O this|O individual|O was|O homozygous|O for|O the|O CYP2C9|O *|O 3|O allele|O and|O did|O not|O possess|O any|O of|O the|O known|O defective|O CYP2C19|O alleles|O .|O
Starting|O from|O the|O MCC|O gene|O ,|O a|O strategy|O was|O undertaken|O to|O identify|O constitutional|O submicroscopic|O deletions|O in|O familial|B-DISE adenomatous|I-DISE polyposis|I-DISE patients|O that|O might|O considerably|O narrow|O down|O the|O position|O of|O the|O APC|O gene|O .|O
Patients|O with|O the|O classical|B-DISE form|I-DISE (|I-DISE type|I-DISE I|I-DISE )|I-DISE and|I-DISE the|I-DISE more|I-DISE severely|I-DISE affected|I-DISE ,|I-DISE connatal|I-DISE variant|I-DISE of|I-DISE Pelizaeus|I-DISE -|I-DISE Merzbacher|I-DISE disease|I-DISE (|I-DISE type|I-DISE II|I-DISE )|I-DISE would|O be|O predicted|O to|O display|O mutation|O at|O the|O PLP|O locus|O .|O
Loss|O of|O heterozygosity|O (|O LOH|O )|O in|O the|O region|O close|O to|O the|O adenomatous|B-DISE polyposis|I-DISE coli|I-DISE (|O APC|O )|O gene|O was|O detected|O in|O this|O carcinoma|B-DISE ,|O and|O evidence|O was|O obtained|O that|O there|O was|O a|O loss|O of|O the|O normal|O allele|O of|O the|O APC|O gene|O .|O
A|O comparison|O of|O the|O six|O mutations|O in|O the|O relative|O proportions|O of|O cases|O of|O breast|B-DISE and|I-DISE ovarian|I-DISE cancer|I-DISE was|O suggestive|O of|O an|O effect|O (|O P|O =|O .|O 069|O )|O ,|O with|O 57|O %|O of|O women|O presumed|O affected|O because|O of|O the|O 1294|O del|O 40|O BRCA1|O mutation|O having|O ovarian|B-DISE cancer|I-DISE ,|O compared|O with|O 14|O %|O of|O affected|O women|O with|O the|O splice|O -|O site|O mutation|O in|O intron|O 5|O of|O BRCA1|O .|O
Clinical|O recognition|O of|O VLCAD|B-DISE deficiency|I-DISE is|O important|O because|O it|O is|O one|O of|O the|O few|O directly|O treatable|O causes|O of|O cardiomyopathy|B-DISE in|O children|O .|O .|O
Patients|O with|O the|O Denys|B-DISE -|I-DISE Drash|I-DISE syndrome|I-DISE (|O Wilms|B-DISE '|I-DISE tumor|I-DISE ,|O genital|O anomalies|O ,|O and|O nephropathy|B-DISE )|O have|O been|O demonstrated|O to|O carry|O de|O novo|O constitutional|O mutations|O in|O WT1|O ,|O the|O Wilms|B-DISE '|I-DISE tumor|I-DISE gene|O at|O chromosome|O 11p13|O .|O
Metachromatic|B-DISE leukodystrophy|I-DISE (|O MLD|B-DISE )|O is|O an|O autosomal|O recessive|O lysosomal|B-DISE storage|I-DISE disorder|I-DISE caused|O by|O a|O deficiency|B-DISE of|I-DISE arylsulfatase|I-DISE A|O ARSA|O ;|O EC|O 3|O .|O 1|O .|O 6|O .|O 8|O .|O
The|O study|O of|O mutational|O events|O revealed|O a|O significant|O difference|O between|O somatic|O and|O germline|O mutations|O with|O mutations|O leading|O to|O truncated|O proteins|O observed|O in|O 78|O %|O of|O somatic|O mutations|O vs|O only|O 37|O %|O in|O germline|O mutations|O P|O <|O 0|O .|O 001|O .|O
Four|O mouse|O models|O of|O PWS|B-DISE have|O been|O reported|O but|O these|O do|O not|O definitively|O allow|O the|O delineation|O of|O the|O critical|O region|O and|O the|O associated|O genes|O involved|O in|O the|O aetiology|O of|O PWS|B-DISE .|O
Among|O these|O mutations|O ,|O 50|O %|O correspond|O to|O new|O mutations|O .|O
A|O syndrome|O of|O microcephaly|B-DISE ,|O progressive|O postnatal|B-DISE growth|I-DISE deficiency|I-DISE ,|O and|O mental|B-DISE retardation|I-DISE was|O observed|O in|O two|O brothers|O and|O their|O cousin|O from|O a|O multiply|O consanguineous|O kindred|O of|O Lebanese|O descent|O .|O
The|O role|O of|O FMR1|O remains|O undetermined|O but|O the|O protein|O appears|O to|O be|O involved|O in|O RNA|O metabolism|O .|O
A|O previous|O linkage|O study|O provided|O evidence|O for|O a|O prostate|B-DISE cancer|I-DISE -|O susceptibility|O locus|O at|O 1q24|O -|O 25|O .|O
Mutations|O at|O the|O 5|O '|O end|O of|O APC|O are|O known|O to|O be|O associated|O with|O a|O relatively|O mild|O form|O of|O the|O disease|O ,|O called|O attenuated|B-DISE adenomatous|I-DISE polyposis|I-DISE coli|I-DISE AAPC|B-DISE .|O
Studying|O two|O siblings|O with|O FRDA|B-DISE from|O two|O families|O we|O did|O not|O detect|O a|O mutation|O in|O STM7|O /|O X25|O .|O
Mutations|O in|O the|O gene|O that|O encodes|O type|O II|O collagen|O (|O COL2A1|O )|O ,|O the|O predominant|O protein|O of|O cartilage|O ,|O have|O been|O identified|O in|O a|O number|O of|O individuals|O with|O Kniest|B-DISE dysplasia|I-DISE .|O
The|O present|O results|O provide|O evidence|O that|O mutations|O in|O PDS|O cause|O both|O syndromic|O and|O non|O -|O syndromic|O hearing|B-DISE loss|I-DISE .|O .|O
Of|O the|O causative|O GBA|O mutations|O ,|O N370S|O is|O particularly|O frequent|O in|O the|O AJ|O population|O ,|O (|O q|O approximately|O .|O 03|O )|O ,|O whereas|O the|O 84GG|O insertion|O (|O q|O approximately|O .|O 003|O )|O occurs|O exclusively|O in|O the|O Ashkenazim|O .|O
We|O recently|O reported|O the|O positional|O cloning|O of|O a|O candidate|O gene|O for|O hereditary|B-DISE hemochromatosis|I-DISE called|O HFE|O .|O
Canavan|B-DISE disease|I-DISE ,|O or|O spongy|O degeneration|O of|O the|O brain|O ,|O is|O a|O severe|O leukodystrophy|B-DISE caused|O by|O the|O deficiency|B-DISE of|I-DISE aspartoacylase|I-DISE ASPA|I-DISE .|O
Phenylketonuria|B-DISE (|O PKU|B-DISE )|O is|O a|O genetic|O disorder|O secondary|O to|O a|O deficiency|B-DISE of|I-DISE hepatic|I-DISE phenylalanine|I-DISE hydroxylase|I-DISE PAH|O .|O
All|O affected|O individuals|O presented|O a|O missense|O mutation|O (|O G1757|O -|O -|O >|O A|O )|O that|O replaces|O glycine|O at|O position|O 23|O with|O arginine|O within|O the|O NPII|O domain|O .|O
The|O myotonic|B-DISE dystrophy|I-DISE (|O DM|B-DISE )|O mutation|O is|O an|O unstable|O (|O CTG|O )|O n|O repeat|O ,|O present|O at|O a|O copy|O number|O of|O 5|O -|O 37|O repeats|O on|O normal|O chromosomes|O but|O amplified|O to|O 50|O -|O 3000|O copies|O on|O DM|O chromosomes|O .|O
Our|O findings|O add|O support|O to|O the|O notion|O that|O diverse|O point|O mutations|O may|O account|O largely|O for|O much|O of|O the|O phenotypic|O heterogeneity|O of|O G6PD|B-DISE deficiency|I-DISE .|O .|O
Using|O homologous|O recombination|O to|O disrupt|O the|O normal|O translation|O of|O ATP7B|O ,|O we|O have|O generated|O a|O strain|O of|O mice|O that|O are|O homozygous|O mutants|O (|O null|O )|O for|O the|O Wilson|B-DISE disease|I-DISE gene|O .|O
Then|O ,|O 189|O MPKUCS|O subjects|O were|O grouped|O according|O to|O the|O various|O combinations|O of|O mutation|O classifications|O .|O
In|O contrast|O ,|O hSNF5|O /|O INI1|O point|O mutations|O were|O not|O detected|O in|O breast|B-DISE cancers|I-DISE ,|O Wilms|B-DISE '|I-DISE tumors|I-DISE ,|O gliomas|B-DISE ,|O ependymomas|B-DISE ,|O sarcomas|B-DISE and|O other|O tumor|B-DISE types|O ,|O even|O though|O most|O analyzed|O cases|O harbored|O loss|O of|O heterozygosity|O at|O 22q11|O .|O 2|O loci|O .|O
The|O data|O suggest|O that|O the|O G|O -|O to|O -|O A|O mutation|O may|O be|O common|O in|O human|O plasma|O CETP|B-DISE deficiency|I-DISE .|O
The|O EWS|O gene|O has|O been|O identified|O based|O on|O its|O location|O at|O the|O chromosome|O 22|O breakpoint|O of|O the|O t|O 11|O ;|O 22|O (|O q24|O ;|O q12|O )|O translocation|O that|O characterizes|O Ewing|B-DISE sarcoma|I-DISE and|O related|O neuroectodermal|B-DISE tumors|I-DISE .|O
Of|O 44|O patients|O ,|O nine|O (|O 20|O %|O )|O had|O facial|O angiofibromas|B-DISE ,|O tumours|B-DISE primarily|O occurring|O in|O association|O with|O tuberous|B-DISE sclerosis|I-DISE .|O
To|O our|O knowledge|O ,|O our|O results|O are|O the|O first|O to|O demonstrate|O that|O aminoglycosides|O can|O suppress|O stop|O codons|O not|O only|O in|O vitro|O but|O also|O in|O vivo|O .|O
Mutations|O in|O the|O human|O EGR2|O gene|O have|O recently|O been|O associated|O with|O the|O inherited|B-DISE peripheral|I-DISE neuropathies|I-DISE Charcot|B-DISE -|I-DISE Marie|I-DISE -|I-DISE Tooth|I-DISE type|I-DISE 1|I-DISE ,|O Dejerine|B-DISE -|I-DISE Sottas|I-DISE syndrome|I-DISE and|O congenital|B-DISE hypomyelinating|I-DISE neuropathy|I-DISE .|O
Motor|B-DISE development|I-DISE was|I-DISE delayed|I-DISE .|O
The|O HFE|O candidate|O gene|O encoding|O an|O HLA|O class|O I|O -|O like|O protein|O involved|O in|O HH|B-DISE was|O identified|O in|O 1996|O .|O
We|O have|O cloned|O cDNAs|O for|O the|O rat|O gene|O (|O Atp7b|O )|O homologous|O to|O the|O human|O Wilson|B-DISE disease|I-DISE gene|O (|O ATP7B|O )|O and|O have|O used|O them|O to|O identify|O a|O partial|O deletion|O in|O the|O Atp7b|O gene|O in|O the|O LEC|O rat|O .|O
The|O disorder|O exhibits|O considerable|O allelic|O heterogeneity|O and|O ,|O at|O the|O end|O of|O 1998|O ,|O more|O than|O 150|O different|O base|O changes|O were|O recorded|O in|O 24|O different|O populations|O and|O ethnic|O groups|O in|O 15|O countries|O worldwide|O .|O
A|O 5|O -|O bp|O sequence|O ,|O GGAAT|O ,|O found|O exactly|O at|O the|O translocation|O breakpoints|O on|O both|O normal|O chromosomes|O X|O and|O 4|O ,|O has|O been|O preserved|O only|O on|O the|O der|O (|O 4|O )|O chromosome|O .|O
Information|O on|O DMPK|O mRNA|O and|O protein|O isoform|O expression|O patterns|O will|O be|O useful|O for|O recognizing|O differential|O effects|O of|O CTG|O (|O n|O )|O expansion|O in|O DM|B-DISE manifestation|O .|O .|O
The|O presence|O of|O nebulin|O in|O a|O muscle|O specimen|O from|O a|O patient|O with|O Duchenne|B-DISE muscular|I-DISE dystrophy|I-DISE (|O DMD|B-DISE )|O due|O to|O a|O large|O deletion|O precludes|O the|O possibility|O that|O this|O protein|O is|O the|O DMD|O gene|O product|O .|O .|O
In|O cotransfection|O experiments|O ,|O Fas|O constructs|O with|O either|O intra|O -|O or|O extracellular|O mutations|O caused|O dominant|O inhibition|O of|O apoptosis|O mediated|O by|O wild|O -|O type|O Fas|O .|O
These|O linkage|O data|O narrow|O the|O boundaries|O within|O which|O the|O WAS|B-DISE locus|O maps|O to|O the|O chromosomal|O region|O bracketed|O by|O TIMP|O and|O DXS146|O and|O support|O the|O loci|O order|O Xpter|O -|O DXS7|O -|O TIMP|O -|O OATL1|O ,|O WAS|O ,|O DXS255|O -|O DXS146|O .|O .|O
One|O tumor|O had|O a|O 1|O -|O bp|O deletion|O in|O an|O intron|O near|O the|O splicing|O site|O .|O
These|O data|O provide|O insight|O into|O the|O possible|O disease|O mechanisms|O underlying|O EGR2|O mutations|O and|O the|O reason|O for|O varying|O severity|O and|O differences|O in|O inheritance|O patterns|O .|O .|O
A|O series|O of|O subclones|O prepared|O from|O a|O '|O phage|O library|O (|O lambda|O DASH|O II|O )|O of|O the|O YAC|O have|O been|O characterised|O and|O have|O been|O employed|O to|O determine|O the|O end|O point|O of|O the|O deletion|O of|O a|O Norrie|B-DISE disease|I-DISE (|O NDP|B-DISE )|O patient|O who|O has|O been|O shown|O to|O lack|O both|O DXS7|O and|O MAO|O coding|O sequences|O .|O
Given|O that|O the|O skin|O of|O these|O adult|O mice|O also|O exhibits|O signs|O of|O de|O novo|O hair|B-DISE -|I-DISE follicle|I-DISE morphogenesis|I-DISE ,|O we|O wondered|O whether|O human|O pilomatricomas|B-DISE might|O originate|O from|O hair|O matrix|O cells|O and|O whether|O they|O might|O possess|O beta|O -|O catenin|O -|O stabilizing|O mutations|O .|O
We|O have|O constructed|O a|O physical|O map|O of|O a|O 4|O cM|O region|O on|O chromosome|O 17q12|O -|O 21|O that|O contains|O the|O hereditary|B-DISE breast|I-DISE and|I-DISE ovarian|I-DISE cancer|I-DISE gene|O BRCA1|O .|O
MRI|O demonstrated|O white|B-DISE matter|I-DISE abnormalities|I-DISE in|O the|O lateral|O and|O dorsal|O columns|O of|O the|O spinal|O cord|O .|O
The|O gene|O encoding|O receptor|O activator|O of|O nuclear|O factor|O -|O kappa|O B|O (|O RANK|O ;|O ref|O .|O 5|O )|O ,|O TNFRSF11A|O ,|O maps|O to|O this|O region|O .|O
Mutations|O in|O the|O OCRL1|O gene|O have|O been|O associated|O with|O the|O disease|O .|O
Denys|B-DISE -|I-DISE Drash|I-DISE syndrome|I-DISE is|O a|O rare|O human|O developmental|B-DISE disorder|I-DISE affecting|O the|O urogenital|O system|O and|O leading|O to|O renal|B-DISE failure|I-DISE ,|O intersex|B-DISE disorders|I-DISE and|O Wilms|B-DISE '|I-DISE tumour|I-DISE .|O
We|O have|O searched|O for|O hSNF5|O /|O INI1|O mutations|O in|O 229|O tumors|B-DISE of|O various|O origins|O using|O a|O screening|O method|O based|O on|O denaturing|O high|O -|O performance|O liquid|O chromatography|O .|O
Analysis|O of|O mosaic|O mice|O showed|O that|O in|O heart|O ,|O lung|O ,|O kidney|O ,|O brain|O ,|O and|O liver|O ,|O mainly|O wild|O -|O type|O Piga|O is|O active|O ,|O suggesting|O that|O these|O tissues|O require|O GPI|O -|O linked|O proteins|O .|O
Although|O MHC|O genes|O ,|O including|O HLA|O -|O B27|O ,|O contribute|O only|O 20|O -|O 50|O %|O of|O the|O genetic|O risk|O for|O the|O disease|O ,|O no|O non|O -|O MHC|O gene|O has|O yet|O been|O convincingly|O demonstrated|O to|O influence|O either|O susceptibility|O to|O the|O disease|O or|O its|O phenotypic|O expression|O .|O
Reexamination|O of|O all|O 29|O mutations|O and|O polymorphisms|O thus|O far|O described|O in|O HGO|O shows|O that|O these|O nucleotide|O changes|O are|O not|O randomly|O distributed|O ;|O the|O CCC|O sequence|O motif|O and|O its|O inverted|O complement|O ,|O GGG|O ,|O are|O preferentially|O mutated|O .|O
Age|O of|O onset|O (|O AO|O )|O of|O Huntington|B-DISE disease|I-DISE (|O HD|B-DISE )|O is|O known|O to|O be|O correlated|O with|O the|O length|O of|O an|O expanded|O CAG|O repeat|O in|O the|O HD|O gene|O .|O
Recent|O studies|O in|O animal|O models|O elucidated|O a|O central|O role|O of|O alpha|O -|O MSH|O in|O the|O regulation|O of|O food|O intake|O by|O activation|O of|O the|O brain|O melanocortin|O -|O 4|O -|O receptor|O (|O MC4|O -|O R|O ;|O refs|O 3|O -|O 5|O )|O and|O the|O linkage|O of|O human|O obesity|B-DISE to|O chromosome|O 2|O in|O close|O proximity|O to|O the|O POMC|O locus|O ,|O led|O to|O the|O proposal|O of|O an|O association|O of|O POMC|O with|O human|O obesity|B-DISE .|O The|O dual|O role|O of|O alpha|O -|O MSH|O in|O regulating|O food|O intake|O and|O influencing|O hair|O pigmentation|O predicts|O that|O the|O phenotype|O associated|O with|O a|O defect|O in|O POMC|O function|O would|O include|O obesity|O ,|O alteration|O in|O pigmentation|O and|O ACTH|B-DISE deficiency|I-DISE .|O
Aspartylglucosaminuria|B-DISE (|O AGU|B-DISE )|O is|O a|O lysosomal|B-DISE storage|I-DISE disorder|I-DISE caused|O by|O deficiency|B-DISE of|I-DISE aspartylglucosaminidase|I-DISE AGA|O .|O
Most|O missense|O mutations|O involved|O amino|O acids|O conserved|O in|O homologous|O gene|O products|O ,|O including|O PMP70|O ,|O mALDRP|O ,|O and|O Pxa1p|O .|O
For|O A|O -|O T|O heterozygotes|O younger|O than|O age|O 45|O ,|O the|O risk|O of|O dying|O from|O a|O malignant|B-DISE neoplasm|I-DISE was|O estimated|O to|O be|O greater|O than|O 5|O times|O the|O risk|O for|O the|O general|O population|O .|O
A|O G|O -|O -|O >|O A|O transition|O at|O nt|O 1444|O (|O exon|O 13|O )|O corresponding|O to|O the|O E482K|O substitution|O was|O found|O in|O the|O third|O family|O .|O
On|O the|O basis|O of|O clinical|O and|O biochemical|O observations|O ,|O the|O younger|O boy|O was|O considered|O to|O have|O a|O classical|O type|O of|O the|O disease|O ,|O while|O the|O older|O boy|O had|O an|O atypical|O form|O characterized|O by|O partial|O impairment|O of|O the|O skin|O histidase|O activity|O and|O a|O moderately|O prolonged|O half|O -|O life|O of|O blood|O histidine|O .|O
Four|O heterozygous|O carriers|O were|O patients|O with|O bilateral|B-DISE breast|I-DISE cancer|I-DISE .|O
An|O exon|O 1|O nonsense|O mutation|O (|O 856C|O -|O -|O >|O T|O )|O introduces|O a|O premature|O stop|O codon|O at|O amino|O acid|O 286|O .|O
The|O human|O genotype|O -|O phenotype|O correlations|O are|O consistent|O with|O a|O role|O for|O Dp260|O in|O normal|O retinal|O electrophysiology|O and|O may|O also|O reflect|O the|O expression|O of|O other|O C|O -|O terminal|O dystrophin|O isoforms|O and|O their|O contributions|O to|O retinal|O signal|O transmission|O .|O .|O
In|O this|O report|O ,|O four|O individuals|O with|O this|O syndrome|O are|O described|O carrying|O germline|O point|O mutations|O in|O the|O Wilms|B-DISE '|I-DISE tumour|I-DISE suppressor|O gene|O ,|O WT1|O .|O
These|O observations|O link|O ATM|O and|O p95|O /|O nbs1|O in|O a|O common|O signalling|O pathway|O and|O provide|O an|O explanation|O for|O phenotypic|O similarities|O in|O these|O two|O diseases|O .|O .|O
First|O ,|O repeat|O expansion|O may|O alter|O the|O processing|O or|O transport|O of|O the|O mutant|O DMPK|O mRNA|O and|O consequently|O reduce|O DMPK|O levels|O .|O
Interestingly|O ,|O all|O patients|O with|O cardiac|O involvement|O were|O homozygous|O for|O one|O of|O these|O mutations|O :|O R59H|O ,|O Y591C|O ,|O Y591N|O ,|O or|O IVS14|O -|O 2A|O >|O G|O .|O
Most|O multiple|O case|O families|O of|O young|O onset|O breast|B-DISE cancer|I-DISE and|O ovarian|B-DISE cancer|I-DISE are|O thought|O to|O be|O due|O to|O highly|O penetrant|O mutations|O in|O the|O predisposing|O genes|O BRCA1|O and|O BRCA2|O .|O
CETP|B-DISE deficiency|I-DISE ,|O reflecting|O two|O prevalent|O mutations|O (|O D442G|O and|O Int14|O A|O )|O ,|O is|O the|O first|O example|O of|O a|O genetic|O deficiency|O state|O which|O is|O sufficiently|O common|O to|O explain|O a|O significant|O fraction|O of|O the|O variation|O in|O HDL|O -|O C|O in|O the|O general|O population|O .|O .|O
While|O a|O few|O cases|O of|O isolated|O ACTH|B-DISE deficiency|I-DISE have|O been|O reported|O (|O OMIM|O 201400|O )|O ,|O an|O inherited|O POMC|O defect|O has|O not|O been|O described|O so|O far|O .|O
After|O birth|O he|O showed|O hypotonia|B-DISE with|O poor|O sucking|O ,|O for|O which|O gavage|O feeding|O was|O needed|O .|O
Ankylosing|B-DISE spondylitis|I-DISE ,|O psoriatic|B-DISE arthropathy|I-DISE and|O entero|O -|O arthropathy|B-DISE may|O be|O regarded|O as|O clinical|O sub|O -|O types|O of|O the|O syndrome|O .|O .|O
The|O Schwartz|B-DISE -|I-DISE Jampel|I-DISE syndrome|I-DISE (|O SJS|B-DISE ;|O chondrodystrophic|B-DISE myotonia|I-DISE ;|O McK|O 255|O ,|O 800|O )|O is|O a|O recessively|O inherited|O condition|O defined|O by|O myotonia|B-DISE ,|O short|O stature|O ,|O and|O bone|B-DISE dysplasia|I-DISE .|O
We|O report|O here|O the|O molecular|O characterization|O of|O two|O galactosemia|B-DISE mutations|O ,|O L74P|O and|O F171S|O ,|O and|O one|O polymorphism|O ,|O S135L|O ,|O in|O human|O galactose|O -|O 1|O -|O phosphate|O uridyltransferase|O GALT|O .|O
Here|O we|O use|O muscle|O biopsies|O from|O classical|O adult|O -|O onset|O myotonic|B-DISE dystrophy|I-DISE patients|O to|O study|O the|O accumulation|O of|O transcripts|O from|O both|O the|O normal|O and|O expanded|O DM|O kinase|O genes|O in|O patient|O muscle|O ,|O and|O compare|O the|O results|O to|O normal|O and|O myopathic|O controls|O .|O
Sequencing|O of|O the|O index|O patients|O '|O genomic|O DNA|O identified|O four|O new|O dominant|O mutations|O in|O COL2A1|O that|O result|O in|O Kniest|B-DISE dysplasia|I-DISE :|O a|O 21|O -|O bp|O deletion|O in|O exon|O 16|O ,|O an|O 18|O -|O bp|O deletion|O in|O exon|O 19|O ,|O and|O 4|O -|O bp|O deletions|O in|O the|O splice|O donor|O sites|O of|O introns|O 14|O and|O 20|O .|O
This|O mutation|O occurs|O at|O a|O CpG|O dinucleotide|O .|O
This|O finding|O supports|O simple|O autosomal|O recessive|O inheritance|O for|O HMS|B-DISE in|O these|O families|O .|O
We|O compared|O horizontal|O eye|O movements|O (|O visually|O guided|O saccades|O ,|O antisaccades|O ,|O and|O smooth|O pursuit|O )|O in|O control|O subjects|O (|O n|O =|O 14|O )|O and|O patients|O with|O three|O forms|O of|O autosomal|B-DISE dominant|I-DISE cerebellar|I-DISE ataxias|I-DISE type|I-DISE I|I-DISE :|O spinocerebellar|B-DISE ataxias|I-DISE 1|I-DISE and|I-DISE 2|I-DISE (|O SCA1|B-DISE ,|O n|O =|O 11|O ;|O SCA2|B-DISE ,|O n|O =|O 10|O )|O and|O SCA3|B-DISE /|O Machado|B-DISE -|I-DISE Joseph|I-DISE disease|I-DISE (|O MJD|B-DISE )|O n|O =|O 16|O .|O
To|O assess|O the|O prevalence|O and|O clinical|O expression|O of|O the|O HFE|O gene|O ,|O we|O conducted|O a|O population|O -|O based|O study|O in|O Busselton|O ,|O Australia|O .|O
To|O investigate|O the|O actions|O of|O these|O transcription|O factors|O ,|O both|O Pax3|O and|O PAX3|O -|O FKHR|O were|O introduced|O into|O NIH|O 3T3|O cells|O ,|O and|O the|O resultant|O gene|O expression|O changes|O were|O analyzed|O with|O a|O murine|O cDNA|O microarray|O containing|O 2|O ,|O 225|O elements|O .|O
These|O studies|O will|O not|O only|O help|O to|O illuminate|O the|O molecular|O basis|O of|O the|O general|O class|O of|O human|O diseases|O with|O trinucleotide|O repeat|O expansion|O but|O also|O provide|O an|O avenue|O to|O understand|O aspects|O of|O human|O cognition|O and|O intelligence|O .|O .|O
However|O ,|O only|O one|O (|O 1|O .|O 15|O %|O ;|O 95|O %|O confidence|O interval|O ,|O 0|O -|O 3|O .|O 6|O %|O )|O of|O the|O patients|O was|O heterozygous|O for|O the|O BRCA1|O mutant|O allele|O ,|O and|O only|O two|O were|O heterozygous|O for|O the|O BRCA2|O mutation|O 2|O .|O 4|O %|O ;|O 95|O %|O confidence|O interval|O ,|O 0|O -|O 6|O .|O 2|O %|O .|O
Their|O relatives|O were|O described|O with|O respect|O to|O absence|O /|O presence|O of|O breast|B-DISE and|I-DISE /|I-DISE or|I-DISE ovarian|I-DISE cancer|I-DISE .|O
RS1|O encodes|O a|O 224|O amino|O acid|O protein|O ,|O retinoschisin|O ,|O which|O contains|O a|O discoidin|O domain|O but|O is|O of|O unknown|O function|O .|O
One|O splice|O -|O site|O mutation|O (|O IVS10|O -|O 6T|O -|O -|O >|O G|O )|O was|O detected|O three|O times|O in|O our|O series|O .|O
To|O discover|O genes|O involved|O in|O von|B-DISE Hippel|I-DISE -|I-DISE Lindau|I-DISE (|I-DISE VHL|I-DISE )|I-DISE -|I-DISE mediated|I-DISE carcinogenesis|I-DISE ,|O we|O used|O renal|B-DISE cell|I-DISE carcinoma|I-DISE cell|O lines|O stably|O transfected|O with|O wild|O -|O type|O VHL|O -|O expressing|O transgenes|O .|O
These|O data|O demonstrate|O that|O :|O 1|O there|O is|O an|O identical|O 2|O -|O base|O pair|O deletion|O in|O an|O exon|O of|O the|O C5|O gene|O in|O several|O different|O C5|B-DISE -|I-DISE deficient|I-DISE mouse|O strains|O ;|O 2|O the|O mRNA|O transcribed|O from|O the|O C5D|O gene|O retains|O this|O deletion|O ;|O and|O 3|O this|O mutation|O should|O result|O in|O C5|B-DISE protein|I-DISE deficiency|I-DISE .|O .|O
An|O antibody|O against|O the|O synthetic|O C|O -|O terminal|O peptides|O deduced|O from|O the|O cDNA|O of|O the|O gene|O responsible|O for|O X|O -|O linked|O adrenoleukodystrophy|B-DISE (|O ALD|B-DISE )|O was|O produced|O to|O characterize|O the|O product|O of|O the|O ALD|O gene|O .|O
Southern|O blot|O and|O PCR|O analyses|O have|O indicated|O that|O the|O individual|O with|O anhaptoglobinemia|B-DISE was|O homozygous|O for|O the|O gene|O deletion|O and|O that|O the|O gene|O deletion|O was|O included|O at|O least|O from|O the|O promoter|O region|O of|O Hp|O to|O Hpr|O alpha|O but|O not|O to|O Hpr|O beta|O Hpdel|O .|O
Ataxia|B-DISE -|I-DISE telangiectasia|I-DISE (|O A|B-DISE -|I-DISE T|I-DISE )|O is|O an|O autosomal|B-DISE recessive|I-DISE syndrome|I-DISE associated|O with|O a|O greatly|O increased|O incidence|O of|O malignant|B-DISE neoplasms|I-DISE in|O homozygous|O affected|O individuals|O .|O
We|O have|O studied|O the|O genetic|O linkage|O of|O two|O markers|O ,|O the|O apolipoprotein|O C1|O (|O APOC1|O )|O gene|O and|O a|O cytochrome|O P450|O (|O CYP2A|O )|O gene|O ,|O in|O relation|O to|O the|O gene|O for|O myotonic|B-DISE dystrophy|I-DISE DM|B-DISE .|O
Purified|O BRCT|O polypeptide|O was|O used|O as|O a|O probe|O to|O screen|O a|O human|O placenta|O cDNA|O expression|O library|O by|O Far|O Western|O analysis|O .|O
Mutations|O in|O the|O diastrophic|B-DISE dysplasia|I-DISE sulfate|O transporter|O gene|O DTDST|O have|O been|O associated|O with|O a|O family|O of|O chondrodysplasias|B-DISE that|O comprises|O ,|O in|O order|O of|O increasing|O severity|O ,|O diastrophic|B-DISE dysplasia|I-DISE (|O DTD|B-DISE )|O ,|O atelosteogenesis|B-DISE type|I-DISE 2|I-DISE (|O AO2|B-DISE )|O ,|O and|O achondrogenesis|B-DISE type|I-DISE 1B|I-DISE ACG1B|B-DISE .|O
In|O Sri|O Lanka|O we|O have|O found|O H63D|O on|O three|O new|O haplotypes|O and|O have|O found|O C282Y|O on|O one|O new|O haplotype|O ,|O demonstrating|O that|O these|O mutations|O have|O arisen|O independently|O on|O this|O island|O .|O
The|O Rb1|O gene|O has|O been|O implicated|O with|O retinoblastoma|B-DISE and|O is|O located|O on|O human|O Chromosome|O (|O Chr|O )|O 13q14|O .|O 2|O .|O A|O unique|O sequence|O human|O Rb1|O cosmid|O DNA|O probe|O has|O been|O used|O to|O localize|O this|O region|O on|O apes|O '|O Chr|O 14|O by|O the|O FISH|O technique|O .|O
A|O total|O of|O 26|O families|O had|O both|O breast|B-DISE and|I-DISE ovarian|I-DISE cancers|I-DISE ,|O 4|O families|O had|O ovarian|B-DISE cancers|I-DISE only|O ,|O and|O 36|O families|O had|O breast|B-DISE cancers|I-DISE only|O .|O
A|O novel|O C|O to|O A|O mutation|O in|O the|O sterol|O 27|O -|O hydroxylase|O gene|O (|O CYP27|O )|O was|O identified|O by|O sequencing|O amplified|O CYP27|O gene|O products|O from|O a|O patient|O with|O cerebrotendinous|B-DISE xanthomatosis|I-DISE CTX|B-DISE .|O
We|O have|O discovered|O that|O a|O Tay|B-DISE -|I-DISE Sachs|I-DISE mutation|O ,|O IVS|O -|O 9|O +|O 1|O G|O -|O -|O >|O A|O ,|O first|O detected|O by|O Akli|O et|O al|O .|O
We|O report|O here|O the|O complete|O characterization|O of|O the|O 48|O exons|O of|O the|O COL4A4|O gene|O ,|O a|O comprehensive|O gene|O screen|O ,|O and|O the|O subsequent|O detection|O of|O 10|O novel|O mutations|O in|O eight|O patients|O diagnosed|O with|O autosomal|O recessive|O Alport|B-DISE syndrome|I-DISE .|O
Mucopolysaccharidosis|O IVA|O (|O MPS|O IVA|O )|O is|O an|O autosomal|O recessive|O lysosomal|O storage|O disorder|O caused|O by|O a|O genetic|O defect|O in|O N|O -|O acetylgalactosamine|O -|O 6|O -|O sulfate|O sulfatase|O GALNS|O .|O
This|O cohort|O underwent|O follow|O -|O up|O for|O cancer|B-DISE incidence|O through|O the|O Finnish|O Cancer|O Registry|O to|O the|O end|O of|O 1995|O .|O
Sera|O from|O eight|O family|O members|O who|O were|O apparently|O heterozygous|O for|O C5|B-DISE deficiency|I-DISE gave|O normal|O chemotactic|O scores|O .|O
However|O ,|O following|O splenectomy|O to|O increase|O the|O platelet|O count|O ,|O biopsy|O of|O the|O mediastinal|B-DISE mass|I-DISE revealed|O T|O -|O cell|O large|O cell|O lymphoma|B-DISE .|O
For|O case|O -|O control|O studies|O ,|O 617|O unrelated|O individuals|O with|O AS|B-DISE (|O 361|O probands|O from|O sibling|O -|O pair|O and|O parent|O -|O case|O trio|O families|O and|O 256|O unrelated|O non|O -|O familial|O sporadic|O cases|O )|O and|O 402|O healthy|O ethnically|O matched|O controls|O were|O employed|O .|O
This|O observed|O increase|O in|O ventilatory|O output|O was|O not|O correlated|O to|O changes|O in|O body|O mass|O index|O .|O
We|O developed|O methods|O to|O detect|O the|O three|O mutations|O in|O the|O HEXA|O gene|O that|O occur|O with|O high|O frequency|O among|O Ashkenazi|O Jews|O :|O two|O mutations|O cause|O infantile|O Tay|B-DISE -|I-DISE Sachs|I-DISE disease|I-DISE ,|O and|O the|O third|O causes|O the|O adult|O -|O onset|O form|O of|O the|O disease|O .|O
The|O electroretinograms|O (|O ERGs|O )|O of|O Prph2Rd2|O /|O Rd2|O mice|O have|O greatly|O diminished|O a|O -|O wave|O and|O b|O -|O wave|O amplitudes|O ,|O which|O decline|O to|O virtually|O undetectable|O concentrations|O by|O two|O months|O .|O
The|O segregation|O distortion|O favoring|O the|O mutant|O RB1|O allele|O does|O not|O seem|O to|O occur|O during|O spermatogenesis|O ,|O and|O ,|O thus|O ,|O meiotic|O drive|O may|O result|O either|O from|O various|O mechanisms|O ,|O including|O a|O fertilization|O advantage|O or|O a|O better|O mobility|O in|O sperm|O bearing|O a|O mutant|O RB1|O gene|O ,|O or|O from|O the|O existence|O of|O a|O defectively|O imprinted|O gene|O located|O on|O the|O human|O X|O chromosome|O .|O .|O
Ataxia|B-DISE -|I-DISE telangiectasia|I-DISE (|O A|B-DISE -|I-DISE T|I-DISE )|O is|O a|O recessive|O multi|B-DISE -|I-DISE system|I-DISE disorder|I-DISE caused|O by|O mutations|O in|O the|O ATM|O gene|O at|O 11q22|O -|O q23|O ref|O .|O 3|O .|O
Similar|O defects|O were|O found|O in|O a|O Fas|O -|O negative|O cell|O line|O transfected|O with|O cDNAs|O bearing|O each|O of|O the|O mutations|O .|O
The|O prepromyelocytic|O cell|O line|O HL60|O expressed|O MEFV|O only|O at|O granulocytic|O and|O monocytic|O differentiation|O .|O
One|O further|O B27|O negative|O patients|O had|O a|O sister|O with|O ankylosing|B-DISE spondylitis|I-DISE and|O ulcerative|B-DISE colitis|I-DISE and|O a|O mother|O with|O ulcerative|B-DISE colitis|I-DISE .|O
The|O three|O novel|O AKU|B-DISE mutations|O are|O most|O likely|O specific|O for|O the|O Finnish|O population|O and|O have|O originated|O recently|O .|O .|O
In|O contrast|O ,|O anti|O -|O Br|O (|O a|O )|O (|O HPA|O -|O 5b|O )|O only|O recognized|O the|O Lys|O 505|O Thr|O (|O 799|O )|O form|O ,|O whereas|O anti|O -|O Br|O (|O b|O )|O (|O HPA|O -|O 5a|O )|O reacted|O with|O both|O Glu|O 505|O Thr|O (|O 799|O )|O and|O Glu|O 505|O Met|O (|O 799|O )|O isoforms|O .|O
An|O observed|O excess|O of|O mutation|O carriers|O could|O not|O be|O accounted|O for|O by|O methodological|O problems|O ;|O possible|O explanations|O were|O a|O true|O "|O low|O penetrance|O or|O preferential|O segregation|O .|O .|O "|O
These|O findings|O establish|O that|O some|O neuropathological|B-DISE abnormalities|I-DISE seen|O in|O A|B-DISE -|I-DISE T|I-DISE patients|O also|O are|O present|O in|O Atm|O mutant|O mice|O .|O
However|O ,|O the|O nucleotide|O change|O resulted|O in|O exon|O 3|O skipping|O ,|O whereas|O the|O latter|O K247Q|O mutation|O had|O a|O drastic|O effect|O on|O enzyme|O activity|O .|O
This|O represents|O a|O unique|O inheritance|O pattern|O due|O to|O imprinting|O .|O .|O
Six|O of|O the|O point|O mutations|O represented|O missense|O mutations|O ,|O 1|O was|O a|O nonsense|O mutation|O ,|O and|O 1|O was|O a|O frameshift|O mutation|O .|O
Hepatoblastoma|B-DISE is|O a|O rare|O malignant|B-DISE tumor|I-DISE of|I-DISE the|I-DISE liver|I-DISE that|O occurs|O in|O children|O at|O an|O average|O age|O of|O 2|O to|O 3|O years|O .|O
We|O have|O approached|O this|O question|O by|O producing|O G6PD|O B|O ,|O A|O ,|O A|O -|O ,|O and|O G6PD|O 68|O Val|O -|O -|O >|O Met|O in|O a|O bacterial|O expression|O system|O and|O analysing|O their|O biochemical|O properties|O .|O
The|O high|O prevalence|O of|O glucose|B-DISE 6|I-DISE -|I-DISE phosphate|I-DISE dehydrogenase|I-DISE (|I-DISE G6PD|I-DISE )|I-DISE deficiency|I-DISE in|O African|O populations|O is|O due|O almost|O entirely|O to|O the|O enzyme|O variant|O A|O -|O ,|O which|O differs|O from|O the|O wild|O -|O type|O G6PD|O B|O by|O two|O amino|O acid|O replacements|O ,|O 68|O Val|O -|O -|O >|O Met|O and|O 126|O Asn|O -|O -|O >|O Asp|O .|O
The|O mutations|O 2871delC|O and|O R778L|O have|O been|O previously|O reported|O in|O a|O relatively|O large|O number|O of|O Japanese|O patients|O .|O
The|O mutations|O were|O identical|O in|O each|O of|O 2|O pairs|O of|O brothers|O .|O
We|O had|O not|O seen|O a|O case|O of|O homozygosity|O for|O c862t|O (|O R279W|O )|O until|O we|O analysed|O DNA|O from|O a|O 36|O year|O old|O male|O with|O tall|O -|O normal|O stature|O (|O 180|O cm|O )|O who|O asked|O for|O genetic|O counselling|O for|O suspected|O multiple|O epiphyseal|B-DISE dysplasia|I-DISE .|O
S135L|O is|O found|O almost|O exclusively|O in|O African|O Americans|O .|O
Here|O ,|O it|O is|O shown|O that|O BRCA1|O interacts|O in|O vitro|O and|O in|O vivo|O with|O hRad50|O ,|O which|O forms|O a|O complex|O with|O hMre11|O and|O p95|O /|O nibrin|O .|O
Both|O mutations|O were|O predicted|O to|O truncate|O the|O E|O -|O cadherin|O protein|O in|O the|O signal|O peptide|O domain|O .|O
Mice|O carrying|O each|O of|O the|O two|O mutations|O were|O bred|O and|O analyzed|O .|O
However|O ,|O there|O are|O differences|O in|O the|O abundance|O of|O GALT|O protein|O in|O lymphoblastoid|O cells|O lines|O from|O D2|O and|O D1|O individuals|O .|O
Despite|O the|O ubiquitous|O expression|O of|O the|O truncated|O HMG|O I|O -|O C|O protein|O ,|O the|O transgenic|O mice|O develop|O a|O selective|O abundance|O of|O fat|O tissue|O early|O in|O life|O ,|O show|O marked|O adipose|O tissue|O inflammation|B-DISE ,|O and|O have|O an|O abnormally|O high|O incidence|O of|O lipomas|O .|O
The|O history|O further|O indicated|O intrauterine|O growth|B-DISE retardation|I-DISE at|O the|O end|O of|O the|O pregnancy|O .|O
Within|O the|O families|O with|O male|O -|O to|O -|O male|O disease|O transmission|O ,|O alpha|O increased|O with|O the|O early|O mean|O age|O at|O diagnosis|O (|O <|O 65|O years|O ,|O alpha|O =|O .|O 19|O ,|O with|O 1|O -|O LOD|O support|O interval|O .|O 06|O -|O .|O 34|O )|O and|O the|O number|O of|O affected|O family|O members|O five|O or|O more|O family|O members|O ,|O alpha|O =|O .|O 15|O ,|O with|O 1|O -|O LOD|O support|O interval|O .|O 04|O -|O .|O 28|O .|O
The|O observed|O increase|O in|O ventilation|O and|O inspiratory|O drive|O may|O contribute|O to|O the|O improved|O activity|O level|O reported|O by|O parents|O of|O PWS|B-DISE children|O during|O growth|O hormone|O therapy|O .|O .|O
Reduced|O levels|O of|O a|O normal|O -|O size|O WASP|O with|O a|O missense|O mutation|O were|O seen|O in|O two|O individuals|O with|O XLT|B-DISE .|O
We|O postulate|O that|O altered|O metabolism|O of|O a|O natural|O toxin|O or|O antigen|O by|O the|O CYP2D6|O gene|O may|O increase|O susceptibility|O to|O AS|B-DISE .|O .|O
Some|O patients|O have|O only|O palmoplantar|B-DISE keratosis|I-DISE or|O periodontitis|B-DISE ,|O and|O in|O rare|O individuals|O the|O periodontitis|B-DISE is|O mild|O and|O of|O late|O onset|O .|O
Two|O novel|O mutations|O ,|O c|O .|O 38T|O -|O -|O >|O C|O (|O L13P|O )|O and|O c|O .|O 667T|O -|O -|O >|O C|O (|O C223R|O )|O ,|O respectively|O ,|O present|O the|O first|O genetic|O evidence|O for|O the|O functional|O significance|O of|O the|O putative|O leader|O peptide|O sequence|O and|O for|O the|O functional|O significance|O at|O the|O carboxyl|O terminal|O of|O the|O XLRS1|O protein|O beyond|O the|O discoidin|O domain|O .|O
Reintroduced|O wild|O -|O type|O VHL|O strongly|O inhibited|O the|O overexpression|O of|O the|O CA12|O gene|O in|O the|O parental|O renal|B-DISE cell|I-DISE carcinoma|I-DISE cell|O lines|O .|O
Here|O we|O show|O that|O phosphorylation|O of|O NBS1|O ,|O induced|O by|O ionizing|O radiation|O ,|O requires|O catalytically|O active|O ATM|O .|O
Likelihood|O -|O based|O analysis|O of|O segregation|O distortion|O in|O the|O single|O sperm|O data|O using|O the|O SPERMSEG|O program|O also|O showed|O no|O support|O for|O segregation|O distortion|O at|O the|O gamete|O level|O in|O this|O patient|O population|O .|O
The|O FMF|O gene|O (|O MEFV|O )|O was|O cloned|O recently|O ,|O and|O four|O missense|O mutations|O were|O identified|O .|O
G6PD|B-DISE deficiency|I-DISE in|O different|O geographical|O areas|O appears|O to|O have|O arisen|O through|O independent|O mutational|O events|O ,|O but|O within|O the|O same|O population|O it|O may|O also|O be|O heterogeneous|O .|O
The|O Wiskott|B-DISE -|I-DISE Aldrich|I-DISE syndrome|I-DISE protein|O (|O WASP|O )|O gene|O was|O found|O to|O be|O mutated|O in|O patients|O presenting|O with|O WAS|B-DISE and|O in|O patients|O showing|O X|B-DISE -|I-DISE linked|I-DISE thrombocytopenia|I-DISE .|O
Nevertheless|O ,|O like|O the|O human|O gene|O ,|O mouse|O Mefv|O is|O expressed|O in|O peripheral|O blood|O granulocytes|O but|O not|O lymphocytes|O .|O
Loss|O of|O heterozygosity|O data|O from|O familial|O tumors|O suggest|O that|O BRCA1|O ,|O a|O gene|O that|O confers|O susceptibility|O to|O ovarian|B-DISE and|I-DISE early|I-DISE -|I-DISE onset|I-DISE breast|I-DISE cancer|I-DISE ,|O encodes|O a|O tumor|O suppressor|O .|O
Fluorescence|O in|O situ|O hybridisation|O using|O yeast|O artificial|O chromosome|O clones|O from|O Xq26|O localised|O the|O duplication|O breakpoint|O to|O an|O approximately|O 400|O -|O kb|O interval|O in|O the|O Xq26|O .|O 3|O region|O between|O DXS155|O and|O DXS294|O /|O DXS730|O .|O
The|O mutation|O in|O the|O remaining|O allele|O was|O a|O single|O -|O base|O transition|O in|O the|O donor|O splice|O site|O of|O the|O alpha|O -|O subunit|O intron|O 9|O .|O
The|O AMELX|O gene|O located|O at|O Xp22|O .|O 1|O -|O p22|O .|O 3|O encodes|O for|O the|O enamel|O protein|O amelogenin|O and|O has|O been|O implicated|O as|O the|O gene|O responsible|O for|O the|O inherited|O dental|O abnormality|O X|O -|O linked|O amelogenesis|B-DISE imperfecta|I-DISE XAI|O .|O
The|O same|O residue|O is|O often|O mutated|O in|O the|O Bruton|O '|O s|O tyrosine|O kinase|O (|O Btk|O )|O gene|O in|O patients|O with|O an|O X|B-DISE -|I-DISE linked|I-DISE agammaglobulinemia|I-DISE .|O
Fifteen|O missense|O mutations|O and|O two|O newly|O engineered|O active|O site|O mutations|O (|O C79S|O ,|O C79T|O )|O were|O characterized|O by|O transient|O expression|O analysis|O .|O
Clinically|O observed|O dysgenesis|O does|O not|O correlate|O with|O IOP|O ,|O however|O ,|O and|O the|O etiology|O of|O glaucoma|B-DISE development|O is|O not|O understood|O .|O
Implementation|O of|O this|O method|O of|O mutation|O screening|O in|O the|O research|O and|O clinical|O setting|O should|O permit|O rapid|O accrual|O of|O quantitative|O data|O on|O genotype|O -|O phenotype|O associations|O for|O the|O evaluation|O of|O diagnostic|O testing|O .|O .|O
We|O report|O on|O a|O family|O in|O which|O a|O male|O and|O a|O female|O paternal|O first|O cousin|O both|O have|O PWS|B-DISE with|O cytogenetically|O normal|O karyotypes|O .|O
Phosphorylation|O of|O BRCA1|O at|O serine|O 988|O is|O required|O for|O the|O release|O of|O BRCA1|O from|O hCds1|O .|O
We|O conclude|O that|O these|O mice|O very|O closely|O mimic|O severe|O human|O von|B-DISE Willebrand|I-DISE disease|I-DISE and|O will|O be|O very|O useful|O for|O investigating|O the|O role|O of|O vWf|O in|O normal|O physiology|O and|O in|O disease|O models|O .|O .|O
Pulse|O -|O chase|O studies|O demonstrated|O that|O the|O COLIA1|O /|O PDGFB|O precursor|O was|O processed|O to|O an|O end|O product|O that|O was|O indistinguishable|O from|O wild|O -|O type|O PDGF|O -|O BB|O .|O
In|O a|O large|O pedigree|O with|O autosomal|O dominant|O aniridia|B-DISE ,|O we|O found|O close|O linkage|O between|O the|O aniridia|B-DISE locus|O AN2|O and|O the|O markers|O catalase|O (|O CAT|O )|O (|O zeta|O =|O 7|O .|O 27|O at|O theta|O =|O 0|O .|O 00|O )|O and|O D11S151|O (|O zeta|O =|O 3|O .|O 86|O at|O theta|O =|O 0|O .|O 10|O )|O flanking|O the|O AN2|O locus|O on|O 11p13|O .|O
A|O clear|O correlation|O between|O the|O genotype|O and|O phenotype|O has|O not|O been|O established|O .|O
Increased|O iron|O deposition|O and|O evidence|O of|O oxidative|O damage|O have|O also|O been|O observed|O in|O cardiac|O tissue|O and|O cultured|O fibroblasts|O from|O patients|O with|O FRDA|B-DISE .|O
The|O difference|O in|O frequency|O of|O these|O two|O alleles|O is|O not|O significant|O P|O =|O 0|O .|O 8423|O .|O
Chem|O .|O 273|O ,|O 22068|O -|O 22074|O ;|O Feder|O ,|O J|O .|O N|O .|O ,|O Penny|O ,|O D|O .|O M|O .|O ,|O Irrinki|O ,|O A|O .|O ,|O Lee|O ,|O V|O .|O K|O .|O ,|O Lebron|O ,|O J|O .|O A|O .|O ,|O Watson|O ,|O N|O .|O ,|O Tsuchihashi|O ,|O Z|O .|O ,|O Sigal|O ,|O E|O .|O ,|O Bjorkman|O ,|O P|O .|O J|O .|O ,|O and|O Schatzman|O ,|O R|O .|O C|O .|O (|O 1998|O )|O Proc|O .|O
Hence|O ,|O molecular|O screening|O for|O Wolfram|B-DISE syndrome|I-DISE in|O affected|O families|O and|O for|O Wolfram|B-DISE syndrome|I-DISE -|O carrier|O status|O in|O subjects|O with|O psychiatric|B-DISE disorders|I-DISE or|O diabetes|B-DISE mellitus|I-DISE will|O require|O complete|O analysis|O of|O exon|O 8|O and|O upstream|O exons|O .|O .|O
We|O have|O also|O found|O that|O DCC|O is|O a|O substrate|O for|O metalloprotease|O -|O dependent|O ectodomain|O shedding|O ,|O and|O that|O the|O inhibitors|O block|O proteolytic|O processing|O of|O DCC|O and|O cause|O an|O increase|O in|O DCC|O protein|O levels|O on|O axons|O within|O spinal|O cord|O explants|O .|O
This|O method|O ,|O also|O called|O antibody|O test|O
Within|O the|O English|O and|O US|O families|O there|O was|O little|O evidence|O for|O a|O recent|O common|O origin|O of|O the|O MSH2|O splice|O site|O mutation|O in|O most|O families|O .|O
However|O ,|O we|O report|O that|O combining|O these|O drugs|O with|O 5|O -|O azadC|O results|O in|O a|O 2|O -|O to|O 5|O -|O fold|O increase|O in|O FMR1|O mRNA|O levels|O obtained|O with|O 5|O -|O azadC|O alone|O ,|O thus|O showing|O a|O marked|O synergistic|O effect|O of|O histone|O hyperacetylation|O and|O DNA|O demethylation|O in|O the|O reactivation|O of|O FMR1|O full|O mutations|O .|O .|O
In|O the|O present|O study|O ,|O a|O TCTAC|O deletion|O spanning|O the|O nucleotides|O 631|O -|O 635|O of|O the|O emerin|O gene|O caused|O an|O unusually|O severe|O disease|O phenotype|O including|O loss|B-DISE of|I-DISE ambulation|I-DISE and|O severe|O muscle|B-DISE wasting|I-DISE in|O two|O affected|O brothers|O .|O
Allelic|O loss|O is|O selected|O strongly|O in|O cells|O with|O one|O mutation|O near|O codon|O 1|O ,|O 300|O .|O
METHODS|O :|O The|O APC|O gene|O was|O analysed|O in|O 190|O unrelated|O FAP|B-DISE and|O 15|O non|O -|O FAP|B-DISE colorectal|B-DISE cancer|I-DISE patients|O using|O denaturing|O gradient|O gel|O electrophoresis|O ,|O the|O protein|O truncation|O test|O ,|O and|O direct|O sequencing|O .|O
The|O frequent|O occurrence|O of|O color|O vision|O anomalies|O observed|O in|O patients|O with|O adrenomyeloneuropathy|B-DISE (|O the|O adult|O onset|O form|O of|O ALD|B-DISE )|O thus|O does|O not|O represent|O a|O contiguous|O gene|O syndrome|O but|O a|O secondary|O manifestation|O of|O ALD|B-DISE .|O .|O
We|O have|O studied|O genetic|O linkage|O between|O the|O gene|O for|O creatine|O kinase|O muscle|O type|O (|O CKMM|O )|O and|O the|O gene|O for|O myotonic|B-DISE dystrophy|I-DISE DM|B-DISE .|O
The|O extraordinary|O conservation|O of|O the|O PAX6|O protein|O at|O the|O amino|O acid|O level|O amongst|O vertebrates|O predicts|O that|O pathological|O missense|O mutations|O should|O in|O fact|O be|O common|O even|O though|O they|O are|O hardly|O ever|O seen|O in|O aniridia|B-DISE patients|O .|O
Pelizaeus|B-DISE -|I-DISE Merzbacher|I-DISE Disease|I-DISE (|O PMD|B-DISE )|O is|O an|O X|O -|O linked|O developmental|O defect|B-DISE of|I-DISE myelination|I-DISE affecting|O the|O central|O nervous|O system|O and|O segregating|O with|O the|O proteolipoprotein|O (|O PLP|O )|O locus|O .|O
Mice|O containing|O this|O allele|O display|O all|O of|O the|O hallmarks|O of|O human|O hypobetalipoproteinemia|B-DISE :|O they|O produce|O a|O truncated|O apoB|O protein|O ,|O apoB70|O ,|O and|O have|O markedly|O decreased|O plasma|O concentrations|O of|O apoB|O ,|O beta|O -|O lipoproteins|O ,|O and|O total|O cholesterol|O .|O
Molecular|O study|O and|O neuropsychological|O analysis|O were|O performed|O concurrently|O on|O 49|O patients|O with|O Duchenne|B-DISE muscular|I-DISE dystrophy|I-DISE (|O DMD|B-DISE )|O in|O order|O to|O find|O a|O molecular|O explanation|O for|O the|O cognitive|B-DISE impairment|I-DISE observed|O in|O most|O DMD|B-DISE patients|O .|O
To|O derive|O an|O animal|B-DISE model|I-DISE for|I-DISE the|I-DISE Lesch|I-DISE -|I-DISE Nyhan|I-DISE syndrome|I-DISE ,|O we|O have|O used|O cultured|O mouse|O embryonic|O stem|O cells|O ,|O mutagenized|O by|O retroviral|O insertion|O and|O selected|O for|O loss|O of|O HPRT|O activity|O ,|O to|O construct|O chimaeric|O mice|O .|O
Our|O studies|O provide|O the|O direct|O proof|O of|O the|O genetic|O heterogeneity|O of|O G6PD|B-DISE deficiency|I-DISE in|O the|O Chinese|O populations|O of|O Taiwan|O and|O the|O PCR|O /|O RE|O digestion|O method|O is|O suitable|O for|O simultaneous|O detection|O of|O the|O 487|O G|O -|O -|O -|O -|O A|O and|O 493|O A|O -|O -|O -|O -|O G|O mutations|O .|O .|O
The|O Zellweger|B-DISE spectrum|O of|O disease|O ,|O encompassing|O Zellweger|B-DISE syndrome|I-DISE and|O the|O progressively|O milder|O phenotypes|O of|O neonatal|B-DISE adrenoleukodystrophy|I-DISE and|O infantile|B-DISE Refsum|I-DISE disease|I-DISE ,|O is|O due|O to|O a|O failure|O to|O form|O functional|O peroxisomes|O .|O
Normotriglyceridemic|O abetalipoproteinemia|B-DISE is|O a|O rare|O familial|B-DISE disorder|I-DISE characterized|O by|O an|O isolated|O deficiency|O of|O apoB|O -|O 100|O .|O
The|O severity|O of|O the|O condition|O varied|O among|O the|O closely|O related|O patients|O .|O
A|O spectrum|O of|O different|O mutations|O has|O been|O reported|O in|O this|O disease|B-DISE ,|O one|O missense|O mutation|O (|O Cys163Ser|O )|O being|O responsible|O for|O the|O majority|O of|O Finnish|O cases|O .|O
We|O have|O brought|O together|O information|O on|O 864|O affected|O individuals|O in|O 164|O families|O (|O including|O three|O new|O pedigrees|O )|O reported|O in|O the|O 137|O year|O period|O since|O 1845|O when|O Demarquay|O first|O described|O a|O family|O with|O what|O was|O later|O called|O van|B-DISE der|I-DISE Woude|I-DISE syndrome|I-DISE VWS|B-DISE .|O
This|O data|O strongly|O supports|O the|O candidature|O of|O PAX6|O as|O the|O gene|O responsible|O for|O hereditary|O aniridia|B-DISE .|O .|O
Here|O ,|O because|O of|O the|O similarities|O between|O AT|B-DISE and|O NBS|B-DISE ,|O we|O evaluated|O the|O functional|O interactions|O between|O ATM|O and|O p95|O /|O nbs1|O .|O
CONCLUSION|O :|O Treatment|O of|O children|O with|O Prader|B-DISE -|I-DISE Willi|I-DISE syndrome|I-DISE (|O PWS|B-DISE )|O seems|O to|O have|O a|O stimulatory|O effect|O on|O central|O respiratory|O structures|O .|O
These|O data|O suggest|O that|O an|O early|O event|O in|O the|O pathogenesis|O of|O SCA3|B-DISE /|O MJD|B-DISE may|O be|O an|O altered|O conformation|O of|O ataxin|O -|O 3|O within|O the|O nucleus|O that|O exposes|O the|O polyglutamine|O domain|O .|O .|O
Moreover|O ,|O p53|O -|O mediated|O stimulation|O of|O transcription|O by|O BRCA1|O was|O completely|O abrogated|O by|O either|O a|O dominant|O -|O negative|O mutant|O of|O BRG1|O or|O the|O cancer|B-DISE -|O causing|O deletion|O in|O exon|O 11|O of|O BRCA1|O .|O
Finally|O ,|O one|O frameshift|O mutation|O ,|O 2799delC|O ,|O modifies|O the|O C|O -|O terminal|O part|O of|O OCRL1|O ,|O with|O an|O extension|O of|O six|O amino|O acids|O .|O
To|O date|O we|O have|O identified|O 65|O missense|O mutations|O in|O the|O GALNS|O gene|O from|O MPS|B-DISE IVA|I-DISE patients|O ,|O but|O the|O correlation|O between|O genotype|O and|O phenotype|O has|O remained|O unclear|O .|O
We|O report|O on|O a|O boy|O with|O a|O maternal|O uniparental|B-DISE disomy|I-DISE for|I-DISE chromosome|I-DISE 14|I-DISE UPD|B-DISE 14|I-DISE .|O
A|O family|O with|O inherited|O deficiency|B-DISE of|I-DISE complement|I-DISE factor|I-DISE 2|I-DISE (|O C2|O )|O is|O described|O in|O which|O two|O family|O members|O with|O homozygous|O C2|B-DISE deficiency|I-DISE developed|O cutaneous|B-DISE vasculitis|I-DISE and|O sicca|B-DISE syndrome|I-DISE .|O
FHF2|O is|O a|O large|O gene|O extending|O over|O approximately|O 200|O kb|O in|O Xq26|O .|O 3|O and|O is|O composed|O of|O at|O least|O seven|O exons|O .|O
Loss|O of|O expression|O of|O imprinted|O ,|O paternally|O expressed|O genes|O has|O been|O implicated|O in|O PWS|B-DISE .|O
An|O auxiliary|O beta|O (|O 1|O )|O -|O subunit|O ,|O widely|O expressed|O in|O excitable|O tissues|O ,|O shifts|O the|O voltage|O dependence|O of|O steady|O -|O state|O inactivation|O toward|O more|O negative|O potentials|O and|O restores|O normal|O gating|O kinetics|O of|O brain|O and|O skeletal|O muscle|O Na|O (|O +|O )|O channels|O expressed|O in|O Xenopus|O oocytes|O but|O has|O little|O if|O any|O functional|O effect|O on|O the|O cardiac|O isoform|O .|O
The|O phenotype|O is|O likely|O to|O be|O a|O contiguous|B-DISE gene|I-DISE syndrome|I-DISE involving|O genes|O which|O are|O paternally|O expressed|O only|O ,|O located|O in|O the|O human|O 15q11|O -|O q13|O region|O .|O
MEFV|O messenger|O RNA|O was|O detected|O by|O reverse|O transcriptase|O -|O polymerase|O chain|O reaction|O in|O bone|O marrow|O leukocytes|O ,|O with|O differential|O expression|O observed|O among|O cells|O by|O in|O situ|O hybridization|O .|O
Here|O we|O present|O data|O from|O non|O -|O Ashkenazi|O Jewish|O and|O Arab|O patients|O in|O whom|O we|O had|O not|O originally|O found|O mutations|O and|O from|O a|O new|O ,|O more|O ethnically|O diverse|O panel|O .|O
Chromosomal|O analysis|O was|O normal|O 46|O ,|O XY|O .|O
These|O data|O not|O only|O allow|O use|O of|O flanking|O markers|O for|O presymptomatic|O diagnosis|O of|O FAP|O but|O also|O provide|O a|O high|O -|O density|O map|O of|O the|O region|O for|O isolation|O of|O the|O APC|O gene|O itself|O and|O for|O further|O assessment|O of|O the|O role|O of|O chromosome|O 5|O deletions|O in|O the|O biology|O of|O sporadic|O colorectal|B-DISE cancer|I-DISE .|O .|O
An|O altered|O beta|O -|O alanine|O ,|O uracil|O and|O thymine|O homeostasis|O might|O underlie|O the|O various|O clinical|O abnormalities|O encountered|O in|O patients|O with|O DPD|B-DISE deficiency|I-DISE .|O .|O
Myotonic|B-DISE dystrophy|I-DISE (|O DM|B-DISE )|O is|O an|O autosomal|O dominant|O disorder|O resulting|O from|O the|O expansion|O of|O a|O CTG|O repeat|O in|O the|O 3|O '|O untranslated|O region|O of|O a|O putative|O protein|O kinase|O DMPK|O .|O
We|O hypothesize|O that|O ,|O although|O loss|O of|O necdin|O expression|O may|O be|O important|O in|O the|O neonatal|O presentation|O of|O PWS|B-DISE ,|O loss|O of|O MAGEL2|O may|O be|O critical|O to|O abnormalities|B-DISE in|I-DISE brain|I-DISE development|I-DISE and|O dysmorphic|B-DISE features|I-DISE in|O individuals|O with|O PWS|B-DISE .|O .|O
Lipid|O metabolism|O was|O studied|O in|O cultured|O skin|O fibroblasts|O from|O patients|O with|O the|O inherited|O disorder|O ,|O Sjogren|B-DISE -|I-DISE Larsson|I-DISE syndrome|I-DISE SLS|B-DISE .|O
Molecular|O analysis|O of|O an|O unusual|O patient|O with|O the|O Lesch|B-DISE -|I-DISE Nyhan|I-DISE syndrome|I-DISE has|O suggested|O that|O the|O mutation|O is|O due|O to|O a|O partial|O HPRT|O gene|O duplication|O .|O
Most|O PLS|B-DISE patients|O display|O both|O periodontitis|B-DISE and|O hyperkeratosis|B-DISE .|O
Protein|B-DISE S|I-DISE deficiency|I-DISE is|O a|O recognized|O risk|O factor|O for|O venous|B-DISE thrombosis|I-DISE .|O
Homozygosity|O mapping|O in|O this|O family|O assigned|O the|O gene|O to|O a|O 26|O .|O 8|O -|O cM|O region|O on|O the|O chromosome|O band|O 8q21|O .|O 3|O -|O 22|O .|O 1|O ,|O between|O the|O microsatellites|O at|O D8S270|O and|O D8S514|O .|O
Polymerase|O chain|O reaction|O -|O restriction|O fragment|O length|O polymorphism|O analysis|O on|O DNA|O derived|O from|O 100|O donors|O using|O the|O restriction|O enzyme|O Mae|O III|O showed|O that|O the|O Met|O (|O 799|O )|O form|O of|O GPIa|O is|O restricted|O to|O Sit|O (|O a|O )|O (|O +|O )|O phenotype|O .|O
The|O observation|O of|O the|O same|O APC|O mutation|O in|O five|O families|O from|O the|O same|O geographic|O area|O demonstrates|O a|O founder|O effect|O .|O
The|O factor|O X|O (|O F10|O )|O genes|O of|O 14|O unrelated|O individuals|O with|O factor|B-DISE X|I-DISE deficiency|I-DISE (|O 12|O familial|O and|O two|O sporadic|O cases|O )|O were|O sequenced|O yielding|O a|O total|O of|O 13|O novel|O mutations|O .|O
Our|O studies|O implicate|O a|O role|O for|O HMGIC|O in|O fat|O -|O cell|O proliferation|O ,|O indicating|O that|O it|O may|O be|O an|O adipose|O -|O specific|O target|O for|O the|O treatment|O of|O obesity|B-DISE .|O .|O
The|O sequencing|O of|O the|O patient|O '|O s|O cDNA|O fragment|O disclosed|O a|O direct|O conjuction|O of|O exon|O 6|O and|O exon|O 8|O .|O
Restriction|O mapping|O and|O sequencing|O of|O clones|O that|O span|O both|O translocation|O breakpoints|O as|O well|O as|O the|O corresponding|O normal|O regions|O indicate|O the|O loss|O of|O approximately|O 5|O kb|O in|O the|O formation|O of|O the|O derivative|O X|O chromosome|O ,|O with|O 4|O -|O 6|O bp|O deleted|O from|O chromosome|O 4|O .|O
The|O relatives|O (|O parents|O and|O one|O sister|O )|O had|O half|O -|O normal|O levels|O of|O both|O immunochemically|O and|O functionally|O determined|O C7|O ,|O indicating|O a|O heterozygous|O state|O for|O C7|B-DISE deficiency|I-DISE .|O .|O
Mutations|O in|O 25|O of|O the|O families|O were|O localized|O to|O exons|O 4|O -|O 6|O ,|O emphasizing|O the|O critical|O functional|O significance|O of|O the|O discoidin|O domain|O of|O the|O XLRS1|O protein|O .|O .|O
Interestingly|O ,|O although|O liver|O iron|O stores|O are|O greatly|O increased|O ,|O splenic|O iron|O is|O decreased|O .|O
The|O overall|O findings|O were|O that|O disease|O started|O to|O occur|O at|O age|O 30|O years|O and|O that|O by|O age|O 50|O years|O 48|O %|O of|O the|O mutation|O -|O carrying|O women|O had|O experienced|O breast|B-DISE and|I-DISE /|I-DISE or|I-DISE ovarian|I-DISE cancer|I-DISE .|O
Two|O other|O normal|O family|O members|O had|O the|O underlying|O direct|O insertion|O of|O chromosome|O 5|O dir|O ins|O 5|O q31|O .|O 3q22q23|O .|O 2|O .|O
An|O allele|O loss|O assay|O was|O performed|O using|O a|O novel|O highly|O polymorphic|O marker|O ,|O D1S3753|O .|O
Despite|O its|O clinical|O variability|O ,|O this|O dominant|O condition|O segregates|O as|O a|O single|O locus|O at|O chromosome|O 19q13|O .|O 3|O in|O every|O population|O studied|O .|O
An|O estimated|O frequency|O (|O 0|O .|O 12|O %|O )|O of|O complete|O C9|B-DISE deficiency|I-DISE due|O to|O homozygous|O Arg95Stop|O mutation|O was|O consistent|O with|O frequencies|O determined|O by|O serological|O studies|O .|O .|O
Duodenal|O expression|O of|O DMT1|O (|O non|O -|O IRE|O )|O was|O not|O increased|O ,|O nor|O was|O hepatic|O expression|O of|O DMT1|O increased|O .|O
In|O vitro|O ,|O activated|O lymphocytes|O from|O all|O 17|O patients|O showed|O apoptotic|O defects|O when|O exposed|O to|O an|O anti|O -|O Fas|O agonist|O monoclonal|O antibody|O .|O
Three|O of|O the|O four|O EGR2|O mutations|O are|O dominant|O and|O occur|O within|O the|O zinc|O finger|O DNA|O -|O binding|O domain|O .|O
This|O can|O be|O problematic|O when|O only|O part|O of|O the|O gene|O is|O examined|O or|O when|O relevant|O DNA|O alterations|O are|O not|O recognized|O by|O standard|O methods|O .|O
The|O fact|O that|O the|O mouse|O Snrpn|O gene|O is|O maternally|O imprinted|O in|O brain|O suggests|O that|O loss|O of|O the|O paternally|O derived|O SNRPN|O allele|O may|O be|O involved|O in|O the|O PWS|B-DISE phenotype|O .|O .|O
The|O pedigree|O and|O clinical|O findings|O were|O compatible|O with|O autosomal|O recessive|O transmission|O of|O analbuminemia|O .|O
These|O findings|O indicate|O that|O frataxin|O is|O essential|O for|O mitochondrial|O iron|O homeostasis|O and|O protection|O from|O iron|O -|O induced|O formation|O of|O free|O radicals|O .|O
The|O brain|O was|O normal|O on|O CT|O scan|O and|O magnetic|O resonance|O imaging|O .|O
These|O analyses|O also|O demonstrated|O that|O the|O nucleotide|O substitutions|O in|O HGO|O do|O not|O involve|O CpG|O dinucleotides|O ,|O which|O illustrates|O important|O differences|O between|O HGO|O and|O other|O genes|O for|O the|O occurrence|O of|O mutation|O at|O specific|O short|O -|O sequence|O motifs|O .|O
We|O have|O determined|O the|O structure|O of|O GLDC|O and|O of|O its|O pseudogene|O (|O psiGLDC|O )|O and|O studied|O their|O expression|O for|O a|O molecular|O analysis|O of|O NKH|B-DISE .|O
In|O contrast|O to|O other|O Atm|O mutant|O mice|O ,|O Atm|O (|O y|O /|O y|O )|O mice|O show|O a|O lower|O incidence|O of|O thymic|B-DISE lymphoma|I-DISE and|O survive|O beyond|O a|O few|O months|O of|O age|O .|O
There|O was|O evidence|O of|O a|O somewhat|O later|O age|O of|O onset|O of|O symptoms|O in|O B27|O negative|O patients|O .|O
We|O analyzed|O four|O multiplex|O VWS|B-DISE families|O .|O
Foxc1|O (|O +|O /|O -|O )|O and|O Foxc2|O (|O +|O /|O -|O )|O mice|O are|O useful|O models|O for|O studying|O anterior|O segment|O development|O and|O its|O anomalies|O ,|O and|O may|O allow|O identification|O of|O genes|O that|O interact|O with|O Foxc1|O and|O Foxc2|O (|O or|O FKHL7|O and|O FKHL14|O )|O to|O produce|O a|O phenotype|O with|O elevated|O IOP|O and|O glaucoma|B-DISE .|O .|O
Detection|O of|O FAS|O transcripts|O via|O real|O -|O time|O quantitative|O PCR|O made|O a|O severe|O transcriptional|O defect|O unlikely|O .|O
The|O size|O of|O the|O (|O CAG|O )|O n|O repeat|O array|O in|O the|O 3|O '|O end|O of|O the|O MJD1|O gene|O and|O the|O haplotype|O at|O a|O series|O of|O microsatellite|O markers|O surrounding|O the|O MJD1|O gene|O were|O examined|O in|O a|O large|O cohort|O of|O Japanese|O and|O Caucasian|O subjects|O affected|O with|O Machado|B-DISE -|I-DISE Joseph|I-DISE disease|I-DISE MJD|B-DISE .|O
Most|O of|O the|O nonsense|O ,|O frameshift|O and|O splice|O site|O mutations|O were|O found|O in|O exons|O 6|O -|O 11|O .|O
Thus|O ,|O this|O child|O is|O a|O unique|O individual|O with|O inherited|O C3|B-DISE deficiency|I-DISE presenting|O with|O absence|O of|O repeated|O infections|B-DISE ,|O whose|O symptoms|O of|O fever|O ,|O skin|B-DISE rash|I-DISE ,|O and|O arthralgia|B-DISE were|O abated|O by|O whole|O blood|O transfusion|O .|O .|O
This|O is|O presently|O the|O only|O animal|B-DISE model|I-DISE for|I-DISE X|I-DISE -|I-DISE linked|I-DISE G6PD|I-DISE deficiency|I-DISE in|O humans|O .|O .|O
This|O finding|O underlines|O the|O importance|O of|O DNA|O analysis|O for|O maternal|O UPD|B-DISE (|I-DISE 14|I-DISE )|I-DISE in|O patients|O with|O a|O similar|O PWS|B-DISE -|O like|O phenotype|O even|O without|O previous|O identification|O of|O a|O Robertsonian|O translocation|O involving|O chromosome|O 14|O .|O .|O
These|O findings|O provide|O evidence|O that|O PLS|B-DISE and|O HMS|B-DISE are|O allelic|O variants|O of|O cathepsin|O C|O gene|O mutations|O .|O .|O
Copper|O concentration|O in|O the|O livers|O of|O the|O newborn|O homozygous|O null|O mutants|O was|O decreased|O dramatically|O .|O
Atm|O ,|O the|O mouse|O homolog|O of|O the|O human|O ATM|O gene|O defective|O in|O ataxia|B-DISE -|I-DISE telangiectasia|I-DISE (|O A|B-DISE -|I-DISE T|I-DISE )|O ,|O has|O been|O identified|O .|O
In|O 51|O families|O with|O Wilson|B-DISE disease|I-DISE ,|O we|O have|O studied|O DNA|O haplotypes|O of|O dinucleotide|O repeat|O polymorphisms|O (|O CA|O repeats|O )|O in|O the|O 13q14|O .|O 3|O region|O ,|O to|O examine|O these|O markers|O for|O association|O with|O the|O Wilson|B-DISE disease|I-DISE gene|O WND|O .|O
Skin|O fibroblasts|O of|O affected|O individuals|O showed|O several|O orders|O of|O magnitude|O more|O chromosome|O breakage|O than|O lymphocytes|O .|O
The|O antisense|O riboprobe|O detected|O RS1|O mRNA|O only|O in|O the|O photoreceptor|O layer|O but|O the|O protein|O product|O of|O the|O gene|O was|O present|O both|O in|O the|O photoreceptors|O and|O within|O the|O inner|O portions|O of|O the|O retina|O .|O
This|O mutation|O creates|O an|O Fnu4HI|O restriction|O site|O .|O
Fluorescence|O in|O situ|O hybridization|O (|O FISH|O )|O analysis|O shows|O a|O submicroscopic|O deletion|O of|O SNRPN|O ,|O but|O not|O the|O closely|O associated|O loci|O D15S10|O ,|O D15S11|O ,|O D15S63|O ,|O and|O GABRB3|O .|O
WNT|O signalling|O orchestrates|O a|O number|O of|O developmental|O programs|O .|O
Frataxin|O function|O is|O still|O unknown|O but|O the|O knockout|O of|O the|O yeast|O frataxin|O homologue|O gene|O (|O YFH1|O )|O showed|O a|O severe|O defect|O of|O mitochondrial|O respiration|O and|O loss|O of|O mtDNA|O associated|O with|O elevated|O intramitochondrial|O iron|O .|O
This|O has|O implications|O regarding|O the|O mechanism|O by|O which|O the|O mutant|O allele|O exerts|O its|O effect|O .|O .|O
To|O determine|O the|O molecular|O basis|O of|O autosomal|O dominant|O neurohypophyseal|B-DISE diabetes|I-DISE insipidus|I-DISE ,|O the|O AVP|O genes|O of|O members|O of|O a|O large|O kindred|O were|O analyzed|O .|O
This|O response|O includes|O S|O -|O phase|O checkpoint|O activation|O ,|O formation|O of|O the|O NBS1|O /|O Mrel1|O /|O Rad50|O nuclear|O foci|O and|O rescue|O of|O hypersensitivity|O to|O ionizing|O radiation|O .|O
Two|O of|O the|O patients|O ,|O 4|O -|O 5|O month|O old|O boys|O ,|O were|O found|O to|O have|O a|O novel|O disease|O ,|O VLCAD|B-DISE deficiency|I-DISE ,|O as|O judged|O from|O the|O results|O of|O very|O low|O palmitoyl|O -|O CoA|O dehydrogenase|O activity|O and|O the|O lack|O of|O immunoreactivity|O toward|O antibody|O raised|O to|O purified|O VLCAD|O .|O .|O
In|O contrast|O ,|O all|O other|O patients|O were|O compound|O heterozygous|O for|O one|O of|O the|O following|O mutations|O :|O R201H|O ,|O R482H|O ,|O G579D|O ,|O IVS8|O +|O 2T|O >|O C|O .|O
Missense|O mutations|O in|O the|O functional|O domain|O of|O Mxi1|O in|O these|O cases|O may|O be|O involved|O in|O the|O pathogenesis|O of|O neurofibrosarcoma|B-DISE .|O .|O
The|O mother|O is|O a|O heterozygous|O carrier|O ,|O while|O the|O father|O and|O sister|O seem|O to|O be|O normal|O .|O .|O
However|O ,|O attempts|O to|O confirm|O that|O G6PD|B-DISE deficiency|I-DISE is|O protective|O in|O case|O -|O control|O studies|O of|O malaria|B-DISE have|O yielded|O conflicting|O results|O .|O
Type|O I|O von|B-DISE Willebrand|I-DISE disease|I-DISE (|O vWD|B-DISE )|O is|O characterized|O by|O equally|O low|O plasma|O concentrations|O of|O von|O Willebrand|O factor|O antigen|O (|O vWF|O :|O Ag|O )|O and|O ristocetin|O cofactor|O (|O RiCof|O )|O and|O by|O the|O presence|O of|O all|O vWF|O multimers|O in|O sodium|O dodecyl|O sulfate|O (|O SDS|O )|O -|O agarose|O gel|O electrophoresis|O .|O
Consistent|O with|O its|O expression|O in|O granulocytes|O ,|O Mefv|O was|O detected|O at|O high|O levels|O in|O the|O primary|O follicles|O and|O marginal|O zones|O of|O the|O splenic|O white|O pulp|O .|O
Pedigree|O data|O suggest|O that|O this|O mutation|O has|O been|O in|O the|O Cajun|O population|O since|O its|O founding|O over|O 2|O centuries|O ago|O and|O that|O it|O may|O be|O widely|O distributed|O within|O the|O population|O .|O
These|O studies|O demonstrate|O the|O importance|O of|O proline|O 183|O for|O the|O proper|O structure|O /|O function|O of|O emerin|O .|O .|O
All|O of|O the|O parents|O tested|O were|O heterozygous|O for|O the|O mutation|O ,|O suggesting|O that|O the|O patients|O were|O homozygous|O .|O
Since|O the|O original|O report|O ,|O we|O have|O diagnosed|O congenital|B-DISE hypothyroidism|I-DISE by|O newborn|O TSH|O screening|O in|O 9|O additional|O children|O from|O the|O family|O .|O
We|O reexamined|O a|O group|O of|O VHL|B-DISE patients|O shown|O previously|O by|O single|O -|O strand|O conformation|O and|O sequencing|O analysis|O not|O to|O harbor|O point|O mutations|O in|O the|O VHL|O locus|O .|O
Interestingly|O ,|O all|O three|O subjects|O were|O probably|O heterozygous|O for|O both|O subtotal|O C6|O and|O complete|O C6|B-DISE deficiency|I-DISE .|O .|O
Friedreich|B-DISE ataxia|I-DISE ,|O an|O autosomal|O recessive|O neurodegenerative|B-DISE disease|I-DISE ,|O is|O the|O most|O common|O of|O the|O inherited|O ataxias|B-DISE .|O
Glycerol|O kinase|O (|O GK|O )|O represents|O the|O primary|O entry|O of|O glycerol|O into|O glucose|O and|O triglyceride|O metabolism|O .|O
Thirty|O -|O two|O unrelated|O patients|O with|O features|O of|O Saethre|B-DISE -|I-DISE Chotzen|I-DISE syndrome|I-DISE ,|O a|O common|O autosomal|B-DISE dominant|I-DISE condition|I-DISE of|O craniosynostosis|B-DISE and|O limb|B-DISE anomalies|I-DISE ,|O were|O screened|O for|O mutations|O in|O TWIST|O ,|O FGFR2|O ,|O and|O FGFR3|O .|O
We|O show|O herein|O that|O CTLA|O -|O 4|O is|O present|O in|O enlarged|O ,|O abnormal|O vesicles|O in|O CHS|B-DISE T|O cells|O and|O is|O not|O properly|O expressed|O at|O the|O cell|O surface|O after|O T|O cell|O activation|O ,|O whereas|O its|O surface|O expression|O is|O not|O impaired|O .|O
Papillon|B-DISE -|I-DISE Lefevre|I-DISE syndrome|I-DISE ,|O or|O keratosis|B-DISE palmoplantaris|I-DISE with|I-DISE periodontopathia|I-DISE (|O PLS|B-DISE ,|O MIM|O 245000|O )|O ,|O is|O an|O autosomal|O recessive|O disorder|O that|O is|O mainly|O ascertained|O by|O dentists|O because|O of|O the|O severe|O periodontitis|B-DISE that|O afflicts|O patients|O .|O
The|O severity|O of|O the|O disease|O in|O patients|O and|O controls|O was|O determined|O using|O a|O modified|O score|O ,|O developed|O previously|O .|O
We|O suggest|O that|O Coats|B-DISE '|I-DISE telangiectasis|I-DISE is|O secondary|O to|O somatic|O mutation|O in|O the|O NDP|O gene|O which|O results|O in|O a|O deficiency|B-DISE of|I-DISE norrin|I-DISE (|O the|O protein|O product|O of|O the|O NDP|O gene|O )|O within|O the|O developing|O retina|O .|O
For|O individuals|O with|O EA|B-DISE -|I-DISE 2|I-DISE ,|O the|O mutations|O described|O thus|O far|O are|O presumed|O to|O result|O in|O a|O truncated|O protein|O product|O .|O
Von|B-DISE Hippel|I-DISE -|I-DISE Lindau|I-DISE (|I-DISE VHL|I-DISE )|I-DISE disease|I-DISE is|O a|O hereditary|B-DISE tumor|I-DISE syndrome|I-DISE characterized|O by|O predisposition|O for|O bilateral|O and|O multi|O -|O centric|O hemangioblastoma|B-DISE in|O the|O retina|O and|O central|O nervous|O system|O ,|O pheochromocytoma|B-DISE ,|O renal|B-DISE cell|I-DISE carcinoma|I-DISE ,|O and|O cysts|B-DISE in|I-DISE the|I-DISE kidney|I-DISE ,|I-DISE pancreas|I-DISE ,|I-DISE and|I-DISE epididymis|I-DISE .|O
We|O speculate|O that|O emerin|O contributes|O to|O maintain|O the|O nuclear|O structure|O and|O stability|O ,|O as|O well|O as|O nuclear|O functions|O ,|O particularly|O in|O muscle|O tissues|O that|O have|O severe|O stress|O with|O rigorous|O contraction|O -|O relaxation|O movements|O and|O calcium|O flux|O .|O .|O
The|O identification|O of|O common|O BRCA1|O and|O BRCA2|O mutations|O will|O facilitate|O carrier|O detection|O in|O French|O Canadian|O breast|B-DISE cancer|I-DISE and|O breast|B-DISE /|I-DISE ovarian|I-DISE cancer|I-DISE families|O .|O .|O
These|O rearrangements|O were|O initially|O revealed|O by|O analyzing|O cDNAs|O and|O could|O not|O have|O been|O identified|O by|O using|O mutation|O detection|O methods|O that|O screened|O each|O exon|O individually|O .|O
Our|O findings|O suggest|O that|O subtle|O differences|O in|O the|O course|O of|O the|O neurodegeneration|B-DISE in|O HD|B-DISE may|O allow|O interacting|O genes|O to|O exert|O gender|O specific|O effects|O upon|O AO|O .|O .|O
Using|O these|O methods|O ,|O we|O report|O striking|O linkage|O disequilibrium|O for|O diastrophic|B-DISE dysplasia|I-DISE (|O DTD|B-DISE )|O in|O Finland|O indicating|O that|O the|O DTD|O gene|O should|O lie|O within|O 0|O .|O 06|O centimorgans|O (|O or|O about|O 60|O kilobases|O )|O of|O the|O CSF1R|O gene|O .|O
We|O report|O here|O the|O linkage|O relationship|O of|O the|O myotonic|B-DISE dystrophy|I-DISE (|O DM|O )|O locus|O to|O twelve|O of|O these|O markers|O as|O studied|O in|O 45|O families|O with|O DM|B-DISE .|O
Our|O data|O support|O the|O previously|O established|O observation|O that|O families|O with|O a|O germline|O deletion|O have|O a|O low|O risk|O for|O pheochromocytoma|B-DISE .|O
Here|O we|O report|O that|O the|O human|O Cds1|O kinase|O (|O hCds1|O /|O Chk2|O )|O regulates|O BRCA1|O function|O after|O DNA|O damage|O by|O phosphorylating|O serine|O 988|O of|O BRCA1|O .|O
Moreover|O ,|O targeted|O mutagenesis|O of|O mouse|O homologues|O of|O the|O human|O candidate|O PWS|O genes|O does|O not|O appear|O to|O result|O in|O any|O of|O the|O features|O of|O PWS|B-DISE .|O
HPRT|O -|O deficient|O mice|O generated|O using|O mouse|O embryonic|O stem|O cells|O exhibit|O none|O of|O the|O behavioral|O symptoms|O associated|O with|O the|O Lesch|B-DISE -|I-DISE Nyhan|I-DISE syndrome|I-DISE .|O
The|O study|O group|O consisted|O of|O 66|O Polish|O families|O with|O cancer|B-DISE who|O have|O at|O least|O three|O related|O females|O affected|O with|O breast|B-DISE or|I-DISE ovarian|I-DISE cancer|I-DISE and|O who|O had|O cancer|O diagnosed|O ,|O in|O at|O least|O one|O of|O the|O three|O affected|O females|O ,|O at|O age|O <|O 50|O years|O .|O
RESULTS|O :|O A|O homozygous|O G|O to|O A|O transition|O at|O the|O 5|O '|O end|O of|O intron|O 7|O was|O detected|O in|O the|O patient|O .|O
It|O is|O invariably|O associated|O with|O a|O severe|O phenotype|O .|O
IFN|O -|O alpha|O also|O induced|O MEFV|O expression|O .|O
beta|O -|O Glucuronidase|O activity|O was|O undetectable|O in|O affected|O cat|O fibroblasts|O and|O restored|O by|O retroviral|O gene|O transfer|O of|O rat|O beta|O -|O glucuronidase|O cDNA|O .|O
van|B-DISE der|I-DISE Woude|I-DISE syndrome|I-DISE (|O vWS|B-DISE ,|O MIM|O 119300|O )|O is|O a|O rare|O autosomal|O dominant|O clefting|B-DISE condition|I-DISE with|O cardinal|O features|O of|O mucous|B-DISE cysts|I-DISE (|O lower|B-DISE -|I-DISE lip|I-DISE pits|I-DISE )|O and|O clefts|B-DISE to|I-DISE the|I-DISE lip|I-DISE and|I-DISE /|I-DISE or|I-DISE palate|I-DISE .|O
Mutations|O at|O the|O ataxia|B-DISE -|I-DISE telangiectasia|I-DISE (|O A|O -|O T|O )|O locus|O on|O chromosome|O band|O 11q22|O cause|O a|O distinctive|O autosomal|B-DISE recessive|I-DISE syndrome|I-DISE in|O homozygotes|O and|O predispose|O heterozygotes|O to|O cancer|B-DISE ,|O ischemic|B-DISE heart|I-DISE disease|I-DISE ,|O and|O early|B-DISE mortality|I-DISE .|O
Complexes|O containing|O ATM|O and|O NBS1|O exist|O in|O vivo|O in|O both|O untreated|O cells|O and|O cells|O treated|O with|O ionizing|O radiation|O .|O
The|O deletion|O chromosome|O has|O acquired|O a|O maternal|O methylation|O imprint|O in|O his|O somatic|O cells|O .|O
To|O date|O ,|O its|O diagnosis|O ,|O which|O can|O be|O made|O only|O retrospectively|O ,|O is|O one|O of|O exclusion|O ,|O based|O entirely|O on|O nonspecific|O clinical|O signs|O that|O result|O from|O serosal|B-DISE inflammation|I-DISE and|O that|O may|O lead|O to|O unnecessary|O surgery|O .|O
Resequencing|O of|O the|O GK|O gene|O in|O family|O members|O led|O to|O the|O discovery|O of|O a|O N288D|O missense|O mutation|O in|O exon|O 10|O ,|O which|O resulted|O in|O the|O substitution|O of|O a|O highly|O conserved|O asparagine|O residue|O by|O a|O negatively|O charged|O aspartic|O acid|O .|O
Three|O BRCA1|O abnormalities|O -|O 5382insC|O ,|O C61G|O ,|O and|O 4153delA|O -|O accounted|O for|O 51|O %|O ,|O 20|O %|O ,|O and|O 11|O %|O of|O the|O identified|O mutations|O ,|O respectively|O .|O .|O
Friedreich|B-DISE ataxia|I-DISE is|O an|O autosomal|B-DISE recessive|I-DISE disorder|I-DISE caused|O by|O mutations|O in|O the|O FRDA|O gene|O that|O encodes|O a|O 210|O -|O amino|O acid|O protein|O called|O frataxin|O .|O
Analysis|O of|O the|O prevalence|O of|O the|O various|O mutations|O among|O DPD|O patients|O has|O shown|O that|O the|O G|O -|O -|O >|O A|O point|O mutation|O in|O the|O invariant|O splice|O donor|O site|O is|O by|O far|O the|O most|O common|O (|O 52|O %|O )|O ,|O whereas|O the|O other|O six|O mutations|O are|O less|O frequently|O observed|O .|O
The|O sample|O sizes|O were|O large|O enough|O for|O statistical|O testing|O in|O four|O groups|O with|O at|O least|O one|O mutation|O that|O completely|O abolishes|O enzyme|O activity|O .|O
STUDY|O DESIGN|O :|O One|O hundred|O twenty|O -|O two|O patients|O with|O CHH|O were|O identified|O through|O 2|O countrywide|O epidemiologic|O surveys|O in|O 1974|O and|O in|O 1986|O .|O
We|O discuss|O these|O findings|O in|O the|O context|O of|O the|O hypothesis|O that|O abnormal|B-DISE development|I-DISE of|I-DISE Purkinje|I-DISE cells|O and|O lymphocytes|O contributes|O to|O the|O pathogenesis|O of|O A|B-DISE -|I-DISE T|I-DISE .|O .|O
Three|O other|O peroxisomal|O ABC|O transporters|O currently|O are|O known|O :|O adrenoleukodystrophy|B-DISE -|O related|O protein|O (|O ALDRP|O )|O ,|O 70|O kDa|O peroxisomal|O membrane|O protein|O (|O PMP70|O )|O and|O PMP70|O -|O related|O protein|O .|O
OBJECTIVE|O :|O To|O monitor|O the|O effects|O of|O dietary|O treatment|O in|O adult|O -|O onset|O adrenoleukodystrophy|B-DISE (|O ALD|B-DISE )|O by|O means|O of|O somatosensory|O evoked|O potentials|O (|O SEPs|O )|O and|O motor|O evoked|O potentials|O MEPs|O .|O
The|O C282Y|O mutation|O occurs|O on|O a|O haplotype|O that|O extends|O <|O /|O =|O 6|O Mb|O ,|O suggesting|O that|O this|O mutation|O has|O arisen|O during|O the|O past|O 2|O ,|O 000|O years|O .|O
We|O have|O made|O identical|O findings|O in|O chimaeric|O mice|O generated|O from|O two|O independent|O embryonic|O stem|O (|O ES|O )|O cell|O lines|O harbouring|O a|O similar|O deletion|O .|O
To|O determine|O the|O frequency|O and|O nature|O of|O constitutional|O RB1|O -|O gene|O mutations|O in|O patients|O with|O isolated|O unilateral|B-DISE retinoblastoma|I-DISE ,|O we|O analyzed|O DNA|O from|O peripheral|O blood|O and|O from|O tumor|O tissue|O .|O
Our|O findings|O also|O indicate|O a|O new|O mechanism|O for|O disease|O severity|O :|O if|O a|O broader|O spectrum|O of|O mutations|O is|O selected|O in|O tumors|B-DISE ,|O the|O somatic|O mutation|O rate|O is|O effectively|O higher|O and|O more|O tumors|B-DISE grow|O .|O .|O
This|O family|O study|O provides|O further|O support|O for|O the|O proposal|O that|O C3|B-DISE deficiency|I-DISE predisposes|O to|O nephritis|B-DISE .|O .|O
Previous|O characterization|O of|O a|O mutant|O form|O of|O HPRT|O ,|O HPRTYale|O ,|O from|O a|O subject|O with|O the|O Lesch|B-DISE -|I-DISE Nyhan|I-DISE syndrome|I-DISE revealed|O normal|O mRNA|O and|O protein|O concentrations|O ,|O no|O residual|O catalytic|O activity|O ,|O and|O cathodal|O migration|O upon|O PAGE|O .|O
The|O hemochromatosis|B-DISE gene|O ,|O HFE|O ,|O recently|O has|O been|O identified|O ,|O and|O characterization|O of|O this|O gene|O has|O shown|O that|O it|O contains|O two|O mutations|O that|O result|O in|O amino|O acid|O substitutions|O -|O cDNA|O nucleotides|O 845|O G|O -|O -|O A|O (|O C282Y|O )|O and|O 187|O C|O -|O -|O G|O H63D|O .|O
To|O test|O this|O hypothesis|O ,|O we|O have|O conducted|O linkage|O analysis|O in|O a|O large|O Brazilian|O kindred|O with|O VWS|B-DISE ,|O considering|O as|O affected|O the|O individuals|O with|O CP|B-DISE ,|O regardless|O of|O whether|O it|O is|O associated|O with|O other|O clinical|O signs|O of|O VWS|B-DISE .|O
A|O 40|O -|O year|O -|O old|O man|O with|O childhood|O -|O onset|O Tourette|B-DISE syndrome|I-DISE (|O TS|B-DISE )|O developed|O Huntington|B-DISE disease|I-DISE HD|B-DISE .|O
Linkage|O analysis|O of|O the|O data|O from|O 12|O microsatellite|O markers|O surrounding|O the|O Xp21|O .|O 3|O GK|O gene|O resulted|O in|O a|O peak|O LOD|O score|O of|O 3|O .|O 46|O ,|O centered|O around|O marker|O DXS8039|O .|O
We|O hypothesize|O that|O structural|O rearrangement|O of|O 14q|O is|O directly|O related|O to|O abnormal|B-DISE growth|I-DISE of|I-DISE lymphocytes|I-DISE and|O that|O it|O may|O be|O a|O step|O toward|O the|O development|O of|O lymphoid|B-DISE malignancies|I-DISE .|O
Although|O we|O found|O no|O FEN1|O mutations|O ,|O a|O frameshift|O mutation|O in|O MSH3|O was|O observed|O in|O an|O endometrial|B-DISE carcinoma|I-DISE and|O in|O an|O endometrial|B-DISE carcinoma|I-DISE cell|O line|O .|O
The|O known|O Duchenne|B-DISE muscular|I-DISE dystrophy|I-DISE (|O DMD|O )|O gene|O products|O ,|O the|O muscle|O -|O and|O brain|O -|O type|O dystrophin|O isoforms|O ,|O are|O 427|O -|O kDa|O proteins|O translated|O from|O 14|O -|O kilobase|O (|O kb|O )|O mRNAs|O .|O
The|O mean|O survival|O and|O height|O distribution|O of|O 134|O A|B-DISE -|I-DISE T|I-DISE patients|O correlated|O significantly|O with|O the|O specific|O mutations|O present|O in|O the|O patients|O .|O
Phenylketonuria|B-DISE (|O PKU|B-DISE )|O ,|O a|O disorder|O of|O amino|O acid|O metabolism|O prevalent|O among|O Caucasians|O and|O other|O ethnic|O groups|O ,|O is|O caused|O primarily|O by|O a|O deficiency|B-DISE of|I-DISE the|I-DISE hepatic|I-DISE enzyme|I-DISE phenylalanine|I-DISE hydroxylase|I-DISE PAH|I-DISE .|O
The|O Rho|O -|O family|O GTPase|O ,|O Cdc42|O ,|O can|O regulate|O the|O actin|O cytoskeleton|O through|O activation|O of|O Wiskott|B-DISE -|I-DISE Aldrich|I-DISE syndrome|I-DISE protein|O (|O WASP|O )|O family|O members|O .|O
Carriers|O identified|O in|O this|O manner|O produced|O affected|O kittens|O in|O prospective|O breedings|O ,|O and|O a|O feline|O MPS|B-DISE VII|I-DISE breeding|O colony|O has|O been|O established|O .|O .|O
No|O linkage|O for|O C5|B-DISE deficiency|I-DISE and|O the|O A|O or|O B|O loci|O of|O the|O major|O histocompatibility|O complex|O could|O be|O found|O .|O
Carriers|O of|O G6PD|B-DISE deficiency|I-DISE are|O residents|O of|O 11|O villages|O located|O in|O Alasani|O -|O Aphtalan|O valley|O ,|O highly|O endemic|O with|O malaria|B-DISE in|O the|O past|O ;|O nearly|O all|O marriages|O are|O endogamic|O .|O
We|O report|O on|O a|O thrombocytopenic|O female|O belonging|O to|O a|O pedigree|O with|O the|O Wiskott|B-DISE -|I-DISE Aldrich|I-DISE syndrome|I-DISE WAS|B-DISE .|O
In|O the|O study|O reported|O here|O we|O describe|O PAX6|O mutations|O in|O one|O sporadic|O and|O five|O familial|O cases|O with|O aniridia|B-DISE .|O
Counselling|O was|O given|O for|O a|O recessive|O disorder|O ,|O thereby|O considerably|O reducing|O the|O probability|O of|O affected|O offspring|O .|O
Mutational|O analysis|O revealed|O absence|O of|O M694V|O homozygosity|O ,|O P|O <|O 0|O .|O 01|O ,|O compared|O to|O our|O regular|O FMF|B-DISE population|O .|O
An|O abbreviated|O Wechsler|O Adult|O Intelligence|O Scale|O Revised|O (|O WAIS|O -|O R|O )|O was|O used|O to|O assess|O verbal|O and|O arithmetical|O cognitive|O performance|O in|O 55|O subjects|O with|O myotonic|B-DISE dystrophy|I-DISE (|O DM|B-DISE )|O ,|O covering|O all|O grades|O of|O disease|O severity|O ,|O and|O 31|O controls|O at|O 50|O %|O risk|O of|O inheriting|O DM|B-DISE .|O
Mutations|O in|O the|O glycine|O decarboxylase|O gene|O (|O GLDC|O )|O cause|O nonketotic|B-DISE hyperglycinemia|I-DISE (|O NKH|B-DISE )|O ,|O an|O in|B-DISE -|I-DISE born|I-DISE error|I-DISE of|I-DISE metabolism|I-DISE characterized|O by|O severe|O neurological|B-DISE disturbance|I-DISE .|O
In|O four|O families|O ,|O partial|O deletions|O of|O one|O or|O more|O exons|O were|O detected|O by|O Southern|O blot|O analysis|O .|O
RESULTS|O :|O Before|O treatment|O ,|O brain|O MRI|O was|O normal|O in|O five|O patients|O .|O
Studies|O of|O immune|O function|O including|O immunoglobulin|O levels|O and|O T|O -|O cell|O subsets|O were|O normal|O .|O
During|O GH|O treatment|O ,|O resting|O ventilation|O increased|O by|O 26|O %|O ,|O P|O (|O 0|O .|O 1|O )|O by|O 72|O %|O and|O the|O response|O to|O CO|O (|O 2|O )|O by|O 65|O %|O P|O Y|O 0|O .|O 002|O ,|O <|O 0|O .|O 04|O and|O <|O 0|O .|O 02|O ,|O respectively|O .|O
The|O Wiskott|B-DISE -|I-DISE Aldrich|I-DISE syndrome|I-DISE (|O WAS|B-DISE )|O is|O caused|O by|O defects|O in|O the|O WAS|O protein|O (|O WASP|O )|O gene|O on|O the|O X|O chromosome|O .|O
A|O previously|O described|O 28|O -|O bp|O deletion|O at|O the|O COL2A1|O exon|O 12|O -|O intron|O 12|O junction|O ,|O deleting|O the|O splice|O donor|O site|O ,|O was|O identified|O in|O the|O fifth|O case|O .|O
Brain|O and|O heart|O transcripts|O of|O the|O DM|O -|O kinase|O (|O DMR|O -|O B15|O )|O gene|O are|O subject|O to|O alternative|O RNA|O splicing|O in|O both|O human|O and|O mouse|O .|O
Friedreich|B-DISE ataxia|I-DISE (|O FRDA|B-DISE )|O ,|O the|O most|O common|O of|O the|O inherited|O ataxias|B-DISE ,|O is|O an|O autosomal|O recessive|O degenerative|B-DISE disorder|I-DISE ,|O characterized|O clinically|O by|O onset|O before|O the|O age|O of|O 25|O of|O progressive|O gait|O and|O limb|B-DISE ataxia|I-DISE ,|O absence|B-DISE of|I-DISE deep|I-DISE tendon|I-DISE reflexes|I-DISE ,|O extensor|O plantar|O responses|O ,|O and|O loss|O of|O position|O and|O vibration|O sense|O in|O the|O lower|O limbs|O .|O
An|O exception|O is|O BRCA1|O ,|O which|O contributes|O to|O a|O significant|O fraction|O of|O familial|B-DISE breast|I-DISE and|I-DISE ovarian|I-DISE cancer|I-DISE ,|O but|O undergoes|O mutation|O at|O very|O low|O rates|O in|O sporadic|B-DISE breast|I-DISE and|I-DISE ovarian|I-DISE cancers|I-DISE .|O
In|O this|O study|O ,|O we|O quantified|O the|O mRNA|O level|O of|O GCH1|O in|O phytohemagglutinin|O (|O PHA|O )|O -|O stimulated|O mononuclear|O blood|O cells|O from|O one|O Japanese|O family|O that|O do|O not|O have|O a|O mutation|O in|O the|O coding|O region|O or|O splice|O junctions|O of|O the|O gene|O .|O
The|O heterozygous|O family|O members|O did|O not|O have|O the|O ALPS|B-DISE phenotype|O ,|O indicating|O that|O the|O disease|O -|O causing|O FAS|O mutation|O in|O this|O family|O is|O autosomal|O recessive|O .|O .|O
Abnormal|O amplification|O of|O a|O CTG|O repeat|O on|O chromosome|O 19|O is|O the|O molecular|O basis|O of|O myotonic|B-DISE dystrophy|I-DISE DM|B-DISE .|O
Studies|O were|O performed|O on|O seven|O members|O (|O four|O clinically|O affected|O )|O of|O the|O family|O .|O
One|O possible|O explanation|O for|O our|O finding|O is|O an|O altered|O alpha|O -|O /|O beta|O (|O 1|O )|O -|O subunit|O association|O in|O the|O mutant|O .|O .|O
To|O clarify|O whether|O colchicine|O is|O excreted|O in|O breast|O milk|O ,|O and|O to|O compare|O its|O concentrations|O in|O the|O serum|O and|O breast|O milk|O of|O lactating|O women|O who|O have|O familial|B-DISE Mediterranean|I-DISE fever|I-DISE FMF|B-DISE .|O
Based|O on|O this|O idea|O ,|O DNAs|O isolated|O from|O gastric|B-DISE cancers|I-DISE were|O examined|O by|O means|O of|O a|O RNase|O protection|O analysis|O coupled|O with|O polymerase|O chain|O reaction|O followed|O by|O sequencing|O of|O the|O polymerase|O chain|O reaction|O products|O .|O
An|O additional|O blood|O sample|O was|O obtained|O from|O this|O individual|O to|O determine|O if|O he|O possessed|O any|O of|O the|O known|O CYP2C9|O or|O CYP2C19|O allelic|O variants|O that|O would|O account|O for|O his|O poor|O clearance|O of|O the|O CYP2C9|O substrates|O (|O phenytoin|O and|O glipizide|O )|O compared|O with|O the|O CYP3A4|O (|O nifedipine|O )|O and|O CYP2D6|O (|O chlorpheniramine|O )|O substrates|O .|O
The|O osteolytic|B-DISE lesions|I-DISE ,|O which|O develop|O usually|O in|O the|O long|O bones|O during|O early|O adulthood|O ,|O show|O increased|O osteoblast|O and|O osteoclast|O activity|O .|O
Interestingly|O ,|O the|O I1307K|O APC|O polymorphism|O ,|O associated|O with|O an|O increased|O risk|O of|O colorectal|B-DISE cancer|I-DISE ,|O is|O also|O present|O in|O this|O family|O .|O
These|O results|O establish|O a|O molecular|O link|O between|O HFE|O and|O a|O key|O protein|O involved|O in|O iron|O transport|O ,|O the|O TfR|O ,|O and|O raise|O the|O possibility|O that|O alterations|O in|O this|O regulatory|O mechanism|O may|O play|O a|O role|O in|O the|O pathogenesis|O of|O hereditary|B-DISE hemochromatosis|I-DISE .|O .|O
PEX1|O mutations|O were|O detected|O in|O all|O four|O patients|O ,|O including|O a|O 1|O -|O bp|O insertion|O (|O c|O .|O 2097insT|O )|O in|O exon|O 13|O that|O was|O present|O in|O three|O of|O the|O four|O patients|O .|O
These|O results|O suggest|O that|O some|O novel|O mutations|O should|O exist|O on|O one|O of|O the|O alleles|O in|O some|O unknown|O region|O of|O the|O GCH1|O gene|O ,|O and|O may|O decrease|O the|O GCH1|O mRNA|O causing|O the|O HPD|B-DISE /|O DRD|B-DISE symptoms|O .|O .|O
The|O odds|O of|O detection|O of|O any|O of|O the|O four|O BRCA1|O mutations|O was|O 18|O .|O 7x|O greater|O if|O one|O or|O more|O cases|O of|O ovarian|B-DISE cancer|I-DISE were|O also|O present|O in|O the|O family|O .|O
The|O location|O of|O the|O germ|O -|O line|O mutations|O seems|O to|O correlate|O with|O the|O two|O clinical|O types|O ;|O germ|O -|O line|O mutations|O in|O five|O FAP|B-DISE patients|O with|O profuse|O polyps|B-DISE were|O observed|O between|O codon|O 1250|O and|O codon|O 1464|O ,|O whereas|O mutations|O in|O 17|O FAP|B-DISE patients|O with|O fewer|O polyps|B-DISE were|O observed|O in|O the|O other|O regions|O of|O the|O APC|O gene|O .|O
(|O 4|O )|O G6PD|O Betica|O ,|O which|O is|O the|O most|O frequent|O variant|O found|O in|O subjects|O of|O Southern|O Spanish|O origin|O ,|O has|O been|O observed|O associated|O with|O favism|B-DISE in|O all|O cases|O except|O one|O .|O .|O
RESULTS|O :|O Our|O study|O should|O have|O been|O able|O to|O detect|O a|O 4|O -|O 5|O -|O fold|O increase|O in|O the|O risk|O of|O prostate|B-DISE cancer|I-DISE due|O to|O mutation|O of|O BRCA1|O or|O BRCA2|O .|O
Nevertheless|O ,|O E148Q|O helps|O account|O for|O recessive|O inheritance|O in|O an|O Ashkenazi|O family|O previously|O reported|O as|O an|O unusual|O case|O of|O dominantly|O inherited|O FMF|B-DISE .|O
Meningococcal|B-DISE disease|I-DISE is|O endemic|O in|O the|O Cape|O and|O almost|O all|O pedigrees|O of|O total|O C6|B-DISE deficiency|I-DISE (|O C6Q0|O )|O have|O been|O ascertained|O because|O of|O recurrent|O disease|O .|O
To|O facilitate|O our|O understanding|O of|O the|O normal|O function|O of|O MEFV|O ,|O we|O extended|O our|O previous|O studies|O .|O
These|O alterations|O predict|O the|O replacement|O of|O a|O proline|O residue|O at|O position|O 183|O with|O either|O a|O histidine|O or|O a|O threonine|O .|O
Germ|O -|O line|O mutations|O of|O the|O tumor|O suppressor|O APC|O are|O implicated|O in|O attenuated|B-DISE adenomatous|I-DISE polyposis|I-DISE coli|I-DISE (|O AAPC|B-DISE )|O ,|O a|O variant|O of|O familial|O adenomatous|B-DISE polyposis|I-DISE FAP|B-DISE .|O
This|O change|O generates|O an|O early|O termination|O codon|O 6|O bp|O downstream|O from|O the|O insertion|O site|O .|O
The|O mutation|O was|O located|O in|O the|O 10th|O transmembrane|O helix|O .|O
Chromosomal|O studies|O were|O performed|O on|O peripheral|O blood|O lymphocytes|O and|O cultured|O skin|O fibroblasts|O from|O five|O Israeli|O -|O Moroccan|O families|O with|O ataxia|B-DISE -|I-DISE telangiectasia|I-DISE .|O
The|O main|O symptom|O is|O progressive|B-DISE mental|I-DISE retardation|I-DISE .|O
Females|O with|O moderate|O or|O mild|O PKU|B-DISE who|O were|O treated|O early|O and|O treated|O for|O >|O 6|O years|O showed|O IQ|O scores|O 10|O points|O above|O average|O for|O their|O group|O .|O
By|O using|O transient|O and|O stable|O overexpression|O of|O human|O cDNAs|O encoding|O ALDP|O and|O its|O closest|O relative|O ALDRP|O ,|O we|O could|O restore|O the|O impaired|O peroxisomal|O beta|O -|O oxidation|O in|O fibroblasts|O of|O X|O -|O ALD|O patients|O .|O
The|O c862t|O (|O R279W|O )|O transition|O is|O the|O most|O common|O mutation|O in|O non|O -|O Finnish|O patients|O ,|O but|O in|O these|O disorders|O it|O is|O usually|O combined|O with|O other|O DTDST|O mutations|O .|O
By|O contrast|O ,|O no|O such|O relationship|O could|O be|O discerned|O between|O laboratory|O phenotype|O and|O polymorphism|O genotype|O .|O .|O
Mutations|O at|O the|O hexosaminidase|O A|O (|O HEXA|O )|O gene|O which|O cause|O Tay|B-DISE -|I-DISE Sachs|I-DISE disease|I-DISE (|O TSD|B-DISE )|O have|O elevated|O frequency|O in|O the|O Ashkenazi|O Jewish|O and|O French|O -|O Canadian|O populations|O .|O
The|O serum|O of|O a|O 44|O -|O yr|O -|O old|O woman|O of|O French|O -|O Canadian|O descent|O having|O a|O B|O -|O 27|O positive|O ankylosing|B-DISE spondylitis|I-DISE was|O deficient|O in|O the|O seventh|O component|O of|O complement|O (|O C7|O )|O as|O determined|O by|O hemolytic|O and|O immunochemical|O methods|O .|O
By|O use|O of|O chemical|O cleavage|O of|O mismatches|O adapted|O to|O fluorescence|O -|O based|O detection|O systems|O ,|O we|O have|O characterized|O the|O mutations|O underlying|O alpha|B-DISE -|I-DISE Gal|I-DISE A|I-DISE deficiency|I-DISE in|O 16|O individuals|O from|O six|O unrelated|O families|O with|O FD|B-DISE .|O
We|O found|O nuclear|O LEF|O -|O 1|O in|O the|O dividing|O tumour|B-DISE cells|O ,|O providing|O biochemical|O evidence|O that|O pilomatricomas|B-DISE are|O derived|O from|O hair|O matrix|O cells|O .|O
The|O recent|O discovery|O of|O the|O gene|O that|O is|O mutated|O in|O this|O condition|O ,|O FRDA|O ,|O has|O led|O to|O rapid|O advances|O in|O the|O understanding|O of|O the|O pathogenesis|O of|O Friedreich|B-DISE ataxia|I-DISE .|O
We|O show|O that|O organs|O which|O develop|O pathologic|O changes|O in|O the|O Atm|B-DISE -|I-DISE deficient|I-DISE mice|O are|O targets|O of|O oxidative|O damage|O ,|O and|O that|O cerebellar|O Purkinje|O cells|O are|O particularly|O affected|O .|O
Before|O leukemia|B-DISE was|O diagnosed|O ,|O the|O patient|O had|O a|O lymphocyte|O clone|O with|O a|O 14q|O translocation|O .|O
Mutations|O identified|O in|O this|O study|O include|O 19|O missense|O mutations|O ,|O two|O nonsense|O mutations|O ,|O one|O intragenic|O deletion|O ,|O four|O microdeletions|O ,|O one|O insertion|O ,|O and|O one|O intronic|O sequence|O substitution|O that|O is|O likely|O to|O result|O in|O a|O splice|O site|O defect|O .|O
These|O data|O show|O that|O '|O intrinsically|O unstructured|O '|O peptides|O such|O as|O the|O GTPase|O -|O binding|O domain|O of|O WASP|O can|O be|O induced|O into|O distinct|O structural|O and|O functional|O states|O depending|O on|O context|O .|O .|O
Prader|B-DISE -|I-DISE Willi|I-DISE syndrome|I-DISE (|O PWS|B-DISE )|O and|O Angelman|B-DISE syndrome|I-DISE (|O AS|B-DISE )|O are|O distinct|O neurobehavioral|B-DISE disorders|I-DISE that|O most|O often|O arise|O from|O a|O 4|O -|O Mb|O deletion|O of|O chromosome|O 15q11|O -|O q13|O during|O paternal|O or|O maternal|O gametogenesis|O ,|O respectively|O .|O
Although|O a|O genotype|O -|O phenotype|O correlation|O between|O the|O locations|O of|O APC|O germline|O mutations|O and|O the|O development|O of|O AFAP|B-DISE has|O been|O well|O documented|O ,|O the|O mechanism|O for|O AFAP|B-DISE has|O not|O been|O well|O defined|O .|O
The|O PTS1R|O cDNA|O also|O complements|O the|O PTS1|O protein|O -|O import|O defect|O in|O skin|O fibroblasts|O from|O patients|O -|O -|O belonging|O to|O complementation|O group|O two|O -|O -|O diagnosed|O as|O having|O neonatal|O adrenoleukodystrophy|B-DISE or|O Zellweger|B-DISE syndrome|I-DISE .|O
In|O contrast|O ,|O mutant|O APC|O gene|O products|O that|O are|O associated|O with|O attenuated|O polyposis|B-DISE (|O codon|O 386|O or|O 1465|O )|O interfered|O only|O weakly|O with|O wild|O -|O type|O APC|O activity|O .|O
In|O this|O study|O ,|O further|O segregation|O analysis|O has|O been|O performed|O using|O a|O newly|O identified|O WAS|B-DISE family|O as|O well|O as|O an|O additional|O marker|O probe|O ,|O HOATL1|O .|O
It|O is|O likely|O that|O the|O X|O -|O derived|O sequence|O GGAATCA|O has|O been|O lost|O in|O the|O formation|O of|O the|O der|O (|O X|O )|O chromosome|O ,|O as|O it|O matches|O an|O inverted|O GAATCA|O sequence|O present|O on|O the|O opposite|O strand|O exactly|O at|O the|O other|O end|O of|O the|O deleted|O 5|O -|O kb|O fragment|O .|O
A|O few|O other|O patients|O and|O families|O with|O features|O similar|O to|O our|O proband|O have|O been|O described|O previously|O and|O considered|O to|O have|O autosomal|O recessive|O MED|O EDM4|O ,|O McKusick|O 226900|O .|O
We|O have|O analysed|O 60|O families|O with|O a|O history|O of|O breast|B-DISE and|I-DISE /|I-DISE or|I-DISE ovarian|I-DISE cancer|I-DISE for|O germline|O mutations|O in|O BRCA1|O .|O
Since|O continuing|O advances|O in|O molecular|O methodologies|O have|O dramatically|O accelerated|O the|O rate|O in|O which|O new|O mutations|O are|O being|O identified|O and|O characterized|O ,|O this|O register|O of|O mutations|O will|O be|O updated|O periodically|O .|O .|O
Affected|O human|O tissues|O are|O rarely|O available|O to|O further|O examine|O this|O hypothesis|O .|O
Thus|O ,|O it|O appears|O that|O severe|O G6PD|B-DISE deficiency|I-DISE affects|O adversely|O the|O proliferation|O or|O the|O survival|O of|O nucleated|O blood|O cells|O and|O that|O this|O phenotypic|O characteristic|O is|O critical|O during|O hematopoiesis|B-DISE .|O .|O
The|O subjects|O were|O followed|O for|O up|O to|O four|O years|O .|O
We|O have|O confirmed|O that|O germline|O mutations|O in|O the|O CDH1|O gene|O cause|O familial|B-DISE gastric|I-DISE cancer|I-DISE in|O non|O -|O Maori|O populations|O .|O
The|O puzzling|O linkage|O between|O genetic|O hemochromatosis|B-DISE and|O histocompatibility|O loci|O became|O even|O more|O so|O when|O the|O gene|O involved|O ,|O HFE|O ,|O was|O identified|O .|O
The|O inactivation|O of|O the|O von|B-DISE Hippel|I-DISE -|I-DISE Lindau|I-DISE (|O VHL|B-DISE )|O tumor|O suppressor|O gene|O predisposes|O affected|O individuals|O to|O the|O human|O VHL|B-DISE cancer|I-DISE syndrome|I-DISE and|O is|O associated|O with|O sporadic|O renal|B-DISE cell|I-DISE carcinomas|I-DISE (|O RCC|B-DISE )|O and|O brain|O hemangioblastomas|B-DISE .|O
We|O report|O here|O a|O newly|O identified|O HPRT|O mutation|O in|O a|O Japanese|O patient|O with|O Lesch|B-DISE -|I-DISE Nyhan|I-DISE syndrome|I-DISE .|O
On|O the|O other|O hand|O ,|O hereditary|O mutations|O of|O TP57KIP2|O ,|O P15INK4B|O ,|O and|O P16INK4A|O ,|O which|O affect|O the|O cell|O cycle|O similar|O to|O TP53|O ,|O were|O observed|O in|O some|O types|O of|O cancer|B-DISE .|O
Using|O a|O transgenic|O DMPK|O -|O overexpressor|O mouse|O model|O ,|O we|O demonstrate|O here|O that|O the|O endogenous|O mouse|O DMPK|O gene|O and|O the|O human|O DMPK|O transgene|O produce|O six|O major|O alternatively|O spliced|O mRNAs|O which|O have|O almost|O identical|O cell|O type|O -|O dependent|O distribution|O frequencies|O and|O expression|O patterns|O .|O
Pendred|B-DISE syndrome|I-DISE is|O the|O most|O common|O form|O of|O syndromic|O deafness|B-DISE and|O characterized|O by|O congenital|B-DISE sensorineural|I-DISE hearing|I-DISE loss|I-DISE and|O goitre|B-DISE .|O
These|O results|O show|O that|O the|O former|O five|O mutations|O account|O for|O more|O than|O 90|O %|O of|O G6PD|B-DISE deficiency|I-DISE cases|O in|O Taiwan|O .|O
Two|O distinct|O loci|O have|O been|O proposed|O for|O aniridia|B-DISE ;|O AN1|O for|O autosomal|B-DISE dominant|I-DISE aniridia|I-DISE on|O chromosome|O 2p|O and|O AN2|O for|O the|O aniridia|O in|O the|O WAGR|B-DISE contiguous|I-DISE gene|I-DISE syndrome|I-DISE on|O chromosome|O 11p13|O .|O
A|O single|O base|O pair|O insertion|O at|O nucleotide|O position|O 821|O in|O exon|O 6|O resulted|O in|O the|O generation|O of|O a|O premature|O stop|O codon|O in|O the|O last|O patient|O .|O
We|O conclude|O this|O single|O -|O base|O deletion|O causes|O defective|O Kx|O protein|O ,|O which|O is|O responsible|O for|O the|O McLeod|B-DISE phenotype|I-DISE in|O this|O patient|O .|O .|O
Two|O products|O shorter|O than|O the|O wild|O -|O type|O product|O were|O amplified|O .|O
We|O have|O generated|O a|O mouse|O model|O for|O ataxia|B-DISE -|I-DISE telangiectasia|I-DISE by|O using|O gene|O targeting|O to|O generate|O mice|O that|O do|O not|O express|O the|O Atm|O protein|O .|O
In|O addition|O the|O analysis|O revealed|O 5|O polymorphisms|O useful|O for|O internal|O control|O .|O .|O
In|O ten|O independent|O cases|O of|O Denys|B-DISE -|I-DISE Drash|I-DISE syndrome|I-DISE ,|O point|O mutations|O in|O the|O zinc|O finger|O domains|O of|O one|O WT1|O gene|O copy|O were|O found|O .|O
The|O 1376|O G|O -|O -|O -|O -|O T|O mutation|O seems|O to|O be|O the|O dominant|O allele|O that|O causes|O G6PD|B-DISE deficiency|I-DISE in|O Taiwan|O .|O
Deletion|O of|O the|O SNRPN|O promoter|O /|O exon|O 1|O region|O (|O the|O PWS|O IC|O element|O )|O appears|O to|O impair|O the|O establishment|O of|O the|O paternal|O imprint|O in|O the|O male|O germ|O line|O and|O leads|O to|O PWS|B-DISE .|O
In|O the|O first|O family|O ,|O the|O extra|O copy|O was|O first|O detected|O by|O the|O presence|O of|O heterozygosity|O of|O the|O AhaII|B-DISE dimorphism|I-DISE within|O the|O PLP|O gene|O .|O
This|O approach|O now|O allows|O HPRT|O mutation|O detection|O in|O 50|O percent|O of|O the|O cases|O of|O Lesch|B-DISE -|I-DISE Nyhan|I-DISE syndrome|I-DISE .|O
The|O disease|O locus|O was|O assigned|O to|O chromosome|O 9|O and|O the|O disease|O gene|O ,|O STM7|O /|O X25|O ,|O has|O been|O isolated|O .|O
The|O levels|O of|O p19|O /|O nm23|O were|O compared|O between|O resting|O and|O mitotically|O stimulated|O normal|O human|O PBLs|O and|O in|O leukemia|B-DISE cells|O .|O
Recent|O findings|O of|O a|O nonsense|O mutation|O in|O the|O rd|O mouse|O PDE|O beta|O -|O subunit|O gene|O (|O Pdeb|O )|O prompted|O us|O to|O investigate|O the|O chromosome|O locations|O of|O the|O mouse|O and|O human|O genes|O .|O
A|O survey|O instrument|O is|O used|O to|O assess|O temperature|O regulation|O characteristics|O in|O children|O with|O Prader|B-DISE -|I-DISE Willi|I-DISE syndrome|I-DISE (|O PWS|B-DISE )|O compared|O to|O 3|O control|O groups|O :|O sibs|O of|O PWS|B-DISE patients|O (|O SIB|O )|O ,|O neurodevelopmentally|O handicapped|O children|O (|O ND|O )|O ,|O and|O age|O and|O gender|O matched|O well|O children|O WC|O .|O
Phenylketonuria|B-DISE (|O PKU|B-DISE )|O and|O mild|O hyperphenylalaninemia|B-DISE (|O MHP|B-DISE )|O are|O allelic|O disorders|O caused|O by|O mutations|O in|O the|O gene|O encoding|O phenylalanine|O hydroxylase|O PAH|O .|O
In|O the|O 14|O later|O patients|O ,|O we|O identified|O truncating|O mutations|O in|O 9|O patients|O (|O 64|O %|O )|O using|O PTT|O only|O .|O
OBJECTIVE|O :|O To|O determine|O whether|O hereditary|B-DISE ovarian|I-DISE cancers|I-DISE have|O distinct|O clinical|O and|O pathological|O features|O compared|O with|O sporadic|O (|O nonhereditary|O )|O ovarian|O cancers|O .|O
As|O part|O of|O a|O strategy|O to|O clone|O the|O HD|O gene|O on|O the|O basis|O of|O its|O chromosomal|O location|O ,|O we|O isolated|O genomic|O DNA|O from|O the|O HD|O region|O as|O a|O set|O of|O overlapping|O yeast|O artificial|O chromosome|O (|O YAC|O )|O clones|O .|O
Apparent|O compensatory|O mechanisms|O which|O come|O into|O play|O when|O serum|O albumin|O is|O low|O include|O prolonged|O half|O -|O life|O of|O albumin|O and|O transferrin|O ,|O an|O increase|O in|O serum|O globulins|O ,|O beta|O lipoprotein|O ,|O and|O glycoproteins|O ,|O arterial|O hypotension|O with|O reduced|O capillary|O hydrostatic|O pressure|O ,|O and|O the|O ability|O to|O respond|O with|O rapid|O sodium|O and|O chloride|O diuresis|O in|O response|O to|O small|O volume|O changes|O .|O
We|O studied|O cultured|O skin|O fibroblasts|O from|O 2|O brothers|O with|O Pelizaeus|B-DISE -|I-DISE Merzbacher|I-DISE disease|I-DISE who|O exhibited|O no|O detectable|O exonic|O mutation|O of|O the|O PLP|O gene|O .|O
Previous|O analyses|O have|O revealed|O that|O the|O pattern|O of|O germline|O mutations|O in|O the|O factor|O IX|O gene|O (|O F9|O )|O is|O similar|O among|O a|O variety|O of|O ethnically|O and|O geographically|O diverse|O populations|O and|O compatible|O with|O the|O ancient|O pattern|O that|O has|O shaped|O the|O mammalian|O genome|O .|O
The|O resultant|O PAX3|O -|O FKHR|O gene|O possesses|O transforming|O properties|O ;|O however|O ,|O the|O effects|O of|O this|O chimeric|O oncogene|O on|O gene|O expression|O are|O largely|O unknown|O .|O
Using|O an|O immunocytochemical|O technique|O on|O blood|O smears|O ,|O we|O recently|O developed|O a|O novel|O test|O for|O identification|O of|O patients|O with|O fragile|B-DISE X|I-DISE syndrome|I-DISE .|O
We|O previously|O identified|O the|O first|O causative|O mutations|O in|O a|O nonconsanguineous|O Swiss|O family|O ;|O the|O 4|O affected|O persons|O have|O homozygous|O deletions|O of|O approximately|O 11|O kb|O of|O the|O fibrinogen|O alpha|O (|O FGA|O )|O gene|O .|O
In|O contrast|O ,|O WT1|O missense|O mutations|O ,|O associated|O with|O male|O pseudohermaphroditism|B-DISE in|O Denys|B-DISE -|I-DISE Drash|I-DISE syndrome|I-DISE ,|O fail|O to|O synergize|O with|O SF|O -|O 1|O .|O
Examination|O on|O G6PD|B-DISE deficiency|I-DISE in|O 349|O patients|O of|O Shekii|O district|O hospital|O (|O Azerbaijan|O )|O revealed|O 16|O hemi|O -|O ,|O 4|O homo|O -|O and|O 9|O heterozygotic|O carriers|O of|O the|O defect|O .|O
This|O suggests|O that|O pendrin|O in|O fact|O may|O not|O be|O a|O sulfate|O transporter|O ,|O and|O emphasizes|O the|O importance|O of|O functional|O studies|O on|O this|O novel|O protein|O .|O .|O
The|O analysis|O of|O diseases|O linked|O specifically|O with|O WT1|O mutations|O ,|O such|O as|O Denys|B-DISE -|I-DISE Drash|I-DISE syndrome|I-DISE (|O DDS|B-DISE )|O ,|O can|O provide|O valuable|O insight|O concerning|O the|O role|O of|O WT1|O in|O development|O and|O disease|O .|O
No|O protein|O was|O detected|O in|O two|O individuals|O with|O severe|O WAS|B-DISE .|O
We|O found|O that|O the|O immune|O -|O labeled|O colloidal|O gold|O particles|O were|O localized|O on|O the|O nucleoplasmic|O surface|O of|O the|O inner|O nuclear|O membrane|O ,|O but|O not|O on|O the|O nuclear|O pore|O .|O
Thus|O ,|O CDH1|O should|O be|O investigated|O as|O a|O cause|O of|O inherited|O susceptibility|O to|O both|O gastric|B-DISE and|I-DISE colorectal|I-DISE cancers|I-DISE .|O .|O
It|O lacks|O the|O entire|O large|O domain|O of|O spectrin|O -|O like|O repeats|O and|O the|O actin|O -|O binding|O N|O -|O terminal|O domain|O of|O dystrophin|O .|O
Indeed|O ,|O a|O six|O -|O marker|O haplotype|O extending|O over|O a|O region|O of|O 5|O .|O 5|O cM|O was|O observed|O in|O all|O families|O .|O
This|O first|O case|O of|O recurrent|O meningitis|B-DISE in|O a|O white|O patient|O with|O complete|O C9|B-DISE deficiency|I-DISE suggests|O that|O this|O complement|O defect|O may|O also|O be|O a|O risk|O factor|O for|O bacterial|B-DISE ,|I-DISE especially|I-DISE neisserial|I-DISE ,|I-DISE infections|I-DISE .|O .|O
The|O mutation|O can|O be|O assayed|O easily|O by|O amplification|O and|O digestion|O with|O Msel|O .|O
Nineteen|O of|O the|O missense|O mutations|O resulted|O in|O a|O severe|O reduction|O of|O FALDH|O enzyme|O catalytic|O activity|O when|O expressed|O in|O mammalian|O cells|O ,|O but|O one|O mutation|O 798G|O -|O -|O >|O C|O K266N|O seemed|O to|O have|O a|O greater|O effect|O on|O mRNA|O stability|O .|O
Although|O patients|O with|O the|O N288D|O mutation|O suffered|O from|O severe|O hyperglycerolemia|B-DISE ,|O they|O were|O apparently|O otherwise|O healthy|O .|O
A|O total|O of|O 2|O ,|O 952|O single|O sperm|O from|O the|O six|O donors|O were|O analyzed|O .|O
Patients|O present|O with|O partial|B-DISE ,|I-DISE then|I-DISE generalized|I-DISE seizures|I-DISE ,|O with|O onset|O at|O age|O three|O months|O .|O
However|O ,|O because|O effective|O treatments|O should|O begin|O before|O the|O onset|O of|O severe|O neurologic|B-DISE symptoms|I-DISE ,|O SEPs|O and|O MEPs|O should|O be|O considered|O to|O evaluate|O the|O effectiveness|O of|O other|O experimental|O treatments|O in|O the|O patient|O with|O a|O negative|O brain|O MRI|O .|O .|O
METHODS|O :|O We|O examined|O genomic|O DNA|O from|O 83|O (|O for|O BRCA1|O 185delAG|O )|O or|O 82|O (|O for|O BRCA2|O 6174delT|O )|O Ashkenazi|O Jewish|O prostate|B-DISE cancer|I-DISE patients|O ,|O most|O of|O whom|O were|O treated|O at|O a|O relatively|O young|O age|O ,|O for|O the|O most|O common|O germline|O mutation|O in|O each|O gene|O seen|O in|O the|O Ashkenazi|O population|O .|O
In|O 28|O families|O with|O G6PD|B-DISE deficiency|I-DISE living|O in|O 3|O settlements|O of|O Shekii|O district|O of|O Azerbaijan|O 11|O G6PD|O variants|O of|O II|O and|O III|O classes|O differing|O by|O kinetic|O properties|O were|O identified|O according|O WHO|O program|O .|O 9|O of|O them|O are|O characterized|O with|O the|O same|O electrophoretic|O mobility|O .|O
The|O majority|O (|O 81|O %|O )|O of|O the|O breast|B-DISE -|I-DISE ovarian|I-DISE cancer|I-DISE families|O were|O due|O to|O BRCA1|O ,|O with|O most|O others|O (|O 14|O %|O )|O due|O to|O BRCA2|O .|O
An|O unexpectedly|O low|O proportion|O of|O the|O breast|B-DISE -|I-DISE ovarian|I-DISE cancer|I-DISE families|O were|O estimated|O to|O be|O linked|O to|O BRCA1|O ,|O which|O could|O be|O due|O to|O a|O founder|O effect|O in|O the|O Dutch|O population|O .|O
Hereditary|B-DISE hemochromatosis|I-DISE (|O HH|B-DISE )|O is|O a|O common|O autosomal|O recessive|O disorder|O characterized|O by|O tissue|O iron|O deposition|O secondary|O to|O excessive|O dietary|O iron|O absorption|O .|O
Using|O similar|O methods|O ,|O we|O now|O find|O that|O C5|B-DISE deficiency|I-DISE in|O each|O of|O five|O different|O mouse|O strains|O (|O AKR|O ,|O SWR|O ,|O DBA|O /|O 2J8|O A|O /|O HeJ|O and|O B10|O .|O D2|O /|O old|O line|O )|O is|O due|O to|O a|O failure|O in|O secretion|O of|O C5|O protein|O and|O not|O to|O a|O failure|O in|O biosynthesis|O of|O pro|O -|O C5|O .|O .|O
Molecular|O ,|O kinetic|O ,|O and|O functional|O studies|O were|O carried|O out|O on|O erythrocytes|O and|O leukocytes|O in|O a|O Spanish|O male|O with|O G6PD|B-DISE deficiency|I-DISE ,|O congenital|B-DISE nonspherocytic|I-DISE hemolytic|I-DISE anemia|I-DISE (|O CNSHA|B-DISE )|O ,|O and|O increased|O susceptibility|O to|O infections|B-DISE .|O
Here|O we|O describe|O two|O new|O families|O in|O which|O males|O affected|O with|O PMD|B-DISE were|O found|O to|O have|O a|O copy|O of|O PLP|O on|O the|O short|O arm|O of|O the|O X|O chromosome|O ,|O in|O addition|O to|O a|O normal|O copy|O on|O Xq22|O .|O
Aside|O from|O showing|O that|O G|O to|O T|O change|O at|O nt|O 1376|O is|O the|O most|O common|O mutation|O ,|O our|O research|O indicates|O that|O nt|O 493|O mutation|O is|O a|O frequent|O mutation|O among|O Chinese|O in|O Taiwan|O .|O
These|O intersex|O differences|O in|O colorectal|B-DISE cancer|I-DISE risks|O have|O implications|O for|O screening|O programmes|O and|O for|O attempts|O to|O identify|O colorectal|O cancer|O susceptibility|O modifiers|O .|O .|O
This|O study|O utilizes|O cDNA|O microarrays|O to|O elucidate|O the|O pattern|O of|O gene|O expression|O induced|O by|O an|O oncogenic|O transcription|O factor|O and|O demonstrates|O the|O profound|O myogenic|O properties|O of|O PAX3|O -|O FKHR|O in|O NIH|O 3T3|O cells|O .|O .|O
Electrophoresis|O of|O cell|O extracts|O revealed|O the|O absence|O of|O the|O A|O form|O of|O acid|O lipase|O ,|O consistent|O with|O the|O diagnosis|O of|O Wolman|B-DISE disease|I-DISE .|O
Attempts|O to|O define|O the|O clinical|O significance|O of|O BRCA|O mutation|O status|O in|O ovarian|B-DISE cancer|I-DISE have|O produced|O conflicting|O results|O ,|O especially|O regarding|O survival|O .|O
CONCLUSIONS|O :|O It|O is|O suggested|O that|O coexpression|O of|O hbeta|O (|O 1|O )|O exposes|O a|O more|O severe|O functional|O defect|O that|O results|O in|O a|O greater|O overlap|O in|O the|O relationship|O between|O channel|O inactivation|O and|O activation|O (|O window|O current|O )|O in|O T1620M|O ,|O which|O is|O proposed|O to|O be|O a|O potential|O pathophysiological|O mechanism|O of|O IVF|B-DISE in|O vivo|O .|O
The|O mother|O ,|O who|O has|O aniridia|B-DISE ,|O was|O also|O found|O to|O carry|O a|O deletion|O including|O both|O the|O aniridia|B-DISE candidate|O gene|O (|O AN2|O )|O and|O the|O Wilms|B-DISE tumor|I-DISE predisposition|O gene|O WT1|O .|O
Mechanisms|O by|O which|O abnormal|O sulfate|O transport|O could|O deleteriously|O affect|O iodide|O organification|O have|O been|O proposed|O .|O
An|O mRNA|O -|O containing|O extract|O of|O cultured|O fibroblasts|O obtained|O from|O one|O of|O the|O probands|O was|O used|O as|O a|O template|O to|O amplify|O the|O coding|O sequence|O of|O the|O hexosaminidase|O A|O (|O Hex|O A|O )|O alpha|O -|O subunit|O .|O
Mutations|O of|O APC|O appear|O to|O initiate|O sporadic|O and|O inherited|O forms|O of|O human|O colorectal|B-DISE cancer|I-DISE .|O
Complex|O formation|O induces|O the|O rapid|O degradation|O of|O betacatenin|O .|O
Classical|O Phenylketonuria|B-DISE (|O PKU|B-DISE )|O is|O an|O autosomal|O recessive|O human|O genetic|O disorder|O caused|O by|O a|O deficiency|O of|O hepatic|O phenylalanine|O hydroxylase|O PAH|O .|O
Familial|B-DISE neurohypophyseal|I-DISE diabetes|I-DISE insipidus|I-DISE (|O FNDI|B-DISE )|O is|O an|O inherited|O deficiency|B-DISE of|I-DISE the|I-DISE hormone|I-DISE arginine|O vasopressin|O (|O AVP|O )|O and|O is|O transmitted|O as|O an|O autosomal|O dominant|O trait|O .|O
METHODS|O :|O An|O alteration|O in|O CYP27|O of|O the|O proband|O was|O searched|O for|O by|O polymerase|O chain|O reaction|O -|O single|O strand|O conformation|O polymorphism|O (|O PCR|O -|O SSCP|O )|O analysis|O and|O subsequent|O sequencing|O .|O
The|O differential|O diagnosis|O of|O the|O genetic|O bleeding|O disorders|O ,|O hemophilia|B-DISE A|I-DISE and|O von|B-DISE Willebrand|I-DISE disease|I-DISE ,|O is|O occasionally|O confounded|O by|O the|O close|O molecular|O relationship|O of|O coagulation|O factor|O VIII|O and|O von|O Willebrand|O factor|O vWF|O .|O
By|O use|O of|O this|O strategy|O ,|O carrier|O status|O was|O accurately|O assessed|O in|O all|O seven|O at|O -|O risk|O females|O tested|O ,|O whereas|O enzymatic|O dosages|O failed|O to|O diagnose|O or|O exclude|O heterozygosity|O .|O .|O
In|O addition|O ,|O we|O isolated|O the|O ends|O of|O the|O human|O DNA|O inserts|O of|O most|O of|O the|O YAC|O clones|O to|O assist|O in|O the|O construction|O of|O the|O contig|O .|O
We|O have|O retrospectively|O analyzed|O 837|O random|O anonymized|O dried|O blood|O spot|O (|O DBS|O )|O samples|O from|O neonatal|O screening|O programs|O in|O Scandinavia|O for|O mutations|O in|O HFE|O ,|O the|O candidate|O gene|O for|O hemochromatosis|B-DISE .|O
In|O addition|O to|O loss|O of|O heterozygosity|O (|O LOH|O )|O at|O the|O APC|O locus|O in|O 30|O tumors|B-DISE ,|O 43|O other|O somatic|O mutations|O were|O detected|O .|O
Recently|O ,|O mutations|O of|O the|O cathepsin|O C|O gene|O have|O been|O identified|O as|O the|O underlying|O genetic|O defect|O in|O PLS|B-DISE .|O
He|O also|O has|O a|O defect|B-DISE of|I-DISE the|I-DISE anterior|I-DISE midline|I-DISE scalp|I-DISE with|O involvement|O of|O the|O frontal|O bone|O as|O documented|O by|O a|O computed|O tomography|O (|O CT|O )|O scan|O .|O
Two|O siblings|O with|O chronic|O discoid|B-DISE lupus|I-DISE erythematosus|I-DISE and|O several|O family|O members|O were|O found|O with|O heterozygous|O C2|B-DISE deficiency|I-DISE .|O
To|O compare|O somatic|O and|O germline|O mutations|O ,|O we|O used|O the|O VHL|B-DISE database|O ,|O which|O includes|O 507|O mutations|O .|O
To|O identify|O additional|O imprinted|O genes|O that|O could|O contribute|O to|O the|O PWS|B-DISE phenotype|O and|O to|O understand|O the|O regional|O control|O of|O imprinting|O in|O 15q11|O -|O q13|O ,|O we|O have|O constructed|O an|O imprinted|O transcript|O map|O of|O the|O PWS|O -|O AS|O deletion|O interval|O .|O
A|O gene|O mutated|O in|O the|O human|O genetic|O disorder|O ataxia|B-DISE -|I-DISE telangiectasia|I-DISE (|O A|B-DISE -|I-DISE T|I-DISE )|O ,|O ATM|O ,|O was|O recently|O identified|O by|O positional|O cloning|O .|O
These|O results|O provide|O further|O evidence|O that|O inherited|B-DISE breast|I-DISE and|I-DISE ovarian|I-DISE cancer|I-DISE can|O occur|O as|O a|O consequence|O of|O a|O wide|O array|O of|O BRCA1|O mutations|O .|O
OBJECTIVE|O :|O To|O examine|O the|O relationship|O of|O phenylalanine|O hydroxylase|O (|O PAH|O )|O genotypes|O to|O biochemical|O phenotype|O and|O cognitive|O development|O in|O maternal|O phenylketonuria|B-DISE PKU|B-DISE .|O
Skin|O was|O seborrhoeic|O in|O adolescent|O and|O adult|O patients|O ,|O with|O erythema|B-DISE of|O the|O facial|O skin|O already|O common|O in|O childhood|O .|O
Mutant|O proteins|O ,|O except|O for|O C79S|O and|O C79T|O ,|O were|O destabilized|O and|O detected|O as|O insoluble|O precursor|O forms|O while|O the|O C79S|O and|O C79T|O mutants|O were|O of|O a|O soluble|O mature|O size|O .|O
METHODS|O :|O Ten|O patients|O with|O XLRS|B-DISE underwent|O full|O ophthalmologic|O examination|O ,|O including|O slitlamp|O biomicroscopy|O and|O dilated|O funduscopy|O .|O
Those|O who|O were|O untreated|O or|O treated|O late|O had|O lower|O than|O average|O IQ|O scores|O for|O their|O group|O of|O mutation|O combinations|O .|O
Because|O LpA|O -|O I|O has|O been|O proposed|O to|O be|O more|O protective|O than|O LpA|O -|O I|O :|O A|O -|O II|O against|O atherosclerosis|B-DISE ,|O this|O selective|O effect|O on|O the|O metabolism|O of|O LpA|O -|O I|O :|O A|O -|O II|O may|O provide|O a|O potential|O explanation|O why|O patients|O with|O classic|O LCAT|B-DISE deficiency|I-DISE and|O Fish|B-DISE -|I-DISE eye|I-DISE disease|I-DISE are|O not|O at|O increased|O risk|O for|O premature|O atherosclerosis|B-DISE despite|O markedly|O decreased|O levels|O of|O HDL|O cholesterol|O and|O apoA|O -|O I|O .|O .|O
In|O patients|O with|O fragile|B-DISE X|I-DISE syndrome|I-DISE ,|O the|O expanded|O CGG|O triplet|O repeats|O are|O hypermethylated|O and|O the|O expression|O of|O the|O FMR1|O gene|O is|O repressed|O ,|O which|O leads|O to|O the|O absence|O of|O FMR1|O protein|O (|O FMRP|O )|O and|O subsequent|O mental|B-DISE retardation|I-DISE .|O
Twenty|O -|O three|O different|O mutations|O including|O 12|O novel|O ones|O were|O identified|O in|O 28|O patients|O .|O
Thus|O ,|O the|O occurrence|O of|O sensorineural|B-DISE deafness|I-DISE in|O this|O patient|O extends|O considerably|O the|O phenotypic|O range|O of|O piebaldism|B-DISE due|O to|O KIT|O gene|O mutation|O in|O humans|O and|O tightens|O the|O clinical|O similarity|O between|O piebaldism|B-DISE and|O the|O various|O forms|O of|O Waardenburg|B-DISE syndrome|I-DISE .|O .|O
The|O clinical|O significance|O of|O this|O second|O mutation|O is|O such|O that|O it|O appears|O to|O predispose|O 1|O %|O -|O 2|O %|O of|O compound|O heterozygotes|O to|O expression|O of|O the|O disease|B-DISE .|O
However|O ,|O in|O a|O small|O subset|O of|O hemizygous|O males|O who|O suffer|O from|O chronic|O nonspherocytic|O hemolytic|B-DISE anemia|I-DISE ,|O the|O underlying|O mutations|O (|O designated|O class|O I|O )|O cause|O more|O -|O severe|O G6PD|B-DISE deficiency|I-DISE ,|O and|O this|O might|O provide|O an|O opportunity|O for|O selection|O in|O heterozygous|O females|O during|O development|O .|O
In|O this|O manuscript|O ,|O we|O report|O the|O characterization|O of|O MAGEL2|O and|O its|O mouse|O homologue|O Magel2|O .|O
The|O Arg610Gln|O mutation|O represents|O the|O first|O case|O of|O a|O mutation|O in|O the|O PH|O domain|O of|O the|O FGD1|O gene|O and|O additional|O evidence|O that|O mutations|O in|O PH|O domains|O can|O be|O associated|O to|O human|O diseases|O .|O .|O
Here|O we|O report|O in|O vivo|O evidence|O of|O impaired|O mitochondrial|O respiration|O in|O skeletal|O muscle|O of|O FRDA|B-DISE patients|O .|O
Even|O though|O we|O found|O no|O gross|O cerebellar|B-DISE degeneration|I-DISE in|O older|O Atm|O (|O y|O /|O y|O )|O animals|O ,|O ectopic|O and|O abnormally|O differentiated|O Purkinje|O cells|O were|O apparent|O in|O mutant|O mice|O of|O all|O ages|O .|O
CONCLUSIONS|O :|O DCC|O is|O a|O prognostic|O marker|O in|O patients|O with|O stage|B-DISE II|I-DISE or|I-DISE stage|I-DISE III|I-DISE colorectal|I-DISE cancer|I-DISE .|O
A|O translocation|O involving|O 14q|O was|O found|O in|O clones|O obtained|O from|O seven|O of|O the|O eight|O patients|O whereas|O a|O ring|O 14|O chromosome|O was|O found|O in|O a|O clone|O obtained|O from|O the|O other|O .|O
Sequencing|O of|O exon|O 3|O of|O the|O beta|O -|O catenin|O gene|O (|O CTNNB1|O )|O revealed|O an|O activating|O mutation|O in|O one|O of|O the|O tumor|B-DISE samples|O .|O
A|O maximum|O two|O -|O point|O lod|O score|O of|O 7|O .|O 13|O (|O theta|O =|O 0|O .|O 00|O )|O for|O marker|O D2S2110|O and|O a|O maximum|O cumulative|O multipoint|O lod|O score|O of|O 9|O .|O 16|O for|O marker|O D2S2110|O were|O observed|O ,|O further|O supporting|O linkage|O to|O chromosome|O 2p13|O .|O
To|O evaluate|O the|O role|O of|O the|O HMG|O I|O -|O C|O component|O ,|O the|O three|O DNA|O -|O binding|O domains|O of|O HMG|O I|O -|O C|O have|O now|O been|O expressed|O in|O transgenic|O mice|O .|O
Pendred|B-DISE syndrome|I-DISE is|O a|O recessive|B-DISE inherited|I-DISE disorder|I-DISE that|O consists|O of|O developmental|B-DISE abnormalities|I-DISE of|I-DISE the|I-DISE cochlea|I-DISE ,|O sensorineural|B-DISE hearing|I-DISE loss|I-DISE ,|O and|O diffuse|B-DISE thyroid|I-DISE enlargement|I-DISE goiter|B-DISE .|O
We|O report|O on|O the|O first|O patient|O identified|O with|O myotonic|B-DISE dystrophy|I-DISE and|O Duchenne|B-DISE muscular|I-DISE dystrophy|I-DISE DMD|B-DISE .|O
We|O identified|O five|O additional|O copies|O of|O the|O LCR22|O on|O 22q11|O that|O may|O mediate|O other|O rearrangements|O leading|O to|O disease|O .|O .|O
We|O were|O unable|O to|O find|O a|O mutation|O in|O one|O patient|O despite|O complete|O sequencing|O of|O the|O genomic|O sequence|O of|O the|O gene|O .|O
Familial|B-DISE Mediterranean|I-DISE fever|I-DISE (|O FMF|B-DISE )|O is|O a|O recessively|O inherited|O disorder|O that|O is|O common|O in|O patients|O of|O Armenian|O ancestry|O .|O
For|O both|O sexes|O combined|O ,|O the|O penetrances|O at|O age|O 60|O years|O for|O all|O cancers|B-DISE and|O for|O colorectal|B-DISE cancer|I-DISE were|O 0|O .|O 86|O and|O 0|O .|O 57|O ,|O respectively|O .|O
To|O support|O this|O idea|O further|O ,|O we|O identified|O a|O family|O that|O carries|O an|O interstitial|O duplication|O of|O the|O same|O 3|O Mb|O region|O that|O is|O deleted|O in|O VCFS|B-DISE /|O DGS|B-DISE patients|O .|O
In|O humans|O ,|O alteration|O of|O the|O tumor|O suppressor|O gene|O ,|O APC|O ,|O causes|O adenomatous|B-DISE polyposis|I-DISE coli|I-DISE ,|O a|O condition|O causing|O predisposition|O to|O colorectal|B-DISE cancer|I-DISE .|O
The|O gene|O responsible|O for|O Huntington|B-DISE disease|I-DISE has|O been|O localized|O to|O a|O 2|O .|O 5|O million|O base|O pair|O (|O Mb|O )|O region|O between|O the|O loci|O D4S10|O and|O D4S168|O on|O the|O short|O arm|O of|O chromosome|O 4|O .|O
APC|O is|O not|O ,|O therefore|O ,|O a|O classical|O tumor|B-DISE suppressor|O .|O
We|O studied|O the|O relationship|O between|O the|O autosomal|O recessive|O trait|O familial|B-DISE Mediterranean|I-DISE fever|I-DISE (|O FMF|B-DISE )|O and|O the|O serum|O amyloid|O A|O (|O SAA|O )|O genes|O by|O comparing|O alleles|O of|O a|O highly|O polymorphic|O dinucleotide|O repeat|O and|O a|O conventional|O restriction|O fragment|O length|O polymorphism|O (|O RFLP|O )|O in|O the|O SAA|O gene|O cluster|O in|O Israeli|O FMF|B-DISE kindreds|O .|O
We|O therefore|O hypothesized|O that|O A|B-DISE -|I-DISE T|I-DISE is|O due|O to|O oxidative|O damage|O resulting|O from|O loss|O of|O function|O of|O the|O A|O -|O T|O gene|O product|O .|O
Our|O results|O suggest|O that|O a|O gene|O at|O 17p11|O .|O 2|O -|O 11|O .|O 1|O ,|O together|O with|O the|O VWS|O gene|O at|O 1p32|O -|O 41|O ,|O enhances|O the|O probability|O of|O CP|B-DISE in|O an|O individual|O carrying|O the|O two|O at|O -|O risk|O genes|O .|O
In|O two|O of|O these|O families|O we|O used|O a|O functional|O assay|O to|O demonstrate|O an|O almost|O total|O loss|O of|O cathepsin|O C|O activity|O in|O PLS|B-DISE patients|O and|O reduced|O activity|O in|O obligate|O carriers|O .|O .|O
We|O performed|O direct|O sequencing|O of|O the|O PCR|O products|O of|O each|O NIS|O (|O sodium|O /|O iodide|O symporter|O )|O gene|O exon|O with|O flanking|O introns|O amplified|O from|O genomic|O DNA|O extracted|O from|O peripheral|O blood|O cells|O of|O the|O patients|O .|O
Linkage|O studies|O using|O restriction|O fragment|O length|O polymorphisms|O were|O conducted|O in|O the|O X|O -|O linked|O disorder|O ,|O choroideremia|B-DISE ,|O designated|O TCD|O for|O Progressive|O Tapeto|O -|O Choroidal|B-DISE Dystrophy|I-DISE .|O
We|O have|O identified|O a|O male|O patient|O with|O BFLS|B-DISE -|O like|O features|O and|O a|O duplication|O ,|O 46|O ,|O Y|O ,|O dup|O X|O (|O q26q28|O )|O ,|O inherited|O from|O his|O phenotypically|O normal|O mother|O .|O
Nevertheless|O ,|O the|O above|O DGGE|O approach|O has|O incidentally|O led|O to|O the|O identification|O of|O a|O common|O polymorphism|O in|O exon|O 13|O .|O
These|O data|O suggest|O that|O BRCA1|O is|O important|O for|O the|O cellular|O responses|O to|O DNA|O damage|O that|O are|O mediated|O by|O the|O hRad50|O -|O hMre11|O -|O p95|O complex|O .|O .|O
We|O present|O a|O child|O in|O whom|O phenylketonuria|B-DISE was|O apparently|O caused|O by|O homozygosity|O for|O the|O mutation|O E390G|O in|O exon|O 11|O of|O the|O phenylalanine|O hydroxylase|O (|O PAH|O )|O gene|O .|O
Expression|O of|O recombinant|O forms|O of|O the|O mutant|O RANK|O proteins|O revealed|O perturbations|O in|O expression|O levels|O and|O lack|O of|O normal|O cleavage|O of|O the|O signal|O peptide|O .|O
These|O results|O show|O that|O formation|O of|O preassociated|O receptor|O complexes|O is|O necessary|O for|O Fas|O signaling|O and|O dominant|O interference|O in|O human|O disease|O .|O .|O
These|O results|O provide|O evidence|O that|O the|O DM|B-DISE mutation|O acts|O in|O cis|O to|O reduce|O protein|O production|O (|O consistent|O with|O DMPK|O haploinsufficiency|O )|O and|O in|O trans|O as|O a|O '|O riboregulator|O '|O to|O inhibit|O myogenesis|O .|O .|O
We|O also|O suggest|O that|O C9|B-DISE deficiency|I-DISE may|O be|O more|O common|O among|O Caucasians|O than|O has|O been|O reported|O .|O .|O
Our|O results|O provide|O evidence|O of|O a|O direct|O role|O for|O WT1|O in|O Denys|B-DISE -|I-DISE Drash|I-DISE syndrome|I-DISE and|O thus|O urogenital|O system|O development|O .|O .|O
Our|O findings|O revealed|O the|O following|O characteristics|O of|O the|O germ|O -|O line|O mutations|O of|O APC|O :|O 1|O the|O great|O majority|O of|O the|O mutations|O were|O found|O to|O truncate|O the|O APC|O product|O ;|O 2|O almost|O all|O of|O the|O mutations|O were|O located|O within|O the|O first|O half|O of|O the|O coding|O region|O ;|O 3|O no|O correlation|O was|O observed|O between|O the|O locations|O of|O germ|O -|O line|O mutations|O and|O extracolonic|O manifestations|O in|O FAP|B-DISE patients|O ;|O 4|O more|O than|O 80|O %|O of|O base|O substitutions|O in|O the|O APC|O gene|O were|O from|O cytosine|O to|O other|O nucleotides|O ,|O nearly|O one|O -|O third|O of|O which|O occurred|O at|O the|O GpG|O site|O .|O
We|O performed|O a|O sperm|O typing|O study|O of|O five|O MJD|B-DISE patients|O of|O French|O descent|O and|O analysis|O of|O the|O pooled|O data|O shows|O a|O ratio|O of|O mutant|O to|O normal|O alleles|O of|O 379|O :|O 436|O (|O 46|O .|O 5|O :|O 53|O .|O 5|O %|O )|O ,|O which|O does|O not|O support|O meiotic|O segregation|O distortion|O .|O
We|O also|O report|O a|O mutation|O of|O the|O same|O exon|O 6|O CTSC|O codon|O (|O 2126C|O -|O -|O >|O T|O )|O in|O a|O Turkish|O family|O with|O classical|O PLS|B-DISE .|O
CETP|B-DISE deficiency|I-DISE appears|O to|O be|O a|O frequent|O cause|O of|O increased|O HDL|O levels|O in|O the|O population|O of|O Japan|O ,|O possibly|O because|O of|O a|O founder|O effect|O .|O
A|O variant|O of|O FAP|B-DISE is|O attenuated|O adenomatous|B-DISE polyposis|I-DISE coli|I-DISE ,|O which|O results|O from|O germ|O -|O line|O mutations|O in|O the|O 5|O '|O and|O 3|O '|O regions|O of|O the|O APC|O gene|O .|O
We|O have|O used|O single|O strand|O conformation|O polymorphism|O analysis|O to|O study|O the|O 27|O exons|O of|O the|O RB1|O gene|O in|O individuals|O from|O a|O family|O showing|O '|O mild|O '|O expression|O of|O the|O retinoblastoma|B-DISE phenotype|O .|O
Clues|O from|O attenuated|B-DISE polyposis|I-DISE ,|O missense|O germline|O variants|O with|O mild|O disease|O and|O the|O somatic|O mutation|O cluster|O region|O (|O codons|O 1|O ,|O 250|O -|O 1|O ,|O 450|O )|O indicate|O ,|O however|O ,|O that|O APC|O mutations|O might|O not|O result|O in|O simple|O loss|O of|O protein|O function|O .|O
A|O total|O of|O 84|O different|O mutations|O were|O detected|O ,|O and|O complete|O genotype|O was|O obtained|O in|O 199|O individuals|O .|O
The|O proband|O was|O found|O to|O carry|O the|O duplication|O ,|O thus|O confirming|O the|O diagnosis|O of|O Pelizaeus|B-DISE Merzbacher|I-DISE disease|I-DISE ,|O but|O neither|O the|O aunt|O nor|O the|O fetus|O carried|O a|O duplication|O .|O .|O
Chediak|B-DISE -|I-DISE Higashi|I-DISE syndrome|I-DISE (|O CHS|B-DISE )|O is|O an|O inherited|O disorder|O caused|O by|O mutations|O in|O the|O lysosomal|O trafficking|O regulator|O gene|O ,|O LYST|O .|O
The|O phenotypic|O analysis|O of|O the|O family|O members|O ,|O however|O ,|O showed|O that|O glycerol|O levels|O correlated|O with|O impaired|B-DISE glucose|I-DISE metabolism|I-DISE and|I-DISE body|I-DISE -|I-DISE fat|I-DISE distribution|I-DISE .|O
Machado|B-DISE -|I-DISE Joseph|I-DISE disease|I-DISE (|O MJD|B-DISE )|O belongs|O to|O a|O group|O of|O clinically|O and|O genetically|O heterogeneous|B-DISE neurodegenerative|I-DISE disorders|I-DISE characterized|O by|O progressive|B-DISE cerebellar|I-DISE ataxia|I-DISE .|O
Parental|O consanguinity|O is|O a|O characteristic|O of|O many|O cases|O of|O both|O conditions|O .|O
The|O oculocerebrorenal|B-DISE syndrome|I-DISE of|I-DISE Lowe|I-DISE (|O OCRL|B-DISE )|O is|O an|O X|O -|O linked|O disorder|O characterized|O by|O major|O abnormalities|B-DISE of|I-DISE eyes|I-DISE ,|I-DISE nervous|I-DISE system|I-DISE ,|I-DISE and|I-DISE kidneys|I-DISE .|O
Deletions|O and|O other|O abnormalities|O of|O human|O chromosome|O 15q11|O -|O q13|O are|O associated|O with|O two|O developmental|B-DISE disorders|I-DISE ,|O Prader|B-DISE -|I-DISE Willi|I-DISE syndrome|I-DISE (|O PWS|B-DISE )|O and|O Angelman|B-DISE syndrome|I-DISE AS|B-DISE .|O
Their|O parents|O and|O nonaffected|O siblings|O were|O identified|O through|O the|O Population|O Register|O Center|O .|O
Furthermore|O ,|O mutations|O in|O the|O PMP70|O gene|O have|O also|O been|O identified|O in|O two|O Zellweger|B-DISE syndrome|I-DISE patients|O from|O CG1|O ,|O raising|O the|O possibility|O that|O CG1|O patients|O may|O represent|O a|O mixture|O of|O PEX1|B-DISE -|I-DISE deficient|I-DISE and|O PMP70|B-DISE -|I-DISE deficient|I-DISE individuals|O .|O
We|O have|O identified|O WASP|O ,|O the|O protein|O that|O is|O defective|O in|O Wiskott|B-DISE -|I-DISE Aldrich|I-DISE syndrome|I-DISE (|O WAS|B-DISE )|O ,|O as|O a|O novel|O effector|O for|O CDC42Hs|O ,|O but|O not|O for|O the|O other|O Rho|O family|O members|O ,|O Rac|O and|O Rho|O .|O
Myotonic|B-DISE dystrophy|I-DISE (|O DM|B-DISE )|O ,|O the|O most|O prevalent|O muscular|B-DISE disorder|I-DISE in|O adults|O ,|O is|O caused|O by|O (|O CTG|O )|O n|O -|O repeat|O expansion|O in|O a|O gene|O encoding|O a|O protein|O kinase|O (|O DM|O protein|O kinase|O ;|O DMPK|O )|O and|O involves|O changes|O in|O cytoarchitecture|O and|O ion|O homeostasis|O .|O
These|O results|O suggest|O that|O the|O HFE|O gene|O has|O been|O the|O subject|O of|O selection|O pressure|O .|O
Of|O these|O four|O rearrangements|O ,|O one|O resulted|O in|O the|O deletion|O of|O exons|O 11|O and|O 12|O and|O two|O others|O resulted|O in|O either|O complete|O or|O partial|O deletion|O of|O exon|O 14|O .|O
CONCLUSION|O :|O The|O mutation|O at|O splice|O donor|O site|O and|O the|O truncation|O of|O mRNA|O were|O identical|O with|O those|O of|O a|O recently|O reported|O Italian|O patient|O ,|O although|O different|O in|O symptomatology|O .|O
Fragile|B-DISE X|I-DISE syndrome|I-DISE ,|O a|O common|O form|O of|O inherited|O mental|B-DISE retardation|I-DISE ,|O is|O mainly|O caused|O by|O massive|O expansion|O of|O CGG|O triplet|O repeats|O located|O in|O the|O 5|O '|O -|O untranslated|O region|O of|O the|O fragile|O X|O mental|O retardation|O -|O 1|O (|O FMR1|O )|O gene|O .|O
We|O performed|O two|O -|O point|O and|O multipoint|O limit|O of|O detection|O (|O LOD|O )|O score|O analyses|O using|O a|O high|O penetrance|O autosomal|O dominant|O model|O .|O
In|O a|O South|O African|O girl|O of|O Xhosa|O stock|O with|O severe|O piebaldism|B-DISE and|O profound|O congenital|B-DISE sensorineural|I-DISE deafness|I-DISE we|O identified|O a|O novel|O missense|O substitution|O at|O a|O highly|O conserved|O residue|O in|O the|O intracellular|O kinase|O domain|O of|O the|O KIT|O proto|O -|O oncogene|O ,|O R796G|O .|O
In|O a|O proportion|O of|O GH|B-DISE patients|O ,|O two|O mutations|O are|O present|O ,|O C282Y|O and|O H63D|O .|O
This|O results|O in|O the|O fusion|O of|O PAX3|O ,|O a|O developmental|O transcription|O factor|O required|O for|O limb|O myogenesis|O ,|O with|O FKHR|O ,|O a|O member|O of|O the|O forkhead|O family|O of|O transcription|O factors|O .|O
One|O hundred|O and|O twenty|O -|O six|O W27|O -|O negative|O controls|O matched|O for|O race|O ,|O sex|O ,|O and|O age|O failed|O to|O yield|O a|O single|O case|O .|O
The|O hereditary|B-DISE breast|I-DISE and|I-DISE ovarian|I-DISE cancer|I-DISE gene|O ,|O BRCA1|O ,|O encodes|O a|O large|O polypeptide|O that|O contains|O the|O cysteine|O -|O rich|O RING|O motif|O ,|O a|O zinc|O -|O binding|O domain|O found|O in|O a|O variety|O of|O regulatory|O proteins|O .|O
A|O 50|O -|O year|O -|O old|O man|O showed|O progressive|O muscular|B-DISE atrophy|I-DISE ,|O choreic|B-DISE movement|I-DISE ,|O elevated|B-DISE level|I-DISE of|I-DISE serum|I-DISE creatinine|I-DISE kinase|I-DISE ,|O and|O acanthocytosis|B-DISE .|O
Twenty|O -|O five|O first|O -|O degree|O relatives|O with|O ankylosing|B-DISE spondylitis|I-DISE were|O all|O B27|O positive|O .|O
It|O mainly|O involves|O the|O nervous|O system|O white|O matter|O ,|O adrenal|O cortex|O and|O testes|O .|O
Subsequent|O studies|O demonstrated|O that|O this|O mutation|O is|O present|O in|O one|O -|O half|O of|O all|O CG1|O patients|O and|O correlates|O with|O the|O Zellweger|B-DISE syndrome|I-DISE phenotype|O .|O
DTD|B-DISE is|O caused|O by|O mutations|O in|O the|O recently|O identified|O diastrophic|B-DISE dysplasia|I-DISE sulfate|O -|O transporter|O gene|O DTDST|O .|O
After|O treatment|O ,|O the|O three|O patients|O with|O pure|O spinal|O abnormalities|O showed|O clinical|O and|O neurophysiologic|O worsening|O ,|O whereas|O the|O two|O patients|O with|O a|O more|O advanced|O stage|O of|O disease|O (|O exhibited|O by|O SEPs|O )|O showed|O substantially|O unchanged|O clinical|O and|O neurophysiologic|O features|O .|O
To|O characterize|O the|O functional|O and|O structural|O properties|O of|O the|O COLIA1|O /|O PDGFB|O fusion|O protein|O ,|O we|O generated|O a|O stable|O NIH3T3|O cell|O line|O that|O contained|O a|O tumor|O -|O derived|O chimeric|O gene|O resulting|O from|O a|O COIA1|O intron|O 7|O -|O PDGFB|O intron|O 1|O fusion|O .|O
Hereditary|B-DISE coproporphyria|I-DISE (|O HCP|B-DISE )|O is|O an|O autosomal|O dominant|O disease|O characterized|O by|O a|O deficiency|B-DISE of|I-DISE coproporphyrinogen|I-DISE oxidase|I-DISE (|O CPO|O )|O caused|O by|O a|O mutation|O in|O the|O CPO|O gene|O .|O
The|O innermost|O four|O markers|O were|O found|O to|O be|O tightly|O linked|O to|O one|O another|O ,|O with|O no|O evidence|O for|O recombination|O .|O
As|O a|O step|O toward|O understanding|O the|O function|O of|O FMR1|O and|O the|O determination|O of|O the|O potential|O for|O therapeutic|O approaches|O to|O fragile|B-DISE X|I-DISE syndrome|I-DISE ,|O yeast|O artificial|O chromosome|O (|O YAC|O )|O transgenic|O mice|O were|O generated|O in|O order|O to|O determine|O whether|O the|O Fmr1|O knockout|O mouse|O phenotype|O could|O be|O rescued|O .|O
The|O normal|O botrocetin|O -|O induced|O binding|O and|O the|O defective|O ristocetin|O -|O induced|O binding|O of|O rvWF|O (|O G561S|O )|O suggest|O that|O the|O primary|O defect|O in|O von|B-DISE Willebrand|I-DISE disease|I-DISE type|O B|O may|O be|O a|O failure|O of|O normal|O allosteric|O regulation|O of|O the|O glycoprotein|O Ib|O binding|O function|O of|O vWF|O .|O .|O
These|O findings|O have|O significant|O implications|O for|O gene|O therapy|O for|O fragile|B-DISE X|I-DISE syndrome|I-DISE since|O overexpression|O of|O the|O gene|O may|O harbor|O its|O own|O phenotype|O .|O .|O
We|O have|O identified|O a|O Duchenne|B-DISE muscular|I-DISE dystrophy|I-DISE (|O DMD|B-DISE )|O pedigree|O where|O the|O disease|O is|O associated|O with|O a|O molecular|O deletion|O within|O the|O DMD|O locus|O .|O
OBJECTIVE|O :|O To|O analyze|O Japanese|O patients|O clinically|O diagnosed|O as|O having|O XLRS|B-DISE formutational|O changes|O in|O the|O XLRS1|O gene|O .|O
BRCA1|O contains|O a|O carboxyl|O -|O terminal|O domain|O (|O BRCT|O )|O that|O is|O shared|O with|O several|O other|O proteins|O involved|O in|O maintaining|O genome|O integrity|O .|O
Leu|O -|O AVP|O was|O a|O weak|O agonist|O with|O approximately|O 30|O -|O fold|O reduced|O binding|O to|O the|O human|O V2|O receptor|O .|O
Index|O cases|O for|O the|O present|O study|O were|O found|O two|O different|O ways|O :|O through|O a|O series|O of|O consecutive|O ovarian|B-DISE cancers|I-DISE (|O n|O =|O 16|O )|O and|O through|O our|O family|O cancer|O clinic|O n|O =|O 14|O .|O
Point|O mutations|O were|O scattered|O along|O the|O coding|O sequence|O and|O included|O 15|O nonsense|O ,|O 15|O frameshift|O ,|O three|O splice|O site|O ,|O two|O missense|O and|O one|O editing|O mutations|O .|O
The|O direct|O sequencing|O of|O the|O polymerase|O chain|O reaction|O -|O amplified|O product|O of|O reverse|O -|O transcribed|O HPRT|O mRNA|O enabled|O the|O rapid|O identification|O of|O the|O mutations|O found|O in|O 17|O previously|O uncharacterized|O cell|O lines|O derived|O from|O patients|O with|O the|O Lesch|B-DISE -|I-DISE Nyhan|I-DISE syndrome|I-DISE .|O .|O
Finally|O ,|O COLIA1|O /|O PDGFB|O -|O expressing|O cells|O generated|O tumors|B-DISE after|O s|O .|O c|O .|O injection|O into|O nude|O mice|O ,|O and|O tumor|B-DISE growth|O was|O reduced|O by|O treatment|O with|O CGP57148B|O .|O
The|O predicted|O protein|O environment|O in|O which|O the|O mutation|O occurs|O is|O compared|O to|O that|O of|O the|O adult|O -|O onset|O Tay|B-DISE -|I-DISE Sachs|I-DISE disease|I-DISE mutation|O caused|O by|O a|O Gly269|O -|O -|O >|O Ser|O substitution|O in|O exon|O 7|O .|O ABSTRACT|O TRUNCATED|O AT|O 250|O WORDS|O .|O
We|O present|O a|O review|O of|O the|O 23|O published|O cases|O with|O this|O syndrome|O .|O
Of|O an|O expected|O 177|O unknown|O mutations|O ,|O we|O detected|O approximately|O 70|O %|O ,|O mostly|O protein|O truncating|O mutations|O that|O would|O have|O been|O detectable|O by|O protein|O truncation|O testing|O if|O RNA|O starting|O material|O had|O been|O available|O .|O
Genetic|O inactivation|O of|O the|O yeast|O frataxin|O homologue|O (|O Yfh1p|O )|O results|O in|O mitochondrial|O iron|O accumulation|O and|O hypersensitivity|O to|O oxidative|O stress|O .|O
The|O same|O mutation|O has|O been|O reported|O previously|O in|O an|O unrelated|O family|O showing|O a|O significantly|O milder|O phenotype|O .|O
Studies|O of|O biopsied|O tissue|O for|O the|O presence|O of|O Epstein|B-DISE -|I-DISE Barr|I-DISE virus|I-DISE and|O cytomegalovirus|B-DISE were|O negative|O ,|O as|O were|O studies|O of|O blood|O ,|O including|O the|O polymerase|O chain|O reaction|O ,|O for|O the|O presence|O of|O the|O human|B-DISE immunodeficiency|I-DISE virus|I-DISE HIV|B-DISE .|O
We|O describe|O a|O patient|O with|O typical|O clinical|O features|O of|O the|O fragile|B-DISE X|I-DISE syndrome|I-DISE ,|O but|O without|O cytogenetic|O expression|O of|O the|O fragile|O X|O or|O an|O amplified|O CCG|O trinucleotide|O repeat|O fragment|O .|O
One|O patient|O was|O heterozygous|O for|O the|O previously|O identified|O deletion|O .|O
The|O boy|O '|O s|O maternal|O aunt|O came|O for|O prenatal|O diagnosis|O when|O 16|O +|O weeks|O pregnant|O and|O carrying|O a|O male|O fetus|O .|O
Another|O three|O affected|O males|O from|O the|O family|O had|O similar|O findings|O .|O
We|O observed|O a|O striking|O pattern|O of|O STR|O allele|O sharing|O at|O several|O closely|O linked|O loci|O among|O our|O four|O Caucasian|O VWS|B-DISE families|O recruited|O at|O three|O different|O locations|O in|O the|O US|O .|O
A|O chromosome|O 15|O anomaly|O was|O observed|O in|O 12|O of|O 20|O patients|O ,|O 17|O of|O whom|O were|O clinically|O suspected|O of|O having|O Prader|B-DISE -|I-DISE Willi|I-DISE syndrome|I-DISE PWS|B-DISE .|O
These|O observations|O provide|O a|O mechanistic|O basis|O for|O the|O A|B-DISE -|I-DISE T|I-DISE phenotype|O and|O lay|O a|O rational|O foundation|O for|O therapeutic|O intervention|O .|O .|O
Furthermore|O ,|O these|O results|O raise|O the|O possibility|O of|O a|O novel|O treatment|O regimen|O for|O muscular|B-DISE dystrophy|I-DISE and|O other|O diseases|O caused|O by|O premature|O stop|O codon|O mutations|O .|O
Subsequent|O reports|O in|O additional|O collections|O of|O families|O have|O yielded|O conflicting|O results|O .|O
This|O supports|O recent|O observations|O that|O the|O protein|O is|O critical|O for|O normal|O retinal|O vasculogenesis|O .|O .|O
Reciprocal|O chromosome|O translocations|O are|O common|O de|O novo|O rearrangements|O that|O occur|O randomly|O throughout|O the|O human|O genome|O .|O
This|O localization|O makes|O Wasp|O a|O candidate|O for|O involvement|O in|O scurfy|O ,|O a|O T|O cell|O -|O mediated|O fatal|O lymphoreticular|O disease|O of|O mice|O that|O has|O previously|O been|O proposed|O as|O a|O mouse|O homolog|O of|O Wiskott|B-DISE -|I-DISE Aldrich|I-DISE syndrome|I-DISE .|O
Titration|O of|O mYfh1p|O with|O increasing|O iron|O concentrations|O supports|O a|O stepwise|O mechanism|O of|O multimer|O assembly|O .|O
Variation|O in|O the|O antigen|O level|O of|O heterozygous|O relatives|O of|O probands|O was|O found|O to|O be|O significantly|O higher|O between|O families|O than|O within|O families|O ,|O consistent|O with|O the|O view|O that|O the|O nature|O of|O the|O F10|O lesion|O (|O s|O )|O segregating|O in|O a|O given|O family|O is|O a|O prime|O determinant|O of|O the|O laboratory|O phenotype|O .|O
Significant|O ALPS|B-DISE -|O related|O morbidity|O occurred|O in|O 44|O %|O of|O relatives|O with|O intracellular|O mutations|O ,|O versus|O 0|O %|O of|O relatives|O with|O extracellular|O mutations|O .|O
Mutations|O in|O the|O COL3A1|O gene|O have|O been|O implicated|O as|O a|O cause|O of|O type|B-DISE IV|I-DISE Ehlers|I-DISE -|I-DISE Danlos|I-DISE syndrome|I-DISE ,|O a|O disease|O leading|O to|O aortic|B-DISE rupture|I-DISE in|O early|O adult|O life|O .|O
The|O identification|O of|O a|O mouse|O X|O -|O linked|O mutant|O showing|O muscular|O dystrophy|O ,|O mdx|O ,|O has|O provided|O a|O candidate|O mouse|O genetic|O homologue|O to|O the|O DMD|O locus|O ;|O the|O relatively|O mild|O pathological|O features|O of|O mdx|O suggest|O it|O may|O have|O more|O in|O common|O with|O mutations|O of|O the|O Becker|B-DISE muscular|I-DISE dystrophy|I-DISE type|O at|O the|O same|O human|O locus|O ,|O however|O .|O
BACKGROUND|O :|O Mutations|O in|O the|O gene|O encoding|O the|O human|O cardiac|O Na|O (|O +|O )|O channel|O alpha|O -|O subunit|O (|O hH1|O )|O are|O responsible|O for|O chromosome|O 3|O -|O linked|O congenital|O long|B-DISE -|I-DISE QT|I-DISE syndrome|I-DISE (|O LQT3|B-DISE )|O and|O idiopathic|B-DISE ventricular|I-DISE fibrillation|I-DISE IVF|B-DISE .|O
Gc|O -|O protein|O levels|O were|O normal|O in|O the|O patient|O and|O together|O with|O normal|O chromosomal|O banding|O studies|O make|O it|O unlikely|O that|O a|O chromosomal|O deletion|O caused|O analbuminemia|B-DISE .|O
These|O common|O mutations|O have|O an|O etiological|O role|O in|O many|O breast|B-DISE and|I-DISE ovarian|I-DISE cancer|I-DISE cases|O and|O provide|O the|O opportunity|O to|O examine|O genotype|O -|O phenotype|O correlations|O and|O genotype|O -|O environment|O interactions|O in|O individuals|O with|O the|O identical|O BRCA1|O lesion|O .|O
To|O achieve|O this|O ,|O we|O determined|O the|O prevalence|O of|O BRCA1|O alterations|O in|O a|O population|O -|O based|O series|O of|O consecutive|O ovarian|B-DISE cancer|I-DISE cases|O .|O
The|O objective|O of|O this|O study|O was|O to|O provide|O more|O accurate|O frequency|O estimates|O of|O breast|B-DISE cancer|I-DISE susceptibility|O gene|O 1|O (|O BRCA1|O )|O germline|O alterations|O in|O the|O ovarian|B-DISE cancer|I-DISE population|O .|O
Ataxia|B-DISE -|I-DISE telangiectasia|I-DISE is|O a|O hereditary|B-DISE multisystemic|I-DISE disease|I-DISE resulting|O from|O mutations|O of|O ataxia|B-DISE telangiectasia|I-DISE ,|O mutated|O (|O ATM|O )|O and|O is|O characterized|O by|O neurodegeneration|B-DISE ,|O cancer|B-DISE ,|O immune|B-DISE defects|I-DISE ,|O and|O hypersensitivity|B-DISE to|I-DISE ionizing|I-DISE radiation|I-DISE .|O
All|O PLS|B-DISE patients|O were|O homozygous|O for|O cathepsin|O C|O mutations|O inherited|O from|O a|O common|O ancestor|O .|O
The|O introns|O (|O 421|O bp|O and|O 1|O .|O 2|O kb|O )|O encompass|O a|O 142|O -|O bp|O exon|O with|O the|O 2|O polymorphic|O bases|O 2531|O and|O 2532|O .|O
Several|O lines|O of|O evidence|O indicate|O reduced|O penetrance|O among|O Ashkenazi|O Jews|O ,|O especially|O for|O E148Q|O ,|O P369S|O ,|O and|O K695R|O .|O
Patients|O with|O familial|O APC|B-DISE (|O FAP|O )|O carry|O germ|O -|O line|O mutations|O in|O the|O APC|O gene|O and|O develop|O multiple|O colorectal|B-DISE adenomas|I-DISE and|I-DISE subsequent|I-DISE carcinomas|I-DISE early|O in|O life|O .|O
The|O patients|O with|O G6PD|O Huron|O were|O under|O medical|O observation|O for|O a|O considerable|O period|O of|O time|O without|O the|O diagnosis|O of|O G6PD|B-DISE deficiency|I-DISE being|O entertained|O because|O the|O family|O was|O of|O Northern|O European|O origin|O .|O
Recently|O ,|O a|O missense|O mutation|O was|O identified|O in|O human|O ASPA|O coding|O sequence|O from|O patients|O with|O Canavan|B-DISE disease|I-DISE .|O
We|O screened|O 31|O new|O unrelated|O patients|O and|O families|O for|O XLRS1|O mutations|O in|O addition|O to|O previously|O reported|O mutations|O for|O 60|O of|O our|O families|O Retinoschisis|B-DISE Consortium|O ,|O Hum|O Mol|O Genet|O 1998|O ;|O 7|O :|O 1185|O -|O 1192|O .|O
The|O results|O suggest|O that|O the|O two|O syndromes|O originate|O from|O the|O same|O WT1|O gene|O abnormality|O .|O
Germline|O mutations|O of|O the|O Brca1|O tumor|O suppressor|O gene|O predispose|O women|O to|O breast|B-DISE and|I-DISE ovarian|I-DISE cancers|I-DISE .|O
We|O conclude|O that|O CyS2010|O is|O essential|O for|O normal|O dimerization|O of|O vWF|O subunits|O through|O disulfide|O bonding|O of|O carboxyl|O -|O terminal|O domains|O and|O that|O a|O heterozygous|O mutation|O in|O the|O corresponding|O codon|O is|O responsible|O for|O defective|O multimer|O formation|O in|O type|O III|O von|B-DISE Willebrand|I-DISE disease|O .|O
We|O have|O previously|O shown|O that|O human|O piebaldism|B-DISE results|O from|O mutations|O of|O the|O KIT|O gene|O ,|O which|O encodes|O the|O receptor|O for|O the|O mast|O /|O stem|O cell|O growth|O factor|O and|O is|O located|O in|O chromosome|O segment|O 4q12|O .|O
The|O result|O suggests|O that|O the|O number|O of|O colorectal|B-DISE polyps|I-DISE in|O FAP|B-DISE patients|O may|O be|O associated|O with|O a|O difference|O in|O the|O stability|O or|O biological|O function|O of|O the|O truncated|O APC|O protein|O .|O .|O
We|O conclude|O that|O '|O spinal|B-DISE xanthomatosis|I-DISE '|O is|O a|O clinical|O and|O radiological|O separate|O entity|O of|O CTX|B-DISE that|O should|O be|O included|O in|O the|O differential|O diagnosis|O of|O '|O chronic|O myelopathy|B-DISE '|O .|O .|O
Fibroblasts|O from|O the|O patient|O '|O s|O mother|O and|O father|O had|O 42|O and|O 34|O %|O ,|O respectively|O ,|O of|O the|O activity|O of|O the|O lowest|O normal|O .|O
Exposure|O of|O mdx|O myotubes|O to|O gentamicin|O led|O to|O the|O expression|O and|O localization|O of|O dystrophin|O to|O the|O cell|O membrane|O .|O
Wolfram|B-DISE syndrome|I-DISE (|O WFS|B-DISE ;|O OMIM|O 222300|O )|O is|O an|O autosomal|B-DISE recessive|I-DISE neurodegenerative|I-DISE disorder|I-DISE defined|O by|O young|B-DISE -|I-DISE onset|I-DISE non|I-DISE -|I-DISE immune|I-DISE insulin|I-DISE -|I-DISE dependent|I-DISE diabetes|I-DISE mellitus|O and|O progressive|O optic|B-DISE atrophy|I-DISE .|O
Her|O fresh|O serum|O lacked|O complement|O -|O mediated|O bactericidal|O activity|O against|O Neisseria|B-DISE gonorrhoeae|I-DISE ,|O but|O the|O addition|O of|O fresh|O normal|O serum|O or|O purified|O C7|O restored|O bactericidal|O activity|O as|O well|O as|O hemolytic|O activity|O .|O
Twenty|O -|O two|O tumors|B-DISE had|O frameshift|O mutations|O due|O to|O deletion|O or|O insertion|O ;|O nineteen|O of|O them|O were|O deletions|O of|O one|O to|O 31|O bp|O and|O three|O were|O a|O 1|O -|O bp|O insertion|O .|O
The|O mutation|O introduces|O a|O termination|O codon|O within|O exon|O 8|O of|O the|O dystrophin|O gene|O .|O
The|O association|O between|O normal|O alleles|O at|O the|O CTG|O repeat|O and|O two|O nearby|O polymorphisms|O in|O the|O myotonin|O protein|O kinase|O gene|O ,|O the|O Alu|O insertion|O /|O deletion|O polymorphism|O and|O the|O myotonic|B-DISE dystrophy|I-DISE kinase|O DMK|O (|O G|O /|O T|O )|O intron|O 9|O /|O HinfI|O polymorphism|O ,|O has|O been|O analyzed|O in|O South|O African|O Negroids|O ,|O a|O population|O in|O which|O myotonic|B-DISE dystrophy|I-DISE (|O DM|B-DISE )|O has|O not|O been|O described|O .|O
This|O initial|O delineation|O of|O human|O mutations|O in|O VLCAD|O suggests|O that|O VLCAD|B-DISE deficiency|I-DISE reduces|I-DISE myocardial|I-DISE fatty|I-DISE acid|I-DISE beta|I-DISE -|I-DISE oxidation|I-DISE and|O energy|O production|O and|O is|O associated|O with|O cardiomyopathy|B-DISE and|O sudden|B-DISE death|I-DISE in|O childhood|O .|O .|O
We|O have|O found|O C282Y|O allele|O frequencies|O of|O 2|O .|O 3|O %|O (|O +|O 2|O .|O 0|O %|O )|O (|O -|O 1|O .|O 3|O %|O )|O in|O Greenland|O ,|O 4|O .|O 5|O %|O +|O /|O -|O 1|O .|O 9|O %|O in|O Iceland|O ,|O 5|O .|O 1|O %|O +|O /|O -|O 2|O .|O 3|O %|O in|O the|O Faeroe|O Islands|O ,|O and|O 8|O .|O 2|O %|O +|O /|O -|O 2|O .|O 7|O %|O in|O Denmark|O .|O
In|O order|O to|O demonstrate|O the|O effect|O of|O prophylactic|O colchicine|O treatment|O on|O the|O natural|O history|O of|O familial|B-DISE Mediterranean|I-DISE fever|I-DISE (|O FMF|B-DISE )|O ,|O a|O family|O is|O presented|O with|O 6|O out|O of|O 9|O siblings|O affected|O by|O FMF|B-DISE .|O
We|O recently|O showed|O that|O alkaptonuria|B-DISE (|O AKU|B-DISE )|O is|O caused|O by|O loss|O -|O of|O -|O function|O mutations|O in|O the|O homogentisate|O 1|O ,|O 2|O dioxygenase|O gene|O HGO|O .|O
Both|O genes|O are|O intronless|O with|O tandem|O direct|O repeat|O sequences|O contained|O within|O a|O CpG|O island|O in|O the|O 5|O '|O -|O untranscribed|O region|O .|O
Twelve|O of|O the|O missense|O mutations|O apparently|O result|O from|O the|O methylation|O and|O subsequent|O deamination|O of|O highly|O mutagenic|O CpG|O dinucleotides|O .|O
Missense|O mutations|O were|O studied|O by|O means|O of|O molecular|O modelling|O ,|O whereas|O single|O basepair|O substitutions|O in|O splice|O sites|O and|O the|O 5|O '|O flanking|O region|O were|O examined|O by|O in|O vitro|O splicing|O assay|O and|O luciferase|O reporter|O gene|O assay|O respectively|O .|O
The|O disease|O -|O causing|O mutation|O has|O recently|O been|O identified|O as|O an|O unstable|O and|O expanded|O (|O CAG|O )|O n|O trinucleotide|O repeat|O in|O a|O novel|O gene|O of|O unknown|O function|O .|O
While|O demonstration|O of|O alpha|B-DISE -|I-DISE galactosidase|I-DISE deficiency|I-DISE in|O leukocytes|O is|O diagnostic|O in|O affected|O males|O ,|O enzymatic|O detection|O of|O female|O carriers|O is|O often|O inconclusive|O ,|O due|O to|O random|O X|O -|O chromosomal|O inactivation|O ,|O underlining|O the|O need|O of|O molecular|O investigations|O for|O accurate|O genetic|O counseling|O .|O
A|O wide|O spectrum|O of|O mutations|O ,|O ranging|O from|O point|O mutations|O to|O large|O deletions|O ,|O have|O been|O described|O in|O the|O retinoblastoma|B-DISE gene|O RB1|O .|O
The|O genetic|O basis|O of|O myotonic|B-DISE dystrophy|I-DISE (|O DM|B-DISE )|O is|O the|O expansion|O of|O an|O unstable|O CTG|O repeat|O in|O the|O 34|O UTR|O of|O the|O DM|O protein|O kinase|O gene|O on|O chromosome|O 19|O .|O
In|O vitro|O expression|O of|O mutant|O cDNA|O clones|O demonstrated|O that|O all|O of|O these|O mutations|O led|O to|O a|O deficiency|B-DISE of|I-DISE ASPA|I-DISE and|O should|O therefore|O result|O in|O Canavan|B-DISE disease|I-DISE .|O .|O
Our|O data|O further|O support|O the|O notion|O of|O molecular|O heterogeneity|O of|O galactosemia|B-DISE and|O suggest|O that|O galactosemia|B-DISE mutations|O and|O GALT|O polymorphisms|O may|O be|O useful|O tools|O in|O highlighting|O different|O functional|O domains|O in|O human|O GALT|O .|O .|O
The|O prevalence|O was|O similar|O in|O both|O sexes|O .|O
Increased|O rates|O of|O chromosome|O damage|O were|O also|O observed|O in|O the|O fibroblasts|O of|O some|O phenotypically|O normal|O family|O members|O (|O obligate|O heterozygotes|O and|O sibs|O )|O when|O compared|O to|O normal|O controls|O .|O
The|O mutant|O DMPK|O messenger|O RNA|O (|O mRNA|O )|O contains|O an|O expanded|O CUG|O repeat|O and|O is|O retained|O in|O the|O nucleus|O .|O
In|O the|O present|O study|O ,|O we|O have|O screened|O several|O individuals|O for|O mutations|O in|O all|O 47|O exons|O in|O the|O CACNA1A|O gene|O by|O single|O -|O strand|O conformation|O analysis|O .|O
These|O results|O suggest|O that|O the|O milder|O phenotype|O in|O humans|O is|O due|O to|O residual|O frataxin|O expression|O associated|O with|O the|O expansion|O mutations|O .|O
Here|O we|O present|O a|O detailed|O clinical|O and|O genetic|O study|O of|O a|O subset|O of|O 51|O patients|O homozygous|O for|O an|O expansion|O of|O the|O GAA|O repeat|O .|O
We|O describe|O seven|O Dutch|O patients|O from|O six|O families|O with|O a|O slowly|O progressive|O ,|O mainly|O spinal|O cord|O syndrome|O that|O remained|O for|O many|O years|O the|O sole|O expression|O of|O cerebrotendinous|B-DISE xanthomatosis|I-DISE CTX|B-DISE .|O
For|O genetic|O counseling|O and|O predictive|O testing|O in|O families|O with|O inherited|B-DISE breast|I-DISE -|I-DISE ovarian|I-DISE cancer|I-DISE ,|O penetrances|O and|O expressions|O of|O the|O underlying|O mutations|O should|O be|O known|O .|O
Consequently|O ,|O familial|O studies|O in|O patients|O affected|O by|O this|O syndrome|O are|O recommended|O .|O .|O
This|O gene|O ,|O designated|O HPRT|O Tokyo|O ,|O had|O a|O single|O nucleotide|O change|O from|O G|O to|O A|O ,|O as|O identified|O by|O sequencing|O cDNA|O amplified|O by|O the|O polymerase|O chain|O reaction|O .|O
Two|O groups|O of|O subjects|O with|O hyperbilirubinaemia|B-DISE of|O non|O -|O immunological|O origin|O were|O examined|O :|O (|O a|O )|O 302|O newborn|O babies|O of|O Sardinian|O extraction|O (|O on|O cord|O blood|O )|O and|O (|O b|O )|O 201|O newborn|O babies|O of|O south|O Italian|O ancestry|O on|O peripheral|O blood|O .|O
This|O is|O the|O first|O report|O of|O diagnosis|O of|O maternal|O UPD|B-DISE (|I-DISE 14|I-DISE )|I-DISE based|O on|O clinical|O features|O .|O
Heterozygotes|O for|O the|O gene|O for|O A|B-DISE -|I-DISE T|I-DISE are|O thought|O to|O comprise|O about|O 1|O %|O of|O the|O general|O population|O and|O ,|O therefore|O ,|O it|O is|O important|O to|O know|O whether|O this|O gene|O also|O predisposes|O the|O heterozygous|O carrier|O to|O cancers|B-DISE .|O
We|O found|O that|O PAX3|O -|O FKHR|O but|O not|O PAX3|O activated|O a|O myogenic|O transcription|O program|O including|O the|O induction|O of|O transcription|O factors|O MyoD|O ,|O Myogenin|O ,|O Six1|O ,|O and|O Slug|O as|O well|O as|O a|O battery|O of|O genes|O involved|O in|O several|O aspects|O of|O muscle|O function|O .|O
A|O patient|O who|O showed|O an|O intermediate|O saliva|O /|O serum|O technetium|O ratio|O (|O 14|O .|O 0|O ;|O normal|O ,|O >|O or|O =|O 20|O )|O and|O was|O considered|O to|O have|O a|O partial|O or|O less|O severe|O defect|O in|O the|O previous|O report|O (|O IX|O -|O 24|O )|O did|O not|O have|O a|O NIS|O gene|O mutation|O .|O
BACKGROUND|O AND|O METHODS|O :|O Hereditary|B-DISE hemochromatosis|I-DISE is|O associated|O with|O homozygosity|O for|O the|O C282Y|O mutation|O in|O the|O hemochromatosis|O (|O HFE|O )|O gene|O on|O chromosome|O 6|O ,|O elevated|O serum|O transferrin|O saturation|O ,|O and|O excess|O iron|O deposits|O throughout|O the|O body|O .|O
Because|O the|O intact|O chromosome|O 7|O ,|O opposite|O the|O deleted|O homolog|O ,|O maintains|O the|O correct|O imprint|O in|O somatic|O cells|O of|O PWS|B-DISE and|O AS|B-DISE mice|O and|O establishes|O the|O correct|O imprint|O in|O male|O and|O female|O germ|O cells|O of|O AS|B-DISE mice|O ,|O homologous|O association|O and|O replication|O asynchrony|O are|O not|O part|O of|O the|O imprinting|O mechanism|O .|O
The|O presence|O of|O normally|O spliced|O transcripts|O was|O correlated|O with|O a|O milder|O phenotype|O .|O
This|O is|O the|O first|O population|O -|O based|O ovarian|B-DISE cancer|I-DISE study|O reporting|O BRCA1|O alterations|O derived|O from|O a|O comprehensive|O screen|O of|O the|O entire|O coding|O region|O .|O
Evidence|O for|O placing|O OCRL|O at|O Xq25|O also|O comes|O from|O a|O female|O with|O Lowe|B-DISE syndrome|I-DISE and|O an|O X|O ;|O 3|O translocation|O .|O
BssSI|O digestion|O of|O polymerase|O chain|O reaction|O products|O amplified|O from|O genomic|O DNA|O indicated|O that|O affected|O cats|O were|O homozygous|O and|O cats|O with|O half|O -|O normal|O beta|O -|O glucuronidase|O activity|O were|O heterozygous|O for|O the|O missense|O mutation|O .|O
Interstitial|O cytogenetic|O deletions|O involving|O the|O paternally|O derived|O chromosome|O 15q11|O -|O 13|O have|O been|O described|O in|O patients|O with|O the|O Prader|B-DISE -|I-DISE Willi|I-DISE syndrome|I-DISE PWS|B-DISE .|O
Three|O exon|O 2|O mutations|O were|O identified|O ,|O including|O a|O single|O nucleotide|O deletion|O (|O 2692delA|O )|O of|O codon|O 349|O introducing|O a|O frameshift|O and|O premature|O termination|O codon|O ,|O a|O 2|O bp|O deletion|O (|O 2673|O -|O 2674delCT|O )|O that|O results|O in|O introduction|O of|O a|O stop|O codon|O at|O amino|O acid|O 343|O ,|O and|O a|O G|O -|O -|O >|O A|O substitution|O in|O codon|O 429|O (|O 2931G|O -|O -|O >|O A|O )|O introducing|O a|O premature|O termination|O codon|O .|O
When|O the|O site|O -|O specific|O mutagenized|O alpha|O cDNA|O carrying|O the|O T|O -|O -|O >|O C|O transition|O at|O nt|O 1453|O was|O expressed|O in|O COS|O 1|O cells|O hexosaminidase|O S|O activity|O was|O not|O detectable|O above|O background|O .|O
All|O children|O with|O homozygous|O or|O heterozygous|O C3|B-DISE deficiency|I-DISE were|O ,|O to|O a|O varying|O degree|O ,|O susceptible|O to|O infection|B-DISE .|O
The|O AG|O dinucleotide|O deletion|O at|O position|O 1081|O -|O 1082|O ,|O which|O has|O been|O reported|O previously|O to|O be|O the|O most|O common|O mutation|O in|O white|O patients|O (|O 12|O %|O -|O 17|O %|O )|O ,|O was|O also|O identified|O as|O the|O most|O common|O mutation|O in|O Japanese|O patients|O 12|O %|O .|O
Structural|O information|O of|O GLDC|O and|O psiGLDC|O should|O facilitate|O the|O molecular|O analysis|O of|O NKH|B-DISE .|O .|O
The|O results|O suggest|O that|O the|O prenatal|O diagnosis|O of|O Wolman|B-DISE disease|I-DISE be|O made|O using|O the|O radioassay|O of|O acid|O lipase|O and|O /|O or|O electrophoresis|O .|O .|O
Our|O results|O demonstrate|O that|O SLS|B-DISE is|O caused|O by|O a|O strikingly|O heterogeneous|O group|O of|O mutations|O in|O the|O FALDH|O gene|O and|O provide|O a|O framework|O for|O understanding|O the|O genetic|O basis|O of|O SLS|B-DISE and|O the|O development|O of|O DNA|O -|O based|O diagnostic|O tests|O .|O .|O
However|O ,|O their|O proliferative|O responses|O to|O anti|O -|O CD43|O antibody|O and|O periodate|O were|O diminished|O ,|O consistent|O with|O the|O clinical|O diagnosis|O of|O WAS|B-DISE .|O
Single|O strand|O conformational|O polymorphism|O analysis|O and|O direct|O sequencing|O of|O amplified|O exon|O 13|O revealed|O a|O T|O -|O -|O >|O C|O transition|O at|O nt|O 1453|O with|O the|O corresponding|O amino|O acid|O substitution|O W485R|O in|O the|O second|O family|O .|O
The|O duration|O of|O disease|O is|O correlated|O with|O wheelchair|O use|O and|O the|O presence|O of|O diabetes|B-DISE ,|O scoliosis|B-DISE ,|O bladder|B-DISE symptoms|I-DISE and|O impaired|B-DISE proprioception|I-DISE ,|O and|O vibration|O sense|O but|O no|O other|O complications|O studied|O .|O .|O
Such|O a|O sex|O difference|O in|O AO|O was|O not|O apparent|O for|O any|O of|O the|O other|O APOE|O genotypes|O .|O
Magel2|O distribution|O partially|O overlaps|O that|O of|O NDN|O :|O ,|O with|O strong|O expression|O being|O detected|O in|O the|O central|O nervous|O system|O in|O mid|O -|O gestation|O mouse|O embryos|O by|O in|O situ|O hybridization|O .|O
Existence|O of|O the|O P16INK4A|O mutation|O and|O the|O hereditary|O TP53|O mutation|O with|O or|O without|O loss|O of|O heterozygosity|O in|O the|O TP53|O gene|O (|O seminoma|B-DISE /|O medulloblastoma|B-DISE )|O may|O be|O evidence|O for|O a|O common|O mechanism|O involved|O in|O tumorogenesis|O .|O
We|O have|O developed|O a|O multiplex|O heteroduplex|O analysis|O that|O is|O designed|O to|O analyze|O one|O -|O quarter|O of|O the|O coding|O sequence|O in|O a|O single|O -|O step|O screening|O procedure|O and|O that|O will|O detect|O approximately|O 50|O %|O of|O all|O BRCA1|O mutations|O so|O far|O reported|O in|O breast|B-DISE /|I-DISE ovarian|I-DISE cancer|I-DISE families|O .|O
This|O is|O the|O first|O report|O of|O protein|O studies|O on|O patients|O with|O missense|O mutations|O resulting|O in|O the|O clinical|O features|O of|O EDMD|B-DISE .|O
Many|O of|O the|O DNA|O changes|O we|O detected|O were|O intragenic|O polymorphisms|O .|O
The|O two|O HL|O -|O A|O haplotypes|O closely|O linked|O to|O C2|B-DISE deficiency|I-DISE are|O different|O :|O 2|O ,|O W18|O and|O W24|O ,|O W18|O .|O
We|O report|O that|O heterozygosity|O for|O a|O targeted|O murine|O Wt1|O allele|O ,|O Wt1|O (|O tmT396|O )|O ,|O which|O truncates|O ZF3|O at|O codon|O 396|O ,|O induces|O mesangial|B-DISE sclerosis|I-DISE characteristic|O of|O DDS|B-DISE in|O adult|O heterozygous|O and|O chimeric|O mice|O .|O
Restriction|O mapping|O and|O DNA|O sequencing|O were|O then|O used|O to|O identify|O the|O Hgd|O (|O aku|B-DISE )|O mouse|O mutation|O ,|O found|O to|O be|O a|O single|O base|O change|O in|O a|O splice|O donor|O consensus|O sequence|O ,|O causing|O exon|O skipping|O and|O frame|O -|O shifted|O products|O .|O
We|O show|O that|O the|O mutant|O cells|O maintain|O an|O intact|O G1|O -|O S|O cell|O cycle|O checkpoint|O and|O proliferate|O poorly|O .|O
We|O discuss|O here|O the|O recent|O progress|O made|O towards|O understanding|O the|O molecular|O mechanism|O of|O CGG|O repeat|O expansion|O and|O physiological|O function|O (|O s|O )|O of|O FMRP|O .|O
Duarte|B-DISE 1|I-DISE (|O or|O Los|O Angeles|O )|O and|O Duarte|B-DISE 2|I-DISE (|O or|O Duarte|O )|O variants|O carry|O the|O same|O amino|O acid|O substitution|O ,|O N314D|O ,|O even|O though|O D1|O is|O associated|O with|O increased|O erythrocyte|O GALT|O activity|O and|O D2|O with|O reduced|O activity|O .|O
Eighty|O unrelated|O individuals|O with|O Duchenne|B-DISE muscular|I-DISE dystrophy|I-DISE (|O DMD|B-DISE )|O or|O Becker|B-DISE muscular|I-DISE dystrophy|I-DISE (|O BMD|B-DISE )|O were|O found|O to|O have|O deletions|O in|O the|O major|O deletion|O -|O rich|O region|O of|O the|O DMD|O locus|O .|O
We|O have|O found|O that|O FAP|B-DISE patients|O with|O germline|O APC|O mutations|O within|O a|O small|O region|O (|O codons|O 1|O ,|O 194|O -|O 1|O ,|O 392|O at|O most|O )|O mainly|O show|O allelic|O loss|O in|O their|O colorectal|B-DISE adenomas|I-DISE ,|O in|O contrast|O to|O other|O FAP|B-DISE patients|O ,|O whose|O '|O second|O hits|O '|O tend|O to|O occur|O by|O truncating|O mutations|O in|O the|O mutation|O cluster|O region|O .|O
Germline|O mutations|O in|O the|O p16|O and|O CDK4|O genes|O have|O been|O reported|O in|O a|O subset|O of|O melanoma|B-DISE pedigrees|O ,|O but|O their|O prevalence|O is|O not|O well|O known|O .|O
His|O oral|O clearance|O of|O phenytoin|O was|O 21|O %|O of|O the|O mean|O of|O the|O other|O 11|O individuals|O participating|O in|O the|O study|O ,|O and|O his|O oral|O clearance|O of|O glipizide|O ,|O a|O second|O generation|O sulfonylurea|O structurally|O similar|O to|O tolbutamide|O ,|O was|O only|O 188|O %|O of|O the|O mean|O of|O the|O other|O 10|O individuals|O .|O
Recently|O ,|O this|O autosomal|O recessive|O disorder|O was|O shown|O to|O be|O caused|O by|O mutations|O in|O the|O PDS|O gene|O ,|O which|O encodes|O an|O anion|O transporter|O called|O pendrin|O .|O
In|O order|O to|O understand|O the|O genetic|O and|O phenotypic|O basis|O for|O DPD|B-DISE deficiency|I-DISE ,|O we|O have|O reviewed|O 17|O families|O presenting|O 22|O patients|O with|O complete|O deficiency|O of|O DPD|O .|O
The|O fourth|O occurred|O within|O intron|O 9|O ,|O preventing|O splicing|O at|O one|O of|O the|O alternatively|O chosen|O splice|O donor|O sites|O of|O exon|O 9|O when|O assayed|O in|O vitro|O .|O
We|O have|O analysed|O the|O DNA|O sequence|O in|O constitutional|O cells|O from|O eight|O patients|O and|O have|O shown|O heterozygous|O mutations|O in|O six|O of|O them|O .|O
Moreover|O ,|O the|O re|O -|O establishment|O of|O the|O structural|O integrity|O of|O the|O photoreceptor|O layer|O also|O results|O in|O electrophysiological|O correction|O .|O
The|O breast|B-DISE and|I-DISE ovarian|I-DISE cancer|I-DISE susceptibility|O gene|O ,|O BRCA1|O ,|O has|O been|O cloned|O and|O shown|O to|O encode|O a|O zinc|O -|O finger|O protein|O of|O unknown|O function|O .|O
DNA|O analysis|O showed|O maternal|O heterodisomy|B-DISE for|O chromosome|O 14|O .|O
Consequently|O ,|O sporadic|O and|O VHL|O -|O associated|O forms|O of|O renal|B-DISE cell|I-DISE carcinoma|I-DISE might|O both|O result|O from|O alterations|O causing|O loss|O of|O function|O of|O the|O same|O '|O tumour|O suppressor|O '|O gene|O on|O this|O chromosome|O .|O .|O
On|O the|O other|O hand|O ,|O the|O occurrence|O of|O an|O extremely|O heterogeneous|O spectrum|O of|O mutations|O spread|O throughout|O the|O entire|O length|O of|O the|O large|O APC|O gene|O among|O the|O FAP|B-DISE patients|O indicates|O that|O this|O approach|O may|O not|O be|O useful|O as|O a|O rapid|O presymptomatic|O diagnostic|O procedure|O in|O a|O routine|O laboratory|O .|O
A|O common|O recurrent|O mutation|O ,|O at|O the|O donor|O splice|O site|O of|O FGA|O intron|O 4|O (|O IVS4|O +|O 1|O G|O >|O T|O )|O ,|O accounted|O for|O 14|O of|O the|O 26|O (|O 54|O %|O )|O alleles|O .|O
The|O presence|O of|O dimeric|O COLIA1|O /|O PDGFB|O precursors|O was|O demonstrated|O through|O PDGFB|O immunoprecipitations|O of|O metabolically|O labeled|O cells|O and|O also|O by|O PDGFB|O immunoprecipitations|O followed|O by|O immunoblotting|O with|O COLIA1|O antibodies|O .|O
Although|O many|O of|O the|O same|O regions|O of|O the|O CNS|O in|O both|O Bax|O -|O /|O -|O and|O Atm|O -|O /|O -|O mice|O were|O radioresistant|O ,|O mice|O nullizygous|O for|O both|O Bax|O and|O Atm|O showed|O additional|O reduction|O in|O IR|O -|O induced|O apoptosis|O in|O the|O CNS|O .|O
C4|O phenotyping|O in|O 20|O patients|O and|O in|O 26|O parents|O showed|O that|O 90|O %|O and|O 81|O %|O ,|O respectively|O ,|O had|O null|O allotypes|O at|O either|O the|O C4A|O or|O C4B|O locus|O compared|O with|O 59|O %|O in|O controls|O ,|O indicating|O that|O defective|O expression|O of|O structural|O genes|O may|O contribute|O to|O the|O observed|O C4|B-DISE deficiency|I-DISE .|O .|O
This|O protein|O has|O been|O implicated|O in|O protein|O translation|O as|O it|O is|O found|O associated|O with|O polyribosomes|O and|O the|O rough|O endoplasmic|O reticulum|O .|O
Over|O 100|O distinct|O disease|O -|O associated|O mutations|O have|O been|O identified|O in|O the|O breast|B-DISE -|I-DISE ovarian|I-DISE cancer|I-DISE susceptibility|O gene|O BRCA1|O .|O
A|O susceptibility|O gene|O for|O hereditary|B-DISE breast|I-DISE -|I-DISE ovarian|I-DISE cancer|I-DISE ,|O BRCA1|O ,|O has|O been|O assigned|O by|O linkage|O analysis|O to|O chromosome|O 17q21|O .|O
All|O 14|O mutations|O were|O identified|O ,|O as|O well|O as|O an|O additional|O five|O that|O had|O previously|O escaped|O detection|O .|O
Because|O conventional|O Piga|O gene|O knockout|O is|O associated|O with|O high|O embryonic|O lethality|O in|O chimeric|O mice|O ,|O we|O used|O the|O Cre|O /|O loxP|O system|O .|O
RESULTS|O :|O Point|O mutations|O in|O the|O XLRS1|O gene|O were|O identified|O in|O all|O 10|O patients|O .|O
Coats|B-DISE '|I-DISE disease|I-DISE is|O characterized|O by|O abnormal|O retinal|O vascular|O development|O (|O so|O -|O called|O '|O retinal|B-DISE telangiectasis|I-DISE '|O )|O which|O results|O in|O massive|O intraretinal|O and|O subretinal|O lipid|O accumulation|O exudative|B-DISE retinal|I-DISE detachment|I-DISE .|O
Four|O cases|O of|O adrenoleukodystrophy|B-DISE (|O ALD|B-DISE )|O and|O one|O case|O of|O adrenomyeloneuropathy|B-DISE (|O AMN|B-DISE )|O have|O developed|O in|O a|O kindred|O over|O three|O generations|O demonstrating|O that|O AMN|B-DISE is|O a|O clinical|O variant|O of|O ALD|B-DISE .|O
Of|O 57|O informative|O meioses|O ,|O two|O crossovers|O were|O noted|O between|O the|O C2|B-DISE deficiency|I-DISE gene|O and|O the|O HLA|O -|O B|O gene|O ,|O with|O a|O recombinant|O fraction|O of|O 0|O .|O 035|O .|O
Instead|O ,|O the|O low|O levels|O of|O mRNA|O from|O this|O allele|O were|O comprised|O of|O aberrant|O species|O resulting|O from|O the|O use|O of|O either|O of|O two|O cryptic|O donor|O sites|O ,|O one|O truncating|O exon|O 9|O and|O the|O other|O within|O IVS|O -|O 9|O ,|O spliced|O to|O exon|O 10|O .|O
The|O genetic|O defect|O in|O DM|B-DISE is|O a|O CTG|O repeat|O expansion|O located|O in|O the|O 3|O '|O untranslated|O region|O of|O DMPK|O and|O 5|O '|O of|O a|O homeodomain|O -|O encoding|O gene|O ,|O SIX5|O formerly|O DMAHP|O ;|O refs|O 2|O -|O 5|O .|O
The|O 185delAG|O mutation|O in|O BRCA1|O is|O detected|O in|O Ashkenazi|O Jews|O both|O in|O familial|B-DISE breast|I-DISE and|I-DISE ovarian|I-DISE cancer|I-DISE and|O in|O the|O general|O population|O .|O
Norrie|B-DISE disease|I-DISE is|O a|O human|B-DISE X|I-DISE -|I-DISE linked|I-DISE recessive|I-DISE disorder|I-DISE of|O unknown|O etiology|O characterized|O by|O congenital|B-DISE blindness|I-DISE ,|O sensory|B-DISE neural|I-DISE deafness|I-DISE and|O mental|B-DISE retardation|I-DISE .|O
We|O have|O identified|O 14|O families|O with|O ataxia|B-DISE -|I-DISE telangiectasia|I-DISE (|O A|B-DISE -|I-DISE T|I-DISE )|O in|O which|O mutation|O of|O the|O ATM|O gene|O is|O associated|O with|O a|O less|O severe|O clinical|O and|O cellular|O phenotype|O approximately|O 10|O %|O -|O 15|O %|O of|O A|B-DISE -|I-DISE T|I-DISE families|O identified|O in|O the|O United|O Kingdom|O .|O
Immunoblot|O analysis|O revealed|O that|O VLCAD|O protein|O was|O undetectable|O in|O patients|O 2|O and|O 3|O ,|O whereas|O normal|O -|O size|O VLCAD|O protein|O and|O an|O aberrant|O form|O of|O VLCAD|O (|O 4kDa|O smaller|O )|O were|O detected|O in|O patient|O 1|O .|O
Twelve|O aniridia|B-DISE patients|O ,|O five|O with|O a|O family|O history|O and|O seven|O presumed|O to|O be|O sporadic|O ,|O were|O exhaustively|O screened|O in|O order|O to|O test|O what|O proportion|O of|O people|O with|O aniridia|B-DISE ,|O uncomplicated|O by|O associated|O anomalies|O ,|O carry|O mutations|O in|O the|O human|O PAX6|O gene|O .|O
The|O early|O growth|O response|O 2|O gene|O (|O EGR2|O )|O is|O a|O Cys2His2zinc|O finger|O transcription|O factor|O which|O is|O thought|O to|O play|O a|O role|O in|O the|O regulation|O of|O peripheral|O nervous|O system|O myelination|O .|O
We|O postulated|O that|O a|O specific|O pattern|O of|O VHL|O mutations|O is|O associated|O with|O sporadic|O RCC|B-DISE .|O
The|O overlap|O between|O clinical|O and|O cellular|O phenotypes|O in|O A|B-DISE -|I-DISE T|I-DISE and|O NBS|B-DISE suggests|O that|O ATM|O and|O nibrin|O may|O function|O in|O the|O same|O biochemical|O pathway|O .|O
Those|O with|O hereditary|B-DISE cancers|I-DISE had|O improved|O survival|O compared|O with|O the|O nonhereditary|O group|O P|O =|O .|O 004|O .|O
This|O synergistic|O effect|O was|O also|O demonstrated|O on|O thermal|O stability|O ,|O especially|O at|O low|O NADP|O concentrations|O .|O
The|O results|O of|O FISH|O analysis|O showed|O an|O additional|O copy|O of|O PLP|O in|O Xp22|O .|O 1|O ,|O although|O no|O chromosomal|O rearrangements|O could|O be|O detected|O by|O standard|O karyotype|O analysis|O .|O
Fragments|O of|O the|O adrenoleukodystrophy|B-DISE (|O ALD|B-DISE )|O cDNA|O from|O a|O patient|O with|O adolescent|O ALD|B-DISE were|O amplified|O by|O polymerase|O chain|O reaction|O and|O subcloned|O .|O
The|O cellular|O features|O resulting|O from|O these|O hMRE11|O mutations|O are|O similar|O to|O those|O seen|O in|O A|O -|O T|O as|O well|O as|O NBS|O and|O include|O hypersensitivity|O to|O ionizing|O radiation|O ,|O radioresistant|O DNA|O synthesis|O ,|O and|O abrogation|O of|O ATM|O -|O dependent|O events|O ,|O such|O as|O the|O activation|O of|O Jun|O kinase|O following|O exposure|O to|O gamma|O irradiation|O .|O
All|O of|O the|O French|O patients|O were|O heterozygous|O for|O this|O polymorphism|O .|O
Mefv|O is|O localized|O on|O mouse|O Chromosome|O (|O Chr|O )|O 16|O ,|O region|O A3|O -|O B1|O ,|O extending|O a|O region|O of|O synteny|O with|O human|O Chr|O 16p13|O .|O 3|O .|O
Individuals|O homoallelic|O for|O Q188R|O tend|O to|O have|O a|O severe|O phenotype|O and|O this|O is|O in|O keeping|O with|O the|O virtually|O complete|O loss|B-DISE of|I-DISE enzyme|I-DISE activity|I-DISE observed|O in|O in|O vitro|O expression|O systems|O .|O
ATM|O phosphorylation|O of|O nibrin|O does|O not|O affect|O nibrin|O -|O MRE11|O -|O RAD50|O association|O as|O revealed|O by|O radiation|O -|O induced|O foci|O formation|O .|O
To|O evaluate|O the|O diagnostic|O and|O prognostic|O value|O of|O MEFV|O -|O gene|O analysis|O ,|O we|O investigated|O 90|O Armenian|O FMF|B-DISE patients|O from|O 77|O unrelated|O families|O that|O were|O not|O selected|O through|O genetic|O -|O linkage|O analysis|O .|O
Ten|O variants|O of|O erythrocyte|O glucose|O -|O 6|O -|O phosphate|O dehydrogenase|O were|O identified|O in|O 22|O patients|O with|O G6PD|B-DISE deficiency|I-DISE from|O three|O districts|O of|O Bulgaria|O .|O
It|O results|O in|O defective|O membrane|O targeting|O of|O the|O proteins|O present|O in|O secretory|O lysosomes|O ,|O and|O it|O is|O associated|O with|O a|O variety|O of|O features|O ,|O including|O a|O lymphoproliferative|B-DISE syndrome|I-DISE with|O hemophagocytosis|B-DISE .|O
Overall|O ,|O there|O was|O some|O evidence|O for|O linkage|O ,|O with|O a|O peak|O parametric|O multipoint|O LOD|O score|O assuming|O heterogeneity|O (|O HLOD|O )|O of|O 1|O .|O 40|O (|O P|O =|O .|O 01|O )|O at|O D1S212|O .|O
Benign|B-DISE familial|I-DISE infantile|I-DISE convulsions|I-DISE (|O BFIC|B-DISE )|O is|O a|O rare|O autosomal|B-DISE dominant|I-DISE epilepsy|I-DISE syndrome|I-DISE .|O
Recent|O studies|O have|O shown|O that|O hereditary|B-DISE hemochromatosis|I-DISE (|O HH|B-DISE )|O is|O likely|O to|O be|O caused|O by|O homozygosity|O for|O a|O Cys282Tyr|O mutation|O in|O the|O HFE|O gene|O located|O 4|O .|O 5|O Mb|O telomeric|O to|O HLA|O -|O A|O .|O
Although|O G6PD|B-DISE deficiency|I-DISE is|O now|O regarded|O as|O a|O generally|O benign|O disorder|O ,|O in|O earlier|O environmental|O conditions|O it|O could|O have|O been|O significantly|O disadvantageous|O .|O .|O
Ectopic|B-DISE expression|I-DISE of|O wild|O -|O type|O ,|O but|O not|O mutated|O ,|O BRCA1|O in|O these|O cells|O rendered|O them|O less|O sensitive|O to|O the|O DNA|O damage|O agent|O ,|O methyl|O methanesulfonate|O .|O
We|O present|O here|O a|O pedigree|O of|O a|O 31|O -|O year|O -|O old|O C2|B-DISE -|I-DISE deficient|I-DISE individual|O with|O clinical|O manifestations|O of|O Hodgkins|B-DISE disease|I-DISE .|O
We|O ,|O and|O others|O ,|O have|O demonstrated|O that|O repeat|O expansion|O decreases|O expression|O of|O the|O adjacent|O gene|O SIX5|O (|O refs|O 7|O ,|O 8|O )|O ,|O which|O encodes|O a|O homeodomain|O transcription|O factor|O .|O
Genetic|O polymorphisms|O in|O the|O cytochrome|O P450|O (|O CYP|O )|O family|O are|O widely|O known|O to|O contribute|O to|O interindividual|O differences|O in|O the|O pharmacokinetics|O of|O many|O drugs|O .|O
Somatic|O PTEN|O deletions|O and|O mutations|O were|O observed|O in|O sporadic|O breast|B-DISE ,|I-DISE brain|I-DISE ,|I-DISE prostate|I-DISE and|I-DISE kidney|I-DISE cancer|I-DISE cell|O lines|O and|O in|O several|O primary|B-DISE tumours|I-DISE such|O as|O endometrial|B-DISE carcinomas|I-DISE ,|O malignant|B-DISE melanoma|I-DISE and|O thyroid|B-DISE tumours|I-DISE .|O
When|O one|O such|O case|O was|O studied|O by|O Western|O blotting|O ,|O reduced|O amounts|O of|O normal|O -|O size|O WASP|O were|O present|O .|O
Sequence|O analysis|O revealed|O a|O C|O -|O to|O -|O G|O transversion|O at|O the|O second|O base|O of|O codon|O 322|O ,|O resulting|O in|O a|O substitution|O of|O glycine|O for|O alanine|O ,|O in|O four|O mutant|O haplotype|O 12|O genes|O ,|O and|O a|O G|O -|O to|O -|O A|O transition|O at|O the|O second|O base|O of|O codon|O 408|O ,|O resulting|O in|O a|O substitution|O of|O glutamine|O for|O arginine|O ,|O in|O another|O three|O mutant|O haplotype|O 12|O genes|O .|O
In|O all|O the|O previously|O described|O 11|O cases|O with|O maternal|O UPD|B-DISE (|I-DISE 14|I-DISE )|I-DISE ,|O a|O Robertsonian|O translocation|O involving|O chromosome|O 14|O was|O detected|O cytogenetically|O before|O DNA|O analysis|O .|O
The|O 82|O patients|O included|O in|O this|O study|O had|O developed|O breast|B-DISE cancer|I-DISE at|O age|O <|O 45|O and|O had|O survived|O >|O /|O =|O 5|O years|O (|O mean|O 15|O years|O )|O ,|O and|O in|O 33|O (|O 40|O %|O )|O of|O the|O patients|O a|O contralateral|O breast|B-DISE tumor|I-DISE had|O been|O diagnosed|O .|O
We|O then|O evaluated|O the|O effects|O of|O differing|O dosages|O of|O gentamicin|O on|O expression|O and|O functional|O protection|O of|O the|O muscles|O of|O mdx|O mice|O .|O
The|O 14|O exons|O of|O the|O PAX6|O gene|O have|O been|O analysed|O exon|O -|O by|O -|O exon|O using|O SSCP|O in|O 6|O aniridia|B-DISE families|O .|O
We|O provide|O genetic|O evidence|O supporting|O the|O identity|O of|O the|O candidate|O gene|O for|O BRCA1|O through|O the|O characterization|O of|O germline|O mutations|O in|O 63|O breast|B-DISE cancer|I-DISE patients|O and|O 10|O ovarian|B-DISE cancer|I-DISE patients|O in|O ten|O families|O with|O cancer|O linked|O to|O chromosome|O 17q21|O .|O
Here|O we|O describe|O the|O combined|O results|O of|O more|O than|O 20|O research|O laboratories|O with|O respect|O to|O the|O occurrence|O of|O deletions|O at|O the|O DXS164|O locus|O in|O DNA|O samples|O isolated|O from|O patients|O with|O DMD|B-DISE and|O Becker|B-DISE muscular|I-DISE dystrophy|I-DISE BMD|B-DISE .|O
No|O normally|O spliced|O RNA|O was|O detected|O in|O PCR|O products|O generated|O from|O reverse|O transcription|O of|O RNA|O carrying|O the|O IVS|O -|O 9|O mutation|O .|O
Mutations|O in|O the|O brain|O specific|O P|O /|O Q|O type|O Ca2|O +|O channel|O alpha1|O subunit|O gene|O ,|O CACNA1A|O ,|O have|O been|O identified|O in|O three|O clinically|O distinct|O disorders|O ,|O viz|O .|O
Uniparental|B-DISE disomy|I-DISE has|O recently|O been|O recognized|O to|O cause|O human|O disorders|O ,|O including|O Prader|B-DISE -|I-DISE Willi|I-DISE syndrome|I-DISE PWS|B-DISE .|O
Motor|O incoordination|O ,|O immune|B-DISE deficiencies|I-DISE ,|O and|O an|O increased|O risk|O of|O cancer|B-DISE are|O the|O characteristic|O features|O of|O the|O hereditary|O disease|O ataxia|B-DISE -|I-DISE telangiectasia|I-DISE (|O A|B-DISE -|I-DISE T|I-DISE )|O ,|O which|O is|O caused|O by|O mutations|O in|O the|O ATM|O gene|O .|O
Globally|O ,|O K285N|O is|O rarer|O ,|O but|O in|O many|O European|O populations|O it|O can|O be|O found|O on|O 25|O -|O 40|O %|O of|O mutant|O chromosomes|O .|O
We|O have|O characterized|O expression|O of|O the|O familial|B-DISE breast|I-DISE and|I-DISE ovarian|I-DISE cancer|I-DISE gene|O ,|O BRCA1|O ,|O in|O cases|O of|O non|O -|O hereditary|O (|O sporadic|O )|O breast|B-DISE cancer|I-DISE and|O analyzed|O the|O effect|O of|O antisense|O inhibition|O of|O BRCA1|O on|O the|O proliferative|O rate|O of|O mammary|O epithelial|O cells|O .|O
Germline|O mutations|O in|O the|O RB1|O gene|O confer|O hereditary|O predisposition|O to|O retinoblastoma|B-DISE .|O
Control|O individuals|O showed|O clear|O expression|O of|O FMRP|O in|O nearly|O every|O hair|O root|O ,|O whereas|O male|O fragile|B-DISE X|I-DISE patients|O lacked|O expression|O of|O FMRP|O in|O almost|O all|O their|O hair|O roots|O .|O
Relevance|O of|O this|O model|O was|O suggested|O by|O verification|O that|O three|O of|O these|O genes|O (|O IGFBP5|O ,|O HSIX1|O ,|O and|O Slug|O )|O were|O also|O expressed|O in|O alveolar|B-DISE rhabdomyosarcoma|I-DISE cell|O lines|O .|O
In|O an|O effort|O to|O understand|O the|O function|O of|O BRCA1|O ,|O we|O sought|O to|O isolate|O proteins|O that|O interact|O with|O the|O BRCT|O domain|O .|O
Measured|O by|O radioimmunoassay|O with|O a|O synthetic|O Leu|O -|O AVP|O standard|O ,|O serum|O Leu|O -|O AVP|O levels|O were|O elevated|O in|O all|O three|O children|O and|O further|O increased|O during|O water|B-DISE deprivation|I-DISE to|O as|O high|O as|O 30|O times|O normal|O .|O
RESULTS|O :|O Hereditary|B-DISE cancers|I-DISE were|O rarely|O diagnosed|O before|O age|O 40|O years|O and|O were|O common|O after|O age|O 60|O years|O ,|O with|O mean|O age|O at|O diagnosis|O being|O significantly|O younger|O for|O BRCA1|O -|O vs|O BRCA2|O -|O linked|O patients|O 54|O vs|O 62|O years|O ;|O P|O =|O .|O 04|O .|O
The|O Wiskott|B-DISE -|I-DISE Aldrich|I-DISE syndrome|I-DISE (|O WAS|B-DISE )|O ,|O an|O X|B-DISE -|I-DISE linked|I-DISE immunodeficiency|I-DISE disease|I-DISE caused|O by|O mutation|O in|O the|O recently|O isolated|O gene|O encoding|O WAS|O protein|O (|O WASP|O )|O ,|O is|O known|O to|O be|O associated|O with|O extensive|O clinical|O heterogeneity|O .|O
VHL|B-DISE mutations|O were|O found|O only|O in|O the|O nonpapillary|O renal|B-DISE cell|I-DISE carcinoma|I-DISE (|O RCC|B-DISE )|O subtype|O ,|O as|O previously|O reported|O .|O
Neither|O pyruvate|O carboxylase|O nor|O mitochondrial|O PEPCK|O activity|O in|O lymphocytes|O was|O increased|O by|O a|O 21|O -|O hr|O fast|O .|O .|O
Furthermore|O ,|O this|O mutation|O has|O been|O detected|O in|O a|O family|O member|O with|O mild|O clinical|O signs|O including|O only|O migraine|B-DISE .|O
Classical|B-DISE galactosemia|I-DISE is|O caused|O by|O a|O deficiency|B-DISE in|I-DISE activity|I-DISE of|I-DISE the|I-DISE enzyme|I-DISE galactose|I-DISE -|I-DISE 1|I-DISE -|I-DISE phosphate|I-DISE uridyl|I-DISE transferase|I-DISE (|O GALT|O )|O ,|O which|O ,|O in|O turn|O ,|O is|O caused|O by|O mutations|O at|O the|O GALT|O gene|O .|O
Sixty|O percent|O of|O patients|O had|O childhood|O ALD|B-DISE and|O 17|O %|O adrenomyeloneuropathy|B-DISE ,|O both|O of|O which|O are|O X|O -|O linked|O ,|O with|O the|O gene|O mapped|O to|O Xq28|O .|O
The|O enzymatic|O defect|O leads|O to|O the|O systemic|O accumulation|O of|O neutral|O glycosphingolipids|O with|O terminal|O alpha|O -|O galactosyl|O moieties|O .|O
Deletion|O of|O the|O same|O three|O loci|O in|O all|O 14|O DGS|O probands|O begins|O to|O delineate|O the|O region|O of|O chromosome|O 22|O critical|O for|O DGS|O and|O confirms|O the|O hypothesis|O that|O submicroscopic|O deletions|O of|O 22q11|O are|O etiologic|O in|O the|O vast|O majority|O of|O cases|O .|O .|O
Our|O results|O indicate|O that|O different|O APC|O mutations|O provide|O cells|O with|O different|O selective|O advantages|O ,|O with|O mutations|O close|O to|O codon|O 1|O ,|O 300|O providing|O the|O greatest|O advantage|O .|O
We|O have|O determined|O that|O the|O human|O gene|O (|O PDEB|O )|O maps|O to|O 4p16|O .|O 3|O ,|O very|O close|O to|O the|O Huntington|B-DISE disease|I-DISE (|O HD|O )|O region|O .|O
We|O report|O carrier|O identification|O and|O a|O prenatal|O diagnosis|O using|O DNA|O polymorphisms|O in|O 2|O families|O with|O X|O -|O linked|O Pelizaeus|B-DISE -|I-DISE Merzbacher|I-DISE disease|I-DISE PMD|B-DISE .|O
Hitherto|O accepted|O figures|O may|O underestimate|O the|O frequency|O by|O a|O factor|O of|O 10|O to|O 20|O .|O .|O
In|O the|O fifth|O family|O ,|O FISH|O analysis|O demonstrated|O the|O deletion|O of|O the|O entire|O VHL|B-DISE gene|O .|O
The|O Prader|B-DISE -|I-DISE Willi|I-DISE syndrome|I-DISE (|O PWS|O )|O critical|O region|O on|O 15q11|O -|O q13|O is|O subject|O to|O imprinting|O .|O
DNA|O methylation|O analysis|O of|O D15S63|O is|O consistent|O with|O an|O abnormality|O of|O the|O imprinting|O center|O associated|O with|O PWS|B-DISE .|O Grandmatrilineal|O "|O inheritance|O occurs|O when|O a|O woman|O with|O deletion|O of|O an|O imprinted|O
Prader|B-DISE -|I-DISE Willi|I-DISE syndrome|I-DISE (|O PWS|B-DISE )|O is|O a|O neurogenetic|B-DISE disease|I-DISE characterized|O by|O infantile|O hypotonia|B-DISE ,|O gonadal|B-DISE hypoplasia|I-DISE ,|O obsessive|B-DISE behaviour|I-DISE and|O neonatal|B-DISE feeding|I-DISE difficulties|I-DISE followed|O by|O hyperphagia|B-DISE ,|O leading|O to|O profound|O obesity|B-DISE .|O
A|O family|O study|O revealed|O complete|O C9|B-DISE deficiency|I-DISE in|O the|O patient|O '|O s|O healthy|O brother|O and|O half|O -|O normal|O C9|O concentrations|O in|O his|O sister|O ,|O his|O son|O (|O who|O also|O had|O experienced|O an|O episode|O of|O bacterial|B-DISE meningitis|I-DISE )|O ,|O and|O his|O niece|O ,|O consistent|O with|O an|O inherited|O C9|B-DISE deficiency|I-DISE .|O
The|O relationship|O between|O glycerol|O and|O the|O risk|O of|O IGT|B-DISE ,|O however|O ,|O is|O poorly|O understood|O .|O
In|O comparison|O with|O the|O usual|O EDMD|B-DISE phenotype|O ,|O patients|O with|O P183|O missense|O mutations|O have|O a|O later|O age|O at|O onset|O of|O first|O symptoms|O ,|O elbow|O contractures|O ,|O ankle|O contractures|O ,|O upper|O limb|O weakness|O and|O lower|O limb|O weakness|O ,|O but|O there|O is|O no|O difference|O for|O the|O age|O at|O onset|O of|O cardiac|O involvement|O .|O
The|O results|O suggest|O a|O common|O founder|O for|O this|O mutation|O .|O
BACKGROUND|O :|O X|O -|O linked|O adrenoleukodystrophy|B-DISE (|O ALD|B-DISE )|O is|O an|O inherited|B-DISE disease|I-DISE characterized|O by|O progressive|O neurologic|B-DISE dysfunction|I-DISE ,|O occasionally|O associated|O with|O adrenal|B-DISE insufficiency|I-DISE .|O
In|O myotonic|B-DISE dystrophy|I-DISE (|O DM|B-DISE )|O ,|O the|O size|O of|O a|O CTG|O repeat|O in|O the|O DM|O kinase|O gene|O generally|O increases|O in|O successive|O generations|O with|O clinical|O evidence|O of|O anticipation|O .|O
A|O portion|O of|O the|O Duchenne|B-DISE muscular|I-DISE dystrophy|I-DISE (|O DMD|O )|O gene|O transcript|O from|O human|O fetal|O skeletal|O muscle|O and|O mouse|O adult|O heart|O was|O sequenced|O ,|O representing|O approximately|O 25|O percent|O of|O the|O total|O ,|O 14|O -|O kb|O DMD|O transcript|O .|O
We|O conclude|O that|O the|O autosomal|O dominant|O aniridia|B-DISE in|O this|O family|O is|O due|O to|O a|O mutation|O at|O the|O AN2|O locus|O on|O 11p13|O .|O
We|O identified|O four|O RNA|O splicing|O factors|O -|O -|O hnRNP|O C|O ,|O U2AF|O (|O U2|O auxiliary|O factor|O )|O ,|O PTB|O (|O polypyrimidine|O tract|O binding|O protein|O )|O ,|O and|O PSF|O (|O PTB|O associated|O splicing|O factor|O )|O -|O -|O that|O bind|O to|O two|O short|O regions|O 3|O '|O of|O the|O (|O CUG|O )|O n|O ,|O and|O found|O a|O novel|O 3|O '|O DMPK|O exon|O resulting|O in|O an|O mRNA|O lacking|O the|O repeats|O .|O
We|O describe|O an|O aggressive|O and|O ultimately|O fatal|O case|O of|O PG|O in|O a|O patient|O with|O a|O congenital|B-DISE C7|I-DISE deficiency|I-DISE .|O
A|O large|O phenotypic|O variability|O has|O been|O observed|O ,|O with|O convulsive|B-DISE disorders|I-DISE ,|O motor|B-DISE retardation|I-DISE and|O mental|B-DISE retardation|I-DISE being|O the|O most|O abundant|O manifestations|O .|O
We|O describe|O a|O recurrent|O large|O expansion|O of|O a|O maternal|O allele|O with|O 36|O CAG|O repeats|O (|O to|O 66|O and|O 57|O repeats|O ,|O respectively|O ,|O in|O two|O daughters|O )|O associated|O with|O onset|O of|O Huntington|B-DISE disease|I-DISE (|O HD|B-DISE )|O in|O the|O second|O and|O third|O decade|O in|O a|O family|O without|O history|O of|O HD|B-DISE .|O
The|O previous|O report|O on|O the|O Japanese|O patients|O also|O suggested|O that|O disease|O allele|O stability|O may|O be|O influenced|O by|O a|O trans|O effect|O of|O an|O intragenic|O polymorphism|O (|O 987|O G|O /|O C|O )|O in|O the|O wild|O -|O type|O allele|O .|O
However|O ,|O the|O C|O -|O terminal|O end|O of|O the|O putative|O protein|O differs|O strongly|O from|O the|O published|O human|O sequence|O .|O
Deletion|O of|O this|O IC|O abolishes|O local|O paternally|O derived|O gene|O expression|O and|O results|O in|O Prader|B-DISE -|I-DISE Willi|I-DISE syndrome|I-DISE PWS|B-DISE .|O
In|O contrast|O ,|O mild|O mutations|O were|O mostly|O located|O on|O the|O surface|O of|O the|O GALNS|O protein|O .|O
In|O addition|O ,|O 5|O of|O 12|O nonsense|O mutations|O and|O 1|O missense|O mutation|O were|O associated|O with|O deletion|O in|O the|O cDNA|O of|O the|O exons|O in|O which|O the|O mutations|O occurred|O .|O
A|O high|O percentage|O of|O ATM|O germline|O mutations|O was|O demonstrated|O among|O patients|O with|O sporadic|B-DISE breast|I-DISE cancer|I-DISE .|O
To|O learn|O about|O causative|O mechanisms|O ,|O we|O have|O cloned|O and|O sequenced|O the|O breakpoints|O of|O a|O cytologically|O balanced|O constitutional|O reciprocal|O translocation|O ,|O t|O X|O ;|O 4|O (|O p21|O .|O 2|O ;|O q31|O .|O 22|O )|O ,|O present|O in|O a|O girl|O with|O Duchenne|B-DISE muscular|I-DISE dystrophy|I-DISE DMD|B-DISE .|O
Our|O results|O show|O that|O (|O quantitative|O )|O Southern|O blot|O analysis|O is|O a|O sensitive|O method|O for|O detecting|O germline|O deletions|O of|O the|O VHL|O gene|O and|O should|O be|O implemented|O in|O routine|O DNA|O diagnosis|O for|O VHL|B-DISE disease|I-DISE .|O
Infantile|B-DISE Tay|I-DISE -|I-DISE Sachs|I-DISE disease|I-DISE (|O TSD|B-DISE )|O is|O caused|O by|O mutations|O in|O the|O HEXA|O gene|O that|O result|O in|O the|O complete|O absence|O of|O beta|O -|O hexosaminidase|O A|O activity|O .|O
To|O determine|O if|O a|O cathepsin|O C|O mutation|O is|O also|O responsible|O for|O HMS|B-DISE ,|O we|O sequenced|O the|O gene|O in|O affected|O and|O unaffected|O subjects|O from|O the|O Cochin|O isolate|O in|O which|O both|O the|O PLS|B-DISE and|O HMS|B-DISE phenotypes|O appear|O .|O
Of|O these|O ,|O 31|O had|O severe|O G6PD|B-DISE deficiency|I-DISE ,|O nine|O had|O mild|O to|O moderate|O deficiency|O ,|O and|O three|O had|O a|O non|O -|O deficient|O electrophoretic|O variant|O .|O
However|O ,|O the|O clinical|O severity|O of|O the|O disease|O was|O not|O quite|O as|O mild|O as|O expected|O ,|O the|O mutation|O was|O not|O identified|O in|O the|O father|O despite|O confirmed|O paternity|O ,|O and|O the|O paternal|O allele|O showed|O a|O highly|O unusual|O pattern|O of|O polymorphic|O markers|O in|O the|O PAH|O gene|O .|O
Sequence|O analysis|O of|O CTSC|O from|O subjects|O affected|O with|O PLS|B-DISE from|O five|O consanguineous|O Turkish|O families|O identified|O four|O different|O mutations|O .|O
Together|O these|O data|O define|O the|O obligate|O region|O containing|O the|O NDP|O gene|O to|O a|O chromosomal|O segment|O less|O than|O 150|O kb|O .|O .|O
Previous|O authors|O have|O used|O the|O RNase|O protection|O assay|O and|O the|O single|O -|O strand|O conformation|O polymorphisms|O procedure|O to|O screen|O for|O mutations|O .|O
The|O rates|O of|O transport|O for|O iodide|O and|O chloride|O were|O significantly|O increased|O following|O the|O expression|O of|O pendrin|O in|O both|O cell|O systems|O .|O
Both|O the|O deciduous|O and|O permanent|O dentitions|O are|O affected|O ,|O resulting|O in|O premature|B-DISE tooth|I-DISE loss|I-DISE .|O
An|O Alu|O -|O PCR|O fragment|O from|O the|O right|O arm|O of|O the|O MAO|O YAC|O (|O YMAO|O .|O AluR|O )|O is|O not|O deleted|O in|O this|O patient|O and|O also|O delineates|O the|O centromeric|O extent|O of|O the|O obligate|O disease|O region|O .|O
The|O gene|O for|O EDMD|B-DISE on|O Xq28|O encodes|O a|O novel|O protein|O named|O emerin|O that|O localizes|O at|O the|O nuclear|O membrane|O of|O skeletal|O ,|O cardiac|O and|O smooth|O muscles|O and|O some|O other|O non|O -|O muscle|O tissues|O .|O
We|O report|O here|O on|O the|O analysis|O of|O C282Y|O ,|O H63D|O ,|O and|O the|O 193A|O -|O -|O >|O T|O substitution|O leading|O to|O the|O S65C|O missense|O substitution|O in|O a|O large|O series|O of|O probands|O and|O controls|O .|O
Multiple|B-DISE epiphyseal|I-DISE dysplasia|I-DISE is|O more|O frequently|O caused|O by|O dominant|O mutations|O in|O the|O COMP|O (|O EDM1|O ,|O McKusick|O 132400|O )|O and|O COL9A2|O genes|O EDM2|O ,|O McKusick|O 600204|O .|O
However|O ,|O perhaps|O because|O of|O an|O ancient|O frame|O -|O shift|O mutation|O ,|O neither|O the|O mouse|O nor|O the|O rat|O protein|O has|O an|O intact|O C|O -|O terminal|O B30|O .|O 2|O domain|O ,|O in|O which|O most|O FMF|B-DISE -|O associated|O mutations|O have|O been|O found|O in|O human|O MEFV|O .|O
DNA|O of|O affected|O males|O and|O obligate|O carriers|O was|O PCR|O amplified|O and|O analyzed|O by|O SSCA|O ,|O heteroduplex|O analysis|O ,|O and|O direct|O sequencing|O .|O
Of|O 16|O oral|B-DISE mucosal|I-DISE lesions|I-DISE studied|O histologically|O ,|O 15|O represented|O fibroepithelial|B-DISE or|I-DISE epithelial|I-DISE hyperplasias|I-DISE and|O were|O reactive|O in|O nature|O .|O
Glucose|O 6|O -|O phosphate|O dehydrogenase|O (|O G6PD|O )|O is|O a|O cytosolic|O enzyme|O encoded|O by|O a|O housekeeping|O X|O -|O linked|O gene|O whose|O main|O function|O is|O to|O produce|O NADPH|O ,|O a|O key|O electron|O donor|O in|O the|O defense|O against|O oxidizing|O agents|O and|O in|O reductive|O biosynthetic|O reactions|O .|O
Familial|B-DISE neurohypophyseal|I-DISE diabetes|I-DISE insipidus|I-DISE (|O FNDI|B-DISE )|O is|O an|O autosomal|B-DISE dominant|I-DISE disease|I-DISE caused|O by|O deficiency|B-DISE in|I-DISE the|I-DISE antidiuretic|I-DISE hormone|I-DISE arginine|I-DISE vasopressin|I-DISE (|O AVP|O )|O encoded|O by|O the|O AVP|O -|O neurophysin|O II|O (|O AVP|O -|O NPII|O )|O gene|O on|O chromosome|O 20p13|O .|O
The|O distinction|O between|O the|O two|O fragile|O sites|O is|O important|O clinically|O since|O cytogenetic|O detection|O of|O FRAXE|O ,|O without|O molecular|O analysis|O ,|O could|O result|O in|O misdiagnosis|O of|O fragile|B-DISE X|I-DISE syndrome|I-DISE .|O .|O
Canavan|B-DISE disease|I-DISE is|O an|O autosomal|O recessive|O leukodystrophy|B-DISE caused|O by|O the|O deficiency|B-DISE of|I-DISE aspartoacylase|I-DISE ASPA|O .|O
In|O the|O analyses|O of|O tumor|B-DISE tissues|O from|O the|O propositus|O and|O his|O daughter|O ,|O a|O P16INK4A|O codon|O 94|O missense|O point|O mutation|O (|O GCG|O -|O -|O >|O GAG|O ;|O Ala|O -|O -|O >|O Glu|O )|O was|O observed|O with|O the|O hereditary|O TP53|O mutation|O .|O
The|O phenotype|O in|O these|O families|O was|O compared|O in|O detail|O with|O the|O clinical|O features|O in|O cases|O with|O typical|O null|O mutations|O .|O
DGGE|O analysis|O of|O 10|O APC|O exons|O (|O 4|O ,|O 5|O ,|O 7|O ,|O 8|O ,|O 9|O ,|O 10|O ,|O 12|O ,|O 13|O ,|O 14|O ,|O and|O part|O of|O 15|O )|O in|O 33|O unrelated|O Dutch|O FAP|B-DISE patients|O has|O led|O to|O the|O identification|O of|O eight|O novel|O germ|O line|O mutations|O resulting|O in|O stop|O codons|O or|O frameshifts|O .|O
The|O Denys|B-DISE -|I-DISE Drash|I-DISE syndrome|I-DISE is|O characterised|O by|O a|O typical|O nephropathy|B-DISE ,|O genital|B-DISE abnormalities|I-DISE and|O also|O predisposes|O to|O the|O development|O of|O Wilms|B-DISE '|I-DISE tumor|I-DISE .|O
The|O molecular|O details|O of|O ATM|O function|O in|O the|O nervous|O system|O are|O unclear|O ,|O although|O the|O neurological|O lesion|O in|O ataxia|B-DISE -|I-DISE telangiectasia|I-DISE becomes|O apparent|O early|O in|O life|O ,|O suggesting|O a|O developmental|O origin|O .|O
The|O Gc|O -|O locus|O is|O closely|O linked|O to|O the|O structural|O albumin|O locus|O .|O
The|O mechanism|O by|O which|O (|O CTG|O )|O n|O expansion|O in|O the|O 3|O '|O UTR|O of|O the|O DMPK|O gene|O causes|O myotonic|B-DISE dystrophy|I-DISE (|O DM|B-DISE )|O is|O unknown|O .|O
A|O new|O tumor|O suppressor|O gene|O ,|O PTEN|O /|O MMAC1|O ,|O was|O isolated|O recently|O at|O this|O region|O of|O chromosome|O 10q23|O and|O found|O to|O be|O inactivated|O by|O mutation|O in|O three|O prostate|B-DISE cancer|I-DISE cell|O lines|O .|O
Our|O patient|O illustrates|O the|O importance|O of|O investigating|O for|O underlying|O ocular|O and|O central|O nervous|O system|O pathology|O whenever|O midline|B-DISE scalp|I-DISE defects|I-DISE are|O present|O .|O .|O
All|O missense|O mutations|O were|O located|O in|O exons|O 1|O -|O 4|O .|O
Many|O missense|O and|O protein|O -|O truncating|O mutations|O of|O the|O causative|O gene|O RS1|O have|O now|O been|O identified|O and|O are|O thought|O to|O be|O inactivating|O .|O
We|O have|O searched|O for|O germ|O -|O line|O RB1|O mutations|O in|O 119|O patients|O with|O hereditary|B-DISE retinoblastoma|I-DISE .|O
Coalescence|O analyses|O for|O the|O N370S|O and|O 84GG|O mutations|O estimated|O similar|O coalescence|O times|O ,|O of|O 48|O and|O 55|O .|O 5|O generations|O ago|O ,|O respectively|O .|O
Atm|O (|O y|O /|O y|O )|O mice|O exhibit|O deficits|O in|O motor|O learning|O indicative|O of|O cerebellar|B-DISE dysfunction|I-DISE .|O
Tumor|B-DISE tissue|O obtained|O from|O the|O propositus|O with|O the|O seminoma|B-DISE revealed|O loss|O of|O heterozygosity|O in|O the|O TP53|O gene|O .|O
The|O hereditary|O group|O had|O a|O longer|O disease|O -|O free|O interval|O following|O primary|O chemotherapy|O in|O comparison|O with|O the|O nonhereditary|O group|O ,|O with|O a|O median|O time|O to|O recurrence|O of|O 14|O months|O and|O 7|O months|O ,|O respectively|O P|O <|O .|O 001|O .|O
Variant|O A|O (|O -|O 1|O )|O T|O at|O the|O Fas|O signal|O -|O sequence|O cleavage|O site|O ,|O which|O mediates|O apoptosis|O less|O well|O than|O wild|O -|O type|O Fas|O and|O is|O partially|O inhibitory|O ,|O was|O present|O in|O 13|O %|O of|O African|O American|O alleles|O .|O
These|O data|O functionally|O define|O a|O novel|O genetic|O locus|O ,|O designated|O PAC1|O ,|O for|O prostate|O adenocarcinoma|O 1|O ,|O involved|O in|O tumor|O suppression|O of|O human|O prostate|B-DISE carcinoma|I-DISE and|O furthermore|O strongly|O suggest|O that|O the|O cell|O death|O pathway|O can|O be|O functionally|O restored|O in|O prostatic|B-DISE adenocarcinoma|I-DISE .|O .|O
Use|O of|O a|O cryptic|O 5|O '|O splice|O site|O in|O exon|O 8|O ,|O which|O results|O in|O absence|O or|O presence|O of|O 15|O nucleotides|O specifying|O a|O VSGGG|O peptide|O motif|O ,|O and|O /|O or|O use|O of|O a|O cryptic|O 3|O '|O splice|O site|O in|O exon|O 14|O ,|O which|O leads|O to|O a|O frameshift|O in|O the|O mRNA|O reading|O frame|O ,|O occur|O as|O independent|O stochastic|O events|O in|O all|O tissues|O examined|O .|O
Exons|O 1|O -|O 3|O of|O the|O functional|O GLDC|O gene|O from|O this|O patient|O are|O not|O amplified|O by|O polymerase|O chain|O reaction|O (|O PCR|O )|O ,|O whereas|O those|O from|O control|O subjects|O are|O .|O
Appreciable|O beta|O hexosaminidase|O A|O (|O hex|O A|O )|O activity|O has|O been|O detected|O in|O cultured|O skin|O fibroblasts|O and|O melanoma|B-DISE tissue|O from|O healthy|O individuals|O previously|O reported|O as|O having|O deficiency|B-DISE of|I-DISE hex|I-DISE A|I-DISE activity|O indistinguishable|O from|O that|O of|O patients|O with|O Tay|B-DISE -|I-DISE Sachs|I-DISE disease|I-DISE TSD|B-DISE .|O
A|O gene|O encoding|O a|O novel|O transmembrane|O protein|O was|O identified|O by|O DNA|O sequence|O analysis|O within|O the|O insulin|B-DISE -|I-DISE dependent|I-DISE diabetes|I-DISE mellitus|I-DISE (|O IDDM|O )|O locus|O IDDM4|O on|O chromosome|O 11q13|O .|O
The|O frequency|O of|O G6PD|B-DISE deficiency|I-DISE varies|O between|O 3|O %|O and|O 15|O %|O in|O different|O tribal|O and|O urban|O groups|O .|O
It|O can|O be|O used|O with|O limited|O amounts|O of|O material|O and|O has|O strong|O potential|O for|O clinical|O applications|O .|O .|O
Lymphocytes|O from|O all|O WAS|B-DISE patients|O showed|O WASPdim|O instead|O of|O WASPbright|O .|O
The|O mutation|O introduces|O a|O new|O recognition|O site|O for|O the|O restriction|O enzyme|O Eco|O RV|O ,|O permitting|O identification|O of|O heterozygotes|O for|O this|O allele|O following|O PCR|O amplification|O and|O Eco|O RV|O digestion|O of|O exon|O 7|O sequences|O from|O genomic|O DNA|O templates|O .|O
There|O were|O no|O differences|O in|O phenotypic|O expressions|O between|O missense|O mutations|O involving|O conserved|O amino|O acids|O and|O those|O involving|O nonconserved|O amino|O acids|O .|O
The|O zinc|O finger|O mutations|O affect|O DNA|O binding|O and|O the|O amount|O of|O residual|O binding|O directly|O correlates|O with|O disease|O severity|O .|O
The|O efficiency|O of|O this|O system|O ,|O as|O a|O screening|O test|O for|O BRCA1|O mutations|O ,|O was|O evaluated|O in|O a|O panel|O of|O 60|O samples|O from|O high|O risk|O women|O ,|O 14|O of|O which|O contained|O a|O previously|O identified|O mutation|O in|O BRCA1|O .|O
Homozygosity|O for|O poor|O metabolizer|O alleles|O was|O found|O to|O be|O associated|O with|O AS|B-DISE .|O
We|O describe|O the|O proportion|O of|O hereditary|O breast|O cancer|O explained|O by|O BRCA1|O or|O BRCA2|O in|O a|O sample|O of|O North|O American|O hereditary|B-DISE breast|I-DISE cancers|I-DISE and|O assess|O the|O evidence|O for|O additional|O susceptibility|O genes|O that|O may|O confer|O hereditary|B-DISE breast|I-DISE or|I-DISE ovarian|I-DISE cancer|I-DISE risk|O .|O
Heterozygous|O carriers|O of|O this|O gene|O are|O common|O among|O the|O close|O relatives|O of|O patients|O with|O A|B-DISE -|I-DISE T|I-DISE ,|O although|O individual|O carriers|O cannot|O be|O identified|O by|O any|O clinical|O criterion|O or|O laboratory|O test|O .|O
A|O combination|O of|O multiplex|O PCR|O with|O the|O single|O strand|O conformation|O polymorphism|O (|O SSCP|O )|O technique|O was|O employed|O to|O screen|O for|O point|O mutations|O in|O the|O human|O dystrophin|O gene|O .|O
Mutations|O in|O the|O ATM|O gene|O are|O responsible|O for|O the|O autosomal|B-DISE recessive|I-DISE disorder|I-DISE ataxia|B-DISE -|I-DISE telangiectasia|I-DISE (|O A|B-DISE -|I-DISE T|I-DISE )|O MIM|O 208900|O .|O
Fluorescence|O in|O situ|O hybridisation|O (|O FISH|O )|O studies|O with|O distal|O 11p13|O specific|O cosmids|O showed|O that|O the|O chromosome|O 11|O breakpoint|O lay|O between|O the|O aniridia|B-DISE (|O PAX6|O )|O locus|O and|O a|O region|O approximately|O 100|O kb|O distal|O to|O PAX6|O defined|O by|O the|O cosmid|O FO2121|O .|O
A|O significant|O number|O of|O these|O mutations|O are|O premature|O stop|O codons|O .|O
A|O missense|O mutation|O ,|O R483G|O ,|O was|O located|O in|O the|O highly|O conserved|O PtdIns|O (|O 4|O ,|O 5|O )|O P2|O 5|O -|O phosphatase|O domain|O .|O
The|O expression|O level|O of|O all|O the|O Kell|O antigens|O in|O erythrocyte|O was|O decreased|O and|O molecular|O analysis|O revealed|O a|O single|O -|O base|O (|O T|O )|O deletion|O at|O the|O nucleotide|O position|O 1095|O in|O XK|O .|O
Cutaneous|O and|O ocular|O pigmentation|O were|O evaluated|O in|O 29|O individuals|O with|O the|O Prader|B-DISE -|I-DISE Willi|I-DISE syndrome|I-DISE PWS|B-DISE .|O
Using|O this|O combined|O approach|O ,|O we|O identified|O germline|O APC|O gene|O mutations|O in|O 29|O of|O the|O 48|O FAP|B-DISE patients|O (|O 60|O %|O )|O ,|O including|O 6|O patients|O in|O whom|O SSCP|O analysis|O failed|O to|O distinguish|O the|O mutant|O allele|O .|O
The|O gene|O encodes|O a|O transcriptional|O regulator|O that|O recognizes|O target|O genes|O through|O its|O paired|O -|O type|O DNA|O -|O binding|O domain|O .|O
To|O determine|O the|O genetic|O basis|O for|O reduction|O or|O loss|O of|O enzyme|O activity|O ,|O we|O have|O amplified|O and|O sequenced|O the|O coding|O region|O of|O HPRT|O cDNA|O from|O four|O patients|O :|O one|O with|O Lesch|B-DISE -|I-DISE Nyhan|I-DISE syndrome|I-DISE (|O HPRTPerth|O )|O and|O three|O with|O partial|O deficiencies|O of|O HPRT|O activity|O ,|O which|O have|O been|O designated|O HPRTUrangan|O ,|O HPRTSwan|O and|O HPRTToowong|O .|O
These|O findings|O reveal|O a|O direct|O function|O for|O BRCA1|O in|O transcriptional|O control|O through|O modulation|O of|O chromatin|O structure|O .|O .|O
Several|O transgenic|O lines|O were|O generated|O that|O carried|O the|O entire|O FMR1|O locus|O with|O extensive|O amounts|O of|O flanking|O sequence|O .|O
Of|O the|O 83|O people|O we|O studied|O who|O have|O mutations|O in|O FRDA|O ,|O 78|O are|O homozygous|O for|O an|O expanded|O GAA|O repeat|O ;|O the|O other|O five|O patients|O have|O an|O expansion|O in|O one|O allele|O and|O a|O point|O mutation|O in|O the|O other|O .|O
episodic|B-DISE ataxia|I-DISE type|I-DISE 2|I-DISE (|O EA|B-DISE -|I-DISE 2|I-DISE )|O ,|O familial|B-DISE hemiplegic|I-DISE migraine|I-DISE (|O FHM|B-DISE )|O and|O spinocerebellar|B-DISE ataxia|I-DISE 6|I-DISE SCA6|B-DISE .|O
Altogether|O ,|O 20|O of|O the|O patients|O had|O BRCA1|O 1675delA|O ,|O and|O 10|O had|O 1135insA|O .|O
Although|O the|O mutant|O hMre11|O proteins|O retain|O some|O ability|O to|O interact|O with|O hRad50|O and|O Nbs1|O ,|O formation|O of|O ionizing|O radiation|O -|O induced|O hMre11|O and|O Nbs1|O foci|O was|O absent|O in|O hMRE11|O mutant|O cells|O .|O
Germline|O VHL|O gene|O mutations|O predispose|O to|O the|O development|O of|O retinal|B-DISE ,|I-DISE cerebellar|I-DISE and|I-DISE spinal|I-DISE haemangioblastomas|I-DISE ,|O renal|B-DISE cell|I-DISE carcinoma|I-DISE and|O phaeochromocytoma|B-DISE .|O
The|O mutations|O 2871delC|O and|O 2513delA|O shift|O the|O reading|O frame|O so|O that|O truncated|O abnormal|O protein|O is|O expected|O .|O
Additionally|O ,|O a|O second|O previously|O identified|O recurrent|O muta|O tion|O ,|O C2272T|O ,|O in|O exon|O 16|O has|O been|O discovered|O in|O a|O patient|O with|O FHM|B-DISE .|O .|O
In|O some|O affected|O eyes|O ,|O collagen|B-DISE bundles|I-DISE were|I-DISE half|I-DISE normal|I-DISE diameter|I-DISE ,|O or|O collagen|B-DISE and|I-DISE elastic|I-DISE tissue|I-DISE were|I-DISE very|I-DISE sparse|I-DISE .|O
Moreover|O ,|O G6PD|B-DISE deficiency|I-DISE should|O be|O added|O to|O other|O conditions|O ,|O such|O as|O the|O galactosemic|O states|O and|O riboflavin|B-DISE deficiency|I-DISE ,|O where|O cataracts|B-DISE represent|O a|O sensitive|O indicator|O of|O metabolic|O abnormalities|O of|O the|O RBC|O .|O .|O
He|O was|O found|O to|O be|O homozygous|O ,|O and|O both|O healthy|O parents|O heterozygous|O ,|O for|O the|O R279W|O mutation|O in|O DTDST|O ,|O and|O his|O fibroblasts|O showed|O a|O sulphate|O incorporation|O defect|O typical|O of|O DTDST|O disorders|O .|O
Genetic|B-DISE hemochromatosis|I-DISE (|O GH|B-DISE )|O is|O believed|O to|O be|O a|O disease|O restricted|O to|O those|O of|O European|O ancestry|O .|O
In|O contrast|O to|O these|O mutations|O found|O in|O patients|O with|O hepatic|O -|O type|O of|O early|O onset|O ,|O the|O mutations|O A874V|O ,|O R778L|O ,|O and|O 3892delGTC|O were|O either|O missense|O mutations|O or|O in|O frame|O 1|O -|O amino|O acid|O deletion|O ,|O and|O occurred|O in|O the|O patients|O with|O hepato|O -|O neurologic|O type|O of|O late|O onset|O .|O
A|O population|O -|O based|O series|O of|O 54|O male|B-DISE breast|I-DISE cancer|I-DISE cases|O from|O Southern|O California|O were|O analyzed|O for|O germ|O -|O line|O mutations|O in|O the|O inherited|B-DISE breast|I-DISE /|I-DISE ovarian|I-DISE cancer|I-DISE genes|O ,|O BRCA1|O and|O BRCA2|O .|O
The|O recently|O cloned|O human|O breast|B-DISE and|I-DISE ovarian|I-DISE cancer|I-DISE susceptibility|O gene|O ,|O BRCA1|O ,|O is|O located|O on|O human|O chromosome|O 17q21|O .|O
To|O determine|O the|O prevalence|O of|O heterozygous|O carriers|O of|O the|O Arg95Stop|O mutation|O in|O a|O Japanese|O population|O ,|O we|O collected|O DNA|O samples|O from|O 300|O individuals|O in|O two|O of|O the|O four|O main|O islands|O of|O Japan|O .|O
Comparable|O results|O were|O produced|O when|O the|O replacement|O 119|O Gln|O -|O -|O >|O Glu|O was|O studied|O instead|O of|O 126|O Asn|O -|O -|O >|O Asp|O .|O
Screening|O for|O the|O G6PD|B-DISE deficiency|I-DISE was|O carried|O out|O at|O the|O Maternity|O Division|O of|O the|O Galliera|O Hospital|O in|O Genoa|O ,|O Italy|O .|O
Mutants|O found|O in|O the|O severe|O phenotype|O had|O no|O activity|O .|O
Twenty|O -|O one|O of|O them|O were|O point|O mutations|O ;|O 16|O nonsense|O and|O two|O missense|O mutations|O ,|O and|O three|O occurred|O in|O introns|O at|O the|O splicing|O site|O .|O
A|O -|O T|O heterozygotes|O may|O comprise|O more|O than|O 5|O %|O of|O all|O persons|O dying|O from|O a|O cancer|B-DISE before|O age|O 45|O .|O
The|O single|O family|O with|O a|O BRCA2|O mutation|O had|O the|O breast|B-DISE -|I-DISE ovarian|I-DISE cancer|I-DISE syndrome|O .|O
The|O CTSC|O message|O is|O expressed|O at|O high|O levels|O in|O a|O variety|O of|O immune|O cells|O including|O polymorphonuclear|O leucocytes|O ,|O macrophages|O ,|O and|O their|O precursors|O .|O
The|O considerable|O genetic|O heterogeneity|O documented|O to|O date|O undoubtedly|O contributes|O to|O the|O phenotypic|O heterogeneity|O that|O is|O observed|O in|O galactosemia|B-DISE .|O
Myotonic|B-DISE dystrophy|I-DISE (|O DM|B-DISE )|O is|O associated|O with|O the|O expansion|O of|O a|O (|O CTG|O )|O n|O trinucleotide|O repeat|O in|O the|O 3|O '|O untranslated|O region|O (|O UTR|O )|O of|O the|O DM|O protein|O kinase|O gene|O DMPK|O .|O
We|O have|O undertaken|O a|O systematic|O evaluation|O of|O DMD|B-DISE /|O BMD|B-DISE patients|O through|O clinical|O examination|O and|O review|O of|O the|O literature|O in|O order|O to|O determine|O whether|O the|O position|O -|O specific|O effects|O of|O mutations|O noted|O in|O the|O mouse|O are|O present|O in|O man|O .|O
A|O female|O with|O a|O unilateral|O variant|O of|O Coats|B-DISE '|I-DISE disease|I-DISE gave|O birth|O to|O a|O son|O affected|O by|O Norrie|B-DISE disease|I-DISE .|O
Although|O marked|O differences|O in|O extragenic|O marker|O haplotypes|O were|O seen|O in|O one|O family|O ,|O similar|O intragenic|O haplotyping|O suggests|O the|O same|O mutation|O founder|O for|O this|O family|O with|O the|O differences|O explicable|O by|O two|O recombination|O events|O .|O .|O
Maternal|O uniparental|B-DISE disomy|I-DISE (|O UPD|B-DISE )|O for|O chromosome|O 15|O is|O responsible|O for|O an|O estimated|O 30|O %|O of|O cases|O of|O Prader|B-DISE -|I-DISE Willi|I-DISE syndrome|I-DISE PWS|B-DISE .|O
This|O treatment|O could|O prove|O effective|O in|O up|O to|O 15|O %|O of|O patients|O with|O DMD|B-DISE .|O .|O
These|O results|O suggest|O that|O rhabdoid|B-DISE tumors|I-DISE ,|O choroid|B-DISE plexus|I-DISE carcinomas|I-DISE and|O a|O subset|O of|O medulloblastomas|B-DISE and|O cPNETs|O share|O common|O pathways|O of|O oncogenesis|B-DISE related|O to|O hSNF5|O /|O INI1|O alteration|O and|O that|O hSNF5|O /|O INI1|O mutations|O define|O a|O genetically|O homogeneous|O family|O of|O highly|O aggressive|O cancers|B-DISE mainly|O occurring|O in|O young|O children|O and|O frequently|O ,|O but|O not|O always|O ,|O exhibiting|O a|O rhabdoid|O phenotype|O .|O .|O
Haplotyping|O showed|O that|O they|O are|O likely|O to|O derive|O from|O a|O common|O ancestor|O ,|O possibly|O of|O northern|O British|O origin|O .|O
An|O amelogenin|O gene|O ,|O AMGX|O ,|O has|O been|O mapped|O to|O the|O short|O of|O the|O X|O chromosome|O (|O Xp22|O .|O 1|O -|O p22|O .|O 3|O )|O and|O has|O been|O implicated|O in|O the|O molecular|O pathology|O of|O X|O -|O linked|O amelogenesis|B-DISE imperfecta|I-DISE AIH1|O .|O
Eight|O of|O the|O 16|O homozygous|O subjects|O had|O clinical|O findings|O that|O were|O consistent|O with|O the|O presence|O of|O hereditary|B-DISE hemochromatosis|I-DISE ,|O such|O as|O hepatomegaly|B-DISE ,|O skin|B-DISE pigmentation|I-DISE ,|O and|O arthritis|B-DISE .|O
Autoimmune|B-DISE lymphoproliferative|I-DISE syndrome|I-DISE (|O ALPS|B-DISE )|O is|O characterized|O by|O autoimmune|O features|O and|O lymphoproliferations|O and|O is|O generally|O caused|O by|O defective|O Fas|O -|O mediated|O apoptosis|O .|O
The|O following|O markers|O were|O tested|O :|O C2|O levels|O ,|O factor|O B|O polymorphism|O ,|O blood|O groups|O ,|O and|O enzyme|O typing|O .|O
Cell|O fusion|O complementation|O studies|O demonstrated|O that|O these|O diseases|O are|O genetically|O heterogeneous|O ,|O with|O two|O -|O thirds|O of|O all|O patients|O lying|O within|O a|O single|O complementation|O group|O ,|O CG1|O .|O
We|O conclude|O that|O the|O COLIA1|O /|O PDGFB|O fusion|O associated|O with|O DFSP|O contributes|O to|O tumor|B-DISE development|O through|O ectopic|O production|O of|O PDGF|O -|O BB|O and|O the|O formation|O of|O an|O autocrine|O loop|O .|O
Li|B-DISE -|I-DISE Fraumeni|I-DISE syndrome|I-DISE is|O an|O autosomal|O dominant|O disorder|O that|O is|O characterized|O by|O various|O types|O of|O cancer|B-DISE in|O childhood|O and|O adult|O cases|O .|O
These|O results|O suggest|O the|O possibility|O of|O a|O unique|O origin|O for|O a|O mutation|O responsible|O for|O many|O or|O most|O cases|O of|O VWS|B-DISE .|O .|O
Autosomal|O dominant|O neurohypophyseal|B-DISE diabetes|I-DISE insipidus|I-DISE (|O ADNDI|O )|O is|O an|O inherited|O disease|O caused|O by|O progressive|O degeneration|O of|O the|O magnocellular|O neurons|O of|O the|O hypothalamus|O leading|O to|O decreased|O ability|O to|O produce|O the|O hormone|O arginine|O vasopressin|O AVP|O .|O
The|O maximum|O two|O -|O point|O LOD|O score|O was|O found|O for|O marker|O at|O D8S267|O Zmax|O =|O 3|O .|O 237|O at|O Omax|O =|O 0|O .|O 00|O .|O
The|O gene|O for|O Alstrom|B-DISE syndrome|I-DISE (|O ALMS1|O )|O has|O been|O previously|O localized|O to|O human|O chromosome|O 2p13|O by|O homozygosity|O mapping|O in|O two|O distinct|O isolated|O populations|O -|O French|O Acadian|O and|O North|O African|O .|O
The|O most|O important|O findings|O can|O be|O summarized|O as|O follows|O :|O (|O 1|O )|O The|O Spanish|O population|O is|O characterized|O by|O an|O important|O heterogeneity|O in|O G6PD|B-DISE deficiency|I-DISE .|O
Among|O the|O ALPS|B-DISE -|O associated|O Fas|O mutants|O ,|O dominant|O inhibition|O of|O apoptosis|O was|O much|O more|O pronounced|O in|O mutants|O affecting|O the|O intracellular|O ,|O versus|O extracellular|O ,|O portion|O of|O the|O Fas|O receptor|O .|O
A|O study|O was|O undertaken|O to|O characterize|O the|O mutation|O (|O s|O )|O responsible|O for|O Tay|B-DISE -|I-DISE Sachs|I-DISE disease|I-DISE (|O TSD|B-DISE )|O in|O a|O Cajun|O population|O in|O southwest|O Louisiana|O and|O to|O identify|O the|O origins|O of|O these|O mutations|O .|O
Am|O J|O Hum|O Genet|O ,|O 1992|O ,|O these|O two|O alleles|O accounted|O for|O almost|O 50|O %|O (|O 29|O /|O 64|O )|O of|O TSD|B-DISE or|O carrier|O alleles|O ascertained|O by|O enzyme|O screening|O tests|O in|O non|O -|O Jewish|O Caucasians|O .|O .|O
Patients|O were|O selected|O because|O they|O were|O heterozygous|O or|O homozygous|O for|O C2|B-DISE deficiency|I-DISE .|O 12|O families|O with|O 15|O matings|O informative|O for|O C2|B-DISE deficiency|I-DISE were|O found|O .|O
Given|O the|O expected|O logistical|O problems|O in|O clinical|O management|O now|O that|O BRCA1|O has|O been|O identified|O ,|O we|O propose|O an|O interim|O period|O in|O which|O only|O families|O with|O a|O strong|O positive|O family|O history|O for|O early|B-DISE onset|I-DISE breast|I-DISE and|I-DISE /|I-DISE or|I-DISE ovarian|I-DISE cancer|I-DISE will|O be|O offered|O BRCA1|O mutation|O testing|O .|O .|O
CONCLUSIONS|O :|O The|O S135L|O mutation|O in|O the|O GALT|O gene|O is|O a|O prevalent|O cause|O of|O galactosemia|B-DISE among|O black|O patients|O .|O
In|O a|O study|O of|O G6PD|B-DISE deficient|I-DISE patients|O who|O presented|O with|O clinical|O favism|B-DISE in|O Spain|O ,|O we|O have|O found|O a|O new|O polymorphic|O variant|O that|O we|O have|O called|O G6PD|O Malaga|O ,|O whose|O only|O abnormality|O is|O a|O 542|O A|O -|O -|O T|O (|O 181|O Asp|O -|O -|O Val|O )|O mutation|O .|O
Fluorescence|O in|O situ|O hybridization|O (|O FISH|O )|O with|O biotin|O -|O labeled|O probes|O mapping|O to|O 11p13|O has|O been|O used|O for|O the|O molecular|O analysis|O of|O deletions|O of|O the|O WAGR|O (|O Wilms|B-DISE tumor|I-DISE ,|O aniridia|B-DISE ,|O genitourinary|B-DISE abnormalities|I-DISE ,|O and|O mental|B-DISE retardation|I-DISE )|O locus|O .|O
He|O has|O been|O found|O to|O have|O a|O variant|O of|O hypoxanthine|O guanine|O phosphoribosyl|O transferase|O (|O HPRT|O ;|O E|O .|O C|O .|O 2|O .|O 4|O .|O 2|O .|O 8|O )|O distinct|O from|O the|O enzyme|O present|O in|O patients|O with|O the|O Lesch|B-DISE -|I-DISE Nyhan|I-DISE syndrome|I-DISE .|O
Most|O colon|B-DISE cancers|I-DISE arise|O from|O mutations|O in|O the|O gene|O encoding|O adenomatous|B-DISE polyposis|I-DISE coli|I-DISE (|O APC|O )|O ,|O a|O protein|O required|O for|O ubiquitin|O -|O mediated|O degradation|O of|O beta|O -|O catenin|O ,|O but|O a|O small|O percentage|O of|O colon|O and|O some|O other|O cancers|O harbour|O beta|O -|O catenin|O -|O stabilizing|O mutations|O .|O
We|O report|O on|O a|O new|O allele|O at|O the|O arylsulfatase|O A|O (|O ARSA|O )|O locus|O causing|O late|O -|O onset|O metachromatic|B-DISE leukodystrophy|I-DISE MLD|B-DISE .|O
Most|O emerin|O mutations|O result|O in|O absence|O of|O the|O protein|O .|O
Our|O results|O demonstrate|O that|O it|O is|O strongly|O advisable|O ,|O for|O laboratories|O carrying|O out|O screening|O either|O in|O English|O -|O speaking|O countries|O or|O in|O countries|O with|O historical|O links|O with|O Britain|O ,|O to|O include|O within|O their|O BRCA1|O screening|O protocols|O the|O polymerase|O chain|O reaction|O -|O based|O assay|O described|O in|O this|O report|O .|O .|O
A|O controlled|O ,|O double|O -|O blind|O therapeutic|O trial|O with|O the|O drug|O mazindol|O ,|O a|O growth|O hormone|O inhibitor|O ,|O was|O performed|O in|O a|O pair|O of|O 7|O 1|O /|O 2|O year|O -|O old|O monozygotic|O twins|O ,|O with|O Duchenne|B-DISE muscular|I-DISE dystrophy|I-DISE DMD|B-DISE .|O
Myotonic|B-DISE dystrophy|I-DISE (|O DM|B-DISE )|O is|O the|O most|O common|O form|O of|O adult|O muscular|B-DISE dystrophy|I-DISE ,|O with|O a|O prevalence|O of|O 2|O -|O 14|O per|O 100|O ,|O 000|O individuals|O .|O
The|O complete|O sequence|O and|O characterization|O of|O the|O structure|O of|O the|O DM|O kinase|O gene|O ,|O as|O well|O as|O the|O identification|O of|O novel|O polymorphisms|O within|O the|O gene|O ,|O represent|O an|O important|O step|O in|O a|O further|O understanding|O of|O the|O genetics|O of|O myotonic|B-DISE dystrophy|I-DISE and|O the|O molecular|O biology|O of|O the|O gene|O .|O .|O
No|O mutation|O in|O the|O coding|O region|O of|O the|O proteolipid|O protein|O (|O PLP|O )|O gene|O had|O been|O found|O .|O
The|O HMGI|O family|O of|O proteins|O consists|O of|O three|O members|O ,|O HMGIC|O ,|O HMGI|O and|O HMGI|O (|O Y|O )|O ,|O that|O function|O as|O architectural|O factors|O and|O are|O essential|O components|O of|O the|O enhancesome|O .|O
These|O results|O are|O consistent|O with|O the|O hypothesis|O of|O linkage|O to|O HPC1|O in|O a|O subset|O of|O families|O with|O prostate|O cancer|O ,|O particularly|O those|O with|O an|O early|O age|O at|O diagnosis|O .|O .|O
These|O findings|O strongly|O implicate|O TSG101|O mutations|O in|O human|O breast|B-DISE cancer|I-DISE .|O .|O
The|O Wilms|B-DISE tumor|I-DISE -|O suppressor|O gene|O ,|O WT1|O ,|O plays|O a|O key|O role|O in|O urogenital|O development|O ,|O and|O WT1|O dysfunction|O is|O implicated|O in|O both|O neoplastic|B-DISE (|I-DISE Wilms|I-DISE tumor|I-DISE ,|I-DISE mesothelioma|I-DISE ,|I-DISE leukemias|I-DISE ,|I-DISE and|I-DISE breast|I-DISE cancer|I-DISE )|I-DISE and|I-DISE nonneoplastic|I-DISE (|I-DISE glomerulosclerosis|I-DISE )|I-DISE disease|I-DISE .|O
Pendred|B-DISE syndrome|I-DISE is|O the|O most|O common|O form|O of|O syndromic|O deafness|B-DISE ,|O characterized|O by|O dyshormonogenic|B-DISE goiter|I-DISE associated|O with|O sensory|B-DISE -|I-DISE neural|I-DISE deafness|I-DISE .|O
We|O recently|O described|O a|O Japanese|O family|O with|O increased|O HDL|O levels|O and|O CETP|B-DISE deficiency|I-DISE due|O to|O a|O splicing|O defect|O of|O the|O CETP|O gene|O .|O
We|O report|O here|O fine|O physical|O mapping|O of|O the|O obligate|O region|O containing|O the|O Norrie|B-DISE disease|I-DISE gene|O (|O NDP|O )|O defined|O by|O a|O recombination|O and|O by|O the|O smallest|O submicroscopic|O chromosomal|O deletion|O associated|O with|O Norrie|B-DISE disease|I-DISE identified|O to|O date|O .|O
Recently|O ,|O a|O 6|O -|O kb|O duplication|O of|O exon|O 13|O ,|O which|O creates|O a|O frameshift|O in|O the|O coding|O sequence|O of|O the|O BRCA1|O gene|O ,|O has|O been|O described|O in|O three|O unrelated|O U|O .|O S|O .|O families|O of|O European|O ancestry|O and|O in|O one|O Portuguese|O family|O .|O
We|O examined|O galactosylceramidase|O (|O GALC|O )|O cDNA|O in|O four|O Japanese|O patients|O with|O adult|O onset|O globoid|B-DISE cell|I-DISE leukodystrophy|I-DISE (|O Krabbe|B-DISE disease|I-DISE ;|O AO|O -|O GLD|B-DISE )|O by|O polymerase|O chain|O reaction|O /|O single|O -|O strand|O conformation|O polymorphism|O (|O PCR|O -|O SSCP|O )|O analysis|O ,|O subsequent|O sequence|O determination|O ,|O and|O restriction|O enzyme|O digestion|O of|O PCR|O products|O ,|O initial|O symptoms|O were|O the|O onset|O of|O slowly|O progressive|O spastic|B-DISE paraplegia|I-DISE from|O the|O middle|O of|O the|O second|O decade|O ,|O and|O all|O patients|O had|O diminished|O GALC|O activity|O in|O their|O leukocytes|O .|O
Correlation|O of|O physical|O and|O genetic|O maps|O of|O this|O interval|O indicate|O it|O includes|O at|O least|O 40|O ESTs|O and|O six|O known|O genes|O including|O the|O lysosomal|O protease|O cathepsin|O C|O gene|O CTSC|O .|O
The|O latter|O three|O mutations|O are|O predicted|O to|O result|O in|O exon|O skipping|O in|O the|O mRNA|O encoded|O from|O the|O mutant|O allele|O .|O
We|O have|O previously|O cloned|O and|O sequenced|O a|O Na|O +|O /|O glucose|O cotransporter|O from|O normal|O human|O ileum|O and|O shown|O that|O this|O gene|O ,|O SGLT1|O ,|O resides|O on|O the|O distal|O q|O arm|O of|O chromosome|O 22|O .|O
Mutations|O at|O the|O phenylalanine|O hydroxylase|O (|O PAH|O )|O locus|O are|O the|O major|O cause|O of|O hyperphenylalaninemia|B-DISE .|O
Chromosome|O banding|O disclosed|O that|O the|O clones|O are|O consistently|O marked|O by|O structural|O rearrangement|O of|O the|O long|O arm|O (|O q|O )|O of|O chromosome|O 14|O .|O
It|O should|O now|O be|O possible|O to|O identify|O mutations|O in|O the|O noncoding|O genomic|O sequences|O that|O lead|O to|O Canavan|B-DISE disease|I-DISE and|O to|O study|O the|O regulation|O of|O ASPA|O .|O .|O
Experimental|O models|O of|O polyglutamine|O disease|O implicate|O the|O nucleus|O in|O pathogenesis|O ;|O however|O ,|O the|O link|O between|O intranuclear|O expression|O of|O expanded|O polyglutamine|O and|O neuronal|B-DISE dysfunction|I-DISE remains|O unclear|O .|O
We|O show|O that|O homozygous|O deletions|O cause|O embryonic|O lethality|O a|O few|O days|O after|O implantation|O ,|O demonstrating|O an|O important|O role|O for|O frataxin|O during|O early|O development|O .|O
DNA|O was|O also|O screened|O for|O structural|O rearrangements|O (|O deletions|O and|O duplications|O )|O and|O point|O mutations|O in|O mtDNA|O .|O
The|O frequency|O of|O G6PD|B-DISE deficiency|I-DISE in|O the|O patients|O was|O not|O different|O from|O the|O incidence|O in|O a|O group|O of|O 16|O ,|O 219|O controls|O .|O
Assoc|O .|O ,|O 273|O :|O 564|O -|O 570|O ,|O 1995|O ;|O
This|O agrees|O well|O with|O the|O fact|O that|O cardiac|B-DISE and|I-DISE muscle|I-DISE symptoms|I-DISE are|O characteristic|O for|O patients|O with|O VLCAD|O deficiency|O .|O
Examination|O of|O plasma|O amino|O acids|O ,|O an|O investigation|O not|O previously|O reported|O ,|O revealed|O an|O extremely|O low|O plasma|O tryptophan|O level|O ,|O a|O finding|O which|O may|O be|O important|O in|O view|O of|O the|O role|O of|O tryptophan|O in|O albumin|O synthesis|O .|O .|O
The|O mutation|O causing|O juvenile|O Tay|B-DISE -|I-DISE Sachs|I-DISE disease|I-DISE (|O TSD|B-DISE )|O in|O two|O sibs|O of|O Lebanese|O -|O Maronite|O origin|O is|O described|O .|O
Mutations|O in|O APC|O are|O classically|O associated|O with|O familial|B-DISE adenomatous|I-DISE polyposis|I-DISE (|O FAP|B-DISE )|O ,|O a|O highly|O penetrant|O autosomal|O dominant|O disorder|O characterized|O by|O multiple|O intestinal|B-DISE polyps|I-DISE and|O ,|O without|O surgical|O intervention|O ,|O the|O development|O of|O colorectal|B-DISE cancer|I-DISE CRC|B-DISE .|O
Platelet|O aggregation|O responses|O of|O Sit|O (|O a|O )|O (|O +|O )|O individuals|O were|O diminished|O in|O response|O to|O collagen|O ,|O indicating|O that|O the|O Thr|O (|O 799|O )|O Met|O mutation|O affects|O the|O function|O of|O the|O GPIa|O /|O IIa|O complex|O .|O .|O
Most|O of|O those|O carrying|O the|O allele|O trace|O their|O origins|O to|O the|O United|O Kingdom|O ,|O Ireland|O ,|O or|O Western|O Europe|O .|O
Molecular|O analysis|O of|O the|O PDS|O gene|O was|O performed|O in|O two|O consanguineous|O large|O families|O from|O Southern|O Tunisia|O comprising|O a|O total|O of|O 23|O individuals|O affected|O with|O profound|O congenital|B-DISE deafness|I-DISE ;|O the|O same|O missense|O mutation|O ,|O L445W|O ,|O was|O identified|O in|O all|O affected|O individuals|O .|O
The|O age|O at|O onset|O and|O severity|O of|O the|O disease|O show|O extreme|O variation|O ,|O both|O within|O and|O between|O families|O .|O
Here|O we|O report|O the|O finding|O of|O the|O H63D|O and|O C282Y|O mutations|O on|O new|O haplotypes|O .|O
BRCA1|O mutations|O cosegregating|O with|O breast|B-DISE and|I-DISE ovarian|I-DISE cancer|I-DISE susceptibility|O were|O identified|O in|O 16|O families|O ,|O including|O 1|O family|O with|O a|O case|O of|O male|B-DISE breast|I-DISE cancer|I-DISE .|O
No|O association|O was|O found|O between|O the|O presence|O of|O bilateral|B-DISE breast|I-DISE cancer|I-DISE or|O the|O number|O of|O breast|B-DISE cancers|I-DISE in|O a|O family|O and|O the|O detection|O of|O a|O BRCA1|O mutation|O ,|O or|O between|O the|O position|O of|O the|O mutation|O in|O the|O BRCA1|O gene|O and|O the|O presence|O of|O ovarian|B-DISE cancer|I-DISE in|O a|O family|O .|O
The|O patient|O was|O homozygous|O for|O this|O mutation|O ,|O whereas|O the|O consanguineous|O parents|O and|O the|O siblings|O were|O heterozygous|O .|O
Fragile|B-DISE X|I-DISE syndrome|I-DISE is|O a|O common|O cause|O of|O mental|B-DISE retardation|I-DISE involving|O loss|O of|O expression|O of|O the|O FMR1|O gene|O .|O
On|O the|O basis|O of|O the|O observation|O that|O aminoglycoside|O treatment|O can|O suppress|O stop|O codons|O in|O cultured|O cells|O ,|O we|O tested|O the|O effect|O of|O gentamicin|O on|O cultured|O muscle|O cells|O from|O the|O mdx|O mouse|O -|O an|O animal|O model|O for|O DMD|B-DISE that|O possesses|O a|O premature|O stop|O codon|O in|O the|O dystrophin|O gene|O .|O
We|O postulate|O that|O this|O unstable|O DNA|O sequence|O is|O the|O molecular|O feature|O that|O underlies|O DM|B-DISE .|O .|O
RESULTS|O :|O A|O statistically|O significant|O excess|O risk|O of|O cancer|B-DISE was|O seen|O among|O the|O patients|O with|O CHH|B-DISE (|O standardized|O incidence|O ratio|O 6|O .|O 9|O ,|O 95|O %|O confidence|O interval|O 2|O .|O 3|O to|O 16|O )|O ,|O which|O was|O mainly|O attributable|O to|O non|B-DISE -|I-DISE Hodgkin|I-DISE '|I-DISE s|I-DISE lymphoma|I-DISE standardized|O incidence|O ratio|O 90|O ,|O 95|O %|O confidence|O interval|O 18|O to|O 264|O .|O
We|O therefore|O undertook|O the|O study|O of|O fasting|O plasma|O glycerol|O levels|O in|O a|O cohort|O of|O 1|O ,|O 056|O unrelated|O men|O and|O women|O of|O French|O -|O Canadian|O descent|O .|O
No|O other|O gene|O alteration|O in|O TP53|O ,|O P57KIP2|O ,|O P15INK4B|O ,|O and|O P16INK4A|O was|O observed|O .|O
We|O have|O performed|O linkage|O analysis|O with|O the|O DNA|O markers|O DXS52|O and|O the|O clotting|O factor|O VIII|O gene|O (|O F8C|O )|O ,|O in|O several|O large|O families|O with|O X|O -|O linked|O adrenoleukodystrophy|B-DISE ALD|B-DISE .|O
In|O vitro|O expression|O results|O are|O discrepant|O ,|O but|O some|O individuals|O carrying|O S135L|O appear|O to|O exhibit|O GALT|O activity|O in|O some|O tissues|O .|O
Among|O peripheral|O blood|O leukocytes|O ,|O MEFV|O expression|O was|O detected|O in|O neutrophils|O ,|O eosinophils|O ,|O and|O to|O varying|O degrees|O ,|O monocytes|O .|O
Among|O 90|O symptomatic|O mutation|O -|O positive|O individuals|O ,|O 11|O mutations|O accounted|O for|O 79|O %|O of|O carrier|O chromosomes|O .|O
Flow|O cytometry|O and|O recombinant|O DNA|O techniques|O have|O been|O used|O to|O obtain|O reagents|O for|O a|O molecular|O analysis|O of|O the|O Prader|B-DISE -|I-DISE Willi|I-DISE syndrome|I-DISE PWS|B-DISE .|O
Because|O of|O absence|O of|O a|O distinctive|O facial|O appearance|O ,|O the|O degree|O of|O mental|B-DISE retardation|I-DISE ,|O and|O short|O stature|O ,|O the|O initially|O considered|O clinical|O diagnosis|O of|O Cohen|B-DISE syndrome|I-DISE was|O withdrawn|O and|O a|O novel|O genetic|O entity|O was|O assumed|O .|O
For|O the|O in|O -|O frame|O deletions|O there|O were|O no|O significant|O differences|O .|O
We|O report|O on|O a|O girl|O with|O clinical|O features|O suggesting|O diastrophic|B-DISE dysplasia|I-DISE but|O with|O unusual|O radiographic|O features|O including|O severe|O platyspondyly|B-DISE ,|O wide|B-DISE metaphyses|I-DISE ,|O and|O fibular|B-DISE overgrowth|I-DISE ,|O which|O are|O partially|O reminiscent|O of|O metatropic|B-DISE dysplasia|I-DISE .|O
This|O mutation|O segregates|O with|O HMS|B-DISE in|O four|O nuclear|O families|O .|O
Small|O (|O 100|O -|O 260|O kb|O )|O ,|O nested|O deletions|O were|O characterized|O in|O DNA|O from|O two|O unrelated|O patients|O with|O familial|O adenomatous|B-DISE polyposis|I-DISE coli|I-DISE APC|B-DISE .|O
The|O positive|O control|O for|O DMT1|O up|O -|O regulation|O was|O a|O murine|O model|O of|O dietary|O iron|O deficiency|O that|O demonstrated|O greatly|O increased|O levels|O of|O duodenal|O DMT1|O (|O IRE|O )|O mRNA|O .|O
Patient|O 1|O was|O homozygous|O for|O a|O complex|O mutant|O allele|O containing|O two|O alterations|O ,|O including|O a|O 194C|O >|O T|O transition|O (|O P65L|O )|O and|O 739A|O >|O C|O transversion|O (|O K247Q|O )|O ;|O in|O the|O case|O of|O P65L|O ,|O the|O amino|O acid|O change|O does|O not|O reduce|O enzyme|O activity|O .|O
apoB|O DNA|O ,|O RNA|O ,|O and|O protein|O from|O two|O patients|O with|O homozygous|O hypobetalipoproteinemia|B-DISE (|O HBL|B-DISE )|O were|O evaluated|O and|O compared|O with|O normal|O individuals|O .|O
It|O is|O unclear|O whether|O the|O specific|O molecular|O changes|O that|O distinguish|O the|O D1|O and|O D2|O alleles|O account|O for|O the|O different|O activities|O .|O
Alkaptonuria|B-DISE (|O AKU|B-DISE ;|O McKusick|O no|O .|O 203500|O )|O is|O a|O rare|B-DISE autosomal|I-DISE recessive|I-DISE disorder|I-DISE caused|O by|O the|O lack|B-DISE of|I-DISE homogentisic|I-DISE acid|I-DISE oxidase|I-DISE activity|O .|O
This|O deletion|O caused|O a|O frameshift|O in|O translation|O ,|O leading|O to|O a|O premature|O stop|O codon|O at|O the|O amino|O acid|O position|O 408|O .|O
Many|O individuals|O with|O AAPC|B-DISE develop|O relatively|O few|O colorectal|B-DISE polyps|I-DISE but|O are|O still|O at|O high|O risk|O for|O colorectal|B-DISE cancer|I-DISE .|O
The|O splice|O -|O site|O mutations|O led|O to|O exon|O skipping|O or|O utilization|O of|O cryptic|O acceptor|O -|O splice|O sites|O .|O
In|O colon|B-DISE carcinoma|I-DISE cells|O ,|O loss|O of|O APC|O leads|O to|O the|O accumulation|O of|O betacatenin|O in|O the|O nucleus|O ,|O where|O it|O binds|O to|O and|O activates|O the|O Tcf|O -|O 4|O transcription|O factor|O reviewed|O in|O 1|O 2|O .|O
The|O identification|O of|O two|O frequent|O PDS|O mutations|O will|O facilitate|O the|O molecular|O diagnosis|O of|O Pendred|B-DISE syndrome|I-DISE .|O .|O
Classical|B-DISE phenylketonuria|I-DISE (|O PKU|B-DISE )|O is|O an|O autosomal|O recessive|O disorder|O caused|O by|O a|O deficiency|O of|O hepatic|O phenylalanine|O hydroxylase|O PAH|O .|O
Linkage|O studies|O in|O this|O family|O suggested|O a|O close|O linkage|O between|O the|O C2|B-DISE deficiency|I-DISE gene|O and|O genes|O coding|O for|O B18|O ,|O Dw2|O ,|O and|O BfS|O antigens|O .|O
Kniest|B-DISE dysplasia|I-DISE is|O a|O moderately|O severe|O type|B-DISE II|I-DISE collagenopathy|I-DISE ,|O characterized|O by|O short|B-DISE trunk|I-DISE and|I-DISE limbs|I-DISE ,|O kyphoscoliosis|B-DISE ,|O midface|O hypoplasia|B-DISE ,|O severe|O myopia|B-DISE ,|O and|O hearing|B-DISE loss|I-DISE .|O
In|O hereditary|B-DISE retinoblastoma|I-DISE ,|O different|O epidemiological|O studies|O have|O indicated|O a|O preferential|O paternal|O transmission|O of|O mutant|O retinoblastoma|O alleles|O to|O offspring|O ,|O suggesting|O the|O occurrence|O of|O a|O meiotic|O drive|O .|O
By|O using|O Northern|O blot|O analyses|O ,|O we|O quantitated|O duodenal|O expression|O of|O both|O classes|O of|O DMT1|O transcripts|O :|O one|O containing|O an|O iron|O responsive|O element|O (|O IRE|O )|O ,|O called|O DMT1|O (|O IRE|O )|O ,|O and|O one|O containing|O no|O IRE|O ,|O called|O DMT1|O non|O -|O IRE|O .|O
A|O common|O feature|O of|O these|O diseases|O is|O the|O loss|B-DISE of|I-DISE photoreceptor|I-DISE function|I-DISE ,|O also|O seen|O in|O the|O retinal|B-DISE degeneration|I-DISE slow|O (|O rds|O or|O Prph2|O Rd2|O /|O Rd2|O )|O mouse|O ,|O which|O is|O homozygous|O for|O a|O null|O mutation|O in|O Prph2|O .|O
Caucasians|O ,|O Blacks|O ,|O and|O Mexican|O Hispanics|O and|O stratify|O by|O disease|O severity|O and|O ethnicity|O .|O
The|O propositus|O had|O a|O seminoma|B-DISE ,|O his|O daughter|O a|O medulloblastoma|B-DISE ,|O and|O one|O of|O his|O healthy|O cousins|O ,|O a|O TP53|O codon|O 292|O missense|O point|O mutation|O (|O AAA|O -|O -|O >|O ATA|O ;|O Lys|O -|O -|O >|O Ile|O )|O in|O the|O peripheral|O blood|O cells|O .|O
As|O expected|O ,|O the|O molecular|O analyses|O indicate|O loss|O of|O one|O allele|O at|O the|O MCC|O and|O APC|O loci|O .|O
The|O high|O sequence|O identity|O between|O Hdh|O and|O the|O HD|O gene|O for|O approximately|O 200|O bp|O 5|O '|O to|O the|O putative|O translation|O start|O site|O indicates|O that|O these|O sequences|O may|O play|O a|O role|O in|O regulating|O expression|O of|O the|O Huntington|B-DISE disease|I-DISE gene|O .|O .|O
Although|O HPC1|O accounts|O for|O only|O a|O small|O proportion|O of|O all|O families|O affected|O by|O hereditary|O prostate|B-DISE cancer|I-DISE ,|O it|O appears|O to|O play|O a|O more|O prominent|O role|O in|O the|O subset|O of|O families|O with|O several|O members|O affected|O at|O an|O early|O age|O and|O with|O male|O -|O to|O -|O male|O disease|O transmission|O .|O .|O
However|O ,|O the|O large|O majority|O of|O families|O with|O early|O -|O onset|O breast|B-DISE cancer|I-DISE and|O with|O two|O or|O more|O cases|O of|O ovarian|B-DISE cancer|I-DISE are|O likely|O to|O be|O due|O to|O BRCA1|O mutations|O .|O .|O
By|O screening|O nearly|O one|O -|O half|O of|O the|O coding|O region|O of|O the|O APC|O gene|O in|O 44|O tumors|B-DISE ,|O somatic|O mutations|O were|O detected|O in|O three|O tumors|B-DISE :|O a|O missense|O mutation|O ,|O a|O nonsense|O mutation|O ,|O and|O a|O 5|O -|O base|O pair|O deletion|O resulting|O in|O a|O frame|O shift|O which|O causes|O truncation|O of|O the|O gene|O product|O .|O
This|O base|O change|O allowed|O us|O to|O create|O a|O non|O -|O radioactive|O genotyping|O assay|O for|O this|O allele|O .|O .|O
In|O addition|O ,|O somatic|O Inactivation|O of|O the|O VHL|O gene|O is|O frequent|O in|O sporadic|O renal|B-DISE cell|I-DISE carcinoma|I-DISE and|O haemangioblastoma|B-DISE .|O
A|O subset|O of|O germline|O APC|O mutations|O results|O in|O an|O attenuated|B-DISE FAP|I-DISE (|O AFAP|B-DISE )|O phenotype|O ,|O in|O which|O patients|O develop|O fewer|O tumors|B-DISE and|O develop|O them|O at|O an|O older|O age|O .|O
We|O recently|O showed|O that|O transcriptional|O reactivation|O of|O FMR1|O full|O mutations|O can|O be|O achieved|O by|O inducing|O DNA|O demethylation|O with|O 5|O -|O azadeoxycytidine|O 5|O -|O azadC|O .|O
However|O ,|O the|O number|O of|O imprinted|O genes|O that|O contribute|O to|O PWS|B-DISE ,|O and|O the|O range|O over|O which|O the|O imprinting|O signal|O acts|O to|O silence|O one|O copy|O of|O the|O gene|O in|O a|O parent|O -|O of|O -|O origin|O -|O specific|O manner|O ,|O are|O unknown|O .|O
Combining|O these|O data|O and|O the|O results|O of|O LOH|O ,|O more|O than|O 80|O %|O of|O tumors|B-DISE (|O 14|O adenomas|B-DISE and|O 39|O carcinomas|B-DISE )|O had|O at|O least|O one|O mutation|O in|O the|O APC|O gene|O ,|O of|O which|O more|O than|O 60|O %|O (|O 9|O adenomas|B-DISE and|O 23|O carcinomas|B-DISE )|O had|O two|O mutations|O .|O
The|O (|O CAG|O )|O n|O block|O in|O the|O rat|O cDNA|O consists|O of|O just|O three|O interrupted|O units|O suggesting|O that|O a|O long|O polyglutamine|O stretch|O is|O not|O essential|O for|O the|O normal|O function|O of|O the|O ataxin|O -|O 3|O protein|O in|O rodents|O .|O
A|O strong|O candidate|O for|O the|O 17q|O -|O linked|O BRCA1|O gene|O ,|O which|O influences|O susceptibility|O to|O breast|B-DISE and|I-DISE ovarian|I-DISE cancer|I-DISE ,|O has|O been|O identified|O by|O positional|O cloning|O methods|O .|O
We|O investigated|O the|O expression|O pattern|O in|O the|O retina|O of|O both|O RS1|O mRNA|O (|O using|O in|O situ|O hybridization|O with|O riboprobes|O )|O and|O retinoschisin|O using|O immunohistochemistry|O .|O
The|O mouse|O studies|O suggest|O a|O key|O role|O for|O the|O carboxyl|O terminal|O dystrophin|O isoform|O ,|O Dp260|O ,|O in|O retinal|O electrophysiology|O .|O
Phenylketonuria|B-DISE (|O PKU|B-DISE )|O is|O an|O autosomal|O recessive|O disorder|O of|O amino|O acid|O metabolism|O caused|O by|O a|O deficiency|B-DISE of|I-DISE the|I-DISE hepatic|I-DISE enzyme|I-DISE phenylalanine|I-DISE hydroxylase|I-DISE PAH|O ;|O phenylalanine|O 4|O -|O monooxygenase|O ,|O EC|O 1|O .|O 14|O .|O 16|O .|O 1|O .|O
We|O report|O on|O two|O clinically|O ,|O neurologically|O normal|O relatives|O of|O a|O boy|O affected|O by|O adrenoleukodystrophy|B-DISE (|O ALD|B-DISE )|O ;|O they|O were|O found|O repeatedly|O to|O have|O the|O biochemical|O defect|O of|O an|O ALD|B-DISE hemizygote|O .|O
Long|O -|O term|O follow|O -|O up|O evaluation|O of|O C282Y|O homozygotes|O and|O H63D|O /|O C282Y|O compound|O heterozygotes|O will|O give|O an|O indication|O of|O the|O penetrance|O of|O the|O mutations|O .|O .|O
Furthermore|O ,|O differentiated|O retinoblastoma|B-DISE cells|O (|O Weri|O -|O Rb1|O cells|O )|O were|O found|O to|O express|O RS1|O mRNA|O and|O to|O release|O retinoschisin|O .|O
This|O syndrome|O has|O been|O recently|O described|O in|O Italian|O and|O French|O pedigrees|O .|O
Th|O data|O presented|O here|O together|O with|O those|O of|O previously|O published|O studies|O demonstrate|O a|O degree|O of|O heterogeneity|O of|O G6PD|B-DISE deficiency|I-DISE that|O is|O much|O higher|O than|O that|O in|O other|O regions|O of|O the|O world|O where|O G6PD|B-DISE deficiency|I-DISE is|O common|O .|O .|O
However|O ,|O the|O widespread|O use|O of|O BRCA1|O testing|O has|O been|O limited|O to|O date|O by|O three|O principal|O concerns|O :|O the|O fear|O of|O loss|O of|O health|O and|O life|O insurance|O ,|O the|O uncertain|O clinical|O value|O of|O a|O positive|O test|O result|O ,|O and|O the|O current|O lack|O of|O an|O inexpensive|O and|O sensitive|O screening|O test|O for|O BRCA1|O mutations|O .|O
BRCA1|O mutations|O are|O rare|O in|O sporadic|O cancers|O ,|O but|O loss|O of|O BRCA1|O resulting|O from|O reduced|O expression|O or|O incorrect|O subcellular|O localization|O is|O postulated|O to|O be|O important|O in|O non|O -|O familial|O breast|B-DISE and|I-DISE ovarian|I-DISE cancers|I-DISE .|O
A|O screen|O of|O 20|O individuals|O from|O the|O midwestern|O USA|O with|O non|O -|O syndromic|O hearing|B-DISE loss|I-DISE and|O dilated|B-DISE vestibular|I-DISE aqueducts|I-DISE identified|O three|O people|O (|O 15|O %|O )|O with|O PDS|O mutations|O .|O
Two|O years|O later|O he|O was|O re|O -|O examined|O because|O we|O thought|O his|O features|O fitted|O the|O PWS|B-DISE -|O like|O phenotype|O associated|O with|O maternal|O UPD|B-DISE 14|I-DISE .|O
Germ|O -|O line|O mutations|O in|O the|O BRCA1|O tumor|O -|O suppressor|O gene|O are|O associated|O with|O an|O increased|O susceptibility|O to|O breast|B-DISE and|I-DISE ovarian|I-DISE cancer|I-DISE .|O
Mutations|O of|O the|O X|O -|O chromosome|O -|O linked|O PLP|O gene|O are|O lethal|O ,|O identified|O first|O in|O the|O jimpy|O mouse|O and|O subsequently|O in|O patients|O with|O Pelizaeus|B-DISE -|I-DISE Merzbacher|I-DISE disease|I-DISE .|O
Besides|O the|O classic|O WAS|O phenotype|O ,|O there|O is|O a|O group|O of|O patients|O with|O congenital|B-DISE X|I-DISE -|I-DISE linked|I-DISE thrombocytopenia|I-DISE (|O XLT|B-DISE )|O who|O have|O small|O platelets|O but|O only|O transient|O eczema|B-DISE ,|O if|O any|O ,|O and|O minimal|O immune|B-DISE deficiency|I-DISE .|O
The|O effects|O of|O the|O null|O mutation|O are|O more|O severe|O than|O the|O effects|O of|O the|O C282Y|O mutation|O .|O
More|O recently|O it|O has|O become|O apparent|O that|O elevated|O carrier|O frequencies|O for|O TSD|B-DISE also|O occur|O in|O several|O other|O ethnic|O groups|O ,|O including|O Moroccan|O Jews|O ,|O a|O subgroup|O of|O Sephardic|O Jews|O .|O
G6PD|B-DISE deficiency|I-DISE is|O heterogeneous|O in|O northern|O Algeria|O where|O autochtonous|O variants|O seem|O to|O prevail|O .|O
The|O patients|O with|O abnormal|O brain|O MRI|O at|O the|O onset|O of|O treatment|O showed|O clinical|O and|O neurophysiologic|O worsening|O .|O
Both|O carried|O a|O missense|O mutation|O within|O the|O NDP|O gene|O on|O chromosome|O Xp11|O .|O 2|O .|O
Most|O sporadic|O colorectal|B-DISE cancers|I-DISE also|O have|O two|O APC|O mutations|O .|O
Mass|O spectrometric|O sequencing|O of|O components|O of|O this|O complex|O indicated|O that|O BRCA1|O is|O associated|O with|O a|O SWI|O /|O SNF|O -|O related|O complex|O .|O
It|O is|O believed|O that|O the|O mutated|O allele|O of|O PAX6|O produces|O an|O inactive|O protein|O and|O aniridia|B-DISE is|O caused|O due|O to|O genetic|O haploinsufficiency|O .|O
Homozygous|O mutant|O mice|O had|O no|O apparent|O abnormalities|B-DISE of|I-DISE skeletal|I-DISE muscle|I-DISE function|I-DISE ,|O but|O developed|O lenticular|B-DISE opacities|I-DISE at|O a|O higher|O rate|O than|O controls|O .|O
We|O detected|O abnormal|O SSCP|O pattern|O in|O 73|O samples|O .|O
Intestinal|O uptake|O of|O dietary|O glucose|O and|O galactose|O is|O mediated|O by|O the|O SGLT1|O Na|O +|O /|O glucose|O cotransporter|O of|O the|O brush|O border|O .|O
Eleven|O different|O mutations|O were|O found|O ,|O and|O all|O but|O one|O are|O likely|O to|O give|O rise|O to|O significant|O structural|O changes|O in|O the|O predicted|O protein|O .|O
Northern|O blot|O hybridisation|O showed|O highest|O expression|O in|O brain|O and|O skeletal|O muscle|O .|O
We|O have|O generated|O a|O polyclonal|O antibody|O against|O a|O peptide|O from|O a|O unique|O region|O within|O retinoschisin|O ,|O which|O detects|O a|O protein|O of|O approximately|O 28|O kDa|O in|O retinal|O samples|O reduced|O with|O dithiothreitol|O ,|O but|O multimers|O sized|O >|O 40|O kDa|O under|O non|O -|O reducing|O conditions|O .|O
This|O could|O be|O because|O the|O 68|O Val|O -|O -|O Met|O mutation|O happened|O to|O arise|O in|O an|O A|O gene|O in|O the|O first|O instance|O ,|O or|O because|O the|O 68|O Val|O -|O -|O Met|O mutation|O alone|O is|O not|O sufficient|O to|O cause|O G6PD|B-DISE deficiency|I-DISE .|O
To|O confirm|O these|O findings|O ,|O a|O large|O linkage|O study|O was|O performed|O in|O twelve|O additional|O families|O segregating|O for|O Alstrom|B-DISE syndrome|I-DISE .|O
These|O findings|O demonstrate|O that|O GCH1|O mutations|O must|O be|O considered|O even|O in|O patients|O with|O dystonic|O symptoms|O not|O typical|O of|O dopa|B-DISE -|I-DISE responsive|I-DISE dystonia|I-DISE .|O .|O
Zbar|O ,|O Cancer|B-DISE Surv|O .|O ,|O 25|O :|O 219|O -|O 232|O ,|O 1995|O .|O
Nineteen|O of|O the|O detected|O mutations|O were|O presumed|O to|O be|O novel|O ,|O thus|O emphasizing|O the|O heterogeneity|O of|O the|O mutational|O spectrum|O in|O Korean|O FAP|B-DISE patients|O .|O
Thus|O ,|O exon|O 5a|O appears|O to|O function|O as|O a|O molecular|O switch|O that|O specifies|O target|O genes|O .|O
Both|O penetrance|O and|O expression|O breast|B-DISE cancer|I-DISE vs|O .|O
The|O second|O ,|O a|O C|O -|O -|O >|O T|O transition|O at|O nucleotide|O 739|O (|O Arg247Trp|O )|O ,|O has|O been|O shown|O by|O Triggs|O -|O Raine|O et|O al|O .|O
In|O addition|O ,|O the|O frequency|O at|O which|O we|O have|O found|O PAX6|O mutations|O suggests|O that|O lesions|O in|O PAX6|O will|O account|O for|O most|O cases|O of|O aniridia|B-DISE .|O .|O
beta|O -|O Glucuronidase|O mRNA|O was|O normal|O in|O affected|O cat|O testis|O by|O Northern|O blot|O analysis|O .|O
A|O rare|B-DISE X|I-DISE -|I-DISE linked|I-DISE dysmyelinating|I-DISE disorder|I-DISE of|O the|O central|O nervous|O system|O ,|O Pelizaeus|B-DISE -|I-DISE Merzbacher|I-DISE disease|I-DISE (|O PMD|B-DISE )|O ,|O has|O also|O been|O mapped|O to|O Xq21|O -|O q22|O ,|O and|O is|O caused|O by|O mutations|O in|O the|O proteolipid|O protein|O gene|O (|O PLP|O )|O which|O encodes|O two|O myelin|O proteins|O ,|O PLP|O and|O DM20|O .|O
We|O have|O re|O -|O examined|O an|O extended|O myotonic|B-DISE dystrophy|I-DISE (|O DM|B-DISE )|O family|O ,|O previously|O described|O in|O 1955|O ,|O in|O order|O to|O study|O the|O long|O term|O effects|O of|O anticipation|O in|O DM|B-DISE and|O in|O particular|O the|O implications|O for|O families|O affected|O by|O this|O disease|O .|O
Inherited|O mutations|O in|O BRCA1|O predispose|O to|O breast|B-DISE and|I-DISE ovarian|I-DISE cancer|I-DISE ,|O but|O the|O role|O of|O BRCA1|O in|O sporadic|B-DISE breast|I-DISE and|I-DISE ovarian|I-DISE cancer|I-DISE has|O previously|O been|O elusive|O .|O
The|O presence|O of|O three|O frequent|O MEFV|O mutations|O in|O multiple|O Mediterranean|O populations|O strongly|O suggests|O a|O heterozygote|O advantage|O in|O this|O geographic|O region|O .|O .|O
However|O ,|O these|O patients|O develop|O colorectal|B-DISE tumors|I-DISE more|O frequently|O than|O does|O the|O general|O population|O because|O APC|O (|O AS9|O )|O is|O inactivated|O by|O mutations|O that|O do|O not|O inactivate|O the|O wild|O -|O type|O APC|O .|O .|O
In|O yeast|O the|O DNA|O damage|O response|O and|O the|O replication|O -|O block|O checkpoint|O are|O mediated|O partly|O through|O the|O Cds1|O kinase|O family|O .|O
Recurrent|O hSNF5|O /|O INI1|O alterations|O were|O also|O observed|O in|O choroid|B-DISE plexus|I-DISE carcinomas|I-DISE and|O in|O a|O subset|O of|O central|B-DISE primitive|I-DISE neuroectodermal|I-DISE tumors|I-DISE (|O cPNETs|B-DISE )|O and|O medulloblastomas|B-DISE .|O
We|O screened|O patients|O with|O adrenoleukodystrophy|B-DISE /|O adrenomyeloneuropathy|B-DISE (|O ALD|B-DISE /|O AMN|B-DISE )|O from|O 20|O kindreds|O for|O mutations|O in|O the|O ALD|O gene|O .|O
Seven|O of|O these|O 12|O patients|O had|O elevated|O serum|O ferritin|O levels|O in|O 1994|O ;|O 6|O of|O the|O 7|O had|O further|O increases|O in|O 1998|O ,|O and|O 1|O had|O a|O decrease|O ,|O although|O the|O value|O remained|O elevated|O .|O
The|O human|O gene|O for|O histidase|O (|O histidine|O ammonia|O -|O lyase|O ;|O HAL|O )|O ,|O the|O enzyme|B-DISE deficient|I-DISE in|O histidinemia|B-DISE ,|O was|O assigned|O to|O human|O chromosome|O 12|O by|O Southern|O blot|O analysis|O of|O human|O X|O mouse|O somatic|O cell|O hybrid|O DNA|O .|O
These|O results|O demonstrated|O that|O the|O Met|O (|O 799|O )|O is|O responsible|O for|O formation|O of|O the|O Sit|O (|O a|O )|O alloantigenic|O determinants|O ,|O whereas|O amino|O acid|O 505|O (|O Lys|O or|O Glu|O )|O specifically|O controls|O the|O expression|O of|O Br|O (|O a|O )|O and|O Br|O (|O b|O )|O epitopes|O ,|O respectively|O .|O
Our|O data|O are|O compatible|O with|O the|O hypothesis|O that|O the|O mutations|O tend|O to|O occur|O in|O a|O population|O -|O specific|O manner|O .|O
Latif|O et|O al|O .|O ,|O Science|O (|O Washington|O DC|O )|O ,|O 260|O :|O 1317|O -|O 1320|O ,|O 1993|O .|O
We|O report|O on|O a|O 4|O -|O year|O -|O old|O boy|O with|O Knobloch|B-DISE syndrome|I-DISE .|O
Furthermore|O ,|O we|O propose|O that|O active|O transcription|O of|O these|O repeats|O in|O male|O and|O female|O germ|O cells|O may|O facilitate|O the|O homologous|O recombination|O process|O .|O .|O
Though|O auditory|O anomalies|O have|O been|O observed|O in|O mice|O with|O dominant|O white|O spotting|O (|O W|O )|O due|O to|O KIT|O mutations|O ,|O deafness|B-DISE is|O not|O typical|O in|O human|O piebaldism|B-DISE .|O
To|O determine|O the|O prevalence|O and|O characterize|O demographic|O ,|O clinical|O ,|O and|O genetic|O features|O of|O familial|B-DISE Mediterranean|I-DISE fever|I-DISE (|O FMF|B-DISE )|O of|O late|O onset|O ,|O all|O patients|O experiencing|O their|O first|O FMF|B-DISE attack|O at|O age|O 40|O years|O or|O more|O were|O identified|O using|O the|O computerized|O registry|O of|O our|O FMF|O clinic|O ,|O and|O then|O thoroughly|O interviewed|O and|O examined|O .|O
Endogenous|O APC|O colocalized|O with|O Asef|O in|O mouse|O colon|O epithelial|O cells|O and|O neuronal|O cells|O .|O
A|O fine|O resolution|O radiation|O hybrid|O map|O of|O 31|O genes|O and|O markers|O has|O been|O constructed|O .|O .|O
The|O clinical|O classification|O is|O increasingly|O being|O replaced|O by|O a|O genetic|O one|O .|O
The|O results|O showed|O that|O the|O amounts|O of|O the|O GCH1|O mRNA|O were|O decreased|O to|O about|O 40|O %|O of|O the|O normal|O level|O in|O both|O patients|O and|O carriers|O .|O
ADCA|O type|O I|O patients|O from|O families|O segregating|O SCA3|O share|O clinical|O features|O in|O common|O with|O those|O with|O Machado|B-DISE -|I-DISE Joseph|I-DISE disease|I-DISE (|O MJD|B-DISE )|O ,|O the|O gene|O of|O which|O maps|O to|O the|O same|O region|O .|O
In|O one|O of|O the|O commonest|O ,|O G6PD|O Mediterranean|O ,|O which|O is|O associated|O with|O favism|B-DISE among|O other|O clinical|O manifestations|O ,|O a|O single|O amino|O acid|O replacement|O was|O found|O (|O serine|O -|O -|O -|O -|O phenylalanine|O )|O :|O it|O must|O be|O responsible|O for|O the|O decreased|O stability|O and|O the|O reduced|O catalytic|O efficiency|O of|O this|O enzyme|O .|O
Sulfatases|O ,|O including|O GALNS|O ,|O are|O members|O of|O a|O highly|O conserved|O gene|O family|O sharing|O an|O extensive|O sequence|O homology|O .|O
The|O transcripts|O encode|O putative|O proteins|O that|O are|O homologous|O to|O the|O MAGE|O proteins|O and|O NDN|O .|O
Sequential|O addition|O of|O an|O iron|O chelator|O and|O a|O reducing|O agent|O results|O in|O quantitative|O iron|O release|O with|O concomitant|O disassembly|O of|O the|O multimer|O ,|O indicating|O that|O mYfh1p|O sequesters|O iron|O in|O an|O available|O form|O .|O
The|O six|O new|O aniridia|B-DISE cases|O reported|O here|O have|O mutations|O predicted|O to|O generate|O incomplete|O PAX6|O proteins|O .|O
A|O major|O gene|O locus|O for|O PLS|B-DISE has|O been|O mapped|O to|O a|O 2|O .|O 8|O cM|O interval|O on|O chromosome|O 11q14|O .|O
A|O p95|O /|O nbs1|O construct|O mutated|O at|O the|O ATM|O phosphorylation|O site|O abrogated|O an|O S|O -|O phase|O checkpoint|O induced|O by|O ionizing|O radiation|O in|O normal|O cells|O and|O failed|O to|O compensate|O for|O this|O functional|O deficiency|O in|O NBS|B-DISE cells|O .|O
All|O phenotypes|O were|O associated|O with|O mutations|O resulting|O in|O protein|O truncation|O or|O subtle|O amino|O acid|O changes|O .|O
Spinocerebellar|B-DISE ataxia|I-DISE type|I-DISE -|I-DISE 3|I-DISE or|O Machado|B-DISE -|I-DISE Joseph|I-DISE disease|I-DISE (|O SCA3|B-DISE /|O MJD|B-DISE )|O is|O a|O member|O of|O the|O CAG|O /|O polyglutamine|O repeat|O disease|O family|O .|O
There|O was|O no|O evidence|O of|O premature|O atherosclerosis|B-DISE in|O the|O families|O with|O CETP|B-DISE deficiency|I-DISE .|O
Friedreich|B-DISE ataxia|I-DISE (|O FRDA|B-DISE )|O ,|O the|O most|O frequently|O inherited|B-DISE ataxia|I-DISE ,|O is|O due|O in|O the|O vast|O majority|O of|O cases|O to|O a|O large|O expansion|O of|O an|O intronic|O GAA|O repeat|O .|O
A|O gene|O ,|O FGD1|O ,|O altered|O in|O a|O patient|O with|O AAS|B-DISE phenotype|O ,|O has|O been|O identified|O and|O found|O to|O encode|O a|O protein|O with|O homology|O to|O Rho|O /|O Rac|O guanine|O nucleotide|O exchange|O factors|O Rho|O /|O Rac|O GEF|O .|O
In|O patient|O fibroblasts|O ,|O raising|O VLCAD|O activity|O to|O approximately|O 20|O %|O of|O normal|O control|O fibroblast|O activity|O raised|O palmitic|O acid|O beta|O -|O oxidation|O flux|O to|O the|O level|O found|O in|O control|O fibroblasts|O ,|O which|O may|O offer|O important|O information|O for|O the|O rational|O design|O of|O future|O somatic|O gene|O therapy|O for|O VLCAD|B-DISE deficiency|I-DISE .|O .|O
In|O one|O large|O family|O a|O single|O nucleotide|O (|O T|O )|O insertion|O into|O the|O donor|O splice|O site|O of|O exon|O C|O leads|O to|O two|O aberrantly|O spliced|O mRNAs|O both|O producing|O a|O premature|O stop|O codon|O .|O
He|O has|O vitreoretinal|B-DISE degeneration|I-DISE ,|O high|B-DISE myopia|I-DISE ,|O cataract|B-DISE ,|O telecanthus|B-DISE ,|O hypertelorism|B-DISE ,|O and|O a|O high|B-DISE -|I-DISE arched|I-DISE palate|I-DISE .|O
Polymerase|O chain|O reaction|O -|O single|O -|O strand|O conformation|O polymorphism|O (|O PCR|O -|O SSCP|O )|O and|O subsequent|O sequencing|O revealed|O three|O distinct|O polymorphisms|O in|O the|O intron|O -|O exon|O boundary|O upstream|O from|O exon|O 6|O .|O
In|O a|O Turkish|O family|O with|O the|O diagnosis|O of|O Li|B-DISE -|I-DISE Fraumeni|I-DISE syndrome|I-DISE ,|O we|O analyzed|O the|O mutation|O pattern|O of|O TP53|O ,|O P57KIP2|O ,|O P15INK4B|O ,|O and|O P16INK4A|O in|O the|O peripheral|O blood|O ,|O and|O loss|O of|O heterozygosity|O (|O homo|O /|O hemizygous|O deletion|O )|O pattern|O of|O TP53|O and|O P15INK4B|O /|O P16INK4A|O in|O two|O tumor|B-DISE tissues|O .|O
A|O panel|O of|O patients|O with|O Duchenne|B-DISE and|I-DISE Becker|I-DISE muscular|I-DISE dystrophy|I-DISE (|O DMD|B-DISE and|O BMD|B-DISE )|O has|O been|O screened|O with|O the|O cDNA|O probes|O Cf56a|O and|O Cf23a|O ,|O which|O detect|O exons|O in|O the|O central|O part|O of|O the|O DMD|O gene|O .|O
Restriction|O digestion|O following|O PCR|O amplification|O of|O ARG1|O exon|O 2|O confirmed|O the|O presence|O of|O the|O mutation|O .|O .|O
Studies|O using|O DM|B-DISE patient|O materials|O have|O often|O produced|O confusing|O results|O .|O
The|O unstable|O CTG|O 5|O -|O 30|O motif|O is|O found|O uniquely|O in|O humans|O ,|O although|O the|O flanking|O nucleotides|O are|O also|O present|O in|O mouse|O .|O
The|O expression|O of|O CYP27|O has|O been|O mostly|O explored|O using|O cultured|O fibroblasts|O ,|O prompting|O the|O examination|O of|O the|O transcripts|O from|O blood|O leucocytes|O as|O a|O simple|O and|O rapid|O technique|O .|O
Myotonic|B-DISE dystrophy|I-DISE (|O DM|B-DISE )|O is|O a|O progressive|O neuromuscular|B-DISE disorder|I-DISE which|O results|O from|O elongations|O of|O an|O unstable|O (|O CTG|O )|O n|O repeat|O ,|O located|O in|O the|O 3|O '|O untranslated|O region|O of|O the|O DM|O gene|O .|O
RESULTS|O :|O Three|O patients|O with|O adult|O -|O onset|O cerebral|O ALD|B-DISE were|O identified|O as|O having|O large|O genomic|O rearrangements|O .|O
However|O ,|O p95|O /|O nbs1|O was|O phosphorylated|O on|O serine|O 343|O in|O an|O ATM|O -|O dependent|O manner|O in|O vitro|O and|O in|O vivo|O after|O ionizing|O radiation|O .|O
Mutations|O in|O BRCA1|O account|O for|O at|O least|O 80|O %|O of|O families|O with|O both|O breast|B-DISE and|I-DISE ovarian|I-DISE cancer|I-DISE ,|O as|O well|O as|O some|O non|O -|O familial|O sporadic|O ovarian|B-DISE cancers|I-DISE .|O
Mice|O heterozygous|O for|O either|O mutation|O accumulate|O more|O iron|O than|O normal|O controls|O .|O
Among|O these|O patients|O ,|O 49|O different|O mutations|O -|O including|O 10|O deletions|O ,|O 2|O insertions|O ,|O 22|O amino|O acid|O substitutions|O ,|O 3|O nonsense|O mutations|O ,|O 9|O splice|O -|O site|O defects|O ,|O and|O 3|O complex|O mutations|O -|O were|O found|O .|O
After|O sequencing|O ,|O we|O identified|O microdeletions|O in|O 58|O %|O of|O cases|O ,|O microinsertions|O in|O 17|O %|O ,|O nonsense|O mutations|O in|O 8|O %|O ,|O and|O missense|O mutations|O in|O 17|O %|O .|O
In|O addition|O ,|O we|O report|O a|O previously|O unrecognized|O effect|O of|O Atm|O deficiency|O on|O development|O or|O maintenance|O of|O CD4|O +|O 8|O (|O +|O )|O thymocytes|O .|O
One|O PAX6|O mutation|O found|O in|O the|O PST|O region|O was|O associated|O with|O cataracts|B-DISE in|O an|O aniridia|B-DISE family|O .|O
Van|B-DISE der|I-DISE Woude|I-DISE syndrome|I-DISE (|O VWS|B-DISE )|O is|O an|O autosomal|O dominant|O disorder|O comprising|O cleft|B-DISE lip|I-DISE and|O /|O or|O cleft|B-DISE palate|I-DISE and|O lip|B-DISE pits|I-DISE .|O
While|O only|O 5|O %|O of|O sporadic|O Wilms|B-DISE '|I-DISE tumours|I-DISE have|O intragenic|O WT1|O mutations|O ,|O 90|O %|O of|O patients|O with|O the|O Denys|B-DISE -|I-DISE Drash|I-DISE syndrome|I-DISE (|O renal|O nephropathy|B-DISE ,|O gonadal|O anomaly|O ,|O predisposition|O to|O WT|B-DISE )|O carry|O constitutional|O intragenic|O WT1|O mutations|O .|O
However|O ,|O a|O comparison|O of|O the|O data|O suggested|O that|O both|O missense|O and|O synonymous|O mutations|O can|O occur|O at|O any|O coding|O sequence|O of|O the|O human|O germ|O line|O HPRT|O gene|O ,|O but|O that|O a|O limited|O percentage|O of|O all|O the|O missense|O mutations|O cause|O disease|O .|O
Immunologic|O methods|O revealed|O trace|O amounts|O (|O 17|O mg|O /|O 100|O ml|O )|O of|O apparently|O normal|O serum|O albumin|O .|O
The|O clinical|O features|O were|O similar|O and|O there|O were|O no|O obvious|O stigmata|O of|O Langer|B-DISE -|I-DISE Giedion|I-DISE syndrome|I-DISE LGS|B-DISE .|O
In|O rat|O testis|O ,|O a|O smaller|O transcript|O of|O 1|O .|O 3|O kb|O was|O identified|O .|O
The|O highest|O value|O of|O alpha|O was|O observed|O for|O the|O 48|O families|O that|O met|O all|O three|O criteria|O peak|O HLOD|O =|O 2|O .|O 25|O ,|O P|O =|O .|O 001|O ,|O alpha|O =|O .|O 29|O ,|O with|O 1|O -|O LOD|O support|O interval|O .|O 08|O -|O .|O 53|O .|O
The|O propositus|O was|O found|O to|O have|O low|O quantities|O of|O an|O abnormal|O C6|O which|O was|O both|O antigenically|O deficient|O and|O smaller|O in|O size|O than|O normal|O C6|O (|O 110|O ,|O 000|O daltons|O compared|O with|O 140|O ,|O 000|O daltons|O )|O and|O small|O quantities|O of|O apparently|O normal|O C7|O .|O
Myotonic|B-DISE dystrophy|I-DISE (|O DM|B-DISE )|O is|O caused|O by|O abnormal|O expansion|O of|O a|O polymorphic|O (|O CTG|O )|O n|O repeat|O ,|O located|O in|O the|O DM|O protein|O kinase|O gene|O .|O
In|O an|O ongoing|O immunohistochemical|O study|O of|O beta|O -|O catenin|O expression|O in|O sporadic|O cases|O of|O tumor|B-DISE types|O that|O are|O associated|O with|O adenomatous|B-DISE polyposis|I-DISE coli|I-DISE ,|O we|O observed|O increased|O beta|O -|O catenin|O levels|O in|O the|O cytoplasm|O and|O in|O the|O nuclei|O of|O three|O investigated|O hepatoblastomas|B-DISE .|O
We|O describe|O three|O novel|O mutations|O (|O R58fs|O ,|O R330S|O ,|O and|O H371R|O )|O and|O one|O common|O AKU|B-DISE mutation|O (|O M368V|O )|O ,|O detected|O by|O mutational|O and|O polymorphism|O analysis|O of|O the|O HGO|O gene|O in|O five|O Finnish|O AKU|B-DISE pedigrees|O .|O
All|O other|O tested|O new|O transcripts|O in|O the|O deletion|O region|O were|O expressed|O from|O both|O alleles|O .|O
Cleft|B-DISE palate|I-DISE ,|O swelling|O of|O the|O ear|O pinna|O ,|O and|O hitch|B-DISE hiker|I-DISE thumb|I-DISE were|O absent|O .|O
The|O Wiskott|B-DISE -|I-DISE Aldrich|I-DISE syndrome|I-DISE (|O WAS|B-DISE )|O has|O previously|O been|O mapped|O to|O the|O proximal|O short|O arm|O of|O the|O X|O chromosome|O between|O the|O DXS14|O and|O DXS7|O loci|O .|O
These|O three|O variants|O had|O a|O mild|O to|O moderate|O G6PD|B-DISE deficiency|I-DISE and|O were|O not|O associated|O with|O any|O clinical|O signs|O .|O
To|O facilitate|O the|O evaluation|O of|O ATM|O heterozygotes|O for|O susceptibility|O to|O other|O diseases|O ,|O such|O as|O breast|B-DISE cancer|I-DISE ,|O we|O have|O attempted|O to|O define|O the|O most|O common|O mutations|O and|O their|O frequencies|O in|O ataxia|B-DISE -|I-DISE telangiectasia|I-DISE (|O A|B-DISE -|I-DISE T|I-DISE )|O homozygotes|O from|O 10|O ethnic|O populations|O .|O
Ionizing|O radiation|O oxidizes|O macromolecules|O and|O causes|O tissue|B-DISE damage|I-DISE through|O the|O generation|O of|O reactive|O oxygen|O species|O ROS|O .|O
The|O ATP7B|O null|O mice|O display|O a|O gradual|O accumulation|O of|O hepatic|O copper|O that|O increases|O to|O a|O level|O 60|O -|O fold|O greater|O than|O normal|O by|O 5|O months|O of|O age|O .|O
We|O analyzed|O the|O maternal|O status|O of|O 56|O cases|O to|O determine|O the|O origin|O of|O both|O types|O of|O PLP|O mutation|O ,|O since|O this|O is|O relevant|O to|O genetic|O counseling|O .|O
Sequence|O analyses|O demonstrated|O that|O each|O of|O these|O polymorphisms|O resulted|O from|O single|O base|O pair|O substitutions|O and|O that|O neither|O substitution|O would|O probably|O cause|O or|O contribute|O to|O the|O C5|B-DISE deficiency|I-DISE .|O
This|O conformationally|O altered|O ataxin|O -|O 3|O is|O bound|O to|O the|O nuclear|O matrix|O .|O
Kaelin|O ,|O Jr|O .|O ,|O Medicine|O (|O Baltimore|O )|O ,|O 76|O :|O 381|O -|O 391|O ,|O 1997|O ;|O
Muscle|O expression|O of|O G6PD|B-DISE deficiency|I-DISE has|O been|O investigated|O in|O Mediterranean|O ,|O Seattle|O -|O like|O and|O A|O -|O variants|O .|O
A|O family|O of|O domestic|O cats|O was|O found|O that|O exhibited|O clinical|O and|O biochemical|O abnormalities|O consistent|O with|O mucopolysaccharidosis|B-DISE VII|I-DISE ,|O an|O autosomal|O recessive|O lysosomal|B-DISE storage|I-DISE disorder|I-DISE caused|O by|O beta|B-DISE -|I-DISE glucuronidase|I-DISE deficiency|I-DISE .|O
A|O deletion|O of|O 8q24|O .|O 11|O -|O q24|O .|O 3|O in|O a|O patient|O with|O multiple|B-DISE exostoses|I-DISE was|O found|O to|O overlap|O the|O distal|O end|O of|O the|O LGS|O deletion|O region|O ,|O indicating|O that|O the|O EXT1|O gene|O is|O distal|O to|O the|O TRPS1|O gene|O and|O supporting|O the|O hypothesis|O that|O Langer|B-DISE -|I-DISE Giedion|I-DISE syndrome|I-DISE is|O due|O to|O loss|O of|O functional|O copies|O of|O both|O the|O TRPS1|O and|O the|O EXT1|O genes|O .|O .|O
In|O many|O parts|O of|O the|O world|O the|O Mediterranean|O type|O of|O G6PD|B-DISE deficiency|I-DISE is|O prevalent|O .|O
Two|O missense|O Fas|O variants|O ,|O not|O restricted|O to|O patients|O with|O ALPS|B-DISE ,|O were|O identified|O .|O
The|O axonal|O chemoattractant|O netrin|O -|O 1|O guides|O spinal|O commissural|O axons|O by|O activating|O its|O receptor|O DCC|O Deleted|O in|O Colorectal|B-DISE Cancer|I-DISE .|O
Muscle|O computed|O tomography|O scanning|O revealed|O changes|O characteristic|O of|O muscle|O involvement|O .|O
These|O mutations|O all|O exhibit|O a|O high|O degree|O of|O association|O with|O specific|O restriction|O fragment|O -|O length|O polymorphism|O haplotypes|O at|O the|O PAH|O locus|O .|O
However|O ,|O only|O a|O minority|O of|O familial|B-DISE gastric|I-DISE cancers|I-DISE can|O be|O accounted|O for|O by|O CDH1|O mutations|O .|O
The|O age|O incidence|O curves|O for|O renal|B-DISE cell|I-DISE carcinoma|I-DISE and|O cerebellar|B-DISE haemangioblastoma|I-DISE in|O VHL|O disease|O were|O compatible|O with|O a|O single|O mutation|O model|O ,|O whereas|O the|O age|O incidence|O curves|O for|O sporadic|O renal|B-DISE cell|I-DISE carcinoma|I-DISE and|O cerebellar|B-DISE haemangioblastoma|I-DISE suggested|O a|O two|O stage|O mutation|O process|O .|O
Our|O three|O models|O carrying|O different|O sizes|O of|O CTG|O repeat|O provide|O insight|O on|O the|O different|O factors|O modulating|O the|O CTG|O repeat|O instability|O .|O .|O
We|O have|O identified|O a|O novel|O gene|O containing|O CAG|O repeats|O and|O mapped|O it|O to|O chromosome|O 14q32|O .|O 1|O ,|O the|O genetic|O locus|O for|O Machado|B-DISE -|I-DISE Joseph|I-DISE disease|I-DISE MJD|B-DISE .|O
The|O clinical|O use|O of|O molecular|O analyses|O in|O recessive|O disorders|O relies|O on|O the|O exact|O characterization|O of|O both|O mutant|O alleles|O in|O the|O affected|O patient|O .|O
One|O patient|O presented|O a|O mutation|O that|O results|O in|O a|O nucleotide|O change|O in|O exon|O 10|O of|O the|O FGD1|O gene|O (|O G2559|O >|O A|O )|O substituting|O a|O Gln|O for|O Arg|O in|O position|O 610|O .|O
Dihydropyrimidine|B-DISE dehydrogenase|I-DISE (|I-DISE DPD|I-DISE )|I-DISE deficiency|I-DISE is|O an|O autosomal|O recessive|O disease|O characterised|O by|O thymine|B-DISE -|I-DISE uraciluria|I-DISE in|O homozygous|O deficient|O patients|O and|O has|O been|O associated|O with|O a|O variable|O clinical|O phenotype|O .|O
Dermatofibrosarcoma|B-DISE protuberans|I-DISE (|O DFSP|B-DISE )|O displays|O chromosomal|O rearrangements|O involving|O chromosome|O 17|O and|O 22|O ,|O which|O fuse|O the|O collagen|O type|O Ialpha1|O (|O COLIA1|O )|O gene|O to|O the|O platelet|O -|O derived|O growth|O factor|O (|O PDGF|O )|O B|O -|O chain|O (|O PDGFB|O )|O gene|O .|O
In|O addition|O ,|O a|O significant|O excess|O risk|O of|O basal|B-DISE cell|I-DISE carcinoma|I-DISE was|O seen|O standardized|O incidence|O ratio|O 35|O ,|O 95|O %|O confidence|O interval|O 7|O .|O 2|O to|O 102|O .|O
The|O patient|O ,|O a|O 6|O -|O year|O -|O old|O Japanese|O male|O ,|O was|O noticed|O to|O have|O hemolytic|O anemia|O soon|O after|O birth|O ,|O and|O a|O diagnosis|O of|O G6PD|B-DISE deficiency|I-DISE was|O made|O at|O the|O age|O of|O 2|O .|O
This|O heritable|O -|O deletion|O mouse|O model|O will|O be|O particularly|O useful|O for|O the|O identification|O of|O the|O etiological|O genes|O and|O mechanisms|O ,|O phenotypic|O basis|O ,|O and|O investigation|O of|O therapeutic|O approaches|O for|O PWS|B-DISE .|O .|O
Familial|B-DISE adenomatous|I-DISE polyposis|I-DISE (|O FAP|B-DISE )|O is|O a|O dominantly|O inherited|O condition|O predisposing|O to|O colorectal|B-DISE cancer|I-DISE .|O
One|O child|O with|O heterozygous|O C3|B-DISE deficiency|I-DISE was|O found|O to|O have|O membranoproliferative|B-DISE glomerulonephritis|I-DISE ;|O proteinuria|B-DISE and|O /|O or|O microscopical|O haematuria|B-DISE was|O present|O in|O all|O three|O homozygous|O C3|O -|O deficient|O children|O .|O
Despite|O discovery|O of|O the|O causative|O gene|O ,|O a|O molecular|O basis|O for|O the|O diverse|O clinical|O presentations|O remains|O to|O be|O elucidated|O .|O
N|O -|O terminal|O mutant|O huntingtin|O also|O binds|O to|O synaptic|O vesicles|O and|O inhibits|O their|O glutamate|O uptake|O in|O vitro|O .|O
Second|O ,|O CTG|O expansion|O may|O establish|O a|O region|O of|O heterochromatin|O 3|O '|O of|O the|O repeat|O sequence|O and|O decrease|O SIX5|O transcription|O .|O
A|O somatic|O mutation|O in|O the|O X|O linked|O PIGA|O gene|O is|O responsible|O for|O the|O deficiency|O of|O glycosyl|O phosphatidylinositol|O (|O GPI|O )|O -|O anchored|O proteins|O on|O blood|O cells|O from|O patients|O with|O paroxysmal|B-DISE nocturnal|I-DISE hemoglobinuria|I-DISE .|O
A|O comparison|O of|O the|O clinical|O manifestations|O of|O the|O present|O five|O patients|O and|O reported|O CGKD|B-DISE or|O Duchenne|B-DISE muscular|I-DISE dystrophy|I-DISE (|O DMD|B-DISE )|O patients|O with|O DNA|O deletion|O suggests|O the|O existence|O of|O a|O certain|O gene|O responsible|O for|O gonadotropin|B-DISE deficiency|I-DISE GTD|B-DISE .|O
Angelman|B-DISE syndrome|I-DISE (|O AS|B-DISE )|O is|O caused|O by|O chromosome|O 15q11|O -|O q13|O deletions|O of|O maternal|O origin|O ,|O by|O paternal|O uniparental|B-DISE disomy|I-DISE (|O UPD|B-DISE )|O 15|O ,|O by|O imprinting|O defects|O ,|O and|O by|O mutations|O in|O the|O UBE3A|O gene|O .|O
A|O PCR|O -|O based|O diagnostic|O test|O ,|O which|O detects|O an|O NlaIII|O site|O generated|O by|O the|O mutation|O ,|O revealed|O a|O frequency|O among|O enzyme|O -|O defined|O carriers|O of|O 9|O /|O 64|O 14|O %|O .|O
Multipoint|O linkage|O analysis|O of|O choroideremia|B-DISE (|O TCD|B-DISE )|O and|O seven|O X|O chromosomal|O restriction|O fragment|O length|O polymorphisms|O (|O RFLPs|O )|O was|O carried|O out|O in|O 18|O Finnish|O TCD|B-DISE families|O .|O
An|O anonymous|O DNA|O probe|O ,|O dc12|O ,|O present|O in|O one|O of|O the|O YACs|O and|O in|O a|O patient|O with|O a|O submicroscopic|O deletion|O which|O includes|O MAOA|O and|O MAOB|O but|O not|O L1|O .|O 28|O ,|O serves|O as|O a|O flanking|O marker|O centromeric|O to|O the|O disease|O gene|O .|O
Mutations|O spanning|O the|O emerin|O gene|O have|O been|O identified|O in|O patients|O with|O EDMD|B-DISE .|O
We|O investigated|O the|O mechanism|O for|O AFAP|B-DISE in|O patients|O carrying|O a|O mutant|O APC|O allele|O APC|O AS9|O that|O has|O a|O mutation|O in|O the|O alternatively|O spliced|O region|O of|O exon|O 9|O .|O
The|O Sit|O (|O a|O )|O alloantigen|O is|O of|O low|O frequency|O (|O 1|O /|O 400|O )|O in|O the|O German|O population|O .|O
Inherited|O G6PD|B-DISE deficiency|I-DISE is|O associated|O with|O either|O episodic|O hemolytic|B-DISE anemia|I-DISE (|O triggered|O by|O fava|O beans|O or|O other|O agents|O )|O or|O life|O -|O long|O hemolytic|B-DISE anemia|I-DISE .|O
CONCLUSIONS|O :|O Lorenzo|O '|O s|O oil|O therapy|O had|O no|O effect|O on|O patients|O with|O evidence|O of|O inflammatory|O brain|B-DISE lesions|I-DISE .|O
Although|O both|O PLS|B-DISE and|O HMS|B-DISE share|O the|O cardinal|O features|O of|O PPK|B-DISE and|O severe|O periodontitis|B-DISE ,|O a|O number|O of|O additional|O findings|O are|O reported|O in|O HMS|B-DISE including|O arachnodactyly|B-DISE ,|O acro|B-DISE -|I-DISE osteolysis|I-DISE ,|O atrophic|B-DISE changes|I-DISE of|I-DISE the|I-DISE nails|I-DISE ,|O and|O a|O radiographic|O deformity|B-DISE of|I-DISE the|I-DISE fingers|I-DISE .|O
These|O data|O suggest|O that|O Kniest|B-DISE dysplasia|I-DISE results|O from|O shorter|O type|O II|O collagen|O monomers|O ,|O and|O support|O the|O hypothesis|O that|O alteration|O of|O a|O specific|O COL2A1|O domain|O ,|O which|O may|O span|O from|O exons|O 12|O to|O 24|O ,|O leads|O to|O the|O Kniest|B-DISE dysplasia|I-DISE phenotype|O .|O .|O
Fractionation|O and|O immunochemical|O experiments|O indicate|O that|O this|O novel|O conformation|O of|O intranuclear|O ataxin|O -|O 3|O is|O not|O due|O to|O proteolysis|O ,|O suggesting|O instead|O that|O association|O with|O nuclear|O protein|O (|O s|O )|O alters|O the|O structure|O of|O full|O -|O length|O ataxin|O -|O 3|O which|O exposes|O the|O polyglutamine|O domain|O .|O
We|O assembled|O the|O YAC|O clones|O into|O overlapping|O sets|O by|O hybridizing|O them|O to|O a|O large|O number|O of|O DNA|O probes|O from|O the|O HD|O region|O ,|O including|O the|O STSs|O .|O
Hypotonia|B-DISE ,|O chorioretinal|B-DISE dystrophy|I-DISE ,|O and|O myopia|B-DISE were|O also|O identified|O .|O
We|O report|O a|O rare|O case|O of|O paternally|O transmitted|O congenital|B-DISE myotonic|I-DISE dystrophy|I-DISE DM|B-DISE .|O
The|O difference|O of|O the|O WASPdim|O population|O in|O monocytes|O and|O lymphocytes|O observed|O in|O WAS|B-DISE carriers|O suggests|O that|O WASP|O plays|O a|O more|O critical|O role|O in|O the|O development|O of|O lymphocytes|O than|O in|O that|O of|O monocytes|O .|O
Thus|O ,|O APRT|O -|O HPRT|B-DISE -|I-DISE deficient|I-DISE mice|O ,|O which|O are|O devoid|O of|O any|O purine|O salvage|O pathways|O ,|O show|O no|O novel|O phenotype|O and|O are|O not|O a|O model|O for|O the|O behavioral|O abnormalities|O associated|O with|O the|O Lesch|O -|O Nyhan|O syndrome|O as|O previously|O suggested|O .|O .|O
At|O 7|O years|O of|O age|O he|O was|O referred|O to|O us|O by|O the|O paediatrician|O because|O of|O symptoms|O of|O Prader|B-DISE -|I-DISE Willi|I-DISE syndrome|I-DISE PWS|B-DISE .|O
Identification|O of|O BRCA1|O should|O facilitate|O early|O diagnosis|O of|O breast|B-DISE and|I-DISE ovarian|I-DISE cancer|I-DISE susceptibility|O in|O some|O individuals|O as|O well|O as|O a|O better|O understanding|O of|O breast|O cancer|O biology|O .|O .|O
This|O observation|O may|O provide|O insight|O into|O the|O role|O of|O CTLA|O -|O 4|O in|O humans|O .|O .|O
The|O transcription|O initiation|O site|O has|O been|O assigned|O to|O a|O residue|O 163|O bp|O upstream|O from|O the|O translation|O initiation|O triplet|O by|O primer|O extension|O analysis|O .|O
In|O addition|O ,|O pedigree|O analyses|O suggest|O the|O occurrence|O of|O an|O autosomal|O recessive|O variant|O .|O
Expression|O of|O the|O fusion|O protein|O led|O to|O morphological|O transformation|O and|O increased|O growth|O rate|O of|O these|O cells|O .|O
Mutations|O in|O atm|O and|O p53|O cause|O the|O human|O cancer|B-DISE -|O associated|O diseases|O ataxia|B-DISE -|I-DISE telangiectasia|I-DISE and|O Li|B-DISE -|I-DISE Fraumeni|I-DISE syndrome|I-DISE ,|O respectively|O .|O
VCFS|B-DISE /|O DGS|B-DISE is|O the|O most|O common|O syndrome|O associated|O with|O 22q11|O rearrangements|O .|O
This|O study|O also|O provided|O evidence|O for|O the|O pathological|O nature|O of|O amino|O acid|O changes|O in|O APC|O associated|O with|O both|O FAP|B-DISE and|O non|O -|O FAP|B-DISE colorectal|B-DISE cancer|I-DISE patients|O .|O .|O
We|O report|O a|O G|O -|O -|O A|O transition|O at|O nucleotide|O 431|O of|O the|O proteolipid|O protein|O gene|O (|O PLP|O )|O results|O in|O a|O nonsense|O codon|O in|O a|O family|O with|O an|O unusual|O form|O of|O Pelizaeus|B-DISE -|I-DISE Merzbacher|I-DISE disease|I-DISE PMD|B-DISE .|O
No|O ATM|O protein|O was|O detected|O by|O western|O blotting|O in|O any|O AT|B-DISE cell|O line|O in|O which|O splicing|O mutations|O were|O identified|O .|O
At|O a|O de|O novo|O frequency|O of|O approximately|O .|O 67|O -|O 1|O /|O 10|O ,|O 000|O births|O ,|O these|O deletions|O represent|O a|O common|O structural|O chromosome|O change|O in|O the|O human|O genome|O .|O
Thus|O ,|O gene|O -|O specific|O mechanisms|O were|O selected|O to|O overexpress|O PAX3|O -|O FKHR|O and|O PAX7|O -|O FKHR|O in|O alveolar|O rhabdomyosarcoma|O ,|O presumably|O due|O to|O differences|O in|O regulation|O between|O the|O wild|O -|O type|O loci|O .|O
We|O report|O familial|B-DISE adenomatous|I-DISE polyposis|I-DISE coli|I-DISE (|O FAPC|B-DISE )|O with|O epidermoid|B-DISE cysts|I-DISE ,|O osteomata|B-DISE ,|O and|O areas|O of|O congenital|B-DISE hypertrophy|I-DISE of|I-DISE the|I-DISE retinal|I-DISE pigment|I-DISE epithelium|I-DISE (|O CHRPEs|B-DISE )|O in|O a|O male|O patient|O and|O his|O maternal|O aunt|O ,|O both|O of|O whom|O suffered|O a|O mild|O to|O moderate|O degree|O of|O mental|B-DISE handicap|I-DISE .|O
Increasing|O evidence|O ,|O provided|O by|O others|O ,|O for|O the|O nonrandom|O involvement|O of|O 14q|O in|O African|B-DISE -|I-DISE type|I-DISE Burkitt|I-DISE '|I-DISE s|I-DISE lymphoma|I-DISE and|O other|O lymphoid|B-DISE neoplasms|I-DISE further|O strengthens|O this|O hypothesis|O .|O .|O
A|O DNA|O -|O based|O test|O for|O the|O HFE|O gene|O is|O commercially|O available|O ,|O but|O its|O place|O in|O the|O diagnosis|O of|O hemochromatosis|B-DISE is|O still|O being|O evaluated|O .|O
An|O initial|O inguinal|O lymph|O node|O biopsy|O surprisingly|O revealed|O Kaposi|B-DISE sarcoma|I-DISE .|O
Notable|O among|O this|O group|O were|O the|O growth|O factor|O gene|O Igf2|O and|O its|O binding|O protein|O Igfbp5|O .|O
Family|O screening|O in|O the|O initial|O cohort|O identified|O 18|O men|O from|O five|O families|O with|O severe|O hyperglycerolemia|B-DISE (|O values|O above|O 2|O .|O 0|O mmol|O /|O liter|O )|O and|O demonstrated|O an|O X|O -|O linked|O pattern|O of|O inheritance|O .|O
The|O specific|O characteristics|O of|O our|O population|O of|O patients|O may|O explain|O why|O such|O a|O high|O frequency|O was|O not|O found|O in|O other|O series|O .|O .|O
The|O Fas|O /|O Apo|O -|O 1|O receptor|O plays|O a|O crucial|O role|O in|O the|O regulation|O of|O apoptosis|B-DISE ,|O as|O demonstrated|O by|O lymphoproliferation|O in|O MRL|O -|O lpr|O /|O lpr|O mice|O and|O by|O the|O recently|O described|O autoimmune|B-DISE lymphoproliferative|I-DISE syndrome|I-DISE (|O ALPS|B-DISE )|O in|O humans|O ,|O both|O of|O which|O are|O due|O to|O mutations|O in|O the|O Fas|O gene|O .|O
Apolipoprotein|O E|O (|O APOE|O )|O genotype|O ,|O in|O turn|O ,|O is|O known|O to|O influence|O AO|O in|O Alzheimer|B-DISE disease|I-DISE ,|O rendering|O the|O APOE|O gene|O a|O likely|O candidate|O to|O affect|O AO|O in|O other|O neurological|B-DISE diseases|I-DISE too|O .|O
HFE|O -|O /|O -|O mice|O also|O demonstrated|O an|O increase|O in|O duodenal|O DMT1|O (|O IRE|O )|O mRNA|O (|O average|O 7|O .|O 7|O -|O fold|O )|O ,|O despite|O their|O elevated|O transferrin|O saturation|O and|O hepatic|O iron|O content|O .|O
We|O have|O expressed|O an|O untranslated|O CUG|O repeat|O in|O an|O unrelated|O mRNA|O in|O transgenic|O mice|O .|O
Analyzing|O the|O expression|O level|O of|O the|O SCA3|O gene|O in|O several|O human|O brain|O sections|O revealed|O no|O significant|O higher|O mRNA|O level|O in|O regions|O predominantly|O affected|O in|O MJD|B-DISE .|O
We|O performed|O a|O linkage|O study|O of|O chromosome|O 22|O in|O 200|O families|O with|O AS|B-DISE affected|O sibling|O -|O pairs|O .|O
The|O relationship|O between|O abnormal|O color|O vision|O and|O adrenomyeloneuropathy|B-DISE (|O AMN|B-DISE )|O was|O investigated|O in|O 27|O AMN|B-DISE patients|O and|O 31|O age|O -|O matched|O controls|O by|O using|O the|O Farnsworth|O -|O Munsell|O 100|O Hue|O test|O .|O
Heterozygous|O mutations|O in|O the|O CD95|O (|O APO|O -|O 1|O /|O Fas|O )|O receptor|O occur|O in|O most|O individuals|O with|O autoimmune|B-DISE lymphoproliferative|I-DISE syndrome|I-DISE (|O ALPS|B-DISE )|O and|O dominantly|O interfere|O with|O apoptosis|O by|O an|O unknown|O mechanism|O .|O
We|O compared|O G6PD|O activity|O among|O different|O mutations|O ,|O without|O discovering|O significant|O differences|O between|O them|O .|O .|O
Upon|O irradiation|O ,|O BRCA1|O was|O detected|O in|O discrete|O foci|O in|O the|O nucleus|O ,|O which|O colocalize|O with|O hRad50|O .|O
METHODS|O AND|O RESULTS|O :|O When|O expressed|O alone|O in|O Xenopus|O oocytes|O ,|O T1620M|O exhibited|O no|O persistent|O currents|O ,|O in|O contrast|O to|O the|O LQT3|O mutant|O channels|O ,|O but|O the|O midpoint|O of|O steady|O -|O state|O inactivation|O V|O 1|O /|O 2|O was|O significantly|O shifted|O toward|O more|O positive|O potentials|O than|O for|O wild|O -|O type|O hH1|O .|O
We|O present|O models|O to|O explain|O how|O the|O LCR22s|O can|O mediate|O different|O homologous|O recombination|O events|O ,|O thereby|O generating|O a|O number|O of|O rearrangements|O that|O are|O associated|O with|O congenital|B-DISE anomaly|I-DISE disorders|I-DISE .|O
High|O level|O expression|O of|O the|O nm23|O -|O H1|O gene|O ,|O which|O encodes|O for|O a|O nucleoside|O diphosphate|O kinase|O ,|O has|O been|O found|O to|O correlate|O with|O diminished|O metastasis|O in|O some|O tumors|B-DISE but|O not|O in|O others|O .|O
The|O FRDA|O gene|O encodes|O a|O widely|O expressed|O 210|O -|O aa|O protein|O ,|O frataxin|O ,|O which|O is|O located|O in|O mitochondria|O and|O is|O severely|O reduced|O in|O FRDA|B-DISE patients|O .|O
(|O 1992|O )|O to|O be|O a|O clinically|O benign|O pseudodeficient|O "|O allele|O associated|O with|O reduced|O enzyme|O activity|O against|O artificial|O substrate|O .|O "|O
X|B-DISE -|I-DISE linked|I-DISE recessive|I-DISE Emery|I-DISE -|I-DISE Dreifuss|I-DISE muscular|I-DISE dystrophy|I-DISE (|O EDMD|B-DISE )|O is|O an|O inherited|O muscle|B-DISE disorder|I-DISE characterized|O by|O the|O clinical|O triad|O of|O progressive|B-DISE wasting|I-DISE of|I-DISE humero|I-DISE -|I-DISE peroneal|I-DISE muscles|I-DISE ,|O early|O contractures|B-DISE of|I-DISE the|I-DISE elbows|I-DISE ,|I-DISE Achilles|I-DISE tendons|I-DISE and|I-DISE postcervical|I-DISE muscles|I-DISE ,|O and|O cardiac|B-DISE conduction|I-DISE block|I-DISE with|O a|O high|O risk|O of|O sudden|B-DISE death|I-DISE .|O
Transcription|O of|O rsca3|O was|O detected|O in|O most|O rat|O tissues|O including|O brain|O .|O
Database|O searches|O and|O analysis|O of|O available|O genomic|O DNA|O sequence|O from|O the|O region|O revealed|O the|O presence|O of|O the|O fibroblast|O growth|O factor|O homologous|O factor|O gene|O ,|O FHF2|O ,|O within|O the|O duplication|O breakpoint|O interval|O .|O
The|O sibling|O recurrence|O risk|O ratio|O for|O the|O disease|O is|O 63|O and|O heritability|O assessed|O in|O twins|O >|O 90|O %|O .|O
These|O data|O support|O the|O model|O for|O HH|O in|O which|O HFE|O mutations|O lead|O to|O inappropriately|O low|O crypt|O cell|O iron|O ,|O with|O resultant|O stabilization|O of|O DMT1|O (|O IRE|O )|O mRNA|O ,|O up|O -|O regulation|O of|O DMT1|O ,|O and|O increased|O absorption|O of|O dietary|O iron|O .|O .|O
The|O END|O -|O repeat|O units|O are|O derived|O from|O large|O genomic|O duplications|O of|O a|O novel|O gene|O (|O HERC2|O )|O ,|O many|O copies|O of|O which|O are|O transcriptionally|O active|O in|O germline|O tissues|O .|O
HFE|O -|O deficient|O animals|O were|O analyzed|O for|O a|O comprehensive|O set|O of|O metabolic|O and|O immune|O parameters|O .|O
These|O results|O suggest|O that|O the|O mutation|O of|O the|O APC|O gene|O also|O plays|O an|O important|O role|O during|O the|O carcinogenesis|O of|O at|O least|O some|O gastric|B-DISE cancers|I-DISE .|O .|O
To|O investigate|O mutation|O origin|O and|O mutation|O -|O specific|O phenotypes|O due|O to|O BRCA1|O ,|O we|O constructed|O a|O haplotype|O of|O nine|O polymorphic|O markers|O within|O or|O immediately|O flanking|O the|O BRCA1|O locus|O in|O a|O set|O of|O 61|O breast|B-DISE /|I-DISE ovarian|I-DISE cancer|I-DISE families|O selected|O for|O having|O one|O of|O six|O recurrent|O BRCA1|O mutations|O .|O
Subsequently|O PAX6|O intragenic|O mutations|O were|O demonstrated|O in|O Smalleye|O ,|O a|O mouse|O mutant|O which|O is|O an|O animal|B-DISE model|I-DISE for|I-DISE aniridia|I-DISE ,|O and|O six|O human|O aniridia|B-DISE patients|O .|O
Considerable|O genetic|O heterogeneity|O in|O G6PD|O was|O found|O in|O the|O Bulgarian|O population|O -|O 14|O G6PD|O variants|O isolated|O from|O 117|O hemizygous|O carriers|O of|O G6PD|B-DISE deficiency|I-DISE .|O
Recent|O studies|O have|O demonstrated|O that|O this|O trinucleotide|O motif|O forms|O part|O of|O the|O last|O ,|O 3|O '|O untranslated|O exon|O of|O a|O gene|O which|O potentially|O encodes|O multiple|O protein|O isoforms|O of|O a|O serine|O /|O threonine|O protein|O kinase|O myotonic|B-DISE dystrophy|I-DISE protein|O kinase|O ,|O DM|O -|O PK|O .|O
These|O findings|O suggest|O a|O possible|O mechanism|O which|O may|O have|O juxtaposed|O the|O three|O sites|O and|O mediated|O sequence|O -|O specific|O breakage|O and|O recombination|O between|O nonhomologous|O chromosomes|O in|O male|O meiosis|O .|O .|O
The|O amount|O of|O p19|O /|O nm23|O increased|O in|O normal|O lymphocytes|O in|O response|O to|O mitotic|O stimulation|O and|O paralleled|O the|O increase|O in|O DNA|O synthesis|O .|O
To|O determine|O the|O extent|O of|O heterogeneity|O of|O G6PD|O ,|O we|O have|O studied|O several|O different|O Indian|O populations|O by|O screening|O for|O G6PD|B-DISE deficiency|I-DISE ,|O followed|O by|O molecular|O analysis|O of|O deficient|O alleles|O .|O
This|O observation|O indicates|O that|O the|O WT1|O exon|O 9|O mutation|O affecting|O 394Arg|O demonstrated|O in|O over|O one|O -|O half|O of|O the|O patients|O with|O the|O Denys|B-DISE -|I-DISE Drash|I-DISE syndrome|I-DISE may|O exhibit|O incomplete|O penetrance|O .|O
All|O but|O two|O of|O these|O previously|O described|O mutations|O cause|O in|O -|O frame|O deletions|O in|O type|O II|O collagen|O ,|O either|O by|O small|O deletions|O in|O the|O gene|O or|O splice|O site|O alterations|O .|O
Clinically|O ,|O affected|O hemizygous|O males|O have|O angiokeratoma|B-DISE ,|O severe|O acroparesthesia|B-DISE ,|O renal|B-DISE failure|I-DISE ,|O and|O vasculopathy|O of|O the|O heart|O and|O brain|O .|O
Ataxia|B-DISE -|I-DISE telangiectasia|I-DISE is|O a|O rare|O genetic|B-DISE disorder|I-DISE associated|O with|O immune|B-DISE deficiency|I-DISE ,|O chromosome|O instability|O ,|O and|O a|O predisposition|O to|O lymphoid|B-DISE malignancy|I-DISE .|O
It|O will|O also|O have|O important|O implications|O for|O genetic|O counseling|O ,|O particularly|O for|O more|O accurately|O predicting|O recurrence|O risks|O of|O clefts|O among|O the|O offspring|O of|O patients|O with|O VWS|B-DISE .|O .|O
No|O well|O -|O characterized|O intragenic|O rearrangement|O of|O APC|O has|O been|O described|O ,|O and|O the|O prevalence|O of|O this|O type|O of|O mutation|O in|O FAP|B-DISE patients|O is|O not|O clear|O .|O
By|O Southern|O blot|O analysis|O we|O have|O mapped|O ten|O different|O polymorphic|O DNA|O loci|O relative|O to|O the|O position|O of|O the|O deletion|O and|O the|O choroideremia|B-DISE locus|O TCD|O .|O
In|O yeast|O mitochondria|O ,|O native|O mYfh1p|O exists|O as|O monomer|O and|O a|O higher|O -|O order|O species|O with|O a|O molecular|O weight|O >|O 600|O ,|O 000|O .|O
Pendrin|O is|O closely|O related|O to|O a|O family|O of|O sulfate|O transport|O proteins|O that|O includes|O the|O rat|O sulfate|O -|O anion|O transporter|O (|O encoded|O by|O Sat|O -|O 1|O ;|O 29|O %|O amino|O acid|O sequence|O identity|O )|O ,|O the|O human|O diastrophic|B-DISE dysplasia|I-DISE sulfate|O transporter|O (|O encoded|O by|O DTD|O ;|O 32|O %|O )|O and|O the|O human|O sulfate|O transporter|O '|O downregulated|O in|O adenoma|B-DISE '|O encoded|O by|O DRA|O ;|O 45|O %|O .|O
The|O control|O group|O consisted|O of|O 40|O consecutive|O FMF|B-DISE patients|O ,|O who|O arrived|O at|O the|O FMF|B-DISE clinic|O for|O their|O regular|O follow|O -|O up|O visit|O and|O were|O 40|O years|O of|O age|O or|O older|O at|O the|O time|O of|O the|O examination|O .|O
We|O identified|O a|O KIT|O gene|O mutation|O in|O a|O proband|O with|O classic|O autosomal|B-DISE dominant|I-DISE piebaldism|I-DISE .|O
Familial|O direct|O insertions|O should|O be|O considered|O as|O a|O cause|O of|O recurrent|O microdeletion|O syndromes|O .|O .|O
The|O similar|O pattern|O of|O germline|O mutation|O in|O all|O ethnic|O groups|O studied|O to|O date|O provides|O additional|O data|O compatible|O with|O the|O inference|O that|O endogenous|O processes|O predominate|O in|O germline|O mutations|O .|O .|O
Kniest|B-DISE dysplasia|I-DISE is|O a|O moderately|O severe|O chondrodysplasia|B-DISE phenotype|O that|O results|O from|O mutations|O in|O the|O gene|O for|O type|O II|O collagen|O ,|O COL2A1|O .|O
Linkage|O disequilibrium|O mapping|O in|O isolated|O populations|O provides|O a|O powerful|O tool|O for|O fine|O structure|O localization|O of|O disease|O genes|O .|O
Despite|O its|O widespread|O expression|O ,|O mutant|O huntingtin|O induces|O selective|O neuronal|B-DISE loss|I-DISE in|O striatal|O neurons|O .|O
Germline|O mutations|O in|O the|O tumor|O suppressor|O gene|O ,|O BRCA1|O ,|O predispose|O individuals|O to|O breast|B-DISE and|I-DISE ovarian|I-DISE cancers|I-DISE .|O
We|O now|O report|O two|O mutant|O alleles|O in|O this|O Pennsylvania|O Dutch|O kindred|O ,|O and|O one|O polymorphism|O .|O
Based|O on|O previous|O knowledge|O about|O mutation|O -|O phenotype|O associations|O ,|O 78|O of|O the|O mutations|O could|O be|O assigned|O to|O one|O of|O four|O classes|O of|O severity|O severe|O PKU|B-DISE ,|O moderate|O PKU|B-DISE ,|O mild|O PKU|B-DISE ,|O and|O mild|O hyperphenylalaninemia|B-DISE MHP|B-DISE .|O
Heterozygosity|O for|O the|O most|O frequent|O poor|O metabolizer|O allele|O (|O CYP2D6|O *|O 4|O )|O was|O not|O associated|O with|O increased|O susceptibility|O to|O AS|B-DISE .|O
The|O P65L|O mutation|O locates|O 11|O bases|O upstream|O of|O a|O splice|O donor|O site|O of|O intron|O 3|O .|O
In|O addition|O Hmgic|O -|O /|O -|O mice|O have|O a|O deficiency|B-DISE in|I-DISE fat|I-DISE tissue|I-DISE .|O
These|O results|O suggest|O that|O the|O APC|O -|O Asef|O complex|O may|O regulate|O the|O actin|O cytoskeletal|O network|O ,|O cell|O morphology|O and|O migration|O ,|O and|O neuronal|O function|O .|O .|O
The|O WASP|O gene|O has|O been|O recently|O cloned|O from|O Xp11|O .|O 23|O and|O shown|O to|O be|O mutated|O in|O three|O patients|O with|O the|O Wiskott|B-DISE -|I-DISE Aldrich|I-DISE syndrome|I-DISE WAS|B-DISE .|O
Gaucher|B-DISE disease|I-DISE (|I-DISE GD|I-DISE )|I-DISE is|I-DISE an|I-DISE inherited|I-DISE deficiency|I-DISE of|O beta|O -|O glucocerebrosidase|O EC|O 3|O .|O 1|O .|O 2|O .|O 45|O ,|O gene|O symbol|O GBA|O .|O
We|O have|O screened|O the|O remaining|O five|O families|O for|O point|O mutations|O .|O
Several|O different|O missense|O mutations|O have|O been|O identified|O in|O patients|O with|O FHM|B-DISE .|O
One|O variant|O was|O identified|O in|O intron|O 5|O (|O IVS5|O -|O 10C|O >|O G|O )|O ,|O which|O did|O not|O segregate|O with|O BFIC|B-DISE and|O was|O observed|O in|O 9|O .|O 2|O %|O controls|O .|O
CONCLUSIONS|O :|O Although|O BRCA|O -|O associated|O hereditary|B-DISE ovarian|I-DISE cancers|I-DISE in|O this|O population|O have|O surgical|O and|O pathological|O characteristics|O similar|O to|O those|O of|O sporadic|O cancers|O ,|O advanced|B-DISE -|I-DISE stage|I-DISE hereditary|I-DISE cancer|I-DISE patients|O survive|O longer|O than|O nonhereditary|O cancer|O patients|O .|O
Each|O multimer|O consists|O of|O approximately|O 60|O subunits|O and|O can|O sequester|O >|O 3|O ,|O 000|O atoms|O of|O iron|O .|O
Three|O sisters|O were|O shown|O to|O suffer|O from|O fish|B-DISE -|I-DISE eye|I-DISE disease|I-DISE (|O FED|B-DISE )|O ,|O a|O disorder|O which|O is|O caused|O by|O mutations|O in|O the|O gene|O coding|O for|O lecithin|O :|O cholesterol|O acyltransferase|O LCAT|O .|O
MEFV|O was|O also|O expressed|O in|O the|O monocytic|O cell|O lines|O U937|O and|O THP|O -|O 1|O .|O
In|O Finland|O ,|O there|O are|O more|O than|O 120|O living|O CHM|B-DISE patients|O belonging|O to|O eight|O apparently|O unrelated|O pedigrees|O .|O
Emerin|O stayed|O on|O the|O cytoplasmic|O surface|O of|O the|O nuclear|O lamina|O ,|O even|O after|O detergent|O treatment|O that|O solubilizes|O membrane|O lipids|O and|O washes|O out|O membrane|O proteins|O .|O
Congenital|B-DISE afibrinogenemia|I-DISE is|O a|O rare|O ,|O autosomal|B-DISE ,|I-DISE recessive|I-DISE disorder|I-DISE characterized|O by|O the|O complete|O absence|O of|O detectable|O fibrinogen|O .|O
A|O DNA|O marker|O C7|O ,|O localised|O Xp21|O .|O 1|O -|O Xp21|O .|O 3|O ,|O has|O been|O studied|O in|O kindreds|O segregating|O for|O Duchenne|B-DISE muscular|I-DISE dystrophy|I-DISE (|O DMD|B-DISE )|O and|O Becker|B-DISE muscular|I-DISE dystrophy|I-DISE BMD|B-DISE .|O
Polymerase|O chain|O reaction|O amplification|O of|O VLCAD|O mRNA|O and|O genomic|O exons|O defined|O the|O molecular|O defects|O in|O two|O patients|O with|O VLCAD|O deficiency|O who|O presented|O with|O unexplained|O cardiac|B-DISE arrest|I-DISE and|O cardiomyopathy|B-DISE .|O
Germline|O mutations|O are|O the|O major|O source|O of|O genetic|O variation|O that|O allows|O a|O species|O to|O evolve|O over|O time|O but|O at|O the|O cost|O of|O Mendelian|O disease|O and|O genetic|O predisposition|O to|O multifactorial|O diseases|O .|O
The|O psiGLDC|O gene|O has|O no|O intron|O and|O shares|O 97|O .|O 5|O %|O homology|O with|O the|O coding|O region|O of|O functional|O GLDC|O ,|O suggesting|O that|O psiGLDC|O is|O a|O processed|O pseudogene|O that|O arose|O from|O the|O GLDC|O transcript|O about|O 4|O -|O 8|O million|O years|O ago|O .|O
Both|O the|O A|B-DISE -|I-DISE T|I-DISE phenotype|O and|O the|O similarity|O of|O the|O ATM|O protein|O to|O other|O DNA|O -|O damage|O sensors|O suggests|O a|O role|O for|O ATM|O in|O biochemical|O pathways|O involved|O in|O the|O recognition|O ,|O signalling|O and|O repair|O of|O DNA|O double|O -|O strand|O breaks|O DSBs|O .|O
The|O frequencies|O of|O the|O G6PD|O A|O and|O of|O the|O G6PD|O A|O -|O genes|O in|O parts|O of|O Africa|O are|O both|O about|O 0|O .|O 2|O .|O
A|O new|O CT|O pattern|O was|O observed|O in|O 2|O patients|O with|O adrenoleukodystrophy|B-DISE ALD|B-DISE .|O
These|O findings|O suggest|O a|O thalassemia|B-DISE "|O -|O like|O mutation|O for|O this|O disorder|O .|O .|O "|O
Faithfully|O mimicking|O human|O hemochromatosis|B-DISE ,|O mice|O homozygous|O for|O this|O deletion|O develop|O iron|B-DISE overload|I-DISE ,|O characterized|O by|O a|O higher|O plasma|O iron|O content|O and|O a|O raised|O transferrin|O saturation|O as|O well|O as|O an|O elevated|O hepatic|O iron|O load|O .|O
In|O all|O three|O cases|O ,|O there|O is|O a|O strong|O family|O history|O of|O breast|B-DISE ,|I-DISE ovarian|I-DISE ,|I-DISE or|I-DISE other|I-DISE cancers|I-DISE possibly|O related|O to|O a|O BRCA1|O defect|O and|O family|O members|O showed|O a|O high|O concordance|O of|O cancer|O incidence|O with|O the|O presence|O of|O R841W|O .|O
In|O sensorineural|B-DISE deafness|I-DISE ,|O dystonia|B-DISE ,|O and|O mental|B-DISE retardation|I-DISE ,|O mutations|O were|O found|O in|O the|O gene|O DDP|O coding|O for|O a|O polypeptide|O of|O unknown|O function|O .|O
There|O are|O strong|O parallels|O between|O the|O pattern|O of|O radiosensitivity|O ,|O chromosomal|O instability|O and|O cancer|B-DISE predisposition|O in|O A|B-DISE -|I-DISE T|I-DISE patients|O and|O that|O in|O patients|O with|O Nijmegen|B-DISE breakage|I-DISE syndrome|I-DISE NBS|B-DISE .|O
We|O have|O examined|O 22|O families|O with|O at|O least|O one|O case|O of|O male|B-DISE breast|I-DISE cancer|I-DISE for|O linkage|O to|O the|O hereditary|B-DISE breast|I-DISE and|I-DISE ovarian|I-DISE cancer|I-DISE locus|O ,|O BRCA1|O ,|O on|O chromosome|O 17q|O .|O
Dominant|O myotonia|B-DISE congenita|I-DISE (|O Thomsen|B-DISE '|I-DISE s|I-DISE disease|I-DISE )|O is|O linked|O to|O CLCN1|O ,|O the|O gene|O encoding|O the|O major|O muscle|O chloride|O channel|O ,|O localized|O on|O chromosome|O 7q35|O .|O
We|O describe|O the|O first|O cases|O ,|O to|O our|O knowledge|O ,|O of|O C9|B-DISE deficiency|I-DISE in|O Europe|O that|O were|O detected|O in|O a|O Swiss|O family|O ,|O of|O which|O two|O members|O -|O -|O one|O with|O a|O complete|O deficiency|O and|O the|O other|O with|O approximately|O half|O -|O normal|O C9|O levels|O -|O -|O experienced|O bacterial|B-DISE meningitis|I-DISE .|O
We|O report|O new|O mutations|O in|O exon|O 9|O of|O the|O WT1|O gene|O that|O did|O not|O alter|O the|O ratio|O of|O +|O /|O -|O KTS|O splice|O isoforms|O in|O two|O unrelated|O patients|O with|O Frasier|B-DISE syndrome|I-DISE FS|B-DISE .|O
Autoimmune|B-DISE lymphoproliferative|I-DISE syndrome|I-DISE (|O ALPS|B-DISE )|O is|O a|O disorder|O of|O lymphocyte|O homeostasis|O and|O immunological|O tolerance|O .|O
Mutation|O or|O deletion|O of|O the|O PAX6|O gene|O underlies|O many|O cases|O of|O aniridia|B-DISE .|O
Adrenoleukodystrophy|B-DISE (|O ALD|B-DISE )|O is|O an|O X|O -|O linked|O disease|O affecting|O 1|O /|O 20|O ,|O 000|O males|O either|O as|O cerebral|O ALD|B-DISE in|O childhood|O or|O as|O adrenomyeloneuropathy|B-DISE (|O AMN|B-DISE )|O in|O adults|O .|O
Immunofluorescence|O analysis|O demonstrated|O that|O the|O functional|O replacement|O of|O ALDP|O by|O ALDRP|O was|O not|O due|O to|O stabilization|O of|O the|O mutated|O ALDP|O itself|O .|O
The|O patient|O was|O shown|O to|O be|O heterozygous|O for|O DNA|O markers|O in|O the|O C6|O ,|O C7|O and|O C9|O region|O of|O chromosome|O 5|O and|O therefore|O appears|O to|O be|O a|O compound|O heterozygote|O for|O two|O uncharacterized|O C9|B-DISE deficiency|I-DISE genes|O .|O
The|O seven|O other|O siblings|O were|O heterozygous|O for|O C7|B-DISE deficiency|I-DISE ,|O while|O the|O paternal|O aunt|O had|O a|O normal|O C7|O level|O .|O
The|O H63D|O mutation|O is|O older|O and|O does|O not|O occur|O on|O such|O a|O large|O extended|O haplotype|O ,|O the|O haplotype|O in|O this|O case|O extending|O <|O /|O =|O 700|O kb|O .|O
OBJECTIVES|O :|O A|O Japanese|O family|O with|O cerebrotendinous|B-DISE xanthomatosis|I-DISE (|O CTX|B-DISE )|O was|O investigated|O for|O a|O sequence|O alteration|O in|O the|O sterol|O 27|O -|O hydroxylase|O gene|O CYP27|O .|O
Among|O 910|O sperm|O analyzed|O ,|O the|O allele|O linked|O to|O the|O disease|O chromosome|O was|O detected|O in|O 50|O .|O 3|O %|O of|O the|O samples|O and|O the|O allele|O linked|O to|O the|O normal|O chromosome|O was|O found|O in|O 49|O .|O 6|O %|O of|O the|O sperm|O .|O
Similar|O abnormalities|O were|O found|O in|O Foxc2|O (|O +|O /|O -|O )|O mice|O ,|O but|O no|O disease|O -|O associated|O mutations|O were|O identified|O in|O the|O human|O homolog|O FKHL14|O in|O 32|O ARA|O patients|O .|O
Moreover|O ,|O MAGEL2|O /|O Magel2|O are|O expressed|O only|O from|O the|O paternal|O allele|O in|O brain|O ,|O suggesting|O a|O potential|O role|O in|O the|O aetiology|O of|O PWS|B-DISE and|O its|O mouse|O model|O ,|O respectively|O .|O .|O
The|O protein|O defective|O in|O NBS|B-DISE ,|O nibrin|O (|O encoded|O by|O NBS1|O )|O ,|O forms|O a|O complex|O with|O MRE11|O and|O RAD50|O refs|O 1|O ,|O 2|O .|O
A|O pair|O of|O female|O monozygotic|O (|O MZ|O )|O twins|O ,|O heterozygous|O carriers|O for|O a|O deletion|O in|O the|O DMD|O gene|O and|O discordant|O for|O the|O clinical|O manifestations|O of|O Duchenne|B-DISE muscular|I-DISE dystrophy|I-DISE ,|O were|O analyzed|O by|O molecular|O studies|O ,|O in|O situ|O hybridization|O ,|O and|O methylation|O pattern|O of|O X|O chromosomes|O to|O search|O for|O opposite|O X|O inactivation|O as|O an|O explanation|O of|O their|O clinical|O discordance|O .|O
Here|O we|O present|O four|O novel|O PAX6|O missense|O mutations|O ,|O two|O in|O association|O with|O atypical|O phenotypes|O :|O ectopia|B-DISE pupillae|I-DISE (|O displaced|B-DISE pupils|I-DISE )|O and|O congenital|B-DISE nystagmus|I-DISE (|O searching|B-DISE gaze|I-DISE )|O ,|O and|O two|O in|O association|O with|O more|O recognizable|O aniridia|O phenotypes|O .|O
We|O therefore|O determined|O APOE|O genotype|O and|O normal|O CAG|O repeat|O length|O in|O the|O HD|O gene|O for|O 138|O HD|B-DISE patients|O who|O were|O previously|O analysed|O with|O respect|O to|O CAG|O repeat|O length|O .|O
CONCLUSIONS|O :|O The|O reproductive|O outcome|O in|O maternal|O phenylketonuria|B-DISE is|O dependent|O on|O prenatal|O metabolic|O control|O and|O postnatal|O environmental|O circumstances|O .|O
Here|O we|O report|O a|O PWS|B-DISE family|O in|O which|O the|O father|O is|O mosaic|O for|O an|O IC|O deletion|O on|O his|O paternal|O chromosome|O .|O
Several|O novel|O as|O well|O as|O previously|O reported|O uncharacterized|O variants|O were|O also|O identified|O ,|O some|O of|O which|O were|O associated|O with|O a|O family|O history|O of|O cancer|B-DISE .|O
Eleven|O of|O the|O 16|O homozygous|O subjects|O underwent|O liver|O biopsy|O ;|O 3|O had|O hepatic|B-DISE fibrosis|I-DISE ,|O and|O 1|O ,|O who|O had|O a|O history|O of|O excessive|O alcohol|O consumption|O ,|O had|O cirrhosis|B-DISE and|O mild|O microvesicular|B-DISE steatosis|I-DISE .|O
Previous|O studies|O have|O demonstrated|O that|O a|O dose|O -|O dependent|O loss|O of|O Dm15|O (|O the|O mouse|O DMPK|O homologue|O )|O in|O mice|O produces|O a|O partial|O DM|B-DISE phenotype|O characterized|O by|O decreased|B-DISE development|I-DISE of|I-DISE skeletal|I-DISE muscle|I-DISE force|I-DISE and|O cardiac|B-DISE conduction|I-DISE disorders|I-DISE .|O
In|O the|O autoinhibited|O complex|O ,|O intramolecular|O interactions|O with|O the|O GTPase|O -|O binding|O domain|O occlude|O residues|O of|O the|O C|O terminus|O that|O regulate|O the|O Arp2|O /|O 3|O actin|O -|O nucleating|O complex|O .|O
Our|O findings|O give|O evidence|O of|O a|O gonadal|O mosaicism|O in|O the|O unaffected|O mother|O .|O
To|O define|O the|O molecular|O defects|O causing|O SLS|B-DISE ,|O we|O performed|O mutation|O analysis|O of|O the|O FALDH|O gene|O in|O probands|O from|O 63|O kindreds|O with|O SLS|B-DISE .|O
Electrophoresis|O of|O fetal|O -|O tissue|O extracts|O also|O demonstrated|O the|O absence|O of|O the|O A|O form|O of|O acid|O lipase|O .|O
All|O of|O the|O patients|O with|O SLS|B-DISE were|O found|O to|O carry|O mutations|O .|O
Mutations|O in|O PAX6|O are|O responsible|O for|O human|O aniridia|B-DISE and|O have|O also|O been|O found|O in|O patients|O with|O Peter|B-DISE '|I-DISE s|I-DISE anomaly|I-DISE ,|O with|O congenital|B-DISE cataracts|I-DISE ,|O with|O autosomal|O dominant|O keratitis|B-DISE ,|O and|O with|O isolated|B-DISE foveal|I-DISE hypoplasia|I-DISE .|O
Although|O hereditary|O TP53|O mutation|O is|O very|O rare|O in|O different|O human|O cancers|B-DISE ,|O it|O has|O been|O frequently|O reported|O in|O Li|B-DISE -|I-DISE Fraumeni|I-DISE syndrome|I-DISE .|O
The|O seizures|B-DISE usually|O spontaneously|O cease|O after|O one|O year|O without|O treatment|O ,|O leaving|O no|O neurological|B-DISE abnormalities|I-DISE .|O
Since|O sporadic|O variants|O of|O G6PD|O causing|O HNSHA|O show|O no|O special|O racial|O predilection|O ,|O the|O diagnosis|O of|O G6PD|B-DISE deficiency|I-DISE should|O always|O be|O considered|O in|O patients|O with|O this|O syndrome|O .|O .|O
We|O screened|O 49|O potential|O FAP|B-DISE families|O and|O identified|O 26|O different|O germline|O APC|O mutations|O in|O 30|O families|O .|O
Partial|O gene|O deletion|O is|O the|O major|O cause|O of|O mutation|O leading|O to|O Duchenne|B-DISE muscular|I-DISE dystrophy|I-DISE (|O DMD|B-DISE )|O and|O Becker|B-DISE muscular|I-DISE dystrophy|I-DISE BMD|B-DISE .|O
In|O Sardinians|O with|O the|O beta|B-DISE 0|I-DISE -|I-DISE thalassemia|Mention text="beta 0-thalassemia" start=4 end=8 type=DISE prob=null&Mention text="thalassemia trait" start=7 end=9 type=DISE prob=null trait|I-DISE ,|O parasite|O growth|O was|O normal|O except|O when|O G6PD|B-DISE deficiency|I-DISE occurred|O together|O with|O the|O thalassemia|B-DISE trait|I-DISE .|O
Chromosomes|O of|O lymphocytes|O from|O one|O of|O the|O patients|O were|O studied|O before|O and|O after|O the|O onset|O of|O chronic|B-DISE lymphocytic|I-DISE leukemia|I-DISE .|O
Previous|O study|O disclosed|O that|O flow|O cytometric|O analysis|O of|O intracellular|O WASP|O expression|O (|O FCM|O -|O WASP|O analysis|O )|O in|O lymphocytes|O was|O useful|O for|O the|O diagnosis|O of|O WAS|B-DISE patients|O .|O
Assay|O of|O fetal|O -|O skin|O fibroblasts|O with|O 14C|O -|O triolein|O ,|O as|O well|O as|O with|O artificial|O substrates|O ,|O showed|O marked|O deficiency|B-DISE of|I-DISE acid|I-DISE lipase|I-DISE activity|I-DISE .|O
Both|O factors|O depend|O on|O the|O intellectual|O resources|O of|O the|O mother|O with|O PKU|B-DISE .|O
Pendred|B-DISE syndrome|I-DISE comprises|O congenital|O sensorineural|B-DISE hearing|I-DISE loss|I-DISE ,|O thyroid|B-DISE goiter|I-DISE ,|O and|O positive|O perchlorate|O discharge|O test|O .|O
Clinically|O ,|O all|O patients|O with|O VLCAD|B-DISE deficiency|I-DISE exhibited|O cardiac|B-DISE disease|I-DISE .|O
To|O determine|O the|O origins|O of|O these|O two|O mutations|O in|O the|O Cajun|O population|O ,|O the|O TSD|B-DISE carrier|O status|O was|O enzymatically|O determined|O for|O 90|O members|O of|O four|O of|O the|O six|O families|O ,|O and|O extensive|O pedigrees|O were|O constructed|O for|O all|O carriers|O .|O
This|O finding|O ,|O in|O association|O with|O 3|O other|O instances|O of|O single|O breaks|O at|O 11p13|O and|O aniridia|B-DISE ,|O supports|O the|O assignment|O of|O AN2|O to|O 11p13|O .|O .|O
To|O this|O end|O ,|O YACs|O identified|O by|O the|O MCC|O gene|O were|O screened|O across|O a|O chromosome|O 5|O -|O specific|O cosmid|O library|O to|O provide|O a|O source|O of|O DNA|O probes|O for|O genomic|O scanning|O .|O
Genetic|O analysis|O and|O the|O Cre|O -|O loxP|O system|O were|O used|O to|O clearly|O demonstrate|O that|O the|O myoblast|O fusion|O defect|O could|O be|O rescued|O by|O eliminating|O the|O expression|O of|O the|O mutant|O DMPK|O 3|O '|O -|O UTR|O transcript|O .|O
Sequencing|O of|O the|O FAS|O gene|O revealed|O a|O 20|O -|O nucleotide|O duplication|O in|O the|O last|O exon|O affecting|O the|O cytoplasmic|O signaling|O domain|O .|O
Two|O recent|O studies|O have|O suggested|O the|O involvement|O of|O serum|O amyloid|O A|O (|O SAA|O )|O and|O P|O (|O APCS|O )|O genes|O in|O familial|B-DISE Mediterranean|I-DISE fever|I-DISE MEF|B-DISE .|O
When|O used|O in|O conjunction|O with|O an|O existing|O primer|O set|O ,|O these|O two|O multiplex|O reactions|O detect|O about|O 98|O %|O of|O deletions|O in|O patients|O with|O Duchenne|B-DISE or|I-DISE Becker|I-DISE muscular|I-DISE dystrophy|I-DISE DMD|B-DISE ,|O BMD|B-DISE .|O
Progeny|O of|O the|O homozygous|O mutant|O females|O demonstrated|O neurological|B-DISE abnormalities|I-DISE and|O growth|B-DISE retardation|I-DISE characteristic|O of|O copper|B-DISE deficiency|I-DISE .|O
Mutations|O and|O duplications|O of|O this|O gene|O are|O associated|O with|O Pelizaeus|B-DISE -|I-DISE Merzbacher|I-DISE disease|I-DISE PMD|B-DISE .|O
To|O identify|O the|O genetic|O basis|O of|O C9|B-DISE deficiency|I-DISE ,|O we|O developed|O an|O approach|O using|O exon|O -|O specific|O PCR|O and|O direct|O DNA|O sequencing|O .|O
Gene|O loci|O in|O the|O X|O -|O linked|O recessive|O forms|O have|O been|O assigned|O to|O Xq13|O .|O 1|O in|O the|O X|B-DISE -|I-DISE linked|I-DISE dystonia|I-DISE parkinsonism|I-DISE syndrome|O and|O to|O Xq22|O in|O X|O -|O linked|O sensorineural|B-DISE deafness|I-DISE ,|O dystonia|O ,|O and|O mental|B-DISE retardation|I-DISE .|O
The|O insertion|O ,|O into|O the|O NTS|O ,|O of|O 14|O additional|O amino|O acids|O encoded|O by|O exon|O 5a|O abolishes|O the|O DNA|O -|O binding|O activity|O of|O the|O NTS|O and|O unmasks|O the|O DNA|O -|O binding|O ability|O of|O the|O CTS|O .|O
To|O determine|O whether|O PDS|O mutations|O in|O individuals|O with|O Pendred|B-DISE syndrome|I-DISE differ|O functionally|O from|O PDS|O mutations|O in|O individuals|O with|O non|O -|O syndromic|O hearing|B-DISE loss|I-DISE ,|O we|O compared|O three|O common|O Pendred|B-DISE syndrome|I-DISE allele|O variants|O (|O L236P|O ,|O T416P|O and|O E384G|O )|O ,|O with|O three|O PDS|O mutations|O reported|O only|O in|O individuals|O with|O non|O -|O syndromic|O hearing|B-DISE loss|I-DISE V480D|O ,|O V653A|O and|O I490L|O /|O G497S|O .|O
There|O is|O increasing|O evidence|O that|O there|O exist|O germ|O -|O line|O variants|O of|O the|O APC|O gene|O that|O predispose|O to|O the|O development|O of|O multiple|O colorectal|B-DISE adenomas|I-DISE and|I-DISE carcinoma|I-DISE ,|O but|O without|O the|O florid|O phenotype|O of|O classical|B-DISE FAP|I-DISE ,|O and|O possibly|O with|O importance|O for|O colorectal|B-DISE cancer|I-DISE risk|O in|O the|O general|O population|O .|O .|O
To|O investigate|O the|O genetic|O history|O of|O these|O mutations|O in|O the|O AJ|O population|O ,|O short|O tandem|O repeat|O (|O STR|O )|O markers|O were|O used|O to|O map|O a|O 9|O .|O 3|O -|O cM|O region|O containing|O the|O GBA|O locus|O and|O to|O genotype|O 261|O AJ|O N370S|O chromosomes|O ,|O 60|O European|O non|O -|O Jewish|O N370S|O chromosomes|O ,|O and|O 62|O AJ|O 84GG|O chromosomes|O .|O
By|O electrophysiological|O tests|O and|O magnetic|O resonance|O imaging|O it|O was|O determined|O that|O two|O patients|O had|O cerebral|O ALD|B-DISE ,|O one|O had|O adrenomyeloneuropathy|B-DISE with|O cerebral|O involvement|O ,|O and|O two|O had|O preclinical|O AMN|B-DISE .|O
Here|O ,|O we|O report|O the|O identification|O and|O characterization|O of|O the|O chromosome|O 3|O -|O derived|O translocation|O partner|O gene|O ,|O which|O we|O have|O designated|O LPP|O lipoma|B-DISE preferred|O partner|O gene|O .|O
In|O summary|O ,|O our|O results|O show|O frequent|O involvement|O of|O the|O p16|O gene|O in|O familial|B-DISE melanoma|I-DISE and|O confirm|O the|O role|O of|O the|O CDK4|O gene|O as|O a|O melanoma|O -|O predisposing|O gene|O .|O .|O
This|O was|O the|O first|O reported|O subject|O homozygous|O for|O the|O CETP|B-DISE deficiency|I-DISE who|O also|O demonstrated|O atherosclerotic|B-DISE symptoms|O .|O
The|O murine|O gene|O contains|O ten|O exons|O with|O a|O coding|O sequence|O of|O 2304|O bp|O ,|O while|O the|O rat|O homolog|O has|O nine|O exons|O with|O a|O coding|O sequence|O of|O 2253|O bp|O .|O
Three|O children|O are|O reported|O with|O typical|O cat|B-DISE eye|I-DISE syndrome|I-DISE (|O CES|B-DISE )|O and|O three|O more|O children|O with|O partial|O CES|B-DISE because|O of|O absence|O of|O coloboma|B-DISE ,|O in|O which|O the|O supernumerary|O marker|O chromosome|O was|O studied|O by|O FISH|O .|O
Our|O results|O suggest|O that|O SIX5|B-DISE deficiency|I-DISE contributes|O to|O the|O cataract|B-DISE phenotype|O in|O myotonic|B-DISE dystrophy|I-DISE ,|O and|O that|O myotonic|B-DISE dystrophy|I-DISE represents|O a|O multigenic|B-DISE disorder|I-DISE .|O .|O
This|O is|O the|O first|O demonstration|O of|O a|O mutation|O causing|O VLCAD|B-DISE deficiency|I-DISE .|O
This|O supports|O the|O previously|O described|O hypothesis|O that|O the|O large|O Northern|O Finnish|O choroideremia|B-DISE pedigrees|O ,|O comprising|O a|O total|O of|O over|O 80|O living|O patients|O representing|O more|O than|O a|O fifth|O of|O all|O TCD|B-DISE patients|O described|O worldwide|O ,|O carry|O the|O same|O mutation|O .|O
From|O data|O collected|O in|O a|O North|O American|O Tay|B-DISE -|I-DISE Sachs|I-DISE disease|I-DISE (|O TSD|B-DISE )|O heterozygote|O screening|O program|O ,|O the|O TSD|B-DISE carrier|O frequency|O among|O 46|O ,|O 304|O Jewish|O individuals|O was|O found|O to|O be|O .|O 0324|O 1|O in|O 31|O individuals|O .|O
The|O abnormal|O enzymes|O are|O respectively|O designated|O as|O GdDcbrousse|O -|O like|O ,|O ,|O GdGallura|O and|O GdAgrigento|O .|O .|O
Atypical|O or|O variant|O forms|O of|O well|O -|O known|O chondrodysplasias|B-DISE may|O pose|O diagnostic|O problems|O .|O
His|O mother|O was|O 44|O years|O of|O age|O at|O the|O time|O of|O his|O birth|O .|O
To|O advance|O on|O both|O of|O these|O avenues|O ,|O we|O report|O the|O deletion|O of|O HFE|O alpha1|O and|O alpha2|O putative|O ligand|O binding|O domains|O in|O vivo|O .|O
Inherited|O mutations|O in|O the|O BRCA1|O gene|O are|O associated|O with|O a|O high|O risk|O of|O breast|B-DISE and|I-DISE ovarian|I-DISE cancer|I-DISE in|O some|O families|O .|O
In|O this|O paper|O we|O describe|O four|O additional|O PAX6|O point|O mutations|O in|O aniridia|B-DISE patients|O ,|O both|O sporadic|O and|O familial|O .|O
The|O results|O confirm|O that|O the|O C282Y|O substitution|O was|O the|O main|O mutation|O involved|O in|O hemochromatosis|B-DISE ,|O accounting|O for|O 85|O %|O of|O carrier|O chromosomes|O ,|O whereas|O the|O H63D|O substitution|O represented|O 39|O %|O of|O the|O HH|O chromosomes|O that|O did|O not|O carry|O the|O C282Y|O mutation|O .|O
We|O tested|O sulfate|O transport|O in|O thyrocytes|O obtained|O from|O Pendred|B-DISE syndrome|I-DISE patients|O and|O found|O that|O it|O was|O not|O defective|O .|O
Mxi1|O is|O thought|O to|O negatively|O regulate|O Myc|O function|O and|O may|O therefore|O be|O a|O potential|O tumor|B-DISE suppressor|O gene|O .|O
One|O allele|O ,|O reported|O originally|O in|O a|O French|O TSD|B-DISE patient|O (|O Akli|O et|O al|O .|O ,|O 1991|O )|O ,|O is|O a|O GT|O -|O -|O >|O AT|O transition|O at|O the|O donor|O splice|O -|O site|O of|O intron|O 9|O .|O
Given|O the|O complex|O behavioral|O phenotype|O in|O fragile|B-DISE X|I-DISE patients|O and|O the|O mild|O phenotype|O previously|O reported|O for|O the|O Fmr1|O knockout|O mouse|O ,|O we|O performed|O a|O more|O thorough|O evaluation|O of|O the|O Fmr1|O knockout|O phenotype|O using|O additional|O behavioral|O assays|O that|O had|O not|O previously|O been|O reported|O for|O this|O animal|O model|O .|O
Because|O of|O X|O chromosome|O inactivation|O ,|O female|O offspring|O are|O mosaic|O for|O cells|O that|O express|O or|O lack|O GPI|O -|O linked|O proteins|O .|O
The|O paired|O domain|O is|O composed|O of|O two|O distinct|O DNA|O -|O binding|O subdomains|O ,|O the|O N|O -|O terminal|O subdomain|O (|O NTS|O )|O and|O the|O C|O -|O terminal|O subdomain|O (|O CTS|O )|O ,|O which|O bind|O respective|O consensus|O DNA|O sequences|O .|O
There|O is|O mounting|O evidence|O to|O suggest|O that|O Friedreich|B-DISE ataxia|I-DISE is|O the|O result|O of|O accumulation|O of|O iron|O in|O mitochondria|O leading|O to|O excess|O production|O of|O free|O radicals|O ,|O which|O then|O results|O in|O cellular|O damage|O and|O death|O .|O
Moreover|O ,|O a|O high|O level|O of|O instability|O ,|O increasing|O with|O age|O ,|O can|O be|O observed|O in|O tissues|O and|O in|O sperm|O .|O
In|O fact|O ,|O the|O lipoprotein|O profile|O of|O persons|O with|O CETP|B-DISE deficiency|I-DISE is|O potentially|O antiatherogenic|O and|O may|O be|O associated|O with|O an|O increased|O life|O span|O .|O .|O
We|O have|O determined|O the|O parental|O origin|O of|O the|O retained|O allele|O in|O nine|O retinoblastoma|B-DISE tumours|O from|O eight|O unrelated|O non|O -|O familial|O cases|O by|O using|O RB1|O -|O linked|O genetic|O markers|O .|O
First|O -|O degree|O relatives|O with|O a|O PROS1|O gene|O defect|O had|O a|O 5|O .|O 0|O -|O fold|O higher|O risk|O of|O thrombosis|B-DISE (|O 95|O %|O confidence|O interval|O ,|O 1|O .|O 5|O -|O 16|O .|O 8|O )|O than|O those|O with|O a|O normal|O PROS1|O gene|O and|O no|O other|O recognized|O thrombophilic|B-DISE defect|I-DISE .|O
Positional|O cloning|O experiments|O have|O resulted|O recently|O in|O the|O isolation|O of|O a|O candidate|O gene|O for|O Norrie|B-DISE disease|I-DISE (|O pseudoglioma|B-DISE ;|O NDP|O )|O ,|O a|O severe|O X|O -|O linked|O neurodevelopmental|B-DISE disorder|I-DISE .|O
In|O contrast|O ,|O a|O different|O conserved|O haplotype|O at|O these|O markers|O was|O identified|O on|O the|O 84GG|O chromosomes|O ,|O which|O was|O unique|O to|O the|O AJ|O population|O .|O
These|O findings|O suggest|O that|O selection|O against|O the|O WAS|O gene|O occurs|O in|O platelets|O and|O thymus|O -|O derived|O T|O lymphocytes|O and|O that|O the|O defects|O associated|O with|O WAS|O expressed|O in|O these|O cell|O -|O types|O may|O be|O implicated|O in|O the|O genesis|O of|O the|O Wiskott|B-DISE -|I-DISE Aldrich|I-DISE syndrome|I-DISE .|O .|O
By|O expressing|O chimeric|O reporter|O constructs|O containing|O a|O reporter|O gene|O fused|O to|O a|O human|O DMPK|O 3|O '|O -|O UTR|O ,|O we|O identified|O both|O cis|O and|O trans|O effects|O that|O are|O mediated|O by|O the|O DM|B-DISE mutation|O .|O
Alveolar|B-DISE rhabdomyosarcoma|I-DISE is|O an|O aggressive|O pediatric|B-DISE cancer|I-DISE of|O striated|O muscle|O characterized|O in|O 60|O %|O of|O cases|O by|O a|O t|O 2|O ;|O 13|O q35|O ;|O q14|O .|O
Most|O fragile|B-DISE X|I-DISE syndrome|I-DISE patients|O have|O expansion|O of|O a|O CGG|O (|O n|O )|O sequence|O with|O >|O 200|O repeats|O (|O full|O mutation|O )|O in|O the|O FMR1|O gene|O responsible|O for|O this|O condition|O .|O
The|O patient|O inherited|O this|O mutation|O from|O his|O mother|O .|O
Thus|O ,|O potentiation|O of|O netrin|O activity|O by|O inhibitors|O may|O result|O from|O stabilization|O of|O DCC|O on|O the|O axons|O ,|O and|O proteolytic|O activity|O may|O regulate|O axon|O migration|O by|O controlling|O the|O number|O of|O functional|O extracellular|O axon|O guidance|O receptors|O .|O .|O
Mutations|O in|O the|O BRCA1|O (|O ref|O .|O 1|O )|O tumour|O suppressor|O gene|O are|O found|O in|O almost|O all|O of|O the|O families|O with|O inherited|B-DISE breast|I-DISE and|I-DISE ovarian|I-DISE cancers|I-DISE and|O about|O half|O of|O the|O families|O with|O only|O breast|B-DISE cancer|I-DISE .|O
Of|O the|O patients|O with|O PKU|O ,|O 92|O %|O had|O been|O treated|O during|O childhood|O .|O
This|O response|O is|O abrogated|O in|O A|B-DISE -|I-DISE T|I-DISE cells|O that|O either|O do|O not|O express|O ATM|O protein|O or|O express|O near|O full|O -|O length|O mutant|O protein|O .|O
Both|O had|O an|O interstitial|O deletion|O of|O the|O long|O arm|O of|O chromosome|O 5|O del|O 5|O q22q23|O .|O 2|O .|O
Here|O the|O APC|O gene|O product|O is|O shown|O to|O bind|O through|O its|O armadillo|O repeat|O domain|O to|O a|O Rac|O -|O specific|O guanine|O nucleotide|O exchange|O factor|O (|O GEF|O )|O ,|O termed|O Asef|O .|O
We|O have|O mapped|O the|O gene|O encoding|O the|O small|O nuclear|O RNA|O associated|O polypeptide|O SmN|O (|O SNRPN|O )|O to|O human|O chromosome|O 15q12|O and|O a|O processed|O pseudogene|O SNRPNP1|O to|O chromosome|O region|O 6pter|O -|O p21|O .|O
Thus|O ,|O altered|O ion|O homeostasis|O within|O the|O lens|O may|O contribute|O to|O cataract|B-DISE formation|O .|O
We|O generated|O all|O six|O full|O -|O length|O mouse|O cDNAs|O that|O result|O from|O combinations|O of|O these|O three|O major|O splicing|O events|O and|O show|O that|O their|O transfection|O into|O cells|O in|O culture|O leads|O to|O production|O of|O four|O different|O approximately|O 74|O kDa|O full|O -|O length|O (|O heart|O -|O ,|O skeletal|O muscle|O -|O or|O brain|O -|O specific|O )|O and|O two|O C|O -|O terminally|O truncated|O approximately|O 68|O kDa|O (|O smooth|O muscle|O -|O specific|O )|O isoforms|O .|O
These|O data|O uncover|O an|O essential|O role|O of|O BRCA1|O in|O maintaining|O genetic|O stability|O through|O the|O regulation|O of|O centrosome|O duplication|O and|O the|O G2|O -|O M|O checkpoint|O and|O provide|O a|O molecular|O basis|O for|O the|O role|O of|O BRCA1|O in|O tumorigenesis|B-DISE .|O .|O
Cognitive|O performance|O (|O IQ|O )|O was|O also|O significantly|O related|O to|O genotype|O .|O
In|O order|O to|O further|O characterize|O the|O dynamics|O of|O DM|O CTG|O repeat|O somatic|O instability|O ,|O we|O have|O studied|O repeat|O length|O changes|O over|O time|O in|O 111|O myotonic|B-DISE dystrophy|I-DISE patients|O with|O varying|O clinical|O severity|O and|O CTG|O repeat|O size|O over|O time|O intervals|O of|O 1|O -|O 7|O years|O .|O
Aspartylglucosaminuria|B-DISE (|O AGU|B-DISE )|O is|O a|O recessive|O autosomally|O inherited|O lysosomal|B-DISE storage|I-DISE disorder|I-DISE due|O to|O deficiency|B-DISE of|I-DISE the|I-DISE enzyme|I-DISE aspartylglucosaminidase|O AGA|O .|O
Of|O the|O two|O mutations|O that|O are|O novel|O ,|O one|O alters|O the|O same|O residue|O (|O 680|O )|O as|O a|O previously|O known|O mutation|O ,|O and|O the|O other|O (|O P369S|O )|O is|O located|O in|O exon|O 3|O .|O
Additionally|O ,|O one|O of|O the|O asymptomatic|O relatives|O (|O a|O girl|O 8|O months|O old|O at|O the|O time|O of|O study|O )|O was|O identified|O as|O carrier|O of|O the|O same|O mutation|O and|O developed|O the|O disease|O 3|O months|O later|O .|O
Heterozygous|O mutations|O encoding|O abnormal|O forms|O of|O the|O death|O receptor|O Fas|O dominantly|O interfere|O with|O Fas|O -|O induced|O lymphocyte|O apoptosis|O in|O human|O autoimmune|B-DISE lymphoproliferative|I-DISE syndrome|I-DISE .|O
Thus|O ,|O X|B-DISE -|I-DISE linked|I-DISE retinoschisis|I-DISE is|O caused|O by|O abnormalities|O in|O a|O putative|O secreted|O photoreceptor|O protein|O and|O is|O the|O first|O example|O of|O a|O secreted|O photo|O -|O receptor|O protein|O associated|O with|O a|O retinal|B-DISE dystrophy|I-DISE .|O .|O
In|O the|O present|O work|O these|O three|O cases|O ,|O each|O with|O severe|O neonatal|B-DISE jaundice|I-DISE ,|O are|O reported|O .|O
Fmr1|O knockout|O mice|O exhibit|O a|O phenotype|O with|O some|O similarities|O to|O humans|O ,|O such|O as|O macroorchidism|B-DISE and|O behavioral|B-DISE abnormalities|I-DISE .|O
Indeed|O ,|O within|O the|O well|O defined|O ,|O mainly|O peptide|O -|O binding|O ,|O MHC|O class|O I|O family|O of|O molecules|O ,|O HFE|O seems|O to|O perform|O an|O unusual|O yet|O essential|O function|O .|O
We|O postulate|O that|O the|O END|O repeats|O flanking|O 15q11|O -|O q13|O mediate|O homologous|O recombination|O resulting|O in|O deletion|O .|O
The|O RB1|O gene|O from|O 12|O human|O retinoblastoma|B-DISE tumors|O has|O been|O analyzed|O exon|O -|O by|O -|O exon|O with|O the|O single|O -|O strand|O conformation|O polymorphism|O technique|O .|O
The|O breast|B-DISE and|I-DISE ovarian|I-DISE cancer|I-DISE susceptibility|O gene|O BRCA1|O encodes|O a|O zinc|O finger|O protein|O of|O unknown|O function|O .|O
A|O lod|O score|O of|O 13|O was|O calculated|O for|O linkage|O between|O C2|B-DISE deficiency|I-DISE and|O HLA|O -|O B|O at|O a|O maximum|O likelihood|O value|O of|O the|O recombinant|O fraction|O of|O 0|O .|O 04|O .|O 18|O families|O with|O 21|O informative|O matings|O for|O both|O properdin|O Factor|O B|O allotype|O and|O HLA|O -|O B|O were|O found|O .|O
Because|O of|O the|O high|O frequency|O of|O these|O particular|O haplotypes|O in|O Bulgaria|O ,|O Italy|O ,|O and|O Turkey|O ,|O it|O appears|O to|O be|O one|O of|O the|O more|O frequent|O defects|O in|O the|O PAH|O gene|O causing|O classical|O phenylketonuria|B-DISE in|O this|O part|O of|O Europe|O .|O
Metachromatic|B-DISE Leukodystrophy|I-DISE (|O MLD|B-DISE )|O is|O a|O neurodegenerative|B-DISE disease|I-DISE in|O which|O the|O lysosomal|O enzyme|O ,|O Aryl|B-DISE sulfatase|I-DISE A|I-DISE (|I-DISE ARSA|I-DISE )|I-DISE is|I-DISE deficient|I-DISE .|O
Characterization|O of|O spontaneous|O deletion|O events|O mapped|O the|O inhibitory|O effect|O to|O the|O (|O CTG|O )|O (|O n|O )|O expansion|O and|O /|O or|O the|O 3|O '|O end|O of|O the|O DMPK|O 3|O '|O -|O UTR|O .|O
In|O Caucasians|O ,|O repeat|O expansions|O in|O the|O MJD1|O gene|O have|O also|O been|O found|O in|O patients|O with|O the|O clinically|O distinct|O autosomal|O dominant|O spinocerebellar|B-DISE ataxia|I-DISE type|I-DISE 3|I-DISE SCA3|B-DISE .|O
Three|O were|O at|O nucleotide|O position|O 1180|O resulting|O in|O an|O arg|O >|O trp|O amino|O acid|O change|O .|O
Using|O methylation|O -|O sensitive|O restriction|O enzymes|O ,|O we|O characterized|O the|O methylation|O pattern|O on|O the|O 5|O '|O side|O of|O the|O CTG|O repeat|O in|O the|O DMPK|O gene|O of|O normal|O individuals|O and|O of|O patients|O affected|O with|O myotonic|B-DISE dystrophy|I-DISE ,|O showing|O expansions|O of|O the|O repetitive|O sequence|O .|O
Induction|O by|O IFN|O -|O gamma|O occurred|O rapidly|O and|O was|O resistant|O to|O cycloheximide|O .|O
The|O identification|O of|O Dmd|O mRNA|O in|O brain|O raises|O the|O possibility|O of|O a|O relation|O between|O human|O Duchenne|B-DISE muscular|I-DISE dystrophy|I-DISE (|O DMD|O )|O gene|O expression|O and|O the|O mental|B-DISE retardation|I-DISE found|O in|O some|O DMD|B-DISE males|O .|O
METHODS|O :|O Eight|O patients|O with|O adult|O -|O onset|O ALD|B-DISE underwent|O clinical|O examination|O ,|O brain|O and|O spine|O MRI|O ,|O and|O SEP|O and|O MEP|O studies|O before|O and|O after|O 3|O years|O of|O Lorenzo|O '|O s|O oil|O dietary|O therapy|O .|O
These|O results|O explain|O the|O decreased|O ferritin|O levels|O seen|O in|O our|O HeLa|O cell|O system|O and|O demonstrate|O the|O specific|O control|O of|O HFE|O over|O the|O Tf|O -|O mediated|O pathway|O of|O iron|O uptake|O .|O
In|O the|O family|O with|O the|O missense|O mutation|O the|O phenotype|O was|O milder|O .|O
The|O complex|O is|O necessary|O for|O the|O stabilization|O of|O the|O discs|O ,|O which|O are|O renewed|O constantly|O throughout|O life|O ,|O and|O which|O contain|O the|O visual|O pigments|O necessary|O for|O photon|O capture|O .|O
Chromosomal|O translocations|O in|O human|O lipomas|B-DISE frequently|O create|O fusion|O transcripts|O encoding|O high|O mobility|O group|O (|O HMG|O )|O I|O -|O C|O DNA|O -|O binding|O domains|O and|O C|O -|O terminal|O sequences|O from|O different|O presumed|O transcription|O factors|O ,|O suggesting|O a|O potential|O role|O for|O HMG|O I|O -|O C|O in|O the|O development|O of|O lipomas|B-DISE .|O
von|B-DISE Willebrand|I-DISE disease|I-DISE (|O vWD|B-DISE )|O ,|O the|O most|O common|O inherited|O bleeding|O disorder|O in|O humans|O ,|O can|O result|O from|O either|O a|O quantitative|O or|O a|O qualitative|O defect|O in|O the|O adhesive|O glycoprotein|O ,|O von|O Willebrand|O factor|O vWF|O .|O
The|O proteolipid|O protein|O gene|O (|O PLP|O )|O is|O normally|O present|O at|O chromosome|O Xq22|O .|O
In|O 1994|O ,|O we|O obtained|O blood|O samples|O for|O the|O determination|O of|O serum|O transferrin|O saturation|O and|O ferritin|O levels|O and|O the|O presence|O or|O absence|O of|O the|O C282Y|O mutation|O and|O the|O H63D|O mutation|O (|O which|O may|O contribute|O to|O increased|O hepatic|O iron|O levels|O )|O in|O 3011|O unrelated|O white|O adults|O .|O
DXS7|O -|O MAOA|O -|O MAOB|O -|O NDP|O -|O dc12|O -|O YMAO|O .|O AluR|O .|O .|O .|O
Truncating|O germline|O and|O somatic|O mutations|O (|O or|O ,|O infrequently|O ,|O allelic|O loss|O )|O occur|O in|O tumors|B-DISE in|O FAP|B-DISE familial|B-DISE adenomatous|I-DISE polyposis|I-DISE .|O
The|O substitution|O was|O confirmed|O by|O restriction|O endonuclease|O analysis|O and|O was|O present|O in|O heterozygosis|O .|O
Two|O or|O 3|O large|O deletions|O ,|O 2|O single|O codon|O deletions|O ,|O and|O 2|O single|O base|O deletions|O have|O been|O found|O .|O
Mice|O that|O expressed|O expanded|O CUG|O repeats|O developed|O myotonia|B-DISE and|O myopathy|B-DISE ,|O whereas|O mice|O expressing|O a|O nonexpanded|O repeat|O did|O not|O .|O
The|O central|O part|O of|O mouse|O chromosome|O 7|O is|O homologous|O to|O human|O 15q11|O -|O q13|O ,|O with|O conservation|O of|O both|O gene|O order|O and|O imprinted|O features|O .|O
We|O have|O investigated|O 5|O novel|O vWS|B-DISE families|O through|O probands|O attended|O for|O cleft|B-DISE lip|I-DISE and|I-DISE /|I-DISE or|I-DISE palate|I-DISE repair|O at|O the|O Department|O of|O Maxillofacial|O Surgery|O of|O Hopital|O Trousseau|O ,|O Paris|O ,|O in|O order|O to|O tentatively|O refine|O the|O genetic|O map|O of|O the|O vWS|O region|O in|O 1q32|O -|O q41|O and|O possibly|O identify|O unlinked|O pedigrees|O .|O
Family|O studies|O were|O performed|O in|O order|O to|O distinguish|O the|O contributions|O of|O individual|O mutant|O F10|O alleles|O to|O the|O clinical|O and|O laboratory|O phenotypes|O .|O
Finally|O ,|O a|O polymorphism|O G|O -|O -|O >|O A|O 759|O ,|O which|O leaves|O valine|O at|O codon|O 253|O unchanged|O ,|O is|O described|O .|O .|O
METHODOLOGY|O :|O PAH|O gene|O mutations|O were|O examined|O in|O 222|O hyperphenylalaninemic|B-DISE females|O enrolled|O in|O the|O Maternal|O PKU|B-DISE Collaborative|O Study|O MPKUCS|O .|O
One|O of|O five|O PWS|B-DISE /|O AS|B-DISE patients|O analyzed|O to|O date|O has|O an|O identifiable|O ,|O rearranged|O HERC2|O transcript|O derived|O from|O the|O deletion|O event|O .|O
To|O begin|O to|O address|O the|O hypothesis|O that|O abnormal|O regulation|O of|O the|O breast|B-DISE /|I-DISE ovarian|I-DISE cancer|I-DISE susceptibility|O gene|O BRCA1|O is|O a|O critical|O step|O in|O sporadic|B-DISE breast|I-DISE /|I-DISE ovarian|I-DISE tumorigenesis|I-DISE ,|O we|O have|O determined|O the|O detailed|O structure|O of|O the|O BRCA1|O genomic|O region|O .|O
Individuals|O with|O subtotal|O complement|O C6|B-DISE deficiency|I-DISE possess|O a|O C6|O molecule|O that|O is|O 14|O %|O shorter|O than|O normal|O C6|O and|O present|O in|O low|O but|O detectable|O concentrations|O 1|O -|O 2|O %|O of|O the|O normal|O mean|O .|O
The|O pathognomonic|O accumulation|O of|O very|O long|O chain|O fatty|O acids|O could|O also|O be|O prevented|O by|O overexpression|O of|O ALDRP|O in|O immortalized|O X|O -|O ALD|B-DISE cells|O .|O
Again|O ,|O a|O significant|O male|O mutation|O imbalance|O was|O observed|O only|O for|O the|O duplications|O .|O
The|O breakpoints|O in|O the|O present|O case|O and|O in|O 3|O previously|O reported|O 5q|O -|O patients|O with|O adenomatous|B-DISE polyposis|I-DISE coli|I-DISE suggest|O that|O the|O gene|O responsible|O for|O GS|O /|O or|O familial|B-DISE polyposis|I-DISE coli|I-DISE (|O FPC|B-DISE )|O is|O in|O the|O 5q22|O region|O ,|O a|O result|O consistent|O with|O the|O findings|O of|O linkage|O studies|O .|O .|O
The|O level|O of|O histone|O acetylation|O is|O another|O important|O factor|O in|O regulating|O gene|O expression|O ;|O therefore|O ,|O we|O treated|O lymphoblastoid|O cell|O lines|O of|O non|O -|O mosaic|O full|O mutation|O patients|O with|O three|O drugs|O capable|O of|O inducing|O histone|O hyperacetylation|O .|O
The|O entire|O coding|O region|O of|O the|O AVP|O -|O NPII|O gene|O of|O all|O family|O members|O was|O amplified|O by|O PCR|O and|O sequenced|O .|O
All|O but|O one|O of|O the|O mutations|O were|O considered|O to|O cause|O truncation|O of|O the|O gene|O product|O by|O frame|O -|O shift|O due|O to|O deletion|O (|O 14|O cases|O )|O or|O nonsense|O mutation|O seven|O cases|O .|O
All|O had|O abdominal|B-DISE attacks|I-DISE and|O in|O most|O these|O were|O the|O only|O manifestation|O of|O their|O disease|O ,|O P|O <|O 0|O .|O 001|O .|O
When|O the|O mutant|O alpha|O -|O cDNA|O was|O the|O only|O gene|O introduced|O into|O COS|O cells|O no|O enzymatic|O activity|O above|O endogenous|O COS|O cell|O activity|O was|O detected|O .|O
Here|O ,|O we|O show|O that|O retroviral|O transfer|O of|O the|O wild|O -|O type|O BRCA1|O gene|O inhibits|O growth|O in|O vitro|O of|O all|O breast|B-DISE and|I-DISE ovarian|I-DISE cancer|I-DISE cell|O lines|O tested|O ,|O but|O not|O colon|B-DISE or|I-DISE lung|I-DISE cancer|I-DISE cells|O or|O fibroblasts|O .|O
Prader|B-DISE -|I-DISE Willi|I-DISE syndrome|I-DISE (|O PWS|B-DISE )|O and|O Angelman|B-DISE syndrome|I-DISE (|O AS|B-DISE )|O result|O from|O the|O loss|O of|O function|O of|O imprinted|O genes|O in|O human|O chromosome|O 15q11|O -|O q13|O .|O
The|O DPC4|O gene|O ,|O which|O is|O located|O at|O 18q21|O ,|O has|O been|O identified|O as|O a|O tumor|O -|O suppressor|O gene|O from|O examination|O of|O pancreatic|B-DISE cancers|I-DISE .|O
Association|O studies|O in|O two|O independent|O samples|O totaling|O 505|O individuals|O revealed|O that|O the|O 5|O -|O HTT|O polymorphism|O accounts|O for|O 3|O to|O 4|O percent|O of|O total|O variation|O and|O 7|O to|O 9|O percent|O of|O inherited|O variance|O in|O anxiety|B-DISE -|O related|O personality|O traits|O in|O individuals|O as|O well|O as|O sibships|O .|O .|O
We|O observed|O that|O the|O YAC|O transgene|O supported|O production|O of|O the|O human|O protein|O (|O FMRP|O )|O which|O was|O present|O at|O levels|O 10|O to|O 15|O times|O that|O of|O endogenous|O protein|O and|O was|O expressed|O in|O a|O cell|O -|O and|O tissue|O -|O specific|O manner|O .|O
Four|O amino|O acid|O substitutions|O ,|O Leu27Phe|O ,|O Thr48Ile|O ,|O Val75Met|O and|O Arg477Lys|O ,|O were|O found|O in|O patients|O with|O congenital|B-DISE thrombocytopenia|I-DISE and|O no|O clinically|O evident|O immune|O defect|O indicating|O that|O the|O WASP|O gene|O is|O the|O site|O for|O mutations|O in|O X|O -|O linked|O thrombocytopenia|O as|O well|O as|O in|O WAS|O .|O
Lesch|B-DISE -|I-DISE Nyhan|I-DISE syndrome|I-DISE caused|O by|O a|O complete|O deficiency|B-DISE of|I-DISE hypoxanthine|I-DISE guanine|I-DISE phosphoribosyltransferase|I-DISE (|O HPRT|O )|O is|O the|O result|O of|O a|O heterogeneous|O group|O of|O germ|O line|O mutations|O .|O
This|O clone|O appears|O to|O have|O given|O rise|O to|O the|O leukemic|O cells|O .|O
The|O results|O show|O that|O 50|O %|O (|O 47|O of|O 94|O )|O were|O G|O to|O T|O mutation|O at|O nucleotide|O (|O nt|O )|O 1376|O ,|O 21|O .|O 3|O %|O (|O 20|O of|O 94|O )|O were|O G|O to|O A|O mutation|O at|O nt|O 1388|O ,|O 7|O .|O 4|O %|O (|O 7|O of|O 94|O )|O were|O A|O to|O G|O mutation|O at|O nt|O 493|O ,|O 7|O .|O 4|O %|O (|O 7|O of|O 94|O )|O were|O A|O to|O G|O mutation|O at|O nt|O 95|O ,|O 4|O .|O 2|O %|O (|O 4|O of|O 94|O )|O were|O C|O to|O T|O mutation|O at|O nt|O 1024|O ,|O 1|O .|O 1|O %|O (|O 1|O of|O 94|O )|O was|O G|O to|O T|O mutation|O at|O nt|O 392|O ,|O and|O 1|O .|O 1|O %|O (|O 1|O of|O 94|O )|O was|O G|O to|O A|O mutation|O at|O nt|O 487|O .|O
Here|O ,|O we|O report|O that|O the|O death|O effector|O Bax|O is|O required|O for|O a|O large|O proportion|O of|O Atm|O -|O dependent|O apoptosis|O in|O the|O developing|O CNS|O after|O ionizing|O radiation|O IR|O .|O
One|O patient|O had|O a|O missense|O mutation|O in|O exon|O 8|O ,|O converting|O an|O arg|O >|O his|O .|O
By|O RT|O -|O PCR|O ,|O we|O found|O CTSC|O is|O also|O expressed|O in|O epithelial|O regions|O commonly|O affected|O by|O PLS|B-DISE ,|O including|O the|O palms|O ,|O soles|O ,|O knees|O ,|O and|O oral|O keratinised|O gingiva|O .|O
A|O detailed|O 10|O -|O point|O map|O of|O the|O 4p16|O region|O constructed|O from|O the|O CEPH|O panel|O provides|O evidence|O for|O heterogeneity|O in|O the|O linkage|O maps|O constructed|O from|O families|O segregating|O for|O Huntington|B-DISE disease|I-DISE HD|B-DISE .|O
To|O assess|O this|O hypothesis|O ,|O we|O employed|O an|O animal|O model|O of|O A|B-DISE -|I-DISE T|I-DISE ,|O the|O mouse|O with|O a|O disrupted|O Atm|O gene|O .|O
More|O than|O 75|O %|O of|O the|O reported|O mutations|O in|O the|O hereditary|B-DISE breast|I-DISE and|I-DISE ovarian|I-DISE cancer|I-DISE gene|O ,|O BRCA1|O ,|O result|O in|O truncated|O proteins|O .|O
The|O high|O prevalence|O of|O the|O disorder|O in|O the|O population|O and|O the|O fact|O that|O most|O cases|O occur|O sporadically|O suggest|O that|O sequences|O at|O or|O near|O the|O breakpoints|O confer|O susceptibility|O to|O chromosome|O rearrangements|O .|O
Despite|O the|O abnormalities|B-DISE in|I-DISE ocular|I-DISE drainage|I-DISE structures|I-DISE in|O Foxc1|O (|O +|O /|O -|O )|O mice|O ,|O IOP|O was|O normal|O in|O almost|O all|O mice|O analyzed|O ,|O on|O all|O genetic|O backgrounds|O and|O at|O all|O ages|O .|O
All|O three|O affected|O children|O were|O homozygous|O and|O the|O parents|O heterozygous|O for|O a|O single|O novel|O mutation|O (|O C301|O -|O >|O T|O )|O in|O exon|O 1|O ,|O replacing|O Pro7|O of|O mature|O AVP|O with|O Leu|O Leu|O -|O AVP|O .|O
Our|O previous|O linkage|O studies|O mapped|O the|O gene|O responsible|O for|O FEO|B-DISE to|O an|O interval|O of|O less|O than|O 5|O cM|O between|O D18S64|O and|O D18S51|O on|O chromosome|O 18q21|O .|O 2|O -|O 21|O .|O 3|O in|O a|O large|O Northern|O Irish|O family|O .|O
These|O results|O suggest|O that|O mutation|O of|O BRCA1|O may|O not|O be|O critical|O in|O the|O development|O of|O the|O majority|O of|O breast|B-DISE and|I-DISE ovarian|I-DISE cancers|I-DISE that|O arise|O in|O the|O absence|O of|O a|O mutant|O germline|O allele|O .|O .|O
Initial|O evaluation|O of|O the|O ATM|O knockout|O animals|O indicates|O that|O inactivation|O of|O the|O mouse|O ATM|O gene|O recreates|O much|O of|O the|O phenotype|O of|O ataxia|B-DISE -|I-DISE telangiectasia|I-DISE .|O
Several|O cases|O of|O exon|O skipping|O in|O both|O normal|O controls|O and|O patients|O for|O whom|O no|O underlying|O defect|O could|O be|O found|O in|O genomic|O DNA|O were|O also|O observed|O ,|O suggesting|O caution|O in|O the|O interpretation|O of|O exon|O deletions|O observed|O in|O ATM|O cDNA|O when|O there|O is|O no|O accompanying|O identification|O of|O genomic|O mutations|O .|O .|O
Physical|O examination|O ,|O creatine|O phosphokinase|O levels|O ,|O and|O muscle|O biopsy|O were|O consistent|O with|O Duchenne|B-DISE muscular|I-DISE dystrophy|I-DISE DMD|B-DISE .|O
The|O first|O mutation|O deletes|O a|O large|O portion|O of|O the|O coding|O sequence|O ,|O generating|O a|O null|O allele|O .|O
These|O results|O suggest|O that|O retinoschisin|O is|O released|O by|O photo|O -|O receptors|O and|O has|O functions|O within|O the|O inner|O retinal|O layers|O .|O
Subsequent|O molecular|O biology|O ,|O biosynthetic|O ,|O and|O immunofluorescence|O studies|O demonstrated|O that|O C2|O secretion|O is|O impaired|O in|O Type|O II|O C2|B-DISE deficiency|I-DISE because|O of|O different|O missense|O mutations|O at|O highly|O conserved|O residues|O in|O each|O of|O the|O C2Q0|O alleles|O .|O
Because|O clear|B-DISE cell|I-DISE papillary|I-DISE cystadenoma|I-DISE is|O similar|O to|O renal|B-DISE cell|I-DISE carcinoma|I-DISE histologically|O ,|O and|O because|O both|O occur|O as|O components|O of|O the|O von|B-DISE Hippel|I-DISE -|I-DISE Lindau|I-DISE disease|I-DISE complex|O ,|O the|O authors|O analyzed|O both|O cases|O for|O the|O presence|O of|O mutations|O in|O the|O VHL|O gene|O .|O
An|O SGLT1|O missense|O mutation|O underlies|O hereditary|B-DISE glucose|I-DISE /|I-DISE galactose|I-DISE malabsorption|I-DISE ,|O characterized|O by|O potentially|O fatal|O diarrhea|B-DISE ;|O conversely|O ,|O oral|O rehydration|O therapy|O exploits|O normal|O transport|O to|O alleviate|O life|O -|O threatening|O diarrhea|B-DISE of|I-DISE infectious|I-DISE origin|I-DISE .|O
Mutations|O of|O the|O human|O PAX6|O gene|O underlie|O aniridia|B-DISE (|O congenital|B-DISE absence|I-DISE of|I-DISE the|I-DISE iris|I-DISE )|O ,|O a|O rare|O dominant|O malformation|B-DISE of|I-DISE the|I-DISE eye|I-DISE .|O
Although|O we|O could|O not|O directly|O correlate|O the|O presence|O of|O cardiac|B-DISE abnormalities|I-DISE with|O specific|O genetic|O lesions|O ,|O the|O mutations|O identified|O in|O patients|O with|O cardiomyopathy|B-DISE fell|O in|O the|O GLB1|O cDNA|O region|O common|O to|O the|O lysosomal|O enzyme|O and|O the|O Hbeta|O -|O Gal|O -|O related|O protein|O ,|O also|O known|O as|O the|O elastin|O binding|O protein|O EBP|O .|O
Further|O unraveling|O of|O genotype|O -|O phenotype|O correlations|O in|O VHL|B-DISE disease|I-DISE has|O revealed|O that|O families|O with|O a|O full|O or|O partial|O deletion|O of|O the|O VHL|O gene|O exhibit|O a|O phenotype|O with|O a|O preponderance|O of|O central|B-DISE nervous|I-DISE system|I-DISE hemangioblastoma|I-DISE .|O .|O
The|O consequence|O of|O this|O mutation|O is|O an|O amino|O acid|O substitution|O at|O a|O highly|O conserved|O position|O within|O the|O CACNA1A|O gene|O .|O
In|O approximately|O 5|O -|O 12|O %|O of|O these|O cases|O ,|O there|O are|O no|O demonstrable|O cardiac|O or|O non|O -|O cardiac|O causes|O to|O account|O for|O the|O episode|O ,|O which|O is|O therefore|O classified|O as|O idiopathic|B-DISE ventricular|I-DISE fibrillation|I-DISE IVF|B-DISE .|O
All|O published|O mutations|O affect|O the|O signal|O peptide|O or|O the|O neurophysin|O -|O II|O carrier|O protein|O and|O are|O presumed|O to|O interfere|O with|O processing|O of|O the|O preprohormone|O ,|O leading|O to|O neuronal|B-DISE damage|I-DISE .|O
We|O evaluated|O all|O subjects|O who|O had|O persistently|O elevated|O transferrin|O -|O saturation|O values|O (|O 45|O percent|O or|O higher|O )|O or|O were|O homozygous|O for|O the|O C282Y|O mutation|O .|O
Individuals|O with|O normal|O ERGs|O have|O mutations|O predominantly|O located|O 5|O '|O of|O the|O transcript|O initiation|O site|O of|O Dp260|O .|O
FISH|O with|O cosmid|O probes|O has|O proved|O to|O be|O a|O fast|O and|O reliable|O technique|O for|O the|O molecular|O analysis|O of|O deletions|O .|O
A|O second|O variant|O in|O intron|O 5|O was|O identified|O IVS5|O +|O 30G|O >|O A|O .|O
This|O report|O documents|O a|O novel|O splice|O -|O site|O mutation|O in|O COL17A1|O in|O a|O patient|O with|O generalized|B-DISE atrophic|I-DISE benign|I-DISE epidermolysis|I-DISE bullosa|I-DISE ,|O and|O applies|O a|O new|O methodology|O to|O define|O and|O characterize|O the|O resulting|O mRNA|O splice|O variants|O .|O
METHODS|O :|O The|O 29|O patients|O comprised|O 13|O patients|O with|O childhood|O cerebral|O ALD|B-DISE ,|O 11|O patients|O with|O adult|O -|O onset|O cerebral|O ALD|B-DISE ,|O and|O 5|O patients|O with|O adrenomyeloneuropathy|B-DISE .|O
Aarskog|B-DISE -|I-DISE Scott|I-DISE Syndrome|I-DISE (|O AAS|B-DISE )|O is|O an|O X|B-DISE -|I-DISE linked|I-DISE disorder|I-DISE characterised|O by|O short|O stature|O and|O multiple|B-DISE facial|I-DISE ,|I-DISE limb|I-DISE and|I-DISE genital|I-DISE abnormalities|I-DISE .|O
Nephropathy|B-DISE was|O detected|O in|O five|O of|O 32|O patients|O with|O the|O Wiskott|B-DISE -|I-DISE Aldrich|I-DISE syndrome|I-DISE who|O were|O participating|O in|O a|O study|O of|O transfer|O factor|O (|O TF|O )|O therapy|O .|O
In|O 16|O families|O with|O myotonic|B-DISE dystrophy|I-DISE (|O DM|B-DISE )|O a|O novel|O approach|O based|O on|O use|O of|O allele|O -|O specific|O oligonucleotides|O has|O been|O employed|O to|O study|O the|O linkage|O relationship|O between|O the|O apolipoprotein|O E|O (|O APOE|O )|O gene|O and|O DM|B-DISE .|O
Furthermore|O ,|O all|O but|O one|O of|O these|O mutations|O is|O located|O between|O exons|O 12|O and|O 24|O in|O the|O COL2A1|O gene|O .|O
Although|O the|O biochemical|O function|O of|O BRCA1|O is|O not|O well|O understood|O ,|O it|O is|O important|O for|O DNA|O damage|O repair|O and|O cell|O -|O cycle|O checkpoint|O .|O
BACKGROUND|O :|O X|B-DISE -|I-DISE linked|I-DISE retinoschisis|I-DISE (|O XLRS|B-DISE )|O is|O a|O relatively|O rare|O vitreoretinal|B-DISE dystrophy|I-DISE that|O causes|O visual|B-DISE loss|I-DISE in|O young|O men|O .|O
Heterozygotes|O had|O subnormal|O levels|O of|O serum|O albumin|O .|O
This|O report|O describes|O a|O child|O with|O clinical|O features|O of|O ALPS|B-DISE without|O detectable|O Fas|O expression|O on|O freshly|O isolated|O blood|O leukocytes|O .|O
We|O have|O detected|O chromosomally|O anomalous|O clones|O of|O lymphocytes|O in|O eight|O patients|O with|O this|O disorder|O .|O
They|O share|O ,|O however|O ,|O the|O SD2|O antigen|O W18|O and|O the|O LD|O type|O 7a|O .|O .|O
These|O results|O support|O the|O Pax|O -|O 6|O homologue|O as|O a|O strong|O candidate|O for|O the|O AN2|O gene|O .|O
This|O study|O provides|O the|O means|O for|O further|O investigation|O of|O additional|O genes|O that|O cause|O or|O modify|O the|O phenotypes|O associated|O with|O rearrangements|O of|O 15q11|O -|O q13|O .|O .|O
Further|O parametric|O analysis|O revealed|O a|O significant|O effect|O of|O the|O presence|O of|O male|O -|O to|O -|O male|O disease|O transmission|O within|O the|O families|O .|O
One|O was|O a|O duplication|O of|O 18|O bases|O and|O the|O other|O a|O duplication|O of|O 27|O bases|O ,|O both|O of|O which|O affected|O the|O signal|O peptide|O region|O of|O the|O RANK|O molecule|O .|O
The|O small|O nuclear|O ribonucleoprotein|O polypeptide|O N|O (|O SNRPN|O )|O gene|O is|O regarded|O as|O one|O of|O the|O candidates|O for|O Prader|B-DISE -|I-DISE Willi|I-DISE syndrome|I-DISE PWS|B-DISE .|O
On|O the|O basis|O of|O the|O linkage|O disequilibrium|O (|O LD|O )|O delta|O values|O ,|O the|O non|O -|O Jewish|O European|O N370S|O chromosomes|O had|O greater|O haplotype|O diversity|O and|O less|O LD|O at|O the|O markers|O flanking|O the|O conserved|O haplotype|O than|O did|O the|O AJ|O N370S|O chromosomes|O .|O
He|O was|O treated|O for|O club|B-DISE foot|I-DISE and|O hip|B-DISE dysplasia|I-DISE at|O birth|O .|O
Haplotype|O data|O implied|O that|O these|O deletions|O occurred|O on|O distinct|O ancestral|O chromosomes|O ,|O suggesting|O that|O this|O region|O may|O be|O susceptible|O to|O deletion|O by|O a|O common|O mechanism|O .|O
All|O families|O showed|O positive|O LOD|O scores|O without|O any|O recombination|O in|O the|O candidate|O region|O .|O
Meiotic|O drive|O at|O the|O myotonic|B-DISE dystrophy|I-DISE (|O DM|O )|O locus|O has|O recently|O been|O suggested|O as|O being|O responsible|O for|O maintaining|O the|O frequency|O ,|O in|O the|O human|O population|O ,|O of|O DM|O chromosomes|O capable|O of|O expansion|O to|O the|O disease|O state|O .|O
A|O genetic|O recombinant|O in|O a|O breast|B-DISE -|I-DISE ovarian|I-DISE cancer|I-DISE family|O indicates|O a|O placement|O of|O BRCA1|O telomeric|O to|O D17S776|O ,|O and|O helps|O to|O define|O the|O region|O of|O assignment|O of|O the|O cancer|O susceptibility|O gene|O .|O
In|O addition|O to|O the|O epidemiologic|O data|O ,|O molecular|O genetic|O studies|O suggest|O that|O inactivation|O of|O the|O APC|O tumor|B-DISE suppressor|O may|O be|O involved|O in|O hepatoblastoma|B-DISE tumorigenesis|B-DISE .|O
Immunohistochemical|O staining|O for|O AGA|O was|O performed|O on|O 15|O oral|O specimens|O .|O
Recently|O ,|O we|O and|O others|O have|O isolated|O a|O candidate|O gene|O for|O X|O linked|O Norrie|B-DISE disease|I-DISE (|O ND|B-DISE )|O which|O was|O found|O to|O be|O deleted|O or|O disrupted|O in|O several|O patients|O .|O
This|O results|O in|O infertility|O and|O congenital|B-DISE myotonic|I-DISE dystrophy|I-DISE (|O CDM|B-DISE )|O with|O the|O disappearance|O of|O DM|O in|O that|O pedigree|O .|O
If|O this|O hypothesis|O is|O confirmed|O in|O other|O VWS|B-DISE pedigrees|O ,|O it|O will|O represent|O one|O of|O the|O first|O examples|O of|O a|O gene|O ,|O mapped|O through|O linkage|O analysis|O ,|O which|O modifies|O the|O expression|O of|O a|O major|O gene|O .|O
In|O contrast|O to|O (|O CUG|O )|O n|O containing|O mRNAs|O ,|O the|O novel|O isoform|O is|O not|O retained|O in|O the|O nucleus|O in|O DM|B-DISE cells|O ,|O resulting|O in|O imbalances|O in|O relative|O levels|O of|O cytoplasmic|O DMPK|O mRNA|O isoforms|O and|O a|O new|O dominant|O effect|O of|O the|O mutation|O on|O DMPK|O .|O .|O
The|O present|O study|O confirms|O the|O involvement|O of|O BRCA1|O in|O disease|O predisposition|O for|O a|O subset|O of|O hereditary|B-DISE breast|I-DISE cancer|I-DISE families|O often|O characterized|O by|O ovarian|B-DISE cancers|I-DISE .|O .|O
The|O mutation|O underlying|O myotonic|B-DISE dystrophy|I-DISE (|O DM|B-DISE )|O has|O been|O identified|O as|O an|O expansion|O of|O a|O polymorphic|O CTG|O -|O repeat|O in|O a|O gene|O encoding|O protein|O kinase|O activity|O .|O
Our|O data|O provide|O a|O biochemical|O explanation|O for|O the|O similarity|O in|O phenotype|O between|O A|B-DISE -|I-DISE T|I-DISE and|O NBS|B-DISE .|O .|O
Mucopolysaccharidosis|B-DISE IVA|O (|O MPS|B-DISE IVA|O )|O is|O an|O autosomal|O recessive|O disorder|O caused|O by|O a|O deficiency|B-DISE in|I-DISE N|I-DISE -|I-DISE acetylgalactosamine|I-DISE -|I-DISE 6|I-DISE -|I-DISE sulfatase|I-DISE GALNS|I-DISE .|O
Recently|O the|O FMF|B-DISE gene|O (|O MEFV|O )|O was|O cloned|O ;|O the|O protein|O product|O ,|O pyrin|O /|O marenostrin|O ,|O is|O thought|O to|O regulate|O inflammation|B-DISE in|O myeloid|O cells|O .|O
Since|O a|O mutation|O at|O cDNA|O nucleotide|O 2302|O (|O 2302insC|O )|O had|O been|O previously|O described|O ,|O this|O region|O of|O the|O ATP7B|O gene|O may|O be|O susceptible|O to|O gene|O rearrangements|O causing|O Wilson|B-DISE disease|I-DISE .|O .|O
BACKGROUND|O :|O Women|O with|O mutations|O in|O either|O the|O BRCA1|O or|O the|O BRCA2|O gene|O have|O a|O high|O lifetime|O risk|O of|O ovarian|B-DISE cancer|I-DISE .|O
As|O ocular|O cataracts|B-DISE are|O a|O characteristic|O feature|O of|O DM|B-DISE ,|O these|O results|O demonstrate|O that|O decreased|O SIX5|O transcription|O is|O important|O in|O the|O aetiology|O of|O DM|B-DISE .|O
Parents|O and|O sibs|O heterozygous|O for|O cathepsin|O C|O mutations|O do|O not|O show|O either|O the|O palmoplantar|B-DISE hyperkeratosis|I-DISE or|O severe|O early|O onset|O periodontitis|B-DISE characteristic|O of|O PLS|B-DISE .|O
The|O youngest|O child|O (|O 2|O years|O old|O )|O was|O only|O mildly|O affected|O but|O had|O Leu|O -|O AVP|O levels|O similar|O to|O her|O severely|O affected|O 8|O -|O year|O -|O old|O brother|O ,|O suggesting|O that|O unknown|O mechanisms|O may|O partially|O compensate|O for|O a|O deficiency|B-DISE of|I-DISE active|I-DISE AVP|I-DISE in|O very|O young|O children|O .|O .|O
A|O combination|O of|O DNA|O -|O binding|O assays|O and|O transcriptional|O analysis|O was|O used|O to|O determine|O the|O functional|O consequences|O of|O these|O mutations|O .|O
The|O prevalence|O of|O carriers|O of|O the|O Arg95Stop|O mutation|O was|O 6|O .|O 7|O %|O 20|O /|O 300|O .|O
Gc|O -|O types|O in|O the|O family|O were|O compatible|O with|O ,|O but|O did|O not|O prove|O ,|O linkage|O of|O analbuminemia|B-DISE to|O the|O Gc|O -|O locus|O .|O
MAGEL2|O is|O imprinted|O with|O monoallelic|O expression|O in|O control|O brain|O ,|O and|O paternal|O -|O only|O expression|O in|O the|O central|O nervous|O system|O as|O demonstrated|O by|O its|O lack|O of|O expression|O in|O brain|O from|O a|O PWS|B-DISE -|O affected|O individual|O .|O
WASP|O contains|O several|O functional|O domains|O through|O which|O it|O interacts|O with|O proteins|O involved|O in|O intracellular|O signaling|O and|O regulation|O of|O the|O actin|O cytoskeleton|O .|O
Huntington|B-DISE disease|I-DISE (|O HD|B-DISE )|O is|O a|O severe|O autosomal|B-DISE dominant|I-DISE neurodegenerative|I-DISE disorder|I-DISE associated|O with|O a|O novel|O gene|O IT15|O .|O
However|O ,|O unlike|O patients|O in|O previous|O reports|O ,|O one|O of|O our|O three|O patients|O inherited|O the|O affected|O allele|O from|O his|O phenotypically|O unaffected|O father|O .|O
Germline|O mutations|O in|O the|O ATM|O gene|O are|O responsible|O for|O the|O autosomal|O recessive|O disorder|O ataxia|B-DISE -|I-DISE telangiectasia|I-DISE A|B-DISE -|I-DISE T|I-DISE .|O
This|O is|O the|O first|O report|O of|O Kaposi|B-DISE sarcoma|I-DISE arising|O in|O a|O patient|O with|O a|O congenital|O immunodeficiency|B-DISE syndrome|I-DISE .|O
N|O -|O terminal|O fragments|O of|O mutant|O huntingtin|O form|O aggregates|O and|O induce|O neuritic|O degeneration|O in|O cultured|O striatal|O neurons|O .|O
We|O studied|O 17|O missense|O mutations|O using|O biochemical|O approaches|O and|O 32|O missense|O mutations|O ,|O using|O structural|O analyses|O .|O
A|O total|O of|O 11|O additional|O families|O carrying|O this|O mutation|O were|O identified|O in|O Australia|O (|O 1|O )|O ,|O Belgium|O (|O 1|O )|O ,|O Canada|O (|O 1|O )|O ,|O Great|O Britain|O (|O 6|O )|O ,|O and|O the|O United|O States|O 2|O .|O
Although|O pregnancy|O /|O puerperium|O and|O immobility|B-DISE /|O trauma|B-DISE were|O important|O precipitating|O factors|O for|O thrombosis|B-DISE ,|O almost|O half|O of|O the|O events|O were|O spontaneous|O .|O
Therefore|O at|O present|O there|O is|O no|O evidence|O that|O G6PD|B-DISE deficiency|I-DISE has|O a|O protective|O effect|O against|O development|O of|O hematologic|B-DISE neoplasms|I-DISE .|O .|O
To|O explore|O the|O pathogenesis|O of|O recurrent|O neisserial|B-DISE infections|I-DISE in|O C6|B-DISE deficiency|I-DISE ,|O a|O detailed|O analysis|O of|O her|O immune|O competence|O was|O conducted|O .|O
No|O difference|O ,|O in|O penetrance|O and|O expression|O ,|O between|O the|O two|O mutations|O were|O found|O ,|O whereas|O differences|O according|O to|O method|O of|O ascertainment|O were|O seen|O .|O
We|O have|O examined|O the|O OCRL1|O gene|O in|O eight|O unrelated|O patients|O with|O OCRL|B-DISE and|O have|O found|O seven|O new|O mutations|O and|O one|O recurrent|O in|O -|O frame|O deletion|O .|O
Type|B-DISE 1|I-DISE disease|I-DISE is|O panethnic|O but|O is|O more|O prevalent|O in|O individuals|O of|O Ashkenazi|O Jewish|O (|O AJ|O )|O descent|O .|O
A|O highly|O informative|O microsatellite|O marker|O ,|O DXS426|O ,|O which|O maps|O proximal|O to|O DXS7|O in|O the|O interval|O Xp11|O .|O 4|O -|O Xp11|O .|O 23|O ,|O has|O been|O used|O to|O refine|O further|O the|O localisation|O of|O the|O gene|O for|O Norrie|B-DISE disease|I-DISE NDP|O .|O
We|O report|O here|O the|O result|O of|O a|O screening|O for|O germ|O -|O line|O mutations|O in|O the|O adenomatous|B-DISE polyposis|I-DISE coli|I-DISE (|O APC|O )|O gene|O in|O 61|O new|O familial|B-DISE adenomatous|I-DISE polyposis|I-DISE (|O FAP|B-DISE )|O patients|O as|O well|O as|O a|O summary|O of|O the|O results|O of|O 150|O patients|O .|O
PDS|O codes|O for|O a|O novel|O protein|O ,|O pendrin|O ,|O which|O is|O closely|O related|O to|O a|O number|O of|O sufate|O transporters|O .|O
In|O contrast|O ,|O the|O excision|O of|O exons|O 13|O /|O 14|O that|O causes|O a|O frameshift|O and|O creates|O a|O C|O -|O terminally|O truncated|O protein|O is|O clearly|O cell|O type|O dependent|O and|O occurs|O predominantly|O in|O smooth|O muscle|O .|O
Here|O we|O report|O that|O ,|O in|O mutant|O mice|O expressing|O HD|O repeats|O ,|O the|O production|O and|O aggregation|O of|O N|O -|O terminal|O huntingtin|O fragments|O preferentially|O occur|O in|O HD|B-DISE -|O affected|O neurons|O and|O their|O processes|O and|O axonal|O terminals|O .|O
All|O patients|O had|O the|O severe|O childhood|O form|O of|O VLCAD|B-DISE deficiency|I-DISE with|O early|O onset|O and|O high|O mortality|O .|O
These|O data|O provide|O further|O evidence|O for|O the|O marked|O genetic|O heterogeneity|O of|O G6PD|B-DISE deficiency|I-DISE within|O a|O relatively|O narrow|O geographic|O area|O and|O they|O prove|O the|O presence|O in|O the|O Italian|O peninsula|O of|O a|O gene|O (|O GdA|O -|O )|O regarded|O as|O characteristically|O African|O .|O .|O
For|O stage|O III|O cancers|B-DISE ,|O BRCA|O mutation|O status|O was|O an|O independent|O prognostic|O variable|O P|O =|O .|O 03|O .|O
We|O have|O overcome|O this|O problem|O by|O studying|O a|O cohort|O of|O patients|O from|O a|O single|O center|O where|O the|O diagnosis|O was|O confirmed|O at|O the|O genetic|O level|O .|O
On|O the|O basis|O of|O this|O information|O ,|O we|O compared|O the|O location|O of|O germ|O -|O line|O mutations|O in|O the|O APC|O gene|O in|O 22|O unrelated|O patients|O (|O 12|O of|O whom|O have|O been|O reported|O previously|O )|O with|O the|O number|O of|O colorectal|B-DISE polyps|I-DISE developed|O in|O FAP|B-DISE patients|O ;|O 17|O were|O sparse|O types|O and|O five|O were|O profuse|O types|O .|O
In|O two|O patients|O with|O the|O autosomal|B-DISE recessive|I-DISE disease|I-DISE glucose|I-DISE /|I-DISE galactose|I-DISE malabsorption|I-DISE ,|O the|O underlying|O cause|O was|O found|O to|O be|O a|O missense|O mutation|O in|O SGLT1|O ,|O and|O the|O Asp28|O -|O -|O Asn|O change|O was|O demonstrated|O in|O vitro|O to|O eliminate|O SGLT1|O transport|O activity|O .|O
The|O interfamilial|O heterogeneity|O in|O distribution|O and|O in|O severity|O of|O the|O features|O in|O the|O two|O families|O point|O to|O environmental|O or|O genetic|O modification|O as|O the|O cause|O of|O clinical|O variability|O in|O Emery|B-DISE -|I-DISE Dreifuss|I-DISE muscular|I-DISE dystrophy|I-DISE .|O .|O
A|O total|O of|O 31|O homozygous|O deletions|O and|O 36|O point|O alterations|O were|O identified|O .|O
We|O ascertained|O a|O novel|O missense|O mutation|O in|O four|O pedigrees|O with|O Peters|B-DISE anomaly|I-DISE ,|O congenital|B-DISE cataract|I-DISE ,|O Axenfeldt|B-DISE anomaly|I-DISE ,|O and|O /|O or|O foveal|B-DISE hypoplasia|I-DISE ,|O which|O ,|O to|O our|O knowledge|O ,|O is|O the|O first|O mutation|O identified|O in|O the|O splice|O -|O variant|O region|O .|O
The|O mutation|O underlying|O Huntington|B-DISE disease|I-DISE (|O HD|B-DISE )|O is|O CAG|O expansion|O in|O the|O first|O exon|O of|O the|O HD|O gene|O .|O
These|O results|O are|O significant|O not|O only|O in|O terms|O of|O their|O implications|O for|O furthering|O our|O understanding|O of|O galactosemia|B-DISE and|O GALT|O holoenzyme|O structure|O -|O function|O relationships|O but|O also|O because|O the|O system|O described|O may|O serve|O as|O a|O model|O for|O similar|O studies|O of|O other|O complexes|O composed|O of|O multiple|O subunits|O .|O .|O
Both|O methods|O are|O performed|O on|O DNA|O isolated|O from|O peripheral|O blood|O cells|O and|O measure|O the|O repeat|O size|O in|O FMR1|O .|O
Thus|O additional|O molecules|O and|O /|O or|O regulatory|O events|O are|O necessary|O to|O explain|O the|O exclusive|O degeneration|B-DISE of|I-DISE certain|I-DISE brain|I-DISE areas|I-DISE .|O .|O
We|O conclude|O that|O ATM|O heterozygotes|O have|O an|O approximately|O ninefold|O -|O increased|O risk|O of|O developing|O a|O type|O of|O breast|B-DISE cancer|I-DISE characterized|O by|O frequent|O bilateral|O occurrence|O ,|O early|O age|O at|O onset|O ,|O and|O long|O -|O term|O survival|O .|O
Together|O ,|O these|O results|O demonstrate|O a|O biochemical|O link|O between|O cell|O -|O cycle|O checkpoints|O activated|O by|O DNA|O damage|O and|O DNA|O repair|O in|O two|O genetic|O diseases|O with|O overlapping|O phenotypes|O .|O .|O
Two|O novel|O nonsense|O mutations|O led|O to|O the|O loss|O of|O mutant|O BRCA1|O transcript|O in|O families|O with|O 10|O and|O 6|O cases|O of|O early|B-DISE -|I-DISE onset|I-DISE breast|I-DISE cancer|I-DISE and|I-DISE ovarian|I-DISE cancer|I-DISE .|O
In|O case|O 3|O ,|O loss|O of|O heterozygosity|O was|O also|O demonstrated|O by|O informative|O TTC|O 3|O /|O (|O TTC|O )|O 2|O polymorphism|O .|O
Its|O clinical|O features|O are|O variably|O expressed|O ,|O but|O include|O cleft|B-DISE lip|I-DISE and|I-DISE /|I-DISE or|I-DISE cleft|I-DISE palate|I-DISE ,|O lip|B-DISE pits|I-DISE and|O hypodontia|B-DISE .|O
The|O IQ|O of|O PAH|O -|O deficient|O mothers|O with|O a|O severe|O PKU|B-DISE mutation|O in|O combination|O with|O a|O MHP|B-DISE mutation|O or|O a|O mild|O PKU|B-DISE mutation|O was|O 99|O and|O 96|O ,|O respectively|O ,|O whereas|O the|O IQ|O of|O PKU|B-DISE mothers|O with|O two|O severe|O PKU|B-DISE mutations|O or|O with|O one|O severe|O and|O one|O moderate|O PKU|B-DISE mutation|O was|O 83|O and|O 84|O ,|O respectively|O .|O
Using|O a|O HeLa|O cell|O line|O in|O which|O the|O expression|O of|O HFE|O is|O controlled|O by|O tetracycline|O ,|O we|O show|O that|O the|O expression|O of|O HFE|O reduces|O 55Fe|O uptake|O from|O Tf|O by|O 33|O %|O but|O does|O not|O affect|O the|O endocytic|O or|O exocytic|O rates|O of|O TfR|O cycling|O .|O
This|O result|O supports|O a|O role|O for|O RNA|O gain|O of|O function|O in|O disease|O pathogenesis|O .|O .|O
In|O this|O study|O ,|O we|O analyzed|O mutations|O of|O the|O responsible|O gene|O ,|O ATP7B|O ,|O in|O four|O Japanese|O patients|O with|O WD|B-DISE .|O
We|O subsequently|O noted|O a|O substantial|O variation|O in|O glycerolemia|O in|O subjects|O of|O the|O initial|O cohort|O with|O normal|O plasma|O glycerol|O levels|O and|O demonstrated|O that|O this|O variance|O showed|O significant|O family|O resemblance|O .|O
A|O 24|O year|O old|O male|O with|O a|O history|O of|O eczema|B-DISE ,|O recurrent|B-DISE mild|I-DISE infections|I-DISE ,|O and|O thrombocytopenia|B-DISE consistent|O with|O the|O Wiskott|B-DISE -|I-DISE Aldrich|I-DISE syndrome|I-DISE (|O WAS|B-DISE )|O presented|O with|O a|O mediastinal|B-DISE mass|I-DISE ,|O generalized|O lymphadenopathy|B-DISE ,|O splenomegaly|B-DISE ,|O and|O severe|O thrombocytopenia|B-DISE .|O
